7352670
D009599_D006973 NONE nitroprusside_4\NN|Rebound|.|prevented (r_advmod) hypertensive_1\JJ|NONE
D009599_D006973 NONE SNP_2\NNP|the (r_compound) infusion_3\NN|NONE (r_pobj) During_0\IN|increase|animals|.|,|showed (r_prep) demonstrated_7\VBD|NONE (l_dobj) increase_10\NN|animals|.|,|showed|During (l_prep) in_11\IN|progressive|a|to (l_pobj) pressure_13\NN|NONE
D009599_D007022 CID nitroprusside_19\NN|and|halothane|sodium (l_parataxis) evaluated_24\VBN|NONE (l_nsubjpass) hypotension_22\NN|(|was
D009599_D007022 CID SNP)-induced_21\VBN|NONE (r_amod) hypotension_22\NN|(|was
D009599_D007022 CID SNP_19\NNP|and (r_conj) halothane_17\NN|NONE (r_pobj) of_16\IN|the|hypotensive|combined (r_prep) effects_15\NNS|NONE (l_amod) hypotensive_14\JJ|of|the|combined
D012504_D006973 NONE saralasin_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) prevented_5\VBN|Rebound|.|nitroprusside (r_acl) hypertensive_1\JJ|NONE
D012504_D006973 NONE saralasin_20\NN| (r_npadvmod) treated_22\VBN|the (r_amod) animals_23\NNS|change|whereas (r_nsubj) showed_24\VBD|increase|animals|.|,|During (r_advcl) demonstrated_7\VBD|NONE (l_dobj) increase_10\NN|animals|.|,|showed|During (l_prep) in_11\IN|progressive|a|to (l_pobj) pressure_13\NN|NONE
D006221_D007022 CID halothane_15\NN|and|sodium|nitroprusside (r_compound) anesthesia_16\NN|NONE (l_conj) nitroprusside_19\NN|and|halothane|sodium (l_parataxis) evaluated_24\VBN|NONE (l_nsubjpass) hypotension_22\NN|(|was
D006221_D007022 CID halothane_17\NN|NONE (r_pobj) of_16\IN|the|hypotensive|combined (r_prep) effects_15\NNS|NONE (l_amod) hypotensive_14\JJ|of|the|combined
D000809_D007022 NONE angiotensin_6\NN|in (r_compound) system_7\NN||the (l_prep) in_8\IN|angiotensin (l_pobj) maintenance_10\NN|NONE (l_prep) during_14\IN|of|the (l_pobj) anesthesia_16\NN|NONE (l_conj) nitroprusside_19\NN|and|halothane|sodium (l_parataxis) evaluated_24\VBN|NONE (l_nsubjpass) hypotension_22\NN|(|was
D000809_D007022 NONE angiotensin_8\NN|in (r_compound) system_9\NN|the| (l_prep) in_10\IN|angiotensin (l_pcomp) antagonizing_11\VBG|NONE (l_dobj) effects_15\NNS|NONE (l_amod) hypotensive_14\JJ|of|the|combined
15145918
D008750_D007022 CID methyldopa_10\NN|or (r_conj) rilmenidine_6\NN|,|operated (r_amod) rats_4\NNS|NONE (r_pobj) In_0\IN|.|hypotension (r_prep) elicited_11\VBD|NONE (l_dobj) hypotension_13\NN|In|.
D008750_D007022 CID methyldopa_9\NN|NONE (r_pobj) to_6\IN|the|hypotensive (r_prep) response_5\NN|Ovx|,|significantly|.|in (l_amod) hypotensive_4\JJ|the|to
D008750_D007022 CID methyldopa_9\NN|NONE (r_pobj) to_6\IN|the|hypotensive (r_prep) response_5\NN|Ovx|,|significantly|.|in (r_dobj) enhanced_2\VBD|NONE (l_prep) in_11\IN|Ovx|response|,|significantly|. (l_pobj) contrast_12\NN|NONE (l_prep) to_13\IN|NONE (l_pobj) effect_15\NN|NONE (l_prep) on_16\IN|no (l_pobj) hypotension_18\NN|NONE
D008750_D007022 CID methyldopa_4\NN|in|enhanced|The (r_compound) hypotension_5\NN|with|was|.
D008750_D007022 CID methyldopa_25\NN| (r_compound) estrogen_27\NN|NONE (r_compound) interaction_28\NN|NONE (r_pobj) in_22\IN|autonomic|cardiac|the (r_prep) control_21\NN|NONE (r_pobj) for_17\IN|a (r_prep) role_16\NN|NONE (r_dobj) highlight_14\VB|and|that|alpha|estrogen|hypotension|but (r_conj) downregulates_5\VBZ|.|findings (l_conj) hypotension_12\NN|and|that|alpha|highlight|estrogen|but
D003000_D007022 NONE clonidine_12\NN|NONE (r_pobj) of_11\IN|the|hypotensive (r_prep) effect_10\NN|that|and|negatively|implicates|estrogen (l_amod) hypotensive_9\JJ|the|of
C032302_D007022 CID rilmenidine_6\NN|,|operated (r_amod) rats_4\NNS|NONE (r_pobj) In_0\IN|.|hypotension (r_prep) elicited_11\VBD|NONE (l_dobj) hypotension_13\NN|In|.
C032302_D007022 CID rilmenidine_17\JJ|NONE (r_amod) hypotension_18\NN|NONE (r_pobj) on_16\IN|no (r_prep) effect_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) contrast_12\NN|NONE (r_pobj) in_11\IN|Ovx|response|,|significantly|. (r_prep) enhanced_2\VBD|NONE (l_dobj) response_5\NN|Ovx|,|significantly|.|in (l_amod) hypotensive_4\JJ|the|to
C032302_D007022 CID rilmenidine_17\JJ|NONE (r_amod) hypotension_18\NN|NONE
D048288_D007022 NONE I1-imidazoline_7\NNP|receptor| (r_punct) mediated_10\VBN|and (r_conj) alpha2-adrenergic_5\JJ|in (r_amod) hypotension_11\NN|NONE
D004967_D007022 NONE estrogen_3\NN|NONE (l_prep) of_4\IN|NONE (l_pobj) hypotension_11\NN|NONE
D004967_D007022 NONE estrogen_5\NN|that|and|effect|negatively|implicates (r_nsubj) modulates_7\VBZ|have|We|.|recently (l_dobj) effect_10\NN|that|and|negatively|implicates|estrogen (l_amod) hypotensive_9\JJ|the|of
D004967_D007022 NONE estrogen_4\NN|and|that|alpha|highlight|hypotension|but (r_nsubj) downregulates_5\VBZ|.|findings (l_conj) hypotension_12\NN|and|that|alpha|highlight|estrogen|but
D004967_D007022 NONE estrogen_27\NN|NONE (r_compound) interaction_28\NN|NONE (r_pobj) in_22\IN|autonomic|cardiac|the (r_prep) control_21\NN|NONE (r_pobj) for_17\IN|a (r_prep) role_16\NN|NONE (r_dobj) highlight_14\VB|and|that|alpha|estrogen|hypotension|but (r_conj) downregulates_5\VBZ|.|findings (l_conj) hypotension_12\NN|and|that|alpha|highlight|estrogen|but
D008750_D001523 NONE methyldopa_4\NN|in|enhanced|The (r_compound) hypotension_5\NN|with|was|. (r_nsubjpass) paralleled_10\VBN|NONE (l_prep) with_11\IN|hypotension|was|. (l_pobj) reduction_13\NN|NONE (l_conj) activity_20\NN|and|in|further
11672959
D012460_D056486 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|th|the (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|lady|.|, (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|beginning|lady|.|, (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE (l_conj) fever_11\NN|, (l_conj) lymphadenopathy_13\NN|, (l_conj) hepatitis_15\NN|and
D012460_D003872 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|th|the (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|lady|.|, (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|beginning|lady|.|, (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE
D012460_D008206 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|th|the (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|lady|.|, (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|beginning|lady|.|, (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE (l_conj) fever_11\NN|, (l_conj) lymphadenopathy_13\NN|,
D012460_D005334 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|th|the (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|lady|.|, (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|beginning|lady|.|, (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE (l_conj) fever_11\NN|,
D012460_D001172 NONE sulphasalazine_27\NN|NONE (l_prep) for_28\IN|oral (l_pobj) arthritis_33\NN|NONE
1664218
C042315_D002289 NONE CI-921_7\NNP|NONE (r_punct) (_8\-LRB-||) (r_punct) NSC_9\NNP|.|of|in|II (r_appos) study_2\NN|NONE (l_prep) in_12\IN|.|of|NSC|II (l_pobj) cancer_18\NN|NONE
C042315_D002289 NONE 343499_10\CD|(|) (r_nummod) NSC_9\NNP|.|of|in|II (r_appos) study_2\NN|NONE (l_prep) in_12\IN|.|of|NSC|II (l_pobj) cancer_18\NN|NONE
D000677_D002289 NONE amsacrine_5\NN|the (r_compound) analogue_6\NN|NONE (r_pobj) of_3\IN|.|in|NSC|II (r_prep) study_2\NN|NONE (l_prep) in_12\IN|.|of|NSC|II (l_pobj) cancer_18\NN|NONE
6103707
D005445_D010146 CID flunitrazepam_7\NN|NONE (r_pobj) of_6\IN|i.m. (r_prep) injection_5\NN|NONE (r_pobj) on_3\IN|NONE (r_prep) pain_2\NN|.|There|often
16787750
D014635_D003244 CID VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE (r_pobj) of_3\IN|typical|The (r_prep) signs_2\NNS|consciousness|.|marked|, (r_nsubj) are_8\VBP|NONE (l_attr) consciousness_10\NN|.|marked|signs|,
D014635_D001855 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|,|encephalopathy (r_amod) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE (l_conj) suppression_15\NN|,|haemorrhagic
D014635_D001855 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced (r_conj) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE (l_conj) suppression_15\NN|,|haemorrhagic
D014635_D012640 NONE VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE (r_pobj) of_3\IN|typical|The (r_prep) signs_2\NNS|consciousness|.|marked|, (r_nsubj) are_8\VBP|NONE (l_advcl) marked_13\VBD|consciousness|.|signs|, (l_ccomp) slowing_16\VBG|sometimes (l_dobj) frequency_20\NN|background|, (l_compound) seizure_19\NN|with|increased|,
D014635_D056486 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|,|encephalopathy (r_amod) hepatotoxicity_20\NN|in|may|.|complications
D014635_D056486 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced (r_conj) hepatotoxicity_20\NN|in|may|.|complications
D014635_D001927 CID acid_1\NN|from|encephalopathy|to|.|cases (r_nsubj) induced_2\VBD|NONE (l_advmod) encephalopathy--19_3\NNP|from|to|.|acid|cases
D014635_D001927 CID VPA_18\NNP| (r_compound) therapy_20\NN|NONE (r_pobj) to_17\IN|in (r_prep) associated_16\VBN|a|side| (r_acl) effect_15\NN|NONE (r_pobj) to_10\IN|from|encephalopathy|.|acid|cases (r_prep) induced_2\VBD|NONE (l_advmod) encephalopathy--19_3\NNP|from|to|.|acid|cases
D014635_D001927 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|,|encephalopathy (r_amod) hepatotoxicity_20\NN|in|may|.|complications (l_conj) encephalopathy_25\NN|and|,|induced
D014635_D001927 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced
D014635_D001927 CID VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE
D014635_D001927 CID VPA_9\NNP|NONE (r_pobj) of_8\IN|causative|in (r_prep) effect_7\NN|NONE (l_prep) in_10\IN|causative|of (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) encephalopathy_13\JJ|NONE
D014635_D001927 CID VPA_5\NNP| (r_npadvmod) associated_7\VBN|in (r_amod) encephalopathy_8\NN|NONE
D014635_D022124 NONE VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE (r_pobj) of_3\IN|typical|The (r_prep) signs_2\NNS|consciousness|.|marked|, (r_nsubj) are_8\VBP|NONE (l_advcl) marked_13\VBD|consciousness|.|signs|, (l_ccomp) slowing_16\VBG|sometimes (l_dobj) frequency_20\NN|background|, (l_prep) with_22\IN|increased|,|seizure (l_conj) without_24\IN|or (l_pobj) hyperammonemia_25\NN|NONE
D014635_D010195 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|,|encephalopathy (r_amod) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE
D014635_D010195 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced (r_conj) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE
9931093
C079574_D006973 NONE 139317_14\CD|on (r_nummod) FR_13\NNP|A|receptor (l_prep) on_15\IN| (l_pobj) hypertension_18\NN|NONE
D016559_D007674 NONE 506_5\CD|NONE (r_nummod) FK_4\NNP|NONE (r_pobj) of_3\IN|clinical|The (r_prep) utility_2\NN|.|by|is (r_nsubjpass) complicated_7\VBN|NONE (l_agent) by_8\IN|.|utility|is (l_pobj) hypertension_10\NN|NONE (l_conj) nephrotoxicity_12\NN|substantial|and
D009569_D006973 NONE oxide_44\NN|activity|nitric|.|(|endothelial|the|, (r_compound) synthase_45\NN|ET|converting|the|and|,|of (r_conj) expression_27\NN|effects|we|,|clarify (r_dobj) studied_10\VBD|NONE (l_advcl) clarify_1\VB|effects|we|,|expression (l_dobj) mechanisms_3\NNS|To (l_prep) of_4\IN|the (l_pobj) hypertension_7\NN|NONE
D016559_D006973 CID 506-induced_3\JJ|.|in (r_nummod) hypertension_4\NN|NONE
D016559_D006973 CID 506_5\CD|NONE (r_nummod) FK_4\NNP|NONE (r_pobj) of_3\IN|clinical|The (r_prep) utility_2\NN|.|by|is (r_nsubjpass) complicated_7\VBN|NONE (l_agent) by_8\IN|.|utility|is (l_pobj) hypertension_10\NN|NONE
D016559_D006973 CID 506-induced_6\JJ|FK (r_compound) hypertension_7\NN|NONE
D016559_D006973 CID 506_16\CD|NONE (r_nummod) FK_15\NNP|NONE (r_pobj) of_14\IN|chronic|the|on (r_prep) effects_13\NNS|we|,|clarify|expression (r_dobj) studied_10\VBD|NONE (l_advcl) clarify_1\VB|effects|we|,|expression (l_dobj) mechanisms_3\NNS|To (l_prep) of_4\IN|the (l_pobj) hypertension_7\NN|NONE
D016559_D006973 CID 506-induced_17\JJ|NONE (r_nummod) FK_16\NNP|in (r_poss) hypertension_18\NN|NONE
D016559_D006973 CID 506-induced_4\JJ|in|FK (r_nummod) hypertension_5\NN|d|.
230316
D007464_D001927 CID clioquinol_25\NN|NONE (r_pobj) of_24\IN|a|high|over (r_prep) dose_23\NN|NONE (r_pobj) of_20\IN|the (r_prep) ingestion_19\NN|NONE (r_pobj) to_17\IN|usually (r_prep) related_16\VBN|an|acute|reversible (r_acl) encephalopathy_14\NN|NONE
D006912_D020258 NONE hydroxyquinolines_3\NNS|NONE (r_pobj) of_1\IN|:|analysis (r_prep) Neurotoxicity_0\NN|outside|.
D006912_D020258 NONE hydroxyquinolines_13\NNS|NONE (r_pobj) to_11\IN|possible|neurotoxic (r_prep) reactions_10\NNS|NONE (l_amod) neurotoxic_9\JJ|possible|to
D007464_C538178 NONE clioquinol_13\NN|had|many (l_prep) as_14\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) for_16\IN|NONE (l_pobj) enteropathica_18\NN|NONE
D007464_D009422 NONE clioquinol_25\NN|NONE (r_pobj) of_24\IN|a|high|over (r_prep) dose_23\NN|NONE (r_pobj) of_20\IN|the (r_prep) ingestion_19\NN|NONE (r_pobj) to_17\IN|usually (r_prep) related_16\VBN|an|acute|reversible (r_acl) encephalopathy_14\NN|NONE (r_pobj) of_10\IN|disturbance (r_prep) consisted_9\VBD|probable|the (l_nsubj) disturbance_8\NN|of
9727773
D001067_D006976 CID suppressants_9\NNS|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|of|High|. (r_acl) incidence_1\NN|NONE (l_prep) of_2\IN|associated|High|. (l_pobj) hypertension_5\NN|NONE
D001067_D006976 CID suppressant_21\NN|NONE (r_compound) drugs_22\NNS|NONE (r_pobj) of_19\IN|the (r_prep) intake_18\NN|NONE (r_pobj) with_16\IN|been|which|has (r_prep) associated_15\VBN|rare|,|a (r_relcl) disease_10\NN|hypertension|. (r_attr) is_3\VBZ|NONE (l_nsubj) hypertension_2\NN|disease|.
D001067_D006976 CID suppressants_18\NNS|was|,|.|had| (r_dobj) taken_16\VBN|NONE (l_ccomp) was_9\VBD|,|.|had||suppressants (l_nsubj) diagnosis_4\NN|In|uncertain (l_prep) of_5\IN|the (l_pobj) hypertension_8\NN|NONE
D001067_D006976 CID suppressants_7\NNS|NONE (r_pobj) of_5\IN|unrestricted (r_prep) prescription_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) policy_1\NN|to|.|may (r_nsubj) lead_9\VB|NONE (l_prep) to_10\IN|policy|.|may (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|a (l_pobj) hypertension_18\NN|NONE
8302922
D000527_D007022 CID E1_5\NNP|NONE (r_pobj) during_3\IN|blood|Epidural (r_prep) flow_2\NN|.|hypotension (r_nsubj) induced_8\VBD|NONE (l_dobj) hypotension_9\NN|.|flow
D000527_D007022 CID E1_6\NNP|(|or|)|trimethaphan|prostaglandin (r_nmod) PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|hypotension|during (r_csubj) induced_15\VBN|was|using|EBF|,|. (l_dobj) hypotension_16\NN|during|evaluate
D000527_D007022 CID PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|hypotension|during (r_csubj) induced_15\VBN|was|using|EBF|,|. (l_dobj) hypotension_16\NN|during|evaluate
D000527_D007022 CID PGE1_2\NNP|NONE (r_dobj) starting_1\VBG|NONE (r_pcomp) After_0\IN|,|and|remained|significantly|compared (r_prep) decreased_14\VBD|NONE (l_conj) remained_34\VBD|,|and|significantly|compared|After (l_nsubj) degree_28\NN|constant|until|. (l_prep) of_29\IN|the|due (l_pobj) hypotension_30\NN|NONE
D000527_D007022 CID PGE1_33\NNP|NONE (r_pobj) to_32\IN|NONE (r_pcomp) due_31\IN|the|of (r_prep) degree_28\NN|constant|until|. (l_prep) of_29\IN|the|due (l_pobj) hypotension_30\NN|NONE
D000527_D007022 CID PGE1_4\NNP|preferable|that|decreased|may (r_nsubj) be_6\VB|results|. (l_acomp) preferable_7\JJ|that|decreased|may|PGE (l_xcomp) TMP_9\VB|NONE (l_prep) for_10\IN|to (l_pobj) anaesthesia_12\NN|NONE (l_amod) hypotensive_11\JJ|in
D007530_D007022 NONE isoflurane_47\JJ|NONE (r_amod) anaesthesia_48\NN|NONE (r_pobj) under_46\IN|interbody|lateral (r_prep) fusion_45\NN|who (r_dobj) underwent_40\VBD| (r_relcl) patients_38\NNS|NONE (r_pobj) in_36\IN|method (r_prep) using_31\VBG|was|EBF|,|.|induced (r_advcl) measured_30\VBN|NONE (l_advcl) induced_15\VBN|was|using|EBF|,|. (l_dobj) hypotension_16\NN|during|evaluate
D014294_D007022 CID trimethaphan_7\RB|or|prostaglandin (r_conj) E1_5\NNP|NONE (r_pobj) during_3\IN|blood|Epidural (r_prep) flow_2\NN|.|hypotension (r_nsubj) induced_8\VBD|NONE (l_dobj) hypotension_9\NN|.|flow
D014294_D007022 CID trimethaphan_11\NN|(|or|)|prostaglandin|E (r_conj) PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|hypotension|during (r_csubj) induced_15\VBN|was|using|EBF|,|. (l_dobj) hypotension_16\NN|during|evaluate
D014294_D007022 CID TMP_13\NNP|NONE (r_appos) trimethaphan_11\NN|(|or|)|prostaglandin|E (r_conj) PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|hypotension|during (r_csubj) induced_15\VBN|was|using|EBF|,|. (l_dobj) hypotension_16\NN|during|evaluate
D014294_D007022 CID TMP_4\NNP|or|product (r_conj) PGE1_2\NNP|NONE (r_dobj) starting_1\VBG|NONE (r_pcomp) After_0\IN|,|and|remained|significantly|compared (r_prep) decreased_14\VBD|NONE (l_conj) remained_34\VBD|,|and|significantly|compared|After (l_nsubj) degree_28\NN|constant|until|. (l_prep) of_29\IN|the|due (l_pobj) hypotension_30\NN|NONE
D014294_D007022 CID TMP_9\VB|NONE (l_prep) for_10\IN|to (l_pobj) anaesthesia_12\NN|NONE (l_amod) hypotensive_11\JJ|in
D014294_D007022 CID TMP_17\NNP|EBF|because (r_nsubj) decreased_18\VBD|preferable|that|may|PGE (r_advcl) be_6\VB|results|. (l_acomp) preferable_7\JJ|that|decreased|may|PGE (l_xcomp) TMP_9\VB|NONE (l_prep) for_10\IN|to (l_pobj) anaesthesia_12\NN|NONE (l_amod) hypotensive_11\JJ|in
3437726
D003647_D064420 NONE debrisoquine_13\JJ|in|,|constitutes|, (r_compound) polymorphism_14\NN|NONE (r_pobj) of_10\IN|metabolizer|the (r_prep) phenotype_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) belonging_3\VBG|NONE (r_acl) patients_2\NNS|Therefore|reactions|treated|may|,|. (r_nsubj) experience_29\VB|NONE (l_dobj) reactions_32\NNS|patients|Therefore|treated|may|,|.
D013034_D064420 NONE sparteine_11\NN|/ (r_nmod) debrisoquine_13\JJ|in|,|constitutes|, (r_compound) polymorphism_14\NN|NONE (r_pobj) of_10\IN|metabolizer|the (r_prep) phenotype_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) belonging_3\VBG|NONE (r_acl) patients_2\NNS|Therefore|reactions|treated|may|,|. (r_nsubj) experience_29\VB|NONE (l_dobj) reactions_32\NNS|patients|Therefore|treated|may|,|.
12789195
D008914_D004194 NONE minoxidil_9\NN|NONE (r_pobj) of_8\IN|the|term (r_prep) use_7\NN|NONE (r_pobj) by_2\IN|Pseudoacromegaly|. (r_agent) induced_1\VBN|NONE (l_nsubj) Pseudoacromegaly_0\NNS|by|.
D008914_D004194 NONE minoxidil_15\NN|NONE (r_pobj) of_14\IN|term|the|at (r_prep) use_13\NN|NONE (r_pobj) from_8\IN|that (r_prep) resulted_7\VBD|with|a (r_relcl) patient_3\NN|We|. (l_prep) with_4\IN|a|resulted (l_pobj) pseudoacromegaly_5\NNS|NONE
D008914_D004194 NONE minoxidil_13\JJ|NONE (r_amod) use_14\NN|NONE (r_pobj) of_12\IN|side|a (r_prep) effect_11\NN|NONE (r_pobj) as_8\IN|the|of|first|case (r_prep) report_5\NN|This|. (l_prep) of_6\IN|the|first|case|as (l_pobj) pseudoacromegaly_7\NNS|NONE
12198388
D009388_D012640 CID neostigmine_12\NN|,|and|to (r_conj) Sensitivity_0\NN|.|greater (l_prep) to_1\IN|,|neostigmine|and (l_pobj) endpoints_4\NNS|NONE (l_compound) convulsion_3\NN|several|induced
D009538_D012640 CID nicotine_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|several|convulsion (r_acl) endpoints_4\NNS|NONE (l_compound) convulsion_3\NN|several|induced
D009538_D014202 NONE nicotine_3\NN|and|,|were|Animals|recorded (r_dobj) administered_2\VBN|NONE (l_conj) recorded_25\VBN|and|,|were|nicotine|Animals (l_nsubjpass) latencies_17\NNS|and|converted|.|were (l_relcl) onset_19\VB|the (l_prep) of_20\IN|to (l_pobj) tremor_21\NN|NONE
D009388_D014202 NONE neostigmine_8\JJ|,|or (r_conj) carbachol_5\NN|, (r_conj) nicotine_3\NN|and|,|were|Animals|recorded (r_dobj) administered_2\VBN|NONE (l_conj) recorded_25\VBN|and|,|were|nicotine|Animals (l_nsubjpass) latencies_17\NNS|and|converted|.|were (l_relcl) onset_19\VB|the (l_prep) of_20\IN|to (l_pobj) tremor_21\NN|NONE
D000431_D012640 NONE alcohol_6\NN| (r_compound) na_8\TO|mice (r_aux) ve_9\VB|sensitivity|in|.|was (l_dobj) mice_23\NNS|na (l_nmod) Prone_13\NNP|WSR|)|( (l_compound) Seizure_11\NN||Withdrawal|WSP|Resistant|(|and
D000431_D012640 NONE ethanol_18\NN|NONE (r_compound) withdrawal_19\NN|NONE (r_compound) severity_20\NN|NONE (r_pobj) with_17\IN|may|and|implicate|that|differences|be (r_prep) associated_16\VBN|results|. (l_nsubjpass) differences_4\NNS|may|and|implicate|that|with|be (l_prep) in_5\IN|NONE (l_pobj) activity_7\NN|NONE (l_conj) sensitivity_10\NN|and|cholinergic (l_prep) to_11\IN|postsynaptic (l_pobj) convulsants_13\NNS|NONE
D000431_D012640 NONE alcohol_26\NN|NONE (r_compound) withdrawal_27\NN|NONE (r_pobj) in_25\IN|cholinergic (r_prep) mechanisms_24\NNS|NONE (r_dobj) implicate_22\VB|may|and|that|differences|with|be (r_conj) associated_16\VBN|results|. (l_nsubjpass) differences_4\NNS|may|and|implicate|that|with|be (l_prep) in_5\IN|NONE (l_pobj) activity_7\NN|NONE (l_conj) sensitivity_10\NN|and|cholinergic (l_prep) to_11\IN|postsynaptic (l_pobj) convulsants_13\NNS|NONE
D000109_D012640 NONE acetylcholine_4\NN|hippocampal|sensitivity|and (r_compound) release_5\NN|NONE (l_conj) sensitivity_9\NN|hippocampal|acetylcholine|and (l_prep) in_10\IN|cholinergic|convulsant (l_pobj) lines_22\NNS|NONE (l_amod) prone_14\JJ|resistant|mouse|selected|withdrawal (l_npadvmod) seizure_12\NN||withdrawal|and
D000109_D012640 NONE acetylcholine_4\NN|hippocampal|sensitivity|and (r_compound) release_5\NN|NONE (l_conj) sensitivity_9\NN|hippocampal|acetylcholine|and (l_prep) in_10\IN|cholinergic|convulsant (l_pobj) lines_22\NNS|NONE (l_amod) resistant_19\JJ|mouse|selected|prone|withdrawal (l_npadvmod) seizure_17\NN|
D000109_D012640 NONE ACh_1\NNS|was|during|.|also (r_nsubjpass) measured_4\VBN|NONE (l_prep) during_5\IN|was|.|also|ACh (l_pobj) testing_6\VBG|NONE (l_prep) for_7\IN|NONE (l_pobj) convulsions_11\NNS|NONE
D000109_D012640 NONE ACh_2\NNS|When|was|during (r_nsubjpass) measured_4\VBN|in|,|elevated|but|,|was|significantly|ACh|%|. (l_prep) during_5\IN|When|was|ACh (l_pobj) testing_6\VBG|NONE (l_prep) for_7\IN|NONE (l_pobj) convulsions_11\NNS|NONE
D000109_D012640 NONE ACh_14\NNS|measured|in|,|elevated|but|,|was|significantly|%|. (r_nsubjpass) elevated_17\JJ|NONE (l_advcl) measured_4\VBN|in|,|elevated|but|,|was|significantly|ACh|%|. (l_prep) during_5\IN|When|was|ACh (l_pobj) testing_6\VBG|NONE (l_prep) for_7\IN|NONE (l_pobj) convulsions_11\NNS|NONE
D002217_D014202 NONE carbachol_5\NN|, (r_conj) nicotine_3\NN|and|,|were|Animals|recorded (r_dobj) administered_2\VBN|NONE (l_conj) recorded_25\VBN|and|,|were|nicotine|Animals (l_nsubjpass) latencies_17\NNS|and|converted|.|were (l_relcl) onset_19\VB|the (l_prep) of_20\IN|to (l_pobj) tremor_21\NN|NONE
D002217_D012640 CID carbachol_9\NN|, (r_conj) nicotine_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|several|convulsion (r_acl) endpoints_4\NNS|NONE (l_compound) convulsion_3\NN|several|induced
6518066
D008094_D006331 NONE lithium_9\NN|NONE (r_pobj) to_8\IN|screening|during (r_prep) exposed_7\VBN|assessment|can|. (r_csubj) provide_13\VB|NONE (l_dobj) assessment_18\NN|can|.|exposed (l_prep) of_19\IN|noninvasive|accurate|, (l_pobj) presence_21\NN|NONE (l_prep) of_24\IN|or|the|absence (l_pobj) malformations_29\NNS|NONE
D008094_D006331 NONE lithium_25\NN| (r_npadvmod) induced_27\VBN|cardiac (r_amod) malformations_29\NNS|NONE
D008094_D004437 CID lithium_1\NN|NONE (l_conj) anomaly_6\NN|Maternal|and|.
10520387
D004809_D013610 CID ephedrine_9\NN|NONE (r_pobj) of_8\IN|in|the (r_prep) use_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|marked (r_acl) tachycardia_3\NNS|.|However|,|in|,|reaching
D004809_D013610 CID ephedrine_24\NN|/|the|propofol|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|would|Due|we|.|,|not (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|would|we|.|,|use|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE
D015742_D007022 CID propofol_13\NN|doses (l_prep) in_14\IN|to (l_pobj) order_15\NN|NONE (l_acl) obtund_17\VB|NONE (l_dobj) response_20\NN|to (l_amod) hypotensive_19\JJ|the
D015742_D007022 CID propofol_5\NN|The|of (r_acl) addition_1\NN|be|. (r_nsubj) appears_6\VBZ|NONE (l_xcomp) be_8\VB|addition|. (l_attr) method_11\NN|to (l_prep) of_12\IN|effective|an (l_pcomp) obtunding_13\VBG|NONE (l_dobj) response_16\NN|propofol (l_amod) hypotensive_15\JJ|the
D015742_D007022 CID propofol_18\NN|response (r_advcl) obtunding_13\VBG|NONE (l_dobj) response_16\NN|propofol (l_amod) hypotensive_15\JJ|the
D004809_D017202 NONE ephedrine_24\NN|/|the|propofol|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|would|Due|we|.|,|not (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|would|we|.|,|use|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE (l_acl) inducing_7\VBG|this (l_dobj) ischemia_9\NN|NONE
D004809_D007022 NONE ephedrine_11\NN|NONE (r_pobj) of_10\IN|different (r_prep) doses_9\NNS|propofol (r_dobj) adding_7\VBG|NONE (l_xcomp) propofol_13\NN|doses (l_prep) in_14\IN|to (l_pobj) order_15\NN|NONE (l_acl) obtund_17\VB|NONE (l_dobj) response_20\NN|to (l_amod) hypotensive_19\JJ|the
D004809_D007022 NONE ephedrine_3\NN|NONE (r_pobj) of_2\IN|propofol|The (r_prep) addition_1\NN|be|. (r_nsubj) appears_6\VBZ|NONE (l_xcomp) be_8\VB|addition|. (l_attr) method_11\NN|to (l_prep) of_12\IN|effective|an (l_pcomp) obtunding_13\VBG|NONE (l_dobj) response_16\NN|propofol (l_amod) hypotensive_15\JJ|the
D015742_D013610 CID propofol_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) combination_11\NN|NONE (r_pobj) in_10\IN|of|the (r_prep) use_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|marked (r_acl) tachycardia_3\NNS|.|However|,|in|,|reaching
D015742_D013610 CID propofol_26\NN|/|ephedrine|the|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|would|Due|we|.|,|not (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|would|we|.|,|use|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE
D015742_D017202 NONE propofol_26\NN|/|ephedrine|the|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|would|Due|we|.|,|not (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|would|we|.|,|use|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE (l_acl) inducing_7\VBG|this (l_dobj) ischemia_9\NN|NONE
6888657
D004054_D009369 NONE DES_12\NNP| (r_npadvmod) induced_14\VBN|the (r_amod) tumor_15\NN|as|further
D004054_D010911 CID diethylstilbestrol_12\NN|NONE (r_pobj) with_11\IN|chronic (r_prep) treatment_10\NN|NONE (r_pobj) by_8\IN|in|tumors|.|were|implanted (r_agent) induced_3\VBN|NONE (l_nsubjpass) tumors_1\NNS|in|.|by|were|implanted
D004054_D010911 CID DES_14\NNP|in|(|,|subcutaneously (r_npadvmod) implanted_21\VBN|in|tumors|.|by|were (r_parataxis) induced_3\VBN|NONE (l_nsubjpass) tumors_1\NNS|in|.|by|were|implanted
D004967_D010911 NONE estrogen_2\NN| (r_npadvmod) induced_4\VBN|adenohypophyseal|in (r_amod) tumors_6\NNS|NONE
15036754
D010755_D012640 NONE Organophosphate_0\NNP| (r_npadvmod) induced_2\VBN|of|.|and|prevention (r_amod) convulsions_3\NNS|NONE
D003975_D011041 NONE diazepam_3\NN|after|CPA|When|was|immediately|, (r_nsubjpass) given_7\VBN|,|,|delayed|treatments|. (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|,|,|given|treatments|. (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D003975_D011041 NONE diazepam_5\NN|, (r_conj) CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|.|CPA|and|,|reduced (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D007531_D064420 NONE DFP_4\NNP| (r_compound) atropine_6\NN|NONE (r_pobj) with_3\IN|.|rats|showed (r_prep) treated_2\VBD|NONE (l_conj) showed_7\VBD|with|.|rats (l_dobj) signs_14\NNS|NONE (l_compound) toxicity_13\NN|induced|severe|typical
D007531_D064420 NONE DFP_10\NNP|NONE (r_compound) toxicity_11\NN|NONE
D007531_D064420 NONE DFP_26\NNP|NONE (r_pobj) of_25\IN|the|in (r_prep) toxicity_24\NN|thus
D000109_D064420 NONE acetylcholine_25\NN|)|ACh|( (r_nmod) levels_29\NNS|which (r_dobj) elevates_24\VBZ|nervous|CNS|the|)|central|,|( (r_relcl) system_18\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) AChEs_13\NNP|NONE (r_pobj) with_12\IN|their|irreversible (r_prep) binding_11\NN|NONE (r_pobj) of_8\IN|the (r_prep) result_7\NN|toxicity|. (r_attr) is_5\VBZ|NONE (l_nsubj) toxicity_2\NN|result|.
D000109_D064420 NONE ACh_27\NNS|acetylcholine|)|( (r_nmod) levels_29\NNS|which (r_dobj) elevates_24\VBZ|nervous|CNS|the|)|central|,|( (r_relcl) system_18\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) AChEs_13\NNP|NONE (r_pobj) with_12\IN|their|irreversible (r_prep) binding_11\NN|NONE (r_pobj) of_8\IN|the (r_prep) result_7\NN|toxicity|. (r_attr) is_5\VBZ|NONE (l_nsubj) toxicity_2\NN|result|.
D010755_D064420 NONE OPs_4\NNS|NONE (r_pobj) of_3\IN|The|acute (r_prep) toxicity_2\NN|result|.
D010755_D064420 NONE OP_10\NN| (r_npadvmod) induced_12\VBN|toxicity|severe|typical (r_amod) signs_14\NNS|NONE (l_compound) toxicity_13\NN|induced|severe|typical
D011220_D064420 NONE 2PAM_7\CD|in|and (r_conj) diazepam_5\NN|, (r_conj) CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|.|CPA|and|occurrence|, (l_dobj) toxicity_24\NN|thus
D007531_D011041 NONE DFP_10\NNP| (r_compound) atropine_12\NN|NONE (r_pobj) after_9\IN|CPA|When|diazepam|was|immediately|, (r_prep) given_7\VBN|,|,|delayed|treatments|. (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|,|,|given|treatments|. (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D007531_D011041 NONE DFP_26\NNP|NONE (r_pobj) of_25\IN|the|in (r_prep) toxicity_24\NN|thus (r_dobj) reduced_22\VBD|In|.|CPA|and|occurrence|, (r_conj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|.|CPA|and|,|reduced (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D003975_D064420 NONE diazepam_5\NN|, (r_conj) CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|.|CPA|and|occurrence|, (l_dobj) toxicity_24\NN|thus
C048599_D064420 NONE CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|.|CPA|and|occurrence|, (l_dobj) toxicity_24\NN|thus
D016291_D064420 NONE MK801_2\NNP|protection|not|.|did (r_nsubj) offer_5\VB|NONE (l_dobj) protection_8\NN|not|.|MK|did (l_prep) against_9\IN|additional|any (l_pobj) toxicity_11\NN|NONE
D010755_D004194 NONE Organophosphate_0\NNP| (r_npadvmod) induced_2\VBN|of|.|and|prevention (r_amod) convulsions_3\NNS|NONE (l_prep) of_6\IN|induced|.|and|prevention (l_pobj) damages_8\NNS|NONE
D001285_D011041 NONE atropine_12\NN|NONE (r_pobj) after_9\IN|CPA|When|diazepam|was|immediately|, (r_prep) given_7\VBN|,|,|delayed|treatments|. (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|,|,|given|treatments|. (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D001285_D011041 NONE atropine_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) combination_9\NN|NONE (r_pobj) in_8\IN|PAM|and (r_prep) diazepam_5\NN|, (r_conj) CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|.|CPA|and|,|reduced (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D011220_D011041 NONE 2PAM_5\CD|or (r_conj) diazepam_3\NN|after|CPA|When|was|immediately|, (r_nsubjpass) given_7\VBN|,|,|delayed|treatments|. (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|,|,|given|treatments|. (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D011220_D011041 NONE 2PAM_7\CD|in|and (r_conj) diazepam_5\NN|, (r_conj) CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|.|CPA|and|,|reduced (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D001285_D064420 NONE atropine_6\NN|NONE (r_pobj) with_3\IN|.|rats|showed (r_prep) treated_2\VBD|NONE (l_conj) showed_7\VBD|with|.|rats (l_dobj) signs_14\NNS|NONE (l_compound) toxicity_13\NN|induced|severe|typical
D001285_D064420 NONE Atropine_0\NNP| (r_compound) MK801_2\NNP|protection|not|.|did (r_nsubj) offer_5\VB|NONE (l_dobj) protection_8\NN|not|.|MK|did (l_prep) against_9\IN|additional|any (l_pobj) toxicity_11\NN|NONE
D001285_D064420 NONE atropine_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) combination_9\NN|NONE (r_pobj) in_8\IN|PAM|and (r_prep) diazepam_5\NN|, (r_conj) CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|.|CPA|and|occurrence|, (l_dobj) toxicity_24\NN|thus
C048599_D011041 NONE CPA_1\NN|after|When|diazepam|was|immediately|, (r_nsubjpass) given_7\VBN|,|,|delayed|treatments|. (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|,|,|given|treatments|. (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
C048599_D011041 NONE CPA_3\NN|In|.|and|occurrence|,|reduced (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|.|CPA|and|,|reduced (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
2887062
D001971_D000236 NONE bromocriptine_15\JJ|of (r_amod) treatment_16\NN|NONE (l_prep) of_17\IN|bromocriptine (l_pobj) cells_20\NNS|NONE (l_compound) adenoma_19\NN|the
D004967_D015175 CID estrogen_8\NN| (r_npadvmod) induced_10\VBN|after|rat (r_amod) prolactinomas_12\NNS|NONE
D004967_D015175 CID estrogen_21\NN| (r_npadvmod) induced_23\VBN|rat|h|and|prolactinoma (r_amod) cells_26\NNS|NONE (r_pobj) to_20\IN|clarify|h|were|.|analyses (r_prep) applied_19\VBN|NONE (l_advcl) clarify_1\VB|to|h|were|.|analyses (l_dobj) effects_3\NNS|To (l_prep) on_6\IN|of|the (l_pobj) cells_8\NNS|NONE (l_compound) prolactinoma_7\NN|in
D004967_D015175 CID estrogen_21\NN| (r_npadvmod) induced_23\VBN|rat|h|and|prolactinoma (r_amod) cells_26\NNS|NONE (l_compound) prolactinoma_25\NN|rat|h|and|induced
D001971_D015175 NONE bromocriptine_14\NN|NONE (r_amod) treatment_15\NN|NONE (r_pobj) after_13\IN|induced|rat (r_prep) prolactinomas_12\NNS|NONE
D001971_D015175 NONE bromocriptine_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effects_3\NNS|To (l_prep) on_6\IN|of|the (l_pobj) cells_8\NNS|NONE (l_compound) prolactinoma_7\NN|in
D001971_D015175 NONE bromocriptine_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effects_3\NNS|To (r_dobj) clarify_1\VB|to|h|were|.|analyses (r_advcl) applied_19\VBN|NONE (l_prep) to_20\IN|clarify|h|were|.|analyses (l_pobj) cells_26\NNS|NONE (l_compound) prolactinoma_25\NN|rat|h|and|induced
D001971_D015175 NONE bromocriptine_35\NN|NONE (r_pobj) of_34\IN|NONE (r_prep) injection_33\NN|NONE (r_pobj) after_32\IN|mg/kg| (r_prep) h_31\NN|to|clarify|were|.|analyses (r_conj) applied_19\VBN|NONE (l_advcl) clarify_1\VB|to|h|were|.|analyses (l_dobj) effects_3\NNS|To (l_prep) on_6\IN|of|the (l_pobj) cells_8\NNS|NONE (l_compound) prolactinoma_7\NN|in
D001971_D015175 NONE bromocriptine_35\NN|NONE (r_pobj) of_34\IN|NONE (r_prep) injection_33\NN|NONE (r_pobj) after_32\IN|mg/kg| (r_prep) h_31\NN|to|clarify|were|.|analyses (r_conj) applied_19\VBN|NONE (l_prep) to_20\IN|clarify|h|were|.|analyses (l_pobj) cells_26\NNS|NONE (l_compound) prolactinoma_25\NN|rat|h|and|induced
10669626
D014807_D002114 NONE D_8\JJ|and (r_conj) growth_5\NN|NONE (r_nmod) treatment_9\NN|given|that|extent (r_nsubj) enhance_10\VB|studies|. (l_prep) given_18\VBN|treatment|that|extent (l_advcl) inhibit_24\VB|doses (l_dobj) carboxylation_27\NN|to (l_prep) of_28\IN|gamma| (l_pobj) protein_31\NN|NONE (l_appos) inhibitor_35\NN|,|matrix|Gla (l_compound) calcification_34\NN|known
D014807_D002114 NONE D_30\NN| (r_npadvmod) treated_32\VBN|vitamin (r_amod) rats_33\NNS|NONE (r_pobj) of_28\IN|the (r_prep) media_27\NNS|NONE (r_pobj) in_25\IN|at (r_prep) calcification_24\NN|NONE
D014807_D002114 NONE D_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) produced_12\VBN|serum (r_acl) calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|by|is|best|probably|. (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|had|is|best|probably|. (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D014807_D002114 NONE D_23\NN|NONE (r_pobj) between_19\IN|the (r_prep) synergy_18\NN|vitamin|, (r_appos) D_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) produced_12\VBN|serum (r_acl) calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|by|is|best|probably|. (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|had|is|best|probably|. (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D015055_D002114 NONE carboxyglutamate_8\NN|of|the (r_compound) residues_9\NNS|as|apparently|for|are|although (r_nsubjpass) required_16\VBN|,|for|are|they|that|not (l_prep) as_20\IN|residues|apparently|for|are|although (l_pobj) inhibitor_23\NN|NONE (l_compound) calcification_22\NN|a
D015055_D002114 NONE carboxyglutamate_8\NN|of|the (r_compound) residues_9\NNS|as|apparently|for|are|although (r_nsubjpass) required_16\VBN|,|for|are|they|that|not (r_advcl) required_28\VBN|.|observations (l_prep) for_29\IN|,|required|are|they|that|not (l_pobj) accumulation_31\NN|NONE (l_prep) at_32\IN|its (l_pobj) sites_34\NNS|NONE (l_compound) calcification_33\NN|NONE
D014859_D061205 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|artery (r_amod) calcification_4\NN|is|by
D014859_D061205 CID Warfarin_22\NNP|NONE (r_pobj) of_21\IN|sufficient (r_prep) doses_20\NNS|inhibit (r_dobj) given_18\VBN|treatment|that|extent (r_prep) enhance_10\VB|studies|. (l_dobj) extent_12\NN|given|treatment|that (l_prep) of_13\IN|the (l_pobj) calcification_15\NN|NONE
D014859_D061205 CID Warfarin_17\NNP| (r_npadvmod) treated_19\VBN|NONE (r_amod) rats_20\NNS|NONE (r_pobj) in_16\IN|artery (r_prep) calcification_15\NN|NONE
D014859_D061205 CID Warfarin_5\NNP|NONE (r_pobj) with_4\IN|for (r_prep) Treatment_0\NN|.|calcification (r_nsubj) caused_6\VBD|NONE (l_dobj) calcification_9\NN|Treatment|. (l_prep) of_10\IN|massive|and|in|calcification|focal (l_pobj) media_13\NNS|NONE (l_compound) artery_12\NN|the
D014859_D061205 CID Warfarin_20\NNP|NONE (r_compound) treatment_21\NN|NONE (r_pobj) of_19\IN| (r_prep) weeks_18\NNS|even (r_pobj) after_16\IN|calcification|,|.|could|be|In|in (r_prep) detected_8\VBN|NONE (l_nsubjpass) calcification_5\NN|,|.|could|be|after|In|in
D014859_D061205 CID Warfarin_8\NNP| (r_npadvmod) induced_10\VBN|artery|in (r_amod) calcification_12\NN|NONE
D014859_D061205 CID Warfarin_7\NNP|NONE (r_pobj) with_6\IN|dietary|both (r_prep) groups_5\NNS|NONE (r_pobj) of_2\IN|Concurrent (r_prep) treatment_1\NN|.|calcification (r_nsubj) produced_8\VBD|NONE (l_dobj) calcification_11\NN|treatment|. (l_prep) of_12\IN|massive|focal|in|calcification|but (l_pobj) media_15\NNS|NONE (l_compound) artery_14\NN|the
D014859_D061205 CID Warfarin_7\NNP|NONE (r_pobj) with_6\IN|dietary|both (r_prep) groups_5\NNS|NONE (r_pobj) of_2\IN|Concurrent (r_prep) treatment_1\NN|.|calcification (r_nsubj) produced_8\VBD|NONE (l_dobj) calcification_11\NN|treatment|. (l_conj) calcification_27\NN|massive|focal|in|of|but
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|artery (r_amod) calcification_65\NN|NONE (r_pobj) to_60\IN|NONE (r_prep) resistant_59\JJ|that (r_acomp) was_58\VBD|the (r_relcl) groups_56\NNS|NONE (r_pobj) of_54\IN|NONE (r_prep) either_53\DT|NONE (r_pobj) with_52\IN|rats (r_prep) compared_51\VBN|ad|fed (r_prep) rats_50\NNS|with|,|,|a|between (r_appos) relationship_24\NN|determined|there|,|. (r_attr) was_22\VBD|NONE (l_advcl) determined_15\VBN|relationship|there|,|. (l_nsubjpass) explanation_2\NN|be|not|from|can|Although (l_prep) for_3\IN|the (l_pobj) association_5\NN|NONE (l_prep) between_6\IN|the (l_pobj) calcification_8\NN|NONE
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|artery (r_amod) calcification_65\NN|NONE (r_pobj) to_60\IN|NONE (r_prep) resistant_59\JJ|that (r_acomp) was_58\VBD|the (r_relcl) groups_56\NNS|NONE (r_pobj) of_54\IN|NONE (r_prep) either_53\DT|NONE (r_pobj) with_52\IN|rats (r_prep) compared_51\VBN|ad|fed (r_prep) rats_50\NNS|with|,|,|a|between (r_appos) relationship_24\NN|determined|there|,|. (l_prep) between_25\IN|with|,|,|a|rats (l_pobj) phosphate_28\NN|NONE (l_conj) susceptibility_30\NN|higher|serum|and (l_prep) to_31\IN|NONE (l_pobj) calcification_33\NN|NONE
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|artery (r_amod) calcification_65\NN|NONE
D014859_D061205 CID Warfarin_7\NNP| (r_npadvmod) induced_9\VBN|artery (r_amod) calcification_11\NN|NONE
D014859_D061205 CID Warfarin_13\NNP|and|vitamin (r_conj) D_11\NN|NONE (r_pobj) between_9\IN|the|possible|in (r_prep) synergy_8\NN|.|set (l_prep) in_14\IN|the|possible|between (l_pobj) calcification_16\NN|NONE
D014859_D061205 CID Warfarin_0\NNP|also|.|,|are|cause|at|but (r_nsubjpass) known_3\VBN|NONE (l_xcomp) cause_5\VB|also|.|,|are|at|but|Warfarin (l_dobj) calcification_6\NN|to (l_prep) of_7\IN|NONE (l_pobj) media_10\NNS|NONE (l_compound) artery_9\NN|the
D014859_D061205 CID Warfarin_20\NNP|plus|vitamin (r_conj) D_18\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|artery (r_prep) calcification_12\NN|NONE
D010710_D061205 NONE phosphate_28\NN|NONE (r_pobj) between_25\IN|with|,|,|a|rats (r_prep) relationship_24\NN|determined|there|,|. (r_attr) was_22\VBD|NONE (l_advcl) determined_15\VBN|relationship|there|,|. (l_nsubjpass) explanation_2\NN|be|not|from|can|Although (l_prep) for_3\IN|the (l_pobj) association_5\NN|NONE (l_prep) between_6\IN|the (l_pobj) calcification_8\NN|NONE
D010710_D061205 NONE phosphate_28\NN|NONE (l_conj) susceptibility_30\NN|higher|serum|and (l_prep) to_31\IN|NONE (l_pobj) calcification_33\NN|NONE
D010710_D061205 NONE phosphate_28\NN|NONE (r_pobj) between_25\IN|with|,|,|a|rats (r_prep) relationship_24\NN|determined|there|,|. (l_appos) rats_50\NNS|with|,|,|a|between (l_prep) compared_51\VBN|ad|fed (l_prep) with_52\IN|rats (l_pobj) either_53\DT|NONE (l_prep) of_54\IN|NONE (l_pobj) groups_56\NNS|NONE (l_relcl) was_58\VBD|the (l_acomp) resistant_59\JJ|that (l_prep) to_60\IN|NONE (l_pobj) calcification_65\NN|NONE
D010710_D061205 NONE phosphate_42\NN|NONE (r_pobj) of_40\IN|in|higher (r_prep) levels_39\NNS|NONE (r_pobj) with_35\IN|,|,|a|between|rats (r_prep) relationship_24\NN|determined|there|,|. (r_attr) was_22\VBD|NONE (l_advcl) determined_15\VBN|relationship|there|,|. (l_nsubjpass) explanation_2\NN|be|not|from|can|Although (l_prep) for_3\IN|the (l_pobj) association_5\NN|NONE (l_prep) between_6\IN|the (l_pobj) calcification_8\NN|NONE
D010710_D061205 NONE phosphate_42\NN|NONE (r_pobj) of_40\IN|in|higher (r_prep) levels_39\NNS|NONE (r_pobj) with_35\IN|,|,|a|between|rats (r_prep) relationship_24\NN|determined|there|,|. (l_prep) between_25\IN|with|,|,|a|rats (l_pobj) phosphate_28\NN|NONE (l_conj) susceptibility_30\NN|higher|serum|and (l_prep) to_31\IN|NONE (l_pobj) calcification_33\NN|NONE
D010710_D061205 NONE phosphate_42\NN|NONE (r_pobj) of_40\IN|in|higher (r_prep) levels_39\NNS|NONE (r_pobj) with_35\IN|,|,|a|between|rats (r_prep) relationship_24\NN|determined|there|,|. (l_appos) rats_50\NNS|with|,|,|a|between (l_prep) compared_51\VBN|ad|fed (l_prep) with_52\IN|rats (l_pobj) either_53\DT|NONE (l_prep) of_54\IN|NONE (l_pobj) groups_56\NNS|NONE (l_relcl) was_58\VBD|the (l_acomp) resistant_59\JJ|that (l_prep) to_60\IN|NONE (l_pobj) calcification_65\NN|NONE
D010710_D061205 NONE phosphate_18\NN|higher (r_compound) levels_19\NNS|NONE (r_pobj) to_15\IN|could|susceptibility|be|that (r_prep) related_14\VBN|observation|. (l_nsubjpass) susceptibility_5\NN|could|to|be|that (l_prep) to_6\IN|increased (l_pobj) calcification_11\NN|NONE
D002118_D002114 NONE calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|by|is|best|probably|. (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|had|is|best|probably|. (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D014807_D061205 NONE D._11\NNP|vitamin|and (r_conj) growth_8\NN|NONE (r_pobj) by_7\IN|is|calcification (r_agent) accelerated_6\VBN|NONE (l_nsubjpass) calcification_4\NN|is|by
D014807_D061205 NONE D_8\JJ|and (r_conj) growth_5\NN|NONE (r_nmod) treatment_9\NN|given|that|extent (r_nsubj) enhance_10\VB|studies|. (l_dobj) extent_12\NN|given|treatment|that (l_prep) of_13\IN|the (l_pobj) calcification_15\NN|NONE
D014807_D061205 NONE D_11\NN|NONE (r_pobj) between_9\IN|the|possible|in (r_prep) synergy_8\NN|.|set (l_prep) in_14\IN|the|possible|between (l_pobj) calcification_16\NN|NONE
D014807_D061205 NONE D_4\NNP|NONE (r_pobj) of_2\IN|High (r_prep) doses_1\NNS|cause|.|are (r_nsubjpass) known_6\VBN|NONE (l_xcomp) cause_8\VB|.|doses|are (l_dobj) calcification_9\NN|in|to (l_prep) of_10\IN|NONE (l_pobj) media_13\NNS|NONE (l_compound) artery_12\NN|the
D014807_D061205 NONE D_10\NN|on (r_compound) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D014807_D061205 NONE D_10\NN|on (r_compound) dose_11\NN|NONE (r_pobj) of_8\IN|the|and|effect (r_prep) effect_7\NN|NONE (l_conj) effect_17\NN|the|and|of (l_prep) of_18\IN|the (l_pobj) dose_21\NN|NONE (l_prep) on_22\IN|D (l_pobj) elevation_24\NN|NONE (l_relcl) suggests_30\VBZ|,|the|of (l_ccomp) induce_35\VB|which (l_dobj) calcification_37\NN|that|through|D|may
D014807_D061205 NONE D_20\NNP|on (r_compound) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|and|of (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|and|effect (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D014807_D061205 NONE D_20\NNP|on (r_compound) dose_21\NN|NONE (l_prep) on_22\IN|D (l_pobj) elevation_24\NN|NONE (l_relcl) suggests_30\VBZ|,|the|of (l_ccomp) induce_35\VB|which (l_dobj) calcification_37\NN|that|through|D|may
D014807_D061205 NONE D_33\NN|that|through|calcification|may (r_nsubj) induce_35\VB|which (r_ccomp) suggests_30\VBZ|,|the|of (r_relcl) elevation_24\NN|NONE (r_pobj) on_22\IN|D (r_prep) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|and|of (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|and|effect (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D014807_D061205 NONE D_33\NN|that|through|calcification|may (r_nsubj) induce_35\VB|which (l_dobj) calcification_37\NN|that|through|D|may
D014807_D061205 NONE D_18\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|artery (r_prep) calcification_12\NN|NONE
D014859_D002114 NONE Warfarin_22\NNP|NONE (r_pobj) of_21\IN|sufficient (r_prep) doses_20\NNS|inhibit (r_dobj) given_18\VBN|treatment|that|extent (l_advcl) inhibit_24\VB|doses (l_dobj) carboxylation_27\NN|to (l_prep) of_28\IN|gamma| (l_pobj) protein_31\NN|NONE (l_appos) inhibitor_35\NN|,|matrix|Gla (l_compound) calcification_34\NN|known
D014859_D002114 NONE Warfarin_5\NNP|NONE (r_pobj) with_4\IN|for (r_prep) Treatment_0\NN|.|calcification (r_nsubj) caused_6\VBD|NONE (l_dobj) calcification_9\NN|Treatment|. (l_conj) calcification_23\NN|massive|and|in|focal|of
D014859_D002114 NONE Warfarin_17\NNP|concurrent (r_compound) administration_18\NN|that|extent|dramatically (r_nsubj) increased_20\VBD|NONE (l_dobj) extent_22\NN|that|administration|dramatically (l_prep) of_23\IN|the (l_pobj) calcification_24\NN|NONE
D014859_D002114 NONE Warfarin_1\NNP|NONE (r_compound) treatment_2\NN|Because|effect (r_nsubj) had_3\VBD|by|is|best|probably|. (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|had|is|best|probably|. (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D014859_D002114 NONE Warfarin_20\NNP|NONE (r_nmod) D_23\NN|NONE (r_pobj) between_19\IN|the (r_prep) synergy_18\NN|vitamin|, (r_appos) D_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) produced_12\VBN|serum (r_acl) calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|by|is|best|probably|. (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|had|is|best|probably|. (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D014859_D002114 NONE Warfarin_32\NNP|activity|as|that (r_nsubj) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D002118_D061205 NONE calcium_27\NN|NONE (r_pobj) of_25\IN|,|the|suggests (r_prep) elevation_24\NN|NONE (r_pobj) on_22\IN|D (r_prep) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|and|of (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|and|effect (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D002118_D061205 NONE calcium_27\NN|NONE (r_pobj) of_25\IN|,|the|suggests (r_prep) elevation_24\NN|NONE (l_relcl) suggests_30\VBZ|,|the|of (l_ccomp) induce_35\VB|which (l_dobj) calcification_37\NN|that|through|D|may
D002118_D061205 NONE calcium_43\NN|NONE (r_pobj) on_41\IN|its (r_prep) effect_40\NN|NONE (r_pobj) through_38\IN|that|calcification|D|may (r_prep) induce_35\VB|which (r_ccomp) suggests_30\VBZ|,|the|of (r_relcl) elevation_24\NN|NONE (r_pobj) on_22\IN|D (r_prep) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|and|of (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|and|effect (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D002118_D061205 NONE calcium_43\NN|NONE (r_pobj) on_41\IN|its (r_prep) effect_40\NN|NONE (r_pobj) through_38\IN|that|calcification|D|may (r_prep) induce_35\VB|which (l_dobj) calcification_37\NN|that|through|D|may
D015055_D061205 NONE carboxylated_36\JJ|protein|indeed|that (r_acomp) was_31\VBD|.|analysis (r_ccomp) showed_25\VBD|,|and|levels|are|at (r_conj) found_7\VBN|NONE (l_prep) at_8\IN|,|and|levels|showed|are (l_pobj) sites_9\NNS|NONE (l_prep) of_10\IN|NONE (l_pobj) calcification_12\NN|NONE
18004067
D000082_D056486 CID paracetamol_15\JJ|NONE (r_pobj) of_14\IN|therapeutic (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|NONE (r_acl) hepatotoxicity_9\NN|NONE
D000082_D056486 CID acetaminophen_17\NN|(|) (r_appos) paracetamol_15\JJ|NONE (r_pobj) of_14\IN|therapeutic (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|NONE (r_acl) hepatotoxicity_9\NN|NONE
D000082_D056486 CID paracetamol_15\NN|NONE (r_pobj) of_14\IN|therapeutic (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) treated_10\VBN|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|the|of (r_prep) development_5\NN|NONE (l_prep) of_6\IN|the|in (l_pobj) hepatotoxicity_7\NN|NONE
D000082_D017114 NONE paracetamol_11\NN|at (r_dobj) ingesting_10\VBG|regular|alcohol (r_acl) consumption_9\NN|NONE (r_pobj) with_6\IN|two (r_prep) patients_5\NNS|NONE (r_pobj) in_3\IN|.|liver|Acute (r_prep) failure_2\NN|NONE
D000431_D017114 NONE alcohol_8\NN|ingesting|regular (r_compound) consumption_9\NN|NONE (r_pobj) with_6\IN|two (r_prep) patients_5\NNS|NONE (r_pobj) in_3\IN|.|liver|Acute (r_prep) failure_2\NN|NONE
D000431_D056486 NONE alcohol_4\NN|NONE (r_pobj) of_3\IN|possible|The|in (r_prep) role_2\NN|.|currently|is (l_prep) in_5\IN|possible|The|of (l_pobj) development_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) hepatotoxicity_9\NN|NONE
D000082_D017093 CID paracetamol_32\JJ|NONE (r_advmod) 4_30\CD|/ (r_nummod) day_34\NN|NONE (r_pobj) with_29\IN|being|while (r_prep) treated_28\VBN|consumption (r_advcl) stopping_23\VBG|who|within|and|failure (r_conj) developed_12\VBD|and|consumers|who (l_dobj) failure_14\NN|stopping|who|within|and
D000431_D017093 NONE alcohol_9\NN|NONE (r_pobj) of_8\IN|regular (r_prep) consumers_7\NNS|and|developed|who (r_attr) were_5\VBD| (l_conj) developed_12\VBD|and|consumers|who (l_dobj) failure_14\NN|stopping|who|within|and
D000431_D017093 NONE alcohol_24\NN|NONE (r_compound) consumption_25\NN|treated (r_dobj) stopping_23\VBG|who|within|and|failure (r_conj) developed_12\VBD|and|consumers|who (l_dobj) failure_14\NN|stopping|who|within|and
D000431_D017093 NONE alcohol_10\NN|NONE (r_pobj) of_9\IN|regular|e.g. (r_prep) consumption_8\NN|,|risk (r_appos) factors_4\NNS|NONE (r_pobj) with_2\IN|NONE (r_prep) patients_1\NNS|NONE (r_pobj) In_0\IN|.|ingested|,|possible|failure (r_prep) is_14\VBZ|NONE (l_nsubj) failure_13\NN|In|.|ingested|,|possible
17439425
D003907_D015431 CID Dex_0\NNP|+/|;|mmHg|SBP|P|. (r_nsubj) increased_1\VBD|NONE (l_dep) P_13\NN|Dex|+/|;|mmHg|SBP|. (l_conj) decreased_18\VBN|.|)|and (l_dobj) thymus_19\NN|NONE (l_conj) bodyweights_26\NNS|P|and|(|)
D019820_D006973 NONE xanthine_2\NN|NONE (r_compound) oxidase_3\NN|NONE (r_pobj) of_1\IN|in|. (r_prep) Role_0\NN|NONE (l_prep) in_4\IN|of|. (l_pobj) hypertension_8\NN|NONE
D019820_D006973 NONE xanthine_5\NN|implicated|,|XO|, (r_compound) oxidase_6\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) role_3\NN|We|. (l_prep) in_22\IN|the|of (l_pobj) hypertension_26\NN|NONE
D019820_D006973 NONE xanthine_5\NN|implicated|,|XO|, (r_compound) oxidase_6\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) role_3\NN|We|. (l_prep) in_22\IN|the|of (l_pobj) hypertension_26\NN|NONE (l_appos) HT_30\NNP|induced
D000493_D006973 NONE Allopurinol_0\NNP|not|.|HT|did (r_nsubj) prevent_3\VB|NONE (l_dobj) HT_6\NNP|not|Allopurinol|.|did
D000493_D006973 NONE allopurinol_8\NN|that|prevent (r_nsubj) failed_9\VBD|previous|our (r_acl) findings_6\NNS|together (r_pobj) with_3\IN|,|This|hypertension (r_prep) induced_14\VBN|.|is|, (l_dobj) hypertension_15\NN|,|This|with
D000493_D006973 NONE allopurinol_8\NN|that|prevent (r_nsubj) failed_9\VBD|previous|our (r_acl) findings_6\NNS|together (r_pobj) with_3\IN|,|This|hypertension (r_prep) induced_14\VBN|.|is|, (r_ccomp) suggests_17\VBZ|NONE (l_ccomp) is_21\VBZ|.|induced|, (l_attr) determinant_25\NN|activity|not|that (l_prep) of_26\IN|major|a|in (l_pobj) HT_29\NNP|NONE
D003907_D006973 CID dexamethasone_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) hypertension_8\NN|NONE
D003907_D006973 CID dexamethasone_23\NN| (r_npadvmod) induced_25\VBN|HT (r_amod) hypertension_26\NN|NONE
D003907_D006973 CID dexamethasone_23\NN| (r_npadvmod) induced_25\VBN|HT (r_amod) hypertension_26\NN|NONE (l_appos) HT_30\NNP|induced
D003907_D006973 CID dex_28\NN|)|(| (r_compound) HT_30\NNP|induced (r_appos) hypertension_26\NN|NONE
D003907_D006973 CID dex_28\NN|)|(| (r_compound) HT_30\NNP|induced
D003907_D006973 CID Dex_0\NNP|+/|;|mmHg|SBP|P|. (r_nsubj) increased_1\VBD|NONE (l_dobj) SBP_2\NNP|Dex|+/|;|mmHg|P|.
D003907_D006973 CID dex_4\NN| (r_compound) HT_6\NNP|not|Allopurinol|.|did
D009569_D006973 NONE oxide_16\NN| (r_compound) redox_18\NN|nitric (r_compound) imbalance_19\NN|NONE (r_pobj) with_14\IN|is|.|hypertension (r_prep) associated_13\VBN|NONE (l_nsubjpass) hypertension_3\NN|is|.|with
D009569_D006973 NONE oxide_16\NN| (r_compound) redox_18\NN|nitric (r_compound) imbalance_19\NN|NONE (r_pobj) with_14\IN|is|.|hypertension (r_prep) associated_13\VBN|NONE (l_nsubjpass) hypertension_3\NN|is|.|with (l_appos) HT_7\NNP|induced|in
18996674
D003042_D011317 CID cocaine_9\NN|an|frequent|admitted (r_compound) user_10\NN|old|,|,|A (r_appos) man_4\NN|.|on|to (r_nsubj) presented_12\VBN|NONE (l_prep) on_20\IN|man|.|to (l_pobj) occasions_23\NNS|NONE (l_prep) with_24\IN|separate|two (l_pobj) history_26\NN|NONE (l_prep) of_27\IN|after|a (l_pobj) priapism_28\NN|NONE
D003042_D011317 CID cocaine_30\NN|NONE (r_compound) use_31\NN|NONE (r_pobj) after_29\IN|of|a (r_prep) history_26\NN|NONE (l_prep) of_27\IN|after|a (l_pobj) priapism_28\NN|NONE
D004837_D011317 NONE epinephrine_1\NN|NONE (l_appos) treatment_6\NN|:|Intracavernous|. (l_prep) for_7\IN|a|invasive (l_pobj) priapism_8\NN|NONE
9653867
D013974_D013971 CID Thyroxine_0\NNP|:|.|case (r_compound) abuse_1\NN|NONE (l_appos) case_5\NN|:|Thyroxine|. (l_prep) of_6\IN|unusual|an (l_pobj) thyrotoxicosis_7\NN|NONE
D013974_D013971 CID thyroxine_28\NN|NONE (r_compound) abuse_29\NN|and|explored|,|should|remains|be|that (r_nsubjpass) considered_32\VBN|us (l_advcl) remains_25\VBZ|and|explored|,|should|abuse|be|that (l_nsubj) cause_22\NN|obscure|when (l_prep) for_23\IN|a (l_pobj) thyrotoxicosis_24\NN|NONE
D013974_D001068 NONE thyroxine_28\NN|NONE (r_compound) abuse_29\NN|and|explored|,|should|remains|be|that (r_nsubjpass) considered_32\VBN|us (r_ccomp) reminds_17\VBZ|In|derangements|it|and|. (r_conj) illustrates_3\VBZ|NONE (l_dobj) derangements_5\NNS|In|it|and|.|reminds (l_prep) of_6\IN|the (l_pobj) function_8\NN|NONE (l_acl) seen_9\VBN|thyroid (l_prep) with_13\IN|in (l_pcomp) eating_14\VBG|NONE (l_dobj) disorders_15\NNS|NONE
2348231
D010431_D006940 NONE Pentoxifylline_0\NNP|does|not|hyperemia|. (r_nsubj) inhibit_6\VB|NONE (l_dobj) hyperemia_11\NN|Pentoxifylline|does|not|.
D010431_D006940 NONE Trental_2\NNP|(|) (r_appos) Pentoxifylline_0\NNP|does|not|hyperemia|. (r_nsubj) inhibit_6\VB|NONE (l_dobj) hyperemia_11\NN|Pentoxifylline|does|not|.
D010431_D006940 NONE pentoxifylline_1\NN|hyperemia|and|stopped (r_nsubj) inhibits_2\VBZ|unknown|. (l_dobj) hyperemia_7\NN|and|stopped|pentoxifylline
D010431_D006940 NONE pentoxifylline_3\NN|NONE (r_pobj) of_2\IN|Neither (r_prep) dose_1\NN|less|.|peak|,|significantly|)|hyperemia (r_nsubj) decreased_5\VBD|NONE (l_dobj) hyperemia_10\NN|dose|less|.|peak|,|significantly|)
D010431_D006940 NONE pentoxyifylline_3\NN|not|does|hyperemia|that|at (r_nsubj) inhibit_6\VB|We|. (l_dobj) hyperemia_11\NN|not|does|that|pentoxyifylline|at
D013793_D006940 NONE thallium-201_17\NN|myocardial (r_nmod) imaging_19\NN|NONE (r_pobj) for_14\IN|NONE (r_prep) implications_13\NNS|coronary|induced|: (r_appos) hyperemia_11\NN|Pentoxifylline|does|not|.
D013793_D006940 NONE thallium-201_22\NN|NONE (r_compound) imaging_23\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|should|be (r_advmod) stopped_17\VBN|hyperemia|and|pentoxifylline (r_conj) inhibits_2\VBZ|unknown|. (l_dobj) hyperemia_7\NN|and|stopped|pentoxifylline
C008514_D007383 NONE methylxanthine_12\NN|improve|a (r_compound) derivative_13\NN|Many|are|pentoxifylline|)|(|Trental|,|. (l_relcl) improve_16\VB|methylxanthine|a (l_dobj) claudication_18\NN|which|may
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|coronary|implications|: (r_amod) hyperemia_11\NN|Pentoxifylline|does|not|.
D004176_D006940 CID dipyridamole_15\JJ| (r_npadvmod) thallium-201_17\NN|myocardial (r_nmod) imaging_19\NN|NONE (r_pobj) for_14\IN|NONE (r_prep) implications_13\NNS|coronary|induced|: (r_appos) hyperemia_11\NN|Pentoxifylline|does|not|.
D004176_D006940 CID dipyridamole_3\NN| (r_dep) induced_5\VBN|like|coronary (r_amod) hyperemia_7\NN|and|stopped|pentoxifylline
D004176_D006940 CID dipyridamole_20\NN| (r_compound) thallium-201_22\NN|NONE (r_compound) imaging_23\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|should|be (r_advmod) stopped_17\VBN|hyperemia|and|pentoxifylline (r_conj) inhibits_2\VBZ|unknown|. (l_dobj) hyperemia_7\NN|and|stopped|pentoxifylline
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|the (r_amod) hyperemia_10\NN|dose|less|.|peak|,|significantly|)
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|coronary (r_amod) hyperemia_11\NN|not|does|that|pentoxyifylline|at
D013806_D006940 NONE theophylline_13\NN|such (r_pobj) as_12\IN|other (r_prep) methylxanthines_10\NNS|NONE (r_pobj) like_8\IN|induced|coronary (r_prep) hyperemia_7\NN|and|stopped|pentoxifylline
D013806_D006940 NONE theophylline_21\NN|NONE (r_pobj) after_20\IN|flow|lower (r_prep) was_17\VBD|while (r_ccomp) peak_13\JJ|dose|less|.|,|significantly|)|hyperemia (r_advcl) decreased_5\VBD|NONE (l_dobj) hyperemia_10\NN|dose|less|.|peak|,|significantly|)
C008514_D006940 NONE methylxanthines_10\NNS|NONE (r_pobj) like_8\IN|induced|coronary (r_prep) hyperemia_7\NN|and|stopped|pentoxifylline
D010431_D007383 CID pentoxifylline_6\NN|Many|are|)|(|Trental|,|.|derivative (r_dobj) taking_5\VBG|NONE (l_conj) derivative_13\NN|Many|are|pentoxifylline|)|(|Trental|,|. (l_relcl) improve_16\VB|methylxanthine|a (l_dobj) claudication_18\NN|which|may
D010431_D007383 CID Trental_8\NNP|Many|are|pentoxifylline|)|(|,|.|derivative (r_npadvmod) taking_5\VBG|NONE (l_conj) derivative_13\NN|Many|are|pentoxifylline|)|(|Trental|,|. (l_relcl) improve_16\VB|methylxanthine|a (l_dobj) claudication_18\NN|which|may
10807237
D003042_D017542 CID Cocaine_0\NN|NONE (r_compound) use_1\NN|at|.|rupture (r_nsubj) predisposed_2\VBN|NONE (l_dobj) rupture_4\NN|use|at|.
D003042_D000783 NONE cocaine_12\NN| (r_npadvmod) related_14\VBN|NONE (r_amod) aneurysms_15\NNS|NONE
D003042_D000783 NONE cocaine_25\NN| (r_npadvmod) related_27\VBN|NONE (r_amod) aneurysms_28\NNS|NONE
D003042_D000783 NONE Cocaine_0\NN|NONE (r_compound) use_1\NN|at|.|rupture (r_nsubj) predisposed_2\VBN|NONE (l_prep) at_5\IN|use|.|rupture (l_conj) in_11\IN|age|and (l_pobj) aneurysms_14\NNS|NONE
3865016
D005047_D017254 NONE etoposide_4\NN|NONE (r_nmod) A_7\NNP|NONE (r_pobj) of_3\IN|concomitant|The (r_prep) administration_2\NN|in|. (r_nsubj) resulted_8\VBD|NONE (l_prep) in_9\IN|administration|. (l_pobj) eradication_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) infiltration_15\NN|NONE
D016572_D054218 NONE A_7\NNP|NONE (r_pobj) of_3\IN|synergistic|A (r_prep) effect_2\NN|in|in|was|. (r_nsubjpass) observed_9\VBN|NONE (l_prep) in_10\IN|in|was|.|effect (l_pobj) patient_12\NN|NONE (l_prep) with_13\IN|a (l_pobj) leukemia_18\NN|NONE
D016572_D017254 NONE A_7\NNP|NONE (r_pobj) of_3\IN|concomitant|The (r_prep) administration_2\NN|in|. (r_nsubj) resulted_8\VBD|NONE (l_prep) in_9\IN|administration|. (l_pobj) eradication_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) infiltration_15\NN|NONE
D005047_D054218 NONE etoposide_4\NN|NONE (r_nmod) A_7\NNP|NONE (r_pobj) of_3\IN|synergistic|A (r_prep) effect_2\NN|in|in|was|. (r_nsubjpass) observed_9\VBN|NONE (l_prep) in_10\IN|in|was|.|effect (l_pobj) patient_12\NN|NONE (l_prep) with_13\IN|a (l_pobj) leukemia_18\NN|NONE
3192036
10791295
D001058_D010554 CID apomorphine_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Development_0\NN|.|:||comparison|behavior (r_nsubj) induced_4\VBN|NONE (l_dobj) behavior_6\NN|.|:||comparison|Development
D001058_D010554 CID apomorphine_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) development_1\NN||.|)|daily|studied|s.c.|behavior (r_nsubj) induced_5\VBN|NONE (l_dobj) behavior_14\NN||.|development|)|daily|studied|s.c.
D001058_D010554 CID apomorphine_5\NN|repeated (r_compound) treatment_6\NN|development|In|evidenced|.|, (r_nsubj) induced_7\VBD|NONE (l_dobj) development_10\NN|In|treatment|evidenced|.|, (l_prep) of_11\IN|gradual|a (l_pobj) behavior_13\NN|NONE
D001058_D010554 CID apomorphine_5\NN|repeated (r_compound) treatment_6\NN|development|In|evidenced|.|, (r_nsubj) induced_7\VBD|NONE (l_advcl) evidenced_15\VBN|development|In|treatment|.|, (l_agent) by_16\IN|and|shortened|as (l_pobj) intensity_19\NN|NONE (l_prep) of_20\IN|the|increased (l_pobj) aggressiveness_21\NN|NONE
D001058_D010554 CID apomorphine_14\NN|NONE (r_preconj) the_13\DT|aggressive|induced (r_det) behavior_18\NN|NONE
1992636
D009853_D000743 CID omeprazole_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) use_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Hemolytic (r_acl) anemia_1\NN|NONE
D009853_D000743 CID omeprazole_17\NN|NONE (r_pobj) of_16\IN|the (r_prep) use_15\NN|NONE (r_pobj) with_13\IN|serious|a|adverse|term (r_prep) reaction_12\NN|NONE (r_pobj) of_5\IN|first|the|:|anemia (r_prep) case_4\NN|We|. (l_appos) anemia_20\NN|first|of|the|:
D009853_D000743 CID omeprazole_4\NN|by|is (r_nsubj) caused_5\VBD|The|alerted|but|, (l_ccomp) is_11\VBZ|by|omeprazole (l_nsubj) anemia_10\NN|uncertain
D009853_D053609 CID omeprazole_17\NN|NONE (r_pobj) with_16\IN|therapy (r_prep) starting_14\VBG|days (r_pcomp) after_13\IN|.|developed|,|lethargy (r_prep) weakness_3\NN|NONE (l_conj) lethargy_5\NN|.|developed|,|after
D009853_D004417 CID omeprazole_17\NN|NONE (r_pobj) with_16\IN|therapy (r_prep) starting_14\VBG|days (r_pcomp) after_13\IN|.|developed|,|lethargy (r_prep) weakness_3\NN|NONE (l_conj) lethargy_5\NN|.|developed|,|after (l_conj) shortness_8\NN|and|, (l_prep) of_9\IN|NONE (l_pobj) breath_10\NN|NONE
9660111
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ|the (r_poss) head_23\NN|in (r_compound) twitches_24\NNS|does|not (r_dobj) potentiate_20\VB|not|In|and|.|hypothermia|TRI|does|in (r_conj) antagonize_11\VB|NONE (l_dobj) hypothermia_14\VBN|not|In|and|.|TRI|does|in|potentiate
D003000_D010554 NONE clonidine_28\NN|NONE (r_pobj) by_27\IN|in (r_agent) evoked_26\VBN|the (r_acl) aggressiveness_25\NN|in|as
D014299_D006948 CID TRI_0\NNP|hyperactivity|. (r_nsubj) increases_5\VBZ|NONE (l_dobj) hyperactivity_8\NN|TRI|.
D003913_D006948 CID amphetamine_13\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|locomotor|the (r_acl) hyperactivity_8\NN|TRI|.
D012110_D007035 CID reserpine_13\NN|the (r_compound) hypothermia_14\VBN|not|In|and|.|TRI|does|in|potentiate
D010656_D010554 NONE phenylephrine_7\NN|NONE (l_acl) evaluated_15\VBN|given (l_conj) aggressiveness_25\NN|in|as
D019257_D006948 CID quinpirole_15\NN|d|,| (r_conj) amphetamine_13\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|locomotor|the (r_acl) hyperactivity_8\NN|TRI|.
D004298_D006948 NONE dopamine_24\NN|and|effects (r_compound) D2_25\NN|)|)|(||hydroxy (r_appos) dipropyloaminotetralin_22\NN|(|+|and (r_conj) quinpirole_15\NN|d|,| (r_conj) amphetamine_13\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|locomotor|the (r_acl) hyperactivity_8\NN|TRI|.
D014299_D007035 NONE TRI_4\NNP|not|In|and|.|hypothermia|does|in|potentiate (r_nsubj) antagonize_11\VB|NONE (l_dobj) hypothermia_14\VBN|not|In|and|.|TRI|does|in|potentiate
19211690
D017673_D006973 NONE salt_11\NN| (r_npadvmod) sensitive_13\JJ|Dahl (r_amod) rats_14\NNS|NONE (r_pobj) in_9\IN|of (r_prep) upregulation_5\NN|dependent|and|. (r_conj) hypertension_3\NN|NONE
D000809_D006973 NONE angiotensin_25\NN|intrarenal|the (r_compound) system_26\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) upregulation_19\NN|possibly (r_pobj) through_18\IN|Testosterone|.|to (r_prep) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE
D013739_D006973 NONE Testosterone_0\NN| (r_npadvmod) dependent_2\JJ|and|upregulation|. (r_amod) hypertension_3\NN|NONE
D013739_D006973 NONE Testosterone_0\NN|.|through|to (r_nsubj) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE
D000809_D007674 NONE angiotensin_25\NN|intrarenal|the (r_compound) system_26\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) upregulation_19\NN|possibly (r_pobj) through_18\IN|Testosterone|.|to (r_prep) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE (l_conj) injury_9\NN|in|and
D013739_D007674 NONE testosterone_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) mediated_22\VBN|intrarenal (r_acl) angiotensinogen_21\NN|NONE (r_pobj) of_19\IN|induced (r_prep) upregulation_18\NN|NONE (r_pobj) in_14\IN|sexual|a|causes (r_prep) dimorphism_13\NN|there|that (l_relcl) causes_27\VBZ|sexual|a|in (l_dobj) increases_28\NNS|also|that (l_prep) in_29\IN|NONE (l_pobj) BP_30\NNP|NONE (l_conj) injury_33\NN|and
D013739_D007674 NONE Testosterone_0\NN|in (r_compound) replacement_1\NN|.|BP (r_nsubj) increased_6\VBD|NONE (l_npadvmod) BP_7\NNP|.|replacement (l_appos) injury_10\NN|,
D013739_D007674 NONE Testosterone_0\NN|.|through|to (r_nsubj) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE (l_conj) injury_9\NN|in|and
18410508
D015632_D009422 CID MPTP_17\NNP| (r_npadvmod) induced_19\VBN|of (r_amod) neurodegeneration_20\NN|NONE
D015632_D009422 CID MPTP_8\NNP|and (r_conj) METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective
D008694_D020258 NONE Methamphetamine_0\NN| (r_npadvmod) induced_2\VBN|neurotoxicity (r_amod) activation_6\NN|by|.|are|not (l_nmod) neurotoxicity_3\NN|induced
D008694_D020258 NONE METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|plays|.|, (l_prep) for_12\IN|Because|damage|selective (l_pobj) system_16\NN|NONE (l_prep) in_17\IN|DA|the|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D008694_D020258 NONE METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|plays|.|, (r_advcl) hypothesized_24\VBD|NONE (l_ccomp) plays_28\VBZ|is|we|.|, (l_dobj) role_30\NN|that|CXCR (l_prep) in_31\IN|a (l_pobj) neurotoxicity_35\NN|NONE
D008694_D020258 NONE METH_32\NNP| (r_npadvmod) induced_34\VBN|activation|and (r_amod) neurotoxicity_35\NN|NONE (r_pobj) in_31\IN|a (r_prep) role_30\NN|that|CXCR (r_dobj) plays_28\VBZ|is|we|.|, (r_ccomp) hypothesized_24\VBD|NONE (l_advcl) is_9\VBZ|we|plays|.|, (l_prep) for_12\IN|Because|damage|selective (l_pobj) system_16\NN|NONE (l_prep) in_17\IN|DA|the|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D008694_D020258 NONE METH_32\NNP| (r_npadvmod) induced_34\VBN|activation|and (r_amod) neurotoxicity_35\NN|NONE
D008694_D020258 NONE METH_25\NNP|NONE (r_pobj) with_24\IN|Mice|.|and|were|examined (r_prep) treated_23\VBN|NONE (l_conj) examined_27\VBN|Mice|.|and|were|with (l_prep) for_28\IN|NONE (l_pobj) neurotoxicity_30\NN|NONE
D008694_D020258 NONE METH_11\NNP|activation|or (r_compound) neurotoxicity_12\NN|signaling|that|does|not
D004298_D009422 NONE DA_22\NNP|NONE (r_compound) neurons_23\NNS|NONE (r_pobj) of_21\IN|induced (r_prep) neurodegeneration_20\NN|NONE
D004298_D009422 NONE DA_14\NNP|in|the|neuronal (r_compound) system_16\NN|NONE (r_pobj) for_12\IN|Because|damage|selective (r_prep) is_9\VBZ|we|plays|.|, (l_nsubj) damage_3\NN|for|Because|selective
D004298_D020258 NONE DA_14\NNP|in|the|neuronal (r_compound) system_16\NN|NONE (l_prep) in_17\IN|DA|the|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D004298_D020258 NONE DA_14\NNP|in|the|neuronal (r_compound) system_16\NN|NONE (r_pobj) for_12\IN|Because|damage|selective (r_prep) is_9\VBZ|we|plays|.|, (r_advcl) hypothesized_24\VBD|NONE (l_ccomp) plays_28\VBZ|is|we|.|, (l_dobj) role_30\NN|that|CXCR (l_prep) in_31\IN|a (l_pobj) neurotoxicity_35\NN|NONE
D008694_D009422 CID METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective
D008694_D009422 CID METH_32\NNP| (r_npadvmod) induced_34\VBN|activation|and (r_amod) neurotoxicity_35\NN|NONE (r_pobj) in_31\IN|a (r_prep) role_30\NN|that|CXCR (r_dobj) plays_28\VBZ|is|we|.|, (r_ccomp) hypothesized_24\VBD|NONE (l_advcl) is_9\VBZ|we|plays|.|, (l_nsubj) damage_3\NN|for|Because|selective
D015632_D020258 NONE MPTP_8\NNP|and (r_conj) METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|plays|.|, (l_prep) for_12\IN|Because|damage|selective (l_pobj) system_16\NN|NONE (l_prep) in_17\IN|DA|the|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D015632_D020258 NONE MPTP_8\NNP|and (r_conj) METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|plays|.|, (r_advcl) hypothesized_24\VBD|NONE (l_ccomp) plays_28\VBZ|is|we|.|, (l_dobj) role_30\NN|that|CXCR (l_prep) in_31\IN|a (l_pobj) neurotoxicity_35\NN|NONE
10743446
D002211_D006930 CID capsaicin_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|of|.|Differential (r_acl) effects_1\NNS|NONE (l_prep) of_2\IN|.|Differential|induced (l_pobj) ketamine_5\NN|NONE (l_prep) on_8\IN|administered|and|lidocaine (l_pobj) hyperalgesia_12\NN|NONE
D002211_D006930 CID capsaicin_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|of|the (r_acl) effect_4\NN|.|have|We (l_prep) of_5\IN|induced|the (l_pobj) administration_7\NN|NONE (l_prep) on_12\IN|systemic|of (l_pobj) hyperalgesia_27\NN|NONE
D008012_D010146 NONE lidocaine_11\NN|and (r_conj) ketamine_9\NN|NONE (r_pobj) of_8\IN|systemic|on (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|systemic|of (l_pobj) hyperalgesia_27\NN|NONE (l_nmod) pain_19\NN|evoked|(|static|)
D007649_D006930 NONE ketamine_5\NN|NONE (l_prep) on_8\IN|administered|and|lidocaine (l_pobj) hyperalgesia_12\NN|NONE
D007649_D006930 NONE ketamine_9\NN|NONE (r_pobj) of_8\IN|systemic|on (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|systemic|of (l_pobj) hyperalgesia_27\NN|NONE
D007649_D006930 NONE Ketamine_0\NN|area|significantly|tended|and (r_nsubj) reduced_1\VBD|NONE (l_dobj) area_4\NN|Ketamine|significantly|tended|and (l_prep) of_5\IN|both|the (l_pobj) hyperalgesia_13\NN|NONE
D007649_D006930 NONE ketamine_4\NN|NONE (r_pobj) of_3\IN|on|The|differential (r_prep) effects_2\NNS|mediated|. (l_prep) on_7\IN|The|differential|of (l_pobj) hyperalgesia_11\NN|NONE
D007649_D006930 NONE ketamine_4\NN|NONE (r_pobj) of_3\IN|on|The|differential (r_prep) effects_2\NNS|mediated|. (r_nsubj) suggest_12\VBP|NONE (l_ccomp) mediated_20\VBN|.|effects (l_nsubjpass) types_16\NNS|that|and|by|have|are (l_prep) of_17\IN|the|two (l_pobj) hyperalgesia_18\NN|NONE
D008012_D006930 NONE lidocaine_7\NN|on|administered|and (r_conj) ketamine_5\NN|NONE (l_prep) on_8\IN|administered|and|lidocaine (l_pobj) hyperalgesia_12\NN|NONE
D008012_D006930 NONE lidocaine_11\NN|and (r_conj) ketamine_9\NN|NONE (r_pobj) of_8\IN|systemic|on (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|systemic|of (l_pobj) hyperalgesia_27\NN|NONE
D008012_D006930 NONE Lidocaine_0\NN|area|significantly|. (r_nsubj) reduced_1\VBD|NONE (l_dobj) area_3\NN|significantly|.|Lidocaine (l_prep) of_4\IN|the (l_pobj) hyperalgesia_8\NN|NONE
D008012_D006930 NONE lidocaine_6\NN|and (r_conj) ketamine_4\NN|NONE (r_pobj) of_3\IN|on|The|differential (r_prep) effects_2\NNS|mediated|. (l_prep) on_7\IN|The|differential|of (l_pobj) hyperalgesia_11\NN|NONE
D008012_D006930 NONE lidocaine_6\NN|and (r_conj) ketamine_4\NN|NONE (r_pobj) of_3\IN|on|The|differential (r_prep) effects_2\NNS|mediated|. (r_nsubj) suggest_12\VBP|NONE (l_ccomp) mediated_20\VBN|.|effects (l_nsubjpass) types_16\NNS|that|and|by|have|are (l_prep) of_17\IN|the|two (l_pobj) hyperalgesia_18\NN|NONE
D002211_D010146 CID capsaicin_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|of|the (r_acl) effect_4\NN|.|have|We (l_prep) of_5\IN|induced|the (l_pobj) administration_7\NN|NONE (l_prep) on_12\IN|systemic|of (l_pobj) hyperalgesia_27\NN|NONE (l_nmod) pain_19\NN|evoked|(|static|)
D007649_D010146 NONE ketamine_9\NN|NONE (r_pobj) of_8\IN|systemic|on (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|systemic|of (l_pobj) hyperalgesia_27\NN|NONE (l_nmod) pain_19\NN|evoked|(|static|)
D007649_D010146 NONE Ketamine_0\NN|area|significantly|tended|and (r_nsubj) reduced_1\VBD|NONE (l_conj) tended_17\VBD|area|Ketamine|significantly|and (l_xcomp) reduce_19\VB|.|it (l_dobj) pain_23\NN|to
18442015
D004872_D014456 CID D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_conj) ulcer_37\NN|in|gastric|and
D002784_D050197 CID cholesterol_49\NN|and|vitamin (r_conj) D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_prep) in_38\IN|gastric|and|ulcer (l_pobj) rats_39\NNS|NONE (l_prep) with_40\IN|NONE (l_pobj) atherosclerosis_41\NN|NONE
D002784_D050197 CID cholesterol_23\NN|and|vitamin (r_conj) D2_21\NN|kg|induce (r_dobj) containing_19\VBG|NONE (l_advcl) induce_25\VB|kg|D (l_dobj) atherosclerosis_26\NN|to
D002784_D050197 CID cholesterol_10\NN|serum|, (r_conj) calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (l_amod) atherosclerotic_1\JJ|,|Elevated|as
D002784_D050197 CID cholesterol_10\NN|serum|, (r_conj) calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (r_nsubjpass) obtained_18\VBN|NONE (l_prep) in_19\IN|were|.|parameters (l_pobj) rats_21\NNS|NONE (l_amod) atherosclerotic_20\JJ|NONE
D002118_D050197 NONE calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (l_amod) atherosclerotic_1\JJ|,|Elevated|as
D002118_D050197 NONE calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (r_nsubjpass) obtained_18\VBN|NONE (l_prep) in_19\IN|were|.|parameters (l_pobj) rats_21\NNS|NONE (l_amod) atherosclerotic_20\JJ|NONE
D006632_D050197 NONE histamine_19\NN|,|mast|peroxide (r_compound) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_prep) in_38\IN|gastric|and|ulcer (l_pobj) rats_39\NNS|NONE (l_prep) with_40\IN|NONE (l_pobj) atherosclerosis_41\NN|NONE
D006632_D050197 NONE histamine_6\NN|NONE (r_pobj) of_5\IN|a|positive|to (r_prep) correlation_4\NN|.|Moreover|in|,|was (r_nsubjpass) found_14\VBN|NONE (l_prep) in_15\IN|.|Moreover|correlation|,|was (l_pobj) rats_18\NNS|NONE (l_amod) atherosclerotic_17\JJ|those
D006632_D050197 NONE histamine_18\NN|permeability|and (r_compound) release_19\NN|produce|ameliorated|,|.|,|LPO (r_conj) generation_16\NN|NONE (l_ccomp) produce_2\VB|ameliorated|,|.|release|,|LPO (l_nsubj) Atherosclerosis_0\NN|ulcer|via|could
D010634_D014456 NONE luminal_16\JJ|and|hemoglobin|areas (r_amod) content_18\NN|,|microvascular (l_conj) areas_21\NNS|and|hemoglobin|luminal (l_compound) ulcer_20\NN|NONE
D010634_D014456 NONE luminal_22\JJ|hemoglobin (r_amod) content_24\NN|and|LPO (r_conj) generation_20\NN|histamine|, (r_conj) release_17\NN|acid|,|back|gastric| (r_conj) diffusion_14\NN|NONE (r_pobj) including_9\VBG|ulcerogenic|,|increased (r_prep) factors_7\NNS|NONE (r_pobj) with_4\IN|ulcers (r_prep) accompanied_3\VBN|also|.|in|were (l_nsubj) ulcers_2\NNS|with
D006632_D014456 NONE histamine_19\NN|,|mast|peroxide (r_compound) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_conj) ulcer_37\NN|in|gastric|and
D006632_D014456 NONE histamine_10\NN|permeability|, (r_compound) concentration_11\NN|mucosal|LPO|, (l_conj) permeability_14\NN|histamine|, (l_conj) content_18\NN|,|microvascular (l_conj) areas_21\NNS|and|hemoglobin|luminal (l_compound) ulcer_20\NN|NONE
D006632_D014456 NONE histamine_16\NN|generation|, (r_compound) release_17\NN|acid|,|back|gastric| (r_conj) diffusion_14\NN|NONE (r_pobj) including_9\VBG|ulcerogenic|,|increased (r_prep) factors_7\NNS|NONE (r_pobj) with_4\IN|ulcers (r_prep) accompanied_3\VBN|also|.|in|were (l_nsubj) ulcers_2\NNS|with
D006632_D014456 NONE histamine_6\NN|NONE (r_pobj) of_5\IN|a|positive|to (r_prep) correlation_4\NN|.|Moreover|in|,|was (l_prep) to_7\IN|of|a|positive (l_conj) to_11\IN|and|hemorrhage (l_pobj) ulcer_12\NN|NONE
D006632_D014456 NONE histamine_18\NN|permeability|and (r_compound) release_19\NN|produce|ameliorated|,|.|,|LPO (r_conj) generation_16\NN|NONE (l_ccomp) produce_2\VB|ameliorated|,|.|release|,|LPO (l_dobj) ulcer_5\NN|Atherosclerosis|via|could
D002784_D014456 CID cholesterol_49\NN|and|vitamin (r_conj) D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_conj) ulcer_37\NN|in|gastric|and
D004872_D006471 CID D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE
D014700_D050197 NONE verapamil_3\NN|NONE (r_pobj) of_2\IN|.|on|Protective (r_prep) effect_1\NN|NONE (l_prep) on_4\IN|.|of|Protective (l_pobj) ulcers_7\NNS|NONE (l_prep) in_8\IN|gastric|hemorrhagic (l_pobj) rats_11\NNS|NONE (l_amod) atherosclerotic_10\JJ|severe
D014700_D050197 NONE verapamil_28\NN|NONE (r_pobj) by_27\IN|be|could|that|in (r_agent) ameliorated_26\VBN|produce|,|.|release|,|LPO (r_relcl) generation_16\NN|NONE (l_ccomp) produce_2\VB|ameliorated|,|.|release|,|LPO (l_nsubj) Atherosclerosis_0\NN|ulcer|via|could
D002784_D006471 CID cholesterol_49\NN|and|vitamin (r_conj) D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE
D014700_D006471 NONE verapamil_3\NN|NONE (r_pobj) of_2\IN|.|on|Protective (r_prep) effect_1\NN|NONE (l_prep) on_4\IN|.|of|Protective (l_pobj) ulcers_7\NNS|NONE (l_amod) hemorrhagic_6\JJ|gastric|in
D014700_D006471 NONE verapamil_15\NN|NONE (r_pobj) by_12\IN|dependently (r_agent) ameliorated_11\VBN|ulcer|. (r_acomp) were_7\VBD|NONE (l_nsubj) ulcer_2\NN|.|ameliorated (l_amod) hemorrhagic_1\JJ|parameters|and|This
D014700_D006471 NONE verapamil_28\NN|NONE (r_pobj) by_27\IN|be|could|that|in (r_agent) ameliorated_26\VBN|produce|,|.|release|,|LPO (r_relcl) generation_16\NN|NONE (l_ccomp) produce_2\VB|ameliorated|,|.|release|,|LPO (l_dobj) ulcer_5\NN|Atherosclerosis|via|could (l_amod) hemorrhagic_4\JJ|gastric
D004872_D050197 CID D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_prep) in_38\IN|gastric|and|ulcer (l_pobj) rats_39\NNS|NONE (l_prep) with_40\IN|NONE (l_pobj) atherosclerosis_41\NN|NONE
D004872_D050197 CID D2_21\NN|kg|induce (r_dobj) containing_19\VBG|NONE (l_advcl) induce_25\VB|kg|D (l_dobj) atherosclerosis_26\NN|to
D006632_D006471 NONE histamine_19\NN|,|mast|peroxide (r_compound) release_20\NN|by|, (l_conj) peroxide_23\NN|histamine|,|mast (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|generation|microvascular (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE
D006632_D006471 NONE histamine_6\NN|NONE (r_pobj) of_5\IN|a|positive|to (r_prep) correlation_4\NN|.|Moreover|in|,|was (l_prep) to_7\IN|of|a|positive (l_pobj) hemorrhage_9\NN|to|and
D006632_D006471 NONE histamine_18\NN|permeability|and (r_compound) release_19\NN|produce|ameliorated|,|.|,|LPO (r_conj) generation_16\NN|NONE (l_ccomp) produce_2\VB|ameliorated|,|.|release|,|LPO (l_dobj) ulcer_5\NN|Atherosclerosis|via|could (l_amod) hemorrhagic_4\JJ|gastric
D014700_D014456 NONE verapamil_3\NN|NONE (r_pobj) of_2\IN|.|on|Protective (r_prep) effect_1\NN|NONE (l_prep) on_4\IN|.|of|Protective (l_pobj) ulcers_7\NNS|NONE
D014700_D014456 NONE verapamil_6\NN|NONE (r_pobj) of_5\IN|the|on|protective (r_prep) effect_4\NN|was|,|.|Additionally (l_prep) on_7\IN|the|protective|of (l_pobj) model_10\NN|NONE (l_compound) ulcer_9\NN|this
D014700_D014456 NONE verapamil_15\NN|NONE (r_pobj) by_12\IN|dependently (r_agent) ameliorated_11\VBN|ulcer|. (r_acomp) were_7\VBD|NONE (l_nsubj) ulcer_2\NN|.|ameliorated
D014700_D014456 NONE verapamil_28\NN|NONE (r_pobj) by_27\IN|be|could|that|in (r_agent) ameliorated_26\VBN|produce|,|.|release|,|LPO (r_relcl) generation_16\NN|NONE (l_ccomp) produce_2\VB|ameliorated|,|.|release|,|LPO (l_dobj) ulcer_5\NN|Atherosclerosis|via|could
6286738
D002762_D054559 CID D3_5\NNP|NONE (r_pobj) of_3\IN|Large|(|)|parenteral|D (r_prep) doses_2\NNS|with|.|were (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|.|were|doses (l_pobj) hypercalcemia_21\NN|NONE (l_conj) hyperphosphatemia_23\NN|,|prolonged
D002762_D054559 CID D3_15\NNP|Large|of|(|)|parenteral (r_appos) doses_2\NNS|with|.|were (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|.|were|doses (l_pobj) hypercalcemia_21\NN|NONE (l_conj) hyperphosphatemia_23\NN|,|prolonged
D002762_D054559 CID D3_30\NNP|NONE (r_pobj) of_28\IN|large (r_prep) increases_27\NNS|and|, (r_conj) hyperphosphatemia_23\NN|,|prolonged
D002762_D064420 NONE D3_1\NN|.|in (r_compound) toxicity_2\NN|NONE
D002762_D064420 NONE D3_3\NNP|NONE (r_compound) toxicity_4\NN|NONE
D002762_D064420 NONE D3_3\NNP|NONE (r_compound) toxicity_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Signs_0\NNS|not|were|in (r_nsubjpass) observed_7\VBN|.|signs|;|cows|died|commonly|,|however (r_ccomp) developed_18\VBN|NONE (l_dobj) signs_20\NNS|.|observed|;|cows|died|commonly|,|however (l_prep) of_21\IN|severe (l_pobj) toxicity_24\NN|NONE
D002762_D064420 NONE D3_23\NNP|and|cows (r_compound) toxicity_24\NN|NONE (r_pobj) of_21\IN|severe (r_prep) signs_20\NNS|.|observed|;|cows|died|commonly|,|however (r_dobj) developed_18\VBN|NONE (l_ccomp) observed_7\VBN|.|signs|;|cows|died|commonly|,|however (l_nsubjpass) Signs_0\NNS|not|were|in (l_prep) of_1\IN|NONE (l_pobj) toxicity_4\NN|NONE
D002762_D064420 NONE D3_23\NNP|and|cows (r_compound) toxicity_24\NN|NONE
D002762_D064420 NONE D3_7\NN|NONE (r_pobj) of_5\IN|margin|the|extreme|in|and (r_prep) toxicity_4\NN|of
D002762_D064420 NONE D3_22\NNP|NONE (r_pobj) of_20\IN|NONE (r_prep) doses_19\NNS|NONE (r_pobj) between_18\IN|NONE (r_prep) safety_17\NN|NONE (r_pobj) of_16\IN|low|the (r_prep) margin_15\NN|the|extreme|in|and|of (r_conj) toxicity_4\NN|of
D002762_D064420 NONE D3_38\NNP|injected|not|that|can|be|prevent (r_nsubjpass) used_42\VBN|Because|,|we|. (r_ccomp) concluded_35\VBD|NONE (l_prep) Because_0\IN|,|we|used|. (l_pobj) toxicity_4\NN|of
D002762_D010319 NONE D3_7\NNP|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN|the (r_acl) cows_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|signs|during (r_nsubj) showed_8\VBD|.|during|however|,|signs|%|; (l_dobj) signs_9\NNS|None|during (l_prep) of_10\IN|NONE (l_pobj) fever_12\NN|NONE
D002762_D010319 NONE D3_7\NNP|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN|the (r_acl) cows_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|signs|during (r_nsubj) showed_8\VBD|.|during|however|,|signs|%|; (r_ccomp) developed_26\VBD|NONE (l_dobj) signs_28\NNS|showed|.|during|however|,|%|; (l_prep) of_29\IN|clinical (l_pobj) fever_31\NN|NONE
D002762_D010319 NONE D3_7\NN|NONE (r_pobj) of_5\IN|margin|the|extreme|in|and (r_prep) toxicity_4\NN|of (l_conj) margin_15\NN|the|extreme|in|and|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that
D002762_D010319 NONE D3_7\NN|NONE (r_pobj) of_5\IN|margin|the|extreme|in|and (r_prep) toxicity_4\NN|of (l_conj) margin_15\NN|the|extreme|in|and|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that (l_relcl) induce_30\VBP|milk|and|doses (l_dobj) fever_32\NN|that
D002762_D010319 NONE D3_7\NN|NONE (r_pobj) of_5\IN|margin|the|extreme|in|and (r_prep) toxicity_4\NN|of (r_pobj) Because_0\IN|,|we|used|. (r_prep) concluded_35\VBD|NONE (l_ccomp) used_42\VBN|Because|,|we|. (l_xcomp) prevent_45\VB|injected|not|that|can|be|D (l_dobj) fever_47\NN|to|practically
D002762_D010319 NONE D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that
D002762_D010319 NONE D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that (l_relcl) induce_30\VBP|milk|and|doses (l_dobj) fever_32\NN|that
D002762_D010319 NONE D3_22\NNP|NONE (r_pobj) of_20\IN|NONE (r_prep) doses_19\NNS|NONE (r_pobj) between_18\IN|NONE (r_prep) safety_17\NN|NONE (r_pobj) of_16\IN|low|the (r_prep) margin_15\NN|the|extreme|in|and|of (r_conj) toxicity_4\NN|of (r_pobj) Because_0\IN|,|we|used|. (r_prep) concluded_35\VBD|NONE (l_ccomp) used_42\VBN|Because|,|we|. (l_xcomp) prevent_45\VB|injected|not|that|can|be|D (l_dobj) fever_47\NN|to|practically
D002762_D010319 NONE D3_38\NNP|injected|not|that|can|be|prevent (r_nsubjpass) used_42\VBN|Because|,|we|. (r_ccomp) concluded_35\VBD|NONE (l_prep) Because_0\IN|,|we|used|. (l_pobj) toxicity_4\NN|of (l_conj) margin_15\NN|the|extreme|in|and|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that
D002762_D010319 NONE D3_38\NNP|injected|not|that|can|be|prevent (r_nsubjpass) used_42\VBN|Because|,|we|. (r_ccomp) concluded_35\VBD|NONE (l_prep) Because_0\IN|,|we|used|. (l_pobj) toxicity_4\NN|of (l_conj) margin_15\NN|the|extreme|in|and|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that (l_relcl) induce_30\VBP|milk|and|doses (l_dobj) fever_32\NN|that
D002762_D010319 NONE D3_38\NNP|injected|not|that|can|be|prevent (r_nsubjpass) used_42\VBN|Because|,|we|. (l_xcomp) prevent_45\VB|injected|not|that|can|be|D (l_dobj) fever_47\NN|to|practically
D002762_D006934 CID D3_5\NNP|NONE (r_pobj) of_3\IN|Large|(|)|parenteral|D (r_prep) doses_2\NNS|with|.|were (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|.|were|doses (l_pobj) hypercalcemia_21\NN|NONE
D002762_D006934 CID D3_15\NNP|Large|of|(|)|parenteral (r_appos) doses_2\NNS|with|.|were (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|.|were|doses (l_pobj) hypercalcemia_21\NN|NONE
D002762_D006934 CID D3_30\NNP|NONE (r_pobj) of_28\IN|large (r_prep) increases_27\NNS|and|, (r_conj) hyperphosphatemia_23\NN|,|prolonged (r_conj) hypercalcemia_21\NN|NONE
603022
D005702_D062787 NONE hydrobromide_1\RB|.|was|in (r_nsubjpass) used_16\VBN|NONE (l_prep) in_17\IN|hydrobromide|.|was (l_pobj) patient_19\JJ|NONE (l_acl) demonstrating_20\NN|a (l_dobj) effects_22\NNS|NONE (l_prep) of_23\IN|central (l_pobj) overdosage_28\NN|NONE
D012601_D062787 CID scopolamine_24\NN|(|)|hyoscine (r_nmod) overdosage_28\NN|NONE
D012601_D062787 CID hyoscine_26\NN|(|scopolamine|) (r_nmod) overdosage_28\NN|NONE
1601297
D003042_D009203 CID cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE (l_acl) defined_17\VBN|myocardial|significant (l_prep) as_18\IN|NONE (l_pobj) infarction_20\NN|NONE
D003042_D007511 NONE cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE (l_acl) defined_17\VBN|myocardial|significant (l_prep) as_18\IN|NONE (l_pobj) infarction_20\NN|NONE (l_conj) ischemia_22\NN|,|myocardial
D003042_D012559 NONE cocaine_7\NN| (r_npadvmod) abusing_9\VBG| (r_amod) patients_10\NNS|NONE (r_pobj) of_5\IN|)|( (r_prep) ECG_3\NNP|The (r_appos) electrocardiograms_1\NNS|with|were|. (r_nsubjpass) compared_12\VBN|NONE (l_prep) with_13\IN|electrocardiograms|were|. (l_pobj) ECGs_15\NNS|NONE (l_prep) of_16\IN|the (l_pobj) controls_19\NNS|NONE (l_amod) schizophrenic_18\JJ|
D003042_D009202 NONE cocaine_8\NN|hospitalized (r_compound) abusers_9\NNS|NONE (r_pobj) in_5\IN|myocardial (r_prep) injury_4\NN|NONE
D003042_D009202 NONE cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE
D003042_D002037 CID cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE (l_acl) defined_17\VBN|myocardial|significant (l_prep) as_18\IN|NONE (l_pobj) infarction_20\NN|NONE (l_conj) ischemia_22\NN|,|myocardial (l_conj) block_27\NN|and|,
8643971
D017239_D064420 NONE paclitaxel_16\NN|combined|escalating (r_compound) doses_17\NNS|NONE (r_pobj) of_14\IN|toxicity|the|and (r_prep) response_11\NN|to (l_conj) toxicity_13\NN|of|the|and
D017239_D064420 NONE paclitaxel_5\NN|escalating (r_compound) doses_6\NNS|permitted|,|levels|and (r_dobj) incorporate_3\VBP|NONE (l_conj) permitted_17\VBN|,|levels|and|doses (l_advcl) permits_20\VBZ|escalations|.|are (l_nsubj) toxicity_19\NN|if
D002945_D064420 NONE cisplatin_23\NN|NONE (r_pobj) with_19\IN|with (r_prep) combined_18\VBN|paclitaxel|escalating (r_acl) doses_17\NNS|NONE (r_pobj) of_14\IN|toxicity|the|and (r_prep) response_11\NN|to (l_conj) toxicity_13\NN|of|the|and
D017239_D006258 NONE paclitaxel_7\NN|NONE (r_pobj) of_6\IN|II (r_prep) study_5\NN|plus|A|cisplatin|. (r_dobj) phase_1\NN|NONE (l_conj) cisplatin_9\NN|plus|A|study|. (l_prep) as_10\IN|NONE (l_pobj) therapy_14\NN|NONE (l_prep) for_15\IN|line|results|: (l_pobj) cancers_19\NNS|NONE
D017239_D006258 NONE paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|.|used (r_nsubj) reported_27\VBD|NONE (l_dobj) rate_32\NN|.|used|results (l_prep) in_33\IN|and|%|a|response|, (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D017239_D006258 NONE Taxol_15\NNP|agent (r_appos) paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|.|used (r_nsubj) reported_27\VBD|NONE (l_dobj) rate_32\NN|.|used|results (l_prep) in_33\IN|and|%|a|response|, (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D017239_D006258 NONE paclitaxel_43\NN|the|cisplatin (r_nmod) combination_46\NN|and|successfully|improved|been|has (r_nsubjpass) used_49\VBN|rate|.|results (r_conj) reported_27\VBD|NONE (l_dobj) rate_32\NN|.|used|results (l_prep) in_33\IN|and|%|a|response|, (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D017239_D006258 NONE paclitaxel_16\NN|combined|escalating (r_compound) doses_17\NNS|NONE (l_acl) combined_18\VBN|paclitaxel|escalating (l_prep) with_24\IN|with (l_pobj) support_30\NN|NONE (l_prep) in_31\IN|granulocyte|factor (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN|NONE (l_pobj) head_38\NN|NONE (l_conj) carcinoma_41\NN|advanced|and|untreated|inoperable
D017239_D006258 NONE Paclitaxel_0\NNP|regimen|warranted|cisplatin (r_nsubj) is_3\VBZ|NONE (l_attr) regimen_9\NN|warranted|cisplatin|Paclitaxel (l_prep) for_10\IN|an|and|line|effective (l_pobj) head_13\NN|NONE (l_conj) cancer_16\NN|advanced|and
D017239_D010051 NONE paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|.|used (r_nsubj) reported_27\VBD|NONE (l_conj) used_49\VBN|rate|.|results (l_conj) improved_54\VBN|and|combination|successfully|been|has (l_dobj) duration_57\NN|has|significantly (l_prep) in_58\IN|response|median (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
D017239_D010051 NONE Taxol_15\NNP|agent (r_appos) paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|.|used (r_nsubj) reported_27\VBD|NONE (l_conj) used_49\VBN|rate|.|results (l_conj) improved_54\VBN|and|combination|successfully|been|has (l_dobj) duration_57\NN|has|significantly (l_prep) in_58\IN|response|median (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
D017239_D010051 NONE paclitaxel_43\NN|the|cisplatin (r_nmod) combination_46\NN|and|successfully|improved|been|has (r_nsubjpass) used_49\VBN|rate|.|results (l_conj) improved_54\VBN|and|combination|successfully|been|has (l_dobj) duration_57\NN|has|significantly (l_prep) in_58\IN|response|median (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
D002945_D010051 NONE cisplatin_45\NN|paclitaxel|the (r_compound) combination_46\NN|and|successfully|improved|been|has (r_nsubjpass) used_49\VBN|rate|.|results (l_conj) improved_54\VBN|and|combination|successfully|been|has (l_dobj) duration_57\NN|has|significantly (l_prep) in_58\IN|response|median (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
D002945_D006258 NONE cisplatin_9\NN|plus|A|study|. (l_prep) as_10\IN|NONE (l_pobj) therapy_14\NN|NONE (l_prep) for_15\IN|line|results|: (l_pobj) cancers_19\NNS|NONE
D002945_D006258 NONE cisplatin_45\NN|paclitaxel|the (r_compound) combination_46\NN|and|successfully|improved|been|has (r_nsubjpass) used_49\VBN|rate|.|results (r_conj) reported_27\VBD|NONE (l_dobj) rate_32\NN|.|used|results (l_prep) in_33\IN|and|%|a|response|, (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D002945_D006258 NONE cisplatin_23\NN|NONE (r_pobj) with_19\IN|with (r_prep) combined_18\VBN|paclitaxel|escalating (l_prep) with_24\IN|with (l_pobj) support_30\NN|NONE (l_prep) in_31\IN|granulocyte|factor (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN|NONE (l_pobj) head_38\NN|NONE (l_conj) carcinoma_41\NN|advanced|and|untreated|inoperable
D002945_D006258 NONE cisplatin_2\NN|regimen|warranted|Paclitaxel (r_advmod) is_3\VBZ|NONE (l_attr) regimen_9\NN|warranted|cisplatin|Paclitaxel (l_prep) for_10\IN|an|and|line|effective (l_pobj) head_13\NN|NONE (l_conj) cancer_16\NN|advanced|and
9523805
D008012_D009422 CID lidocaine_16\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) than_14\IN|a|with|lower (r_prep) incidence_9\NN|Transient|.|neurologic|:|after (r_appos) symptoms_2\NNS|NONE
D008012_D009422 CID lidocaine_12\NN|spinal (r_amod) anesthesia_14\NN|frequently|but|that|symptoms|are (r_dobj) follow_11\VBP|evidence|. (l_nsubj) symptoms_6\NNS|frequently|anesthesia|but|that|are
D008012_D009422 CID lidocaine_12\NN|spinal (r_amod) anesthesia_14\NN|frequently|but|that|symptoms|are (r_dobj) follow_11\VBP|evidence|. (l_nsubj) symptoms_6\NNS|frequently|anesthesia|but|that|are (l_appos) TNSs_8\NNS|transient|)|neurologic|(
D008012_D009422 CID lidocaine_13\NN|NONE (l_conj) bupivacaine_15\NN|and (l_prep) with_16\IN|NONE (l_pobj) respect_17\NN|NONE (l_prep) to_18\IN|NONE (l_pobj) duration_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) action_21\NN|NONE (l_conj) risk_24\NN|and (l_prep) of_25\IN|relative (l_pobj) TNSs_26\NNS|NONE
D008012_D009422 CID lidocaine_6\NN|TNSs (r_dobj) receiving_5\VBG| (l_dobj) TNSs_8\NNS|lidocaine
D008012_D009422 CID lidocaine_6\NN|TNSs (r_dobj) receiving_5\VBG| (r_acl) patients_4\NNS|:|them|patients|had|,|,|and (r_nsubj) had_21\VBD|NONE (l_conj) had_31\VBD|:|them|patients|,|patients|,|and (l_dobj) TNSs_32\NNS|none|.
D008012_D009422 CID lidocaine_5\NN|NONE (r_xcomp) preferable_3\JJ|may|.|has|Prilocaine (r_acomp) be_2\VB|NONE (l_advcl) has_12\VBZ|preferable|may|.|Prilocaine (l_dobj) duration_15\NN|because|it (l_conj) incidence_21\NN|but|a|of|similar (l_prep) of_22\IN|lower|a (l_pobj) TNSs_23\NNS|NONE
D011318_D009422 CID prilocaine_11\NN|NONE (r_pobj) with_10\IN|a|than|lower (r_prep) incidence_9\NN|Transient|.|neurologic|:|after (r_appos) symptoms_2\NNS|NONE
D011318_D009422 CID prilocaine_11\JJ|,|.|,|Accordingly|study|present (l_prep) with_12\IN|NONE (l_pobj) lidocaine_13\NN|NONE (l_conj) bupivacaine_15\NN|and (l_prep) with_16\IN|NONE (l_pobj) respect_17\NN|NONE (l_prep) to_18\IN|NONE (l_pobj) duration_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) action_21\NN|NONE (l_conj) risk_24\NN|and (l_prep) of_25\IN|relative (l_pobj) TNSs_26\NNS|NONE
D011318_D009422 CID prilocaine_15\NN|NONE (r_dobj) receiving_14\VBG| (r_acl) patients_13\NNS|:|them|had|,|patients|,|and (r_nsubj) had_21\VBD|NONE (l_nsubj) patients_4\NNS|:|them|patients|had|,|,|and (l_acl) receiving_5\VBG| (l_dobj) TNSs_8\NNS|lidocaine
D011318_D009422 CID prilocaine_15\NN|NONE (r_dobj) receiving_14\VBG| (r_acl) patients_13\NNS|:|them|had|,|patients|,|and (r_nsubj) had_21\VBD|NONE (l_conj) had_31\VBD|:|them|patients|,|patients|,|and (l_dobj) TNSs_32\NNS|none|.
D011318_D009422 CID Prilocaine_0\NNP|preferable|may|.|has (r_nsubj) be_2\VB|NONE (l_advcl) has_12\VBZ|preferable|may|.|Prilocaine (l_dobj) duration_15\NN|because|it (l_conj) incidence_21\NN|but|a|of|similar (l_prep) of_22\IN|lower|a (l_pobj) TNSs_23\NNS|NONE
D002045_D009422 NONE bupivacaine_13\NN|and (r_conj) prilocaine_11\NN|NONE (r_pobj) with_10\IN|a|than|lower (r_prep) incidence_9\NN|Transient|.|neurologic|:|after (r_appos) symptoms_2\NNS|NONE
D002045_D009422 NONE bupivacaine_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) infrequent_17\JJ|NONE (r_acomp) are_16\VBP|frequently|anesthesia|but|that|symptoms (r_conj) follow_11\VBP|evidence|. (l_nsubj) symptoms_6\NNS|frequently|anesthesia|but|that|are
D002045_D009422 NONE bupivacaine_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) infrequent_17\JJ|NONE (r_acomp) are_16\VBP|frequently|anesthesia|but|that|symptoms (r_conj) follow_11\VBP|evidence|. (l_nsubj) symptoms_6\NNS|frequently|anesthesia|but|that|are (l_appos) TNSs_8\NNS|transient|)|neurologic|(
D002045_D009422 NONE bupivacaine_15\NN|and (l_prep) with_16\IN|NONE (l_pobj) respect_17\NN|NONE (l_prep) to_18\IN|NONE (l_pobj) duration_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) action_21\NN|NONE (l_conj) risk_24\NN|and (l_prep) of_25\IN|relative (l_pobj) TNSs_26\NNS|NONE
D002045_D009422 NONE bupivacaine_30\NN|NONE (r_dobj) receiving_29\VBG| (r_acl) patients_28\NNS|NONE (r_pobj) of_26\IN|NONE (r_prep) none_25\NN|TNSs|. (r_nsubj) had_31\VBD|:|them|patients|,|patients|,|and (r_conj) had_21\VBD|NONE (l_nsubj) patients_4\NNS|:|them|patients|had|,|,|and (l_acl) receiving_5\VBG| (l_dobj) TNSs_8\NNS|lidocaine
D002045_D009422 NONE bupivacaine_30\NN|NONE (r_dobj) receiving_29\VBG| (r_acl) patients_28\NNS|NONE (r_pobj) of_26\IN|NONE (r_prep) none_25\NN|TNSs|. (r_nsubj) had_31\VBD|:|them|patients|,|patients|,|and (l_dobj) TNSs_32\NNS|none|.
16167916
D020849_D054556 CID raloxifene_11\NN|NONE (r_compound) treatment_12\NN|NONE (r_pobj) to_10\IN|NONE (r_pcomp) due_9\IN|venous (r_amod) thromboembolism_8\NN|NONE
8092427
-1_D007645 NONE BPO_8\NNP|NONE (r_pobj) to_7\IN|NONE (r_prep) negative_6\JJ|skin (r_amod) test_5\NN|patients (r_attr) were_3\VBD|;|,|also|.||and|negative| (r_ccomp) were_17\VBD|NONE (l_acomp) negative_19\JJ|;|,|also|were|.||and| (l_prep) to_20\IN|NONE (l_pobj) MDM_21\NNP|NONE
D047090_D004342 NONE lactam_12\NN|NONE (r_amod) antibiotics_13\NNS|NONE (r_pobj) to_9\IN|suspected|allergic (r_prep) reactions_8\NNS|NONE
D047090_D004342 NONE lactam_31\NN|NONE (r_amod) antibiotics_32\NNS|NONE (r_pobj) to_28\IN|patients|whether (r_prep) allergic_27\JJ|to
D047090_D004342 NONE lactam_31\NN|NONE (r_amod) antibiotics_32\NNS|NONE (r_pobj) to_28\IN|patients|whether (r_prep) allergic_27\JJ|to (r_ccomp) establish_24\VB|history|,|RAST|was|had|.|,|with (r_xcomp) used_22\VBN|NONE (l_conj) had_33\VBD|history|,|RAST|was|.|,|with|establish (l_dobj) responses_37\NNS|or|were (l_amod) allergic_36\JJ|selective|to|immediate
D047090_D004342 NONE lactam_12\NN|NONE (r_amod) antibiotics_13\NNS|NONE (r_pobj) to_9\IN|NONE (r_prep) allergic_8\JJ|NONE
D010400_D004342 NONE PG_17\NNP|NONE (r_pobj) of_16\IN|good (r_prep) tolerance_15\NN|NONE (r_pobj) with_13\IN|immediate|AX (r_prep) allergy_12\NN|NONE
D010400_D004342 NONE PG_13\NNP|have|who (r_dobj) tolerated_12\VBN|allergic (r_relcl) patients_9\NNS|NONE (l_amod) allergic_8\JJ|tolerated
D000658_D004342 CID amoxicillin_4\NNP|NONE (r_pobj) to_3\IN|.|allergic|Immediate (r_prep) reactions_2\NNS|NONE
D000658_D004342 CID amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|selective|allergic|immediate (r_prep) responses_37\NNS|or|were (r_dobj) had_33\VBD|history|,|RAST|was|.|,|with|establish (r_conj) used_22\VBN|NONE (l_xcomp) establish_24\VB|history|,|RAST|was|had|.|,|with (l_ccomp) allergic_27\JJ|to
D000658_D004342 CID amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|selective|allergic|immediate (r_prep) responses_37\NNS|or|were (l_amod) allergic_36\JJ|selective|to|immediate
D000658_D004342 CID AX_41\NN|NONE (r_appos) amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|selective|allergic|immediate (r_prep) responses_37\NNS|or|were (r_dobj) had_33\VBD|history|,|RAST|was|.|,|with|establish (r_conj) used_22\VBN|NONE (l_xcomp) establish_24\VB|history|,|RAST|was|had|.|,|with (l_ccomp) allergic_27\JJ|to
D000658_D004342 CID AX_41\NN|NONE (r_appos) amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|selective|allergic|immediate (r_prep) responses_37\NNS|or|were (l_amod) allergic_36\JJ|selective|to|immediate
D000658_D004342 CID AX_11\NNP|immediate|with (r_compound) allergy_12\NN|NONE
D000658_D004342 CID AX_3\NN|NONE (r_pobj) with_2\IN|Challenge (r_prep) tests_1\NNS|establish|were|were|and|in (r_nsubjpass) performed_5\VBN|NONE (l_advcl) establish_14\VB|were|were|tests|and|in (l_dobj) diagnosis_16\NN|to|, (l_prep) of_17\IN|the (l_pobj) reaction_20\NN|NONE
D000658_D004342 CID AX_22\NN|NONE (r_pobj) to_21\IN|immediate|allergic (r_prep) reaction_20\NN|NONE
D000658_D004342 CID AX_38\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) RAST_36\NNP|skin|and|both (r_conj) test_34\NN||) (r_appos) %_30\NN|in|.|(|negative (r_nsubj) were_39\VBD|establish|were|tests|and|in (r_conj) performed_5\VBN|NONE (l_advcl) establish_14\VB|were|were|tests|and|in (l_dobj) diagnosis_16\NN|to|, (l_prep) of_17\IN|the (l_pobj) reaction_20\NN|NONE
D000658_D004342 CID AX_6\NN| (r_npadvmod) allergic_8\JJ|tolerated
D010406_D004342 NONE penicillin_50\NN|other (r_compound) derivatives_51\NNS|NONE (r_pobj) with_48\IN||cross (r_prep) reacting_47\VBG|NONE (r_acomp) were_44\VBD|or|responses (r_conj) had_33\VBD|history|,|RAST|was|.|,|with|establish (r_conj) used_22\VBN|NONE (l_xcomp) establish_24\VB|history|,|RAST|was|had|.|,|with (l_ccomp) allergic_27\JJ|to
D010406_D004342 NONE penicillin_50\NN|other (r_compound) derivatives_51\NNS|NONE (r_pobj) with_48\IN||cross (r_prep) reacting_47\VBG|NONE (r_acomp) were_44\VBD|or|responses (r_conj) had_33\VBD|history|,|RAST|was|.|,|with|establish (l_dobj) responses_37\NNS|or|were (l_amod) allergic_36\JJ|selective|to|immediate
D010400_D007645 NONE PG_32\NNP|NONE (r_pobj) to_31\IN|of|)|% (r_prep) 44_24\CD|;|,|also|were|.|and|negative| (r_conj) were_17\VBD|NONE (l_acomp) negative_19\JJ|;|,|also|were|.||and| (l_prep) to_20\IN|NONE (l_pobj) MDM_21\NNP|NONE
11807648
D014148_D012640 CID tAMCA_5\NN|whether|incorporated|action (r_nsubj) retains_6\VBZ|to (l_dobj) action_9\NN|tAMCA|whether|incorporated (l_amod) convulsive_8\JJ|its
D014148_D012640 CID tAMCA_4\NN|FS|: (r_appos) FINDINGS_0\NNS|.|activity (r_nsubj) caused_5\VBD|NONE (l_dobj) activity_8\NN|.|FINDINGS (l_relcl) associated_11\VBN|paroxysmal|brain (l_prep) with_12\IN|which|was (l_pobj) behaviours_15\NNS|NONE (l_amod) convulsive_14\JJ|distinct
D014148_D012640 CID tAMCA_10\CD|NONE (r_pobj) of_9\IN|increasing (r_prep) concentration_8\NN|NONE (r_pobj) with_6\IN|degree|. (r_prep) increased_5\VBD|NONE (l_nsubj) degree_1\NN|.|with (l_prep) of_2\IN|The (l_pobj) seizures_4\NNS|NONE
D014148_D012640 CID tAMCA_0\NN|seizures|.|evoked (r_advmod) evoked_1\VBD|NONE (l_dobj) seizures_3\NNS|.|tAMCA|evoked
D014148_D012640 CID tAMCA_0\NN|seizures|.|evoked (r_advmod) evoked_1\VBD|NONE (l_advcl) evoked_24\VBD|seizures|.|tAMCA (l_dobj) episodes_26\NNS|only|)|while|concentration (l_prep) of_27\IN|brief (l_pobj) potentials_32\NNS|NONE (l_amod) convulsive_31\JJ|correlated|in
D014148_D012640 CID tAMCA_16\NN|/|(|.|mg (r_nmod) ml_21\NNS|NONE (r_pobj) of_15\IN|the|lowest (r_prep) concentration_14\NN|only|)|while|episodes (r_nsubj) evoked_24\VBD|seizures|.|tAMCA (r_advcl) evoked_1\VBD|NONE (l_dobj) seizures_3\NNS|.|tAMCA|evoked
D014148_D012640 CID tAMCA_16\NN|/|(|.|mg (r_nmod) ml_21\NNS|NONE (r_pobj) of_15\IN|the|lowest (r_prep) concentration_14\NN|only|)|while|episodes (r_nsubj) evoked_24\VBD|seizures|.|tAMCA (l_dobj) episodes_26\NNS|only|)|while|concentration (l_prep) of_27\IN|brief (l_pobj) potentials_32\NNS|NONE (l_amod) convulsive_31\JJ|correlated|in
D014148_D012640 CID acid_1\NN|.|action (r_nsubj) retains_2\VBZ|NONE (l_dobj) action_5\NN|.|acid (l_amod) convulsive_4\JJ|its|within
D014148_D004827 NONE acid_10\NN|in (r_dobj) containing_8\VBG|fibrin (r_acl) sealants_7\NNS|NONE (r_pobj) of_5\IN|cortical (r_prep) application_4\NN|NONE (r_dobj) following_2\VBG|.|Epileptic (r_prep) seizures_1\NNS|NONE
D014148_D004827 NONE tAMCA_2\NN|However|,|.|cause|has|been (r_nsubjpass) shown_5\VBN|NONE (l_xcomp) cause_7\VB|tAMCA|However|,|.|has|been (l_dobj) seizures_9\NNS|to
3101906
D007654_D003643 NONE ketoconazole_9\JJ|NONE (r_compound) treatment_10\NN|NONE (r_pobj) with_8\IN|probably (r_prep) associated_7\VBN|the|three (r_acl) deaths_5\NNS|NONE
D007654_D056486 CID ketoconazole_9\JJ|NONE (r_compound) treatment_10\NN|NONE (r_pobj) with_8\IN|probably (r_prep) associated_7\VBN|the|three (r_acl) deaths_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) two_1\CD|NONE (r_pobj) In_0\IN|been|after|had|drug|. (r_prep) continued_15\VBN|NONE (l_prep) after_16\IN|In|been|had|drug|. (l_pobj) onset_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) jaundice_20\NN|NONE (l_conj) symptoms_23\NNS|and (l_prep) of_24\IN|other (l_pobj) hepatitis_25\NN|NONE
D007654_D056486 CID ketoconazole_18\NN|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|NONE (r_pobj) during_13\IN|.|prevent|monitoring|is (r_prep) advised_12\VBN|NONE (l_nsubjpass) monitoring_3\NN|.|prevent|during|is (l_prep) for_7\IN|Clinical|at (l_pobj) evidence_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) hepatitis_10\NN|NONE
D007654_D056486 CID ketoconazole_18\NN|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|NONE (r_pobj) during_13\IN|.|prevent|monitoring|is (r_prep) advised_12\VBN|NONE (l_advcl) prevent_20\VB|.|monitoring|during|is (l_dobj) injury_24\NN|to
D007654_D007565 CID ketoconazole_9\JJ|NONE (r_compound) treatment_10\NN|NONE (r_pobj) with_8\IN|probably (r_prep) associated_7\VBN|the|three (r_acl) deaths_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) two_1\CD|NONE (r_pobj) In_0\IN|been|after|had|drug|. (r_prep) continued_15\VBN|NONE (l_prep) after_16\IN|In|been|had|drug|. (l_pobj) onset_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) jaundice_20\NN|NONE
17244258
D003520_D003556 CID cyclophosphamide_9\NN| (r_npadvmod) induced_11\VBN|in (r_amod) cystitis_12\NN|NONE
D003520_D003556 CID cyclophosphamide_1\NN| (r_npadvmod) induced_3\VBN|in (r_amod) cystitis_4\NN|NONE
26094
D008750_D001523 NONE dopa_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) occurring_10\VBG|NONE (r_acl) depressions_9\NNS|NONE (r_pobj) of_8\IN|a|treated|significant (r_prep) number_7\NN|NONE (l_acl) treated_14\VBD|a|of|significant (l_dobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) histories_18\NNS|NONE (l_amod) psychiatric_17\JJ|NONE
D008750_D003866 CID dopa_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) occurring_10\VBG|NONE (r_acl) depressions_9\NNS|NONE
1428568
D015784_D003866 NONE betaxolol_4\NN|could|less|that (r_nsubj) be_6\VB|.|results (l_attr) less_7\JJR|betaxolol|could|that (l_prep) of_8\IN|than (l_pobj) inducer_12\NN|NONE (l_compound) depression_10\NN|a|
D013999_D003866 CID timolol_6\NN|NONE (r_compound) 0.5%/12h_7\CD|NONE (r_pobj) with_5\IN|,|suffering|chronically|patients (r_prep) treated_4\VBN|were|,|.|in (l_advcl) suffering_9\VBG|,|chronically|patients|with (l_prep) from_10\IN|diagnosed (l_pobj) depression_11\NN|NONE
D013999_D003866 CID timolol_15\NN|NONE (r_compound) treatment_16\NN|NONE (r_pobj) under_14\IN|the (r_prep) patients_13\NNS|In|,|values|. (r_nsubj) presented_17\VBD|NONE (l_dobj) values_20\NNS|In|,|patients|. (l_compound) depression_19\NN|measured|.|higher
D013999_D003866 CID timolol_14\NN|NONE (r_pobj) than_13\IN|of (r_prep) less_7\JJR|betaxolol|could|that (l_prep) of_8\IN|than (l_pobj) inducer_12\NN|NONE (l_compound) depression_10\NN|a|
D013999_D005901 NONE timolol_6\NN|NONE (r_compound) 0.5%/12h_7\CD|NONE (r_pobj) with_5\IN|,|suffering|chronically|patients (r_prep) treated_4\VBN|were|,|.|in (l_nsubj) patients_2\NNS|,|suffering|chronically|with (l_amod) glaucomatous_1\JJ|Eight
20722491
D005472_D009369 NONE 5-FU_1\CD|,|mainstay|.|have (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|,|.|have|FU (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE
C110904_D007674 NONE capecitabine_10\NN|NONE (r_pobj) of_9\IN|the|in (r_prep) safety_8\NN|NONE (l_prep) in_11\IN|of|the (l_pobj) populations_13\NNS|NONE (l_prep) as_15\IN|special (l_pobj) patients_16\NNS|such (l_prep) with_17\IN|NONE (l_pobj) disease_24\NN|NONE
C110904_D007674 NONE Capecitabine_0\NNP|.|and|given|profile (r_nsubj) has_1\VBZ|NONE (l_conj) given_11\VBN|.|and|Capecitabine|profile (l_prep) to_13\IN|safely|can|be (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) dysfunctions_22\NNS|NONE
D005472_D001943 NONE 5-FU_1\CD|,|mainstay|.|have (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|,|.|have|FU (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE (l_prep) including_15\VBG|several|solid|,|, (l_pobj) colorectal_16\NN|NONE (l_conj) breast_18\NN|, (l_conj) cancers_23\NNS|and
C110904_D014839 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|toxic|reported|The (r_prep) effects_5\NNS|diarrhea|. (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|, (l_conj) vomiting_13\NN|,
C110904_D013280 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|toxic|reported|The (r_prep) effects_5\NNS|diarrhea|. (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|, (l_conj) vomiting_13\NN|, (l_conj) stomatitis_15\JJ|,
C110904_D003967 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|toxic|reported|The (r_prep) effects_5\NNS|diarrhea|. (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|.
C110904_D009325 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|toxic|reported|The (r_prep) effects_5\NNS|diarrhea|. (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|,
C110904_D008107 NONE Capecitabine_0\NNP|.|and|given|profile (r_nsubj) has_1\VBZ|NONE (l_conj) given_11\VBN|.|and|Capecitabine|profile (l_prep) to_13\IN|safely|can|be (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) dysfunctions_22\NNS|NONE
D005472_D015179 NONE 5-FU_1\CD|,|mainstay|.|have (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|,|.|have|FU (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE (l_prep) including_15\VBG|several|solid|,|, (l_pobj) colorectal_16\NN|NONE (l_conj) breast_18\NN|, (l_conj) cancers_23\NNS|and
C110904_D060831 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|toxic|reported|The (r_prep) effects_5\NNS|diarrhea|. (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|, (l_conj) vomiting_13\NN|, (l_conj) stomatitis_15\JJ|, (l_conj) syndrome_20\NN|and
D005472_D006258 NONE 5-FU_1\CD|,|mainstay|.|have (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|,|.|have|FU (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE (l_prep) including_15\VBG|several|solid|,|, (l_pobj) colorectal_16\NN|NONE (l_conj) breast_18\NN|, (l_conj) cancers_23\NNS|and
9855119
D016559_D007674 NONE FK506_28\NN|type|)|n|nephropathy|chronic|and|(|, (r_compound) nephropathy_29\NN|n|,|normal|,
D016559_D007674 NONE FK506_28\NN|type|)|n|nephropathy|chronic|and|(|, (r_compound) nephropathy_29\NN|n|,|normal|, (l_conj) nephropathy_41\NN|type|FK|)|n|chronic|and|(|,
D016559_D007674 NONE FK506_40\NN|n|)|( (r_compound) nephropathy_41\NN|type|FK|)|n|chronic|and|(|, (r_conj) nephropathy_29\NN|n|,|normal|,
D016559_D007674 NONE FK506_40\NN|n|)|( (r_compound) nephropathy_41\NN|type|FK|)|n|chronic|and|(|,
D016559_D007674 NONE FK506_18\NN|chronic|type (r_compound) nephropathy_19\NN|.|Of|respectively|,|biopsies|,
D016559_D007674 NONE FK506_1\NNP|NONE (r_compound) nephropathy_2\NN|of|,
D016559_D007674 NONE FK506_12\NN|NONE (r_compound) nephropathy_13\NN|type|included|chronic|,|,|the
D016559_D007674 NONE FK506_12\NN|NONE (r_compound) nephropathy_13\NN|type|included|chronic|,|,|the (r_compound) group_14\NN|NONE (r_pobj) in_6\IN|NONE (r_prep) patients_5\NNS|NONE (r_pobj) of_4\IN|creatinine|The|serum (r_prep) levels_3\NNS|higher|. (r_nsubj) were_22\VBD|NONE (l_acomp) higher_24\JJR|levels|. (l_prep) than_25\IN|statistically (l_pobj) those_26\DT|NONE (l_prep) in_27\IN|NONE (l_pobj) group_34\NN|NONE (l_compound) FK506-nephropathy_33\NNP|(|)|type|P|the
D016559_D007674 NONE FK506-nephropathy_33\NNP|(|)|type|P|the (r_compound) group_34\NN|NONE (r_pobj) in_27\IN|NONE (r_prep) those_26\DT|NONE (r_pobj) than_25\IN|statistically (r_prep) higher_24\JJR|levels|. (r_acomp) were_22\VBD|NONE (l_nsubj) levels_3\NNS|higher|. (l_prep) of_4\IN|creatinine|The|serum (l_pobj) patients_5\NNS|NONE (l_prep) in_6\IN|NONE (l_pobj) group_14\NN|NONE (l_compound) nephropathy_13\NN|type|included|chronic|,|,|the
D016559_D007674 NONE FK506-nephropathy_33\NNP|(|)|type|P|the
D016559_D007674 NONE FK506_5\NNP|chronic (r_compound) nephropathy_6\NN|,|that|primarily|of
D016559_D007674 NONE FK506_5\NNP|chronic (r_compound) nephropathy_6\NN|,|that|primarily|of (r_nsubj) consists_7\VBZ|suggests|study|and|. (r_ccomp) demonstrates_2\VBZ|NONE (l_conj) suggests_21\VBZ|consists|study|and|. (l_ccomp) is_29\VBZ|NONE (l_nsubj) nephropathy_28\NN|condition|that
D016559_D007674 NONE FK506_27\NN|type|chronic (r_compound) nephropathy_28\NN|condition|that (r_nsubj) is_29\VBZ|NONE (r_ccomp) suggests_21\VBZ|consists|study|and|. (r_conj) demonstrates_2\VBZ|NONE (l_ccomp) consists_7\VBZ|suggests|study|and|. (l_nsubj) nephropathy_6\NN|,|that|primarily|of
D016559_D007674 NONE FK506_27\NN|type|chronic (r_compound) nephropathy_28\NN|condition|that
D003404_D007674 NONE creatinine_2\NN|of|The|serum (r_compound) levels_3\NNS|higher|. (l_prep) of_4\IN|creatinine|The|serum (l_pobj) patients_5\NNS|NONE (l_prep) in_6\IN|NONE (l_pobj) group_14\NN|NONE (l_compound) nephropathy_13\NN|type|included|chronic|,|,|the
D003404_D007674 NONE creatinine_2\NN|of|The|serum (r_compound) levels_3\NNS|higher|. (r_nsubj) were_22\VBD|NONE (l_acomp) higher_24\JJR|levels|. (l_prep) than_25\IN|statistically (l_pobj) those_26\DT|NONE (l_prep) in_27\IN|NONE (l_pobj) group_34\NN|NONE (l_compound) FK506-nephropathy_33\NNP|(|)|type|P|the
D016559_D005923 CID FK506_1\NNP|NONE (r_compound) nephropathy_2\NN|of|, (r_nsubj) consisted_3\VBD|arteriolopathy|biopsies|of|(|;|. (r_ccomp) angiodegeneration_17\NN|NONE (l_appos) biopsies_24\NNS|arteriolopathy|of|(|consisted|;|. (l_conj) glomerulosclerosis_29\NN|)|,|
D016559_D005355 NONE FK506_1\NNP|NONE (r_compound) nephropathy_2\NN|of|, (r_nsubj) consisted_3\VBD|arteriolopathy|biopsies|of|(|;|. (r_ccomp) angiodegeneration_17\NN|NONE (l_appos) biopsies_24\NNS|arteriolopathy|of|(|consisted|;|. (l_conj) glomerulosclerosis_29\NN|)|,| (l_conj) form_37\NN|segmental|focal|biopsies|)|(|and (l_prep) of_38\IN|striped|the (l_pobj) fibrosis_40\NN|NONE
D016559_D005922 NONE FK506_28\NN|type|)|n|nephropathy|chronic|and|(|, (r_compound) nephropathy_29\NN|n|,|normal|, (r_conj) findings_17\NNS|recurrent|,|.|IgA|n (r_conj) nephropathy_9\NN|n
D016559_D005922 NONE FK506_40\NN|n|)|( (r_compound) nephropathy_41\NN|type|FK|)|n|chronic|and|(|, (r_conj) nephropathy_29\NN|n|,|normal|, (r_conj) findings_17\NNS|recurrent|,|.|IgA|n (r_conj) nephropathy_9\NN|n
16755009
D003975_D000647 CID Diazepam-_0\NN|NONE (l_appos) amnesia_7\NN|.|,
D003975_D000647 CID diazepam_16\NN|(|mg/kg|and|) (r_conj) scopolamine_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|the (r_acl) amnesia_5\NN|,|.|Furthermore|DCE
D012601_D000647 CID scopolamine-_2\NN|served (r_nmod) amnesia_7\NN|.|,
D012601_D000647 CID scopolamine_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|the (r_acl) amnesia_5\NN|,|.|Furthermore|DCE
D002784_D003072 NONE cholesterol_30\NN|activity (r_nsubj) lowering_31\VBG|, (r_conj) property_28\NN|memory (r_dobj) improving_27\VBG|useful|a|for (r_acl) remedy_9\NN|to (l_prep) for_10\IN|useful|improving|a (l_pobj) management_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) dysfunctions_15\NNS|NONE
D010936_D000647 NONE DCE_2\NNP|,|.|Furthermore|amnesia (r_nsubj) reversed_3\VBD|NONE (l_dobj) amnesia_5\NN|,|.|Furthermore|DCE
D010936_D003072 NONE DCE_2\NNP|may|.|Therefore|be|, (r_nsubj) prove_4\VB|NONE (l_xcomp) be_6\VB|may|DCE|.|Therefore|, (l_attr) remedy_9\NN|to (l_prep) for_10\IN|useful|improving|a (l_pobj) management_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) dysfunctions_15\NNS|NONE
19843802
D004837_D006973 CID epinephrine_5\NN|NONE (r_pobj) of_4\IN|a|injected (r_prep) bolus_3\NN|.|However|crisis|, (r_nsubj) provoked_11\VBD|NONE (l_dobj) crisis_14\NN|.|bolus|However|, (l_amod) hypertensive_13\JJ|a
6534871
D007545_D009203 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|myocardial (r_amod) infarction_12\NN|NONE
7449470
D004317_D066126 NONE doxorubicin_3\NN|.|late|Late|, (r_compound) cardiotoxicity_4\NN|NONE
D004317_D066126 NONE adriamycin_11\NNS|NONE (r_pobj) of_10\IN|as|the (r_prep) use_9\NN|which (r_dobj) limits_7\VBZ|major|a (r_relcl) complication_5\NN|.|toxicity (r_attr) is_2\VBZ|NONE (l_nsubj) toxicity_1\NN|complication|.
11419773
D002110_D008945 NONE caffeine_34\NN|NONE (r_pobj) of_33\IN|high|a (r_prep) concentration_32\NN|NONE (r_dobj) containing_29\VBG|guarana|a|"|health|"|energy (r_acl) drink_28\NN|NONE (r_dobj) consuming_20\VBG|NONE (r_pcomp) after_19\IN|who|fibrillation (r_prep) developed_15\VBD|a|with|old (r_relcl) woman_6\NN|.|We (l_prep) with_7\IN|a|old|developed (l_pobj) prolapse_13\NN|NONE
D002110_D014693 CID caffeine_34\NN|NONE (r_pobj) of_33\IN|high|a (r_prep) concentration_32\NN|NONE (r_dobj) containing_29\VBG|guarana|a|"|health|"|energy (r_acl) drink_28\NN|NONE (r_dobj) consuming_20\VBG|NONE (r_pcomp) after_19\IN|who|fibrillation (r_prep) developed_15\VBD|a|with|old (l_dobj) fibrillation_18\NN|after|who
D002110_D001145 NONE Caffeine_0\NN| (r_nsubj) induced_2\VBN|.|danger|cardiac|: (r_amod) arrhythmia_4\NN|NONE
6287825
D007538_D009422 NONE Isoniazid_0\NNP|agent|. (r_nsubj) was_1\VBD|NONE (l_attr) agent_5\NN|Isoniazid|. (l_prep) in_6\IN|the|frequent (l_pobj) neuropathy_10\NN|NONE
D013831_D044342 NONE thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to
D013831_D010523 CID thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|presented|%|common|and|.
D013831_D010523 CID thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|presented|%|common|and|. (r_nsubj) was_10\VBD|NONE (l_conj) presented_17\VBN|%|common|and|neuropathy|. (l_prep) as_19\IN|NONE (l_pobj) neuropathy_25\NN|mainly
D012256_D044342 NONE riboflavin_9\NN|and (r_conj) thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to
D012256_D010523 CID riboflavin_9\NN|and (r_conj) thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|presented|%|common|and|.
D012256_D010523 CID riboflavin_9\NN|and (r_conj) thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|presented|%|common|and|. (r_nsubj) was_10\VBD|NONE (l_conj) presented_17\VBN|%|common|and|neuropathy|. (l_prep) as_19\IN|NONE (l_pobj) neuropathy_25\NN|mainly
19820426
C558899_D066126 NONE ritonavir_10\NNS|NONE (r_compound) therapy_11\NN|/ (r_appos) lopinavir_8\NNS|NONE (r_pobj) to_7\IN|NONE (r_prep) related_6\VBN|cardiac (r_acl) toxicity_5\NN|NONE
C558899_D001919 CID ritonavir_15\NNS|,|agent (r_compound) therapy_16\NN|/ (r_appos) lopinavir_13\NNS|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|dilated (r_acl) cardiomyopathy_10\NN|complete|heart|and (r_conj) block_7\NN|developed|One|,|. (r_dobj) developed_4\VBD|NONE (l_advcl) developed_29\VBD|One|block|,|. (l_dobj) bradycardia_31\NNS|twin|while
C558899_D002311 CID ritonavir_15\NNS|,|agent (r_compound) therapy_16\NN|/ (r_appos) lopinavir_13\NNS|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|dilated (r_acl) cardiomyopathy_10\NN|complete|heart|and
C558899_D006327 CID ritonavir_15\NNS|,|agent (r_compound) therapy_16\NN|/ (r_appos) lopinavir_13\NNS|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|dilated (r_acl) cardiomyopathy_10\NN|complete|heart|and (r_conj) block_7\NN|developed|One|,|.
9766615
D003024_D015430 NONE clozapine_40\NN|(|seizure|) (r_appos) threshold_37\NN|effects|agranulocytosis|,|and (r_dobj) lowered_35\VBD|,|are|in (l_nsubj) effects_21\NNS|threshold|agranulocytosis|,|and (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic
D003024_D015430 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|threshold|effects|,|and (r_conj) lowered_35\VBD|,|are|in (l_nsubj) effects_21\NNS|threshold|agranulocytosis|,|and (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic
D003024_D012640 NONE clozapine_40\NN|(|seizure|) (r_appos) threshold_37\NN|effects|agranulocytosis|,|and (l_compound) seizure_36\NN|clozapine|(|)
D003024_D012640 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|threshold|effects|,|and (r_conj) lowered_35\VBD|,|are|in (l_dobj) threshold_37\NN|effects|agranulocytosis|,|and (l_compound) seizure_36\NN|clozapine|(|)
D003024_D001480 NONE clozapine_40\NN|(|seizure|) (r_appos) threshold_37\NN|effects|agranulocytosis|,|and (r_dobj) lowered_35\VBD|,|are|in (r_conj) associated_13\VBN|but|risk|.|agents|, (r_conj) have_4\VBP|NONE (l_dobj) risk_7\NN|but|.|agents|associated|, (l_prep) of_8\IN|lower|a (l_pobj) EPS_9\NNP|NONE
D003024_D001480 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|threshold|effects|,|and (r_conj) lowered_35\VBD|,|are|in (r_conj) associated_13\VBN|but|risk|.|agents|, (r_conj) have_4\VBP|NONE (l_dobj) risk_7\NN|but|.|agents|associated|, (l_prep) of_8\IN|lower|a (l_pobj) EPS_9\NNP|NONE
D003024_D000380 CID clozapine_40\NN|(|seizure|) (r_appos) threshold_37\NN|effects|agranulocytosis|,|and (r_dobj) lowered_35\VBD|,|are|in (l_conj) agranulocytosis_44\NN|threshold|effects|,|and
D003024_D000380 CID clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|threshold|effects|,|and
D003024_D012735 NONE clozapine_40\NN|(|seizure|) (r_appos) threshold_37\NN|effects|agranulocytosis|,|and (r_dobj) lowered_35\VBD|,|are|in (l_nsubj) effects_21\NNS|threshold|agranulocytosis|,|and (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic (l_conj) dysfunction_30\NN|,|weight
D003024_D012735 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|threshold|effects|,|and (r_conj) lowered_35\VBD|,|are|in (l_nsubj) effects_21\NNS|threshold|agranulocytosis|,|and (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic (l_conj) dysfunction_30\NN|,|weight
16330766
C040029_D009437 NONE gabapentin_11\NN|NONE (l_appos) drug_14\NN|, (l_amod) effective_15\JJ|a (l_prep) in_16\IN|NONE (l_pobj) patients_19\NNS|NONE (l_compound) pain_18\NN|neuropathic
D002211_D006930 CID capsaicin_32\NN| (r_npadvmod) induced_34\VBN|secondary (r_amod) hyperalgesia_36\NN|and|normal
C040029_D006930 NONE gabapentin_15\NN| (r_npadvmod) induced_17\VBN|of|in|the (r_amod) modulation_18\NN|we|Using|.|, (l_prep) in_22\IN|of|induced|the (l_pobj) response_23\NN|NONE (l_prep) to_24\IN|NONE (l_pobj) stimulation_27\NN|NONE (l_prep) of_28\IN|mechanical|nociceptive (l_pobj) skin_30\NN|NONE (l_conj) hyperalgesia_36\NN|and|normal
6640832
D004317_D002277 NONE adriamycin_2\NNS|Early|. (l_prep) in_3\IN|NONE (l_pobj) carcinoma_6\NN|NONE
D004317_D001749 NONE adriamycin_2\NNS|Early|. (l_prep) in_3\IN|NONE (l_pobj) carcinoma_6\NN|NONE
D004317_D001749 NONE Adriamycin_0\NNP|.|was|intravesically|within|after (r_nsubjpass) administered_7\VBN|NONE (l_prep) after_12\IN|.|Adriamycin|was|intravesically|within (l_pobj) resection_14\NN|NONE (l_prep) of_15\IN|transurethral (l_pobj) tumors_25\NNS|NONE
8421099
D015282_D002764 NONE octreotide_25\NN|in (r_compound) therapy_26\NN|NONE (r_pobj) during_24\IN|successive|of|the (r_prep) formation_15\NN|NONE (l_prep) of_16\IN|during|successive|the (l_pobj) sludge_18\NN|NONE (l_conj) gallstones_20\NNS|,|bile (l_conj) cholecystitis_23\NN|,|and
D015282_D000172 NONE octreotide_12\NN|)|(|somatostatin (r_appos) analog_10\NN|NONE (r_pobj) of_8\IN|the|on|term (r_prep) effects_7\NNS|NONE (l_prep) on_14\IN|the|term|of (l_pobj) function_16\NN|NONE (l_prep) in_20\IN|gallbladder|formation|and (l_pobj) patients_23\NNS|NONE (l_compound) acromegalic_22\JJ|Chinese
D015282_D000172 NONE octreotide_26\NN|somatostatin|the (r_appos) analog_25\NN|NONE (r_pobj) of_22\IN|sc (r_prep) injection_21\NN|NONE (r_pobj) with_19\IN|day|for|in (r_prep) treated_18\VBN|with|Chinese| (r_acl) patients_14\NNS|NONE (l_prep) with_15\IN|treated|Chinese| (l_pobj) acromegaly_17\NNS|NONE
D015282_D000172 NONE octreotide_25\NN|in (r_compound) therapy_26\NN|NONE (l_prep) in_27\IN|octreotide (l_pobj) patients_30\NNS|NONE (l_compound) acromegalic_29\JJ|Chinese
D015282_D000172 NONE octreotide_16\NN|term|of (r_compound) therapy_17\NN|NONE (l_prep) of_18\IN|term|octreotide (l_pobj) patients_20\NNS|NONE (l_compound) acromegalic_19\JJ|NONE
D015282_D042882 CID octreotide_12\NN|)|(|somatostatin (r_appos) analog_10\NN|NONE (r_pobj) of_8\IN|the|on|term (r_prep) effects_7\NNS|NONE (l_prep) on_14\IN|the|term|of (l_pobj) function_16\NN|NONE (l_conj) formation_19\NN|in|gallbladder|and (l_compound) gallstone_18\NN|NONE
D015282_D042882 CID octreotide_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) treatment_1\NN|NONE (r_pobj) During_0\IN|patients|,|had|sludge|. (r_prep) developed_7\VBD|NONE (l_conj) had_11\VBD|patients|,|During|sludge|. (l_dobj) gallstones_12\NNS|and|,||developed
D015282_D042882 CID octreotide_3\NN|NONE (r_pobj) of_2\IN|in (r_prep) withdrawal_1\NN|NONE (l_prep) in_4\IN|of (l_pobj) patients_6\NNS|NONE (l_prep) without_7\IN| (l_pobj) gallstones_8\NNS|NONE
D015282_D042882 CID octreotide_25\NN|in (r_compound) therapy_26\NN|NONE (r_pobj) during_24\IN|successive|of|the (r_prep) formation_15\NN|NONE (l_prep) of_16\IN|during|successive|the (l_pobj) sludge_18\NN|NONE (l_conj) gallstones_20\NNS|,|bile
D015282_D041881 CID octreotide_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) treatment_1\NN|NONE (r_pobj) During_0\IN|patients|,|had|sludge|. (r_prep) developed_7\VBD|NONE (l_conj) had_11\VBD|patients|,|During|sludge|. (l_conj) developed_16\VBD|and|,||gallstones (l_dobj) cholecystitis_18\NN||requiring
7453952
D011188_D003919 NONE potassium_48\NN|the (r_compound) level_49\NN|NONE (r_pobj) in_45\IN|an (r_prep) elevation_44\NN|the|in|and|lithium (r_conj) concentration_31\NN|NONE (r_pobj) between_28\IN|the (r_prep) ratio_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) reduction_24\NN|NONE (r_pobj) by_22\IN|In|.|attenuation|was|, (r_agent) accompanied_21\VBN|NONE (l_nsubjpass) attenuation_6\NN|In|.|by|was|, (l_prep) of_7\IN|the (l_pobj) syndrome_17\NN|NONE
D000584_D011141 NONE amiloride_3\NN|NONE (r_pobj) of_2\IN|The|on (r_prep) effect_1\NN|in|treated|,|.|was (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|on|and (l_conj) polyuria_10\NN|and|induced
D000584_D011141 NONE amiloride_5\NN|to|acute (r_compound) administration_6\NN|might|result|that|patients|but (l_prep) to_7\IN|amiloride|acute (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D000584_D011141 NONE amiloride_23\JJ|prolonged (r_compound) supplementation_24\NN|and|in|be|would (r_nsubj) result_26\VB|might|that|patients|administration|but (r_conj) relieve_18\VB|.|It|is (l_nsubj) administration_6\NN|might|result|that|patients|but (l_prep) to_7\IN|amiloride|acute (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D008094_D011141 NONE lithium_5\NN| (r_npadvmod) induced_7\VBN|polyuria|and (r_amod) polydipsia_8\NN|on|and (l_conj) polyuria_10\NN|and|induced
D008094_D011141 NONE lithium_14\NN|the|in (r_compound) concentration_15\NN|NONE (r_pobj) on_12\IN|polydipsia|and (r_conj) on_4\IN|of|The (l_pobj) polydipsia_8\NN|on|and (l_conj) polyuria_10\NN|and|induced
D008094_D011141 NONE lithium_8\NN| (r_npadvmod) treated_10\VBN|suffering (r_amod) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D008094_D011141 NONE lithium_29\NN|elevated (r_compound) levels_30\NNS|NONE (r_pobj) in_27\IN|supplementation|and|be|would (r_prep) result_26\VB|might|that|patients|administration|but (r_conj) relieve_18\VB|.|It|is (l_nsubj) administration_6\NN|might|result|that|patients|but (l_prep) to_7\IN|amiloride|acute (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D000584_D059606 NONE amiloride_3\NN|NONE (r_pobj) of_2\IN|The|on (r_prep) effect_1\NN|in|treated|,|.|was (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|on|and
D000584_D059606 NONE amiloride_5\NN|to|acute (r_compound) administration_6\NN|might|result|that|patients|but (l_prep) to_7\IN|amiloride|acute (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
D000584_D059606 NONE amiloride_23\JJ|prolonged (r_compound) supplementation_24\NN|and|in|be|would (r_nsubj) result_26\VB|might|that|patients|administration|but (r_conj) relieve_18\VB|.|It|is (l_nsubj) administration_6\NN|might|result|that|patients|but (l_prep) to_7\IN|amiloride|acute (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
D008094_D059606 NONE lithium_5\NN| (r_npadvmod) induced_7\VBN|polyuria|and (r_amod) polydipsia_8\NN|on|and
D008094_D059606 NONE lithium_14\NN|the|in (r_compound) concentration_15\NN|NONE (r_pobj) on_12\IN|polydipsia|and (r_conj) on_4\IN|of|The (l_pobj) polydipsia_8\NN|on|and
D008094_D059606 NONE lithium_8\NN| (r_npadvmod) treated_10\VBN|suffering (r_amod) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
D008094_D059606 NONE lithium_29\NN|elevated (r_compound) levels_30\NNS|NONE (r_pobj) in_27\IN|supplementation|and|be|would (r_prep) result_26\VB|might|that|patients|administration|but (r_conj) relieve_18\VB|.|It|is (l_nsubj) administration_6\NN|might|result|that|patients|but (l_prep) to_7\IN|amiloride|acute (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
D000584_D003919 NONE amiloride_13\NN|NONE (r_pobj) by_12\IN|like|the|in|induced (r_prep) syndrome_11\NN|NONE
D000584_D003919 NONE amiloride_19\NN|NONE (r_pobj) by_18\IN|like|the|induced (r_prep) syndrome_17\NN|NONE
D008094_D003919 CID lithium_3\NN| (r_npadvmod) induced_5\VBN|like|the|in|by (r_amod) syndrome_11\NN|NONE
D008094_D003919 CID lithium_9\NN| (r_npadvmod) induced_11\VBN|by|like|the (r_amod) syndrome_17\NN|NONE
D008094_D003919 CID lithium_30\NN|the|in|and|elevation (r_compound) concentration_31\NN|NONE (r_pobj) between_28\IN|the (r_prep) ratio_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) reduction_24\NN|NONE (r_pobj) by_22\IN|In|.|attenuation|was|, (r_agent) accompanied_21\VBN|NONE (l_nsubjpass) attenuation_6\NN|In|.|by|was|, (l_prep) of_7\IN|the (l_pobj) syndrome_17\NN|NONE
D018021_D011141 NONE LiCl_37\NNP|NONE (r_pobj) with_36\IN|chronically (r_prep) treated_35\VBN|in|,|.|was|effect (r_conj) investigated_30\VBN|NONE (l_nsubjpass) effect_1\NN|in|treated|,|.|was (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|on|and (l_conj) polyuria_10\NN|and|induced
D018021_D059606 NONE LiCl_37\NNP|NONE (r_pobj) with_36\IN|chronically (r_prep) treated_35\VBN|in|,|.|was|effect (r_conj) investigated_30\VBN|NONE (l_nsubjpass) effect_1\NN|in|treated|,|.|was (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|on|and
3564823
D008012_D020301 NONE lidocaine_11\NN|was|,|counteract|.|,|,|precluded|with (r_nsubjpass) given_13\VBN|NONE (l_advcl) counteract_24\VB|was|,|.|,|,|lidocaine|precluded|with (l_dobj) vasospasm_26\NN|to
D008012_D013035 NONE lidocaine_7\NN|NONE (r_pobj) by_6\IN|.|spasm (r_prep) relieved_5\VBN|NONE (l_nsubj) spasm_4\NN|.|by
D013874_D002545 NONE pentothal_12\NNS|Following|.|intravenously|,|minimize|was (r_nsubjpass) infused_15\VBN|NONE (l_advcl) minimize_17\VB|Following|.|pentothal|intravenously|,|was (l_dobj) ischaemia_19\NN|to
2304736
D011224_D014550 CID Prazosin_0\NN| (r_npadvmod) induced_2\VBN|stress|. (r_amod) incontinence_4\NN|NONE
D011224_D014550 CID prazosin_8\NN|to (r_pobj) due_6\IN|of|A (r_amod) case_1\NN|.|is (l_prep) of_2\IN|due|A (l_pobj) incontinence_5\NN|NONE
D011224_D014550 CID prazosin_8\NN|while (r_dobj) taking_7\VBG|with|who (r_advcl) present_2\VBP|NONE (l_prep) with_3\IN|taking|who (l_pobj) incontinence_5\NN|NONE
D011224_D014549 NONE prazosin_8\NN|while (r_dobj) taking_7\VBG|with|who (r_advcl) present_2\VBP|NONE (r_relcl) Patients_0\NNS|should|.|,|resolve|before|medication (r_nsubj) change_10\VB|NONE (l_advcl) resolve_22\VB|Patients|should|.|,|before|medication (l_nsubj) incontinence_20\NN|may|with|because|spontaneously
4071154
D007213_D001201 CID indomethacin_24\NN|case|.|We|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|.|We|have (l_prep) in_12\IN|of|a (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a (l_pobj) cirrhosis_16\NN|NONE (l_conj) ascites_18\NNS|,
D007213_D006947 CID indomethacin_24\NN|case|.|We|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|.|We|have (l_prep) of_5\IN|in|a (l_pobj) failure_9\NN|NONE (l_prep) with_10\IN|acute|oliguric|renal (l_pobj) hyperkalemia_11\NN|NONE
D007213_D051437 NONE Indomethacin_0\NNP| (r_npadvmod) induced_2\VBN|:|.|recurrence|renal (r_amod) insufficiency_4\NN|NONE
D007213_D051437 NONE indomethacin_24\NN|case|.|We|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|.|We|have (l_prep) of_5\IN|in|a (l_pobj) failure_9\NN|NONE
D007213_D011660 CID indomethacin_24\NN|case|.|We|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|.|We|have (l_prep) in_12\IN|of|a (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a (l_pobj) cirrhosis_16\NN|NONE (l_conj) ascites_18\NNS|, (l_conj) pulmonale_22\NN|and|,
D007213_D005355 CID indomethacin_24\NN|case|.|We|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|.|We|have (l_prep) in_12\IN|of|a (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a (l_pobj) cirrhosis_16\NN|NONE
D007213_D009846 CID indomethacin_18\NN|NONE (r_pobj) of_17\IN|a|single (r_prep) dose_16\NN|exposure (r_pobj) to_13\IN|recurrence (r_punct) caused_19\VBD|,|withdrawal|restoration|. (l_dobj) recurrence_20\NN|to (l_prep) of_21\IN|NONE (l_pobj) oliguria_24\NN|NONE
3800626
D010423_D020425 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to (r_pobj) due_6\IN|Compression|.|of (r_prep) neuropathy_1\NN|NONE (l_prep) of_2\IN|Compression|.|due (l_pobj) nerve_5\NN|NONE
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to
D010423_D005355 CID pentazocine_13\NN|repeated (r_compound) injection_14\NN|NONE (r_pobj) of_11\IN|known|common|a|,|side (r_prep) effect_10\NN|myopathy|. (r_attr) is_2\VBZ|NONE (l_nsubj) myopathy_1\NN|effect|.
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous|documented|of (r_amod) myopathy_12\NNS|NONE
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous|documented|of (r_amod) myopathy_12\NNS|NONE (r_pobj) with_6\IN|a|old|bilaterally|and|history (r_prep) woman_5\NN|NONE (r_pobj) In_0\IN|,|lesion|examination|in|,|. (r_prep) showed_32\VBD|NONE (l_prep) in_51\IN|,|In|lesion|examination|,|. (l_pobj) addition_52\NN|NONE (l_prep) to_53\IN|NONE (l_pobj) myopathy_56\NN|NONE
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to
D010423_D009135 CID pentazocine_13\NN|repeated (r_compound) injection_14\NN|NONE (r_pobj) of_11\IN|known|common|a|,|side (r_prep) effect_10\NN|myopathy|. (r_attr) is_2\VBZ|NONE (l_nsubj) myopathy_1\NN|effect|.
D010423_D009135 CID pentazocine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_compound) myopathy_13\NN|NONE
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous|documented|of (r_amod) myopathy_12\NNS|NONE
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous|documented|of (r_amod) myopathy_12\NNS|NONE (r_pobj) with_6\IN|a|old|bilaterally|and|history (r_prep) woman_5\NN|NONE (r_pobj) In_0\IN|,|lesion|examination|in|,|. (r_prep) showed_32\VBD|NONE (l_prep) in_51\IN|,|In|lesion|examination|,|. (l_pobj) addition_52\NN|NONE (l_prep) to_53\IN|NONE (l_pobj) myopathy_56\NN|NONE
D010423_D009408 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to (r_pobj) due_6\IN|Compression|.|of (r_prep) neuropathy_1\NN|NONE (l_prep) of_2\IN|Compression|.|due (l_pobj) nerve_5\NN|NONE
D010423_D009408 CID pentazocine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_compound) myopathy_13\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) affected_8\VBN|fibrotic (r_acl) muscle_7\NN|to (r_pobj) due_4\IN|compression (r_amod) neuropathy_3\NN|has|been|,|However|.|not|previously
15804801
D017239_D003323 CID paclitaxel_6\NN| (r_compound) eluting_8\VBG|a (r_amod) stent_9\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) implantation_3\NN|NONE (r_pobj) after_2\IN|.|Coronary (r_prep) aneurysm_1\NN|NONE
D017239_D003323 CID paclitaxel_22\NN| (r_compound) eluting_24\VBG|a (r_amod) stent_25\NN|NONE (r_dobj) receiving_20\VBG|months (r_pcomp) after_19\IN|who|in|aneurysm (r_prep) developed_8\VBD|a|old (l_dobj) aneurysm_11\NN|who|in|after
11773892
D016559_D007674 CID tacrolimus_5\NN|and (r_conj) cyclosporine_3\VBP|calcineurin|The (r_appos) inhibitors_2\NNS|are|.|both|be (r_nsubjpass) known_8\VBN|NONE (l_xcomp) be_10\VB|are|inhibitors|.|both (l_acomp) nephrotoxic_11\JJ|to
D003404_D006530 NONE creatinine_13\NN|,|requirement|preoperative|,|percentage|higher (r_compound) levels_14\NNS|Compared|.|,|patients (l_appos) percentage_18\NN|,|requirement|preoperative|creatinine|,|higher (l_prep) of_19\IN|greater|a (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) syndrome_23\NN|NONE
D003404_D006530 NONE creatinine_42\NN|,|in|and|for|higher|percentage (r_conj) requirement_27\NN|,|preoperative|creatinine|,|percentage|higher (r_appos) levels_14\NNS|Compared|.|,|patients (l_appos) percentage_18\NN|,|requirement|preoperative|creatinine|,|higher (l_prep) of_19\IN|greater|a (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) syndrome_23\NN|NONE
D003404_D006530 NONE creatinine_11\NN|Patients|and|.|are (r_dobj) have_4\VBP|NONE (l_conj) are_13\VBP|Patients|and|.|creatinine (l_acomp) likely_15\JJ|NONE (l_xcomp) have_17\VB|more (l_dobj) syndrome_19\NN|to
D016572_D007674 CID cyclosporine_3\VBP|calcineurin|The (r_appos) inhibitors_2\NNS|are|.|both|be (r_nsubjpass) known_8\VBN|NONE (l_xcomp) be_10\VB|are|inhibitors|.|both (l_acomp) nephrotoxic_11\JJ|to
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|;|CRF|, (r_conj) Controls_7\NNS|and|:|n=|three|;|> (l_conj) CRF_10\NNP|;|,|CRF
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|;|CRF|, (r_conj) Controls_7\NNS|and|:|n=|three|;|> (l_conj) CRF_10\NNP|;|,|CRF (l_conj) ESRD_12\NNP|or|no
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|;|CRF|,
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|;|CRF|, (r_conj) Controls_7\NNS|and|:|n=|three|;|> (r_appos) groups_5\NNS|NONE (l_conj) n=45_32\JJ|and|:|Controls|three|;|> (l_nmod) ESRD_30\NNS|.
D003404_D007676 NONE creatinine_13\NN|,|requirement|preoperative|,|percentage|higher (r_compound) levels_14\NNS|Compared|.|,|patients (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|Compared|.|,|levels (l_nmod) CRF_5\NNP|ESRD
D003404_D007676 NONE creatinine_13\NN|,|requirement|preoperative|,|percentage|higher (r_compound) levels_14\NNS|Compared|.|,|patients (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|Compared|.|,|levels (l_compound) ESRD_7\NNP|CRF
D003404_D007676 NONE creatinine_42\NN|,|in|and|for|higher|percentage (r_conj) requirement_27\NN|,|preoperative|creatinine|,|percentage|higher (r_appos) levels_14\NNS|Compared|.|,|patients (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|Compared|.|,|levels (l_nmod) CRF_5\NNP|ESRD
D003404_D007676 NONE creatinine_42\NN|,|in|and|for|higher|percentage (r_conj) requirement_27\NN|,|preoperative|creatinine|,|percentage|higher (r_appos) levels_14\NNS|Compared|.|,|patients (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|Compared|.|,|levels (l_compound) ESRD_7\NNP|CRF
D003404_D007676 NONE creatinine_16\NN|NONE (r_pobj) of_14\IN|an|compared|,|and (r_prep) increase_13\NN|that|factors|respectively|postoperatively (r_nsubj) were_31\VBD|analysis|. (l_attr) factors_34\NNS|that|respectively|postoperatively|increase (l_prep) for_35\IN|with|independent|risk (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) CRF_39\NNP|NONE
D003404_D007676 NONE creatinine_16\NN|NONE (r_pobj) of_14\IN|an|compared|,|and (r_prep) increase_13\NN|that|factors|respectively|postoperatively (r_nsubj) were_31\VBD|analysis|. (l_attr) factors_34\NNS|that|respectively|postoperatively|increase (l_prep) for_35\IN|with|independent|risk (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) CRF_39\NNP|NONE (l_conj) ESRD_41\NNP|or
D003404_D007676 NONE creatinine_11\NN|Patients|and|.|are (r_dobj) have_4\VBP|NONE (l_nsubj) Patients_0\NNS|and|.|creatinine|are (l_relcl) develop_2\VBP|NONE (l_dobj) ESRD_3\NNS|who
D003404_D007676 NONE creatinine_6\NN|NONE (r_pobj) of_4\IN|postoperatively|at|an (r_prep) increase_3\NN|.|However|,|predictive (r_nsubj) is_11\VBZ|NONE (l_acomp) predictive_13\JJ|increase|.|However|, (l_prep) of_14\IN|more (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) CRF_18\NNP|NONE
D003404_D007676 NONE creatinine_6\NN|NONE (r_pobj) of_4\IN|postoperatively|at|an (r_prep) increase_3\NN|.|However|,|predictive (r_nsubj) is_11\VBZ|NONE (l_acomp) predictive_13\JJ|increase|.|However|, (l_prep) of_14\IN|more (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) CRF_18\NNP|NONE (l_conj) ESRD_20\NNP|or
17466854
D008775_D006261 CID methylprednisolone_3\NN|NONE (r_pobj) of_2\IN|and|The|gentamicin (r_prep) administration_1\NN|to|.|was (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|administration|.|was (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|a|high (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|, (l_conj) headache_29\NN|and|,
D008775_D020250 CID methylprednisolone_3\NN|NONE (r_pobj) of_2\IN|and|The|gentamicin (r_prep) administration_1\NN|to|.|was (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|administration|.|was (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|a|high (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|,
D005839_D006261 CID gentamicin_5\NN|and|The|of (r_conj) administration_1\NN|to|.|was (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|administration|.|was (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|a|high (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|, (l_conj) headache_29\NN|and|,
D008775_D002386 NONE methylprednisolone_13\NN|NONE (r_pobj) of_12\IN|the (r_prep) administration_11\NN|NONE (r_pobj) after_9\IN|of|the (r_prep) incidence_3\NN|and|To|gentamicin|. (r_dobj) assess_1\VB|NONE (l_conj) gentamicin_15\NN|and|incidence|To|. (l_prep) at_24\IN|into (l_pobj) end_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) surgery_30\NN|NONE (l_compound) cataract_29\NN|routine
D005839_D020250 CID gentamicin_5\NN|and|The|of (r_conj) administration_1\NN|to|.|was (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|administration|.|was (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|a|high (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|,
D005839_D002386 NONE gentamicin_15\NN|and|incidence|To|. (l_prep) at_24\IN|into (l_pobj) end_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) surgery_30\NN|NONE (l_compound) cataract_29\NN|routine
8590259
C016986_D015814 CID apraclonidine_8\NN| (r_npadvmod) treated_10\VBN|NONE (r_amod) eyes_11\NNS|NONE (r_pobj) for_7\IN|statistically|significant|and|throughout (r_prep) significant_6\JJ|.|effects (r_acomp) were_4\VBD|NONE (l_nsubj) effects_3\NNS|significant|. (l_amod) hypotensive_2\JJ|The|ocular
C016986_D015814 CID apraclonidine_31\NN|NONE (r_pobj) of_28\IN|topical (r_prep) administration_27\NN|NONE (r_pobj) after_25\IN|three (r_prep) hours_24\NNS|NONE (r_pobj) from_22\IN|for|also|statistically (r_prep) significant_18\JJ|statistically|for|and|throughout (r_conj) significant_6\JJ|.|effects (r_acomp) were_4\VBD|NONE (l_nsubj) effects_3\NNS|significant|. (l_amod) hypotensive_2\JJ|The|ocular
14568327
D015632_D004409 NONE MPTP_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) parkinsonism_10\NN|NONE (r_pobj) of_6\IN|different (r_prep) types_5\NNS|NONE (r_pobj) with_3\IN|monkeys (r_prep) Using_0\VBG|study|degree|.|, (r_advcl) evaluated_15\VBD|NONE (l_dobj) degree_17\NN|Using|study|.|, (l_relcl) involved_38\VBN|the (l_prep) in_39\IN|may|severity|be|to (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) LIDs_43\NNS|NONE
D015632_D004409 NONE MPTP_8\NNP|onset|,|acute (r_compound) exposure_9\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Monkeys_0\NNS|days|prior|dyskinesia|. (r_nsubj) developed_24\VBD|NONE (l_dobj) dyskinesia_25\RB|days|Monkeys|prior|.
D015632_D004409 NONE MPTP_8\NNP|term (r_compound) exposure_9\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) monkeys_3\NNS|In|slow|,|symptom|duration|,|and/or|prior (r_nsubj) progression_13\NN|resistant|.|developed (r_nsubj) were_24\VBD|NONE (l_acomp) resistant_26\JJ|.|developed|progression (l_prep) to_27\IN|more (l_pcomp) developing_28\VBG|NONE (l_dobj) LIDs_29\NNS|NONE
D015632_D004409 NONE MPTP_8\NNP|term (r_compound) exposure_9\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) monkeys_3\NNS|In|slow|,|symptom|duration|,|and/or|prior (r_nsubj) progression_13\NN|resistant|.|developed (r_nsubj) were_24\VBD|NONE (l_parataxis) developed_34\VBD|resistant|.|progression (l_nsubj) dyskinesia_33\NN|(|e.g.|)|,|sooner
D007980_D010302 NONE levodopa_34\NN|NONE (r_compound) therapy_35\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) duration_32\NN|to|and (r_conj) response_29\NN|rate|,|,|symptom|and (r_conj) severity_26\NN|in|may|be|to (r_nsubjpass) involved_38\VBN|the (r_relcl) degree_17\NN|Using|study|.|, (r_dobj) evaluated_15\VBD|NONE (l_advcl) Using_0\VBG|study|degree|.|, (l_prep) with_3\IN|monkeys (l_pobj) types_5\NNS|NONE (l_prep) of_6\IN|different (l_pobj) parkinsonism_10\NN|NONE
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|in (r_amod) dyskinesias_5\NNS|NONE
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|(|LIDs|) (r_amod) dyskinesias_3\NNS|.|problem
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|(|LIDs|) (r_amod) dyskinesias_3\NNS|.|problem (l_appos) LIDs_5\NNPS|(|)|induced
D007980_D004409 CID levodopa_34\NN|NONE (r_compound) therapy_35\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) duration_32\NN|to|and (r_conj) response_29\NN|rate|,|,|symptom|and (r_conj) severity_26\NN|in|may|be|to (r_nsubjpass) involved_38\VBN|the (l_prep) in_39\IN|may|severity|be|to (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) LIDs_43\NNS|NONE
D007980_D004409 CID levodopa_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) initiation_20\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|days|Monkeys|dyskinesia|. (r_advmod) developed_24\VBD|NONE (l_dobj) dyskinesia_25\RB|days|Monkeys|prior|.
D007980_D004409 CID levodopa_33\JJ|daily (r_compound) administration_34\NN|NONE (r_pobj) of_31\IN| (r_prep) days_30\NNS|Monkeys|prior|dyskinesia|. (r_npadvmod) developed_24\VBD|NONE (l_dobj) dyskinesia_25\RB|days|Monkeys|prior|.
D007980_D004409 CID levodopa_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) initiation_20\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|In|slow|monkeys|,|symptom|duration|,|and/or (r_advmod) progression_13\NN|resistant|.|developed (r_nsubj) were_24\VBD|NONE (l_acomp) resistant_26\JJ|.|developed|progression (l_prep) to_27\IN|more (l_pcomp) developing_28\VBG|NONE (l_dobj) LIDs_29\NNS|NONE
D007980_D004409 CID levodopa_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) initiation_20\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|In|slow|monkeys|,|symptom|duration|,|and/or (r_advmod) progression_13\NN|resistant|.|developed (r_nsubj) were_24\VBD|NONE (l_parataxis) developed_34\VBD|resistant|.|progression (l_nsubj) dyskinesia_33\NN|(|e.g.|)|,|sooner
D007980_D004409 CID levodopa_42\JJ|chronic (r_compound) administration_43\NN|NONE (r_pobj) of_40\IN| (r_prep) days_39\NNS|NONE (r_pobj) than_37\IN|no (r_prep) sooner_36\RBR|dyskinesia|(|e.g.|)|, (r_advmod) developed_34\VBD|resistant|.|progression (r_parataxis) were_24\VBD|NONE (l_acomp) resistant_26\JJ|.|developed|progression (l_prep) to_27\IN|more (l_pcomp) developing_28\VBG|NONE (l_dobj) LIDs_29\NNS|NONE
D007980_D004409 CID levodopa_42\JJ|chronic (r_compound) administration_43\NN|NONE (r_pobj) of_40\IN| (r_prep) days_39\NNS|NONE (r_pobj) than_37\IN|no (r_prep) sooner_36\RBR|dyskinesia|(|e.g.|)|, (r_advmod) developed_34\VBD|resistant|.|progression (l_nsubj) dyskinesia_33\NN|(|e.g.|)|,|sooner
D007980_D004409 CID levodopa_24\VB|NONE (r_pobj) to_23\IN|NONE (r_prep) prior_22\RB|LIDs|with|to (r_advmod) develop_9\VB|the (l_dobj) LIDs_10\NNS|with|prior|to
D007980_D004409 CID levodopa_24\VB|NONE (r_pobj) to_23\IN|NONE (r_prep) prior_22\RB|LIDs|with|to (r_advmod) develop_9\VB|the (r_acl) propensity_7\NN|NONE (r_pobj) in_5\IN|distinct (r_prep) differences_4\NNS|and|demonstrate|.|data (r_dobj) suggest_2\VBP|NONE (l_conj) demonstrate_26\VB|differences|and|.|data (l_dobj) value_28\NN|NONE (l_prep) for_32\IN|the|of (l_pcomp) studying_34\VBG|NONE (l_dobj) pathophysiology_36\NN|further (l_prep) of_37\IN|the (l_pobj) LIDs_38\NNS|NONE
D007980_D010300 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|in (r_amod) dyskinesias_5\NNS|NONE (l_prep) in_6\IN|induced (l_pobj) monkeys_8\NNS|NONE (l_amod) parkinsonian_7\JJ|NONE
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|(|LIDs|) (r_amod) dyskinesias_3\NNS|.|problem (r_nsubj) present_7\VBP|NONE (l_dobj) problem_10\NN|.|dyskinesias (l_prep) for_11\IN|major|a (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|term|the (l_pobj) patients_24\NNS|NONE (l_nmod) disease_20\NN|(|PD|)
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|(|LIDs|) (r_amod) dyskinesias_3\NNS|.|problem (r_nsubj) present_7\VBP|NONE (l_dobj) problem_10\NN|.|dyskinesias (l_prep) for_11\IN|major|a (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|term|the (l_pobj) patients_24\NNS|NONE (l_nmod) PD_22\NNP|disease|(|)
D015632_D010302 CID MPTP_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) parkinsonism_10\NN|NONE
9522143
D011318_D034381 CID prilocaine_2\NN|NONE (r_dobj) given_1\VBN|P (r_acl) Patients_0\NNS|.|likely (r_nsubj) were_3\VBD|NONE (l_acomp) likely_5\JJ|.|Patients (l_xcomp) develop_7\VB|more (l_xcomp) hearing_8\VBG|to (l_dobj) loss_9\NN|NONE
D011318_D034381 CID prilocaine_12\NN|NONE (r_pobj) after_11\IN|dB|loss|. (r_prep) was_7\VBD|NONE (l_nsubj) loss_3\NN|dB|after|.
D002045_D034381 CID bupivacaine_19\NN|NONE (r_pobj) than_16\IN| (r_prep) loss_9\NN|NONE
D002045_D034381 CID bupivacaine_17\NN|NONE (r_pobj) after_16\IN| (r_prep) dB_15\NN|and (r_conj) prilocaine_12\NN|NONE (r_pobj) after_11\IN|dB|loss|. (r_prep) was_7\VBD|NONE (l_nsubj) loss_3\NN|dB|after|.
15233872
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|in|myocardial (r_amod) infarction_11\NN|NONE
C007145_D009203 NONE Crataegus_5\NNP|NONE (r_pobj) of_4\IN|NONE (r_prep) tincture_3\NN|NONE (r_pobj) of_2\IN|.|Cardioprotective|on (r_prep) effect_1\NN|NONE (l_prep) on_6\IN|of|.|Cardioprotective (l_pobj) infarction_11\NN|NONE
C007145_D009203 NONE TCR_11\NNP|NONE (r_pobj) of_10\IN|the|protective|on (r_prep) effect_9\NN|to (l_prep) on_12\IN|the|of|protective (l_pobj) infarction_16\NN|NONE
1378968
D008094_D007676 CID lithium_8\NN| (r_npadvmod) induced_10\VBN|chronic|in|renal (r_amod) failure_13\NN|NONE
D008094_D051437 NONE lithium_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) nephropathy_5\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Rats_0\NNS|in|to|,|were|. (r_nsubjpass) subjected_7\VBN|NONE (l_prep) in_26\IN|to|Rats|,|were|. (l_pobj) attempt_28\NN|NONE (l_acl) induce_30\VB|an (l_dobj) hyperfiltration_32\NN|to (l_conj) progression_35\NN|and|glomerular (l_prep) of_36\IN|further (l_pobj) failure_38\NN|NONE
D008094_D051437 NONE lithium_21\NN|pretreated (r_nmod) rats_23\NNS|NONE (r_pobj) in_20\IN|plasma|creatinine (r_prep) levels_19\NNS|NONE (r_dobj) decrease_16\NN|to|GFR (r_conj) increase_13\VB|.|in (r_xcomp) tended_11\VBD|and|accentuante|HP (r_conj) failed_1\VBD|NONE (l_xcomp) accentuante_3\NN|and|tended|HP (l_dobj) progression_4\NN|to (l_prep) of_5\IN|NONE (l_pobj) failure_7\NN|NONE
D008094_D007674 NONE lithium_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) nephropathy_5\NN|NONE
D008094_D007674 NONE Li_4\NNP| (r_npadvmod) induced_6\VBN|reduced|,|, (r_amod) nephropathy_7\NN|that|with|is
D008094_D005921 NONE Lithium_0\NN|in|.|proteinuria|also (r_nsubj) caused_2\VBD|NONE (l_prep) in_7\IN|Lithium|.|proteinuria|also (l_pobj) absence_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) glomerulosclerosis_10\NN|NONE
D003404_D051437 NONE creatinine_18\NN|plasma|in (r_compound) levels_19\NNS|NONE (r_dobj) decrease_16\NN|to|GFR (r_conj) increase_13\VB|.|in (r_xcomp) tended_11\VBD|and|accentuante|HP (r_conj) failed_1\VBD|NONE (l_xcomp) accentuante_3\NN|and|tended|HP (l_dobj) progression_4\NN|to (l_prep) of_5\IN|NONE (l_pobj) failure_7\NN|NONE
D008094_D006973 CID Lithium_0\NN|in|.|proteinuria|also (r_nsubj) caused_2\VBD|NONE (l_dobj) proteinuria_3\NN|Lithium|in|.|also (l_conj) hypertension_6\NN|and
D008094_D006973 CID Li_4\NNP| (r_npadvmod) induced_6\VBN|reduced|,|, (r_amod) nephropathy_7\NN|that|with|is (r_nsubjpass) associated_19\VBN|results|. (l_prep) with_20\IN|that|is|nephropathy (l_pobj) proteinuria_21\NN|NONE (l_conj) hypertension_25\NN|and
D008094_D011507 CID Lithium_0\NN|in|.|proteinuria|also (r_nsubj) caused_2\VBD|NONE (l_dobj) proteinuria_3\NN|Lithium|in|.|also
D008094_D011507 CID Li_4\NNP| (r_npadvmod) induced_6\VBN|reduced|,|, (r_amod) nephropathy_7\NN|that|with|is (r_nsubjpass) associated_19\VBN|results|. (l_prep) with_20\IN|that|is|nephropathy (l_pobj) proteinuria_21\NN|NONE
3503576
D003676_D014786 NONE deferoxamine_26\NN|NONE (r_pobj) with_23\IN|who|therapy|were (r_prep) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|was|.|previously|neurotoxicity (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|was|.|in|previously
D003676_D000740 NONE deferoxamine_26\NN|NONE (r_pobj) with_23\IN|who|therapy|were (r_prep) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE
D007501_D006311 NONE iron_20\NN|chelation (r_compound) therapy_22\NN|who|with|were (r_dobj) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|was|.|previously|neurotoxicity (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|was|.|in|previously
D003676_D064420 NONE deferoxamine_9\NN|NONE (r_compound) doses_10\NNS|initially|were|Since||in (r_dobj) receiving_8\VBG|demonstrated|therapy|,|was|with|,|and (r_advcl) restarted_24\VBN|NONE (l_conj) demonstrated_55\VBN|receiving|therapy|,|was|with|,|and (l_nsubjpass) toxicity_53\NN|.|with|was
D007501_D014786 NONE iron_20\NN|chelation (r_compound) therapy_22\NN|who|with|were (r_dobj) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|was|.|previously|neurotoxicity (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|was|.|in|previously
D003676_D006311 NONE deferoxamine_8\NN|NONE (r_compound) therapy_9\NN|NONE (r_dobj) receiving_7\VBG|NONE (r_acl) patients_6\NNS|NONE (r_pobj) in_5\IN|Serial|of|. (r_prep) studies_1\NNS|NONE (l_prep) of_2\IN|Serial|.|in (l_pobj) neurotoxicity_4\NN|NONE
D003676_D006311 NONE deferoxamine_26\NN|NONE (r_pobj) with_23\IN|who|therapy|were (r_prep) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|was|.|previously|neurotoxicity (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|was|.|in|previously
D003676_D006311 NONE deferoxamine_9\NN|NONE (r_compound) doses_10\NNS|initially|were|Since||in (r_dobj) receiving_8\VBG|demonstrated|therapy|,|was|with|,|and (r_advcl) restarted_24\VBN|NONE (l_prep) with_25\IN|demonstrated|receiving|therapy|,|was|,|and (l_pobj) doses_27\NNS|NONE (l_prep) depending_36\VBG|,|lower|mg/kg (l_prep) on_37\IN|NONE (l_pobj) degree_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) abnormality_42\NN|NONE
D003676_D006311 NONE deferoxamine_14\NN|not (r_dobj) receiving_13\VBG|and (r_conj) receiving_10\VBG|individual (r_acl) patients_9\NNS|NONE (r_pobj) in_7\IN|,|deterioration|provided|,|,|serially|respectively|. (r_prep) demonstrated_5\VBD|NONE (l_prep) provided_18\VBD|,|deterioration|in|,|,|serially|respectively|. (l_pcomp) convincing_19\JJ|NONE (l_dobj) evidence_20\NN|NONE (l_prep) for_21\IN|NONE (l_pobj) relation_28\NN|NONE (l_prep) between_29\IN|cause|a (l_pobj) administration_31\NN|NONE (l_conj) ototoxicity_33\NN|deferoxamine|and
D003676_D006311 NONE deferoxamine_30\NN|ototoxicity|and (r_compound) administration_31\NN|NONE (l_conj) ototoxicity_33\NN|deferoxamine|and
D007501_D000740 NONE iron_20\NN|chelation (r_compound) therapy_22\NN|who|with|were (r_dobj) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE
7628595
D002955_D064420 NONE acid_9\NN|in|folinic (r_compound) supplementation_10\NN|vitamin|and (l_prep) in_11\IN|acid|folinic (l_pcomp) preventing_12\VBG|NONE (l_dobj) toxicity_14\NN|NONE
D015215_D001855 CID zidovudine_20\NNP|ZDV)induced|marrow|( (r_nmod) suppression_25\NN|NONE
D015215_D001855 CID ZDV)-induced_22\VBN|marrow|zidovudine|( (r_amod) suppression_25\NN|NONE
D015215_D001855 CID ZDV_7\NNP|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|folinic|acid (r_prep) supplementation_5\NN|Vitamin|and (r_conj) B12_1\NN|excluded|,|useful|does|.|not (r_nsubj) seem_11\VB|NONE (l_oprd) useful_12\JJ|B|excluded|,|does|.|not (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_conj) reducing_16\VBG|or (l_dobj) myelotoxicity_20\NN|in
D015215_D001855 CID ZDV_17\NNP| (r_npadvmod) induced_19\VBN|NONE (r_amod) myelotoxicity_20\NN|in
D015215_D015658 NONE ZDV_21\NNP|alone|to (r_dobj) receive_19\VB|were|virus (r_xcomp) randomized_17\VBN|NONE (l_nsubjpass) virus_5\NN|were|receive (l_appos) patients_8\NNS|immunodeficiency|five|human (l_amod) HIV)-infected_7\VBN|(|with
D005492_D001855 NONE folate_8\JJ|development|and (r_compound) levels_9\NNS|vitamin|or (l_conj) development_11\NN|and|folate (l_prep) of_12\IN|NONE (l_pobj) myelosuppression_13\NN|NONE
D015215_D064420 NONE zidovudine_16\NN|NONE (r_pobj) of_15\IN|hematologic (r_prep) toxicity_14\NN|NONE
D014805_D001855 NONE B12_13\NN|NONE (l_conj) supplementation_17\NN|vitamin|and (l_prep) in_18\IN|acid|folinic (l_pcomp) preventing_19\VBG|NONE (l_dobj) suppression_25\NN|NONE
D014805_D001855 NONE B12_6\NN|NONE (l_conj) levels_9\NNS|vitamin|or (l_conj) development_11\NN|and|folate (l_prep) of_12\IN|NONE (l_pobj) myelosuppression_13\NN|NONE
D014805_D001855 NONE B12_1\NN|excluded|,|useful|does|.|not (r_nsubj) seem_11\VB|NONE (l_oprd) useful_12\JJ|B|excluded|,|does|.|not (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_conj) reducing_16\VBG|or (l_dobj) myelotoxicity_20\NN|in
D014805_D064420 NONE B12_6\NN|NONE (l_conj) supplementation_10\NN|vitamin|and (l_prep) in_11\IN|acid|folinic (l_pcomp) preventing_12\VBG|NONE (l_dobj) toxicity_14\NN|NONE
D002955_D001855 NONE acid_16\NN|in|folinic (r_compound) supplementation_17\NN|vitamin|and (l_prep) in_18\IN|acid|folinic (l_pcomp) preventing_19\VBG|NONE (l_dobj) suppression_25\NN|NONE
D002955_D001855 NONE acid_4\NN|of|folinic (r_compound) supplementation_5\NN|Vitamin|and (r_conj) B12_1\NN|excluded|,|useful|does|.|not (r_nsubj) seem_11\VB|NONE (l_oprd) useful_12\JJ|B|excluded|,|does|.|not (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_conj) reducing_16\VBG|or (l_dobj) myelotoxicity_20\NN|in
16298782
D019331_D034381 NONE NAME_2\NN|but|.|in|,|gave|loss (r_nsubj) reduced_3\VBN|NONE (l_dobj) loss_8\NN|but|.|NAME|in|,|gave
D009569_D006319 NONE NO_17\DT|NONE (r_pobj) of_16\IN|the (r_prep) production_15\NN|as|mechanism (r_dobj) involves_13\VBZ|ototoxicity|and|,|problem (r_conj) is_2\VBZ|.|assess|,|we (r_ccomp) need_20\VBP|NONE (l_xcomp) assess_22\VB|.|is|,|we (l_dobj) use_24\NN|to (l_prep) for_28\IN|the|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) loss_37\NN|NONE
D009569_D006319 NONE NO_26\DT|NONE (r_det) inhibitors_27\NNS|NONE (r_pobj) of_25\IN|the|for (r_prep) use_24\NN|to (l_prep) for_28\IN|the|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) loss_37\NN|NONE
D019331_D006311 NONE ester_6\NN|NONE (l_appos) protector_10\NN|:|methyl|arginine|. (l_prep) against_11\IN|a|potential (l_pobj) ototoxicity_13\NN|NONE
D019331_D006316 NONE ester_13\NN|The|nitric|( (r_appos) oxide_2\NN|,|but|may|as|needed (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|oxide|,|but|may|needed (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D019331_D006316 NONE NAME_17\NN|inhibitor|arginine|)|(|NO|methyl (r_appos) ester_13\NN|The|nitric|( (r_appos) oxide_2\NN|,|but|may|as|needed (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|oxide|,|but|may|needed (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D005839_D006316 NONE gentamicin_32\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) caused_30\VBN|hearing|frequency (r_acl) loss_29\NN|NONE
D005839_D006311 NONE gentamicin_12\NN|NONE (r_compound) ototoxicity_13\NN|NONE
D000617_D006319 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|hearing (r_amod) loss_37\NN|NONE
D009569_D006311 NONE NO_17\DT|NONE (r_pobj) of_16\IN|the (r_prep) production_15\NN|as|mechanism (r_dobj) involves_13\VBZ|ototoxicity|and|,|problem (r_conj) is_2\VBZ|.|assess|,|we (l_nsubj) ototoxicity_1\NN|involves|and|,|problem
D009569_D006311 NONE NO_17\DT|NONE (r_pobj) of_16\IN|the (r_prep) production_15\NN|as|mechanism (r_dobj) involves_13\VBZ|ototoxicity|and|,|problem (l_nsubj) mechanism_12\NN|as|production (l_compound) ototoxic_11\JJ|their
D009569_D006311 NONE NO_26\DT|NONE (r_det) inhibitors_27\NNS|NONE (r_pobj) of_25\IN|the|for (r_prep) use_24\NN|to (r_dobj) assess_22\VB|.|is|,|we (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|.|assess|,|we (l_nsubj) ototoxicity_1\NN|involves|and|,|problem
D009569_D006311 NONE NO_26\DT|NONE (r_det) inhibitors_27\NNS|NONE (r_pobj) of_25\IN|the|for (r_prep) use_24\NN|to (r_dobj) assess_22\VB|.|is|,|we (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|.|assess|,|we (l_conj) involves_13\VBZ|ototoxicity|and|,|problem (l_nsubj) mechanism_12\NN|as|production (l_compound) ototoxic_11\JJ|their
D005839_D034381 CID gentamicin_4\NN| (r_npadvmod) induced_6\VBN|hearing (r_amod) loss_8\NN|but|.|NAME|in|,|gave
D009569_D006316 NONE oxide_2\NN|,|but|may|as|needed (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|oxide|,|but|may|needed (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D009569_D006316 NONE NO_4\NNP|inhibitor|arginine|NAME|)|(|methyl (r_intj) ester_13\NN|The|nitric|( (r_appos) oxide_2\NN|,|but|may|as|needed (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|oxide|,|but|may|needed (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D000617_D006311 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|hearing (r_amod) loss_37\NN|NONE (r_pobj) of_31\IN|the (r_prep) prevention_30\NN|NONE (r_pobj) for_28\IN|the|of (r_prep) use_24\NN|to (r_dobj) assess_22\VB|.|is|,|we (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|.|assess|,|we (l_nsubj) ototoxicity_1\NN|involves|and|,|problem
D000617_D006311 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|hearing (r_amod) loss_37\NN|NONE (r_pobj) of_31\IN|the (r_prep) prevention_30\NN|NONE (r_pobj) for_28\IN|the|of (r_prep) use_24\NN|to (r_dobj) assess_22\VB|.|is|,|we (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|.|assess|,|we (l_conj) involves_13\VBZ|ototoxicity|and|,|problem (l_nsubj) mechanism_12\NN|as|production (l_compound) ototoxic_11\JJ|their
6538499
D004317_D009202 CID ADR_8\NNP| (r_npadvmod) induced_10\VBN|morphological|cardiac (r_amod) alterations_13\NNS|NONE
D004317_D002286 NONE ADR_6\NNP|the|antitumor|in|tumor (r_compound) activity_8\NN|treatment|not|did|. (l_relcl) tumor_16\NN|the|antitumor|in|ADR
D004317_D064420 NONE adriamycin_6\JJ||Effect|. (l_dobj) toxicity_7\NN|NONE
D011092_D064420 NONE 400_4\CD|Effect|adriamycin|. (r_nummod) glycol_3\NN|NONE (l_advcl) adriamycin_6\JJ||Effect|. (l_dobj) toxicity_7\NN|NONE
D004317_D007939 NONE ADR_6\NNP|the|antitumor|in|tumor (r_compound) activity_8\NN|treatment|not|did|. (l_prep) in_9\IN|the|antitumor|tumor|ADR (l_pobj) leukemia_11\NN|and
12653683
D000450_D009404 NONE aldosterone_38\NN|NONE (r_pobj) by_37\IN|the (r_prep) regulation_36\NN|NONE (r_pobj) from_34\IN|to|after (r_prep) escape_33\VB|NONE (r_xcomp) appears_31\VBZ|In|,|expression|but|.|,|is|in (r_conj) increased_11\VBN|NONE (l_prep) in_12\IN|In|,|expression|appears|but|.|,|is (l_pobj) phase_16\NN|NONE (l_prep) of_17\IN|the|early (l_pobj) model_20\NN|NONE (l_prep) of_21\IN|experimental|the (l_pobj) syndrome_26\NN|NONE
D012964_D009404 NONE sodium_1\NN|Epithelial|subunit|(|ENaC|)|. (r_compound) channel_2\NN|NONE (l_appos) subunit_6\NN|Epithelial|sodium|(|ENaC|)|. (l_appos) mRNA_7\NN|NONE (l_conj) expression_10\NN|and (l_prep) in_11\IN|protein (l_pobj) rats_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) syndrome_19\NN|NONE
D012964_D009404 NONE sodium_6\NN|NONE (r_compound) excretion_7\NN|.|,|is|during|In (r_nsubjpass) decreased_9\VBN|NONE (l_prep) In_0\IN|.|,|is|during|excretion (l_pobj) syndrome_3\NN|NONE
D000450_D011507 NONE aldosterone_9\NN|and|proteinuria (r_compound) concentration_10\NN|,|sodium (l_conj) proteinuria_12\NN|and|aldosterone
D011692_D009404 CID aminonucleoside_15\RB| (r_advmod) induced_17\VBN|nephrotic|puromycin (r_amod) syndrome_19\NN|NONE
D011692_D009404 CID aminonucleoside_12\NN|We|in|.|abundance (l_pobj) syndrome_16\NN|NONE
D011692_D009404 CID PAN)-induced_14\VBN|nephrotic (r_amod) syndrome_16\NN|NONE
D011692_D009404 CID PAN_22\NNP| (r_npadvmod) induced_24\VBN|nephrotic|in (r_amod) syndrome_26\NN|NONE
D011692_D011507 CID PAN_28\NNP|NONE (r_pobj) of_26\IN|single|a (r_prep) dose_25\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treated_21\VBN|Dawley|male (r_acl) rats_20\NNS|NONE (r_pobj) in_15\IN|were|courses|. (r_prep) studied_14\VBN|NONE (l_nsubjpass) courses_2\NNS|were|.|in (l_prep) of_3\IN|The|time (l_pobj) excretion_6\NN|NONE (l_conj) concentration_10\NN|,|sodium (l_conj) proteinuria_12\NN|and|aldosterone
D012964_D011507 NONE sodium_5\NN|concentration|, (r_compound) excretion_6\NN|NONE (l_conj) concentration_10\NN|,|sodium (l_conj) proteinuria_12\NN|and|aldosterone
D012964_D011507 NONE sodium_4\NN|NONE (r_compound) excretion_5\NN|NONE (r_pobj) of_2\IN|and|The|appearance (r_prep) kinetics_1\NNS|comparable|. (l_conj) appearance_8\NN|of|and|The (l_prep) of_9\IN|the (l_pobj) proteinuria_10\NN|NONE
3615541
D000661_D006948 CID amphetamine_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) hyperactivity_9\NN|NONE
D002116_D006948 NONE calcitonin_12\NN|intracerebral (r_compound) injections_13\NNS|NONE (r_pobj) by_10\IN|of|the (r_prep) antagonism_4\NN|NONE (l_prep) of_5\IN|the|by (l_pobj) hyperactivity_9\NN|NONE
20084309
D008874_D000402 NONE MZ_42\NNP|NONE (r_compound) use_43\NN|NONE (r_pobj) by_41\IN|NONE (r_agent) caused_40\VBN|NONE (r_acl) hypoxia_39\NN|to (r_pobj) due_37\JJ|was|due|.|;|hypoxia|patients (r_prep) presented_20\VBD|NONE (l_prep) due_23\IN|was|.|;|hypoxia|due|patients (l_pobj) obstruction_27\NN|to
D008874_D009202 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of (r_conj) duration_26\NN|to|influence (r_dobj) test_7\VB|were|analyses|. (l_dobj) influence_9\NN|to|duration (l_prep) of_10\IN|the (l_pobj) variables_13\NNS|NONE (l_appos) age_15\NN|the|clinical|,|: (l_conj) sex_17\NN|, (l_conj) stroke_19\UH|, (l_conj) MP_23\NNP|, (l_amod) myocardiopathy_21\NN|)|(
D008874_D009202 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of (r_conj) duration_26\NN|to|influence (r_dobj) test_7\VB|were|analyses|. (l_dobj) influence_9\NN|to|duration (l_prep) of_10\IN|the (l_pobj) variables_13\NNS|NONE (l_appos) age_15\NN|the|clinical|,|: (l_conj) sex_17\NN|, (l_conj) stroke_19\UH|, (l_conj) MP_23\NNP|,
D008874_D009202 NONE MZ_17\NNP|NONE (r_pobj) of_16\IN|high (r_prep) doses_15\NNS|%|MR|(|severe|,|associated (r_appos) MP_8\NNP|NONE
D008874_D020521 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of (r_conj) duration_26\NN|to|influence (r_dobj) test_7\VB|were|analyses|. (l_dobj) influence_9\NN|to|duration (l_prep) of_10\IN|the (l_pobj) variables_13\NNS|NONE (l_appos) age_15\NN|the|clinical|,|: (l_conj) sex_17\NN|, (l_conj) stroke_19\UH|,
D008874_D000860 CID MZ_42\NNP|NONE (r_compound) use_43\NN|NONE (r_pobj) by_41\IN|NONE (r_agent) caused_40\VBN|NONE (r_acl) hypoxia_39\NN|to (r_pobj) due_37\JJ|was|due|.|;|hypoxia|patients (r_prep) presented_20\VBD|NONE (l_dobj) hypoxia_22\NN|was|due|.|;|due|patients
D008874_D000860 CID MZ_42\NNP|NONE (r_compound) use_43\NN|NONE (r_pobj) by_41\IN|NONE (r_agent) caused_40\VBN|NONE (r_acl) hypoxia_39\NN|to
D008874_D008944 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of
D008874_D008944 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral
D008874_D008944 NONE MZ_17\NNP|NONE (r_pobj) of_16\IN|high (r_prep) doses_15\NNS|%|MR|(|severe|,|associated (r_appos) MP_8\NNP|NONE (l_nmod) MR_6\NNP|%|(|severe|,|doses|associated
1786266
D000928_D001480 NONE antidepressant_3\NN|and|,|findings (r_compound) use_4\NN|.|Rabbit|, (r_conj) syndrome_1\NN|NONE
15325671
D017239_D001943 NONE paclitaxel_2\NN|. (l_conj) melphalan_4\NN|combined|, (l_conj) cyclophosphamide_9\NN|and (l_conj) thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|dose|sequential|triple|a (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D003520_D001943 NONE cyclophosphamide_9\NN| (r_npadvmod) based_11\VBN|dose|for (r_amod) chemotherapy_12\NN|NONE (l_prep) for_13\IN|dose|based (l_pobj) cancer_16\NN|NONE
D003520_D001943 NONE cyclophosphamide_9\NN|and (l_conj) thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|dose|sequential|triple|a (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D003520_D001943 NONE cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|characteristics|breast|responsive|metastatic|and (r_acl) cancer_12\NN|NONE
D008558_D001943 NONE melphalan_4\NN|combined|, (l_conj) cyclophosphamide_9\NN|and (l_conj) thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|dose|sequential|triple|a (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D003520_D066126 NONE cyclophosphamide_9\NN| (r_npadvmod) based_11\VBN|dose|for (r_amod) chemotherapy_12\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) association_4\NN|NONE (r_pobj) in_3\IN|toxicity|. (r_prep) observed_2\VBD|NONE (l_nsubj) toxicity_1\NN|in|.
D003520_D066126 NONE cyclophosphamide_3\NN| (r_npadvmod) related_5\VBN|)|transient|(|cardiac|% (r_amod) toxicity_7\NN|NONE
D003520_D003920 NONE cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|characteristics|breast|responsive|metastatic|and (r_acl) cancer_12\NN|NONE (l_conj) characteristics_44\NNS|breast|responsive|metastatic|receiving|and (l_appos) presence_46\NN|pretreatment|the|:|following (l_appos) history_60\NN|of|, (l_conj) smoking_62\NN|prior|,|cardiac (l_conj) mellitus_65\NN|,
D016190_D001943 NONE carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|dose|sequential|triple|a (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D018943_D006973 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|irradiation|,|and (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|pretreatment|the|:|following (l_prep) of_47\IN|history|, (l_pobj) electrocardiogram_48\NN|NONE (l_appos) abnormalities_52\NNS|(|EKG (l_appos) hypertension_56\NN|,|age
D003520_D006973 NONE cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|characteristics|breast|responsive|metastatic|and (r_acl) cancer_12\NN|NONE (l_conj) characteristics_44\NNS|breast|responsive|metastatic|receiving|and (l_appos) presence_46\NN|pretreatment|the|:|following (l_prep) of_47\IN|history|, (l_pobj) electrocardiogram_48\NN|NONE (l_appos) abnormalities_52\NNS|(|EKG (l_appos) hypertension_56\NN|,|age
D013852_D001943 NONE thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|dose|sequential|triple|a (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D018943_D001943 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|irradiation|,|and (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|pretreatment|the|:|following (r_appos) characteristics_44\NNS|breast|responsive|metastatic|receiving|and (r_conj) cancer_12\NN|NONE
D018943_D006333 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|irradiation|,|and (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|pretreatment|the|:|following (r_appos) characteristics_44\NNS|breast|responsive|metastatic|receiving|and (r_conj) cancer_12\NN|NONE (l_acl) receiving_13\VBG|characteristics|breast|responsive|metastatic|and (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|sequential|triple|a|dose (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE
D018943_D006333 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|irradiation|,|and (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|pretreatment|the|:|following (r_appos) characteristics_44\NNS|breast|responsive|metastatic|receiving|and (r_conj) cancer_12\NN|NONE (l_acl) receiving_13\VBG|characteristics|breast|responsive|metastatic|and (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|sequential|triple|a|dose (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE (l_appos) CHF_38\NNP|peritransplant|heart
D003520_D006333 CID cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|characteristics|breast|responsive|metastatic|and (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|sequential|triple|a|dose (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE
D003520_D006333 CID cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|characteristics|breast|responsive|metastatic|and (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|sequential|triple|a|dose (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE (l_appos) CHF_38\NNP|peritransplant|heart
D003520_D006333 CID cyclophosphamide_16\NN|with (r_dobj) following_14\VBG|grade|Six|. (r_prep) developed_8\VBD|NONE (l_dobj) grade_11\NN|following|Six|. (l_appos) CHF_13\NNP|reversible
D003520_D006333 CID cyclophosphamide_5\NN|NONE (r_pobj) during_3\IN|EKG (r_prep) monitoring_2\NN|.|not|did|development (r_nsubj) predict_8\VB|NONE (l_dobj) development_10\NN|.|not|monitoring|did (l_compound) CHF_9\NNP|NONE
D018943_D003920 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|irradiation|,|and (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|,
2802551
D000666_D007674 CID B_5\NN|in|chronic (r_compound) nephrotoxicity_6\NN|status|.
D000666_D007674 CID B_5\NNP|NONE (r_pobj) of_3\IN|The|nephrotoxic (r_prep) potential_2\NN|for|) (l_amod) nephrotoxic_1\JJ|The|of
D012964_D007674 NONE Sodium_0\NN|NONE (r_compound) status_1\NN|nephrotoxicity|. (r_nsubj) influences_2\VBZ|NONE (l_dobj) nephrotoxicity_6\NN|status|.
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN|that|metabolite (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|chloroacetaldehyde|that (l_relcl) carried_23\VBN|of|important|an|, (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|to|role (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D006470 CID CAA_9\NNP|NONE (r_appos) chloroacetaldehyde_7\NN|that|metabolite (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|chloroacetaldehyde|that (l_relcl) carried_23\VBN|of|important|an|, (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|to|role (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D006470 CID CAA_32\NNP|NONE (r_pobj) of_31\IN|the (r_prep) role_30\NN|to|in (r_dobj) elucidate_28\VB|NONE (l_prep) in_33\IN|to|role (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D001745 NONE CAA_4\NNP|administration|to|does|that|after|not (r_nsubj) contribute_10\VB|data|. (l_prep) to_11\IN|administration|CAA|does|that|after|not (l_pobj) damage_13\NN|NONE
C004656_D003556 CID chloroacetaldehyde_7\NN|that|metabolite (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|chloroacetaldehyde|that (l_relcl) carried_23\VBN|of|important|an|, (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|to|role (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D003556 CID CAA_9\NNP|NONE (r_appos) chloroacetaldehyde_7\NN|that|metabolite (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|chloroacetaldehyde|that (l_relcl) carried_23\VBN|of|important|an|, (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|to|role (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D003556 CID CAA_32\NNP|NONE (r_pobj) of_31\IN|the (r_prep) role_30\NN|to|in (r_dobj) elucidate_28\VB|NONE (l_prep) in_33\IN|to|role (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
11532387
D004298_D001480 NONE dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D004298_D001480 NONE dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_advcl) suggesting_29\VBG|to|.|been|mechanism|,|have|may (l_dobj) influence_32\NN|NONE (l_prep) in_37\IN|the|pathophysiologic|of (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
D012701_D001480 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D012701_D001480 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_advcl) suggesting_29\VBG|to|.|been|mechanism|,|have|may (l_dobj) influence_32\NN|NONE (l_prep) in_37\IN|the|pathophysiologic|of (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
D012701_D001480 NONE serotonin_35\NN|the (r_compound) system_36\NN|NONE (r_pobj) of_33\IN|the|pathophysiologic|in (r_prep) influence_32\NN|NONE (r_dobj) suggesting_29\VBG|to|.|been|mechanism|,|have|may (r_advcl) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D012701_D001480 NONE serotonin_35\NN|the (r_compound) system_36\NN|NONE (r_pobj) of_33\IN|the|pathophysiologic|in (r_prep) influence_32\NN|NONE (l_prep) in_37\IN|the|pathophysiologic|of (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
D018967_D013375 CID risperidone_9\NN|NONE (r_pobj) of_8\IN|dose (r_prep) reduction_7\NN|NONE (r_pobj) during_5\IN|emergent|.|rabbit (r_prep) syndrome_4\NN|NONE
D018967_D013375 CID risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D004298_D013375 NONE dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D012701_D013375 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D012701_D013375 NONE serotonin_35\NN|the (r_compound) system_36\NN|NONE (r_pobj) of_33\IN|the|pathophysiologic|in (r_prep) influence_32\NN|NONE (r_dobj) suggesting_29\VBG|to|.|been|mechanism|,|have|may (r_advcl) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D018967_D001480 CID risperidone_9\NN|NONE (r_pobj) of_8\IN|dose (r_prep) reduction_7\NN|NONE (r_pobj) during_5\IN|emergent|.|rabbit (r_prep) syndrome_4\NN|NONE
D018967_D001480 CID risperidone_8\NN|NONE (r_pobj) of_7\IN|dose (r_prep) reduction_6\NN|NONE (r_pobj) during_4\IN|patient|RS|. (r_prep) developed_2\VBN|NONE (l_dobj) RS_3\NN|patient|during|.
D018967_D001480 CID risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|to|suggesting|.|been|,|have|may (l_prep) of_3\IN|The|in|underlying (l_pobj) RS_7\NN|NONE
D018967_D001480 CID risperidone_21\NN|NONE (r_pobj) of_20\IN|pharmacological|the (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|suggesting|.|been|mechanism|,|have|may (r_prep) related_15\VBN|NONE (l_advcl) suggesting_29\VBG|to|.|been|mechanism|,|have|may (l_dobj) influence_32\NN|NONE (l_prep) in_37\IN|the|pathophysiologic|of (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
7420681
D005839_D051437 CID sulfate_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) day_22\NN|mg||/|/ (r_appos) kg_20\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|and||with (r_conj) patients_5\NNS|In|were|,|for|up|.|prospectively (r_nsubjpass) followed_36\VBN|NONE (l_prep) for_39\IN|In|were|,|up|.|prospectively|patients (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) failure_47\NN|NONE
D005839_D051437 CID gentamicin_23\NN| (r_npadvmod) treated_25\VBN|the (r_amod) patients_26\NNS|NONE (r_pobj) of_21\IN|%|)|of (r_prep) 16_14\CD|failure|Five|. (r_nsubj) had_27\VBD|NONE (l_dobj) failure_29\NN|Five|.|
D005839_D051437 CID gentamicin_2\NN|,|was|was|with|Thus|. (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|,|was|was|gentamicin|Thus|. (l_pobj) failure_7\NN|NONE
D014031_D007674 NONE tobramycin_3\JJ|NONE (r_pobj) of_2\IN|Clinical|gentamicin|and|. (r_prep) nephrotoxicity_1\NN|NONE
D014031_D007674 NONE sulfate_4\NN|Gentamicin|and (r_conj) sulfate_1\NN|.|demonstrate (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to (l_conj) nephrotoxicity_10\NN|and|in
D005839_D007674 NONE gentamicin_5\NN|of|Clinical|and|. (r_conj) nephrotoxicity_1\NN|NONE
D005839_D007674 NONE sulfate_1\NN|.|demonstrate (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to (l_conj) nephrotoxicity_10\NN|and|in
D014031_D006311 NONE sulfate_4\NN|Gentamicin|and (r_conj) sulfate_1\NN|.|demonstrate (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to
D005839_D006311 NONE sulfate_1\NN|.|demonstrate (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to
D000617_D051437 NONE aminoglycoside_43\NN| (r_npadvmod) related_45\VBN|renal|,|defined (r_amod) failure_47\NN|NONE
D014031_D051437 CID sulfate_28\NN|or|for|gentamicin (r_conj) sulfate_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) day_22\NN|mg||/|/ (r_appos) kg_20\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|and||with (r_conj) patients_5\NNS|In|were|,|for|up|.|prospectively (r_nsubjpass) followed_36\VBN|NONE (l_prep) for_39\IN|In|were|,|up|.|prospectively|patients (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) failure_47\NN|NONE
D014031_D051437 CID tobramycin_9\RB| (r_npadvmod) treated_11\VBN|the (r_amod) patients_12\NNS|NONE (r_pobj) of_7\IN||and|(|)| (r_prep) %_5\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Five_0\CD|failure|.| (r_nsubj) had_27\VBD|NONE (l_dobj) failure_29\NN|Five|.|
D014031_D051437 CID tobramycin_16\JJ|often|as (r_acomp) was_15\VBD|,|was|with|gentamicin|Thus|. (r_advcl) associated_4\VBN|NONE (l_prep) with_5\IN|,|was|was|gentamicin|Thus|. (l_pobj) failure_7\NN|NONE
12905102
D003024_D003693 CID clozapine_2\NN|NONE (r_amod) treatment_3\NN|NONE (r_pobj) during_1\IN|.|:|factors (r_prep) Delirium_0\NN|NONE
D003024_D003693 CID clozapine_7\NN|NONE (r_compound) treatment_8\NN|NONE (r_pobj) during_6\IN|Incidence|for (r_prep) factors_3\NNS|.|clarification (l_prep) for_4\IN|during|Incidence (l_pobj) delirium_5\NN|NONE
D003024_D003693 CID clozapine_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|adult|psychiatric|all (r_acl) inpatients_10\NNS|to (r_dobj) identify_6\VB|.|reviewed|We|,|records (r_xcomp) used_1\VBD|NONE (l_conj) reviewed_20\VBD|.|identify|We|,|records (l_advcl) score_25\VB|records|,|tested|and (l_dobj) incidence_26\NN|to (l_prep) of_29\IN|severity|and (l_pobj) delirium_30\NN|NONE
D003024_D003693 CID clozapine_7\NN| (r_npadvmod) treated_9\VBN|NONE (r_amod) inpatients_10\NNS|NONE (r_pobj) of_6\IN| (r_prep) %_5\NN|NONE (r_pobj) in_3\IN|in|.|Delirium|,|was (r_prep) found_2\VBN|NONE (l_nsubjpass) Delirium_0\NNP|in|.|in|,|was
D003024_D001523 NONE clozapine_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|adult|psychiatric|all (r_acl) inpatients_10\NNS|to (l_amod) psychiatric_9\JJ|treated|adult|all
8864707
D010672_D004827 NONE phenytoin_10\NNP|NONE (r_compound) overdosages_11\NNS|NONE (r_pobj) after_9\IN|of|.|in|resonance (r_prep) volumetry_2\NN|NONE (l_prep) in_6\IN|of|.|after|resonance (l_pobj) patients_8\NNS|NONE (l_amod) epileptic_7\JJ|NONE
D010672_D062787 CID phenytoin_10\NNP|NONE (r_compound) overdosages_11\NNS|NONE
D010672_D062787 CID phenytoin_3\JJ|NONE (r_compound) overdosage_4\NN|not|that|necessarily|in|does|and|is
D010672_D062787 CID phenytoin_17\JJ|NONE (r_compound) medication_18\NN|that|cause (r_nsubj) was_19\VBD|unlikely|it (r_ccomp) is_14\VBZ|not|that|necessarily|in|overdosage|does|and (r_conj) result_8\VB|.|We (l_nsubj) overdosage_4\NN|not|that|necessarily|in|does|and|is
D010672_D012640 NONE phenytoin_15\JJ|serum|volume|and (r_compound) levels_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) elevation_13\NN|,|seizure (r_conj) duration_11\NN|NONE (l_compound) seizure_10\NN|elevation|,
D010672_D002526 NONE phenytoin_11\JJ|and|atrophy (r_compound) medication_12\NN|NONE (l_conj) atrophy_15\NN|and|phenytoin
D010672_D002526 NONE phenytoin_3\JJ|NONE (r_compound) overdosage_4\NN|not|that|necessarily|in|does|and|is (r_nsubj) result_8\VB|.|We (l_prep) in_9\IN|not|that|necessarily|overdosage|does|and|is (l_pobj) atrophy_11\NN|NONE
D010672_D002526 NONE phenytoin_3\JJ|NONE (r_compound) overdosage_4\NN|not|that|necessarily|in|does|and|is (r_nsubj) result_8\VB|.|We (l_conj) is_14\VBZ|not|that|necessarily|in|overdosage|does|and (l_ccomp) was_19\VBD|unlikely|it (l_attr) cause_22\NN|that|medication (l_prep) of_23\IN|the|only (l_pobj) atrophy_25\NN|NONE
D010672_D002526 NONE phenytoin_17\JJ|NONE (r_compound) medication_18\NN|that|cause (r_nsubj) was_19\VBD|unlikely|it (r_ccomp) is_14\VBZ|not|that|necessarily|in|overdosage|does|and (r_conj) result_8\VB|.|We (l_prep) in_9\IN|not|that|necessarily|overdosage|does|and|is (l_pobj) atrophy_11\NN|NONE
D010672_D002526 NONE phenytoin_17\JJ|NONE (r_compound) medication_18\NN|that|cause (r_nsubj) was_19\VBD|unlikely|it (l_attr) cause_22\NN|that|medication (l_prep) of_23\IN|the|only (l_pobj) atrophy_25\NN|NONE
8372922
20003049
C031942_D013921 NONE argatroban_4\NN|NONE (l_prep) in_5\IN|elevation|. (l_pobj) patient_9\NN|NONE (l_prep) with_10\IN|a|transplant (l_pobj) history_13\NN|NONE (l_prep) of_14\IN|a|suspected (l_pobj) thrombocytopenia_18\NN|NONE
C031942_D013921 NONE argatroban_20\NN|In|during|.|patient|,|was (r_oprd) administered_19\VBN|NONE (l_nsubjpass) patient_11\JJ|In|argatroban|during|.|,|was (l_prep) with_12\IN|a|ill|old (l_pobj) history_15\NN|NONE (l_prep) of_16\IN|suspected|a (l_pobj) HITT_17\NNP|NONE
C031942_D013927 NONE argatroban_4\NN|NONE (l_prep) in_5\IN|elevation|. (l_pobj) patient_9\NN|NONE (l_prep) with_10\IN|a|transplant (l_pobj) history_13\NN|NONE (l_prep) of_14\IN|a|suspected (l_pobj) thrombocytopenia_18\NN|NONE (l_prep) with_19\IN|induced (l_pobj) thrombosis_20\NN|NONE
C031942_D013927 NONE argatroban_20\NN|In|during|.|patient|,|was (r_oprd) administered_19\VBN|NONE (l_nsubjpass) patient_11\JJ|In|argatroban|during|.|,|was (l_prep) with_12\IN|a|ill|old (l_pobj) history_15\NN|NONE (l_prep) of_16\IN|suspected|a (l_pobj) HITT_17\NNP|NONE
C031942_D008107 NONE argatroban_4\NN|NONE (r_pobj) of_3\IN|high (r_prep) concentrations_2\NNS|is|.|,|observed|in|were|and (r_nsubjpass) measured_6\VBN|NONE (l_conj) is_42\VBZ|.|,|observed|in|were|concentrations|and (l_attr) minutes_46\NNS|) (l_appos) minutes_52\NNS|||]|[ (l_prep) with_53\IN||=|< (l_pobj) impairment_55\NN|NONE
C031942_D008107 NONE argatroban_25\JJ|t(/|half (r_amod) life_27\NN|prolonged|a|of|) (r_npadvmod) plasma_24\NN|was|published (r_nsubjpass) observed_36\VBN|is|.|,|in|were|concentrations|and (r_conj) measured_6\VBN|NONE (l_conj) is_42\VBZ|.|,|observed|in|were|concentrations|and (l_attr) minutes_46\NNS|) (l_appos) minutes_52\NNS|||]|[ (l_prep) with_53\IN||=|< (l_pobj) impairment_55\NN|NONE
C031942_D001778 NONE argatroban_3\JJ|Correlation|versus (r_amod) concentration_4\NN|.|contributed (r_nsubj) suggest_14\VBP|NONE (l_ccomp) contributed_24\VBN|.|concentration (l_prep) to_25\IN|levels|that|have|may (l_pobj) coagulopathy_30\NN|NONE
C031942_D001778 NONE argatroban_21\NN|elevated|prolonged|of (r_amod) levels_18\NNS|that|have|may|to (r_nsubj) contributed_24\VBN|.|concentration (l_prep) to_25\IN|levels|that|have|may (l_pobj) coagulopathy_30\NN|NONE
C031942_D001778 NONE argatroban_8\JJ|in (r_amod) concentration_9\NN|to|and|extended|plasma (r_dobj) measure_6\VB|first|the (l_conj) extended_16\VBN|to|concentration|and|plasma (l_dobj) coagulopathy_17\NN|NONE
C031942_D016638 NONE argatroban_20\NN|In|during|.|patient|,|was (r_oprd) administered_19\VBN|NONE (l_nsubjpass) patient_11\JJ|In|argatroban|during|.|,|was (l_amod) ill_10\JJ|a|with|old
D006493_D013927 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|with (r_amod) thrombocytopenia_18\NN|NONE (l_prep) with_19\IN|induced (l_pobj) thrombosis_20\NN|NONE
D006493_D013927 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|.|inhibitors|HIT|or (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|.|inhibitors|method|or (l_prep) with_27\IN|undergoing (l_pobj) thrombosis_28\NN|NONE
D006493_D013927 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|.|inhibitors|HIT|or (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|.|inhibitors|method|or (l_prep) with_27\IN|undergoing (l_pobj) thrombosis_28\NN|NONE (l_appos) HITT_30\NNP|NONE
D006493_D013921 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|with (r_amod) thrombocytopenia_18\NN|NONE
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (l_appos) HIT_23\NNP|induced|(
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|.|inhibitors|HIT|or (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|.|inhibitors|method|or
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|.|inhibitors|HIT|or (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|.|inhibitors|method|or (l_prep) with_27\IN|undergoing (l_pobj) thrombosis_28\NN|NONE (l_appos) HITT_30\NNP|NONE
17111419
D002125_C536214 NONE gluconate_5\NN|NONE (r_pobj) with_2\IN|Empirical (r_prep) treatment_1\NN|subsided|and|,|was (r_nsubjpass) initiated_7\VBN|NONE (l_conj) subsided_13\VBD|and|treatment|,|was (l_nsubj) contractions_11\NNS|.|over|slowly
D002034_D006996 NONE bumetanide_9\NN|that|loop (r_nsubj) is_10\VBZ|it|Upon|.|,|was (l_attr) loop_12\NN|bumetanide|that (l_relcl) cause_16\VB|a|diuretic (l_dobj) hypocalcemia_18\NN|may|that
D002118_D006996 NONE calcium_9\NN|NONE (r_compound) chelation_10\NN|NONE (r_pobj) to_8\IN|resulting|severe|by|a (r_prep) reaction_7\NN|NONE (l_acl) resulting_15\VBG|severe|by|a|to (l_prep) in_16\IN|NONE (l_pobj) hypocalcemia_19\NN|NONE
D049994_D006996 NONE diuretic_13\NN|a|cause (r_amod) loop_12\NN|bumetanide|that (l_relcl) cause_16\VB|a|diuretic (l_dobj) hypocalcemia_18\NN|may|that
C102006_D064420 NONE citrate_1\JJ|Severe (r_compound) toxicity_2\NN|donation|.
C102006_D064420 NONE citrate_6\JJ|severe (r_compound) toxicity_7\NN|NONE
C102006_D064420 NONE citrate_22\JJ|NONE (r_compound) toxicity_23\NN|NONE
C102006_D006996 CID citrate_13\NN|NONE (r_compound) anticoagulant_14\NN|NONE (r_pobj) by_11\IN|resulting|severe|a|to (r_prep) reaction_7\NN|NONE (l_acl) resulting_15\VBG|severe|by|a|to (l_prep) in_16\IN|NONE (l_pobj) hypocalcemia_19\NN|NONE
C102006_D006996 CID citrate_22\JJ|NONE (r_compound) toxicity_23\NN|NONE (r_pobj) to_21\IN|NONE (r_pcomp) due_20\IN|severe (r_amod) reactions_19\NNS|NONE (r_dobj) prevent_17\VB|to (r_xcomp) help_16\VB|is|screening|that (r_xcomp) recommended_14\VBN|.|We (l_nsubjpass) screening_4\NN|help|is|that (l_prep) for_5\IN|careful (l_pobj) medications_6\NNS|NONE (l_conj) conditions_9\NNS|and (l_acl) predisposing_10\VBG|underlying (l_prep) to_11\IN|NONE (l_pobj) hypocalcemia_12\NN|NONE
2070391
D008012_D010146 CID lidocaine_6\NN|as (r_dobj) using_4\VBG|in|. (r_acl) Reduction_0\NN|NONE (l_prep) in_1\IN|using|. (l_pobj) pain_3\NN|NONE
D008012_D010146 CID lidocaine_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) injection_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|NONE (r_acl) pain_5\NN|that|to|is
D008012_D010146 CID lidocaine_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) pH_12\NN|to|into (r_dobj) adjust_10\VB|a|buffering (r_relcl) solution_8\NN|NONE (r_pobj) of_5\IN|the (r_prep) addition_4\NN|would|during|if|pain (r_nsubj) reduce_20\VB|To (l_dobj) pain_21\NN|would|during|if|addition
D008012_D010146 CID lidocaine_13\NN|lidocaine|in|and (r_dobj) receiving_11\VBG|NONE (r_pcomp) after_10\IN|to|severity (r_prep) quantify_5\VB|patients|.|were (l_dobj) severity_7\NN|to|after (l_prep) of_8\IN|the (l_pobj) pain_9\NN|NONE
D008012_D010146 CID lidocaine_20\NN|in|lidocaine|and (r_conj) receiving_11\VBG|NONE (r_pcomp) after_10\IN|to|severity (r_prep) quantify_5\VB|patients|.|were (l_dobj) severity_7\NN|to|after (l_prep) of_8\IN|the (l_pobj) pain_9\NN|NONE
D008012_D010146 CID lidocaine_6\NN|NONE (r_pobj) for_4\IN|The|mean|pain (r_prep) score_3\NN|lower|. (l_compound) pain_2\NN|for|The|mean
D008012_D010146 CID lidocaine_16\NN|NONE (r_pobj) for_14\IN|)|(|mean|the|+/|P|, (r_prep) score_13\NN|NONE (r_pobj) than_10\IN|significantly (r_prep) lower_9\JJR|.|score (r_acomp) was_7\VBD|NONE (l_nsubj) score_3\NN|lower|. (l_compound) pain_2\NN|for|The|mean
D008012_D010146 CID lidocaine_5\NN|NONE (r_pobj) of_3\IN|pH|The (r_prep) adjustment_2\NN|can|.|easily|be|in (r_nsubjpass) accomplished_8\VBN|NONE (l_prep) in_10\IN|can|.|easily|be|adjustment (l_pobj) laboratory_13\NN|NONE (l_prep) before_14\IN|the|catheterization (l_pobj) injection_15\NN|NONE (l_prep) in_18\IN|and|results (l_pobj) reduction_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) pain_23\NN|NONE
2611118
D004008_D056486 CID diclofenac_23\NNP|NONE (r_pobj) by_22\IN|,|,|commonly|.|hepatitis (r_agent) induced_21\VBN|tolerated|,|abnormalities|and|have|been (r_conj) recorded_13\VBN|NONE (l_nsubjpass) abnormalities_7\NNS|tolerated|,|and|induced|have|been (l_prep) of_8\IN|asymptomatic (l_pobj) function_10\NN|NONE
D004008_D056486 CID diclofenac_23\NNP|NONE (r_pobj) by_22\IN|,|,|commonly|.|hepatitis (r_agent) induced_21\VBN|tolerated|,|abnormalities|and|have|been (l_nsubj) hepatitis_20\NN|,|by|,|commonly|.
D004008_D006521 NONE sodium_6\NN|diclofenac (r_compound) therapy_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|active|.|Chronic (r_acl) hepatitis_2\NN|NONE
D004008_D006521 NONE sodium_13\NN|NONE (r_pobj) with_11\IN|progressed|months (r_prep) therapy_10\NN|NONE (r_pobj) after_7\IN|hepatitis|.|patient|finding|, (r_prep) developed_3\VBD|NONE (l_dobj) hepatitis_6\NN|after|.|patient|finding|,
2484011
D002395_D011596 NONE catecholamine_18\NN|and/or|turnover|metabolism (r_compound) rate_20\NN|NONE (r_pobj) of_17\IN|a|and|probable|increase|by (r_prep) decrease_16\NN|results|. (l_conj) increase_29\NN|a|and|probable|of|by (l_relcl) account_38\VB|resulting|a|in (l_prep) for_39\IN|which|may (l_pobj) depression_42\NN|NONE
D000547_D011596 CID amantadine_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Readministration_0\NN|after|in|from|.|,|motility|,|with (r_nsubj) increased_12\VBN|NONE (l_prep) with_21\IN|Readministration|after|in|from|.|,|motility|, (l_pobj) exception_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) mice_28\NNS|NONE (l_relcl) occurred_33\VBD|C|the (l_nsubj) suppression_30\NN|where (l_prep) of_31\IN|NONE (l_pobj) motility_32\NN|NONE
D000547_D011596 CID amantadine_45\NN|NONE (r_pobj) by_44\IN|in (r_agent) caused_43\VBN|a|behavioral (r_acl) depression_42\NN|NONE
D000588_D011596 NONE amines_6\NNS|NONE (r_pobj) of_3\IN|biochemical|The (r_prep) results_2\NNS|.|decrease (r_nsubj) suggest_13\VBP|NONE (l_dobj) decrease_16\NN|results|. (l_conj) increase_29\NN|a|and|probable|of|by (l_relcl) account_38\VB|resulting|a|in (l_prep) for_39\IN|which|may (l_pobj) depression_42\NN|NONE
D009638_D011596 NONE norepinephrine_35\NN|NONE (r_pobj) of_34\IN||O (r_prep) methylation_33\NN|NONE (r_pobj) in_30\IN|account|resulting|a (r_prep) increase_29\NN|a|and|probable|of|by (l_relcl) account_38\VB|resulting|a|in (l_prep) for_39\IN|which|may (l_pobj) depression_42\NN|NONE
D000547_D003866 NONE amantadine_4\JJ|depressed|locomotor (r_nmod) activity_7\NN|NONE (l_amod) depressed_5\JJ|amantadine|locomotor
9754849
D003932_D002819 NONE heroine_30\NN|previously (r_dobj) abusing_29\VBG|an (r_acl) inpatient_27\NN|NONE (r_pobj) in_25\IN|to|rapid (r_prep) adjustment_15\NN|NONE (r_pobj) by_13\IN|transiently|both (r_agent) induced_12\VBN|movements (r_xcomp) choreoathetoid_8\JJ|and|report|This|. (l_dobj) movements_9\NNS|induced
D003042_D002819 CID cocaine_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) intoxications_10\NNS|NONE (r_pobj) during_9\IN|to|abnormalities (r_prep) be_5\VB|are|.|hyperkinesias (r_xcomp) known_3\VBN|NONE (l_nsubjpass) hyperkinesias_1\NNS|are|.|be
D003042_D002819 CID cocaine_32\NN|and (r_conj) heroine_30\NN|previously (r_dobj) abusing_29\VBG|an (r_acl) inpatient_27\NN|NONE (r_pobj) in_25\IN|to|rapid (r_prep) adjustment_15\NN|NONE (r_pobj) by_13\IN|transiently|both (r_agent) induced_12\VBN|movements (r_xcomp) choreoathetoid_8\JJ|and|report|This|. (l_dobj) movements_9\NNS|induced
D008691_D002819 CID methadone_7\NN|NONE (r_pobj) to_6\IN|rapid (r_prep) adjustment_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Choreoathetoid|. (r_acl) movements_1\NNS|NONE
D008691_D002819 CID methadone_24\NN|NONE (r_pobj) to_16\IN|rapid|in (r_prep) adjustment_15\NN|NONE (r_pobj) by_13\IN|transiently|both (r_agent) induced_12\VBN|movements (r_xcomp) choreoathetoid_8\JJ|and|report|This|. (l_dobj) movements_9\NNS|induced
D003042_D020820 NONE cocaine_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) intoxications_10\NNS|NONE (r_pobj) during_9\IN|to|abnormalities (r_prep) be_5\VB|are|.|hyperkinesias (l_attr) abnormalities_8\NNS|to|during
D003042_D006948 CID cocaine_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) intoxications_10\NNS|NONE (r_pobj) during_9\IN|to|abnormalities (r_prep) be_5\VB|are|.|hyperkinesias (r_xcomp) known_3\VBN|NONE (l_nsubjpass) hyperkinesias_1\NNS|are|.|be
354896
D008012_D003866 NONE lidocaine_8\NN|NONE (r_pobj) of_7\IN|mg|in|single|a (r_prep) bolus_6\NN|NONE (r_pobj) of_2\IN|Intravenous (r_prep) administration_1\NN|in|. (r_nsubj) resulted_15\VBD|NONE (l_prep) in_16\IN|administration|. (l_pobj) depression_18\NN|NONE
D008012_D006323 CID Lidocaine_0\NN| (r_npadvmod) induced_2\VBN|.|cardiac (r_amod) asystole_4\NN|NONE
D008012_D001919 NONE lidocaine_29\NN|NONE (r_pobj) to_28\IN|a|true (r_prep) idiosyncrasy_27\NN|probably|this|.|,|,|thus (r_dobj) represented_24\VBD|;|patient|conditions|and (r_conj) had_2\VBD|NONE (l_dobj) conditions_6\NNS|represented|;|patient|and (l_relcl) predisposed_10\VBN|apparent|no|associated (l_prep) to_12\IN|which|might|have|him (l_pobj) development_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) bradyarrhythmias_16\NNS|NONE
20619828
D002997_-1 NONE Clomipramine_0\NNP|in (r_compound) exposure_1\NN|inflexibility|changes|. (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|changes|.
D002997_-1 NONE Clomipramine_0\NNP|in (r_compound) exposure_1\NN|inflexibility|changes|. (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|changes|. (l_appos) impairment_41\NN|behavioral|(|,|,|perseveration (l_conj) hoarding_51\NN|(|paradigm|working|memory|, (l_conj) dysfunction_55\NN|and|,
D002997_D060845 CID Clomipramine_0\NNP|in (r_compound) exposure_1\NN|inflexibility|changes|. (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|changes|. (l_appos) impairment_41\NN|behavioral|(|,|,|perseveration (l_conj) hoarding_51\NN|(|paradigm|working|memory|,
D002997_D008569 CID Clomipramine_0\NNP|in (r_compound) exposure_1\NN|inflexibility|changes|. (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|changes|. (l_appos) impairment_41\NN|behavioral|(|,|,|perseveration
D002997_D001008 CID Clomipramine_0\NNP|in (r_compound) exposure_1\NN|inflexibility|changes|. (r_nsubj) produced_5\VBD|NONE (l_dobj) changes_10\NNS|inflexibility|exposure|. (l_relcl) include_12\VBP|significant|behavioral (l_dobj) anxiety_14\NN|that
18329269
D006220_D002375 CID haloperidol_36\NN| (r_npadvmod) induced_38\VBN|for|rat|catalepsy (r_amod) model_40\NN|NONE (l_compound) catalepsy_39\NN|for|rat|induced
D006220_D010300 NONE haloperidol_36\NN| (r_npadvmod) induced_38\VBN|for|rat|catalepsy (r_amod) model_40\NN|NONE (l_prep) for_41\IN|rat|catalepsy|induced (l_pobj) disease_44\NN|NONE
18752389
D019821_D017114 NONE simvastatin_21\NN|mg||/ (r_nmod) day_25\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) conversion_19\NN|weeks (r_pobj) after_18\IN|transplantation|simvastatin (r_prep) necessitating_13\VBG|hepatic|fulminant (r_acl) failure_12\NN|who
C492458_D017093 NONE ezetimibe_2\NN| (r_npadvmod) induced_4\VBN|.|hepatic|necessitating (r_amod) failure_6\NN|NONE
C492458_D017093 NONE ezetimibe_13\NN| (r_npadvmod) induced_15\VBN|resulted|liver (r_amod) failure_17\NN|NONE
C532833_D056486 NONE acid_25\NN|NONE (r_pobj) of_22\IN|the (r_prep) glucuronidation_21\NN|,|resulting|have|may (r_dobj) inhibited_19\VBN|and|glucuronidation|Ezetimibe|. (l_advcl) resulting_27\VBG|,|glucuronidation|have|may (l_prep) in_28\IN|NONE (l_pobj) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|and|simvastatin|increased
D015283_D003866 NONE escitalopram_2\NNP|taking|and|(|) (r_conj) Simvastatinezetimibe_0\NNP|and|excluded|were|, (l_relcl) taking_7\VBG|escitalopram|and|(|) (l_prep) for_8\IN|she|which|was (l_pobj) depression_9\NN|NONE
C492458_D056486 CID ezetimibe_17\NN|combination|the (r_appos) agent_14\NN|or (r_conj) ezetimibe_10\NN|NONE (r_pobj) with_9\IN|been|.|However|,|widely|events|have|not (r_prep) published_8\VBN|NONE (l_nsubjpass) events_3\NNS|been|.|with|However|,|widely|have|not (l_amod) hepatotoxic_2\JJ|NONE
C492458_D056486 CID Simvastatinezetimibe_0\NNP|and|excluded|were|, (r_nsubjpass) discontinued_12\VBN|NONE (l_conj) excluded_21\VBN|and|were|,|Simvastatinezetimibe (l_nsubjpass) causes_17\NNS|were|. (l_prep) of_18\IN|potential|other (l_pobj) hepatotoxicity_19\NN|NONE
C492458_D056486 CID simvastatinezetimibe_7\NN| (r_npadvmod) induced_9\VBN|the (r_amod) hepatotoxicity_10\NN|NONE
C492458_D056486 CID ezetimibe_10\NN|NONE (r_pobj) with_7\IN|potential (r_prep) hepatotoxicity_6\NN|NONE
C492458_D003866 NONE Simvastatinezetimibe_0\NNP|and|excluded|were|, (l_relcl) taking_7\VBG|escitalopram|and|(|) (l_prep) for_8\IN|she|which|was (l_pobj) depression_9\NN|NONE
C108606_D056486 NONE ezetimibe_10\NN|NONE (r_pobj) with_9\IN|been|.|However|,|widely|events|have|not (r_prep) published_8\VBN|NONE (l_nsubjpass) events_3\NNS|been|.|with|However|,|widely|have|not (l_amod) hepatotoxic_2\JJ|NONE
C108606_D056486 NONE Ezetimibe_0\NNP|and|inhibited|glucuronidation|. (r_nsubj) undergoes_1\VBZ|NONE (l_conj) inhibited_19\VBN|and|glucuronidation|Ezetimibe|. (l_advcl) resulting_27\VBG|,|glucuronidation|have|may (l_prep) in_28\IN|NONE (l_pobj) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|and|simvastatin|increased
C108606_D056486 NONE ezetimibe_17\NN|of (r_compound) inhibition_18\NN|NONE (r_pobj) by_16\IN|simvastatin|increased|the (r_prep) exposure_15\NN|mechanism|that (r_attr) is_11\VBZ|.|We (l_nsubj) mechanism_4\NN|exposure|that (l_prep) of_5\IN|the (l_pobj) hepatotoxicity_10\NN|NONE
D014530_D056486 NONE diphosphate_6\NN|UGT|in (r_compound) glucoronosyltransferases_7\NNS|NONE (r_pobj) by_4\IN|extensive (r_prep) glucuronidation_3\NN|and|inhibited|Ezetimibe|. (r_dobj) undergoes_1\VBZ|NONE (l_conj) inhibited_19\VBN|and|glucuronidation|Ezetimibe|. (l_advcl) resulting_27\VBG|,|glucuronidation|have|may (l_prep) in_28\IN|NONE (l_pobj) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|and|simvastatin|increased
D019821_D056486 NONE simvastatin_9\NN|NONE (r_pobj) with_8\IN|.|for|had|been|panel (r_prep) maintained_7\VBN|NONE (l_prep) for_10\IN|with|.|had|been|panel (l_pobj) months_12\NNS|NONE (l_prep) before_13\IN| (l_pobj) conversion_15\NN|NONE (l_prep) without_16\IN|the (l_pobj) evidence_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) hepatotoxicity_19\NN|NONE
D019821_D056486 NONE simvastatin_30\NN|and|hepatotoxicity|increased (r_amod) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|and|simvastatin|increased
D019821_D056486 NONE simvastatin_14\NN|by|increased|the (r_amod) exposure_15\NN|mechanism|that (r_attr) is_11\VBZ|.|We (l_nsubj) mechanism_4\NN|exposure|that (l_prep) of_5\IN|the (l_pobj) hepatotoxicity_10\NN|NONE
D015283_D056486 NONE escitalopram_2\NNP|taking|and|(|) (r_conj) Simvastatinezetimibe_0\NNP|and|excluded|were|, (r_nsubjpass) discontinued_12\VBN|NONE (l_conj) excluded_21\VBN|and|were|,|Simvastatinezetimibe (l_nsubjpass) causes_17\NNS|were|. (l_prep) of_18\IN|potential|other (l_pobj) hepatotoxicity_19\NN|NONE
C492458_D017114 CID mg_33\NN|/ (r_nummod) day_35\NN||mg| (r_npadvmod) ezetimibe_31\NN|to (r_dobj) simvastatin_27\NN|transplantation|after (r_advcl) necessitating_13\VBG|hepatic|fulminant (r_acl) failure_12\NN|who
8996652
D005665_D006311 NONE furosemide_19\NN|and|particularly (r_conj) aminoglycosides_17\NNS|a|,|dose|prolonged|and (r_appos) administration_7\NN|NONE (r_pobj) to_4\IN|closely (r_prep) related_3\JJ|Ototoxicity|. (r_oprd) appeared_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|related|.
D005665_D006311 NONE furosemide_19\NN|and|particularly (r_conj) aminoglycosides_17\NNS|a|,|dose|prolonged|and (r_appos) administration_7\NN|NONE (l_conj) dose_11\NN|aminoglycosides|a|,|prolonged|and (l_prep) of_12\IN|higher|total (l_pobj) drugs_14\NNS|NONE (l_compound) ototoxic_13\JJ|NONE
D000617_D006311 NONE aminoglycosides_17\NNS|a|,|dose|prolonged|and (r_appos) administration_7\NN|NONE (r_pobj) to_4\IN|closely (r_prep) related_3\JJ|Ototoxicity|. (r_oprd) appeared_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|related|.
D000617_D006311 NONE aminoglycosides_17\NNS|a|,|dose|prolonged|and (r_appos) administration_7\NN|NONE (l_conj) dose_11\NN|aminoglycosides|a|,|prolonged|and (l_prep) of_12\IN|higher|total (l_pobj) drugs_14\NNS|NONE (l_compound) ototoxic_13\JJ|NONE
19759529
D006220_D006948 NONE haloperidol_5\NN|clozapine (r_nmod) antipsychotics_16\NNS|effective|. (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|antipsychotics|. (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
-1_D006948 NONE SSR103800_12\NNP|NONE (r_pobj) of_11\IN|like|potential|the|involving (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|,|properties (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|particular|a|, (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
-1_D006948 NONE SSR103800_3\NNP|(|p.o.|)|mg/kg|blocked|induced (r_nmod) hyperactivity_12\NN|NONE
-1_D006948 NONE SSR103800_3\NNP|(|p.o.|)|mg/kg|blocked|induced (r_nmod) hyperactivity_12\NN|NONE (r_punct) that_2\IN|.|reversed|and|Results (r_dobj) showed_1\VBD|NONE (l_conj) reversed_26\VBD|.|that|and|Results (l_dobj) hyperactivity_28\NN|partially
-1_D006948 NONE SSR103800_3\NNP|or|observed|affect|)|In|, (r_nsubj) failed_4\VBD|NONE (l_xcomp) affect_6\VB|or|observed|)|In|,|SSR (l_dobj) hyperactivity_7\NN|to
-1_D002375 NONE SSR103800_6\NNP|up|However|Together|,|unlike|retention|not|did|catalepsy|, (r_nsubj) produce_9\VB|NONE (l_dobj) catalepsy_10\NN|up|However|Together|,|unlike|retention|SSR|not|did|,
D016202_D012559 NONE aspartate_15\NNP||N (r_appos) methyl_11\NN|glutamate|NMDA|)|the|( (r_nmod) receptor_19\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) antagonists_5\NNS|symptoms|that (r_nsubj) produce_20\VBP|the (l_dobj) symptoms_24\NNS|that|antagonists (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D016202_D012559 NONE NMDA_17\NNP|glutamate|methyl|)|the|( (r_nmod) receptor_19\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) antagonists_5\NNS|symptoms|that (r_nsubj) produce_20\VBP|the (l_dobj) symptoms_24\NNS|that|antagonists (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D016202_D012559 NONE NMDA_41\NNP|its (r_compound) receptor_42\NN|NONE (r_pobj) via_39\IN|a|of (r_prep) dysfunctioning_34\NN|NONE (r_pobj) of_32\IN|the (r_prep) idea_31\NN|NONE (r_pobj) to_29\IN|has|However|,|.|observation (r_prep) led_28\VBN|NONE (l_nsubj) observation_3\NN|has|However|,|.|to (l_relcl) produce_20\VBP|the (l_dobj) symptoms_24\NNS|that|antagonists (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D004298_D006948 NONE dopamine_15\NN|(|)|DAT(/ (r_compound) transporter_16\NN|NONE (r_pobj) in_14\IN|naturally (r_prep) observed_13\VBN|or|affect|)|In|,|SSR (r_conj) failed_4\VBD|NONE (l_xcomp) affect_6\VB|or|observed|)|In|,|SSR (l_dobj) hyperactivity_7\NN|to
D000661_D006948 CID amphetamine_30\NN|drug|or|either|mice (r_appos) challenge_26\NN|NONE (r_dobj) involving_23\VBG|like|potential|of|the (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|,|properties (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|particular|a|, (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
D000661_D006948 CID amphetamine_10\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|NONE (r_acl) hyperactivity_7\NN|to
D003024_D006948 NONE clozapine_12\NN|haloperidol (r_nmod) antipsychotics_16\NNS|effective|. (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|antipsychotics|. (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
D016291_D006948 CID MK-801_32\NNP|NONE (r_punct) )_33\-RRB-|ie|,|(|and (r_punct) amphetamine_30\NN|drug|or|either|mice (r_appos) challenge_26\NN|NONE (r_dobj) involving_23\VBG|like|potential|of|the (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|,|properties (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|particular|a|, (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
D016291_D006948 CID MK-801_23\NNP|NONE (r_punct) and_24\CC|.|that|reversed|Results (r_cc) showed_1\VBD|NONE (l_dobj) that_2\IN|.|reversed|and|Results (l_punct) hyperactivity_12\NN|NONE
D016291_D006948 CID MK-801_23\NNP|NONE (r_punct) and_24\CC|.|that|reversed|Results (r_cc) showed_1\VBD|NONE (l_conj) reversed_26\VBD|.|that|and|Results (l_dobj) hyperactivity_28\NN|partially
C094645_D006948 NONE aripiprazole_14\NN|(|and|olanzapine|)|, (r_conj) clozapine_12\NN|haloperidol (r_nmod) antipsychotics_16\NNS|effective|. (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|antipsychotics|. (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
D004298_D012559 NONE dopamine_8\NN|NONE (r_compound) neurotransmission_9\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) dysfunction_6\NN|NONE (r_pobj) with_5\IN|.|has|been|Schizophrenia|initially (r_prep) associated_4\VBN|NONE (l_nsubjpass) Schizophrenia_0\NNP|.|has|been|with|initially
D018698_D012559 NONE glutamate_8\NN|methyl|NMDA|)|the|( (r_nmod) receptor_19\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) antagonists_5\NNS|symptoms|that (r_nsubj) produce_20\VBP|the (l_dobj) symptoms_24\NNS|that|antagonists (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D016202_D006948 NONE NMDA_40\NNP|DAT(/|,|ie|and|)|( (r_compound) Nr1(neo-/-_41\NNP|transgenic|) (r_appos) mice_36\NNS|drug|or|either|amphetamine (r_conj) challenge_26\NN|NONE (r_dobj) involving_23\VBG|like|potential|of|the (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|,|properties (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|particular|a|, (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
D016202_D006948 NONE NMDA_19\NNP|the|receptor|,|competitive (r_compound) antagonist_21\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|(|p.o.|)|mg/kg|SSR|blocked (r_acl) hyperactivity_12\NN|NONE
D016202_D006948 NONE NMDA_19\NNP|the|receptor|,|competitive (r_compound) antagonist_21\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|(|p.o.|)|mg/kg|SSR|blocked (r_acl) hyperactivity_12\NN|NONE (r_punct) that_2\IN|.|reversed|and|Results (r_dobj) showed_1\VBD|NONE (l_conj) reversed_26\VBD|.|that|and|Results (l_dobj) hyperactivity_28\NN|partially
D016202_D006948 NONE NMDA_30\NNP|Nr(neo/|) (r_nmod) mice_33\NNS|NONE (r_pobj) of_29\IN|spontaneous (r_prep) hyperactivity_28\NN|partially (r_dobj) reversed_26\VBD|.|that|and|Results (r_conj) showed_1\VBD|NONE (l_dobj) that_2\IN|.|reversed|and|Results (l_punct) hyperactivity_12\NN|NONE
D016202_D006948 NONE NMDA_30\NNP|Nr(neo/|) (r_nmod) mice_33\NNS|NONE (r_pobj) of_29\IN|spontaneous (r_prep) hyperactivity_28\NN|partially
C076029_D006948 NONE olanzapine_10\NN|(|and|)|aripiprazole|, (r_nmod) clozapine_12\NN|haloperidol (r_nmod) antipsychotics_16\NNS|effective|. (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|antipsychotics|. (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
8170551
D000086_D053040 NONE Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|implications|:|. (r_amod) nephrolithiasis_3\NN|NONE
D000086_D053040 NONE acetazolamide_5\NN|NONE (r_pobj) of_4\IN|a (r_prep) complication_3\NN|Nephrolithiasis|but|.|preclude (r_attr) is_1\VBZ|NONE (l_nsubj) Nephrolithiasis_0\NNP|complication|but|.|preclude
D000086_D007669 CID acetazolamide_3\NN|NONE (r_pobj) on_2\IN|Three (r_prep) patients_1\NNS|calculi|. (r_nsubj) developed_8\VBN|NONE (l_dobj) calculi_10\NNS|patients|.
D000086_D009468 NONE Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|implications|:|. (r_amod) nephrolithiasis_3\NN|NONE (l_appos) implications_5\NNS|:|induced|. (l_prep) for_6\IN|NONE (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) disorders_10\NNS|NONE
10342929
D000806_D000799 CID inhibitors_4\NNS|NONE (r_pobj) to_2\IN|NONE (r_pcomp) due_1\IN|. (r_prep) Angioedema_0\NNP|NONE
D000806_D000799 CID inhibitor_13\NN|)|ACE (r_compound) treatment_14\NN|incidence|patients|(|. (r_nsubj) is_15\VBZ|NONE (l_nsubj) incidence_2\NN|patients|(|treatment|. (l_prep) of_3\IN|estimated|during|The (l_pobj) angioedema_4\NN|NONE
15275829
D009538_D012640 CID nicotine_11\NN| (r_npadvmod) induced_13\VBN|and|hypolocomotion (r_amod) seizures_14\NNS|NONE
D009538_D012640 CID nicotine_2\NN|NONE (r_pobj) of_1\IN|to (r_prep) Binding_0\NN|series|. (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|Binding|. (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|,|that|from (l_pobj) seizures_30\NNS|NONE
D009538_D012640 CID nicotine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) seizures_12\NNS|NONE
D009538_D012640 CID nicotine_10\NN|NONE (r_pobj) of_9\IN|the|at (r_prep) effects_8\NNS|NONE (r_pobj) to_6\IN|less (r_prep) sensitive_5\JJ|mice|measured|.|, (r_acomp) were_3\VBD|NONE (l_advcl) measured_16\VBN|mice|sensitive|.|, (l_conj) measured_30\VBN|and|as|at|, (l_prep) as_31\IN|NONE (l_pobj) sensitivity_32\NN|NONE (l_prep) to_33\IN|NONE (l_pobj) seizures_37\NNS|NONE
D009538_D012640 CID nicotine_34\NN| (r_npadvmod) induced_36\VBN|NONE (r_amod) seizures_37\NNS|NONE
D009538_D012640 CID nicotine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) seizures_10\NNS|NONE
D009538_D012640 CID nicotine_15\NN| (r_npadvmod) induced_17\VBN|and|hypolocomotion (r_amod) seizures_18\NNS|NONE
D009538_D014202 NONE nicotine_2\NN|NONE (r_pobj) of_1\IN|to (r_prep) Binding_0\NN|series|. (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|Binding|. (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) from_20\IN|to|,|that (l_pobj) exploration_22\NN|NONE (l_conj) sedation_24\NN|,|altered (l_conj) tremors_27\NNS|and|,
D000109_D006948 NONE acetylcholine_5\NN|alpha|nicotinic|receptor (r_compound) subunits_7\NNS|for|.|necessary (r_nsubj) are_8\VBP|NONE (l_prep) for_10\IN|.|necessary|subunits (l_pobj) seizures_14\NNS|NONE (l_conj) hypolocomotion_16\NN|induced|and
D009538_D006948 NONE nicotine_11\NN| (r_npadvmod) induced_13\VBN|and|hypolocomotion (r_amod) seizures_14\NNS|NONE (l_conj) hypolocomotion_16\NN|induced|and
D009538_D006948 NONE nicotine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) seizures_12\NNS|NONE (r_pobj) in_8\IN|hypolocomotion|beta|and|the (r_prep) subunits_7\NNS|NONE (l_conj) hypolocomotion_14\NN|beta|and|in|the
D009538_D006948 NONE nicotine_15\NN| (r_npadvmod) induced_17\VBN|and|hypolocomotion (r_amod) seizures_18\NNS|NONE (l_conj) hypolocomotion_20\NN|and|induced
D000109_D003643 NONE acetylcholine_5\NN|(|nAChRs|)|nicotinic (r_compound) receptors_6\NNS|NONE (r_pobj) to_3\IN|of (r_prep) Binding_0\NN|series|. (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|Binding|. (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|,|that|from (l_pobj) seizures_30\NNS|NONE (l_conj) death_32\NN|and
D000109_D012640 NONE acetylcholine_5\NN|alpha|nicotinic|receptor (r_compound) subunits_7\NNS|for|.|necessary (r_nsubj) are_8\VBP|NONE (l_prep) for_10\IN|.|necessary|subunits (l_pobj) seizures_14\NNS|NONE
D000109_D012640 NONE acetylcholine_5\NN|(|nAChRs|)|nicotinic (r_compound) receptors_6\NNS|NONE (r_pobj) to_3\IN|of (r_prep) Binding_0\NN|series|. (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|Binding|. (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|,|that|from (l_pobj) seizures_30\NNS|NONE
D000109_D014202 NONE acetylcholine_5\NN|(|nAChRs|)|nicotinic (r_compound) receptors_6\NNS|NONE (r_pobj) to_3\IN|of (r_prep) Binding_0\NN|series|. (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|Binding|. (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) from_20\IN|to|,|that (l_pobj) exploration_22\NN|NONE (l_conj) sedation_24\NN|,|altered (l_conj) tremors_27\NNS|and|,
D009538_D003643 NONE nicotine_2\NN|NONE (r_pobj) of_1\IN|to (r_prep) Binding_0\NN|series|. (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|Binding|. (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|,|that|from (l_pobj) seizures_30\NNS|NONE (l_conj) death_32\NN|and
9812111
D006220_D011595 NONE haloperidol_12\NN|phase|, (r_appos) A_7\NNP|who (r_dobj) completed_5\VBD||the (r_relcl) patients_3\NNS|NONE (r_pobj) For_0\IN|efficacious|. (r_prep) was_13\VBD|NONE (l_acomp) efficacious_14\JJ|.|For (l_prep) to_17\IN|superior|and (l_pobj) haloperidol_22\NN|NONE (l_prep) for_25\IN|placebo|dose|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_conj) on_36\IN|factor|and (l_pobj) agitation_38\NN|NONE
D006220_D011595 NONE haloperidol_22\NN|NONE (l_prep) for_25\IN|placebo|dose|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_conj) on_36\IN|factor|and (l_pobj) agitation_38\NN|NONE
D006220_D000544 NONE haloperidol_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) psychosis_13\NN|NONE (l_prep) in_17\IN|behaviors|and (l_pobj) disease_20\NN|NONE
D006220_D000544 NONE haloperidol_17\NN|NONE (r_pobj) of_16\IN|two (r_prep) doses_15\NNS|NONE (r_pobj) of_13\IN|and|the|effects (r_prep) efficacy_9\NN|to|in (r_dobj) compare_7\VB|.|goal (l_prep) in_20\IN|to|efficacy (l_pobj) treatment_22\NN|NONE (l_prep) in_28\IN|of|the (l_pobj) patients_29\NNS|NONE (l_prep) with_30\IN|NONE (l_pobj) disease_33\NN|NONE
D006220_D000544 NONE haloperidol_20\NN|(|)|,|and|haloperidol|,|A (r_appos) phase_16\NN|trial (r_preconj) In_0\IN|,|in|.|were (r_prep) compared_48\VBN|NONE (l_prep) in_49\IN|In|,|.|were (l_pobj) outpatients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_55\NN|NONE
D006220_D000544 NONE haloperidol_34\NN|(|haloperidol|)|,|and|,|A (r_conj) phase_16\NN|trial (r_preconj) In_0\IN|,|in|.|were (r_prep) compared_48\VBN|NONE (l_prep) in_49\IN|In|,|.|were (l_pobj) outpatients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_55\NN|NONE
D006220_D000544 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|window (r_prep) observed_4\VBN|may|to|.|also (r_nsubj) apply_9\VB|NONE (l_prep) to_10\IN|may|observed|.|also (l_pobj) neuroleptics_12\NNS|NONE (l_acl) used_13\VBN|other (l_prep) in_14\IN|NONE (l_pobj) patients_18\NNS|NONE (l_compound) disease_17\NN|Alzheimer|with
D006220_D019958 NONE haloperidol_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) psychosis_13\NN|NONE (l_conj) behaviors_16\NNS|in|and
D006220_D019958 NONE haloperidol_17\NN|NONE (r_pobj) of_16\IN|two (r_prep) doses_15\NNS|NONE (r_pobj) of_13\IN|and|the|effects (r_prep) efficacy_9\NN|to|in (r_dobj) compare_7\VB|.|goal (l_prep) in_20\IN|to|efficacy (l_pobj) treatment_22\NN|NONE (l_prep) of_23\IN|in|the (l_pobj) psychosis_24\NN|NONE (l_conj) behaviors_27\NNS|and
D006220_D019958 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|window (r_prep) observed_4\VBN|may|to|.|also (r_nsubj) apply_9\VB|NONE (l_prep) to_10\IN|may|observed|.|also (l_pobj) neuroleptics_12\NNS|NONE (l_acl) used_13\VBN|other (l_prep) in_14\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|disease|Alzheimer (l_pobj) psychosis_20\NN|NONE (l_conj) behaviors_23\NNS|and
D006220_D011618 NONE haloperidol_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) psychosis_13\NN|NONE
D006220_D011618 NONE haloperidol_17\NN|NONE (r_pobj) of_16\IN|two (r_prep) doses_15\NNS|NONE (r_pobj) of_13\IN|and|the|effects (r_prep) efficacy_9\NN|to|in (r_dobj) compare_7\VB|.|goal (l_prep) in_20\IN|to|efficacy (l_pobj) treatment_22\NN|NONE (l_prep) of_23\IN|in|the (l_pobj) psychosis_24\NN|NONE
D006220_D011618 NONE haloperidol_12\NN|phase|, (r_appos) A_7\NNP|who (r_dobj) completed_5\VBD||the (r_relcl) patients_3\NNS|NONE (r_pobj) For_0\IN|efficacious|. (r_prep) was_13\VBD|NONE (l_acomp) efficacious_14\JJ|.|For (l_prep) to_17\IN|superior|and (l_pobj) haloperidol_22\NN|NONE (l_prep) for_25\IN|placebo|dose|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_pobj) factor_34\NN|on|and (l_compound) psychosis_33\NN|the|Scale|Brief
D006220_D011618 NONE haloperidol_22\NN|NONE (l_prep) for_25\IN|placebo|dose|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_pobj) factor_34\NN|on|and (l_compound) psychosis_33\NN|the|Scale|Brief
D006220_D011618 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|window (r_prep) observed_4\VBN|may|to|.|also (r_nsubj) apply_9\VB|NONE (l_prep) to_10\IN|may|observed|.|also (l_pobj) neuroleptics_12\NNS|NONE (l_acl) used_13\VBN|other (l_prep) in_14\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|disease|Alzheimer (l_pobj) psychosis_20\NN|NONE
D006220_D001480 CID haloperidol_8\NN|NONE (r_pobj) for_7\IN|in|a|favorable|therapeutic (r_prep) profile_6\NN|.|developed|results|, (r_dobj) indicated_2\VBD|NONE (l_advcl) developed_22\VBD|.|results|,|profile (l_acomp) moderate_23\JJ|although|subgroup (l_prep) to_24\TO|NONE (l_pobj) signs_27\NNS|NONE
9351491
D018967_D010302 CID risperidone_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|.|observed|and|was|parkinsonism (r_prep) observed_5\VBN|NONE (l_nsubjpass) parkinsonism_3\NN|.|observed|and|was|in
D006220_D010302 CID haloperidol_16\NN|%|)|and|( (r_conj) risperidone_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|.|observed|and|was|parkinsonism (r_prep) observed_5\VBN|NONE (l_nsubjpass) parkinsonism_3\NN|.|observed|and|was|in
D018967_D011618 NONE risperidone_6\NN|pharmacologic (r_poss) profile_9\NN|may|decreased|efficacy|that|and (r_nsubj) produce_11\VB|studies|have (l_dobj) efficacy_13\NN|may|decreased|profile|that|and (l_prep) for_14\IN|improved (l_pobj) symptoms_17\NNS|NONE
8829025
D016559_D007674 NONE tacrolimus_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|the (r_acl) nephrotoxicity_9\NN|NONE
D009543_D006973 NONE nifedipine_23\NN|were|who (r_dobj) receiving_22\VBG|hypertensive (r_relcl) patients_19\NNS|NONE (l_amod) hypertensive_18\JJ|receiving
D009543_D006973 NONE nifedipine_33\NN|not (r_dobj) receiving_32\VBG|nonhypertensive (r_acl) patients_30\NNS|NONE (r_dobj) comprising_28\VBG|the (r_acl) other_27\JJ|one|,|and|comprising (r_conj) group_16\NN|,|groups|were|.|over (l_acl) comprising_17\VBG|one|,|other|and (l_dobj) patients_19\NNS|NONE (l_amod) hypertensive_18\JJ|receiving
D009543_D006973 NONE nifedipine_5\NN|NONE (r_pobj) of_4\IN|The|on|observed|positive (r_prep) impact_3\NN|should|factor|. (r_nsubj) be_18\VB|NONE (l_attr) factor_21\NN|impact|should|. (l_prep) in_22\IN|an|important (l_pcomp) selecting_23\VBG|NONE (l_xcomp) treat_27\VB|agent (l_dobj) hypertension_28\NN|to
D009543_D007674 NONE nifedipine_5\NN|NONE (r_pobj) of_4\IN|The|on|observed|positive (r_prep) impact_3\NN|should|factor|. (l_prep) on_6\IN|The|of|observed|positive (l_pcomp) reducing_7\VBG|NONE (l_dobj) nephrotoxicity_9\NN|NONE
D016559_D006973 CID tacrolimus_5\NNS|NONE (r_dobj) receiving_4\VBG|NONE (r_acl) patients_3\NNS|NONE (r_pobj) of_2\IN|Two (r_prep) groups_1\NNS|group|,|were|.|over (r_nsubjpass) compared_7\VBN|NONE (l_appos) group_16\NN|,|groups|were|.|over (l_acl) comprising_17\VBG|one|,|other|and (l_dobj) patients_19\NNS|NONE (l_amod) hypertensive_18\JJ|receiving
D016559_D006973 CID tacrolimus_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|the (r_acl) nephrotoxicity_9\NN|NONE (r_dobj) reducing_7\VBG|NONE (r_pcomp) on_6\IN|The|of|observed|positive (r_prep) impact_3\NN|should|factor|. (r_nsubj) be_18\VB|NONE (l_attr) factor_21\NN|impact|should|. (l_prep) in_22\IN|an|important (l_pcomp) selecting_23\VBG|NONE (l_xcomp) treat_27\VB|agent (l_dobj) hypertension_28\NN|to
2670794
D002216_D011665 NONE Captopril_9\NNP|(|) (r_appos) enzyme_7\NN|on (r_dobj) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D002216_D011665 NONE Captopril_2\NNP|NONE (r_pobj) of_1\IN|,|)|inhibitor|,|mg/kg|( (r_prep) Injection_0\NN|.|insufficiency (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|.|Injection
D014148_D004211 CID acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (l_prep) of_1\IN|by (l_pobj) coagulation_3\NN|NONE
D014148_D004211 CID AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (l_prep) of_1\IN|by (l_pobj) coagulation_3\NN|NONE
D000809_D051437 NONE angiotensin_5\NN|NONE (l_acl) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D000809_D051437 NONE angiotensin_11\NN|NONE (r_pobj) of_10\IN|an (r_prep) inhibitor_9\NN|,|)|,|of|mg/kg|( (r_appos) Injection_0\NN|.|insufficiency (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|.|Injection
D002216_D007674 NONE Captopril_17\NNP|NONE (r_pobj) by_16\IN|.|damage|was (r_agent) prevented_15\VBN|NONE (l_nsubjpass) damage_1\NN|.|by|was
D002216_D007674 NONE Captopril_0\NNP|diminishing|,|by|,|,|may|increase|. (r_nsubj) reduce_8\VB|NONE (l_advcl) diminishing_26\VBG|Captopril|,|by|,|,|may|increase|. (l_prep) with_36\IN|aggregation|thereby|, (l_pobj) result_38\NN|NONE (l_acl) deposited_44\VBN|the (l_conj) produced_52\VBN|that|be|fibrin|and|will (l_nsubjpass) damage_49\NN|be|will
D002216_D051437 NONE Captopril_9\NNP|(|) (r_appos) enzyme_7\NN|on (r_dobj) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D002216_D051437 NONE Captopril_2\NNP|NONE (r_pobj) of_1\IN|,|)|inhibitor|,|mg/kg|( (r_prep) Injection_0\NN|.|insufficiency (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|.|Injection
D002216_D004211 NONE Captopril_9\NNP|(|) (r_appos) enzyme_7\NN|on (r_dobj) converting_6\VBG|NONE (r_acl) angiotensin_5\NN|NONE (r_pobj) of_4\IN|an (r_prep) inhibitor_3\NN|NONE (r_pobj) of_1\IN|.|due (r_prep) Effects_0\NNS|NONE (l_amod) due_16\IN|.|of (l_pobj) coagulation_19\NN|to
D014148_D051437 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|Induction|.|resembling (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
D014148_D051437 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|Induction|.|resembling (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
D000809_D004211 NONE angiotensin_5\NN|NONE (r_pobj) of_4\IN|an (r_prep) inhibitor_3\NN|NONE (r_pobj) of_1\IN|.|due (r_prep) Effects_0\NNS|NONE (l_amod) due_16\IN|.|of (l_pobj) coagulation_19\NN|to
D014508_D007674 NONE urea_9\NN|and|in (r_pobj) in_7\IN|an (r_prep) increase_6\NN|NONE (r_pobj) by_4\IN|as (r_agent) reflected_3\VBN|Renal (r_advcl) damage_1\NN|.|by|was
D014148_D014947 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|Induction|.|rise (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE
D014148_D014947 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|Induction|.|rise (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE
D000809_D011665 NONE angiotensin_5\NN|NONE (l_acl) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D000809_D011665 NONE angiotensin_11\NN|NONE (r_pobj) of_10\IN|an (r_prep) inhibitor_9\NN|,|)|,|of|mg/kg|( (r_appos) Injection_0\NN|.|insufficiency (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|.|Injection
D014148_D018805 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|Induction|.|rise (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE (l_conj) sepsis_34\NN|in|or
D014148_D018805 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|Induction|.|rise (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE (l_conj) sepsis_34\NN|in|or
D014148_D011665 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|Induction|.|resembling (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
D014148_D011665 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|.|resembling|rise (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|Induction|.|resembling (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
1728522
D019980_D056486 CID acid_9\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) combination_4\NN|to (r_pobj) due_2\JJ|.|Granulomatous (r_prep) hepatitis_1\NN|NONE
D019980_D056486 CID acid_11\NN| (r_npadvmod) induced_13\VBN|clavulanic (r_amod) hepatitis_14\NN|NONE
D019980_D006099 CID acid_9\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) combination_4\NN|to (r_pobj) due_2\JJ|.|Granulomatous (r_prep) hepatitis_1\NN|NONE
D019980_D006099 CID acid_11\NN| (r_npadvmod) induced_13\VBN|clavulanic (r_amod) hepatitis_14\NN|NONE (r_pobj) with_7\IN|a (r_prep) patient_6\NN|NONE (r_pobj) of_4\IN|the|with (r_prep) case_3\NN|.|We (l_prep) with_15\IN|of|the (l_pobj) granulomas_18\NNS|NONE
7890216
D014580_D042882 NONE acid_13\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) response_9\NN|.|of|: (r_appos) Composition_0\NN|NONE (l_prep) of_1\IN|.|response|: (l_pobj) stones_4\NNS|NONE
D015282_D000172 NONE Octreotide_0\NNP|.|,|in|stones (l_appos) treatment_4\NN|, (l_prep) for_5\IN|an|effective (l_pobj) acromegaly_6\NNS|NONE
D015282_D000172 NONE octreotide_28\NN|NONE (r_pobj) in_26\IN|direct (r_prep) methods_25\NNS|NONE (r_pobj) by_21\IN|this|treated|,|was|.|is (r_agent) investigated_20\VBN|NONE (l_conj) treated_29\VBD|this|by|,|was|.|is (l_dobj) patients_31\NNS|with (l_compound) acromegalic_30\JJ|NONE
D002118_D042882 NONE calcium_41\NN|NONE (r_dobj) containing_40\VBG|some|gall (r_acl) stones_39\NNS|blocked|and|cystic|a (r_conj) duct_35\NN|at|patients|.|will (r_dobj) have_31\VB|In|octreotide|stones|,|are (r_conj) induced_4\VBN|NONE (l_dobj) stones_6\NNS|In|octreotide|have|,|are
D002118_D042882 NONE calcium_41\NN|NONE (r_dobj) containing_40\VBG|some|gall (r_acl) stones_39\NNS|blocked|and|cystic|a (r_conj) duct_35\NN|at|patients|.|will (r_dobj) have_31\VB|In|octreotide|stones|,|are (r_conj) induced_4\VBN|NONE (l_ccomp) are_7\VBP|In|octreotide|stones|have|, (l_prep) in_18\IN|generally|although|,|,|small (l_pobj) common_19\JJ|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_24\NN|NONE
D002118_D042882 NONE calcium_41\NN|NONE (r_dobj) containing_40\VBG|some|gall (r_acl) stones_39\NNS|blocked|and|cystic|a
D015282_D042882 CID octreotide_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|bladder|gall (r_acl) stones_4\NNS|NONE
D015282_D042882 CID Octreotide_0\NNP|.|,|in|stones (r_nsubj) induces_8\VBZ|NONE (l_dobj) stones_11\NNS|.|,|in|Octreotide
D015282_D042882 CID octreotide_28\NN|NONE (r_pobj) in_26\IN|direct (r_prep) methods_25\NNS|NONE (r_pobj) by_21\IN|this|treated|,|was|.|is (r_agent) investigated_20\VBN|NONE (l_conj) treated_29\VBD|this|by|,|was|.|is (l_prep) with_32\IN|patients (l_pobj) stones_34\NNS|NONE
D015282_D042882 CID octreotide_3\NN|In|stones|have|,|are (r_advmod) induced_4\VBN|NONE (l_dobj) stones_6\NNS|In|octreotide|have|,|are
D015282_D042882 CID octreotide_3\NN|In|stones|have|,|are (r_advmod) induced_4\VBN|NONE (l_ccomp) are_7\VBP|In|octreotide|stones|have|, (l_prep) in_18\IN|generally|although|,|,|small (l_pobj) common_19\JJ|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_24\NN|NONE
D015282_D042882 CID octreotide_3\NN|In|stones|have|,|are (r_advmod) induced_4\VBN|NONE (l_conj) have_31\VB|In|octreotide|stones|,|are (l_dobj) duct_35\NN|at|patients|.|will (l_conj) stones_39\NNS|blocked|and|cystic|a
D002784_D042882 NONE cholesterol_21\NN|and| (r_conj) %_17\NN|they|that (r_dobj) contained_15\VBD|analysis|,|. (r_ccomp) showed_12\VBD|NONE (l_nsubj) analysis_1\NN|contained|,|. (l_prep) of_2\IN|Chemical (l_pobj) stones_4\NNS|NONE
D002784_D042882 NONE cholesterol_36\NN|NONE (r_nsubj) rich_37\JJ|that|stones (r_acomp) were_35\VBD|NONE (r_ccomp) suggesting_31\VBG|five|,|,|.|After|dissolution (r_advcl) showed_12\VBD|NONE (l_dobj) dissolution_29\NN|five|,|,|suggesting|.|After (l_compound) stone_28\NN|partial|gall|either
D002784_D042882 NONE cholesterol_14\NN|,|rich|and (r_conj) multiple_11\JJ|, (r_conj) small_9\JJ|generally|although|,|,|in (r_acomp) are_7\VBP|In|octreotide|stones|have|, (r_ccomp) induced_4\VBN|NONE (l_dobj) stones_6\NNS|In|octreotide|have|,|are
D002784_D042882 NONE cholesterol_14\NN|,|rich|and (r_conj) multiple_11\JJ|, (r_conj) small_9\JJ|generally|although|,|,|in (r_acomp) are_7\VBP|In|octreotide|stones|have|, (l_prep) in_18\IN|generally|although|,|,|small (l_pobj) common_19\JJ|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_24\NN|NONE
D002784_D042882 NONE cholesterol_14\NN|,|rich|and (r_conj) multiple_11\JJ|, (r_conj) small_9\JJ|generally|although|,|,|in (r_acomp) are_7\VBP|In|octreotide|stones|have|, (r_ccomp) induced_4\VBN|NONE (l_conj) have_31\VB|In|octreotide|stones|,|are (l_dobj) duct_35\NN|at|patients|.|will (l_conj) stones_39\NNS|blocked|and|cystic|a
9390208
D002955_D064420 NONE leucovorin_19\NN|dose|benefit|)|(|MFL|:|and (r_conj) 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|)|(|MFL|:|leucovorin|and (l_conj) toxicity_32\NN|low|and|palliative
D005472_D001943 NONE 5-FU_17\CD|NONE (r_pobj) of_13\IN|hour|continuous (r_prep) infusion_12\NN|of|. (r_conj) Treatment_0\NN|NONE (l_prep) of_1\IN|infusion|. (l_pobj) cancer_6\NN|NONE
D005472_D001943 NONE 5-FU_34\CD|NONE (r_pobj) of_33\IN|continuous (r_prep) infusion_32\NN||and (r_conj) day_28\NN|NONE (r_pobj) on_27\IN|for|m|m|,|,|,|From|with|.|we|,|by|patients (r_prep) treated_8\VBD|NONE (l_dobj) patients_10\NNS|for|m|m|,|,|,|From|with|.|we|,|by|on (l_prep) with_11\IN| (l_pobj) cancer_18\NN|NONE
D002955_D001943 NONE leucovorin_19\NN|dose|benefit|)|(|MFL|:|and (r_conj) 5-FU_17\CD|NONE (r_pobj) of_13\IN|hour|continuous (r_prep) infusion_12\NN|of|. (r_conj) Treatment_0\NN|NONE (l_prep) of_1\IN|infusion|. (l_pobj) cancer_6\NN|NONE
D002955_D001943 NONE leucovorin_43\NN|together (r_pobj) with_42\IN|for|m|m|,|,|,|From|.|we|,|by|patients|on (r_prep) treated_8\VBD|NONE (l_dobj) patients_10\NNS|for|m|m|,|,|,|From|with|.|we|,|by|on (l_prep) with_11\IN| (l_pobj) cancer_18\NN|NONE
D008942_D064420 NONE mitoxantrone_8\NN|NONE (r_pobj) by_7\IN|metastatic|breast|treated (r_prep) cancer_6\NN|NONE (r_pobj) of_1\IN|infusion|. (r_prep) Treatment_0\NN|NONE (l_conj) infusion_12\NN|of|. (l_prep) of_13\IN|hour|continuous (l_pobj) 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|)|(|MFL|:|leucovorin|and (l_conj) toxicity_32\NN|low|and|palliative
C085788_D064420 NONE MFL_21\NNP|dose|benefit|)|(|:|leucovorin|and (r_appos) 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|)|(|MFL|:|leucovorin|and (l_conj) toxicity_32\NN|low|and|palliative
C085788_D064420 NONE regimen_2\NN|.|induces|and|benefit (r_nsubj) achieves_3\VBZ|NONE (l_conj) induces_8\VBZ|regimen|.|and|benefit (l_dobj) toxicity_10\NN|at
D008942_D001943 NONE mitoxantrone_8\NN|NONE (r_pobj) by_7\IN|metastatic|breast|treated (r_prep) cancer_6\NN|NONE
D008942_D001943 NONE mitoxantrone_20\NN|NONE (r_pobj) by_19\IN|for|m|m|,|,|,|From|with|.|we|,|patients|on (r_prep) treated_8\VBD|NONE (l_dobj) patients_10\NNS|for|m|m|,|,|,|From|with|.|we|,|by|on (l_prep) with_11\IN| (l_pobj) cancer_18\NN|NONE
C085788_D001943 NONE MFL_21\NNP|dose|benefit|)|(|:|leucovorin|and (r_appos) 5-FU_17\CD|NONE (r_pobj) of_13\IN|hour|continuous (r_prep) infusion_12\NN|of|. (r_conj) Treatment_0\NN|NONE (l_prep) of_1\IN|infusion|. (l_pobj) cancer_6\NN|NONE
D005472_D064420 NONE 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|)|(|MFL|:|leucovorin|and (l_conj) toxicity_32\NN|low|and|palliative
7088431
D004054_D014625 CID diethylstilbestrol_21\NN|NONE (r_pobj) to_20\IN|in (r_prep) exposed_17\VBN|young (r_acl) women_16\NNS|NONE (r_pobj) in_14\IN|follow| (r_prep) up_13\NN|NONE (r_pobj) at_10\IN|cases (r_prep) detected_9\VBD|.|are (l_nsubj) cases_1\NNS|at (l_prep) of_2\IN|Two (l_pobj) adenocarcinoma_5\NN|NONE (l_prep) of_6\IN|clear|cell (l_pobj) vagina_8\NN|NONE
D004054_D018262 CID DES_6\NNP| (r_npadvmod) exposed_8\VBN|under (r_amod) offspring_9\NN|NONE (r_pobj) in_5\IN|of|. (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|in|. (l_pobj) adenocarcinoma_4\NN|NONE
D004054_D018262 CID diethylstilbestrol_21\NN|NONE (r_pobj) to_20\IN|in (r_prep) exposed_17\VBN|young (r_acl) women_16\NNS|NONE (r_pobj) in_14\IN|follow| (r_prep) up_13\NN|NONE (r_pobj) at_10\IN|cases (r_prep) detected_9\VBD|.|are (l_nsubj) cases_1\NNS|at (l_prep) of_2\IN|Two (l_pobj) adenocarcinoma_5\NN|NONE (l_prep) of_6\IN|clear|cell (l_pobj) vagina_8\NN|NONE
18417364
D009538_D009759 CID Nicotine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) nystagmus_3\NN|with|.
D009538_D009759 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|(|)|NIN (r_amod) nystagmus_6\NN|NONE
D009538_D009759 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|(|)|NIN (r_amod) nystagmus_6\NN|NONE (l_appos) NIN_8\NNP|induced|(|)
D010100_D009759 NONE oxygen_4\NN|activity|)|BOLD|dependent|(|in (r_nmod) levels_12\NNS|NONE (r_pobj) with_2\IN|.|NIN (r_prep) correlated_1\VBD|NONE (l_nsubj) NIN_0\NNP|.|with
9869257
D012601_D000647 CID scopolamine_36\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|NONE (r_acl) amnesia_27\NN|NONE
C098725_D000647 CID S-(-)-ET-126_41\NNP|Mselective|the (r_appos) antagonist_40\NN|non|drug|and|both|selective|antimuscarinic|the (r_conj) scopolamine_36\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|NONE (r_acl) amnesia_27\NN|NONE
C087567_D000647 NONE PG-9_8\NNP|prevented|In|,|,|before|. (r_nsubj) administered_18\VBN|NONE (l_conj) prevented_26\VBN|In|,|,|PG|before|. (l_dobj) amnesia_27\NN|NONE
C087567_D000647 NONE PG-9_6\NNP|per|)|,|i.c.v. (r_nmod) microg_11\NN|In|,|able|,|demonstrating|.|also (r_nsubj) was_17\VBD|NONE (l_acomp) able_19\JJ|In|microg|,|,|demonstrating|.|also (l_xcomp) prevent_21\VB|NONE (l_dobj) amnesia_25\NN|to
3015567
D009599_D007022 CID Nitroprusside_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|secretion|.
D009599_D007022 CID nitroprusside_7\RB| (r_advmod) induced_9\VBN|NONE (r_amod) hypotension_10\NN|NONE
D003345_D007022 NONE corticosterone_18\NN|a|between (r_compound) level_19\NN|NONE (r_pobj) at_15\IN|NONE (r_prep) occurs_14\VBZ|and|is|Suppression|. (r_conj) observed_12\VBN|NONE (l_nsubjpass) Suppression_0\NN|and|is|occurs|. (l_appos) secretion_3\NN|of (l_prep) in_4\IN|NONE (l_pobj) response_5\NN|NONE (l_prep) to_6\IN|NONE (l_pobj) hypotension_10\NN|NONE
8739323
D008466_D007674 NONE nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|nephrotoxic|administered|The|MTX|FU (r_prep) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D008466_D007674 NONE NG_10\NNP|methotrexate|, (r_appos) nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|nephrotoxic|administered|The|MTX|FU (r_prep) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D005472_D003556 NONE 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|complication|it|did|.|not (r_advcl) cause_14\VB|,|cystitis|in|CY|but (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|,|cause|in|CY|but
D008727_D007674 NONE methotrexate_13\NNP|NG|, (r_conj) nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|nephrotoxic|administered|The|MTX|FU (r_prep) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D008727_D007674 NONE MTX_15\NNP|, (r_appos) methotrexate_13\NNP|NG|, (r_conj) nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|nephrotoxic|administered|The|MTX|FU (r_prep) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D008727_D007674 NONE MTX_33\NNP|nephrotoxic|of|administered|The|FU (r_appos) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D008727_D007674 NONE MTX_6\NNP|NONE (r_pobj) of_5\IN|that|+ (r_prep) nephrotoxicity_4\NN|is|studies|.
D003520_D006470 CID CY_0\NNP|,|cause|cystitis|in|but (r_nsubj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|,|cause|in|CY|but
D005472_D007674 NONE 5-fluorouracil_18\CD|and|)|(|cyclophosphamide (r_punct) 5-FU_20\CD|nephrotoxic|of|administered|The|MTX (r_appos) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D005472_D007674 NONE 5-FU_20\CD|nephrotoxic|of|administered|The|MTX (r_appos) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D005472_D007674 NONE 5-FU_35\CD|+|[ (r_conj) MTX_33\NNP|nephrotoxic|of|administered|The|FU (r_appos) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D005472_D007674 NONE 5-FU_8\CD|lower (r_nsubj) is_13\VBZ|nephrotoxicity|studies|. (r_ccomp) indicate_2\VBP|NONE (l_dobj) nephrotoxicity_4\NN|is|studies|.
D003520_D007674 NONE cyclophosphamide_23\NN|and|)|(|fluorouracil (r_conj) 5-FU_20\CD|nephrotoxic|of|administered|The|MTX (r_appos) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D003520_D007674 NONE CY_25\NNP|NONE (r_appos) cyclophosphamide_23\NN|and|)|(|fluorouracil (r_conj) 5-FU_20\CD|nephrotoxic|of|administered|The|MTX (r_appos) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D003520_D007674 NONE CY_37\NNP|+ (r_conj) 5-FU_35\CD|+|[ (r_conj) MTX_33\NNP|nephrotoxic|of|administered|The|FU (r_appos) action_2\NN|was|in|. (l_amod) nephrotoxic_1\JJ|of|administered|The|MTX|FU
D003520_D007674 NONE CY_10\NNP|+|administered (r_conj) 5-FU_8\CD|lower (r_nsubj) is_13\VBZ|nephrotoxicity|studies|. (r_ccomp) indicate_2\VBP|NONE (l_dobj) nephrotoxicity_4\NN|is|studies|.
D005472_D006470 NONE 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|complication|it|did|.|not (r_advcl) cause_14\VB|,|cystitis|in|CY|but (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|,|cause|in|CY|but
D003520_D003556 CID CY_0\NNP|,|cause|cystitis|in|but (r_nsubj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|,|cause|in|CY|but
D008727_D006470 NONE MTX_22\NNP|and (r_conj) 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|complication|it|did|.|not (r_advcl) cause_14\VB|,|cystitis|in|CY|but (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|,|cause|in|CY|but
D008727_D003556 NONE MTX_22\NNP|and (r_conj) 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|complication|it|did|.|not (r_advcl) cause_14\VB|,|cystitis|in|CY|but (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|,|cause|in|CY|but
20880751
D018698_D004409 NONE glutamate_28\NN|and|systems|ionotropic|, (r_compound) receptors_29\NNS|dopamine|,|receptor (l_conj) systems_36\NNS|and|glutamate|ionotropic|, (l_prep) in_37\IN|dopaminergic|neurotransmitter (l_pobj) pathophysiology_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) dyskinesias_44\NNS|NONE
D004298_D004409 NONE dopamine_9\NN|this (r_compound) precursor_10\NN|NONE (r_pobj) of_7\IN|term|the (r_prep) use_6\NN|is|by|However|,|. (r_nsubjpass) complicated_12\VBN|NONE (l_agent) by_13\IN|is|use|However|,|. (l_pobj) fluctuations_16\NNS|NONE (l_conj) dyskinesias_18\NNS|disabling|and
D004298_D004409 NONE dopamine_21\NN|,|receptors|receptor (r_compound) subtypes_23\NNS|promising|of|, (l_conj) receptors_29\NNS|dopamine|,|receptor (l_conj) systems_36\NNS|and|glutamate|ionotropic|, (l_prep) in_37\IN|dopaminergic|neurotransmitter (l_pobj) pathophysiology_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) dyskinesias_44\NNS|NONE
D007980_D004409 CID Levodopa_0\NNP|filling|:||dyskinesias|. (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesias_3\NNS|filling|:|Levodopa||.
D007980_D004409 CID levodopa_17\NN| (r_npadvmod) induced_19\VBN|underlying (r_amod) dyskinesias_20\NNS|a|key
D007980_D004409 CID levodopa_41\NN| (r_npadvmod) induced_43\VBN|NONE (r_amod) dyskinesias_44\NNS|NONE
D007980_D010300 NONE Levodopa_0\NNP|filling|:||dyskinesias|. (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesias_3\NNS|filling|:|Levodopa||. (l_prep) in_4\IN|NONE (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) disease_9\NN|NONE
D007980_D010300 NONE Levodopa_0\NNP|.|drug (r_nsubj) is_1\VBZ|NONE (l_attr) drug_5\NN|Levodopa|. (l_prep) for_6\IN|effective|the (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) disease_12\NN|NONE
20098969
D008694_D006212 NONE Methamphetamine_0\NN|.|stimulant (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|addictive|powerful (l_conj) produce_16\VB|wakefulness|and|that (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such (l_conj) hypertension_24\NN|cardiac|, (l_conj) hallucinations_26\NNS|,
D008694_D001523 NONE Methamphetamine_0\NN|.|stimulant (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|addictive|powerful (l_conj) produce_16\VB|wakefulness|and|that (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such (l_conj) hypertension_24\NN|cardiac|, (l_conj) hallucinations_26\NNS|, (l_conj) behavior_30\NN|and|,
D008694_-1 NONE methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|with|can|. (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|patients|. (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|,|oral|poor (l_conj) caries_14\NNS|, (l_appos) mouth_18\NN|(|rampant|,|wear|and
D008694_-1 NONE methamphetamines_23\NNS|may|who|be (r_dobj) abusing_22\VBG|NONE (r_relcl) patients_18\NNS|NONE (r_dobj) manage_17\VBP|and|practitioners (r_conj) recognize_15\VBP|to (r_ccomp) help_12\VB|.|case|was (r_advcl) presented_10\VBN|NONE (l_nsubjpass) case_2\NN|.|help|was (l_acl) showing_3\VBG|clinical|This (l_dobj) manifestations_5\NNS|NONE (l_prep) of_6\IN|oral (l_pobj) mouth_8\NN|NONE
D008694_D003731 CID methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|with|can|. (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|patients|. (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|,|oral|poor (l_conj) caries_14\NNS|,
D008694_D003731 CID methamphetamine_5\NN|NONE (r_pobj) of_4\IN|for|her (r_prep) use_3\NN|experienced|She|and|. (r_dobj) reported_1\VBD|NONE (l_conj) experienced_12\VBN|use|She|and|. (l_dobj) episodes_16\NNS|had|started|not
D008694_D001145 NONE Methamphetamine_0\NN|.|stimulant (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|addictive|powerful (l_conj) produce_16\VB|wakefulness|and|that (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such
D008694_D006973 NONE Methamphetamine_0\NN|.|stimulant (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|addictive|powerful (l_conj) produce_16\VB|wakefulness|and|that (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such (l_conj) hypertension_24\NN|cardiac|,
D008694_D014987 NONE methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|with|can|. (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|patients|. (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|,|oral|poor
D008694_D057085 NONE methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|with|can|. (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|patients|. (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|,|oral|poor (l_conj) caries_14\NNS|, (l_conj) wear_25\NN|(|rampant|,|mouth|and
16428221
D008774_D019969 NONE methylphenidate_20\NN|in (r_compound) intake_21\NN|NONE (r_pobj) after_19\IN|has|in|been|.|stroke (r_prep) reported_18\VBN|,|and|is|well|vasculitis (r_conj) documented_8\VBN|NONE (l_nsubjpass) vasculitis_1\NN|,|and|is|reported|well (l_acl) associated_2\VBN|Cerebral (l_prep) with_3\IN|NONE (l_pobj) abuse_5\NN|NONE
D008774_D002544 NONE methylphenidate_20\NN|in (r_compound) intake_21\NN|NONE (r_pobj) after_19\IN|has|in|been|.|stroke (r_prep) reported_18\VBN|,|and|is|well|vasculitis (l_nsubjpass) stroke_15\NN|has|in|after|been|.
D008774_D002544 NONE methylphenidate_14\NN|NONE (r_pobj) with_13\IN|suffered|and|due|who|was (r_prep) treated_12\VBN|a|old (l_conj) suffered_19\VBD|with|and|due|who|was (l_prep) from_20\IN|NONE (l_pobj) strokes_23\NNS|NONE
D008774_D020293 CID methylphenidate_4\NN|in|oral (r_compound) intake_5\NN|NONE (r_dobj) following_2\VBG|.|Cerebral|:|report (r_prep) vasculitis_1\NNS|NONE
D008774_D020293 CID methylphenidate_20\NN|in (r_compound) intake_21\NN|NONE (r_pobj) after_19\IN|has|in|been|.|stroke (r_prep) reported_18\VBN|,|and|is|well|vasculitis (r_conj) documented_8\VBN|NONE (l_nsubjpass) vasculitis_1\NN|,|and|is|reported|well
D008774_D014657 NONE methylphenidate_3\NN|in|be|should|that (l_dobj) vasculitis_5\NN|NONE
D008774_D014657 NONE methylphenidate_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|neurological|and (r_conj) symptoms_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) patients_10\NNS|NONE (r_pobj) in_9\IN|methylphenidate|be|should|that (r_prep) considered_8\VBN|We|. (l_nsubjpass) methylphenidate_3\NN|in|be|should|that (l_dobj) vasculitis_5\NN|NONE
D008774_D006948 NONE methylphenidate_14\NN|NONE (r_pobj) with_13\IN|suffered|and|due|who|was (r_prep) treated_12\VBN|a|old (l_prep) due_15\IN|with|suffered|and|who|was (l_pobj) hyperactivity_17\NN|to
220563
C023470_D010523 CID maleate_1\NN|NONE (l_conj) neuropathy_4\NN|and|.|Perhexiline
C023470_D010523 CID maleate_12\NN|in|and (r_pobj) with_10\IN|of|for|a (r_prep) complication_7\NN|NONE (r_pobj) as_5\IN|has|been|.|neuropathy (r_prep) noted_4\VBN|NONE (l_nsubjpass) neuropathy_1\NN|as|has|been|.
C023470_D000787 NONE maleate_12\NN|in|and (r_pobj) with_10\IN|of|for|a (r_prep) complication_7\NN|NONE (l_prep) for_30\IN|of|with|a (l_pobj) treatment_33\NN|NONE (l_prep) of_34\IN|prophylactic|the (l_pobj) pectoris_36\NN|NONE
9721172
D011241_D002779 NONE prednisone_6\NN|ursodeoxycholic|, (l_conj) tacrolimus_10\VB|,|and (l_conj) disease_14\NN|then|,
D007052_D001649 NONE ibuprofen_30\JJ|NONE (r_compound) use_31\NN|NONE (r_pobj) with_29\IN|child|was|temporally|.|;|this (r_prep) associated_28\VBN|NONE (l_nsubjpass) child_3\NN|was|with|temporally|.|;|this (l_relcl) developed_5\VBD|healthy|described|A (l_dobj) syndrome_15\NN|who
D016559_D002779 NONE tacrolimus_10\VB|,|and (l_conj) disease_14\NN|then|,
D011241_D005355 NONE prednisone_6\NN|ursodeoxycholic|, (r_conj) acid_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) therapy_1\NN|NONE (r_pobj) Despite_0\IN|with|.|unrelenting|, (r_prep) was_15\VBD|NONE (l_prep) with_18\IN|.|unrelenting|,|Despite (l_pobj) cirrhosis_19\NN|NONE
D014580_D005355 NONE acid_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) therapy_1\NN|NONE (r_pobj) Despite_0\IN|with|.|unrelenting|, (r_prep) was_15\VBD|NONE (l_prep) with_18\IN|.|unrelenting|,|Despite (l_pobj) cirrhosis_19\NN|NONE
D007052_D013262 CID ibuprofen_30\JJ|NONE (r_compound) use_31\NN|NONE (r_pobj) with_29\IN|child|was|temporally|.|;|this (r_prep) associated_28\VBN|NONE (l_nsubjpass) child_3\NN|was|with|temporally|.|;|this (l_relcl) described_23\VBN|healthy|developed|A (l_nsubjpass) syndrome_21\NN|is|after
D016559_D005355 NONE tacrolimus_10\VB|,|and (r_conj) prednisone_6\NN|ursodeoxycholic|, (r_conj) acid_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) therapy_1\NN|NONE (r_pobj) Despite_0\IN|with|.|unrelenting|, (r_prep) was_15\VBD|NONE (l_prep) with_18\IN|.|unrelenting|,|Despite (l_pobj) cirrhosis_19\NN|NONE
D014580_D002779 NONE acid_4\NN|NONE (l_conj) prednisone_6\NN|ursodeoxycholic|, (l_conj) tacrolimus_10\VB|,|and (l_conj) disease_14\NN|then|,
7919560
D000667_D009205 CID ampicillin_7\NN|NONE (r_pobj) by_6\IN|.|multiforme (r_agent) caused_5\VBN|NONE (l_nsubj) multiforme_1\NN|by|. (l_conj) myocarditis_4\NN|and|Erythema
D000667_D009205 CID ampicillin_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) caused_10\VBN|a|of (r_acl) case_3\NN|To|. (l_prep) of_4\IN|caused|a (l_pobj) multiforme_6\NNS|NONE (l_conj) myocarditis_9\NN|erythema|and
D000667_D004892 CID ampicillin_7\NN|NONE (r_pobj) by_6\IN|.|multiforme (r_agent) caused_5\VBN|NONE (l_nsubj) multiforme_1\NN|by|.
D000667_D004892 CID ampicillin_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) caused_10\VBN|a|of (r_acl) case_3\NN|To|. (l_prep) of_4\IN|caused|a (l_pobj) multiforme_6\NNS|NONE
D010406_D004342 NONE penicillins_11\NNS|NONE (r_pobj) to_10\IN|.|manifestation|myocarditis (r_prep) is_2\VBZ|NONE (l_attr) manifestation_7\NN|to|.|myocarditis (l_prep) of_8\IN|rare|a (l_pobj) allergy_9\NN|NONE
D010406_D009205 NONE penicillins_11\NNS|NONE (r_pobj) to_10\IN|.|manifestation|myocarditis (r_prep) is_2\VBZ|NONE (l_nsubj) myocarditis_1\NN|to|.|manifestation
D000667_D018805 NONE ampicillin_8\NN|NONE (r_pobj) with_7\IN|.|and|gentamicin|was|boy (r_prep) treated_6\VBN|NONE (l_conj) gentamicin_10\NN|.|and|with|was|boy (l_prep) because_11\IN|NONE (l_pobj) septicemia_14\NN|of
D005839_D018805 NONE gentamicin_10\NN|.|and|with|was|boy (l_prep) because_11\IN|NONE (l_pobj) septicemia_14\NN|of
2425813
D011239_D009133 CID prednisolone_14\NN|NONE (r_pobj) of_13\IN|subcutaneous|the (r_prep) administration_12\NN|NONE (r_pobj) following_9\VBG|in|.|enlargement (r_prep) occurred_5\VBD|NONE (l_nsubj) enlargement_1\NN|in|.|following (l_conj) wastage_4\NN|Liver|and
D011239_D006529 CID prednisolone_14\NN|NONE (r_pobj) of_13\IN|subcutaneous|the (r_prep) administration_12\NN|NONE (r_pobj) following_9\VBG|in|.|enlargement (r_prep) occurred_5\VBD|NONE (l_nsubj) enlargement_1\NN|in|.|following
12695819
D016559_D009422 NONE tacrolimus_17\NNS|NONE (l_relcl) developed_19\VBD|NONE (l_dobj) complications_21\NNS|who
D016559_D020258 NONE tacrolimus_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) neurotoxicity_10\NN|NONE
D016559_D020258 NONE tacrolimus_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) neurotoxicity_18\NN|NONE
6133211
D012460_D000013 NONE sulphasalazine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|who (r_dobj) received_12\VBD|bowel|inflammatory (r_relcl) disease_10\NN|NONE (r_pobj) with_7\IN|two (r_prep) mothers_6\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) born_3\VBN|Three|,|, (r_acl) infants_1\NNS|.|have|were (r_nsubjpass) found_20\VBN|NONE (l_xcomp) have_22\VB|.|were|infants (l_dobj) anomalies_25\NNS|to
D012460_D015212 NONE sulphasalazine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|who (r_dobj) received_12\VBD|bowel|inflammatory (r_relcl) disease_10\NN|NONE
2355241
D007980_D002543 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|hypotensive|mechanism|and|the (r_prep) effect_21\NN|.|incidence|may (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|effect|.|may (l_prep) of_3\IN|low|The|as (l_pobj) haemorrhage_5\NN|NONE
D009638_D003643 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|hypotensive|of|and|the (r_conj) effect_21\NN|.|incidence|may (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|effect|.|may (l_prep) as_6\IN|low|The|of (l_pobj) cause_8\NN|NONE (l_prep) of_9\IN|in|a (l_pobj) death_10\NN|NONE
D007980_D007022 CID levodopa_23\NN|NONE (r_pobj) of_22\IN|hypotensive|mechanism|and|the (r_prep) effect_21\NN|.|incidence|may (l_amod) hypotensive_20\JJ|mechanism|of|and|the
D007980_D007022 CID levodopa_23\NN|NONE (r_pobj) of_22\IN|hypotensive|mechanism|and|the (r_prep) effect_21\NN|.|incidence|may (l_conj) mechanism_27\NN|hypotensive|of|and|the (l_amod) hypotensive_26\JJ|due|a
D007980_D010300 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|hypotensive|mechanism|and|the (r_prep) effect_21\NN|.|incidence|may (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|effect|.|may (l_prep) as_6\IN|low|The|of (l_pobj) cause_8\NN|NONE (l_prep) in_11\IN|of|a (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) disease_16\NN|NONE
D007980_D010300 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|hypotensive|mechanism|and|the (r_prep) effect_21\NN|.|incidence|may (l_conj) mechanism_27\NN|hypotensive|of|and|the (l_amod) due_28\IN|a|hypotensive (l_pobj) levels_32\NNS|to (l_prep) in_33\IN|noradrenaline|reduced (l_pobj) brain_36\NN|NONE (l_amod) parkinsonian_35\JJ|the
D009638_D002543 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|hypotensive|of|and|the (r_conj) effect_21\NN|.|incidence|may (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|effect|.|may (l_prep) of_3\IN|low|The|as (l_pobj) haemorrhage_5\NN|NONE
D009638_D010300 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|hypotensive|of|and|the (r_conj) effect_21\NN|.|incidence|may (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|effect|.|may (l_prep) as_6\IN|low|The|of (l_pobj) cause_8\NN|NONE (l_prep) in_11\IN|of|a (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) disease_16\NN|NONE
D009638_D010300 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (l_prep) in_33\IN|noradrenaline|reduced (l_pobj) brain_36\NN|NONE (l_amod) parkinsonian_35\JJ|the
D009638_D007022 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|hypotensive|of|and|the (r_conj) effect_21\NN|.|incidence|may (l_amod) hypotensive_20\JJ|mechanism|of|and|the
D009638_D007022 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|hypotensive|of|and|the (l_amod) hypotensive_26\JJ|due|a
D007980_D003643 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|hypotensive|mechanism|and|the (r_prep) effect_21\NN|.|incidence|may (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|effect|.|may (l_prep) as_6\IN|low|The|of (l_pobj) cause_8\NN|NONE (l_prep) of_9\IN|in|a (l_pobj) death_10\NN|NONE
17608141
D008070_D005334 NONE Lipopolysaccharide_0\JJ|NONE (r_compound) pretreatment_1\NN|not|did|.|later|temperature (r_nsubj) affect_4\VB|NONE (l_dobj) temperature_8\NN|not|pretreatment|did|.|later (l_conj) hyperthermia_13\NN|basal|body|the|or
D008070_D020258 NONE lipopolysaccharide_11\NN|NONE (r_compound) pretreatment_12\NN|NONE (r_pobj) by_10\IN|nigrostriatal|in|dopaminergic (r_prep) neurotoxicity_7\NN||methamphetamine|Attenuation|.
D008070_D020258 NONE lipopolysaccharide_9\NN|NONE (r_pobj) of_8\IN|factor|the|, (r_prep) roles_7\NNS|In|,|.|we (l_appos) factor_17\NN|of|the|, (l_conj) treatment_19\NN|,|inflammatory|a (l_prep) in_20\IN|NONE (l_pcomp) modulating_21\VBG|NONE (l_dobj) neurotoxicity_28\NN|NONE
D008070_D020258 NONE lipopolysaccharide_8\NN|in|systemic (r_compound) pretreatment_9\NN|NONE (l_prep) in_10\IN|lipopolysaccharide|systemic (l_pcomp) exerting_11\VBG|NONE (l_dobj) protection_13\NN|NONE (l_prep) against_14\IN|effective (l_pobj) neurotoxicity_20\NN|NONE
D008694_D020258 NONE methamphetamine_2\NN||Attenuation|.|neurotoxicity (r_npadvmod) induced_4\VBN|NONE (l_dobj) neurotoxicity_7\NN||methamphetamine|Attenuation|.
D008694_D020258 NONE methamphetamine_23\NN| (r_npadvmod) induced_25\VBN|the|nigrostriatal|dopamine (r_amod) neurotoxicity_28\NN|NONE
D008694_D020258 NONE methamphetamine_15\NN| (r_npadvmod) induced_17\VBN|nigrostriatal|dopamine (r_amod) neurotoxicity_20\NN|NONE
D004298_D020258 NONE dopamine_27\NN|the|nigrostriatal|induced (r_compound) neurotoxicity_28\NN|NONE
D004298_D020258 NONE dopamine_19\NN|induced|nigrostriatal (r_compound) neurotoxicity_20\NN|NONE
D008694_D009422 NONE methamphetamine_10\NN| (r_npadvmod) induced_12\VBN|dopaminergic|terminal (r_amod) damage_15\NN|NONE
D008694_D005334 CID methamphetamine_10\NN| (r_npadvmod) elicited_12\VBN|NONE (r_amod) hyperthermia_13\NN|basal|body|the|or
1130930
D002512_D007683 CID sodium_23\NN|NONE (r_pobj) of_21\IN|a (r_prep) combination_20\NN|while|they|and|gentamicin|were (r_dobj) receiving_18\VBG|,|.|necrosis|patients (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|,|.|receiving|patients
D005839_D007683 CID sulfate_26\NN|NONE (r_compound) therapy_27\NN|NONE (r_dobj) gentamicin_25\NN|while|they|and|combination|were (r_conj) receiving_18\VBG|,|.|necrosis|patients (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|,|.|receiving|patients
D005839_D007674 NONE gentamicin_5\NN|combined (r_compound) regimen_6\NN|NONE (r_pobj) of_1\IN|. (r_prep) Nephrotoxicity_0\NN|NONE
D002512_D051437 NONE sodium_23\NN|NONE (r_pobj) of_21\IN|a (r_prep) combination_20\NN|while|they|and|gentamicin|were (r_dobj) receiving_18\VBG|,|.|necrosis|patients (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|,|.|receiving|patients (l_acl) characterized_7\VBN|,|tubular|acute (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
D005839_D009846 NONE sulfate_26\NN|NONE (r_compound) therapy_27\NN|NONE (r_dobj) gentamicin_25\NN|while|they|and|combination|were (r_conj) receiving_18\VBG|,|.|necrosis|patients (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|,|.|receiving|patients (l_acl) characterized_7\VBN|,|tubular|acute (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
D005839_D051437 NONE sulfate_26\NN|NONE (r_compound) therapy_27\NN|NONE (r_dobj) gentamicin_25\NN|while|they|and|combination|were (r_conj) receiving_18\VBG|,|.|necrosis|patients (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|,|.|receiving|patients (l_acl) characterized_7\VBN|,|tubular|acute (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
D002512_D009846 NONE sodium_23\NN|NONE (r_pobj) of_21\IN|a (r_prep) combination_20\NN|while|they|and|gentamicin|were (r_dobj) receiving_18\VBG|,|.|necrosis|patients (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|,|.|receiving|patients (l_acl) characterized_7\VBN|,|tubular|acute (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
D002512_D007674 NONE cephalothin_3\NN| (r_compound) gentamicin_5\NN|combined (r_compound) regimen_6\NN|NONE (r_pobj) of_1\IN|. (r_prep) Nephrotoxicity_0\NN|NONE
8649546
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) dyskinesia_5\NN|NONE
D007980_D004409 CID levodopa_14\RB| (r_npadvmod) induced_16\VBN|ballistic|in (r_amod) dyskinesia_20\NN|may|administration|that
D011433_D004409 NONE propranolol_7\NN|NONE (r_pcomp) by_6\IN|of|. (r_prep) Improvement_0\NN|NONE (l_prep) of_1\IN|by|. (l_pobj) dyskinesia_5\NN|NONE
D011433_D004409 NONE propranolol_18\NN|patients|. (r_dobj) received_14\VBN|NONE (l_nsubj) patients_1\NNS|.|propranolol (l_acl) suffering_2\VBG|Seven (l_prep) with_10\IN|from (l_pobj) dyskinesia_13\NN|NONE
D011433_D010300 NONE propranolol_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) disease_11\NN|NONE
D011433_D010300 NONE propranolol_18\NN|patients|. (r_dobj) received_14\VBN|NONE (l_nsubj) patients_1\NNS|.|propranolol (l_acl) suffering_2\VBG|Seven (l_prep) from_3\IN|with (l_pobj) disease_6\NN|NONE
D011433_D010300 NONE propranolol_18\NN|patients|. (r_dobj) received_14\VBN|NONE (l_nsubj) patients_1\NNS|.|propranolol (l_acl) suffering_2\VBG|Seven (l_prep) from_3\IN|with (l_pobj) disease_6\NN|NONE (l_appos) PD_8\NNP|(|Parkinson|)
D007980_D010300 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) dyskinesia_5\NN|NONE (r_pobj) of_1\IN|by|. (r_prep) Improvement_0\NN|NONE (l_prep) by_6\IN|of|. (l_pcomp) propranolol_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) disease_11\NN|NONE
D007980_D010300 NONE levodopa_14\RB| (r_npadvmod) induced_16\VBN|ballistic|in (r_amod) dyskinesia_20\NN|may|administration|that (l_prep) in_21\IN|induced|ballistic (l_pobj) PD_22\NNP|NONE
9406968
D001127_D011141 NONE vasopressin_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) expression_1\NN|was|using|polyuria|gene|.|in (r_nsubjpass) investigated_22\VBN|NONE (l_parataxis) polyuria_29\NN|was|expression|using|gene|.|in
D001127_D011141 NONE AVP_6\NNP|)|in|( (r_nmod) gene_8\NN|was|expression|using|polyuria|.|in (r_nsubjpass) investigated_22\VBN|NONE (l_parataxis) polyuria_29\NN|was|expression|using|gene|.|in
D014667_D003919 NONE vasopressin_5\NN|in (r_compound) gene_6\NN|NONE (l_prep) in_7\IN|vasopressin (l_pobj) nuclei_12\NNS|NONE (l_prep) of_13\IN|paraventricular|the (l_pobj) rat_20\NN|NONE (l_compound) insipidus_19\NN|diabetes|the
D008094_D003919 NONE lithium_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) diabetes_18\NN|insipidus|the (r_compound) rat_20\NN|NONE (l_compound) insipidus_19\NN|diabetes|the
D008094_D003919 NONE Li_35\NNP| (r_npadvmod) induced_37\VBN|NONE (r_amod) diabetes_38\NN|insipidus|the (r_compound) rat_40\NN|NONE (l_compound) insipidus_39\NN|the|diabetes
D001127_D003681 NONE AVP_19\NNP|NONE (r_pobj) of_17\IN|the|upregulation (r_prep) elevation_16\NN|NONE (r_pobj) to_14\IN|dehydration|that|may (r_prep) contribute_13\VB|.|results (l_nsubj) dehydration_4\NN|to|that|may
D001127_D003681 NONE AVP_24\NNP|in|gene (r_compound) expression_26\NN|NONE (r_pobj) of_23\IN|the (r_prep) upregulation_22\NN|the|of (r_conj) elevation_16\NN|NONE (r_pobj) to_14\IN|dehydration|that|may (r_prep) contribute_13\VB|.|results (l_nsubj) dehydration_4\NN|to|that|may
D008094_D003681 NONE Li_35\NNP| (r_npadvmod) induced_37\VBN|NONE (r_amod) diabetes_38\NN|insipidus|the (r_compound) rat_40\NN|NONE (r_pobj) of_33\IN|the (r_prep) SON_32\NN|the|and (r_conj) PVN_29\NN|NONE (r_pobj) in_27\IN|gene|AVP (r_prep) expression_26\NN|NONE (r_pobj) of_23\IN|the (r_prep) upregulation_22\NN|the|of (r_conj) elevation_16\NN|NONE (r_pobj) to_14\IN|dehydration|that|may (r_prep) contribute_13\VB|.|results (l_nsubj) dehydration_4\NN|to|that|may
D008094_D011141 NONE lithium_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) rats_24\NNS|NONE (r_pobj) in_23\IN|was|expression|using|polyuria|gene|. (r_prep) investigated_22\VBN|NONE (l_parataxis) polyuria_29\NN|was|expression|using|gene|.|in
D008094_D011141 NONE Li)-induced_28\JJ|,|( (r_amod) polyuria_29\NN|was|expression|using|gene|.|in
D018021_D011141 CID LiCl_9\NNP|that|for (r_dobj) contained_8\VBD|a (r_relcl) diet_6\NN|NONE (r_dobj) consuming_4\VBG|The|Wistar|male (r_acl) rats_3\NNS|polyuria|. (r_nsubj) developed_19\VBN|NONE (l_dobj) polyuria_21\NN|rats|.
D001127_D003919 NONE AVP_19\NNP|NONE (r_pobj) of_17\IN|the|upregulation (r_prep) elevation_16\NN|NONE (l_conj) upregulation_22\NN|the|of (l_prep) of_23\IN|the (l_pobj) expression_26\NN|NONE (l_prep) in_27\IN|gene|AVP (l_pobj) PVN_29\NN|NONE (l_conj) SON_32\NN|the|and (l_prep) of_33\IN|the (l_pobj) rat_40\NN|NONE (l_compound) insipidus_39\NN|the|diabetes
D001127_D003919 NONE AVP_24\NNP|in|gene (r_compound) expression_26\NN|NONE (l_prep) in_27\IN|gene|AVP (l_pobj) PVN_29\NN|NONE (l_conj) SON_32\NN|the|and (l_prep) of_33\IN|the (l_pobj) rat_40\NN|NONE (l_compound) insipidus_39\NN|the|diabetes
3187073
D005472_D002637 CID 5-FU_6\CD|NONE (r_compound) treatment_7\NN|NONE (r_pobj) on_5\IN|NONE (r_prep) patients_4\NNS|discontinued|that|and|should|under (r_nsubj) be_9\VB|is|.|It (l_conj) discontinued_19\VBN|patients|that|and|should|under (l_advcl) observed_26\VBN|should|treatment|be|that (l_nsubjpass) pain_22\NN|if|is
D005472_D013610 NONE 5-FU_6\CD|NONE (r_compound) treatment_7\NN|NONE (r_pobj) on_5\IN|NONE (r_prep) patients_4\NNS|discontinued|that|and|should|under (r_nsubj) be_9\VB|is|.|It (l_conj) discontinued_19\VBN|patients|that|and|should|under (l_advcl) observed_26\VBN|should|treatment|be|that (l_nsubjpass) pain_22\NN|if|is (l_conj) tachyarrhythmia_24\NN|chest|or
17400887
D013726_D020078 NONE terbutaline_6\JJ|in|neonatal (r_compound) treatment_7\NN|NONE (r_pobj) after_4\IN|implications|Neuroinflammation|:|. (r_prep) abnormalities_3\NNS|NONE (l_nmod) Neuroinflammation_0\NN|implications|after|:|.
D013726_D001523 NONE terbutaline_6\JJ|in|neonatal (r_compound) treatment_7\NN|NONE (r_pobj) after_4\IN|implications|Neuroinflammation|:|. (r_prep) abnormalities_3\NNS|NONE
D013726_D001321 CID terbutaline_6\JJ|in|neonatal (r_compound) treatment_7\NN|NONE (r_pobj) after_4\IN|implications|Neuroinflammation|:|. (r_prep) abnormalities_3\NNS|NONE (l_appos) implications_11\NNS|after|Neuroinflammation|:|. (l_prep) for_12\IN|NONE (l_pobj) autism_13\NN|NONE
D013726_D001321 CID Terbutaline_0\NNP|been|with|.|has (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|been|Terbutaline|.|has (l_pobj) concordance_16\NN|NONE (l_prep) for_17\IN|increased (l_pobj) autism_18\NN|NONE
D013726_D007752 NONE Terbutaline_0\NNP|been|with|.|has (l_appos) agonist_4\NN|,|, (l_acl) used_5\VBN|a|betaadrenoceptor (l_xcomp) arrest_7\VB|NONE (l_dobj) labor_9\NN|to
9522152
D002045_D009461 NONE bupivacaine_11\NN|NONE (r_pobj) of_7\IN|intrathecal (r_prep) injection_6\NN|NONE (r_dobj) following_4\VBG|neurological|.|transient|A (r_acl) deficit_3\NN|NONE
D002045_D009461 NONE bupivacaine_21\NN|NONE (r_pobj) with_14\IN|unilateral|spinal (r_prep) anaesthesia_13\NN|NONE (r_pobj) after_10\IN|that (r_prep) occurred_9\VBD|neurological|transient (r_relcl) deficit_7\NN|NONE
17562951
C044834_D003920 NONE iodixanol_35\NN|NONE (r_pobj) with_34\IN|iopamidol (r_prep) with_23\IN|%|,|dL|increases (r_prep) were_14\VBD|>|In|SCr|,|. (r_conj) increases_6\VBZ|NONE (l_prep) In_0\IN|>|SCr|were|,|. (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) diabetes_3\NNS|NONE
C044834_D003920 NONE iodixanol_25\NN|or (r_conj) iopamidol_23\NN|NONE (r_pobj) of_22\IN|to|intraarterial|,|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|not|different|rate|with|. (r_prep) is_14\VBZ|NONE (l_prep) with_32\IN|not|after|different|rate|. (l_conj) without_34\IN|or (l_pobj) mellitus_36\NN|NONE
D000111_D003920 NONE acetylcysteine_16\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) use_12\NN|presence|contrast|,|, (r_appos) volume_5\NN|SCr|In|.|,|and|,|estimated|, (l_appos) presence_7\NN|contrast|use|,|, (l_prep) of_8\IN|NONE (l_pobj) mellitus_10\NN|NONE
D007479_D007674 CID iopamidol_23\NN|NONE (r_pobj) of_22\IN|to|intraarterial|,|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|not|different|rate|with|. (r_prep) is_14\VBZ|NONE (l_nsubj) rate_1\NN|not|after|different|with|. (l_prep) of_2\IN|defined|,|,|The (l_pobj) nephropathy_6\NN|NONE
C044834_D007674 CID iodixanol_25\NN|or (r_conj) iopamidol_23\NN|NONE (r_pobj) of_22\IN|to|intraarterial|,|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|not|different|rate|with|. (r_prep) is_14\VBZ|NONE (l_nsubj) rate_1\NN|not|after|different|with|. (l_prep) of_2\IN|defined|,|,|The (l_pobj) nephropathy_6\NN|NONE
D007479_D051436 NONE iopamidol_14\NN|NONE (r_pobj) of_13\IN|multicenter|in|blind|,|,|a|randomized (r_prep) comparison_12\NN|.|rate|study (l_prep) in_17\IN|multicenter|blind|,|,|a|randomized|of (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) disease_22\NN|NONE
C044834_D051436 NONE iodixanol_16\NN|and (r_conj) iopamidol_14\NN|NONE (r_pobj) of_13\IN|multicenter|in|blind|,|,|a|randomized (r_prep) comparison_12\NN|.|rate|study (l_prep) in_17\IN|multicenter|blind|,|,|a|randomized|of (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) disease_22\NN|NONE
D007479_D003920 NONE iopamidol_24\NN|with (r_pobj) with_23\IN|%|,|dL|increases (r_prep) were_14\VBD|>|In|SCr|,|. (r_conj) increases_6\VBZ|NONE (l_prep) In_0\IN|>|SCr|were|,|. (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) diabetes_3\NNS|NONE
D007479_D003920 NONE iopamidol_23\NN|NONE (r_pobj) of_22\IN|to|intraarterial|,|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|not|different|rate|with|. (r_prep) is_14\VBZ|NONE (l_prep) with_32\IN|not|after|different|rate|. (l_conj) without_34\IN|or (l_pobj) mellitus_36\NN|NONE
12574103
D003907_D006973 CID dexamethasone_1\NN|Prenatal (r_compound) programs_2\NNS|and|injury|.|in (r_compound) hypertension_3\NN|NONE
D003907_D006973 CID dexamethasone_11\NN|increase|if (r_nsubj) programmed_12\VBD|to (l_dobj) increase_15\NN|if|dexamethasone (l_prep) in_16\IN|progressive|a (l_pobj) pressure_18\NN|NONE
D003907_D006973 CID dexamethasone_5\NN|that|on (r_dobj) received_3\VBD|Male (r_relcl) rats_1\NNS|had|at|pressures (r_nsubj) elevated_23\VBN|;|not|did|reduction|.|group (l_dobj) pressures_25\NNS|had|at|rats
D003907_D006973 CID dexamethasone_5\NN|that|in (r_nsubj) results_8\VBZ|.|study (l_prep) in_9\IN|that|dexamethasone (l_pobj) reduction_11\NN|NONE (l_prep) in_12\IN|a (l_pobj) number_14\NN|NONE (l_conj) glomerulosclerosis_16\NN|glomerular|,|administered (l_conj) hypertension_19\NN|and|,
D003907_D005921 NONE dexamethasone_3\NN|on|had|.|rats (r_dobj) given_2\VBN|NONE (l_advcl) had_11\VBD|on|dexamethasone|.|rats (l_dobj) glomeruli_13\NNS|NONE (l_prep) with_14\IN|than|more (l_pobj) glomerulosclerosis_15\NN|NONE
D003907_D005921 NONE dexamethasone_5\NN|that|in (r_nsubj) results_8\VBZ|.|study (l_prep) in_9\IN|that|dexamethasone (l_pobj) reduction_11\NN|NONE (l_prep) in_12\IN|a (l_pobj) number_14\NN|NONE (l_conj) glomerulosclerosis_16\NN|glomerular|,|administered
D003907_D007674 CID dexamethasone_1\NN|Prenatal (r_compound) programs_2\NNS|and|injury|.|in (r_compound) hypertension_3\NN|NONE (l_conj) injury_6\NN|and|programs|.|in
D003907_D007674 CID dexamethasone_11\NN|increase|if (r_nsubj) programmed_12\VBD|to (l_dobj) increase_15\NN|if|dexamethasone (l_prep) in_16\IN|progressive|a (l_pobj) pressure_18\NN|NONE (l_conj) injury_21\NN|and|blood
D003907_D007674 CID dexamethasone_4\NN|Offspring|on (r_dobj) administered_3\VBN|reduction|.|compared (r_csubj) had_11\VBD|NONE (l_dobj) reduction_15\NN|.|administered|compared (l_prep) in_16\IN|%|a (l_pobj) number_18\NN|NONE
D003907_D007674 CID dexamethasone_5\NN|that|on (r_dobj) received_3\VBD|Male (r_relcl) rats_1\NNS|had|at|pressures (r_nsubj) elevated_23\VBN|;|not|did|reduction|.|group (r_ccomp) have_37\VB|NONE (l_dobj) reduction_39\NN|;|not|did|.|elevated|group (l_prep) in_40\IN|a (l_pobj) number_42\NN|NONE
D003907_D007674 CID dexamethasone_5\NN|that|in (r_nsubj) results_8\VBZ|.|study (l_prep) in_9\IN|that|dexamethasone (l_pobj) reduction_11\NN|NONE (l_prep) in_12\IN|a (l_pobj) number_14\NN|NONE
18023325
D004221_D010243 NONE disulfiram_24\NN|dose (r_compound) intoxication_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) caused_19\VBN|severe|acute|axonal|sensorimotor (r_acl) polyneuropathy_18\NN|NONE (r_dobj) superimposed_13\VBN|and|case|.|This (r_conj) was_1\VBD|NONE (l_attr) case_3\NN|and|superimposed|.|This (l_prep) of_4\IN|a (l_pobj) palsy_6\JJ|NONE
D004221_D014826 CID disulfiram_6\NN|acute (r_compound) intoxication_7\NN|NONE (r_pobj) after_4\IN|fold|Acute|. (r_prep) palsy_3\JJ|NONE
D004221_D014826 CID disulfiram_6\NN|a (r_compound) overdose_7\NN|NONE (r_pobj) by_4\IN|NONE (r_agent) caused_3\VBN|peripheral|Acute (r_acl) neuropathy_2\NN|and|rare|is (r_nsubj) is_8\VBZ|NONE (l_conj) is_13\VBZ|neuropathy|and|rare (l_attr) report_15\NN|.|there (l_acl) leading_18\VBG|of|no (l_prep) to_19\IN|NONE (l_pobj) palsy_22\JJ|NONE
D004221_D010523 CID disulfiram_6\NN|a (r_compound) overdose_7\NN|NONE (r_pobj) by_4\IN|NONE (r_agent) caused_3\VBN|peripheral|Acute (r_acl) neuropathy_2\NN|and|rare|is
D004221_D062787 NONE disulfiram_6\NN|a (r_compound) overdose_7\NN|NONE
D004221_D011115 NONE disulfiram_24\NN|dose (r_compound) intoxication_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) caused_19\VBN|severe|acute|axonal|sensorimotor (r_acl) polyneuropathy_18\NN|NONE
12369736
C103477_D009069 NONE 55562_1\CD|,|side (r_nummod) GR_0\NNP|.|attenuated|shell|prior (r_nsubj) administered_11\VBN|NONE (l_conj) attenuated_23\VBD|.|GR|shell|prior (l_dobj) hyperactivity_29\NN|dependently
C103477_D009069 NONE 55562_38\CD|NONE (r_nummod) GR_37\NNP|receptor|the|(|HTB|) (r_appos) antagonist_35\NN|NONE (r_pobj) of_31\IN|inhibitory (r_prep) effects_30\NNS|NONE (r_pobj) in_26\IN|NONE (r_prep) consisting_25\VBG|agonist|,|respectively|and|core|this (r_acl) modification_24\NN|,|accumbens|but|the (r_conj) shell_17\NN|NONE (r_pobj) into_14\IN|NONE (r_prep) microinjected_13\VBN|receptor|HTB (r_acl) ligands_12\NNS|NONE (r_pobj) by_9\IN|hyperlocomotion|.|is (r_agent) modified_8\VBN|induced|findings (l_nsubjpass) hyperlocomotion_6\NN|by|.|is
D003042_D009069 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|in|the|locomotor (r_amod) hyperactivity_18\NN|NONE
D003042_D009069 CID cocaine_34\NN|NONE (r_pobj) by_33\IN|NONE (r_agent) induced_32\VBN|locomotor|the (r_acl) hyperactivity_31\NN|NONE
D003042_D009069 CID cocaine_18\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) prior_16\RB|.|GR|attenuated|shell (r_advmod) administered_11\VBN|NONE (l_conj) attenuated_23\VBD|.|GR|shell|prior (l_dobj) hyperactivity_29\NN|dependently
D003042_D009069 CID cocaine_4\NN|that (r_nsubj) induced_5\VBN|modified|findings (r_ccomp) indicate_2\VBP|NONE (l_ccomp) modified_8\VBN|induced|findings (l_nsubjpass) hyperlocomotion_6\NN|by|.|is
C065046_D009069 CID 93129_44\CD|)|( (r_nummod) CP_43\NNP|, (r_appos) agonist_41\NN|,|consisting|respectively|and|core|this (r_conj) modification_24\NN|,|accumbens|but|the (r_conj) shell_17\NN|NONE (r_pobj) into_14\IN|NONE (r_prep) microinjected_13\VBN|receptor|HTB (r_acl) ligands_12\NNS|NONE (r_pobj) by_9\IN|hyperlocomotion|.|is (r_agent) modified_8\VBN|induced|findings (l_nsubjpass) hyperlocomotion_6\NN|by|.|is
8953972
D004837_D006323 CID Epinephrine_0\NN|role (r_nsubj) has_1\VBZ|however|;|by|, (l_dobj) role_4\NN|Epinephrine (l_prep) in_5\IN|a|proven (l_pobj) arrest_7\NN|NONE
D004837_D013345 CID epinephrine_8\NN|NONE (r_pobj) of_7\IN|prehospital (r_prep) use_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|intracranial|Fatal|. (r_acl) bleeding_2\NN|NONE
D004837_D012128 NONE epinephrine_26\NN|to (r_dobj) administer_24\VB|.|onset|paramedics (r_xcomp) led_16\VBD|NONE (l_nsubj) onset_2\NN|.|administer|paramedics (l_prep) of_3\IN|The|sudden (l_pobj) distress_5\NN|NONE
D004837_D005076 NONE epinephrine_26\NN|to (r_dobj) administer_24\VB|.|onset|paramedics (r_xcomp) led_16\VBD|NONE (l_nsubj) onset_2\NN|.|administer|paramedics (l_prep) of_3\IN|The|sudden (l_pobj) distress_5\NN|NONE (l_conj) rash_7\JJ|,|respiratory
D004837_D004342 NONE Epinephrine_0\NN|role (r_nsubj) has_1\VBZ|however|;|by|, (r_ccomp) use_14\NN|.|with|should|be (l_prep) by_15\IN|however|;|,|has (l_pobj) paramedics_16\NNS|NONE (l_prep) in_17\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) reaction_22\NN|NONE
D004837_D006973 NONE Epinephrine_0\NN|role (r_nsubj) has_1\VBZ|however|;|by|, (r_ccomp) use_14\NN|.|with|should|be (l_prep) by_15\IN|however|;|,|has (l_pobj) paramedics_16\NNS|NONE (l_prep) in_17\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) reaction_22\NN|NONE (l_conj) hypertension_25\NN|and|allergic|suspected
20588063
D011692_D009401 CID aminonucleoside_17\JJ|puromycin (r_amod) nephrosis_18\NN|NONE
D011692_D009401 CID aminonucleoside_2\JJ|NONE (r_amod) nephrosis_3\NN|PAN|(|)
9293063
D003613_D006222 CID danazol_12\NN|NONE (r_pobj) with_11\IN|term (r_prep) treatment_10\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|NONE (r_prep) occurring_3\VBG|.|duct (r_acl) hamartoma_2\NN|NONE
D003613_D006222 CID danazol_20\NN|term (r_compound) treatment_21\NN|NONE (r_pobj) on_16\IN|who|had (r_prep) been_15\VBN|a (r_relcl) patient_12\NN|NONE (r_pobj) in_10\IN|which (r_prep) developed_9\VBD|duct (r_relcl) hamartoma_7\NN|NONE
D003613_D001650 CID danazol_12\NN|NONE (r_pobj) with_11\IN|term (r_prep) treatment_10\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|NONE (r_prep) occurring_3\VBG|.|duct (r_acl) hamartoma_2\NN|NONE
D003613_D001650 CID danazol_20\NN|term (r_compound) treatment_21\NN|NONE (r_pobj) on_16\IN|who|had (r_prep) been_15\VBN|a (r_relcl) patient_12\NN|NONE (r_pobj) in_10\IN|which (r_prep) developed_9\VBD|duct (r_relcl) hamartoma_7\NN|NONE
6634932
D010042_D017180 CID ouabain_20\RB| (r_npadvmod) induced_22\VBN|ventricular (r_amod) tachycardias_24\NNS|NONE
C002616_D017180 NONE UM-272_0\NNP|)|agent||(|,|N|,|N (r_punct) dimethylpropranolol_6\NNP|.|,|sublingually|to|was (r_nsubjpass) administered_15\VBN|NONE (l_prep) to_17\IN|dimethylpropranolol|.|,|sublingually|was (l_pobj) dogs_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) tachycardias_24\NNS|NONE
C002616_D017180 NONE dimethylpropranolol_6\NNP|.|,|sublingually|to|was (r_nsubjpass) administered_15\VBN|NONE (l_prep) to_17\IN|dimethylpropranolol|.|,|sublingually|was (l_pobj) dogs_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) tachycardias_24\NNS|NONE
C002616_D017180 NONE UM-272_1\NNP|Sublingual|sinus|tachycardia|. (r_punct) converted_2\VBD|NONE (l_dobj) tachycardia_4\NN|Sublingual|sinus|UM|.
15602202
D017963_D009395 CID azithromycin_6\PRP|NONE (r_pobj) by_5\IN|.|nephritis (r_prep) induced_4\VBN|NONE (l_nsubj) nephritis_3\NN|by|.
D017963_D009395 CID azithromycin_10\RB| (r_advmod) induced_12\VBN|acute|,|interstitial (r_amod) nephritis_16\NN|girl|is|,|with|.
8638206
D001279_D010243 CID atracurium_6\NN|NONE (r_pobj) of_5\IN|prolonged|in (r_prep) use_4\NN|NONE (r_pobj) after_2\IN|.|Persistent (r_prep) paralysis_1\NN|NONE
D001279_D010243 CID besylate_1\NN|been|also|but|,|with|has|used (r_nsubjpass) associated_22\VBN|NONE (l_prep) with_23\IN|been|also|but|besylate|,|has|used (l_pobj) paralysis_25\NN|NONE
D001279_D010243 CID atracurium_5\NN| (r_npadvmod) related_7\VBN|persisting (r_amod) paralysis_8\NN|NONE
D014673_D010243 CID bromide_21\NN|such (r_pobj) as_19\IN|based (r_prep) NMBAs_17\NNS|.|have|used|often|Reports|, (r_dobj) involved_13\VBN|NONE (l_nsubj) Reports_0\NNS|.|have|NMBAs|used|often|, (l_prep) of_1\IN|after (l_pobj) paralysis_3\NN|NONE
-1_D010243 NONE benzylisoquinolinium_7\NN|eliminated|acting|a (r_amod) NMBA_8\NNP|Atracurium|,|, (r_appos) besylate_1\NN|been|also|but|,|with|has|used (r_nsubjpass) associated_22\VBN|NONE (l_prep) with_23\IN|been|also|but|besylate|,|has|used (l_pobj) paralysis_25\NN|NONE
15632880
D011188_D006947 NONE K(+_7\NNP|NONE (r_appos) hyperkalemia_5\NN|who
D011188_D006947 NONE potassium_17\NN|higher|doses|and|baseline (r_compound) levels_18\NNS|,|were|and (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_nsubj) Patients_0\NNS|.|older|,|had (l_relcl) developed_2\VBD|NONE (l_dobj) hyperkalemia_3\NN|who
D011188_D006947 NONE potassium_22\NN|NONE (r_compound) supplement_23\NN|lower|baseline (r_compound) doses_24\NNS|higher|and|potassium|baseline (r_conj) levels_18\NNS|,|were|and (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_nsubj) Patients_0\NNS|.|older|,|had (l_relcl) developed_2\VBD|NONE (l_dobj) hyperkalemia_3\NN|who
D013148_D051437 CID Spironolactone_0\NNP||insufficiency|. (r_npadvmod) induced_2\VBN|NONE (l_dobj) insufficiency_4\NN||.|Spironolactone
D013148_D051437 CID spironolactone_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) use_7\NN|NONE (r_dobj) evaluating_5\VBG|controlled|previous|randomized|A (r_acl) trial_4\NN|.|risk (r_nsubj) reported_14\VBD|NONE (l_dobj) risk_17\NN|.|trial (l_prep) of_18\IN|a|low (l_pobj) hyperkalemia_19\NN|NONE (l_conj) insufficiency_26\NN|(|)|%|and
D013148_D051437 CID spironolactone_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) treated_19\VBN|failure (r_acl) patients_18\NNS|NONE (r_pobj) in_15\IN|renal (r_prep) insufficiency_14\NN|and
D013148_D051437 CID spironolactone_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) discontinuation_11\NN|.|seven|due (r_dobj) required_10\VBD|NONE (l_prep) due_14\IN|.|discontinuation|seven (l_pobj) hyperkalemia_16\NN|to (l_conj) failure_24\NN|)|or|(|n
D013148_D051437 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|and (r_amod) hyperkalemia_3\NN|renal (r_nmod) insufficiency_6\NN|common|in|.|reported
D011188_D003920 NONE potassium_17\NN|higher|doses|and|baseline (r_compound) levels_18\NNS|,|were|and (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_acomp) older_5\JJR|.|Patients|,|had (l_conj) likely_8\JJ|and (l_xcomp) have_10\VB|more (l_dobj) diabetes_11\NNS|to
D011188_D003920 NONE potassium_22\NN|NONE (r_compound) supplement_23\NN|lower|baseline (r_compound) doses_24\NNS|higher|and|potassium|baseline (r_conj) levels_18\NNS|,|were|and (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_acomp) older_5\JJR|.|Patients|,|had (l_conj) likely_8\JJ|and (l_xcomp) have_10\VB|more (l_dobj) diabetes_11\NNS|to
D013148_D006333 NONE Spironolactone_0\NNP||insufficiency|. (r_npadvmod) induced_2\VBN|NONE (l_dobj) insufficiency_4\NN||.|Spironolactone (l_prep) in_7\IN|hyperkalemia|renal|and (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) failure_11\NN|NONE
D013148_D006333 NONE spironolactone_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) patients_13\NNS|NONE (l_compound) failure_12\NN|NONE
D013148_D006333 NONE spironolactone_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) benefits_9\NNS|were|since (r_nsubjpass) reported_13\VBN|Because|have|treatments (r_advcl) changed_6\VBN|prevalence|,|in|.|may (l_nsubj) treatments_1\NNS|Because|reported|have (l_prep) for_2\IN|NONE (l_pobj) failure_4\NN|NONE
D013148_D006333 NONE spironolactone_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) treated_19\VBN|failure (r_acl) patients_18\NNS|NONE (l_compound) failure_17\NN|treated
D013148_D006333 NONE spironolactone_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) treated_10\VBN|failure (r_acl) patients_9\NNS|NONE (l_compound) failure_8\NN|treated
D049971_D051437 NONE thiazide_31\NN|than (r_amod) diuretics_32\NNS|NONE (r_pobj) with_30\IN|be|to (r_prep) treated_29\VBN|more (r_xcomp) likely_26\JJ|NONE (r_acomp) were_24\VBD|,|doses|and (r_conj) required_16\VBD|Patients|,|.|weight (r_conj) had_5\VBD|NONE (l_nsubj) Patients_0\NNS|,|required|.|weight (l_relcl) developed_2\VBD|NONE (l_dobj) insufficiency_4\NN|who
D013148_D006947 CID Spironolactone_0\NNP||insufficiency|. (r_npadvmod) induced_2\VBN|NONE (l_dobj) insufficiency_4\NN||.|Spironolactone (l_conj) hyperkalemia_6\NN|renal|in|and
D013148_D006947 CID spironolactone_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) use_7\NN|NONE (r_dobj) evaluating_5\VBG|controlled|previous|randomized|A (r_acl) trial_4\NN|.|risk (r_nsubj) reported_14\VBD|NONE (l_dobj) risk_17\NN|.|trial (l_prep) of_18\IN|a|low (l_pobj) hyperkalemia_19\NN|NONE
D013148_D006947 CID spironolactone_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) treated_19\VBN|failure (r_acl) patients_18\NNS|NONE (r_pobj) in_15\IN|renal (r_prep) insufficiency_14\NN|and (r_conj) hyperkalemia_11\NN|NONE
D013148_D006947 CID spironolactone_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) discontinuation_11\NN|.|seven|due (r_dobj) required_10\VBD|NONE (l_prep) due_14\IN|.|discontinuation|seven (l_pobj) hyperkalemia_16\NN|to
D013148_D006947 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|and (r_amod) hyperkalemia_3\NN|renal
D003404_D051437 NONE creatinine_14\NN|lower|body|and|baseline (r_conj) weight_9\NN|Patients|,|required|. (r_dobj) had_5\VBD|NONE (l_nsubj) Patients_0\NNS|,|required|.|weight (l_relcl) developed_2\VBD|NONE (l_dobj) insufficiency_4\NN|who
D011188_D051437 NONE K(+_7\NNP|NONE (r_appos) hyperkalemia_5\NN|who (r_dobj) developed_4\VBD|NONE (r_relcl) patients_2\NNS|(|Cases (r_attr) were_1\VBD|NONE (l_nsubj) Cases_0\NNS|(|patients (l_appos) L_13\NN|NONE (l_conj) insufficiency_17\NN|or|/|)|mEq|>
6386793
D000639_D014786 CID amitriptyline_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) than_25\IN|with|significantly (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|less|. (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|and|the|severity (l_pobj) vision_13\NN|NONE
D004308_D014987 NONE dothiepin_24\JJ|NONE (r_pobj) with_23\IN|significantly|than (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|less|. (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|and|the|severity (l_pobj) vision_13\NN|NONE (l_conj) mouth_16\NN|blurred|,
D000928_D003866 NONE antidepressant_8\NN|an|effective|associated (r_amod) drug_9\NN|to (l_acl) associated_10\VBN|an|effective|antidepressant (l_prep) with_11\IN|NONE (l_pobj) effects_14\NNS|NONE (l_prep) than_15\IN|fewer|side (l_pobj) amitriptyline_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_22\NNS|NONE (l_amod) depressed_21\JJ|NONE
D000639_D014987 CID amitriptyline_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) than_25\IN|with|significantly (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|less|. (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|and|the|severity (l_pobj) vision_13\NN|NONE (l_conj) mouth_16\NN|blurred|,
D004308_D003866 NONE hydrochloride_12\NN|NONE (r_pobj) of_10\IN|and|the|safety (r_prep) efficacy_7\NN|NONE (r_pobj) of_5\IN|.|in|blind|A (r_prep) study_4\NN|NONE (l_prep) in_13\IN|of|.|blind|A (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
D004308_D003866 NONE dothiepin_10\JJ|In|to|.|,|were (r_nsubjpass) compared_14\VBN|NONE (l_prep) to_15\IN|In|.|,|were|dothiepin (l_pobj) placebo_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_23\NNS|NONE (l_amod) depressed_22\JJ|
D004308_D003866 NONE Dothiepin_0\JJ|,|effective|were|and (r_nsubj) were_3\VBD|NONE (l_acomp) effective_5\JJ|,|were|and|Dothiepin (l_prep) in_6\IN|equally (l_pcomp) alleviating_7\VBG|NONE (l_dobj) symptoms_9\NNS|NONE (l_prep) of_10\IN|the (l_pobj) illness_12\NN|NONE
D004308_D003866 NONE Dothiepin_0\NNP|be|.|thus|was (r_nsubjpass) found_3\VBN|NONE (l_xcomp) be_5\VB|.|Dothiepin|thus|was (l_attr) drug_9\NN|to (l_acl) associated_10\VBN|an|effective|antidepressant (l_prep) with_11\IN|NONE (l_pobj) effects_14\NNS|NONE (l_prep) than_15\IN|fewer|side (l_pobj) amitriptyline_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_22\NNS|NONE (l_amod) depressed_21\JJ|NONE
D004308_D014786 NONE dothiepin_24\JJ|NONE (r_pobj) with_23\IN|significantly|than (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|less|. (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|and|the|severity (l_pobj) vision_13\NN|NONE
D000639_D003866 NONE amitriptyline_12\NN|and (r_conj) dothiepin_10\JJ|In|to|.|,|were (r_nsubjpass) compared_14\VBN|NONE (l_prep) to_15\IN|In|.|,|were|dothiepin (l_pobj) placebo_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_23\NNS|NONE (l_amod) depressed_22\JJ|
D000639_D003866 NONE amitriptyline_2\NN|and (r_conj) Dothiepin_0\JJ|,|effective|were|and (r_nsubj) were_3\VBD|NONE (l_acomp) effective_5\JJ|,|were|and|Dothiepin (l_prep) in_6\IN|equally (l_pcomp) alleviating_7\VBG|NONE (l_dobj) symptoms_9\NNS|NONE (l_prep) of_10\IN|the (l_pobj) illness_12\NN|NONE
D000639_D003866 NONE amitriptyline_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_22\NNS|NONE (l_amod) depressed_21\JJ|NONE
2673163
D003042_D002532 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE
D003042_D020521 NONE cocaine_3\NN|NONE (r_compound) use_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Stroke_0\NN|NONE
D003042_D020521 NONE cocaine_6\NN|NONE (r_compound) use_7\NN|in|was|and|review|to (r_nsubjpass) related_9\VBN|eight (l_prep) to_10\IN|in|use|was|and|review (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_2\NN|by (r_compound) use_3\NN|.|Stroke (r_dobj) followed_1\VBD|NONE (l_nsubj) Stroke_0\NN|.|use
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (l_nsubj) stroke_25\NN|indicate|(|;|primarily|in
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (l_nsubj) stroke_35\NN|occurs|route|may|;
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_conj) 5_63\CD|and|associated|;| (l_prep) in_65\IN|,|(|) (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (l_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|that|is (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (l_nsubj) stroke_35\NN|occurs|route|may|;
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_conj) 5_63\CD|and|associated|;| (l_prep) in_65\IN|,|(|) (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (l_ccomp) occurs_26\VBZ|route|may|;|stroke (l_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|that|is (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (l_ccomp) occurs_26\VBZ|route|may|;|stroke (l_nsubj) stroke_25\NN|indicate|(|;|primarily|in
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (l_nsubj) stroke_35\NN|occurs|route|may|;
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_conj) 5_63\CD|and|associated|;| (l_prep) in_65\IN|,|(|) (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (r_advcl) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|that|;|.|frequency (l_ccomp) occurs_26\VBZ|route|may|;|stroke (l_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|that|is (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (r_advcl) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|that|;|.|frequency (l_ccomp) occurs_26\VBZ|route|may|;|stroke (l_nsubj) stroke_25\NN|indicate|(|;|primarily|in
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (r_advcl) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|that|;|.|frequency (l_nsubj) stroke_35\NN|occurs|route|may|;
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (r_advcl) stroke_47\NN|of|the
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (r_advcl) stroke_47\NN|of|the (l_conj) 5_63\CD|and|associated|;| (l_prep) in_65\IN|,|(|) (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|that|;|.|frequency (l_ccomp) occurs_26\VBZ|route|may|;|stroke (l_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|that|is (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|that|;|.|frequency (l_ccomp) occurs_26\VBZ|route|may|;|stroke (l_nsubj) stroke_25\NN|indicate|(|;|primarily|in
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|that|;|.|frequency (l_nsubj) stroke_35\NN|occurs|route|may|;
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE
D003042_D002544 CID cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|;|.|follow|frequency (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|;|.|follow|frequency (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|;|.|follow|frequency (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (r_advcl) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|;|.|follow|frequency (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|;|.|follow|frequency (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D001165 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_nmod) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the (l_advcl) associated_53\VBN|and||;| (l_prep) with_54\IN|after|is|frequently|use (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D020300 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|that|is (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|(|;|primarily|in|stroke (r_ccomp) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_prep) of_73\IN|stroke|the (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|)| (r_amod) stroke_25\NN|indicate|(|;|primarily|in (r_nsubj) occurs_26\VBZ|route|may|;|stroke (r_ccomp) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_prep) of_73\IN|stroke|the (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|occurs|may|;|stroke (r_dobj) follow_37\VB|that|;|.|frequency (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|that|;|.|follow (l_prep) of_73\IN|stroke|the (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|after|with|is|frequently (r_nsubjpass) associated_53\VBN|and||;| (r_advcl) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (l_prep) of_73\IN|stroke|the (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|,|(|) (r_prep) 5_63\CD|and|associated|;| (r_conj) stroke_47\NN|of|the (r_nmod) frequency_72\NN|that|;|.|follow (l_prep) of_73\IN|stroke|the (l_pobj) hemorrhage_75\NN|NONE
19803309
D013390_D009224 NONE suxamethonium_29\NN|NONE (r_pobj) of_27\IN|standard|a|for (r_prep) dose_26\NN|NONE (r_pobj) following_23\VBG|life|spasm (r_prep) threatening_20\VBG|who (r_ccomp) developed_18\VBD|,|healthy|a|old (r_relcl) primigravida_15\NN|NONE (r_pobj) in_8\IN|undiagnosed|of|an (r_prep) case_4\NN|We|. (l_prep) of_5\IN|in|undiagnosed|an (l_pobj) congenita_7\NN|NONE
D013390_D014313 CID suxamethonium_29\NN|NONE (r_pobj) of_27\IN|standard|a|for (r_prep) dose_26\NN|NONE (r_pobj) following_23\VBG|life|spasm (r_prep) threatening_20\VBG|who (l_dobj) spasm_22\NN|following|life
234669
D002245_D014693 NONE dioxide_32\NN|)|and (r_conj) PO2_28\NNP|( (r_appos) oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|.|,|During|was|threshold|by (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|.|,|During|was|kept|by (l_compound) fibrillation_8\NN|ventricular|the
D002245_D014693 NONE CO2_34\NNP|carbon (r_appos) dioxide_32\NN|)|and (r_conj) PO2_28\NNP|( (r_appos) oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|.|,|During|was|threshold|by (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|.|,|During|was|kept|by (l_compound) fibrillation_8\NN|ventricular|the
C093415_D014693 NONE PO2_28\NNP|( (r_appos) oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|.|,|During|was|threshold|by (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|.|,|During|was|kept|by (l_compound) fibrillation_8\NN|ventricular|the
D000628_D012131 NONE aminophylline_2\NN|NONE (r_pobj) of_1\IN|for|. (r_prep) Effects_0\NNS|NONE (l_prep) for_6\IN|of|. (l_pcomp) initiating_7\VBG|NONE (l_prep) during_10\IN|fibrillation (l_pobj) failure_12\NN|NONE
D000628_D012131 NONE aminophylline_3\NN|NONE (r_pobj) of_2\IN|The|during|and (r_prep) effects_1\NNS|.|were|in (l_conj) during_16\IN|The|of|and (l_pobj) failure_18\NN|NONE
D000628_D012131 NONE aminophylline_30\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) infusion_28\NN|PC|in|produced|,|. (r_nsubj) resulted_31\VBD|NONE (l_advcl) produced_4\VBN|PC|in|infusion|,|. (l_nsubjpass) failure_2\NN|When|was|by
D000628_D012131 NONE aminophylline_24\NN|,|,|pharmacologic (r_appos) agents_21\NNS|role|contribute|may|,|that (r_nsubj) play_27\VB|.|experiments (l_advcl) contribute_8\VB|role|may|agents|,|that (l_prep) to_9\IN|factors|although|may (l_pobj) incidence_12\NN|NONE (l_prep) of_13\IN|the|increased (l_pobj) arrhythmias_15\NNS|NONE (l_prep) in_16\IN|ventricular (l_pobj) failure_18\NN|NONE
D010100_D014693 NONE oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|.|,|During|was|threshold|by (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|.|,|During|was|kept|by (l_compound) fibrillation_8\NN|ventricular|the
D000628_D014693 CID aminophylline_2\NN|NONE (r_pobj) of_1\IN|for|. (r_prep) Effects_0\NNS|NONE (l_prep) for_6\IN|of|. (l_pcomp) initiating_7\VBG|NONE (l_dobj) fibrillation_9\NN|during
D000628_D014693 CID aminophylline_3\NN|NONE (l_prep) on_4\IN|NONE (l_pobj) threshold_8\NN|NONE (l_compound) fibrillation_7\NN|during|the
D000628_D014693 CID aminophylline_4\NN|NONE (r_pobj) of_3\IN|the (r_prep) infusion_2\NN|NONE (r_pobj) During_0\IN|.|,|was|kept|threshold|by (r_prep) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|.|,|During|was|kept|by (l_compound) fibrillation_8\NN|ventricular|the
D000628_D014693 CID aminophylline_30\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) infusion_28\NN|PC|in|produced|,|. (r_nsubj) resulted_31\VBD|NONE (l_prep) in_32\IN|PC|produced|infusion|,|. (l_pobj) decrease_36\NN|NONE (l_prep) in_37\IN|an|greater (l_pobj) threshold_40\NN|NONE (l_compound) fibrillation_39\NN|to
D000628_D007040 NONE aminophylline_30\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) infusion_28\NN|PC|in|produced|,|. (r_nsubj) resulted_31\VBD|NONE (l_advcl) produced_4\VBN|PC|in|infusion|,|. (l_agent) by_5\IN|When|was|failure (l_pobj) hypoventilation_6\NN|NONE
D000628_D001145 NONE aminophylline_24\NN|,|,|pharmacologic (r_appos) agents_21\NNS|role|contribute|may|,|that (r_nsubj) play_27\VB|.|experiments (l_advcl) contribute_8\VB|role|may|agents|,|that (l_prep) to_9\IN|factors|although|may (l_pobj) incidence_12\NN|NONE (l_prep) of_13\IN|the|increased (l_pobj) arrhythmias_15\NNS|NONE
3985451
D014859_D003286 NONE warfarin_12\NN|chronic (r_compound) therapy_13\NN|NONE (r_pobj) on_10\IN|sustained|old|a (r_prep) man_9\NN|NONE (l_relcl) sustained_15\VBD|on|old|a (l_conj) developed_21\VBD|who|tear|and (l_dobj) pain_23\NN|NONE (l_conj) contracture_27\NN|increasing|and
D014859_D003286 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|common|the (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|by|.|is|; (r_ccomp) characterized_20\VBN|NONE (l_agent) by_21\IN|it|.|is|represents|; (l_pobj) pain_23\NN|NONE (l_conj) degrees_30\NNS|severe|,|in (l_conj) contracture_39\NN|varying|and|of|,
D014859_D010523 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE
D014859_D020428 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|with|iliopsoas|. (r_amod) hemorrhage_4\NN|NONE (l_prep) with_5\IN|iliopsoas|.|induced (l_pobj) palsy_9\JJ|NONE
D014859_D020428 CID warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|common|the (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|by|.|is|; (l_nsubj) palsy_5\JJ|form
D014859_D006470 NONE Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|with|iliopsoas|. (r_amod) hemorrhage_4\NN|NONE
D014859_D009135 CID warfarin_12\NN|chronic (r_compound) therapy_13\NN|NONE (r_pobj) on_10\IN|sustained|old|a (r_prep) man_9\NN|NONE (l_relcl) sustained_15\VBD|on|old|a (l_dobj) tear_19\NN|who|developed|and
D014859_D010146 NONE warfarin_12\NN|chronic (r_compound) therapy_13\NN|NONE (r_pobj) on_10\IN|sustained|old|a (r_prep) man_9\NN|NONE (l_relcl) sustained_15\VBD|on|old|a (l_conj) developed_21\VBD|who|tear|and (l_dobj) pain_23\NN|NONE
D014859_D010146 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|common|the (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|by|.|is|; (r_ccomp) characterized_20\VBN|NONE (l_agent) by_21\IN|it|.|is|represents|; (l_pobj) pain_23\NN|NONE
D014859_D015417 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|common|the (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|by|.|is|; (r_ccomp) characterized_20\VBN|NONE (l_agent) by_21\IN|it|.|is|represents|; (l_pobj) pain_23\NN|NONE (l_conj) degrees_30\NNS|severe|,|in (l_prep) of_31\IN|varying|and|contracture|, (l_pobj) impairment_35\NN|NONE
19356053
D020123_D009404 NONE sirolimus_16\NN|NONE (r_pobj) of_15\IN|development|and|the (r_prep) initiation_14\NN|NONE (l_conj) development_19\NN|and|the|of (l_prep) of_20\IN|the (l_pobj) proteinuria_24\NN|NONE (l_compound) range_23\NN|NONE (l_amod) nephrotic_21\JJ|
D003404_D011507 NONE creatinine_22\NN|estimate|, (r_compound) ratios_23\NNS|turbidometric|or|protein (r_conj) measurement_16\NN|NONE (r_pobj) by_14\IN|was|In|,|.|on|magnitude (r_agent) assessed_9\VBN|NONE (l_nsubjpass) magnitude_5\NN|was|In|,|.|on|by (l_prep) of_6\IN|the (l_pobj) proteinuria_7\NN|NONE
D003404_D011507 NONE creatinine_22\NN|estimate|, (r_compound) ratios_23\NNS|turbidometric|or|protein (l_appos) estimate_26\NN|creatinine|, (l_prep) of_27\IN|day|an (l_pobj) grams_28\NNS|NONE (l_prep) of_29\IN|NONE (l_pobj) proteinuria_30\NN|NONE
D020123_D011507 CID sirolimus_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) administration_5\NN|to (r_pobj) following_3\VBG|significant|. (r_prep) proteinuria_2\NN|NONE
D020123_D011507 CID sirolimus_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) use_14\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) linked_11\VBN|significant (r_acl) proteinuria_10\NN|NONE
D020123_D011507 CID sirolimus_11\NN|NONE (r_compound) use_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|substantial (r_acl) proteinuria_8\NN|who
D020123_D011507 CID sirolimus_12\NN|proteinuria|and (r_compound) therapy_13\NN|NONE (l_conj) proteinuria_15\NN|sirolimus|and
D020123_D011507 CID sirolimus_12\NN|proteinuria|and (r_compound) therapy_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) commencement_10\NN|NONE (r_pobj) between_8\IN|temporal|close|the (r_prep) association_7\NN|sirolimus|In|.|as|, (r_nsubj) implicated_16\VBN|NONE (l_prep) as_18\IN|sirolimus|In|.|association|, (l_pobj) etiology_22\NN|NONE (l_prep) of_23\IN|the|likely (l_pobj) proteinuria_25\NN|NONE
D020123_D011507 CID sirolimus_17\NN|In|.|association|as|, (r_dobj) implicated_16\VBN|NONE (l_nsubj) association_7\NN|sirolimus|In|.|as|, (l_prep) between_8\IN|temporal|close|the (l_pobj) commencement_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) therapy_13\NN|NONE (l_conj) proteinuria_15\NN|sirolimus|and
D020123_D011507 CID sirolimus_17\NN|In|.|association|as|, (r_dobj) implicated_16\VBN|NONE (l_prep) as_18\IN|sirolimus|In|.|association|, (l_pobj) etiology_22\NN|NONE (l_prep) of_23\IN|the|likely (l_pobj) proteinuria_25\NN|NONE
D020123_D011507 CID sirolimus_16\NN|NONE (r_pobj) of_15\IN|development|and|the (r_prep) initiation_14\NN|NONE (l_conj) development_19\NN|and|the|of (l_prep) of_20\IN|the (l_pobj) proteinuria_24\NN|NONE
D020123_D011507 CID sirolimus_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) with_4\IN|Proteinuria|.|strongly|compared (r_prep) correlated_1\VBD|NONE (l_nsubj) Proteinuria_0\NNP|.|strongly|with|compared
D020123_D011507 CID sirolimus_6\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) discontinuation_4\NN|,|In|but|in|,|resolution|. (r_nsubj) resulted_7\VBD|NONE (l_conj) resolution_14\NN|,|In|discontinuation|but|in|,|. (l_prep) of_16\IN|,|not (l_pobj) proteinuria_17\NN|NONE
D020123_D011507 CID Sirolimus_0\NNP|or|aggravates|. (r_nsubj) induces_1\VBZ|NONE (l_conj) aggravates_3\VBZ|or|Sirolimus|. (l_dobj) proteinuria_7\NN|in
D020123_D011507 CID sirolimus_10\NN|is|when (r_nsubjpass) withdrawn_12\VBN|not|does|, (r_advcl) resolve_7\VB|Proteinuria|.|may|,|but (r_conj) improve_2\VB|NONE (l_nsubj) Proteinuria_0\NNP|resolve|.|may|,|but
D020123_D007674 NONE Sirolimus_0\NNP|have|,|agent|.|and (r_nsubj) is_1\VBZ|NONE (l_conj) have_13\VB|,|agent|Sirolimus|.|and (l_dobj) nephrotoxicity_15\NN|may
7802851
D000525_D003866 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|.|,|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|.|,|patients|Compared (l_prep) of_18\IN|;|and|adverse|%|effects|(|) (l_pobj) depression_19\NN|NONE
D000525_D008569 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|.|,|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|.|,|patients|Compared (l_conj) effects_31\NNS|;|and|adverse|%|of|(|) (l_appos) sedation_34\NN|side|,|more| (l_conj) irritability_36\NN|,|particularly (l_conj) memory_39\NN|,
D000525_D016584 NONE alprazolam_3\NN|NONE (r_pobj) of_2\IN|effect|and|,|The|in (r_prep) efficacy_1\NN|.|were (l_prep) in_6\IN|effect|of|and|,|The (l_pobj) disorder_8\NN|NONE
D000525_D016584 NONE alprazolam_20\NN|were|.|In (r_xcomp) randomised_18\VBN|NONE (l_prep) In_0\IN|were|.|alprazolam (l_pobj) London_1\NNP|NONE (l_conj) patients_5\NNS|and (l_relcl) met_7\VBD|Toronto| (l_dobj) criteria_11\NNS|who (l_prep) for_12\IN|III (l_pobj) disorder_14\NN|NONE
D000525_D001259 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|.|,|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|.|,|patients|Compared (l_conj) effects_31\NNS|;|and|adverse|%|of|(|) (l_appos) sedation_34\NN|side|,|more| (l_conj) irritability_36\NN|,|particularly (l_conj) memory_39\NN|, (l_conj) loss_42\NN|impaired|, (l_conj) ataxia_44\NN|and|weight
D000525_D001523 NONE alprazolam_5\NN|NONE (r_compound) patients_6\NNS|.|,|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|.|,|patients|Compared (l_prep) of_18\IN|;|and|adverse|%|effects|(|) (l_pobj) depression_19\NN|NONE (l_conj) enuresis_21\NN|, (l_conj) disinhibition_23\NN|, (l_conj) aggression_25\NN|and
D000525_D001523 NONE alprazolam_5\NN|NONE (r_compound) patients_6\NNS|.|,|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|.|,|patients|Compared (l_conj) effects_31\NNS|;|and|adverse|%|of|(|) (l_appos) sedation_34\NN|side|,|more| (l_conj) irritability_36\NN|,|particularly
D000525_D015431 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|.|,|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|.|,|patients|Compared (l_conj) effects_31\NNS|;|and|adverse|%|of|(|) (l_appos) sedation_34\NN|side|,|more| (l_conj) irritability_36\NN|,|particularly (l_conj) memory_39\NN|, (l_conj) loss_42\NN|impaired|,
D000525_D000379 NONE alprazolam_3\NN|NONE (r_pobj) of_2\IN|effect|and|,|The|in (r_prep) efficacy_1\NN|.|were (l_prep) in_6\IN|effect|of|and|,|The (l_pobj) disorder_8\NN|NONE (l_prep) with_9\IN|panic (l_pobj) agoraphobia_10\NNP|NONE
D000525_D000379 NONE alprazolam_20\NN|were|.|In (r_xcomp) randomised_18\VBN|NONE (l_prep) In_0\IN|were|.|alprazolam (l_pobj) London_1\NNP|NONE (l_conj) patients_5\NNS|and (l_relcl) met_7\VBD|Toronto| (l_dobj) criteria_11\NNS|who (l_prep) for_12\IN|III (l_pobj) disorder_14\NN|NONE (l_prep) with_15\IN|panic (l_pobj) agoraphobia_16\NNP|NONE
D000525_D004775 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|.|,|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|.|,|patients|Compared (l_prep) of_18\IN|;|and|adverse|%|effects|(|) (l_pobj) depression_19\NN|NONE (l_conj) enuresis_21\NN|,
6503301
D003606_D008545 NONE dacarbazine_6\NN|(|DTIC|)|for (r_compound) therapy_7\NN|NONE (l_prep) for_11\IN|dacarbazine|(|DTIC|) (l_pobj) melanoma_12\NN|NONE
D003606_D008545 NONE DTIC_9\NNP|dacarbazine|(|)|for (r_appos) therapy_7\NN|NONE (l_prep) for_11\IN|dacarbazine|(|DTIC|) (l_pobj) melanoma_12\NN|NONE
D003606_D008545 NONE dacarbazine_14\NN|DTIC|)|for|( (r_nmod) therapy_18\NN|case|is|after|. (l_prep) for_19\IN|DTIC|)|dacarbazine|( (l_pobj) melanoma_20\NN|NONE
D003606_D008545 NONE DTIC_16\NNP|)|for|dacarbazine|( (r_nmod) therapy_18\NN|case|is|after|. (l_prep) for_19\IN|DTIC|)|dacarbazine|( (l_pobj) melanoma_20\NN|NONE
D003606_D006504 CID dacarbazine_6\NN|(|DTIC|)|for (r_compound) therapy_7\NN|NONE (r_pobj) after_5\IN|liver|.|occlusive (r_prep) disease_4\NN|NONE
D003606_D006504 CID DTIC_9\NNP|dacarbazine|(|)|for (r_appos) therapy_7\NN|NONE (r_pobj) after_5\IN|liver|.|occlusive (r_prep) disease_4\NN|NONE
D003606_D006504 CID dacarbazine_14\NN|DTIC|)|for|( (r_nmod) therapy_18\NN|case|is|after|. (r_nsubjpass) reported_22\VBN|NONE (l_nsubjpass) case_1\NN|therapy|is|after|. (l_prep) of_2\IN|A (l_pobj) disease_6\NN|NONE (l_prep) of_7\IN|with|occlusive (l_pobj) liver_9\NN|NONE
D003606_D006504 CID DTIC_16\NNP|)|for|dacarbazine|( (r_nmod) therapy_18\NN|case|is|after|. (r_nsubjpass) reported_22\VBN|NONE (l_nsubjpass) case_1\NN|therapy|is|after|. (l_prep) of_2\IN|A (l_pobj) disease_6\NN|NONE (l_prep) of_7\IN|with|occlusive (l_pobj) liver_9\NN|NONE
3714122
D010755_D020258 NONE organophosphate_33\NN|N'diisopropylphosphorodiamidofluoridate|)|, (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|neuropathic|and|inhibition (l_pobj) esterase_9\NN|NONE (l_amod) neurotoxic_8\JJ|or|enzyme
D010755_D020258 NONE organophosphate_33\NN|N'diisopropylphosphorodiamidofluoridate|)|, (l_amod) neurotoxic_32\JJ|a
C005238_D013118 CID Mipafox_5\NNP|NONE (r_pobj) of_4\IN|less|inhibited (r_prep) dosages_3\NNS|In|.|in|degree|, (r_nsubj) produced_39\VBN|NONE (l_dobj) degree_41\NN|In|.|in|dosages|, (l_prep) of_42\IN|this (l_pobj) damage_44\NN|NONE
C005238_D009422 NONE mipafox_7\NN| (r_npadvmod) induced_9\VBN|in|neuropathic (r_amod) damage_11\NN|neurotoxic|and|esterase
C005238_D009422 NONE Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE
C005238_D009422 NONE Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|neuropathic|and|inhibition (l_pobj) esterase_9\NN|NONE (l_conj) enzyme_13\NN|or|neurotoxic (l_compound) target_12\NN|NTE|(|) (l_compound) neuropathy_11\NN|NONE
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|)|organophosphate|, (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|)|organophosphate|, (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|neuropathic|and|inhibition (l_pobj) esterase_9\NN|NONE (l_conj) enzyme_13\NN|or|neurotoxic (l_compound) target_12\NN|NTE|(|) (l_compound) neuropathy_11\NN|NONE
C005238_D009422 NONE Mipafox_18\NNP|NONE (r_compound) exposure_19\NN|shortly|damage|later|after|can (r_nsubj) predict_21\VB|NONE (l_dobj) damage_23\NN|shortly|exposure|later|after|can
D010755_D009422 NONE organophosphate_33\NN|N'diisopropylphosphorodiamidofluoridate|)|, (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE
D010755_D009422 NONE organophosphate_33\NN|N'diisopropylphosphorodiamidofluoridate|)|, (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|neuropathic|and|inhibition (l_pobj) esterase_9\NN|NONE (l_conj) enzyme_13\NN|or|neurotoxic (l_compound) target_12\NN|NTE|(|) (l_compound) neuropathy_11\NN|NONE
C005238_D020258 NONE mipafox_7\NN| (r_npadvmod) induced_9\VBN|in|neuropathic (r_amod) damage_11\NN|neurotoxic|and|esterase (r_conj) inhibition_5\NN|NONE (l_amod) neurotoxic_3\JJ|damage|and|esterase
C005238_D020258 NONE Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|neuropathic|and|inhibition (l_pobj) esterase_9\NN|NONE (l_amod) neurotoxic_8\JJ|or|enzyme
C005238_D020258 NONE Mipafox_24\NNP|NONE (l_appos) organophosphate_33\NN|N'diisopropylphosphorodiamidofluoridate|)|, (l_amod) neurotoxic_32\JJ|a
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|)|organophosphate|, (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|.|was (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|.|was|in (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|neuropathic|and|inhibition (l_pobj) esterase_9\NN|NONE (l_amod) neurotoxic_8\JJ|or|enzyme
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|)|organophosphate|, (r_appos) Mipafox_24\NNP|NONE (l_appos) organophosphate_33\NN|N'diisopropylphosphorodiamidofluoridate|)|, (l_amod) neurotoxic_32\JJ|a
2559236
D004317_D000419 CID adriamycin_7\NNS|NONE (r_pobj) of_6\IN|a|and|single (r_prep) dose_5\NN|Rats|were|divided|. (r_dobj) given_2\VBN|NONE (l_advcl) divided_12\VBD|dose|Rats|were|. (l_prep) into_13\IN|later (l_pobj) groups_15\NNS|NONE (l_acl) matched_16\VBN|four (l_prep) for_17\IN|NONE (l_pobj) albuminuria_18\NN|NONE
D004656_D009401 NONE enalapril_10\NN|enzyme (r_appos) inhibitor_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|with|.|was|in (r_nsubjpass) assessed_12\VBN|NONE (l_prep) with_18\IN|.|was|in|effect (l_pobj) nephrosis_21\NN|NONE
D004656_D009401 NONE enalapril_17\NN|NONE (r_pobj) of_16\IN|on|the (r_prep) effect_15\NN|to (l_prep) on_18\IN|the|of (l_pobj) progression_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) injury_22\NN|NONE (l_prep) in_23\IN|renal (l_pobj) nephrosis_25\NN|NONE
D004656_D007674 NONE enalapril_17\NN|NONE (r_pobj) of_16\IN|on|the (r_prep) effect_15\NN|to (l_prep) on_18\IN|the|of (l_pobj) progression_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) injury_22\NN|NONE
D004317_D009401 CID adriamycin_20\NNS|established (r_amod) nephrosis_21\NN|NONE
D004317_D009401 CID adriamycin_24\JJ|NONE (r_amod) nephrosis_25\NN|NONE
D004656_D000419 NONE enalapril_7\DT|that||vs.|pressure (r_nsubj) reduced_8\JJ|studies|. (l_prep) vs._16\IN|that||pressure|enalapril (l_pobj) Hg_21\NNP|NONE (l_conj) pressure_36\NN|)|and|,|mm|P|group|, (l_appos) +/-_39\SYM|(|GFR|or|)|glomerular|(|+/|capillary (l_prep) without_53\IN||vs.| (l_pcomp) reducing_54\VBG|NONE (l_dobj) albuminuria_55\NN|NONE
D004656_D000419 NONE enalapril_1\NN|NONE (r_compound) treatment_2\NN|NONE (r_nsubj) reduced_3\VBN|.|blood|without (r_amod) pressure_5\NN|NONE (l_prep) without_6\IN|.|blood|reduced (l_pcomp) reducing_7\VBG|NONE (l_dobj) albuminuria_8\NN|in
D004317_D007674 NONE adriamycin_9\NNS| (r_npadvmod) induced_11\VBN|NONE (r_amod) nephropathy_12\NN|NONE
D004317_D007674 NONE adriamycin_24\JJ|NONE (r_amod) nephrosis_25\NN|NONE (r_pobj) in_23\IN|renal (r_prep) injury_22\NN|NONE
10739826
D003276_D054556 CID contraceptives_5\NNS|NONE (l_conj) risk_8\NN|oral|newer|and (l_prep) of_9\IN|the (l_pobj) thromboembolism_11\NN|NONE
D003276_D054556 CID contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|)|VTE|(|venous (r_acl) thromboembolism_9\NN|NONE
D003276_D054556 CID contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|)|VTE|(|venous (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|)|(|venous|associated
D003276_D054556 CID OC_19\NNP|newer|oral (r_appos) contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|)|VTE|(|venous (r_acl) thromboembolism_9\NN|NONE
D003276_D054556 CID OC_19\NNP|newer|oral (r_appos) contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|)|VTE|(|venous (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|)|(|venous|associated
D003276_D054556 CID OC_27\NNP|,|users (r_compound) use_28\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) patterns_25\NNS|NONE (r_pobj) between_24\IN|not|.|did|studies (r_prep) distinguish_23\VB|NONE (l_nsubj) studies_2\NNS|not|.|between|did (l_relcl) assessed_4\VBD|epidemiological|The (l_dobj) risk_6\NN|that (l_prep) of_7\IN|the (l_pobj) thromboembolism_9\NN|NONE
D003276_D054556 CID OC_27\NNP|,|users (r_compound) use_28\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) patterns_25\NNS|NONE (r_pobj) between_24\IN|not|.|did|studies (r_prep) distinguish_23\VB|NONE (l_nsubj) studies_2\NNS|not|.|between|did (l_relcl) assessed_4\VBD|epidemiological|The (l_dobj) risk_6\NN|that (l_prep) of_7\IN|the (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|)|(|venous|associated
D003276_D054556 CID OC_12\NNP|NONE (r_pobj) of_9\IN|repeat (r_prep) users_8\NNS|NONE (r_pobj) for_6\IN|of|rate|adjusted|The (r_prep) ratio_3\NN|repeat|%|was|.|, (l_prep) of_4\IN|rate|adjusted|The|for (l_pobj) VTE_5\NN|NONE
12627929
C067311_D054556 CID docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (r_pobj) with_5\IN|venous (r_prep) thromboembolism_4\NN|NONE
C067311_D054556 CID docetaxel_26\NNS|NONE (r_pobj) with_25\IN|were|alone|who (r_prep) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|the|of (r_prep) frequency_6\NN|To (l_prep) of_7\IN|the|in (l_pobj) thromboembolism_9\NN|NONE
C067311_D054556 CID docetaxel_26\NNS|NONE (r_pobj) with_25\IN|were|alone|who (r_prep) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|the|of (r_prep) frequency_6\NN|To (l_prep) of_7\IN|the|in (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|)|venous
C067311_D054556 CID docetaxel_6\NNS|alone|who (r_dobj) received_5\VBD| (r_relcl) patients_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|,|VTE|developed|. (r_nsubj) developed_8\VBN|NONE (l_dobj) VTE_9\NNP|,|None|developed|.
C067311_D054556 CID docetaxel_6\NNS|alone|who (r_dobj) received_5\VBD| (r_relcl) patients_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|,|VTE|developed|. (r_nsubj) developed_8\VBN|NONE (l_advcl) developed_25\VBD|,|None|VTE|. (l_dobj) VTE_26\NNP|whereas|
C067311_D054556 CID docetaxel_22\NNS|who (r_dobj) received_21\VBD|(|%|)| (r_relcl) patients_15\NNS|NONE (r_pobj) of_13\IN|plus|thalidomide (r_prep) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|,|None|VTE|. (r_advcl) developed_8\VBN|NONE (l_dobj) VTE_9\NNP|,|None|developed|.
C067311_D054556 CID docetaxel_22\NNS|who (r_dobj) received_21\VBD|(|%|)| (r_relcl) patients_15\NNS|NONE (r_pobj) of_13\IN|plus|thalidomide (r_prep) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|,|None|VTE|. (l_dobj) VTE_26\NNP|whereas|
C067311_D054556 CID docetaxel_5\NNS|of|The (r_relcl) addition_1\NN|frequency|.|significantly (r_nsubj) increases_13\VBZ|NONE (l_dobj) frequency_15\NN|.|significantly|addition (l_prep) of_16\IN|the (l_pobj) VTE_17\NNP|NONE
D013792_D011471 NONE thalidomide_11\NN|and (r_conj) docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (l_prep) in_12\IN|the|of (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) cancer_20\NN|NONE
D013792_D011471 NONE thalidomide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) combination_30\NN|NONE (r_pobj) in_29\IN|or (r_conj) alone_27\RB|were|with|who (r_advmod) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE
D013792_D011471 NONE thalidomide_3\NN|NONE (r_pobj) of_2\IN|docetaxel|The (r_prep) addition_1\NN|frequency|.|significantly (l_relcl) docetaxel_5\NNS|of|The (l_prep) in_6\IN|to (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) cancer_11\NN|NONE
D013792_D054556 CID thalidomide_11\NN|and (r_conj) docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (r_pobj) with_5\IN|venous (r_prep) thromboembolism_4\NN|NONE
D013792_D054556 CID thalidomide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) combination_30\NN|NONE (r_pobj) in_29\IN|or (r_conj) alone_27\RB|were|with|who (r_advmod) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|the|of (r_prep) frequency_6\NN|To (l_prep) of_7\IN|the|in (l_pobj) thromboembolism_9\NN|NONE
D013792_D054556 CID thalidomide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) combination_30\NN|NONE (r_pobj) in_29\IN|or (r_conj) alone_27\RB|were|with|who (r_advmod) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|the|of (r_prep) frequency_6\NN|To (l_prep) of_7\IN|the|in (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|)|venous
D013792_D054556 CID thalidomide_24\NN|of|plus (r_conj) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|,|None|VTE|. (r_advcl) developed_8\VBN|NONE (l_dobj) VTE_9\NNP|,|None|developed|.
D013792_D054556 CID thalidomide_24\NN|of|plus (r_conj) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|,|None|VTE|. (l_dobj) VTE_26\NNP|whereas|
D013792_D054556 CID thalidomide_3\NN|NONE (r_pobj) of_2\IN|docetaxel|The (r_prep) addition_1\NN|frequency|.|significantly (r_nsubj) increases_13\VBZ|NONE (l_dobj) frequency_15\NN|.|significantly|addition (l_prep) of_16\IN|the (l_pobj) VTE_17\NNP|NONE
C067311_D011471 NONE docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (l_prep) in_12\IN|the|of (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) cancer_20\NN|NONE
C067311_D011471 NONE docetaxel_26\NNS|NONE (r_pobj) with_25\IN|were|alone|who (r_prep) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE
C067311_D011471 NONE docetaxel_5\NNS|of|The (l_prep) in_6\IN|to (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) cancer_11\NN|NONE
8919272
D014635_D009422 NONE valproate_10\NN|NONE (l_dobj) disorders_43\NNS|Polfa|application|to|.|at
D014635_D009422 NONE valproate_49\NNP|(|"|)|" (r_amod) encephalopathy_50\JJ|cerebellum (r_appos) damage_46\NN|NONE (r_dobj) indicating_44\VBG|revealed|neurological (r_acl) disorders_43\NNS|Polfa|application|to|.|at
D014635_D056486 NONE valproate_15\NNP|NONE (r_amod) encephalopathy_16\NNP|NONE (r_pobj) of_14\IN|the (r_prep) development_13\NN|NONE (r_pobj) upon_11\IN|,|mainly|influence (r_prep) hyperammonemia_9\NN|.|is (l_nsubj) influence_2\NN|,|mainly|upon (l_prep) of_3\IN|possible|,|The (l_pobj) damage_6\NN|NONE
D014635_D001927 CID valproate_11\NN|NONE (l_nsubj) features_1\NNS|to|. (l_prep) of_2\IN|Morphological|after (l_pobj) encephalopathy_3\NN|NONE
D014635_D001927 CID valproate_10\NN|NONE (l_dobj) disorders_43\NNS|Polfa|application|to|.|at (l_acl) indicating_44\VBG|revealed|neurological (l_dobj) damage_46\NN|NONE (l_appos) encephalopathy_50\JJ|cerebellum
D014635_D001927 CID valproate_49\NNP|(|"|)|" (r_amod) encephalopathy_50\JJ|cerebellum
D014635_D001927 CID valproate_15\NNP|NONE (r_amod) encephalopathy_16\NNP|NONE
D014635_D002526 NONE valproate_10\NN|NONE (l_dobj) disorders_43\NNS|Polfa|application|to|.|at (l_acl) indicating_44\VBG|revealed|neurological (l_dobj) damage_46\NN|NONE
D014635_D002526 NONE valproate_49\NNP|(|"|)|" (r_amod) encephalopathy_50\JJ|cerebellum (r_appos) damage_46\NN|NONE
D014635_D022124 NONE valproate_15\NNP|NONE (r_amod) encephalopathy_16\NNP|NONE (r_pobj) of_14\IN|the (r_prep) development_13\NN|NONE (r_pobj) upon_11\IN|,|mainly|influence (r_prep) hyperammonemia_9\NN|.|is
18439803
D010862_D012640 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|in (r_amod) seizure_13\NN|NONE
D010862_D012640 CID pilocarpine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) seizure_26\NN|NONE
D010862_D012640 CID pilocarpine_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) seizure_16\NN|NONE
D010862_D012640 CID pilocarpine_12\NN| (r_npadvmod) induced_14\VBN|in (r_amod) increases_15\NNS|drastically|that|could|VPU (r_dobj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|.|Therefore|should|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|.|like|Therefore|should|,|, (l_pobj) activity_30\NN|,|partly (l_acl) observed_31\VBN|its|anticonvulsant (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D010862_D012640 CID pilocarpine_33\NN| (r_npadvmod) induced_35\VBN|in (r_amod) seizure_36\NN|NONE
D000596_D012640 NONE acid_7\NN|hippocampal (r_compound) neurotransmitters_8\NNS|NONE (r_pobj) on_4\IN|.|of|Acute|in (r_prep) effects_1\NNS|NONE (l_prep) in_9\IN|on|.|of|Acute (l_pobj) seizure_13\NN|NONE
D000596_D012640 NONE acid_26\NN|inhibitory (r_compound) neurotransmitters_27\NNS|NONE (r_pobj) of_23\IN|the (r_prep) reduction_22\NN|minor|that|offset|and (r_nsubj) was_28\VBD|Based|it|.|is (r_ccomp) suggested_19\VBN|NONE (l_prep) Based_0\VBN|was|it|.|is (l_prep) on_1\IN|NONE (l_pobj) finding_3\NN|NONE (l_acl) protect_9\VB|the (l_dobj) animals_11\NNS|that|VPU|could (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
C108761_D012640 NONE N-(2-propylpentanoyl)urea_3\NNP|NONE (r_pobj) of_2\IN|on|.|Acute|in (r_prep) effects_1\NNS|NONE (l_prep) in_9\IN|on|.|of|Acute (l_pobj) seizure_13\NN|NONE
C108761_D012640 NONE VPU_0\NNS|exhibiting|potent|.|, (r_nsubj) was_1\VBD|NONE (l_advcl) exhibiting_7\VBG|VPU|potent|.|, (l_dobj) dose_11\NN|was (l_prep) of_16\IN|median|effective|the|ED(|) (l_pobj) mg/kg_18\NNS|NONE (l_prep) in_19\IN| (l_pcomp) protecting_20\VBG|NONE (l_prep) against_22\IN|rats (l_pobj) seizure_26\NN|NONE
C108761_D012640 NONE VPU_5\NNPS|that|animals|could (r_nsubj) protect_9\VB|the (l_dobj) animals_11\NNS|that|VPU|could (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
C108761_D012640 NONE VPU_8\NNP|drastically|that|could|increases (r_nsubj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|.|Therefore|should|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|.|like|Therefore|should|,|, (l_pobj) activity_30\NN|,|partly (l_acl) observed_31\VBN|its|anticonvulsant (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D001224_D012640 NONE aspartate_40\NN|and (r_conj) glutamate_38\NN|NONE (r_pobj) of_37\IN|a|pronounced (r_prep) reduction_36\NN|NONE (r_pobj) by_33\IN|NONE (r_agent) offset_32\VBN|minor|that|and|reduction (r_conj) was_28\VBD|Based|it|.|is (r_ccomp) suggested_19\VBN|NONE (l_prep) Based_0\VBN|was|it|.|is (l_prep) on_1\IN|NONE (l_pobj) finding_3\NN|NONE (l_acl) protect_9\VB|the (l_dobj) animals_11\NNS|that|VPU|could (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
D001224_D012640 NONE aspartate_19\NN|and (r_conj) glutamate_17\NN|NONE (r_pobj) in_16\IN|induced (r_prep) increases_15\NNS|drastically|that|could|VPU (r_dobj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|.|Therefore|should|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|.|like|Therefore|should|,|, (l_pobj) activity_30\NN|,|partly (l_acl) observed_31\VBN|its|anticonvulsant (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D014635_D012640 NONE VPA_5\NNP|NONE (r_pobj) than_4\IN|more (r_prep) potent_3\JJ|exhibiting|VPU|.|, (r_acomp) was_1\VBD|NONE (l_advcl) exhibiting_7\VBG|VPU|potent|.|, (l_dobj) dose_11\NN|was (l_prep) of_16\IN|median|effective|the|ED(|) (l_pobj) mg/kg_18\NNS|NONE (l_prep) in_19\IN| (l_pcomp) protecting_20\VBG|NONE (l_prep) against_22\IN|rats (l_pobj) seizure_26\NN|NONE
D014635_D012640 NONE VPA_32\NNP|NONE (r_pobj) for_31\IN|corresponding|the (r_prep) value_30\NN|whereas|mg/kg (r_nsubj) was_33\VBD|dose (r_advcl) exhibiting_7\VBG|VPU|potent|.|, (l_dobj) dose_11\NN|was (l_prep) of_16\IN|median|effective|the|ED(|) (l_pobj) mg/kg_18\NNS|NONE (l_prep) in_19\IN| (l_pcomp) protecting_20\VBG|NONE (l_prep) against_22\IN|rats (l_pobj) seizure_26\NN|NONE
D014635_D012640 NONE VPA_7\NNP|and (r_conj) VPU_5\NNPS|that|animals|could (r_nsubj) protect_9\VB|the (l_dobj) animals_11\NNS|that|VPU|could (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
D014635_D012640 NONE VPA_3\NNP|NONE (r_pobj) like_2\IN|for|.|Therefore|should|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|.|like|Therefore|should|,|, (l_pobj) activity_30\NN|,|partly (l_acl) observed_31\VBN|its|anticonvulsant (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D018698_D012640 NONE glutamate_38\NN|NONE (r_pobj) of_37\IN|a|pronounced (r_prep) reduction_36\NN|NONE (r_pobj) by_33\IN|NONE (r_agent) offset_32\VBN|minor|that|and|reduction (r_conj) was_28\VBD|Based|it|.|is (r_ccomp) suggested_19\VBN|NONE (l_prep) Based_0\VBN|was|it|.|is (l_prep) on_1\IN|NONE (l_pobj) finding_3\NN|NONE (l_acl) protect_9\VB|the (l_dobj) animals_11\NNS|that|VPU|could (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
D018698_D012640 NONE glutamate_17\NN|NONE (r_pobj) in_16\IN|induced (r_prep) increases_15\NNS|drastically|that|could|VPU (r_dobj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|.|Therefore|should|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|.|like|Therefore|should|,|, (l_pobj) activity_30\NN|,|partly (l_acl) observed_31\VBN|its|anticonvulsant (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
1720453
D007069_D064420 NONE ifosfamide_15\NN|NONE (r_pobj) of_14\IN|g|/| (r_prep) m2_13\NN|NONE (r_pobj) of_9\IN|and|the|age|higher|,|,|cumulative|predominance (r_prep) dose_8\NN|NONE (r_pobj) with_4\IN|was|toxicity|. (r_prep) correlated_3\VBN|NONE (l_nsubjpass) toxicity_1\NN|was|.|with
D007069_C535700 NONE ifosfamide_7\JJ|renal|in (r_amod) toxicity_9\NN|NONE (r_pobj) of_6\IN||term|follow (r_prep) up_5\NN|for|.|Society|: (r_nsubj) treated_12\VBN|NONE (l_prep) for_13\IN|.|Society|up|: (l_pobj) tumors_16\NNS|NONE
D007069_C535700 NONE ifosfamide_19\JJ|same|chemotherapy|(|MMT|the|)|Society (r_compound) protocol_21\NN|have|who (r_dobj) received_16\VBN|and|with|The|of|renal|in (r_relcl) function_2\NN|were|.|after|year (l_prep) with_6\IN|and|received|The|of|renal|in (l_pobj) tumors_9\NNS|NONE
D007069_C535700 NONE ifosfamide_19\JJ|same|chemotherapy|(|MMT|the|)|Society (r_compound) protocol_21\NN|have|who (l_appos) Society_24\NNP|same|chemotherapy|(|MMT|the|)|ifosfamide (l_prep) of_25\IN|International (l_pobj) Study_31\NNP|NONE (l_compound) Tumor_30\NNP|Oncology|Malignant|Mesenchymal
D007069_C535700 NONE ifosfamide_18\NN|NONE (r_pobj) of_17\IN|in|the (r_prep) efficacy_16\NN|NONE (l_prep) in_19\IN|the|of (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|the|in (l_pobj) tumors_24\NNS|NONE
D010710_D011507 NONE phosphate_25\NN|tubular (r_nmod) reabsorption_27\NN|creatinine|, (r_conj) clearance_23\NN|, (r_conj) osmolarity_20\NN|urinary|, (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|,
D010710_D064420 NONE phosphate_51\NN|NONE (r_compound) reabsorption_52\NN||and|beta|elevated (r_conj) microglobulinuria_48\NN|NONE (r_pobj) with_44\IN|five (r_prep) patients_43\NNS|.|group (r_dobj) included_41\VBD|patients|:|;|and|first|identified (r_conj) included_13\VBD|NONE (l_dobj) patients_15\NNS|included|:|;|and|first|identified (l_relcl) developed_25\VBD|%|(|)|four (l_dobj) toxicity_27\NN|who
D007069_D009369 NONE ifosfamide_15\NN|NONE (r_pobj) of_14\IN|g|/| (r_prep) m2_13\NN|NONE (r_pobj) of_9\IN|and|the|age|higher|,|,|cumulative|predominance (r_prep) dose_8\NN|NONE (l_conj) predominance_31\NN|and|the|of|age|higher|,|,|cumulative (l_prep) of_32\IN|a (l_pobj) involvement_35\NN|NONE (l_compound) tumor_34\NN|vesicoprostatic
D003404_D011507 NONE creatinine_22\NN|reabsorption|, (r_compound) clearance_23\NN|, (r_conj) osmolarity_20\NN|urinary|, (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|,
D003404_D000608 NONE creatinine_22\NN|reabsorption|, (r_compound) clearance_23\NN|, (r_conj) osmolarity_20\NN|urinary|, (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|,
D003404_D006030 NONE creatinine_22\NN|reabsorption|, (r_compound) clearance_23\NN|, (r_conj) osmolarity_20\NN|urinary|, (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|, (r_conj) glucosuria_11\NN|electrolytes|and|,
D010710_D006030 NONE phosphate_25\NN|tubular (r_nmod) reabsorption_27\NN|creatinine|, (r_conj) clearance_23\NN|, (r_conj) osmolarity_20\NN|urinary|, (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|, (r_conj) glucosuria_11\NN|electrolytes|and|,
D007069_D007674 CID ifosfamide_7\JJ|renal|in (r_amod) toxicity_9\NN|NONE
D010710_D000608 NONE phosphate_25\NN|tubular (r_nmod) reabsorption_27\NN|creatinine|, (r_conj) clearance_23\NN|, (r_conj) osmolarity_20\NN|urinary|, (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|,
D010710_D005198 NONE phosphate_51\NN|NONE (r_compound) reabsorption_52\NN||and|beta|elevated (r_conj) microglobulinuria_48\NN|NONE (r_pobj) with_44\IN|five (r_prep) patients_43\NNS|.|group (r_dobj) included_41\VBD|patients|:|;|and|first|identified (r_conj) included_13\VBD|NONE (l_dobj) patients_15\NNS|included|:|;|and|first|identified (l_relcl) developed_25\VBD|%|(|)|four (l_dobj) toxicity_27\NN|who (l_acl) resulting_28\VBG|major (l_prep) in_29\IN|NONE (l_pobj) syndrome_32\NN|NONE
D010710_D005198 NONE phosphate_51\NN|NONE (r_compound) reabsorption_52\NN||and|beta|elevated (r_conj) microglobulinuria_48\NN|NONE (r_pobj) with_44\IN|five (r_prep) patients_43\NNS|.|group (r_dobj) included_41\VBD|patients|:|;|and|first|identified (r_conj) included_13\VBD|NONE (l_dobj) patients_15\NNS|included|:|;|and|first|identified (l_relcl) developed_25\VBD|%|(|)|four (l_dobj) toxicity_27\NN|who (l_acl) resulting_28\VBG|major (l_prep) in_29\IN|NONE (l_pobj) syndrome_32\NN|NONE (l_appos) TDFS_34\NNP|Fanconi|)|(
9245658
D009538_D013927 NONE Nicotine_0\NN|.|not|does|enhance (r_nsubj) appear_3\VB|NONE (l_xcomp) enhance_5\VB|.|not|does|Nicotine (l_dobj) thrombosis_6\NN|to
D009538_D050197 CID nicotine_7\NN|,|could|role|that (r_nsubj) play_9\VB|but|studies|is (l_dobj) role_11\NN|,|could|nicotine|that (l_prep) in_12\IN|a (l_pcomp) accelerating_13\VBG|NONE (l_dobj) atherosclerosis_14\NN|NONE
D009538_D002318 CID nicotine_3\NN|NONE (r_pobj) of_2\IN|The|in|. (r_prep) role_1\NN|NONE (l_prep) in_4\IN|of|The|. (l_pobj) disease_9\NN|NONE
D009538_D002318 CID Nicotine_0\NNP|contribute|and|system (r_nsubj) activates_1\VBZ|NONE (l_conj) contribute_11\VB|and|Nicotine|system (l_prep) to_12\IN|in|could|. (l_pobj) disease_14\NN|NONE
9746003
D002220_D009207 CID carbamazepine_9\NN|NONE (l_conj) two_11\CD|and (l_prep) of_12\IN|NONE (l_pobj) jerks_16\NNS|NONE
D002220_D009207 CID carbamazepine_23\NN|NONE (r_pobj) of_22\IN|NONE (r_prep) withdrawal_21\NN|NONE (r_pobj) on_20\IN|which (r_prep) resolved_19\VBD|these|myoclonic|,|developed (r_relcl) jerks_16\NNS|NONE
D020888_D004832 CID vigabatrin_5\VBP|and (l_prep) in_6\IN|NONE (l_pobj) seizures_9\NNS|NONE
D020888_D004832 CID vigabatrin_2\NN|and (r_conj) Carbamazepine_0\NNP|are|in|. (r_nsubjpass) contraindicated_4\VBN|NONE (l_prep) in_5\IN|are|Carbamazepine|. (l_pobj) seizures_8\NNS|NONE
D002220_D004832 CID carbamazepine_3\NN|NONE (l_conj) vigabatrin_5\VBP|and (l_prep) in_6\IN|NONE (l_pobj) seizures_9\NNS|NONE
D002220_D004832 CID Carbamazepine_0\NNP|are|in|. (r_nsubjpass) contraindicated_4\VBN|NONE (l_prep) in_5\IN|are|Carbamazepine|. (l_pobj) seizures_8\NNS|NONE
18081909
C026098_D001927 CID levetiracetam_3\NN|NONE (r_pcomp) by_2\IN|added|Encephalopathy|. (r_prep) induced_1\VBN|NONE (l_nsubj) Encephalopathy_0\JJ|added|by|.
C026098_D001927 CID levetiracetam_7\FW|a|(|LEV)induced (r_amod) encephalopathy_10\JJ|NONE
C026098_D001927 CID LEV)-induced_9\VBN|levetiracetam|a|( (r_amod) encephalopathy_10\JJ|NONE
C026098_C562694 NONE LEV_15\NNP|NONE (r_pobj) with_14\IN|man|)|.|added|was (r_prep) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|)|with|.|added|was (l_acl) suffering_5\VBG|old|A (l_prep) from_6\IN|with (l_pobj) epilepsy_8\NN|NONE
C026098_D012640 NONE LEV_15\NNP|NONE (r_pobj) with_14\IN|man|)|.|added|was (r_prep) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|)|with|.|added|was (l_acl) suffering_5\VBG|old|A (l_prep) with_9\IN|from (l_pobj) seizures_11\NNS|NONE
C026098_D012640 NONE LEV_3\NNP|NONE (r_pobj) of_2\IN|NONE (r_prep) discontinuation_1\NN|improved (r_pobj) Following_0\VBG|NONE (l_preconj) improved_9\VBN|discontinuation (l_conj) decreased_13\VBD|and (l_nsubj) frequency_12\NN|. (l_compound) seizure_11\NN|NONE
D014635_C562694 NONE valproate_22\VB|NONE (r_xcomp) added_20\VBN|man|)|with|.|was (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|)|with|.|added|was (l_acl) suffering_5\VBG|old|A (l_prep) from_6\IN|with (l_pobj) epilepsy_8\NN|NONE
D014635_C562694 NONE VPA_24\NNP|)|mg|(|(|)|to (r_dobj) valproate_22\VB|NONE (r_xcomp) added_20\VBN|man|)|with|.|was (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|)|with|.|added|was (l_acl) suffering_5\VBG|old|A (l_prep) from_6\IN|with (l_pobj) epilepsy_8\NN|NONE
D014635_D001927 CID valproate_6\VB|NONE (r_xcomp) added_4\VBN|by|Encephalopathy|. (r_conj) induced_1\VBN|NONE (l_nsubj) Encephalopathy_0\JJ|added|by|.
D014635_D012640 NONE valproate_22\VB|NONE (r_xcomp) added_20\VBN|man|)|with|.|was (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|)|with|.|added|was (l_acl) suffering_5\VBG|old|A (l_prep) with_9\IN|from (l_pobj) seizures_11\NNS|NONE
D014635_D012640 NONE VPA_24\NNP|)|mg|(|(|)|to (r_dobj) valproate_22\VB|NONE (r_xcomp) added_20\VBN|man|)|with|.|was (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|)|with|.|added|was (l_acl) suffering_5\VBG|old|A (l_prep) with_9\IN|from (l_pobj) seizures_11\NNS|NONE
20520283
C522667_D001480 CID asenapine_21\NN|NONE (r_pobj) of_19\IN||at (r_prep) %_18\NN||,|and (r_conj) %_14\NN|and|%|respectively|,| (r_appos) %_8\NN|NONE (r_pobj) in_6\IN|AEs|as (r_prep) occurred_5\VBD|.|symptoms (r_advcl) reported_2\VBD|NONE (l_nsubj) symptoms_1\NNS|occurred|.
C522667_D001480 CID asenapine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) similar_7\JJ|efficacy|that (r_acomp) was_6\VBD|analyses (r_ccomp) indicated_3\VBD|.|in|were|;|contrasts (r_ccomp) seen_16\VBN|NONE (l_prep) in_17\IN|.|were|;|contrasts|indicated (l_pobj) AEs_18\NNS|NONE (l_appos) symptoms_22\NNS|,
C522667_D001714 NONE Asenapine_0\NNP|in|is|by|. (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|is|by|.|Asenapine (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_conj) of_17\IN|treatment|or (l_pobj) episodes_21\NNS|NONE (l_amod) manic_18\JJ|associated
C522667_D001714 NONE Asenapine_0\NNP|in|is|by|. (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|is|by|.|Asenapine (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_conj) of_17\IN|treatment|or (l_pobj) episodes_21\NNS|NONE (l_acl) associated_22\VBN|manic (l_prep) with_23\IN|NONE (l_pobj) disorder_26\NN|NONE
C522667_D011618 NONE Asenapine_0\NNP|in|is|by|. (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|is|by|.|Asenapine (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_conj) of_17\IN|treatment|or (l_pobj) episodes_21\NNS|NONE (l_acl) associated_22\VBN|manic (l_prep) with_23\IN|NONE (l_pobj) disorder_26\NN|NONE (l_prep) with_27\IN|bipolar|I (l_conj) without_29\IN|or (l_pobj) features_31\NNS|NONE (l_amod) psychotic_30\JJ|NONE
D006220_D001480 CID haloperidol_29\NN|,|mg (r_conj) BID_27\NN|NONE (r_pobj) at_22\IN|of| (r_prep) %_18\NN||,|and (r_conj) %_14\NN|and|%|respectively|,| (r_appos) %_8\NN|NONE (r_pobj) in_6\IN|AEs|as (r_prep) occurred_5\VBD|.|symptoms (r_advcl) reported_2\VBD|NONE (l_nsubj) symptoms_1\NNS|occurred|.
D006220_D001480 CID haloperidol_11\NN|and (r_conj) asenapine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) similar_7\JJ|efficacy|that (r_acomp) was_6\VBD|analyses (r_ccomp) indicated_3\VBD|.|in|were|;|contrasts (r_ccomp) seen_16\VBN|NONE (l_prep) in_17\IN|.|were|;|contrasts|indicated (l_pobj) AEs_18\NNS|NONE (l_appos) symptoms_22\NNS|,
C522667_D012559 NONE asenapine_4\NN|NONE (r_pobj) of_3\IN|.|safety|in|and (r_prep) Efficacy_0\NN|NONE (l_prep) in_5\IN|.|safety|and|of (l_pobj) trial_12\NN|NONE (l_prep) in_13\IN|controlled|placebo (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) exacerbation_17\NN|NONE (l_prep) of_18\IN|acute (l_pobj) schizophrenia_19\NN|NONE
C522667_D012559 NONE Asenapine_0\NNP|in|is|by|. (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|is|by|.|Asenapine (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_pobj) treatment_13\NN|of|or (l_prep) of_14\IN|acute (l_pobj) schizophrenia_15\NN|NONE
C522667_D012559 NONE asenapine_22\NN|NONE (r_pobj) with_21\IN|dose (r_prep) treatment_20\NN|NONE (r_pobj) to_16\IN|In|were|randomly|at|,|,|patients|asenapine|)|. (r_prep) assigned_15\VBN|NONE (l_nsubjpass) patients_9\NNS|In|were|randomly|at|to|,|,|asenapine|)|. (l_prep) with_10\IN| (l_pobj) schizophrenia_12\NN|NONE
C522667_D012559 NONE asenapine_32\NN|In|were|randomly|at|to|,|,|patients|)|. (r_dep) assigned_15\VBN|NONE (l_nsubjpass) patients_9\NNS|In|were|randomly|at|to|,|,|asenapine|)|. (l_prep) with_10\IN| (l_pobj) schizophrenia_12\NN|NONE
D006220_D012559 NONE haloperidol_9\NN| (r_npadvmod) controlled_11\VBN|in|placebo (r_amod) trial_12\NN|NONE (l_prep) in_13\IN|controlled|placebo (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) exacerbation_17\NN|NONE (l_prep) of_18\IN|acute (l_pobj) schizophrenia_19\NN|NONE
D006220_D012559 NONE haloperidol_41\NN|or|, (r_conj) placebo_38\NN|mg|, (r_conj) BID_36\NN|NONE (r_pobj) at_33\IN|verify (r_prep) asenapine_32\NN|In|were|randomly|at|to|,|,|patients|)|. (r_dep) assigned_15\VBN|NONE (l_nsubjpass) patients_9\NNS|In|were|randomly|at|to|,|,|asenapine|)|. (l_prep) with_10\IN| (l_pobj) schizophrenia_12\NN|NONE
7504976
D002231_D002779 CID carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|.|patients (l_nsubj) hepatitis_5\NN|by
D002231_D002779 CID omercazole_11\NN|(|) (r_appos) carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|.|patients (l_nsubj) hepatitis_5\NN|by
D002231_D002779 CID carbimazole_12\NN|.|others (l_amod) mixed_4\JJ|a|following|) (l_conj) cholestatic_6\JJ|(
D002231_D056486 CID carbimazole_16\NN|NONE (r_pobj) between_15\IN||cross (r_prep) reactivity_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) one_10\CD|NONE (r_pobj) including_9\VBG|four (r_prep) cases_8\NNS|.|by|:|hepatitis (r_appos) induced_2\VBN|NONE (l_nsubj) hepatitis_1\NN|.|cases|by|:
D002231_D056486 CID carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|.|patients (l_nsubj) hepatitis_5\NN|by
D002231_D056486 CID omercazole_11\NN|(|) (r_appos) carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|.|patients (l_nsubj) hepatitis_5\NN|by
D002231_D056486 CID carbimazole_12\NN|.|others (l_amod) following_11\VBG|a|mixed|) (l_compound) hepatitis_10\NN|NONE
D002231_D056486 CID carbimazole_21\NN|had|.|experienced (r_dobj) replaced_20\VBN|NONE (l_nsubj) experienced_7\VBD|had|.|carbimazole (l_dobj) hepatitis_10\NN|further|One|)
C019269_D056486 NONE benzylthiouracil_18\NN|and (r_conj) carbimazole_16\NN|NONE (r_pobj) between_15\IN||cross (r_prep) reactivity_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) one_10\CD|NONE (r_pobj) including_9\VBG|four (r_prep) cases_8\NNS|.|by|:|hepatitis (r_appos) induced_2\VBN|NONE (l_nsubj) hepatitis_1\NN|.|cases|by|:
C019269_D056486 NONE Benzylthiouracil_14\NNP|NONE (r_pobj) after_13\IN|which (r_prep) appeared_12\VBD|cytolytic|a (r_relcl) hepatitis_10\NN|further|One|)
C019269_D056486 NONE ne_17\NNP|NONE (r_appos) Benzylthiouracil_14\NNP|NONE (r_pobj) after_13\IN|which (r_prep) appeared_12\VBD|cytolytic|a (r_relcl) hepatitis_10\NN|further|One|)
11007689
D016559_D057049 CID tacrolimus_2\NN| (r_npadvmod) associated_4\VBN|thrombotic (r_amod) microangiopathy_6\NN|and|.
D016559_D057049 CID tacrolimus_6\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) switching_4\VBG|be|,|been|.|As|has (r_nsubjpass) reported_9\VBN|NONE (l_xcomp) be_11\VB|,|been|.|switching|As|has (l_attr) option_15\NN|to (l_prep) in_16\IN|a|viable|therapeutic (l_pobj) setting_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) TMA_23\NNP|NONE
D016559_D057049 CID tacrolimus_6\NN|NONE (r_pobj) of_5\IN|widespread|the (r_prep) application_4\NN|NONE (r_pobj) With_0\IN|been|has|,|.|TMA|also (r_prep) recognized_18\VBN|NONE (l_nsubjpass) TMA_14\NNP|been|has|,|.|also|With
D016559_D057049 CID tacrolimus_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) TMA_14\NNP|been|has|,|.|also|With
D016559_D057049 CID tacrolimus_18\NN|and (r_conj) cyclosporine_16\NN|NONE (r_pobj) to_15\IN|sequentially (r_prep) exposed_13\VBN|NONE (r_acl) patients_12\NNS|NONE (r_pobj) in_11\IN|of|the (r_prep) recurrence_8\NN|NONE (l_prep) of_9\IN|the|in (l_pobj) TMA_10\NNP|NONE
D016559_D057049 CID tacrolimus_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Introduction_0\NN|in|. (r_nsubj) resulted_8\VBD|NONE (l_prep) in_9\IN|.|Introduction (l_pobj) recurrence_11\NN|NONE (l_prep) of_12\IN|the|loss|and (l_pobj) TMA_13\NNP|NONE
D016559_D057049 CID tacrolimus_7\NN|NONE (r_pobj) to_6\IN|are|who|from (r_prep) switched_3\VBN|NONE (r_relcl) Patients_0\NNS|be|for|should|.|closely (r_nsubjpass) monitored_14\VBN|NONE (l_prep) for_15\IN|Patients|be|should|.|closely (l_pobj) signs_17\NNS|NONE (l_prep) of_20\IN|and|the|symptoms (l_pobj) TMA_22\NNP|NONE
D016572_D057049 CID Cyclosporine_0\NN|NONE (l_conj) microangiopathy_6\NN|and|.
D016572_D057049 CID cyclosporine_13\NN|NONE (r_pobj) of_12\IN|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|TMA|thrombotic (r_acl) microangiopathy_4\NN|NONE
D016572_D057049 CID cyclosporine_13\NN|NONE (r_pobj) of_12\IN|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|TMA|thrombotic (r_acl) microangiopathy_4\NN|NONE (l_appos) TMA_6\NNP|associated|thrombotic
D016572_D057049 CID cyclosporine_20\NN| (r_npadvmod) induced_22\VBN|NONE (r_amod) TMA_23\NNP|NONE
D016572_D057049 CID cyclosporine_16\NN|NONE (r_pobj) to_15\IN|sequentially (r_prep) exposed_13\VBN|NONE (r_acl) patients_12\NNS|NONE (r_pobj) in_11\IN|of|the (r_prep) recurrence_8\NN|NONE (l_prep) of_9\IN|the|in (l_pobj) TMA_10\NNP|NONE
D016572_D057049 CID cyclosporine_13\NN| (r_npadvmod) induced_15\VBN|responded (r_amod) TMA_16\NNP|who
D016572_D057049 CID cyclosporine_23\NN|NONE (r_pobj) of_22\IN|the|in (r_prep) withdrawal_21\NN|NONE (r_pobj) to_19\IN|that (r_prep) responded_18\VBD|induced (r_relcl) TMA_16\NNP|who
D016572_D057049 CID cyclosporine_5\NN|NONE (r_pobj) from_4\IN|are|to|who (r_prep) switched_3\VBN|NONE (r_relcl) Patients_0\NNS|be|for|should|.|closely (r_nsubjpass) monitored_14\VBN|NONE (l_prep) for_15\IN|Patients|be|should|.|closely (l_pobj) signs_17\NNS|NONE (l_prep) of_20\IN|and|the|symptoms (l_pobj) TMA_22\NNP|NONE
8682684
D000082_D007022 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|. (r_amod) hypotension_3\NN|NONE
D000082_D007022 CID acetaminophen_2\RB|been|has|However|,|.|produce (r_nsubjpass) demonstrated_5\VBN|NONE (l_xcomp) produce_7\VB|been|has|However|acetaminophen|,|. (l_dobj) symptoms_8\NNS|to (l_prep) including_12\VBG|in|,|,|of (l_pobj) hypotension_13\NN|NONE
D000082_D007022 CID acetaminophen_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) administration_16\NN|NONE (r_pobj) after_15\IN|episodes|reproducibly|in (r_prep) developed_14\VBN|ill|two (l_nsubj) episodes_10\NNS|after|reproducibly|in (l_prep) of_11\IN|transient (l_pobj) hypotension_12\NN|NONE
D000082_D007022 CID acetaminophen_9\NN|clinicians|to|in|for (r_dobj) consider_8\VB|the (l_prep) in_10\IN|acetaminophen|clinicians|to|for (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) hypotension_13\NN|NONE
D000082_D002318 NONE acetaminophen_3\NN|NONE (r_pobj) for_2\IN|produce|The (r_prep) potential_1\NN|low|. (l_acl) produce_5\VB|for|The (l_dobj) toxicities_7\NNS|to
D000082_D000707 NONE acetaminophen_2\RB|been|has|However|,|.|produce (r_nsubjpass) demonstrated_5\VBN|NONE (l_xcomp) produce_7\VB|been|has|However|acetaminophen|,|. (l_dobj) symptoms_8\NNS|to (l_prep) of_9\IN|in|including|,|, (l_pobj) anaphylaxis_10\NN|NONE
D000082_D016638 NONE acetaminophen_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) administration_16\NN|NONE (r_pobj) after_15\IN|episodes|reproducibly|in (r_prep) developed_14\VBN|ill|two (r_relcl) patients_6\NNS|article|. (l_amod) ill_5\JJ|developed|two
15737522
D002443_D001660 CID Ceftriaxone_0\NN| (r_npadvmod) associated_2\VBN|.|biliary|in (r_amod) pseudolithiasis_4\NN|NONE
D002443_D001660 CID ceftriaxone_5\NN|that|pseudolithiasis (r_nsubj) leads_6\VBZ|.|It|is|well (l_xcomp) pseudolithiasis_8\NN|ceftriaxone|that
D002443_D001660 CID ceftriaxone_19\CD|,|had (r_compound) treatment_20\NN|NONE (r_dobj) receiving_18\VBG|surgical|paediatric (r_acl) patients_17\NNS|NONE (r_pobj) in_14\IN|NONE (r_prep) pseudolithiasis_13\NN|NONE
19767176
D010100_D009410 NONE oxygen_5\NN|reactive (r_compound) species_6\NNS|NONE (r_pobj) of_3\IN|as|activation (r_prep) production_2\NN|.|,|Both|in|been|have (r_nsubjpass) implicated_17\VBN|NONE (l_prep) in_18\IN|.|,|Both|been|have|production (l_pobj) damage_21\NN|NONE
D010100_D009410 NONE oxygen_9\NN|of|reactive|and|activation (r_compound) species_10\NNS|NONE (r_pobj) of_7\IN|the (r_prep) generation_6\NN|role|that|compared (r_nsubj) plays_17\VBZ|.|data|might (l_dobj) role_21\NN|that|compared|generation (l_prep) in_22\IN|central|a (l_pobj) damage_27\NN|NONE
C020972_D013226 NONE dithiocarbamate_1\NN|cortex|. (r_nsubj) protects_2\VBZ|NONE (l_dobj) cortex_5\NN|.|dithiocarbamate (l_prep) in_6\IN|piriform|the (l_pobj) model_11\NN|NONE (l_amod) epilepticus_10\NN|the|pilocarpine|status
C020972_D013226 NONE PDTC_3\NNP|NONE (r_pobj) of_2\IN|on|The (r_prep) effect_1\NN|.|was|in (l_prep) on_4\IN|The|of (l_pobj) loss_10\NN|NONE (l_amod) associated_8\VBN|status|in|cell (l_npadvmod) epilepticus_6\NN|
C020972_D013226 NONE PDTC_4\NNP|NONE (r_pobj) with_1\IN|before (r_prep) Treatment_0\NN|rate|epilepticus|significantly|.|to (r_nsubj) increased_11\VBD|NONE (l_advmod) epilepticus_9\NN|rate|significantly|Treatment|.|to
C020972_D013226 NONE PDTC_4\NNP|low|mg/kg||( (r_nmod) dose_8\NN|NONE (r_pobj) of_1\IN|) (r_prep) Administration_0\NN|.|did|effects|not (r_nsubj) exert_12\VB|NONE (l_dobj) effects_14\NNS|Administration|.|did|not (l_prep) on_15\IN|major (l_pobj) development_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) epilepticus_21\NN|NONE
C020972_D013226 NONE PDTC_16\NNP| (r_npadvmod) treated_18\VBN|NONE (r_amod) rats_19\NNS|and (r_conj) vehicle-_14\NN|NONE (r_pobj) in_13\IN|decrease|.|was|following (r_prep) identified_12\VBN|NONE (l_prep) following_20\VBG|decrease|.|was|in (l_pobj) epilepticus_22\NN|NONE
D010862_D013226 CID pilocarpine_8\NN|epilepticus|the|status (r_amod) model_11\NN|NONE (l_amod) epilepticus_10\NN|the|pilocarpine|status
D010862_D013226 CID pilocarpine_23\NN|the|rat|fractionated (r_compound) model_24\NN|NONE (r_pobj) in_19\IN|.|was|effect (r_prep) evaluated_18\VBN|NONE (l_nsubjpass) effect_1\NN|.|was|in (l_prep) on_4\IN|The|of (l_pobj) loss_10\NN|NONE (l_amod) associated_8\VBN|status|in|cell (l_npadvmod) epilepticus_6\NN|
D010100_D012640 NONE oxygen_9\NN|of|reactive|and|activation (r_compound) species_10\NNS|NONE (r_pobj) of_7\IN|the (r_prep) generation_6\NN|role|that|compared (r_nsubj) plays_17\VBZ|.|data|might (l_dobj) role_21\NN|that|compared|generation (l_prep) in_22\IN|central|a (l_pobj) damage_27\NN|NONE (l_amod) associated_25\VBN|in|neuronal (l_npadvmod) seizure_23\NN|
C020972_D009410 NONE PDTC_10\NNP|the|and|kappaB (r_conj) inhibitor_7\NN|In|,|,|cortex|.|affect (r_nsubj) protected_11\VBD|NONE (l_advcl) affect_20\VB|In|,|,|cortex|.|inhibitor (l_dobj) loss_23\NN|did|it|whereas|not
10193204
D001241_D013927 NONE acid_36\NN|,|showed|control|while|,|mg/kg (r_dobj) acetylsalicylic_35\JJ|In|administration|inhibition|.|,|, (r_advcl) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|In|administration|.|,|acetylsalicylic|, (l_prep) of_23\IN|by|,|the|respectively (l_pobj) thrombosis_24\NN|NONE
D001241_D013927 NONE ASA_38\NNP|NONE (r_appos) acid_36\NN|,|showed|control|while|,|mg/kg (r_dobj) acetylsalicylic_35\JJ|In|administration|inhibition|.|,|, (r_advcl) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|In|administration|.|,|acetylsalicylic|, (l_prep) of_23\IN|by|,|the|respectively (l_pobj) thrombosis_24\NN|NONE
D004837_D001791 NONE epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro
D004837_D001791 NONE EP_23\NN|NONE (r_appos) epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro
C009438_D001791 NONE tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE (l_prep) in_8\IN|experimental (l_pobj) mice_9\NNS|NONE (l_conj) aggregation_13\NN|and
C009438_D001791 NONE TET_10\NNP|NONE (r_pobj) of_9\IN|on|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro
C009438_D001791 NONE TET_14\NNP|In|.|dependently|dose|, (r_nsubj) showed_17\VBD|NONE (l_prep) In_0\IN|TET|.|dependently|dose|, (l_pobj) aggregations_5\NNS|NONE
C060802_D001778 NONE FAN_12\NNP|and (r_conj) TET_10\NNP|NONE (r_pobj) of_9\IN|on|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro (l_conj) coagulation_33\NN|platelet|and
C009438_D001778 NONE TET_10\NNP|NONE (r_pobj) of_9\IN|on|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro (l_conj) coagulation_33\NN|platelet|and
D004837_D001778 NONE epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro (l_conj) coagulation_33\NN|platelet|and
D004837_D001778 NONE EP_23\NN|NONE (r_appos) epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro (l_conj) coagulation_33\NN|platelet|and
C060802_D001791 NONE fangchinoline_4\NN|and (r_conj) tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE (l_prep) in_8\IN|experimental (l_pobj) mice_9\NNS|NONE (l_conj) aggregation_13\NN|and
C060802_D001791 NONE FAN_12\NNP|and (r_conj) TET_10\NNP|NONE (r_pobj) of_9\IN|on|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|was|,|study|and|in (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|was|investigate|,|study|and (l_nsubj) aggregation_30\NN|.|vitro
C060802_D001791 NONE FAN_16\NNP|and (r_conj) TET_14\NNP|In|.|dependently|dose|, (r_nsubj) showed_17\VBD|NONE (l_prep) In_0\IN|TET|.|dependently|dose|, (l_pobj) aggregations_5\NNS|NONE
C060802_D013927 NONE fangchinoline_4\NN|and (r_conj) tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE
C060802_D013927 NONE FAN_12\NNP|and (r_conj) TET_10\NNP|NONE (r_pobj) of_9\IN|on|the (r_prep) effects_8\NNS|to (l_prep) on_13\IN|of|the (l_pobj) thrombosis_16\NN|NONE
C060802_D013927 NONE FAN_17\NNP|and (r_conj) TET_15\NNP|NONE (r_pobj) of_14\IN|)|(|the|i.p.|mg/kg (r_prep) administration_7\NN|In|inhibition|.|,|acetylsalicylic|, (r_nsubj) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|In|administration|.|,|acetylsalicylic|, (l_prep) of_23\IN|by|,|the|respectively (l_pobj) thrombosis_24\NN|NONE
C009438_D013927 NONE tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE
C009438_D013927 NONE TET_10\NNP|NONE (r_pobj) of_9\IN|on|the (r_prep) effects_8\NNS|to (l_prep) on_13\IN|of|the (l_pobj) thrombosis_16\NN|NONE
C009438_D013927 NONE TET_15\NNP|NONE (r_pobj) of_14\IN|)|(|the|i.p.|mg/kg (r_prep) administration_7\NN|In|inhibition|.|,|acetylsalicylic|, (r_nsubj) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|In|administration|.|,|acetylsalicylic|, (l_prep) of_23\IN|by|,|the|respectively (l_pobj) thrombosis_24\NN|NONE
D004837_D013927 CID epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE
D004837_D013927 CID EP_23\NN|NONE (r_appos) epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE
7083920
D000638_D013617 NONE amiodarone_13\NN|for (r_compound) treatment_14\NN|NONE (l_prep) for_15\IN|amiodarone (l_pobj) tachycardia_17\NNS|NONE
D000638_D006345 NONE amiodarone_13\NN|for (r_compound) treatment_14\NN|NONE (r_pobj) under_12\IN|without|in (r_prep) occurring_11\VBG|reversible|Hisian|a (l_prep) without_21\IN|under|in (l_pobj) abnormalities_25\NNS|NONE
D000638_D006327 CID amiodarone_13\NN|for (r_compound) treatment_14\NN|NONE (r_pobj) under_12\IN|without|in (r_prep) occurring_11\VBG|reversible|Hisian|a (r_acl) block_10\NN|NONE
D000638_D001282 NONE amiodarone_3\NN|NONE (r_compound) discontinuation_4\NN|days (r_pobj) after_2\IN|,|flutter|.|electrograms (r_prep) showed_9\VBD|NONE (l_dobj) flutter_11\NN|,|.|electrograms|after
8558192
D002945_D064420 NONE cisplatin_9\NN| (r_npadvmod) based_11\VBN|NONE (r_amod) chemotherapy_12\NN|NONE (r_pobj) with_8\IN|patients (r_prep) pretreated_7\VBN|.|assessable (r_csubj) were_13\VBD|NONE (l_acomp) assessable_14\JJ|.|pretreated (l_prep) for_15\IN|NONE (l_pobj) toxicity_16\NN|NONE
C030852_D064420 NONE VNB_0\NNP|well|occurred|and|was (r_nsubjpass) tolerated_3\VBN|NONE (l_conj) occurred_13\VBD|well|VNB|and|was (l_nsubj) toxicity_12\NN|instances|.
C030852_D064420 NONE VNB_12\NNP|NONE (r_pobj) of_11\IN|in|further (r_prep) evaluation_10\NN|.|Given|,|is (r_nsubjpass) warranted_17\VBN|NONE (l_prep) Given_0\VBN|.|evaluation|,|is (l_pobj) profile_4\NN|NONE (l_conj) toxicity_7\NN|tolerance|and|its
C030852_C562729 NONE vinorelbine_4\NN|NONE (r_pobj) of_3\IN|in|.|II (r_prep) trial_2\NN|NONE (l_prep) in_5\IN|of|.|II (l_pobj) carcinoma_10\NN|NONE
C030852_C562729 NONE vinorelbine_9\NN|NONE (r_pobj) of_8\IN|toxic (r_prep) effects_7\NNS|response|administered|the|and (r_conj) rate_4\NN|To|. (l_acl) administered_13\VBN|response|the|effects|and (l_prep) as_14\IN|NONE (l_pobj) agent_17\NN|NONE (l_prep) in_18\IN|single|a (l_pobj) carcinoma_23\NN|NONE
C030852_C562729 NONE VNB_11\NNP|(|) (r_appos) vinorelbine_9\NN|NONE (r_pobj) of_8\IN|toxic (r_prep) effects_7\NNS|response|administered|the|and (r_conj) rate_4\NN|To|. (l_acl) administered_13\VBN|response|the|effects|and (l_prep) as_14\IN|NONE (l_pobj) agent_17\NN|NONE (l_prep) in_18\IN|single|a (l_pobj) carcinoma_23\NN|NONE
C030852_C562729 NONE VNB_4\NNP|agent|that (r_nsubj) is_5\VBZ|.|data (l_attr) agent_8\NN|VNB|that (l_prep) in_9\IN|an|active (l_pobj) carcinoma_14\NN|NONE
19299179
D015662_D008100 NONE trimoxazole_35\NN|for (r_amod) treatment_36\NN|,|Here|cases|.|we (r_dobj) report_3\VBP|NONE (l_dobj) cases_5\NNS|,|Here|.|treatment|we (l_conj) in_20\IN|two|of|and (l_pobj) lesions_23\NNS|, (l_acl) mimicking_24\VBG|patient|one (l_dobj) formation_27\NN|NONE (l_compound) abscess_26\NN|on|liver
D015662_D009894 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|with|generally (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|with|.|generally (l_appos) infection_9\NN|)|,|Pneumocystis|(|PCP|,
D015662_D015658 NONE trimoxazole_11\NN|report||for|dose (r_amod) treatment_12\NN|NONE (l_prep) for_13\IN|report||trimoxazole|dose (l_pobj) pneumonia_15\NN|NONE (l_prep) in_16\IN|Pneumocystis (l_pobj) patients_20\NNS|NONE (l_amod) infected_19\VBN|NONE
D015662_D015658 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|with|generally (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|with|.|generally (l_appos) infection_9\NN|)|,|Pneumocystis|(|PCP|, (l_prep) in_10\IN|opportunistic|a|common (l_pobj) individuals_14\NNS|NONE (l_amod) infected_13\VBN|NONE
D015662_D015658 NONE trimoxazole_35\NN|for (r_amod) treatment_36\NN|,|Here|cases|.|we (r_dobj) report_3\VBP|NONE (l_dobj) cases_5\NNS|,|Here|.|treatment|we (l_prep) of_6\IN|two|and|in (l_pobj) patients_12\NNS|NONE (l_amod) infected_11\VBN|developed|immunocompromised
D015662_D011020 NONE trimoxazole_11\NN|report||for|dose (r_amod) treatment_12\NN|NONE (l_prep) for_13\IN|report||trimoxazole|dose (l_pobj) pneumonia_15\NN|NONE
D015662_D011020 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|with|generally (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|with|.|generally
D015662_D011020 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|with|generally (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|with|.|generally (l_appos) PCP_3\NNP|)|,|Pneumocystis|(|infection|,
D015662_D011020 NONE trimoxazole_35\NN|for (r_amod) treatment_36\NN|,|Here|cases|.|we (l_prep) for_37\IN|trimoxazole (l_pobj) PCP_38\NNP|NONE
D015662_D002779 NONE trimoxazole_11\NN|report||for|dose (r_amod) treatment_12\NN|NONE (r_pobj) after_5\IN|.|Severe (r_prep) cholestasis_4\NN|NONE
D015662_D002780 CID trimoxazole_35\NN|for (r_amod) treatment_36\NN|,|Here|cases|.|we (r_dobj) report_3\VBP|NONE (l_dobj) cases_5\NNS|,|Here|.|treatment|we (l_prep) of_6\IN|two|and|in (l_pobj) patients_12\NNS|NONE (l_relcl) developed_14\VBD|infected|immunocompromised (l_dobj) cholestasis_17\NN|who|,
19889778
12639165
D013988_D007565 CID ticlopidine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) following_4\VBG|showed|and|jaundice|.|patients (r_prep) developed_2\VBD|NONE (l_dobj) jaundice_3\NN|following|showed|and|.|patients
D013988_D056486 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|cholestatic|. (r_amod) hepatitis_4\NN|NONE
D013988_D056486 CID ticlopidine_5\NN| (r_npadvmod) induced_7\VBN|cholestatic (r_amod) hepatitis_9\NN|NONE
D013988_D056486 CID ticlopidine_8\NN|following (r_advmod) receiving_7\VBG|NONE (r_pcomp) after_6\IN|hepatitis|patients|with|.|, (r_prep) developed_2\VBD|NONE (l_dobj) hepatitis_5\NN|patients|after|with|.|,
D013988_D056486 CID ticlopidine_10\NN|rare|of|a (r_advmod) complication_5\NN|hepatitis (r_attr) is_2\VBZ|.|but|few|;|cases|been|have (l_nsubj) hepatitis_1\NN|complication
D013988_D056486 CID ticlopidine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) following_4\VBG|showed|and|jaundice|.|patients (r_prep) developed_2\VBD|NONE (l_conj) showed_9\VBD|following|and|jaundice|.|patients (l_dobj) characteristics_14\NNS|NONE (l_prep) of_15\IN|clinical|the|resolved|, (l_pobj) hepatitis_17\NN|NONE
D013988_D056486 CID ticlopidine_8\NN|NONE (r_pobj) of_7\IN|rare|a|adverse|be (r_prep) effect_6\NN|.|hepatitis (r_attr) is_2\VBZ|NONE (l_nsubj) hepatitis_1\NN|.|effect
D013988_D002779 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|cholestatic|. (r_amod) hepatitis_4\NN|NONE
D013988_D002779 CID ticlopidine_5\NN| (r_npadvmod) induced_7\VBN|cholestatic (r_amod) hepatitis_9\NN|NONE
D013988_D002779 CID ticlopidine_8\NN|following (r_advmod) receiving_7\VBG|NONE (r_pcomp) after_6\IN|hepatitis|patients|with|.|, (r_prep) developed_2\VBD|NONE (l_dobj) hepatitis_5\NN|patients|after|with|.|,
D013988_D002779 CID ticlopidine_10\NN|rare|of|a (r_advmod) complication_5\NN|hepatitis (r_attr) is_2\VBZ|.|but|few|;|cases|been|have (l_nsubj) hepatitis_1\NN|complication
D013988_D002779 CID ticlopidine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) following_4\VBG|showed|and|jaundice|.|patients (r_prep) developed_2\VBD|NONE (l_conj) showed_9\VBD|following|and|jaundice|.|patients (l_dobj) characteristics_14\NNS|NONE (l_prep) of_15\IN|clinical|the|resolved|, (l_pobj) hepatitis_17\NN|NONE
D013988_D002779 CID ticlopidine_4\NN| (r_npadvmod) induced_6\VBN|this (r_amod) cholestasis_7\NN|NONE
D013988_D002779 CID ticlopidine_8\NN|NONE (r_pobj) of_7\IN|rare|a|adverse|be (r_prep) effect_6\NN|.|hepatitis (r_attr) is_2\VBZ|NONE (l_nsubj) hepatitis_1\NN|.|effect
12063090
D004177_D059350 NONE metamizol_9\NN|in|and (r_conj) morphine_7\NN|NONE (r_pobj) between_6\IN|significant|a (r_prep) interaction_5\NN|findings|,|.|suggesting (r_dobj) show_2\VBP|NONE (l_advcl) suggesting_15\VBG|findings|,|.|interaction (l_ccomp) be_20\VB|NONE (l_acomp) useful_21\JJ|combination|could|that (l_prep) for_22\IN|NONE (l_pobj) treatment_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) pain_27\NN|NONE
D009020_D059350 NONE morphine_7\NN|NONE (r_pobj) between_6\IN|significant|a (r_prep) interaction_5\NN|findings|,|.|suggesting (r_dobj) show_2\VBP|NONE (l_advcl) suggesting_15\VBG|findings|,|.|interaction (l_ccomp) be_20\VB|NONE (l_acomp) useful_21\JJ|combination|could|that (l_prep) for_22\IN|NONE (l_pobj) treatment_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) pain_27\NN|NONE
D004177_D003248 NONE Metamizol_0\NNP|antinociception|. (r_nsubj) potentiates_1\VBZ|NONE (l_dobj) antinociception_3\NN|Metamizol|. (l_conj) constipation_6\NN|but|morphine
D004177_D003248 NONE metamizol_20\NN|NONE (r_pobj) with_16\IN|antinociceptive|in|of|the (r_prep) effects_7\NNS|day|work|)|.|(|rats (l_amod) antinociceptive_4\NN|in|of|the|with (l_conj) constipating_6\JJ|and
D004177_D003248 NONE metamizol_20\NN|not|constipation|did (r_nsubj) potentiate_23\VB|NONE (l_dobj) constipation_27\NN|not|metamizol|did
D002606_D010146 NONE charcoal_25\NN|NONE (r_compound) meal_26\NN|the (r_compound) test_27\NN|.|was|evaluate (r_nsubjpass) used_29\VBN|effects|model|using|On|,|were|, (r_conj) assessed_8\VBN|NONE (l_conj) model_21\NN|used|effects|using|On|,|were|, (l_amod) induced_18\VBN|impairment|and|, (l_npadvmod) pain_16\NN|
D009020_D003248 CID morphine_2\NN|but|constipation (r_compound) antinociception_3\NN|Metamizol|. (l_conj) constipation_6\NN|but|morphine
D009020_D003248 CID morphine_15\NN|NONE (r_pobj) of_11\IN|the (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|antinociceptive|in|the|with (r_prep) effects_7\NNS|day|work|)|.|(|rats (l_amod) antinociceptive_4\NN|in|of|the|with (l_conj) constipating_6\JJ|and
D009020_D003248 CID morphine_4\NN|after|,|In|.|suggesting|,|respectively|,|transit (r_nsubj) inhibited_5\VBD|NONE (l_advcl) suggesting_23\VBG|after|,|In|.|,|respectively|morphine|,|transit (l_ccomp) develop_28\VB|NONE (l_prep) to_29\IN|not|did|tolerance|that (l_pobj) effects_32\NNS|NONE (l_amod) constipating_31\JJ|the
D009020_D003248 CID morphine_10\NN|NONE (r_pobj) by_9\IN|regardless (r_agent) produced_8\VBN|NONE (r_acl) that_7\DT|NONE (r_pobj) to_6\IN|NONE (r_prep) similar_5\JJ|intestinal (r_amod) transit_4\NN|combination|.|,|suggesting (r_dobj) inhibited_2\VBD|NONE (l_advcl) suggesting_18\VBG|combination|.|,|transit (l_ccomp) potentiate_23\VB|NONE (l_dobj) constipation_27\NN|not|metamizol|did
D009020_D003248 CID morphine_24\NN| (r_npadvmod) induced_26\VBN|NONE (r_amod) constipation_27\NN|not|metamizol|did
9672936
D008614_D010149 NONE Pethidine_0\NNP| (r_npadvmod) associated_2\VBN|.|in (r_amod) seizure_3\NN|NONE (l_prep) in_4\IN|.|associated (l_pobj) adolescent_7\JJ|NONE (l_acl) receiving_8\VBG|a|healthy (l_prep) for_10\IN|pethidine (l_pobj) control_13\NN|NONE (l_compound) pain_12\NN|postoperative
D008614_D010149 NONE pethidine_9\NN|for (r_dobj) receiving_8\VBG|a|healthy (l_prep) for_10\IN|pethidine (l_pobj) control_13\NN|NONE (l_compound) pain_12\NN|postoperative
D008614_D010149 NONE pethidine_11\NN|NONE (r_pobj) of_10\IN|intermittent|old|healthy|standard|received|A|via (r_prep) doses_9\NNS|.|for (r_nsubj) pump_21\NN|NONE (l_prep) for_22\IN|doses|. (l_pobj) management_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) control_27\NN|NONE (l_compound) pain_26\NN|postoperative
D008614_D012640 CID Pethidine_0\NNP| (r_npadvmod) associated_2\VBN|.|in (r_amod) seizure_3\NN|NONE
D008614_D012640 CID pethidine_9\NN|for (r_dobj) receiving_8\VBG|a|healthy (r_acl) adolescent_7\JJ|NONE (r_pobj) in_4\IN|.|associated (r_prep) seizure_3\NN|NONE
1749407
D003042_D009203 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|observations|.|myocardial|: (r_amod) infarction_4\NN|NONE
D003042_D009203 CID cocaine_13\NN|by|may|in (r_nsubj) result_15\VB|several|possible (l_prep) in_16\IN|cocaine|by|may (l_pobj) infarction_19\NN|NONE
D003042_D009203 CID cocaine_26\NN| (r_npadvmod) induced_28\VBN|in (r_amod) increase_29\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) associated_24\VBN|myocardial|oxygen (r_acl) demand_23\NN|NONE (r_pobj) in_20\IN|an (r_prep) increase_19\NN|NONE (r_pobj) from_17\IN|.|In|infarction|may|, (r_prep) result_16\VB|NONE (l_nsubj) infarction_14\NN|.|In|from|may|,
D003042_D013035 NONE cocaine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) vasoconstriction_19\NN|NONE (r_pobj) of_15\IN|the (r_prep) locus_14\NN|speculative|. (r_nsubj) remains_20\VBZ|circumstantial|With|and|,|findings|, (r_conj) are_8\VBP|NONE (l_prep) With_0\IN|circumstantial|and|,|remains|findings|, (l_pobj) regard_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) spasm_3\NN|NONE
D010100_D009203 NONE oxygen_22\NN|myocardial|associated (r_compound) demand_23\NN|NONE (r_pobj) in_20\IN|an (r_prep) increase_19\NN|NONE (r_pobj) from_17\IN|.|In|infarction|may|, (r_prep) result_16\VB|NONE (l_nsubj) infarction_14\NN|.|In|from|may|,
D003042_D013927 NONE cocaine_11\NN|NONE (r_pobj) of_10\IN|thrombotic|,|a|primary (r_prep) effect_9\NN|NONE (l_amod) thrombotic_8\JJ|,|a|primary|of
4812392
D001379_D011565 NONE azathioprine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) psoriasis_2\NN|NONE
D001379_D011565 NONE Azathioprine_0\JJ|NONE (r_det) treatment_1\NN|.|%|out (r_nsubj) benefited_2\VBD|NONE (l_prep) out_8\IN|.|%|treatment (l_prep) of_9\IN|NONE (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG| (l_prep) from_13\IN|NONE (l_pobj) psoriasis_15\NN|NONE
D001379_D056486 NONE azathioprine_9\JJ|NONE (r_amod) therapy_10\NN|is|if|detected (r_nsubjpass) continued_12\VBN|biopsies|.|be|should|at (l_advcl) detected_20\VBN|is|therapy|if (l_nsubjpass) damage_17\NN|at|may|that|be|so
18343374
D002996_D012170 CID clomiphene_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) ovulation_9\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|.|vein|Central (r_acl) occlusion_3\NN|NONE
D002996_D012170 CID citrate_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|central|vein (r_acl) occlusion_8\NN|NONE
D002996_D012170 CID CC_14\NN|)|clomiphene|( (r_appos) citrate_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|central|vein (r_acl) occlusion_8\NN|NONE
D002996_D012170 CID CC_13\NN|NONE (r_pobj) with_12\IN|ovulation (r_prep) induction_11\NN|NONE (r_pobj) after_9\IN|vein|Central (r_prep) occlusion_8\NN|)|.|:|OUTCOME
D002996_D012170 CID CC_18\NN|NONE (r_pobj) of_17\IN|eight (r_prep) courses_16\NNS|NONE (r_pobj) after_14\IN|RESULT(S|:|woman|occlusion|. (r_prep) developed_9\VBD|NONE (l_dobj) occlusion_13\NN|RESULT(S|:|woman|after|.
D002996_D012170 CID CC_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|NONE (r_pobj) after_12\IN|vein (r_prep) occlusion_11\NN|NONE
D002996_D014786 CID CC_10\NN|NONE (r_pobj) of_9\IN|thromboembolic|the (r_prep) complications_8\NNS|NONE (r_pobj) on_5\IN|of|A (r_prep) search_1\NN|not|complication|.|,|does|is (r_nsubj) include_13\VB|NONE (l_advcl) is_26\VBZ|search|not|complication|.|,|does (l_nsubj) disturbance_22\NN|although|uncommon|not
D002996_D014786 CID CC_24\NN|NONE (r_compound) intake_25\NN|NONE (r_pobj) after_23\IN|visual|mild (r_prep) disturbance_22\NN|although|uncommon|not
D002996_D007247 NONE CC_9\NN|NONE (r_pobj) with_8\IN|patients (r_prep) treating_5\VBG|NONE (l_dobj) patients_7\NNS|with (l_compound) infertility_6\NN|NONE
D002996_D013923 NONE CC_10\NN|NONE (r_pobj) of_9\IN|thromboembolic|the (r_prep) complications_8\NNS|NONE (l_compound) thromboembolic_7\JJ|of|the
D002996_D013923 NONE CC_24\NN|NONE (r_compound) intake_25\NN|NONE (r_pobj) after_23\IN|visual|mild (r_prep) disturbance_22\NN|although|uncommon|not (r_nsubj) is_26\VBZ|search|not|complication|.|,|does (r_advcl) include_13\VB|NONE (l_nsubj) search_1\NN|not|complication|.|,|does|is (l_prep) on_5\IN|of|A (l_pobj) complications_8\NNS|NONE (l_compound) thromboembolic_7\JJ|of|the
6203452
D001761_D002277 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_nsubj) patients_1\NNS|after|microangiopathy|. (l_prep) with_2\IN|Five (l_pobj) carcinoma_3\NN|NONE
D002945_D013921 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|bleomycin|, (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|,|by|)|( (l_conj) thrombocytopenia_19\JJ|microangiopathic|hemolytic|and|,
D002945_D013921 NONE cisplatin_30\VB|and|and|thrombocytopenia|anemia (r_amod) nephrotoxicity_31\NN|NONE (l_conj) thrombocytopenia_36\NN|and|and|cisplatin|anemia
D002945_D051437 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|bleomycin|, (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_agent) by_9\IN|,|)|(|anemia (l_pobj) insufficiency_11\NN|NONE
D002945_D051437 NONE cisplatin_30\VB|and|and|thrombocytopenia|anemia (r_amod) nephrotoxicity_31\NN|NONE (r_pobj) to_29\IN|may|because|be|failure (r_prep) ascribed_28\VBN|may|Diagnosis|,|or|be|.|missed (l_nsubjpass) failure_25\NN|may|because|be|to
D001761_D000743 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|,|by|)|(
D014748_D057049 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|.
D002945_D007674 CID cisplatin_30\VB|and|and|thrombocytopenia|anemia (r_amod) nephrotoxicity_31\NN|NONE
D002945_D002277 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|bleomycin|, (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_nsubj) patients_1\NNS|after|microangiopathy|. (l_prep) with_2\IN|Five (l_pobj) carcinoma_3\NN|NONE
D014748_D051437 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_agent) by_9\IN|,|)|(|anemia (l_pobj) insufficiency_11\NN|NONE
D001761_D013921 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|,|by|)|( (l_conj) thrombocytopenia_19\JJ|microangiopathic|hemolytic|and|,
D002945_D000743 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|bleomycin|, (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|,|by|)|(
D014748_D002277 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_nsubj) patients_1\NNS|after|microangiopathy|. (l_prep) with_2\IN|Five (l_pobj) carcinoma_3\NN|NONE
D002945_D001855 NONE cisplatin_30\VB|and|and|thrombocytopenia|anemia (r_amod) nephrotoxicity_31\NN|NONE (l_conj) thrombocytopenia_36\NN|and|and|cisplatin|anemia (l_prep) to_37\IN|NONE (l_pobj) suppression_43\NN|NONE
D014748_D000743 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|,|by|)|(
D014748_D013921 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|,|by|)|( (l_conj) thrombocytopenia_19\JJ|microangiopathic|hemolytic|and|,
D001761_D051437 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|. (l_acl) characterized_8\VBN|thrombotic (l_agent) by_9\IN|,|)|(|anemia (l_pobj) insufficiency_11\NN|NONE
D001761_D057049 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|.
D002945_D057049 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|bleomycin|, (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|patients|microangiopathy|. (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|patients|after|.
D002945_D000740 NONE cisplatin_30\VB|and|and|thrombocytopenia|anemia (r_amod) nephrotoxicity_31\NN|NONE (l_conj) anemia_34\NN|and|and|thrombocytopenia|cisplatin
11279304
D003630_D006333 CID DNR_16\NNP|NONE (r_pobj) given_15\VBN|heart (r_acl) failure_14\NN|NONE
D003630_D066126 NONE daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) patients_29\NNS|NONE (r_pobj) in_28\IN|induced (r_prep) cardiotoxicity_27\NN|NONE
D003630_D066126 NONE DNR)-containing_38\NN|NONE (r_compound) regimen_39\NNS|(|a (r_appos) daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) patients_29\NNS|NONE (r_pobj) in_28\IN|induced (r_prep) cardiotoxicity_27\NN|NONE
D018943_D015470 NONE anthracycline_24\NN| (r_advmod) induced_26\VBN|in (r_amod) cardiotoxicity_27\NN|NONE (l_prep) in_28\IN|induced (l_pobj) patients_29\NNS|NONE (l_prep) with_30\IN|NONE (l_pobj) leukemia_32\NN|NONE
D018943_D006331 NONE anthracycline_4\NN|conventional (r_amod) therapy_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) cardiotoxicity_1\NN|need|. (r_nsubj) highlights_6\VBZ|NONE (l_dobj) need_8\NN|cardiotoxicity|. (l_acl) search_10\VB|a (l_prep) for_11\IN|to (l_pobj) methods_12\NNS|NONE (l_relcl) are_14\VBP|NONE (l_acomp) sensitive_16\JJ|that (l_conj) capable_18\JJ|highly|and (l_prep) of_19\IN|NONE (l_pcomp) predicting_20\VBG|NONE (l_dobj) dysfunction_22\NN|NONE
D003630_D015470 NONE daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE
D003630_D015470 NONE DNR)-containing_38\NN|NONE (r_compound) regimen_39\NNS|(|a (r_appos) daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE
D003630_D015470 NONE DNR_9\NNP| (r_npadvmod) containing_11\VBG|a (r_amod) regimen_12\NN|NONE (r_pobj) with_7\IN|were|.|patients (r_prep) treated_6\VBN|NONE (l_nsubjpass) patients_1\NNS|were|.|with (l_prep) with_2\IN|Thirteen (l_pobj) leukemia_4\NN|NONE
D018943_D066126 NONE anthracycline_7\NN| (r_advmod) induced_9\VBN|NONE (r_amod) cardiotoxicity_10\NN|NONE
D018943_D066126 NONE Anthracyclines_0\NNS|cause|,|drugs|but (r_nsubj) are_1\VBP|NONE (l_conj) cause_9\VBP|,|Anthracyclines|drugs|but (l_dobj) cardiotoxicity_13\NN|they|frequently|.
D018943_D066126 NONE anthracycline_4\NN|conventional (r_amod) therapy_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) cardiotoxicity_1\NN|need|.
D018943_D066126 NONE anthracycline_24\NN| (r_advmod) induced_26\VBN|in (r_amod) cardiotoxicity_27\NN|NONE
D018943_D066126 NONE anthracycline_16\NN| (r_advmod) induced_18\VBN|NONE (r_compound) cardiotoxicity_19\NN|NONE
20067456
D017367_D012735 NONE inhibitor_16\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|sexual|male (r_acl) dysfunction_9\NN|NONE
D017367_D012735 NONE inhibitor_28\NN|NONE (r_pobj) by_23\IN|is|.|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|is|by|.|, (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|the|and (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE
D017367_D012735 NONE inhibitor_28\NN|NONE (r_pobj) by_23\IN|is|.|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|is|by|.|, (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|the|and (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|)|sexual|male|(
D017367_D012735 NONE inhibitor_28\NN|NONE (r_pobj) by_23\IN|is|.|,|determine (r_agent) induced_22\VBN|NONE (l_advcl) is_35\VBZ|by|.|,|determine (l_nsubj) SD_34\NN|effect|as|have
D017367_D012735 NONE SSRI_30\NNP|)|reuptake|serotonin|selective|a|( (r_appos) inhibitor_28\NN|NONE (r_pobj) by_23\IN|is|.|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|is|by|.|, (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|the|and (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE
D017367_D012735 NONE SSRI_30\NNP|)|reuptake|serotonin|selective|a|( (r_appos) inhibitor_28\NN|NONE (r_pobj) by_23\IN|is|.|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|is|by|.|, (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|the|and (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|)|sexual|male|(
D017367_D012735 NONE SSRI_30\NNP|)|reuptake|serotonin|selective|a|( (r_appos) inhibitor_28\NN|NONE (r_pobj) by_23\IN|is|.|,|determine (r_agent) induced_22\VBN|NONE (l_advcl) is_35\VBZ|by|.|,|determine (l_nsubj) SD_34\NN|effect|as|have
D017367_D012735 NONE SSRIs_42\NNS|NONE (r_pobj) of_41\IN|common|side||a (r_prep) effect_40\NN|SD|as|have (r_attr) is_35\VBZ|by|.|,|determine (r_advcl) induced_22\VBN|NONE (l_csubj) determine_1\VB|is|by|.|, (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|the|and (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE
D017367_D012735 NONE SSRIs_42\NNS|NONE (r_pobj) of_41\IN|common|side||a (r_prep) effect_40\NN|SD|as|have (r_attr) is_35\VBZ|by|.|,|determine (r_advcl) induced_22\VBN|NONE (l_csubj) determine_1\VB|is|by|.|, (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|the|and (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|)|sexual|male|(
D017367_D012735 NONE SSRIs_42\NNS|NONE (r_pobj) of_41\IN|common|side||a (r_prep) effect_40\NN|SD|as|have (r_attr) is_35\VBZ|by|.|,|determine (l_nsubj) SD_34\NN|effect|as|have
D017367_D012735 NONE SSRI_21\NNP|NONE (r_pobj) of_20\IN|NONE (r_prep) type_19\NN|, (r_appos) SD_17\NN|NONE
D017367_D012735 NONE SSRIs_10\NNS|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|for|an|effective (r_acl) treatment_4\NN|Bupropion|. (l_prep) for_5\IN|an|effective|induced (l_pobj) SD_7\NN|NONE
D016642_D012735 NONE bupropion_5\NN|NONE (l_prep) on_6\IN|the|adjunctive (l_pobj) dysfunction_9\NN|NONE
D016642_D012735 NONE bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE
D016642_D012735 NONE bupropion_8\NN|NONE (l_prep) on_15\IN|adjunctive|SR (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|)|sexual|male|(
D016642_D012735 NONE bupropion_8\NN|NONE (r_pobj) of_6\IN|efficacy|the|and (r_prep) safety_3\NN|To (r_dobj) determine_1\VB|is|by|.|, (r_csubj) induced_22\VBN|NONE (l_advcl) is_35\VBZ|by|.|,|determine (l_nsubj) SD_34\NN|effect|as|have
D016642_D012735 NONE Bupropion_0\NN|treatment|. (r_nsubj) is_1\VBZ|NONE (l_attr) treatment_4\NN|Bupropion|. (l_prep) for_5\IN|an|effective|induced (l_pobj) SD_7\NN|NONE
8231633
D015764_D012640 NONE bepridil_31\NN|NONE (r_pcomp) with_30\IN|less (r_prep) pronounced_29\VBN|.|;|effect|modified (r_acomp) was_27\VBD|NONE (l_ccomp) modified_8\VBN|.|;|effect|pronounced (l_conj) decreased_13\VBD|not|significantly|was|but (l_dobj) time_15\NN|blockers (l_relcl) obtain_19\VB|of|the (l_dobj) convulsions_23\NNS|to
D002045_D064420 NONE bupivacaine_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) toxicity_9\NN|NONE
D002045_D064420 NONE bupivacaine_15\NN| (r_npadvmod) induced_17\VBN|acute (r_amod) toxicity_19\NN|NONE
D002045_D012640 CID bupivacaine_4\NN|NONE (r_pobj) of_3\IN|convulsant|The (r_prep) activity_2\NN|NONE (r_nsubj) was_5\VBD|not|significantly|but|decreased (r_auxpass) modified_8\VBN|.|;|effect|pronounced (l_conj) decreased_13\VBD|not|significantly|was|but (l_dobj) time_15\NN|blockers (l_relcl) obtain_19\VB|of|the (l_dobj) convulsions_23\NNS|to
D002045_D012640 CID bupivacaine_20\NN| (r_npadvmod) induced_22\VBN|NONE (r_amod) convulsions_23\NNS|to
D002118_D012640 NONE calcium_10\NN|NONE (r_compound) channel_11\NN|NONE (r_compound) blockers_12\NNS|time (r_nsubj) decreased_13\VBD|not|significantly|was|but (l_dobj) time_15\NN|blockers (l_relcl) obtain_19\VB|of|the (l_dobj) convulsions_23\NNS|to
D002118_D064420 NONE calcium_2\NN|NONE (r_compound) channel_3\NN|on (r_compound) blockers_4\NNS|NONE (l_prep) on_5\IN|channel (l_pobj) toxicity_9\NN|NONE
D002118_D064420 NONE calcium_11\NN|NONE (r_compound) channel_12\NN|on (r_compound) blockers_13\NNS|NONE (l_prep) on_14\IN|channel (l_pobj) toxicity_19\NN|NONE
2549018
D005473_D009771 NONE fluoxetine_3\NN|for (r_dobj) receiving_2\VBG|Five (l_prep) for_4\IN|fluoxetine (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) disorder_10\NN|NONE
D005473_D017109 CID Fluoxetine_0\NNP| (r_npadvmod) induced_2\VBN|implications|:|. (r_amod) akathisia_3\NN|NONE
D005473_D017109 CID fluoxetine_3\NN|for (r_dobj) receiving_2\VBG|Five (r_acl) patients_1\NNS|.|akathisia (r_nsubj) developed_14\VBD|NONE (l_dobj) akathisia_15\NN|.|patients
D005473_D017109 CID fluoxetine_2\NN| (r_npadvmod) induced_4\VBN|of|The|typical (r_amod) symptoms_5\NNS|indistinguishable|. (r_nsubj) were_23\VBD|NONE (l_acomp) indistinguishable_24\JJ|symptoms|. (l_prep) from_25\IN|NONE (l_pobj) those_26\DT|NONE (l_prep) of_27\IN|NONE (l_pobj) akathisia_31\NN|NONE
D005473_D017109 CID fluoxetine_17\NN| (r_advmod) induced_19\VBN|NONE (r_amod) akathisia_20\NN|NONE (r_pobj) of_16\IN|the (r_prep) symptoms_15\NNS|identical|,|that|milder (r_nsubj) were_21\VBD|patients|. (r_ccomp) reported_12\VBD|NONE (l_nsubj) patients_1\NNS|.|were (l_relcl) experienced_4\VBN|Three (l_dobj) akathisia_8\NN|who|had
D005473_D017109 CID fluoxetine_17\NN| (r_advmod) induced_19\VBN|NONE (r_amod) akathisia_20\NN|NONE
D005473_D017109 CID fluoxetine_9\NN|NONE (r_pobj) of_8\IN|common|side|a (r_prep) effect_7\NN|to (r_attr) be_3\VB|.|responded|and|Akathisia (r_xcomp) appeared_1\VBD|NONE (l_nsubj) Akathisia_0\NNP|.|be|responded|and
D005473_D017109 CID fluoxetine_4\NN| (r_advmod) induced_6\VBN|NONE (r_amod) akathisia_7\NN|be|by|that|may|be
D005473_D017109 CID fluoxetine_4\NN| (r_advmod) induced_6\VBN|NONE (r_amod) akathisia_7\NN|be|by|that|may|be (r_nsubjpass) caused_10\VBN|authors|. (l_conj) be_36\VB|be|by|that|may|akathisia (l_nsubj) pathophysiology_21\NN|may|that|"|identical (l_prep) of_22\IN|the (l_pobj) akathisia_26\NN|NONE
D005473_D017109 CID fluoxetine_23\NN| (r_advmod) induced_25\VBN|and|jitteriness (r_amod) akathisia_26\NN|NONE (r_pobj) of_22\IN|the (r_prep) pathophysiology_21\NN|may|that|"|identical (r_nsubj) be_36\VB|be|by|that|may|akathisia (r_conj) caused_10\VBN|authors|. (l_nsubjpass) akathisia_7\NN|be|by|that|may|be
D005473_D017109 CID fluoxetine_23\NN| (r_advmod) induced_25\VBN|and|jitteriness (r_amod) akathisia_26\NN|NONE
D000928_D017109 NONE antidepressant_29\NN| (r_npadvmod) induced_31\VBN|"|tricyclic (r_amod) jitteriness_33\NN|induced|and (r_conj) akathisia_26\NN|NONE (r_pobj) of_22\IN|the (r_prep) pathophysiology_21\NN|may|that|"|identical (r_nsubj) be_36\VB|be|by|that|may|akathisia (r_conj) caused_10\VBN|authors|. (l_nsubjpass) akathisia_7\NN|be|by|that|may|be
D000928_D017109 NONE antidepressant_29\NN| (r_npadvmod) induced_31\VBN|"|tricyclic (r_amod) jitteriness_33\NN|induced|and (r_conj) akathisia_26\NN|NONE
D011433_D017109 NONE propranolol_22\NN|adrenergic|reduction|the|, (r_acl) antagonist_21\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_pobj) to_14\IN|generally|well (r_prep) responded_12\VBD|.|be|and|Akathisia (r_conj) appeared_1\VBD|NONE (l_nsubj) Akathisia_0\NNP|.|be|responded|and
D005473_D001008 NONE fluoxetine_2\NN| (r_npadvmod) induced_4\VBN|of|The|typical (r_amod) symptoms_5\NNS|indistinguishable|. (l_prep) of_6\IN|The|typical|induced (l_pobj) restlessness_7\NN|NONE (l_conj) pacing_10\NN|, (l_conj) movements_13\NNS|,|constant (l_conj) anxiety_22\NN|of|purposeless|and|,
D005473_D003865 NONE fluoxetine_3\NN|for (r_dobj) receiving_2\VBG|Five (l_prep) for_4\IN|fluoxetine (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) disorder_10\NN|NONE (l_conj) depression_13\NN|compulsive|obsessive|or
3997294
D000638_D013617 NONE amiodarone_11\NN|NONE (l_prep) for_28\IN|,|dose|( (l_pobj) control_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) tachyarrhythmias_32\NNS|NONE
D000638_D010490 CID amiodarone_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) during_8\IN|and|neuropathy|pleural (r_prep) effusion_5\NN|NONE
D000638_D011014 CID amiodarone_14\NN|NONE (r_compound) pneumonitis_15\NN|NONE
D000638_D011014 CID amiodarone_20\NN|NONE (r_pobj) of_19\IN|immediate|prompt|and|, (r_prep) withdrawal_18\NN|need|Review|,|. (r_dobj) indicates_7\VBZ|NONE (l_dobj) need_9\NN|Review|,|withdrawal|. (l_prep) for_10\IN|the (l_pobj) diagnosis_12\NN|NONE (l_prep) of_13\IN|early (l_pobj) pneumonitis_15\NN|NONE
D000638_D010996 CID amiodarone_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) during_8\IN|and|neuropathy|pleural (r_prep) effusion_5\NN|NONE
D000638_D009422 NONE amiodarone_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) during_8\IN|and|neuropathy|pleural (r_prep) effusion_5\NN|NONE (l_conj) neuropathy_7\NN|and|during|pleural
D013256_D011014 NONE steroid_26\NN|continued (r_compound) therapy_27\NN|ensure|but (r_conj) prompt_23\JJ|immediate|of|and|, (r_conj) withdrawal_18\NN|need|Review|,|. (r_dobj) indicates_7\VBZ|NONE (l_dobj) need_9\NN|Review|,|withdrawal|. (l_prep) for_10\IN|the (l_pobj) diagnosis_12\NN|NONE (l_prep) of_13\IN|early (l_pobj) pneumonitis_15\NN|NONE
D000638_D002318 NONE amiodarone_11\NN|NONE (r_pobj) with_10\IN|was|patient|. (r_prep) treated_9\VBN|NONE (l_nsubjpass) patient_1\NN|was|with|. (l_prep) with_2\IN|and|A|pacemaker (l_pobj) disease_4\NN|NONE
2265898
C009265_D012640 NONE levodopa_38\JJ|a|carbidopa (r_compound) preparation_39\NN|;|;|.|been|had|both|and|had|had (r_dobj) receiving_34\VBG|NONE (l_conj) had_43\VBD|;|;|.|been|both|and|preparation|had|had (l_dobj) onset_45\NN|both (l_prep) of_46\IN|the (l_pobj) seizures_50\NNS|NONE
C009265_D001523 NONE levodopa_38\JJ|a|carbidopa (r_compound) preparation_39\NN|;|;|.|been|had|both|and|had|had (r_dobj) receiving_34\VBG|NONE (l_conj) had_43\VBD|;|;|.|been|both|and|preparation|had|had (l_dobj) onset_45\NN|both (l_prep) of_46\IN|the (l_pobj) seizures_50\NNS|NONE (l_nmod) hallucinosis_47\NN|were|,
C009265_D004827 CID carbidopa_6\NN|NONE (l_nsubj) epilepsy_1\NN|in|.|/|administration
C009265_D007676 NONE levodopa_38\JJ|a|carbidopa (r_compound) preparation_39\NN|;|;|.|been|had|both|and|had|had (r_dobj) receiving_34\VBG|NONE (l_ccomp) had_11\VBD|;|;|.|been|had|both|and|preparation|had (l_dobj) failure_14\NN|,|begun|on|but|patients|presented|:
1147734
D011441_D006521 CID propylthiouracil_29\NN|NONE (r_pobj) of_28\IN|the (r_prep) administration_27\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) caused_24\VBN|)|aggressive|active|(|chronic (r_acl) hepatitis_23\NN|NONE
D011441_D008107 NONE propylthiouracil_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|Liver|. (r_acl) disease_1\NN|NONE
14659530
D012701_D008881 NONE serotonin_24\NN|NONE (r_compound) release_25\NN|NONE (r_pobj) with_22\IN|negative (r_prep) correlation_21\NN|and|CGRP|)|( (r_conj) concentration_18\NN|calcitonin|plasma|related (r_appos) peptide_14\NN|NONE (r_pobj) in_8\IN|strong (r_prep) increase_7\NN|.|:|induced|migraine (r_appos) attack_4\NN|NONE (l_compound) migraine_3\JJ|increase|.|:|induced
D012701_D008881 NONE serotonin_24\NN|)|concentration|peptide|HT (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|.|aim (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|provoked|genuine|delayed
D012701_D008881 NONE 5-hydroxytriptamine_26\NN|NONE (r_punct) ,_27\,|NONE (r_punct) 5-HT_28\CD|)|serotonin|concentration|peptide (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|.|aim (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|provoked|genuine|delayed
D012701_D008881 NONE 5-HT_28\CD|)|serotonin|concentration|peptide (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|.|aim (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|provoked|genuine|delayed
D012701_D008881 NONE 5-HT_8\CD|NONE (r_nummod) content_9\NN|be (r_nsubj) tended_10\VBD|NONE (l_xcomp) be_12\VB|content (l_prep) in_14\IN|to|lower (l_pobj) subjects_15\NNS|NONE (l_relcl) experienced_17\VBD|NONE (l_dobj) attack_20\NN|who (l_compound) migraine_19\JJ|a
D012701_D008881 NONE serotonin_1\NN|NONE (r_compound) content_2\NN|P<.|but|after|significantly|observed (r_nsubj) decreased_3\VBD|NONE (l_prep) after_8\IN|P<.|content|but|significantly|observed (l_pobj) nitroglycerin_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) subjects_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) attack_15\NN|NONE (l_compound) migraine_14\JJ|no
D012701_D008881 NONE serotonin_1\NN|NONE (r_compound) content_2\NN|P<.|but|after|significantly|observed (r_nsubj) decreased_3\VBD|NONE (l_conj) observed_21\VBN|P<.|content|but|after|significantly (l_prep) in_22\IN|was|.|change (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) attack_26\NN|NONE (l_compound) migraine_25\JJ|NONE
D012701_D008881 NONE serotonin_3\NN|from (r_compound) release_4\NN|In|does|migraine|not|, (r_nsubj) provoke_9\VB|it|.|even|headache|may|, (l_dobj) migraine_10\NN|In|does|not|,|release
D009569_D008881 NONE NO_0\RB| (r_intj) induced_2\VBN|increase|.|:|migraine (r_amod) attack_4\NN|NONE (l_compound) migraine_3\JJ|increase|.|:|induced
D015740_D008881 NONE peptide_14\NN|NONE (r_pobj) in_8\IN|strong (r_prep) increase_7\NN|.|:|induced|migraine (r_appos) attack_4\NN|NONE (l_compound) migraine_3\JJ|increase|.|:|induced
D015740_D008881 NONE CGRP_16\NN|and|correlation|)|( (r_nmod) concentration_18\NN|calcitonin|plasma|related (r_appos) peptide_14\NN|NONE (r_pobj) in_8\IN|strong (r_prep) increase_7\NN|.|:|induced|migraine (r_appos) attack_4\NN|NONE (l_compound) migraine_3\JJ|increase|.|:|induced
D015740_D008881 NONE peptide_17\NN|)|serotonin|concentration|HT (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|.|aim (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|provoked|genuine|delayed
D015740_D008881 NONE CGRP_19\NN|(|)|and (r_nmod) concentration_21\NN|)|serotonin|peptide|HT (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|.|aim (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|provoked|genuine|delayed
D015740_D008881 NONE CGRP_1\NN|Plasma (r_compound) concentration_2\NN|during|P<.|returned|.|and|significantly (r_nsubj) increased_3\VBD|NONE (l_prep) during_8\IN|P<.|returned|.|concentration|and|significantly (l_pobj) attack_11\NN|NONE (l_compound) migraine_10\JJ|the
D015740_D008881 NONE CGRP_1\NN|Plasma (r_compound) concentration_2\NN|during|P<.|returned|.|and|significantly (r_nsubj) increased_3\VBD|NONE (l_conj) returned_13\VBD|during|P<.|.|concentration|and|significantly (l_prep) after_16\IN|to (l_pobj) cessation_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) migraine_21\NN|NONE
D015740_D008881 NONE CGRP_3\NNP|plasma (r_compound) concentrations_4\NNS|change|However|,|. (r_nsubj) failed_5\VBD|NONE (l_xcomp) change_7\VB|concentrations|However|,|. (l_prep) during_8\IN|to (l_conj) in_12\IN|headache|and (l_pobj) subjects_14\NNS|NONE (l_prep) with_15\IN|the (l_pobj) attack_18\NN|NONE (l_compound) migraine_17\JJ|no
D015740_D008881 NONE CGRP_1\NNP|Basal (r_compound) concentration_2\NN|higher|and|platelet|. (r_nsubj) was_3\VBD|NONE (l_conj) platelet_7\NN|higher|concentration|and|. (l_ccomp) tended_10\VBD|NONE (l_xcomp) be_12\VB|content (l_prep) in_14\IN|to|lower (l_pobj) subjects_15\NNS|NONE (l_relcl) experienced_17\VBD|NONE (l_dobj) attack_20\NN|who (l_compound) migraine_19\JJ|a
D015740_D008881 NONE CGRP_7\NN|plasma (r_compound) concentration_8\NN|with|that (r_nsubj) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE (l_compound) migraine_17\JJ|a
D015740_D008881 NONE CGRP_7\NN|plasma (r_compound) concentration_8\NN|with|that (r_nsubj) correlates_9\VBZ|the (r_acl) fact_4\NN|,|relationship|.|In (r_nsubj) suggests_19\VBZ|NONE (l_dobj) relationship_22\NN|,|.|In|fact (l_prep) between_23\IN|direct|a (l_pobj) CGRP_24\NN|NONE (l_conj) migraine_26\NN|and
D015740_D008881 NONE CGRP_24\NN|NONE (r_pobj) between_23\IN|direct|a (r_prep) relationship_22\NN|,|.|In|fact (r_dobj) suggests_19\VBZ|NONE (l_nsubj) fact_4\NN|,|relationship|.|In (l_acl) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE (l_compound) migraine_17\JJ|a
D015740_D008881 NONE CGRP_24\NN|NONE (l_conj) migraine_26\NN|and
D015740_D008881 NONE CGRP_21\NN|the|in|concomitant (r_compound) release_22\NN|and|the (r_conj) headache_17\NN|it|.|provoke|even|may|, (r_dobj) counteract_15\VB|NONE (l_ccomp) provoke_9\VB|it|.|even|headache|may|, (l_dobj) migraine_10\NN|In|does|not|,|release
D005996_D008881 NONE nitroglycerin_43\NN|NONE (r_pobj) by_42\IN|NONE (r_agent) provoked_41\VBN|migraine|the|genuine|delayed (r_acl) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|provoked|genuine|delayed
D005996_D008881 NONE nitroglycerin_16\NN|the (r_compound) application_17\NN|NONE (r_pobj) after_14\IN|min|and (r_conj) before_12\RB|min|,|from|Blood|times|was|and (r_advmod) collected_2\VBN|NONE (l_conj) min_23\NN|,|from|Blood|before|times|was|and (l_prep) after_24\IN|;|subjects|.| (l_pobj) beginning_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) attack_30\NN|NONE (l_compound) migraine_29\JJ|the|mean
D005996_D008881 NONE nitroglycerin_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) subjects_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) attack_15\NN|NONE (l_compound) migraine_14\JJ|no
D005996_D008881 NONE nitroglycerin_9\NN|NONE (r_pobj) after_8\IN|P<.|content|but|significantly|observed (r_prep) decreased_3\VBD|NONE (l_conj) observed_21\VBN|P<.|content|but|after|significantly (l_prep) in_22\IN|was|.|change (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) attack_26\NN|NONE (l_compound) migraine_25\JJ|NONE
D015740_D006261 NONE peptide_17\NN|)|serotonin|concentration|HT (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D015740_D006261 NONE CGRP_19\NN|(|)|and (r_nmod) concentration_21\NN|)|serotonin|peptide|HT (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D015740_D006261 NONE CGRP_3\NNP|plasma (r_compound) concentrations_4\NNS|change|However|,|. (r_nsubj) failed_5\VBD|NONE (l_xcomp) change_7\VB|concentrations|However|,|. (l_prep) during_8\IN|to (l_pobj) headache_10\NN|in|and
D015740_D006261 NONE CGRP_7\NN|plasma (r_compound) concentration_8\NN|with|that (r_nsubj) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE
D015740_D006261 NONE CGRP_24\NN|NONE (r_pobj) between_23\IN|direct|a (r_prep) relationship_22\NN|,|.|In|fact (r_dobj) suggests_19\VBZ|NONE (l_nsubj) fact_4\NN|,|relationship|.|In (l_acl) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE
D015740_D006261 NONE CGRP_21\NN|the|in|concomitant (r_compound) release_22\NN|and|the (r_conj) headache_17\NN|it|.|provoke|even|may|,
D012701_D006261 NONE serotonin_24\NN|)|concentration|peptide|HT (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D012701_D006261 NONE 5-hydroxytriptamine_26\NN|NONE (r_punct) ,_27\,|NONE (r_punct) 5-HT_28\CD|)|serotonin|concentration|peptide (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D012701_D006261 NONE 5-HT_28\CD|)|serotonin|concentration|peptide (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D012701_D006261 NONE serotonin_3\NN|from (r_compound) release_4\NN|In|does|migraine|not|, (r_nsubj) provoke_9\VB|it|.|even|headache|may|, (r_ccomp) counteract_15\VB|NONE (l_dobj) headache_17\NN|it|.|provoke|even|may|,
D005996_D006261 NONE nitroglycerin_43\NN|NONE (r_pobj) by_42\IN|NONE (r_agent) provoked_41\VBN|migraine|the|genuine|delayed (r_acl) attack_40\NN|changes|to|and (r_conj) investigate_8\VB|.|aim (l_dobj) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
9034419
C047426_D003865 NONE venlafaxine_12\NN|NONE (r_pobj) of_11\IN|an (r_prep) overdose_10\NN|in|woman|. (r_dobj) took_8\VBD|NONE (l_nsubj) woman_4\NN|in|overdose|. (l_prep) with_5\IN|old|A (l_pobj) depression_7\NN|NONE
C047426_D012640 CID venlafaxine_4\NNP|a (r_amod) overdose_5\NN|NONE (r_pobj) from_2\IN|NONE (r_prep) resulting_1\VBG|. (r_acl) Seizure_0\NN|NONE
C047426_D012640 CID venlafaxine_5\NNP|NONE (r_pobj) of_3\IN|the|tablets (r_prep) ingestion_2\NN|NONE (r_pobj) After_0\IN|seizure|,|patient|. (r_prep) experienced_11\VBD|NONE (l_dobj) seizure_15\NN|,|After|patient|.
C047426_D012640 CID venlafaxine_11\NNP|NONE (r_amod) overdose_12\NN|NONE (r_pobj) of_10\IN|resulted|the|reported|first (r_prep) case_9\NN|To|,|this|. (l_relcl) resulted_14\VBD|of|the|reported|first (l_prep) in_15\IN|that (l_pobj) seizure_18\NN|NONE
C047426_D012640 CID venlafaxine_1\NNP|in|The (r_amod) overdose_2\NN|in|.|but|elicited (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|.|but|elicited|overdose (l_pobj) episode_10\NN|NONE (l_prep) of_11\IN|single|a (l_pobj) seizure_13\NN|NONE
C047426_D062787 CID venlafaxine_4\NNP|a (r_amod) overdose_5\NN|NONE
C047426_D062787 CID venlafaxine_5\NNP|NONE (r_amod) overdose_6\NN|NONE
C047426_D062787 CID venlafaxine_12\NN|NONE (r_pobj) of_11\IN|an (r_prep) overdose_10\NN|in|woman|.
C047426_D062787 CID venlafaxine_11\NNP|NONE (r_amod) overdose_12\NN|NONE
C047426_D062787 CID venlafaxine_1\NNP|in|The (r_amod) overdose_2\NN|in|.|but|elicited
18560792
D004298_D006349 NONE dopamine_33\NN|ergot (r_compound) agonists_34\NNS|NONE (r_pobj) to_29\IN|treatment|is|when (r_prep) converted_28\VBN|usual|that|improvement (r_advcl) is_22\VBZ|NONE (r_ccomp) reveals_17\VBZ|and|with (r_conj) treated_13\VBN|of|high|the (r_acl) frequency_5\NN|study|. (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE
D010479_D006349 NONE pergolide_11\NN|NONE (r_pobj) with_10\IN|.|disease (r_prep) treated_9\VBN|NONE (l_nsubj) disease_2\NN|.|with
D010479_D006349 NONE pergolide_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|abnormalities|have|been|. (r_prep) reported_5\VBN|NONE (l_nsubjpass) abnormalities_2\NNS|have|in|been|.
D010479_D006349 NONE pergolide_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) role_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) suggestive_7\JJ|A|,|of|restrictive (r_amod) pattern_2\NN|in|,|.|was|patients (l_prep) of_3\IN|A|,|restrictive|suggestive (l_pobj) regurgitation_5\NN|NONE
D010479_D006349 NONE Pergolide_0\NNP|in|returned|resulting|,|.|was (r_nsubjpass) discontinued_2\VBN|NONE (l_prep) in_3\IN|returned|resulting|,|.|Pergolide|was (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN| (l_pobj) disease_9\NN|NONE
D010479_D006349 NONE pergolide_15\NN|NONE (r_pobj) with_14\IN|and|reveals (r_prep) treated_13\VBN|of|high|the (r_acl) frequency_5\NN|study|. (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE
D004298_D010300 NONE dopamine_33\NN|ergot (r_compound) agonists_34\NNS|NONE (r_pobj) to_29\IN|treatment|is|when (r_prep) converted_28\VBN|usual|that|improvement (r_advcl) is_22\VBZ|NONE (r_ccomp) reveals_17\VBZ|and|with (r_conj) treated_13\VBN|of|high|the (r_acl) frequency_5\NN|study|. (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE (l_prep) in_10\IN|restrictive|valve (l_pobj) patients_12\NNS|NONE (l_compound) PD_11\NNP|NONE
D010479_D010300 NONE pergolide_11\NN|NONE (r_pobj) with_10\IN|.|disease (r_prep) treated_9\VBN|NONE (l_nsubj) disease_2\NN|.|with (l_prep) in_3\IN|Valvular|heart (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN|NONE (l_pobj) disease_8\NN|NONE
D010479_D010300 NONE pergolide_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|NONE (l_prep) with_8\IN|treated (l_pobj) disease_11\NN|NONE
D010479_D010300 NONE pergolide_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|NONE (l_prep) with_8\IN|treated (l_pobj) disease_11\NN|NONE (l_appos) PD_13\NNP|(|Parkinson|)
D010479_D010300 NONE pergolide_9\NN|NONE (r_pobj) with_8\IN|patients (r_prep) treated_7\VBN|attend|.|were (l_nsubj) patients_2\NNS|with (l_compound) PD_1\NNP|in|All
D010479_D010300 NONE pergolide_15\NN|NONE (r_pobj) with_14\IN|and|reveals (r_prep) treated_13\VBN|of|high|the (r_acl) frequency_5\NN|study|. (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE (l_prep) in_10\IN|restrictive|valve (l_pobj) patients_12\NNS|NONE (l_compound) PD_11\NNP|NONE
D010479_D006333 NONE pergolide_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) role_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) suggestive_7\JJ|A|,|of|restrictive (r_amod) pattern_2\NN|in|,|.|was|patients (r_nsubjpass) observed_15\VBN|NONE (l_dobj) patients_22\NNS|pattern|in|,|.|was (l_prep) including_23\VBG|NONE (l_pobj) two_24\CD|NONE (l_prep) with_25\IN|NONE (l_pobj) failure_27\NN|NONE
D010479_D006333 NONE Pergolide_0\NNP|in|returned|resulting|,|.|was (r_nsubjpass) discontinued_2\VBN|NONE (l_advcl) resulting_11\VBG|in|returned|,|.|Pergolide|was (l_prep) in_12\IN|NONE (l_pobj) grade_16\NN|NONE (l_prep) at_20\IN|p=.|lower|a|regurgitation (l_pobj) transthoracic_23\NN|NONE (l_conj) patients_28\NNS|and|the|second|echocardiography (l_prep) with_29\IN|the|two (l_pobj) failure_31\NN|NONE
16181582
D014635_D004827 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) encephalopathy_3\NN|.|syndrome (r_nsubj) is_4\VBZ|NONE (l_attr) syndrome_7\NN|.|encephalopathy (l_relcl) manifest_10\VB|rare|a (l_prep) in_11\RP|may|that (l_pobj) individuals_15\NNS|NONE (l_amod) epileptic_14\JJ|normal
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|. (r_amod) encephalopathy_3\NN|NONE
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) encephalopathy_3\NN|.|syndrome
D014635_D001927 CID valproate_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) encephalopathy_6\NN|NONE
869641
D015103_D001919 NONE dihydroxyphenylserine_21\NN|,|L| (r_conj) dopa_15\NNP|NONE (r_pobj) by_12\IN|In|was|,|had|bradycardia|significantly|. (r_agent) enhanced_11\VBN|NONE (l_nsubjpass) bradycardia_4\NN|In|was|,|had|by|significantly|.
D004298_D007022 NONE dopamine_3\NN|beta|| (r_compound) oxidase_7\NN|a (r_compound) inhibitor_8\NN|effect|.|did|,|FLA|not|, (r_nsubj) have_12\VB|NONE (l_dobj) effect_14\NN|.|inhibitor|did|,|FLA|not|, (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE
D005406_D001919 NONE FLA-63_0\NN|effect|.|inhibitor|did|,|not|, (r_mark) have_12\VB|NONE (l_dobj) effect_14\NN|.|inhibitor|did|,|FLA|not|, (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE (l_appos) effect_24\NN|,|the (l_amod) bradycardia_19\NN|of
D007980_D001919 NONE dopa_9\NN|NONE (r_pobj) by_6\IN|via|of|. (r_prep) Mediation_0\NN|NONE (l_prep) of_1\IN|via|by|. (l_pobj) bradycardia_5\NNP|NONE
D007980_D001919 NONE dopa_15\NNP|NONE (r_pobj) by_12\IN|In|was|,|had|bradycardia|significantly|. (r_agent) enhanced_11\VBN|NONE (l_nsubjpass) bradycardia_4\NN|In|was|,|had|by|significantly|.
D007980_D001919 NONE dopa_28\NNP|NONE (r_pobj) of_25\IN|bradycardia (r_prep) effect_24\NN|,|the (l_amod) bradycardia_19\NN|of
D007980_D001919 NONE dopa_4\NNP|bradycardia|.|However|, (r_nsubj) restored_5\VBD|NONE (l_dobj) bradycardia_7\NN|.|dopa|However|,
D007980_D001919 NONE dopa_6\NNP|through|that|bradycardia (r_nsubj) enhances_7\VBZ|is|It|. (l_dobj) bradycardia_9\NN|through|that|dopa
D004298_D001919 NONE dopamine_12\NN|in|central (r_compound) formation_13\NN|NONE (r_pobj) via_10\IN|of|by|. (r_prep) Mediation_0\NN|NONE (l_prep) of_1\IN|via|by|. (l_pobj) bradycardia_5\NNP|NONE
D004298_D001919 NONE dopamine_3\NN|beta|| (r_compound) oxidase_7\NN|a (r_compound) inhibitor_8\NN|effect|.|did|,|FLA|not|, (r_nsubj) have_12\VB|NONE (l_dobj) effect_14\NN|.|inhibitor|did|,|FLA|not|, (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE (l_appos) effect_24\NN|,|the (l_amod) bradycardia_19\NN|of
D005406_D007022 NONE FLA-63_0\NN|effect|.|inhibitor|did|,|not|, (r_mark) have_12\VB|NONE (l_dobj) effect_14\NN|.|inhibitor|did|,|FLA|not|, (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE
D009638_D001919 CID norepinephrine_8\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|reflex (r_acl) bradycardia_4\NN|In|was|,|had|by|significantly|.
D009638_D001919 CID norepinephrine_35\NN|NONE (r_pobj) to_34\IN|reflex (r_prep) responses_33\NNS|heart|or (r_conj) rate_30\NN|,|blood (r_conj) pressure_27\NN|NONE (r_pobj) on_25\IN|no (r_prep) effect_24\NN|NONE (r_dobj) had_22\VBD|In|was|,|by|bradycardia|significantly|. (r_conj) enhanced_11\VBN|NONE (l_nsubjpass) bradycardia_4\NN|In|was|,|had|by|significantly|.
D009638_D001919 CID norepinephrine_10\NN|NONE (r_pobj) by_9\IN|in (r_agent) caused_8\VBN|the (r_acl) bradycardia_7\NN|.|dopa|However|,
D009638_D001919 CID norepinephrine_18\NN|NONE (r_pobj) to_17\IN|the|reflex (r_prep) bradycardia_16\NN|NONE
D007980_D007022 NONE dopa_28\NNP|NONE (r_pobj) of_25\IN|bradycardia (r_prep) effect_24\NN|,|the (r_appos) hypotension_17\NN|NONE
D006916_D001919 NONE 5-HTP_0\NNP|and|pressure|decreased|. (r_nsubj) decreased_6\VBD|NONE (l_conj) decreased_13\VBD|and|pressure|.|HTP (l_dobj) bradycardia_16\NN|NONE
7423039
D004317_D066126 CID adriamycin_3\JJ|NONE (r_amod) cardiotoxicity_4\NN|NONE
D004317_D066126 CID adriamycin_4\NNS|NONE (r_pobj) of_3\IN|cardiotoxic|The (r_prep) effects_2\NNS|were|in|. (l_amod) cardiotoxic_1\JJ|of|The
8386779
D010208_D007172 NONE papaverine_25\NN|:| (r_appos) drugs_21\NNS|NONE (r_pobj) of_19\IN|a (r_prep) combination_18\NN|NONE (r_pobj) of_16\IN|. (r_prep) ml._15\NN|.|total (r_dobj) received_13\VBD|NONE (l_nsubj) total_1\NN|.|ml. (l_prep) of_2\IN|A (l_pobj) patients_5\NNS|NONE (l_relcl) presented_7\VBD||consecutive (l_prep) with_11\IN|to|who (l_pobj) impotence_12\NN|NONE
D017693_D007172 NONE bicarbonate_1\NN|pain|.|induced (r_nsubj) alleviates_2\VBZ|NONE (l_advcl) induced_5\VBN|pain|.|bicarbonate (l_agent) by_6\IN|NONE (l_pobj) injections_8\NNS|NONE (l_prep) for_9\IN|intracavernous (l_pobj) dysfunction_11\NN|NONE
D017693_D004414 NONE bicarbonate_1\NN|pain|.|induced (r_nsubj) alleviates_2\VBZ|NONE (l_dobj) pain_4\NN|.|induced|bicarbonate
D017693_D004414 NONE bicarbonate_43\NN|NONE (r_pobj) of_41\IN|the (r_prep) addition_40\NN|NONE (r_pobj) without_38\IN|or (r_conj) with_36\IN|intracorporeal (r_prep) injections_35\NNS|NONE (r_pobj) following_33\VBG|incidence (r_prep) comparing_27\VBG|randomized|a (r_acl) study_26\NN|In|we|,|medications. (r_dobj) performed_23\VBD|NONE (l_prep) In_0\IN|we|study|,|medications. (l_pobj) attempt_2\NN|NONE (l_acl) determine_4\VB|an (l_ccomp) be_13\VB|to (l_nsubj) pain_7\NN|could|due|whether
D017693_D004414 NONE bicarbonate_43\NN|NONE (r_pobj) of_41\IN|the (r_prep) addition_40\NN|NONE (r_pobj) without_38\IN|or (r_conj) with_36\IN|intracorporeal (r_prep) injections_35\NNS|NONE (r_pobj) following_33\VBG|incidence (r_prep) comparing_27\VBG|randomized|a (l_dobj) incidence_29\NN|following (l_prep) of_30\IN|the (l_pobj) pain_32\NN|NONE
D017693_D004414 NONE bicarbonate_6\NN|NONE (r_pobj) without_4\IN|the|added| (r_prep) patients_3\NNS|NONE (r_pobj) Of_0\IN|of|,|.|complained|due (r_prep) complained_16\VBD|NONE (l_prep) of_17\IN|Of|,|.|complained|due (l_pobj) pain_19\NN|NONE
D017693_D004414 NONE bicarbonate_6\NN|NONE (r_pobj) without_4\IN|the|added| (r_prep) patients_3\NNS|NONE (r_pobj) Of_0\IN|of|,|.|complained|due (r_prep) complained_16\VBD|NONE (l_advcl) complained_40\VBD|Of|of|,|.|due (l_prep) of_41\IN|while| (l_pobj) pain_43\NN|NONE
D017693_D004414 NONE bicarbonate_39\NN|who (r_dobj) received_37\VBD|%|)|(||the (r_relcl) men_31\NNS|NONE (r_pobj) of_28\IN|only (r_prep) 1_27\CD|while|of (r_nsubj) complained_40\VBD|Of|of|,|.|due (r_advcl) complained_16\VBD|NONE (l_prep) of_17\IN|Of|,|.|complained|due (l_pobj) pain_19\NN|NONE
D017693_D004414 NONE bicarbonate_39\NN|who (r_dobj) received_37\VBD|%|)|(||the (r_relcl) men_31\NNS|NONE (r_pobj) of_28\IN|only (r_prep) 1_27\CD|while|of (r_nsubj) complained_40\VBD|Of|of|,|.|due (l_prep) of_41\IN|while| (l_pobj) pain_43\NN|NONE
11569530
C063968_D016171 NONE E4031_19\NNP|and (r_conj) cisapride_17\NN|, (r_conj) terodiline_15\NN|, (r_conj) terfenadine_13\NN|TDP|:|were (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|terfenadine|:|were
D020117_D016171 CID cisapride_17\NN|, (r_conj) terodiline_15\NN|, (r_conj) terfenadine_13\NN|TDP|:|were (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|terfenadine|:|were
D020117_D016171 CID cisapride_14\JJ|, (r_conj) terodiline_12\NN|, (r_conj) terfenadine_10\NN|(|)|the (r_appos) clinic_8\NN|NONE (r_pobj) in_6\IN|TDP|have|that (r_prep) shown_4\VBN|NONE (l_dobj) TDP_5\NNP|in|have|that
D016593_D016171 CID terfenadine_19\NN|the|(|) (r_appos) market_16\NN|NONE (r_pobj) from_14\IN|of (r_prep) withdrawal_10\NN|NONE (r_pobj) to_9\IN|that|has (r_prep) led_8\VBN||side|a (r_relcl) effect_5\NN|.|TDP (r_attr) is_1\VBZ|NONE (l_nsubj) TDP_0\NNP|.|effect
D016593_D016171 CID terfenadine_13\NN|TDP|:|were (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|terfenadine|:|were
D016593_D016171 CID terfenadine_10\NN|(|)|the (r_appos) clinic_8\NN|NONE (r_pobj) in_6\IN|TDP|have|that (r_prep) shown_4\VBN|NONE (l_dobj) TDP_5\NNP|in|have|that
C010637_D016171 CID terodiline_21\NN|e.g.|and (r_conj) terfenadine_19\NN|the|(|) (r_appos) market_16\NN|NONE (r_pobj) from_14\IN|of (r_prep) withdrawal_10\NN|NONE (r_pobj) to_9\IN|that|has (r_prep) led_8\VBN||side|a (r_relcl) effect_5\NN|.|TDP (r_attr) is_1\VBZ|NONE (l_nsubj) TDP_0\NNP|.|effect
C010637_D016171 CID terodiline_15\NN|, (r_conj) terfenadine_13\NN|TDP|:|were (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|terfenadine|:|were
C010637_D016171 CID terodiline_12\NN|, (r_conj) terfenadine_10\NN|(|)|the (r_appos) clinic_8\NN|NONE (r_pobj) in_6\IN|TDP|have|that (r_prep) shown_4\VBN|NONE (l_dobj) TDP_5\NNP|in|have|that
6308277
D010433_D012640 CID pentylenetetrezol_30\NN|NONE (r_pobj) of_29\IN|tests|in|convulsant|the (r_prep) dose_28\NN|did|not (r_dobj) alter_25\VB|seizures|In|acetaminophen|,|did|and|.|not (r_conj) modify_15\VB|NONE (l_dobj) seizures_17\NNS|In|acetaminophen|,|did|alter|and|.|not
D000082_D064420 NONE acetaminophen_5\NN|NONE (r_pobj) by_4\IN|.|in (r_prep) Reduction_0\NN|NONE (l_prep) in_1\IN|.|by (l_pobj) toxicity_3\NN|NONE
D000082_D064420 NONE acetaminophen_26\NN|NONE (r_pobj) of_25\IN|the (r_prep) presence_24\NN|that|toxicity|(|micrograms (r_nsubj) reduced_33\VBD|the (l_dobj) toxicity_36\NN|that|(|presence|micrograms
D002110_D012640 CID caffeine_23\NN|NONE (r_pobj) of_22\IN|the|and|IP|onset (r_prep) administration_21\NN|NONE (l_conj) onset_33\NN|the|and|of|IP (l_prep) of_34\IN|the|;|pretreatment|and|by (l_pobj) convulsions_36\NNS|NONE
D002110_D012640 CID caffeine_23\NN|NONE (r_pobj) of_22\IN|the|and|IP|onset (r_prep) administration_21\NN|NONE (r_pobj) between_19\IN|the (r_prep) interval_18\NN|pretreatment|that|reduced (r_dobj) increased_16\VBD|Studies|. (l_conj) reduced_54\VBD|pretreatment|that|interval (l_dobj) incidence_56\NN|IP|)|( (l_prep) of_57\IN|the (l_pobj) seizures_59\NNS|NONE
D002110_D012640 CID caffeine_65\NN|NONE (r_pobj) of_64\IN|the (r_prep) presence_63\NN|NONE (r_pobj) in_61\IN|NONE (r_prep) produced_60\VBN|audiogenic (r_acl) seizures_59\NNS|NONE (r_pobj) of_57\IN|the (r_prep) incidence_56\NN|IP|)|( (r_dobj) reduced_54\VBD|pretreatment|that|interval (r_conj) increased_16\VBD|Studies|. (l_dobj) interval_18\NN|pretreatment|that|reduced (l_prep) between_19\IN|the (l_pobj) administration_21\NN|NONE (l_conj) onset_33\NN|the|and|of|IP (l_prep) of_34\IN|the|;|pretreatment|and|by (l_pobj) convulsions_36\NNS|NONE
D002110_D012640 CID caffeine_65\NN|NONE (r_pobj) of_64\IN|the (r_prep) presence_63\NN|NONE (r_pobj) in_61\IN|NONE (r_prep) produced_60\VBN|audiogenic (r_acl) seizures_59\NNS|NONE
D002110_D012640 CID caffeine_12\NN|NONE (r_pobj) after_7\IN|The|of (r_prep) frequency_1\NN|.|was|by|from (l_prep) of_2\IN|The|after (l_pobj) seizures_6\NNS|NONE
D002110_D012640 CID caffeine_4\NN|NONE (r_pobj) of_3\IN|the (r_prep) absence_2\NN|NONE (r_pobj) In_0\IN|seizures|acetaminophen|,|did|alter|and|.|not (r_prep) modify_15\VB|NONE (l_dobj) seizures_17\NNS|In|acetaminophen|,|did|alter|and|.|not
D002110_D064420 NONE caffeine_2\NN|NONE (r_compound) toxicity_3\NN|NONE
D002110_D064420 NONE caffeine_11\NN|NONE (r_pobj) of_10\IN|on|stimulatory|the (r_prep) effects_9\NNS|to (r_dobj) augment_6\VB|Because|have|salicylates|been (r_xcomp) reported_4\VBN|was|on|,|attention|. (r_advcl) focused_18\VBN|NONE (l_prep) on_19\IN|was|reported|,|attention|. (l_pobj) possibility_21\NN|NONE (l_acl) reduced_33\VBD|the (l_dobj) toxicity_36\NN|that|(|presence|micrograms
D002110_D064420 NONE caffeine_38\NN|NONE (r_pobj) of_37\IN|CNS|the (r_prep) toxicity_36\NN|that|(|presence|micrograms
D000082_D012640 NONE acetaminophen_11\NN|NONE (r_pobj) with_10\IN|:||) (r_prep) pretreatment_9\NN|that|reduced|interval (r_nsubj) increased_16\VBD|Studies|. (l_dobj) interval_18\NN|pretreatment|that|reduced (l_prep) between_19\IN|the (l_pobj) administration_21\NN|NONE (l_conj) onset_33\NN|the|and|of|IP (l_prep) of_34\IN|the|;|pretreatment|and|by (l_pobj) convulsions_36\NNS|NONE
D000082_D012640 NONE acetaminophen_11\NN|NONE (r_pobj) with_10\IN|:||) (r_prep) pretreatment_9\NN|that|reduced|interval (r_nsubj) increased_16\VBD|Studies|. (l_conj) reduced_54\VBD|pretreatment|that|interval (l_dobj) incidence_56\NN|IP|)|( (l_prep) of_57\IN|the (l_pobj) seizures_59\NNS|NONE
D000082_D012640 NONE acetaminophen_49\NN|NONE (r_pobj) with_48\IN|)| (r_prep) pretreatment_47\NN|the|;|of|and|by (r_conj) onset_33\NN|the|and|of|IP (l_prep) of_34\IN|the|;|pretreatment|and|by (l_pobj) convulsions_36\NNS|NONE
D000082_D012640 NONE acetaminophen_49\NN|NONE (r_pobj) with_48\IN|)| (r_prep) pretreatment_47\NN|the|;|of|and|by (r_conj) onset_33\NN|the|and|of|IP (r_conj) administration_21\NN|NONE (r_pobj) between_19\IN|the (r_prep) interval_18\NN|pretreatment|that|reduced (r_dobj) increased_16\VBD|Studies|. (l_conj) reduced_54\VBD|pretreatment|that|interval (l_dobj) incidence_56\NN|IP|)|( (l_prep) of_57\IN|the (l_pobj) seizures_59\NNS|NONE
D000082_D012640 NONE acetaminophen_21\NN|NONE (r_pobj) by_20\IN|frequency|.|was|from (r_agent) reduced_14\VBN|NONE (l_nsubjpass) frequency_1\NN|.|was|by|from (l_prep) of_2\IN|The|after (l_pobj) seizures_6\NNS|NONE
D000082_D012640 NONE acetaminophen_6\FW|seizures|In|,|did|alter|and|.|not (r_nsubj) modify_15\VB|NONE (l_dobj) seizures_17\NNS|In|acetaminophen|,|did|alter|and|.|not
16574712
D018817_D003072 CID MDMA_0\NN|polydrug (r_compound) users_2\NNS|.|impairments (r_nsubj) show_3\VBP|NONE (l_dobj) impairments_9\NNS|users|. (l_acl) coupled_10\VBN|central|specific|executive (l_prep) with_11\IN|NONE (l_pobj) processes_17\NNS|NONE
D018817_D008569 NONE MDMA_12\NNP|NONE (r_pobj) of_11\IN|NONE (r_prep) users_10\NNS|NONE (r_pobj) in_9\IN|In|.|been|have|deficits (r_prep) reported_8\VBN|NONE (l_nsubjpass) deficits_5\NNS|In|.|been|in|have
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\CD|(|ecstasy (r_intj) MDMA_12\NNP|NONE (r_pobj) of_11\IN|NONE (r_prep) users_10\NNS|NONE (r_pobj) in_9\IN|In|.|been|have|deficits (r_prep) reported_8\VBN|NONE (l_nsubjpass) deficits_5\NNS|In|.|been|in|have
D018817_D008569 NONE ecstasy_16\NN|(|,methylenedioxymethamphetamine (r_appos) MDMA_12\NNP|NONE (r_pobj) of_11\IN|NONE (r_prep) users_10\NNS|NONE (r_pobj) in_9\IN|In|.|been|have|deficits (r_prep) reported_8\VBN|NONE (l_nsubjpass) deficits_5\NNS|In|.|been|in|have
6773726
D005996_D003920 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|in|was|. (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|was|.|effect (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS|,||normal (l_amod) diabetic_19\JJ|without|subjects|and||,
D005996_D003920 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|in|was|. (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|was|.|effect (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS|,||normal (l_conj) subjects_28\NNS|diabetic|without|and||, (l_amod) diabetic_27\JJ|with|
D005996_D003920 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|in|the (r_prep) decrease_13\NN|and|in|the (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|.|occurred|,|similar (r_nsubj) were_20\VBD|NONE (l_acomp) similar_21\JJ|.|course|occurred|, (l_prep) in_22\IN|NONE (l_pobj) subjects_27\NNS|NONE (l_amod) normal_24\JJ|the|without (l_conj) diabetic_26\JJ|and
D005996_D003920 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|in|the (r_prep) decrease_13\NN|and|in|the (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|.|occurred|,|similar (r_nsubj) were_20\VBD|NONE (l_advcl) occurred_47\VBD|.|course|,|similar (l_prep) in_48\IN|whereas|increase (l_pobj) subjects_51\NNS|NONE (l_amod) diabetic_50\JJ|the|with
D005996_D009422 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|in|was|. (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|was|.|effect (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS|,||normal (l_prep) without_21\IN|diabetic|subjects|and||, (l_pobj) neuropathy_23\NN|NONE
D005996_D009422 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|in|was|. (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|was|.|effect (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS|,||normal (l_conj) subjects_28\NNS|diabetic|without|and||, (l_prep) with_29\IN|diabetic| (l_pobj) neuropathy_31\NN|NONE
D005996_D009422 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|in|the (r_prep) decrease_13\NN|and|in|the (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|.|occurred|,|similar (r_nsubj) were_20\VBD|NONE (l_acomp) similar_21\JJ|.|course|occurred|, (l_prep) in_22\IN|NONE (l_pobj) subjects_27\NNS|NONE (l_prep) without_28\IN|the|normal (l_pobj) neuropathy_30\NN|NONE
D005996_D009422 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|in|the (r_prep) decrease_13\NN|and|in|the (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|.|occurred|,|similar (r_nsubj) were_20\VBD|NONE (l_advcl) occurred_47\VBD|.|course|,|similar (l_prep) in_48\IN|whereas|increase (l_pobj) subjects_51\NNS|NONE (l_prep) with_52\IN|the|diabetic (l_pobj) neuropathy_54\NN|NONE
D005996_D007022 CID nitroglycerin_5\NN|NONE (r_pobj) by_4\IN|postural (r_prep) hypotension_3\NN|NONE
D005996_D003929 NONE nitroglycerin_5\NN|NONE (l_prep) in_6\IN|NONE (l_pobj) neuropathy_9\NN|NONE
15130900
D003520_D001749 CID cyclophosphamide_12\NN|NONE (r_pobj) to_11\IN|relation|and (r_prep) risks_8\NNS|Wegener|: (r_appos) granulomatosis_6\NN|NONE (r_pobj) in_3\IN|.|bladder|Urinary (r_prep) cancer_2\NN|NONE
D003520_D001749 CID cyclophosphamide_16\NN|NONE (r_pobj) to_15\IN|in|,|its (r_prep) relation_14\NN|To|and|,|characterise|and (r_conj) assess_3\VB|:|. (l_conj) characterise_5\VB|To|and|,|and|relation (l_dobj) risk_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cancer_10\NN|NONE
D003520_D001749 CID cyclophosphamide_18\NN|NONE (l_conj) cancer_21\NN|and
D003520_D001749 CID cyclophosphamide_12\NN|NONE (r_pobj) in_11\IN|every|OR||g|( (r_prep) increment_10\NN|NONE (r_pobj) for_6\IN|risk|. (r_prep) doubled_5\VBD|NONE (l_nsubj) risk_1\NN|for|. (l_prep) of_2\IN|The (l_pobj) cancer_4\NN|NONE
D003520_D001749 CID cyclophosphamide_9\NN|NONE (r_pobj) between_8\IN|and|response|risk|a (r_prep) relationship_7\NN|.|results (l_conj) risk_12\NN|and|between|response|a (l_prep) of_13\IN|the|,|risks (l_pobj) cancer_15\NN|NONE
D003520_D014890 NONE cyclophosphamide_12\NN|NONE (r_pobj) to_11\IN|relation|and (r_prep) risks_8\NNS|Wegener|: (r_appos) granulomatosis_6\NN|NONE
D003520_D014890 NONE cyclophosphamide_16\NN|NONE (r_pobj) to_15\IN|in|,|its (r_prep) relation_14\NN|To|and|,|characterise|and (l_prep) in_18\IN|,|to|its (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) granulomatosis_23\NN|NONE
D003520_D014890 NONE cyclophosphamide_9\NN|NONE (r_pobj) between_8\IN|and|response|risk|a (r_prep) relationship_7\NN|.|results (l_conj) risk_12\NN|and|between|response|a (l_conj) risks_19\NNS|the|,|of (l_conj) possibility_28\NN|high|,|cumulative|and|in (l_prep) of_29\IN|the (l_pobj) factors_31\NNS|NONE (l_acl) operating_32\VBG|risk (l_prep) before_34\IN|NONE (l_pobj) granulomatosis_37\NN|even
150790
D007538_D001523 NONE isoniazid_22\NN|NONE (r_pobj) of_21\IN|therapeutic|the (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|and|, (r_conj) irritability_12\NN|,
D011736_D002653 NONE pyridoxine_1\JJ| (r_advmod) dependent_3\JJ|behavioral|unmasked|.|A (r_amod) disorder_5\NN|NONE
D007538_D012893 NONE isoniazid_22\NN|NONE (r_pobj) of_21\IN|therapeutic|the (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|and|, (l_dobj) difficulties_16\NNS|after
D011736_D006948 NONE pyridoxine_3\NN|NONE (r_pobj) of_2\IN|Periodic (r_prep) withdrawal_1\NN|was|with|. (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|was|withdrawal|. (l_pobj) return_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) hyperkinesis_10\NN|NONE
D007538_D006948 CID isoniazid_22\NN|NONE (r_pobj) of_21\IN|therapeutic|the (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|and|, (r_conj) irritability_12\NN|, (r_conj) hyperkinesis_10\NN|NONE
D007538_D002653 CID isoniazid_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) unmasked_6\VBD|dependent|behavioral|.|A (r_acl) disorder_5\NN|NONE
D007538_D002653 CID isoniazid_22\NN|NONE (r_pobj) of_21\IN|therapeutic|the (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|and|, (r_conj) irritability_12\NN|, (r_conj) hyperkinesis_10\NN|NONE (r_pobj) with_9\IN|.|deterioration|,|girl (r_prep) had_5\VBD|NONE (l_dobj) deterioration_7\NN|.|,|girl|with
3719553
D011241_D004342 NONE prednisone_3\NNP|Oral|and (r_conj) diphenhydramine_1\NN|ineffective|in|. (r_nsubj) were_4\VBD|NONE (l_prep) in_6\IN|ineffective|diphenhydramine|. (l_pcomp) preventing_7\VBG|NONE (l_dobj) recurrence_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) reaction_13\NN|NONE
D005472_D007674 NONE 5-fluorouracil_11\CD|allergic|consisting|An (r_punct) reaction_2\NN|in|. (r_nsubj) occurred_12\VBD|NONE (l_prep) in_13\IN|.|reaction (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) carcinoma_18\NN|NONE (l_prep) of_19\IN|recurrent (l_pobj) cavity_22\NN|NONE (l_conj) cirrhosis_24\NN|the|oral|, (l_conj) function_32\NN|and|,
D005472_D005355 NONE 5-fluorouracil_11\CD|allergic|consisting|An (r_punct) reaction_2\NN|in|. (r_nsubj) occurred_12\VBD|NONE (l_prep) in_13\IN|.|reaction (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) carcinoma_18\NN|NONE (l_prep) of_19\IN|recurrent (l_pobj) cavity_22\NN|NONE (l_conj) cirrhosis_24\NN|the|oral|,
D005472_D000799 CID 5-fluorouracil_11\CD|allergic|consisting|An (r_punct) reaction_2\NN|in|. (l_acl) consisting_3\VBG|allergic|fluorouracil|An (l_prep) of_4\IN|NONE (l_pobj) edema_6\NN|angioneurotic
D005472_D009062 NONE 5-fluorouracil_11\CD|allergic|consisting|An (r_punct) reaction_2\NN|in|. (r_nsubj) occurred_12\VBD|NONE (l_prep) in_13\IN|.|reaction (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) carcinoma_18\NN|NONE (l_prep) of_19\IN|recurrent (l_pobj) cavity_22\NN|NONE
D005472_D004342 NONE 5-fluorouracil_3\CD|NONE (r_punct) infusion_4\NN|NONE (r_pobj) to_2\IN|Allergic|. (r_prep) reaction_1\NN|NONE
D005472_D004342 NONE 5-fluorouracil_11\CD|allergic|consisting|An (r_punct) reaction_2\NN|in|.
D002945_D005355 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|renal|impaired (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|the|oral|,
D002945_D009062 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|renal|impaired (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|the|oral|, (r_conj) cavity_22\NN|NONE
D002945_D004342 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|renal|impaired (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|the|oral|, (r_conj) cavity_22\NN|NONE (r_pobj) of_19\IN|recurrent (r_prep) carcinoma_18\NN|NONE (r_pobj) with_16\IN|a (r_prep) patient_15\NN|NONE (r_pobj) in_13\IN|.|reaction (r_prep) occurred_12\VBD|NONE (l_nsubj) reaction_2\NN|in|.
D002945_D000799 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|renal|impaired (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|the|oral|, (r_conj) cavity_22\NN|NONE (r_pobj) of_19\IN|recurrent (r_prep) carcinoma_18\NN|NONE (r_pobj) with_16\IN|a (r_prep) patient_15\NN|NONE (r_pobj) in_13\IN|.|reaction (r_prep) occurred_12\VBD|NONE (l_nsubj) reaction_2\NN|in|. (l_acl) consisting_3\VBG|allergic|fluorouracil|An (l_prep) of_4\IN|NONE (l_pobj) edema_6\NN|angioneurotic
D004155_D004342 NONE diphenhydramine_1\NN|ineffective|in|. (r_nsubj) were_4\VBD|NONE (l_prep) in_6\IN|ineffective|diphenhydramine|. (l_pcomp) preventing_7\VBG|NONE (l_dobj) recurrence_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) reaction_13\NN|NONE
D002945_D007674 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|renal|impaired (r_amod) function_32\NN|and|,
12090760
D015215_D000740 CID azidothymidine_9\RB| (r_advmod) induced_11\VBN|NONE (r_amod) anemia_12\NN|in|and
D015215_D000740 CID Azidothymidine_0\NNP|interleukin|.|anemia|be|can|and|by (r_nsubjpass) reversed_8\VBN|NONE (l_nsubjpass) anemia_3\NN|interleukin|.|be|Azidothymidine|can|and|by
D015215_D000740 CID AZT)-induced_2\VBN|in|( (r_compound) anemia_3\NN|interleukin|.|be|Azidothymidine|can|and|by
15120741
D010862_D012640 CID pilocarpine_5\NN|systemic (r_compound) injection_6\NN|identified|SE|,|Similar|,|but (r_nsubj) causes_7\VBZ|NONE (l_dobj) SE_11\NNP|identified|,|Similar|,|but|injection (l_conj) development_16\NN|status|(|and|epilepticus|) (l_prep) of_17\IN|the|eventual (l_pobj) seizures_19\NNS|NONE
D001640_D013226 NONE bicuculline_5\NN|Mg(+)free (r_pobj) In_0\IN|.|stimulation|,|,|conditions|in (r_prep) resulted_21\VBD|NONE (l_prep) in_22\IN|.|stimulation|,|,|conditions|In (l_pobj) spike_26\NN|NONE (l_relcl) experience_41\VB|a|single|in|population (l_dobj) SE_42\NNP|did|not|that
D008274_D013226 NONE Mg(2+)-free_1\JJ|bicuculline (r_pobj) In_0\IN|.|stimulation|,|,|conditions|in (r_prep) resulted_21\VBD|NONE (l_prep) in_22\IN|.|stimulation|,|,|conditions|In (l_pobj) spike_26\NN|NONE (l_relcl) experience_41\VB|a|single|in|population (l_dobj) SE_42\NNP|did|not|that
D010862_D013226 CID pilocarpine_5\NN|systemic (r_compound) injection_6\NN|identified|SE|,|Similar|,|but (r_nsubj) causes_7\VBZ|NONE (l_dobj) SE_11\NNP|identified|,|Similar|,|but|injection (l_nmod) epilepticus_9\NN|status|development|(|and|)
D010862_D013226 CID pilocarpine_5\NN|systemic (r_compound) injection_6\NN|identified|SE|,|Similar|,|but (r_nsubj) causes_7\VBZ|NONE (l_dobj) SE_11\NNP|identified|,|Similar|,|but|injection
D010862_D013226 CID pilocarpine_34\NN| (r_npadvmod) treated_36\VBN|NONE (r_amod) mice_37\NNS|and|control (r_conj) mice_32\NNS|NONE (r_pobj) from_30\IN|granule (r_prep) cells_29\NNS|NONE (r_pobj) in_27\IN|a|single|experience|population (r_prep) spike_26\NN|NONE (l_relcl) experience_41\VB|a|single|in|population (l_dobj) SE_42\NNP|did|not|that
D018698_D013226 NONE glutamate_37\NN|NONE (r_compound) receptor_38\NN|ionotropic (r_compound) antagonists_39\NNS|NONE (r_pobj) by_35\IN|were|which (r_agent) blocked_34\VBN|s|, (r_relcl) duration_30\NN|NONE (r_pobj) of_25\IN|repetitive (r_prep) afterdischarges_24\NNS|DC|negative|and (r_conj) shifts_21\NNS|NONE (r_pobj) by_18\IN|,|at|, (r_prep) followed_11\VBD|In|.|in|stimulation|, (r_advcl) resulted_6\VBD|NONE (l_prep) In_0\IN|.|in|stimulation|,|followed (l_pobj) survivors_2\NNS|NONE (l_compound) SE_1\NNP|NONE
D018698_D013226 NONE glutamate_1\NN|of|at|Focal (r_compound) photostimulation_2\NN|in|. (r_nsubj) resulted_15\VBD|NONE (l_prep) in_16\IN|photostimulation|. (l_pobj) responses_18\NNS|NONE (l_prep) of_19\IN|population (l_pobj) duration_24\NN|NONE (l_prep) in_25\IN|s|groups|but (l_pobj) slices_26\NNS|NONE (l_prep) from_27\IN|NONE (l_pobj) survivors_29\NNS|NONE (l_compound) SE_28\NNP|NONE
14765563
D011803_D003128 CID quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|in|that|may|status (r_nsubj) produce_9\VB|reports|. (l_dobj) status_18\NN|products|complications|in|that|may (l_conj) seizures_20\NNS|altered|,|mental|, (l_conj) coma_23\NN|and|,
D011803_D012640 CID quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|in|that|may|status (r_nsubj) produce_9\VB|reports|. (l_dobj) status_18\NN|products|complications|in|that|may (l_conj) seizures_20\NNS|altered|,|mental|,
D011803_D002493 NONE quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|in|that|may|status (r_nsubj) produce_9\VB|reports|. (l_dobj) complications_11\NNS|products|in|that|may|status
D011803_D020922 NONE quinine_23\NN|available|,|.|banned (r_nsubj) is_24\VBZ|NONE (l_advcl) banned_8\VBD|available|,|quinine|. (l_dobj) use_10\NN|due|Administration|Although (l_prep) for_11\IN|its (l_pobj) cramps_14\NNS|NONE
D011803_D003221 CID quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|in|that|may|status (r_nsubj) produce_9\VB|reports|. (l_dobj) complications_11\NNS|products|in|that|may|status (l_prep) including_13\VBG|,|,|neurological (l_pobj) confusion_14\NN|NONE
10835440
D009553_D007022 CID Nimodipine_2\NNP|Stroke|Intravenous|The|European|West|(|INWEST|) (r_compound) Trial_6\NN|.|correlation (r_nsubj) found_10\VBD|NONE (l_dobj) correlation_12\NN|.|Trial (l_prep) between_13\IN|a (l_pobj) reduction_17\NN|NONE (l_prep) in_18\IN|outcome|and|induced (l_pobj) pressure_20\NN|NONE
D009553_D007022 CID nimodipine_14\NN| (r_npadvmod) induced_16\VBN|outcome|and|in (r_amod) reduction_17\NN|NONE (l_prep) in_18\IN|outcome|and|induced (l_pobj) pressure_20\NN|NONE
D009553_D007022 CID Nimodipine_0\NNP|NONE (r_compound) treatment_1\NN|in|. (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|.|treatment (l_pobj) reduction_7\NN|NONE (l_prep) in_8\IN|significant|a (l_pobj) BP_10\NNP|NONE
D009553_D002544 NONE nimodipine_34\NN|mg|/| (r_parataxis) h_28\NN|to|placebo|, (r_appos) receive_19\VB|METHODS|consecutively|.|were (r_advcl) allocated_17\VBN|NONE (l_nsubjpass) METHODS_0\NNS|consecutively|receive|.|were (l_appos) Patients_2\NNS|: (l_prep) with_3\IN|(|within|) (l_pobj) diagnosis_6\NN|NONE (l_prep) of_7\IN|clinical|a (l_pobj) stroke_9\NN|NONE
D009553_D002544 NONE nimodipine_49\NN|(|dose|n=|)|or (r_conj) nimodipine_34\NN|mg|/| (r_parataxis) h_28\NN|to|placebo|, (r_appos) receive_19\VB|METHODS|consecutively|.|were (r_advcl) allocated_17\VBN|NONE (l_nsubjpass) METHODS_0\NNS|consecutively|receive|.|were (l_appos) Patients_2\NNS|: (l_prep) with_3\IN|(|within|) (l_pobj) diagnosis_6\NN|NONE (l_prep) of_7\IN|clinical|a (l_pobj) stroke_9\NN|NONE
D009553_D020521 NONE nimodipine_3\NN|NONE (r_pobj) of_1\IN|after|. (r_prep) Effect_0\NN|NONE (l_prep) after_9\IN|.|of (l_pobj) stroke_11\NN|NONE
D009553_D020521 NONE Nimodipine_2\NNP|Stroke|Intravenous|The|European|West|(|INWEST|) (r_compound) Trial_6\NN|.|correlation (l_compound) Stroke_5\NNP|Intravenous|The|European|Nimodipine|West|(|INWEST|)
D009553_D020521 NONE Nimodipine_2\NNP|Stroke|Intravenous|The|European|West|(|INWEST|) (r_compound) Trial_6\NN|.|correlation (r_nsubj) found_10\VBD|NONE (l_dobj) correlation_12\NN|.|Trial (l_prep) between_13\IN|a (l_pobj) reduction_17\NN|NONE (l_conj) outcome_27\NN|and|induced|in (l_prep) in_28\IN|unfavorable|an (l_pobj) stroke_30\NN|NONE
D009553_D020521 NONE nimodipine_14\NN| (r_npadvmod) induced_16\VBN|outcome|and|in (r_amod) reduction_17\NN|NONE (r_pobj) between_13\IN|a (r_prep) correlation_12\NN|.|Trial (r_dobj) found_10\VBD|NONE (l_nsubj) Trial_6\NN|.|correlation (l_compound) Stroke_5\NNP|Intravenous|The|European|Nimodipine|West|(|INWEST|)
D009553_D020521 NONE nimodipine_14\NN| (r_npadvmod) induced_16\VBN|outcome|and|in (r_amod) reduction_17\NN|NONE (l_conj) outcome_27\NN|and|induced|in (l_prep) in_28\IN|unfavorable|an (l_pobj) stroke_30\NN|NONE
D009553_D020521 NONE nimodipine_15\NN|NONE (r_pobj) of_11\IN|the|intravenous (r_prep) administration_10\NN|NONE (r_pobj) after_7\IN|neurological|after (r_prep) worsening_6\VBG|NONE (l_prep) after_16\IN|neurological|after (l_pobj) stroke_18\NN|NONE
18464113
D006514_D006509 CID antigen_14\NN|undergoing|(|)|HBSAG|seropositive|cancer (r_nmod) patients_20\NNS|NONE (r_pobj) in_9\IN|virus (r_prep) reactivation_8\NN|NONE (l_compound) virus_7\NN|in (l_compound) B_6\NNP|NONE
D006514_D006509 CID HBSAG_16\NNP|antigen|undergoing|(|)|seropositive|cancer (r_nmod) patients_20\NNS|NONE (r_pobj) in_9\IN|virus (r_prep) reactivation_8\NN|NONE (l_compound) virus_7\NN|in (l_compound) B_6\NNP|NONE
D019259_D056486 NONE lamivudine_3\NN|the|prophylactic (r_compound) group_4\NN|NONE (r_pobj) In_0\IN|.|patient|were|hepatitis (r_prep) observed_8\VBN|NONE (l_nsubjpass) hepatitis_6\NN|.|In|patient|were
D006514_D009369 NONE antigen_14\NN|undergoing|(|)|HBSAG|seropositive|cancer (r_nmod) patients_20\NNS|NONE (l_compound) cancer_19\NN|antigen|undergoing|(|)|HBSAG|seropositive
D006514_D009369 NONE HBSAG_16\NNP|antigen|undergoing|(|)|seropositive|cancer (r_nmod) patients_20\NNS|NONE (l_compound) cancer_19\NN|antigen|undergoing|(|)|HBSAG|seropositive
D019259_D006509 NONE Lamivudine_0\NNP|NONE (l_prep) for_1\IN|. (l_pobj) prevention_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reactivation_8\NN|NONE (l_compound) virus_7\NN|in (l_compound) B_6\NNP|NONE
D019259_D006509 NONE lamivudine_20\NN|prior|,|.|compared|In|patients (r_dobj) received_16\VBD|NONE (l_nsubj) patients_5\NNS|prior|,|.|compared|In|lamivudine (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who (l_prep) with_12\IN|solid (l_pobj) infection_15\NN|NONE
D019259_D006509 NONE lamivudine_34\NN|who|not|did (r_dobj) receive_33\VB|historical|control (r_relcl) group_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) compared_25\VBN|prior|,|.|In|patients|lamivudine (r_prep) received_16\VBD|NONE (l_nsubj) patients_5\NNS|prior|,|.|compared|In|lamivudine (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who (l_prep) with_12\IN|solid (l_pobj) infection_15\NN|NONE
D019259_D019337 NONE lamivudine_20\NN|prior|,|.|compared|In|patients (r_dobj) received_16\VBD|NONE (l_nsubj) patients_5\NNS|prior|,|.|compared|In|lamivudine (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who
D019259_D019337 NONE lamivudine_34\NN|who|not|did (r_dobj) receive_33\VB|historical|control (r_relcl) group_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) compared_25\VBN|prior|,|.|In|patients|lamivudine (r_prep) received_16\VBD|NONE (l_nsubj) patients_5\NNS|prior|,|.|compared|In|lamivudine (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who
D019259_D009369 NONE Lamivudine_0\NNP|NONE (l_prep) for_1\IN|. (l_pobj) prevention_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reactivation_8\NN|NONE (l_prep) in_9\IN|virus (l_pobj) patients_20\NNS|NONE (l_compound) cancer_19\NN|antigen|undergoing|(|)|HBSAG|seropositive
D019259_D009369 NONE lamivudine_20\NN|prior|,|.|compared|In|patients (r_dobj) received_16\VBD|NONE (l_nsubj) patients_5\NNS|prior|,|.|compared|In|lamivudine (l_compound) cancer_4\NN|have
D019259_D009369 NONE lamivudine_34\NN|who|not|did (r_dobj) receive_33\VB|historical|control (r_relcl) group_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) compared_25\VBN|prior|,|.|In|patients|lamivudine (r_prep) received_16\VBD|NONE (l_nsubj) patients_5\NNS|prior|,|.|compared|In|lamivudine (l_compound) cancer_4\NN|have
D019259_D009369 NONE lamivudine_5\NN|significantly|incidence|during|that (r_nsubj) decreases_7\VBZ|study|. (l_dobj) incidence_9\NN|lamivudine|significantly|during|that (l_prep) of_10\IN|the (l_pobj) reactivation_12\NN|NONE (l_conj) morbidity_15\NN|HBV|and (l_prep) in_16\IN|overall (l_pobj) patients_18\NNS|NONE (l_compound) cancer_17\NN|NONE
2924746
D005481_D015430 NONE HFDE_21\NNP| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE (r_pobj) against_20\IN|continuously (r_prep) protective_19\JJ|and|administration|.|was (r_acomp) was_17\VBD|NONE (l_conj) was_26\VBD|and|protective|administration|. (l_advcl) measured_30\VBN|toxic (l_agent) by_31\IN|over|as (l_pobj) gain_33\NN|NONE
D005481_D012640 CID ether_4\NN|NONE (r_pobj) by_2\IN|found|Seizures|. (r_prep) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|found|by|.
D005481_D012640 CID ether_4\NN|NONE (r_pobj) by_2\IN|found|Seizures|. (r_prep) induced_1\VBN|NONE (l_conj) found_10\VBN|by|Seizures|. (l_xcomp) be_12\VB|were|also (l_prep) than_21\IN|to|measure (l_pobj) seizures_22\NNS|NONE
D005481_D012640 CID HFDE_6\NNP|hexafluorodiethyl (r_appos) ether_4\NN|NONE (r_pobj) by_2\IN|found|Seizures|. (r_prep) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|found|by|.
D005481_D012640 CID HFDE_6\NNP|hexafluorodiethyl (r_appos) ether_4\NN|NONE (r_pobj) by_2\IN|found|Seizures|. (r_prep) induced_1\VBN|NONE (l_conj) found_10\VBN|by|Seizures|. (l_xcomp) be_12\VB|were|also (l_prep) than_21\IN|to|measure (l_pobj) seizures_22\NNS|NONE
D005481_D012640 CID HFDE_21\NNP| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE
D002220_D015430 NONE CBZ_3\NNP|NONE (r_pobj) of_2\IN|Oral|as|h (r_prep) administration_1\NN|and|protective|.|was (r_nsubj) was_17\VBD|NONE (l_conj) was_26\VBD|and|protective|administration|. (l_advcl) measured_30\VBN|toxic (l_agent) by_31\IN|over|as (l_pobj) gain_33\NN|NONE
D002220_D012640 NONE CBZ_20\NN|NONE (r_pobj) by_19\IN|NONE (r_prep) protection_18\NN|NONE (r_pobj) of_17\IN|a|sensitive (r_prep) measure_16\NN|to|than (r_attr) be_12\VB|were|also (r_xcomp) found_10\VBN|by|Seizures|. (r_conj) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|found|by|.
D002220_D012640 NONE CBZ_20\NN|NONE (r_pobj) by_19\IN|NONE (r_prep) protection_18\NN|NONE (r_pobj) of_17\IN|a|sensitive (r_prep) measure_16\NN|to|than (r_attr) be_12\VB|were|also (l_prep) than_21\IN|to|measure (l_pobj) seizures_22\NNS|NONE
D002220_D012640 NONE CBZ_3\NNP|NONE (r_pobj) of_2\IN|Oral|as|h (r_prep) administration_1\NN|and|protective|.|was (r_nsubj) was_17\VBD|NONE (l_acomp) protective_19\JJ|and|administration|.|was (l_prep) against_20\IN|continuously (l_pobj) seizures_24\NNS|NONE
D005492_D064420 NONE folate_17\JJ|tissue (r_compound) concentrations_18\NNS|and (r_conj) plasma_14\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) effect_12\NN|and|, (r_conj) toxicity_9\NN|,
D019946_D015430 NONE glycol_13\NN|common|,|a (r_appos) vehicle_10\NN|In|,|.|by|exhibit|was|,|, (r_nsubjpass) found_22\VBN|NONE (l_xcomp) exhibit_24\VB|In|,|vehicle|.|by|was|,|, (l_dobj) properties_26\NNS|to (l_prep) against_27\IN|protective (l_pobj) seizures_29\NNS|NONE (l_conj) gain_33\NN|and|induced
D019946_D012640 NONE glycol_13\NN|common|,|a (r_appos) vehicle_10\NN|In|,|.|by|exhibit|was|,|, (r_nsubjpass) found_22\VBN|NONE (l_xcomp) exhibit_24\VB|In|,|vehicle|.|by|was|,|, (l_dobj) properties_26\NNS|to (l_prep) against_27\IN|protective (l_pobj) seizures_29\NNS|NONE
D002220_D064420 NONE carbamazepine_1\NN|.|efficacy|:|in (r_compound) treatment_2\NN|NONE (l_appos) efficacy_7\NN|.|:|in|carbamazepine (l_conj) toxicity_9\NN|,
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NNP|NONE (r_dobj) bolus_9\NN|)|A|study (r_appos) Phase_1\NN|in|was|. (r_nsubjpass) done_15\VBN|NONE (l_prep) in_16\IN|was|Phase|. (l_pobj) patients_18\NNS|NONE (l_prep) in_19\IN| (l_pobj) status_22\NN|NONE (l_prep) with_23\IN|good|performance (l_pobj) tumors_25\NNS|NONE
C027260_D009369 NONE Pirarubicin_12\NNP|NONE (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NNP|NONE (r_dobj) bolus_9\NN|)|A|study (r_appos) Phase_1\NN|in|was|. (r_nsubjpass) done_15\VBN|NONE (l_prep) in_16\IN|was|Phase|. (l_pobj) patients_18\NNS|NONE (l_prep) in_19\IN| (l_pobj) status_22\NN|NONE (l_prep) with_23\IN|good|performance (l_pobj) tumors_25\NNS|NONE
10721819
D004294_D001919 CID domperidone_26\NN|NONE (r_pobj) by_24\IN|partly|that|was (r_agent) reduced_23\VBN|)|mg/kg|an (r_relcl) effect_19\NN|while|was|to|,|tachycardia (r_npadvmod) reversed_13\VBN|hypotension|,|.|unaffected (l_prep) to_14\IN|while|was|effect|,|tachycardia (l_pobj) bradycardia_16\NNS|NONE
D001971_D007022 CID bromocriptine_5\NN|In|.|,|hypotension (r_nsubj) induced_12\VBD|NONE (l_dobj) hypotension_14\NN|In|bromocriptine|.|,
D001971_D007022 CID Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|,|reversed|.|unaffected
D007545_D007022 NONE isoproterenol_7\JJ|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) by_6\IN|NONE (r_prep) unaffected_5\JJ|hypotension|,|reversed|. (r_acomp) was_4\VBD|NONE (l_nsubj) hypotension_3\NN|,|reversed|.|unaffected
D004298_D013610 NONE dopamine_27\NN|NONE (r_compound) D2_28\NN|peripheral (r_compound) receptors_29\NNS|NONE (r_pobj) at_25\IN|the|of (r_prep) bradycardia_21\NN|to (r_dobj) mask_19\VB|and|to (r_conj) predominate_16\VB|,|,|tachycardia|in|that (r_xcomp) appears_14\VBZ|They|. (l_nsubj) tachycardia_11\NN|,|,|predominate|in|that
D007545_D006332 CID Isoproterenol_0\JJ|for (r_compound) pretreatment_1\NN|.|without|hypertrophy (r_nsubj) caused_5\VBD|NONE (l_dobj) hypertrophy_7\NN|.|pretreatment|without
D007545_D001919 CID isoproterenol_7\JJ|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) by_6\IN|NONE (r_prep) unaffected_5\JJ|hypotension|,|reversed|. (r_acomp) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_prep) to_14\IN|while|was|effect|,|tachycardia (l_pobj) bradycardia_16\NNS|NONE
D007545_D001919 CID isoproterenol_5\JJ|day (r_compound) pretreatment_6\NN|reversed|not|that|but (r_nsubj) abolished_9\VBD|results|. (l_conj) reversed_11\VBD|pretreatment|not|that|but (l_prep) to_16\IN|tachycardia|effect|, (l_pobj) bradycardia_17\NNP|NONE
D001971_D013610 CID bromocriptine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) tachycardia_12\NN|NONE
D001971_D013610 CID bromocriptine_5\NN| (r_npadvmod) induced_7\VBN|persisted|,|, (r_amod) tachycardia_8\NN|that
D001971_D013610 CID bromocriptine_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) tachycardia_16\NN|in|whether|could|pretreatment
D001971_D013610 CID bromocriptine_5\NN|In|.|,|hypotension (r_nsubj) induced_12\VBD|NONE (l_dobj) hypotension_14\NN|In|bromocriptine|.|, (l_conj) tachycardia_16\NN|significant|and
D001971_D013610 CID Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|,|reversed|.|unaffected (r_nsubj) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_nsubjpass) tachycardia_11\NN|while|was|to|effect|,
D001971_D013610 CID bromocriptine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) tachycardia_15\NN|effect|to|,
D001971_D013610 CID bromocriptine_13\NN|NONE (r_pobj) of_12\IN|central|the (r_prep) tachycardia_11\NN|,|,|predominate|in|that
D001971_D001919 NONE Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|,|reversed|.|unaffected (r_nsubj) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_prep) to_14\IN|while|was|effect|,|tachycardia (l_pobj) bradycardia_16\NNS|NONE
D001971_D001919 NONE bromocriptine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) tachycardia_15\NN|effect|to|, (r_dobj) reversed_11\VBD|pretreatment|not|that|but (l_prep) to_16\IN|tachycardia|effect|, (l_pobj) bradycardia_17\NNP|NONE
D001971_D001919 NONE bromocriptine_13\NN|NONE (r_pobj) of_12\IN|central|the (r_prep) tachycardia_11\NN|,|,|predominate|in|that (r_nsubj) appears_14\VBZ|They|. (l_xcomp) predominate_16\VB|,|,|tachycardia|in|that (l_conj) mask_19\VB|and|to (l_dobj) bradycardia_21\NN|to
D004294_D007022 NONE domperidone_26\NN|NONE (r_pobj) by_24\IN|partly|that|was (r_agent) reduced_23\VBN|)|mg/kg|an (r_relcl) effect_19\NN|while|was|to|,|tachycardia (r_npadvmod) reversed_13\VBN|hypotension|,|.|unaffected (r_advcl) was_4\VBD|NONE (l_nsubj) hypotension_3\NN|,|reversed|.|unaffected
D004298_D001919 NONE dopamine_27\NN|NONE (r_compound) D2_28\NN|peripheral (r_compound) receptors_29\NNS|NONE (r_pobj) at_25\IN|the|of (r_prep) bradycardia_21\NN|to
D007545_D013610 NONE isoproterenol_7\NN|NONE (l_prep) on_8\IN|NONE (l_pobj) tachycardia_12\NN|NONE
D007545_D013610 NONE isoproterenol_10\NN|NONE (r_pobj) with_9\IN|prolonged (r_prep) pretreatment_8\NN|in|whether|could|tachycardia (r_nsubj) abolish_12\VB|to (l_dobj) tachycardia_16\NN|in|whether|could|pretreatment
D007545_D013610 NONE isoproterenol_7\JJ|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) by_6\IN|NONE (r_prep) unaffected_5\JJ|hypotension|,|reversed|. (r_acomp) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_nsubjpass) tachycardia_11\NN|while|was|to|effect|,
D007545_D013610 NONE isoproterenol_5\JJ|day (r_compound) pretreatment_6\NN|reversed|not|that|but (r_nsubj) abolished_9\VBD|results|. (l_conj) reversed_11\VBD|pretreatment|not|that|but (l_dobj) tachycardia_15\NN|effect|to|,
D004294_D013610 NONE domperidone_26\NN|NONE (r_pobj) by_24\IN|partly|that|was (r_agent) reduced_23\VBN|)|mg/kg|an (r_relcl) effect_19\NN|while|was|to|,|tachycardia (r_npadvmod) reversed_13\VBN|hypotension|,|.|unaffected (l_nsubjpass) tachycardia_11\NN|while|was|to|effect|,
18754075
D019386_D005923 NONE alendronate_10\JJ|in|bisphosphonate (r_nmod) administration_12\NN|NONE (l_prep) in_13\IN|bisphosphonate|alendronate (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) glomerulosclerosis_19\NN|NONE
D019386_D011507 CID alendronate_10\JJ|in|bisphosphonate (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|Massive|.|and|failure (r_prep) proteinuria_1\NN|NONE
D013256_D009404 NONE steroid_19\NN|NONE (r_compound) therapy_20\NN|NONE (r_pobj) to_18\IN|man|well|.|initially|was (r_prep) responding_16\VBG|NONE (l_nsubj) man_5\NN|well|.|initially|to|was (l_prep) with_6\IN|due|old|Japanese|A (l_pobj) syndrome_8\NN|NONE
D004164_D011507 NONE bisphosphonate_8\NN|in|alendronate (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|Massive|.|and|failure (r_prep) proteinuria_1\NN|NONE
D004164_D011507 NONE bisphosphonates_11\NNS|intravenous|can|that|proteinuria (r_nsubj) aggravate_13\VB|report|. (l_dobj) proteinuria_14\NN|intravenous|can|that|bisphosphonates
D019386_D058186 CID alendronate_10\JJ|in|bisphosphonate (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|Massive|.|and|failure (r_prep) proteinuria_1\NN|NONE (l_conj) failure_5\NN|Massive|.|and|after
D019386_D058186 CID sodium_9\NN|, (r_nmod) administration_11\NN|amount|Within|with|.|rapidly|up (r_nsubj) increased_19\VBD|NONE (l_prep) with_25\IN|amount|Within|.|administration|rapidly|up (l_pobj) failure_28\NN|NONE
D004164_D058186 NONE bisphosphonate_8\NN|in|alendronate (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|Massive|.|and|failure (r_prep) proteinuria_1\NN|NONE (l_conj) failure_5\NN|Massive|.|and|after
D004164_D058186 NONE bisphosphonate_6\NN|NONE (r_pobj) of_3\IN| (r_prep) days_2\NNS|NONE (r_pobj) Within_0\IN|amount|with|.|administration|rapidly|up (r_prep) increased_19\VBD|NONE (l_prep) with_25\IN|amount|Within|.|administration|rapidly|up (l_pobj) failure_28\NN|NONE
D004164_D058186 NONE bisphosphonates_11\NNS|intravenous|can|that|proteinuria (r_nsubj) aggravate_13\VB|report|. (l_dobj) proteinuria_14\NN|intravenous|can|that|bisphosphonates (l_conj) failure_18\NN|and
D013256_D005923 NONE steroid_19\NN|NONE (r_compound) therapy_20\NN|NONE (r_pobj) to_18\IN|man|well|.|initially|was (r_prep) responding_16\VBG|NONE (l_nsubj) man_5\NN|well|.|initially|to|was (l_amod) due_9\IN|old|with|Japanese|A (l_pobj) glomerulosclerosis_13\NN|to
D004164_D005923 NONE bisphosphonate_8\NN|in|alendronate (r_nmod) administration_12\NN|NONE (l_prep) in_13\IN|bisphosphonate|alendronate (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) glomerulosclerosis_19\NN|NONE
6747681
D002330_D005910 NONE BCNU_3\NNP|arterial|for|. (r_compound) chemotherapy_4\NN|NONE (l_prep) for_5\IN|BCNU|arterial|. (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) gliomas_9\NNS|NONE
D002330_D005910 NONE BCNU_7\NNP|(|) (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN|NONE (r_pobj) of_6\IN|systemic|the|rapid (r_prep) clearance_5\NN|of (r_pobj) Because_0\IN|should|advantage|,|administration|. (r_prep) provide_17\VB|NONE (l_dobj) advantage_20\NN|Because|should|,|administration|. (l_prep) over_21\IN|a|substantial (l_pobj) administration_23\NN|NONE (l_prep) for_24\IN|intravenous (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) gliomas_29\NNS|NONE
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN|NONE (r_pobj) of_6\IN|systemic|the|rapid (r_prep) clearance_5\NN|of (r_pobj) Because_0\IN|should|advantage|,|administration|. (r_prep) provide_17\VB|NONE (l_dobj) advantage_20\NN|Because|should|,|administration|. (l_prep) over_21\IN|a|substantial (l_pobj) administration_23\NN|NONE (l_prep) for_24\IN|intravenous (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) gliomas_29\NNS|NONE
D000431_D014786 NONE ethanol_11\NN|the (r_compound) diluent_12\NN|NONE (r_pobj) of_9\IN|the (r_prep) concentration_8\NN|was|after (r_nsubjpass) lowered_14\VBN|frequency|. (r_advcl) decreased_5\VBD|NONE (l_nsubj) frequency_1\NN|.|lowered (l_prep) of_2\IN|The (l_pobj) loss_4\NN|NONE
D002330_D001254 NONE BCNU_29\NNP|arterial (r_compound) therapy_30\NN|NONE (r_pobj) of_25\IN|eight (r_prep) courses_24\NNS|.|patients (r_dobj) received_20\VBD|NONE (l_nsubj) patients_3\NNS|.|courses (l_prep) to_8\IN|four|with (l_pobj) astrocytomas_10\NN|NONE
2522601
D002220_D051437 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|.|presenting (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|.|to (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE (l_conj) failure_15\NN|leukemoid|a|eosinophilia|,
D002220_D051437 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|with|in (r_nsubj) presented_9\VBN|a|,|reaction (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|presented|a|, (l_conj) eosinophilia_19\NN|severe|a|,|leukemoid (l_conj) hyponatremia_21\NN|, (l_conj) failure_25\NN|and|,
D002220_D004802 NONE carbamazepine_2\NN|NONE (r_pobj) to_1\IN|.|presenting (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|.|to (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE (l_conj) eosinophilia_9\NN|leukemoid|a|,|failure
D002220_D004802 NONE carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|with|in (r_nsubj) presented_9\VBN|a|,|reaction (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|presented|a|, (l_conj) eosinophilia_19\NN|severe|a|,|leukemoid
D002220_D004342 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|.|presenting (r_prep) Hypersensitivity_0\NN|NONE
D002220_D004342 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|with|in
D002220_D007955 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|.|presenting (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|.|to (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE
D002220_D007955 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|with|in (r_nsubj) presented_9\VBN|a|,|reaction (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|presented|a|,
D002220_D007010 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|with|in (r_nsubj) presented_9\VBN|a|,|reaction (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|presented|a|, (l_conj) eosinophilia_19\NN|severe|a|,|leukemoid (l_conj) hyponatremia_21\NN|,
D002220_D003873 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|.|presenting (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|.|to (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE (l_conj) eosinophilia_9\NN|leukemoid|a|,|failure (l_conj) erythroderma_11\NN|,
D002220_D003873 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|with|in (r_nsubj) presented_9\VBN|a|,|reaction (l_prep) with_10\IN|in|hypersensitivity (l_pobj) erythroderma_12\NN|NONE
11426838
C050232_D064420 NONE tolylguanidine_22\NN|BD|agonist|)|and|the (r_nmod) DTG_24\NNP|the|putative|, (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|toxicity|.|each (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
C050232_D064420 NONE DTG_24\NNP|the|putative|, (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|toxicity|.|each (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
D003042_D064420 NONE cocaine_42\NN|NONE (r_pobj) of_41\IN|the|behavioral (r_prep) toxicity_40\NN|In|.|each
C093337_D012640 NONE BD1063_12\NNP|, (r_conj) BD1018_10\NN|NONE (r_pobj) with_9\IN|significantly|treatment (r_punct) attenuated_17\VBD|and|lethality|induced (r_amod) convulsions_21\NNS|studies|.
D009838_D012640 NONE oligodeoxynucleotide_23\NN|sigma|, (r_appos) receptors_19\NNS|NONE (r_pobj) of_17\IN|NONE (r_prep) antagonism_16\NN|NONE (r_dobj) involved_15\VBD|novel|the (r_acl) ligands_14\NNS|NONE (r_pobj) of_11\IN|the|cocaine (r_prep) effects_10\NNS|also|attenuate|was|that (r_nsubjpass) shown_29\VBN|the (l_xcomp) attenuate_32\VB|also|was|that|effects (l_dobj) effects_38\NNS|significantly|to (l_amod) convulsive_34\JJ|stimulatory|of|the
-1_D012640 NONE BD1018_10\NN|NONE (r_pobj) with_9\IN|significantly|treatment (r_punct) attenuated_17\VBD|and|lethality|induced (r_amod) convulsions_21\NNS|studies|.
-1_D012640 NONE LR132_15\NNS|,|or (r_conj) BD1063_12\NNP|, (r_conj) BD1018_10\NN|NONE (r_pobj) with_9\IN|significantly|treatment (r_punct) attenuated_17\VBD|and|lethality|induced (r_amod) convulsions_21\NNS|studies|.
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|and|lethality|attenuated (r_amod) convulsions_21\NNS|studies|.
D003042_D012640 CID cocaine_9\NN|the|of (r_compound) effects_10\NNS|also|attenuate|was|that (r_nsubjpass) shown_29\VBN|the (l_xcomp) attenuate_32\VB|also|was|that|effects (l_dobj) effects_38\NNS|significantly|to (l_amod) convulsive_34\JJ|stimulatory|of|the
D003042_D012640 CID cocaine_40\NN|NONE (r_pobj) of_39\IN|stimulatory|convulsive|the (r_prep) effects_38\NNS|significantly|to (l_amod) convulsive_34\JJ|stimulatory|of|the
-1_D064420 NONE BD1031_32\NN|agonist|)|and|the|tolylguanidine (r_conj) DTG_24\NNP|the|putative|, (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|toxicity|.|each (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
-1_D064420 NONE 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_34\NN|agonist|novel|the (r_appos) BD1031_32\NN|agonist|)|and|the|tolylguanidine (r_conj) DTG_24\NNP|the|putative|, (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|toxicity|.|each (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
19957053
D004809_D002534 NONE ephedrine_3\JJ|but (r_conj) Phenylephrine_0\NNP|oxygenation|. (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|.
D004809_D007022 NONE ephedrine_3\JJ|but (r_conj) Phenylephrine_0\NNP|oxygenation|. (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|. (l_prep) following_8\VBG|frontal|lobe (l_dobj) hypotension_12\NN|NONE
D004809_D007022 NONE ephedrine_7\JJ|and (r_conj) phenylephrine_5\NN|NONE (r_pobj) of_4\IN|the|on (r_prep) effect_3\NN|.|We|following (r_dobj) describe_1\VBP|NONE (l_prep) following_16\VBG|.|We|effect (l_dobj) hypotension_20\NN|NONE
D004809_D007022 NONE ephedrine_18\JJ|oxygenation|while (r_nsubj) maintains_19\VBZ|)|utilization|impact|. (r_advcl) has_10\VBZ|NONE (l_nsubj) utilization_1\NN|)|maintains|impact|. (l_acl) correct_5\VB|of|The (l_dobj) hypotension_6\NN|to
D010656_D007022 NONE Phenylephrine_0\NNP|oxygenation|. (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|. (l_prep) following_8\VBG|frontal|lobe (l_dobj) hypotension_12\NN|NONE
D010656_D007022 NONE phenylephrine_5\NN|NONE (r_pobj) of_4\IN|the|on (r_prep) effect_3\NN|.|We|following (r_dobj) describe_1\VBP|NONE (l_prep) following_16\VBG|.|We|effect (l_dobj) hypotension_20\NN|NONE
D010656_D007022 NONE phenylephrine_3\NN|NONE (r_pobj) of_2\IN|correct|The (r_prep) utilization_1\NN|)|maintains|impact|. (l_acl) correct_5\VB|of|The (l_dobj) hypotension_6\NN|to
D010656_D002534 CID Phenylephrine_0\NNP|oxygenation|. (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|.
12684739
D004298_D019966 NONE dopamine_47\NN|( (r_appos) accumbens_43\NNS|we|effects|.|Given|, (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
D004298_D019966 NONE DA_49\NNP|NAcc|)|)|( (r_appos) dopamine_47\NN|( (r_appos) accumbens_43\NNS|we|effects|.|Given|, (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
D003042_D005128 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|in (r_amod) increases_40\NNS|NONE (r_pobj) on_36\IN|chronic|dose (r_prep) GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|we|.|Given|accumbens|, (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D003042_D005128 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|in (r_amod) increases_40\NNS|NONE (r_pobj) on_36\IN|chronic|dose (r_prep) GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|we|.|Given|accumbens|, (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|field|associated
D004298_D005128 NONE dopamine_47\NN|( (r_appos) accumbens_43\NNS|we|effects|.|Given|, (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D004298_D005128 NONE dopamine_47\NN|( (r_appos) accumbens_43\NNS|we|effects|.|Given|, (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|field|associated
D004298_D005128 NONE DA_49\NNP|NAcc|)|)|( (r_appos) dopamine_47\NN|( (r_appos) accumbens_43\NNS|we|effects|.|Given|, (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D004298_D005128 NONE DA_49\NNP|NAcc|)|)|( (r_appos) dopamine_47\NN|( (r_appos) accumbens_43\NNS|we|effects|.|Given|, (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|field|associated
D020888_D005128 CID GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|we|.|Given|accumbens|, (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D020888_D005128 CID GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|we|.|Given|accumbens|, (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|and|substance (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|field|associated
D020888_D019966 NONE GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|we|.|Given|accumbens|, (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
D003042_D019966 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|in (r_amod) increases_40\NNS|NONE (r_pobj) on_36\IN|chronic|dose (r_prep) GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|we|.|Given|accumbens|, (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|effects|.|accumbens|, (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
17919553
C106791_D064420 NONE telithromycin_15\NNS|cause|Based|,|and|,|suggested (r_nsubj) was_16\VBD|NONE (l_prep) Based_0\VBN|cause|,|and|telithromycin|,|suggested (l_prep) on_1\IN|NONE (l_pobj) score_3\NN|NONE (l_prep) on_6\IN|a|of (l_pobj) scale_13\NN|NONE (l_compound) probability_12\NN|the (l_compound) reaction_11\NN|NONE
C106791_D056486 CID telithromycin_6\NNS|NONE (r_relcl) exposure_4\NN|NONE (r_pobj) after_3\IN|.|hepatitis|Acute (r_prep) attack_2\NN|NONE (l_compound) hepatitis_1\NNP|.|after|Acute
C106791_D056486 CID telithromycin_19\NNS|NONE (r_compound) usage_20\NN|NONE (r_pobj) after_18\IN|that|,|"|.|suffered (r_prep) occurred_17\VBD|NONE (l_ccomp) suffered_3\VBN|that|,|"|after|. (l_dobj) episode_6\NN|patient|had (l_prep) of_7\IN|a|previous (l_pobj) hepatitis_10\NN|NONE
C106791_D056486 CID telithromycin_15\NNS|cause|Based|,|and|,|suggested (r_nsubj) was_16\VBD|NONE (l_attr) cause_19\NN|Based|,|and|telithromycin|,|suggested (l_prep) of_20\IN|the|probable (l_pobj) hepatitis_22\NN|NONE
C106791_D056486 CID telithromycin_15\NNS|cause|Based|,|and|,|suggested (r_nsubj) was_16\VBD|NONE (l_conj) suggested_30\VBD|cause|Based|,|and|telithromycin|, (l_dobj) hepatitis_35\NN|findings|.
C106791_D056486 CID telithromycin_21\NNS|who|time (r_dobj) prescribed_20\VBD|attending|the (r_relcl) physician_18\NN|NONE (r_pobj) to_15\IN|if|had|been|incident (r_prep) communicated_14\VBN|been|have|Recurrence|.|might (r_advcl) avoided_7\VBN|NONE (l_nsubjpass) Recurrence_0\NN|been|have|.|communicated|might (l_prep) of_1\IN|NONE (l_pobj) attack_3\NN|NONE (l_compound) hepatitis_2\NN|NONE
C106791_D056486 CID telithromycin_14\NNS|NONE (r_pobj) of_13\IN|the (r_prep) administration_12\NN|NONE (r_pobj) with_10\IN|probably (r_prep) associated_9\VBN|a|of (r_acl) case_4\NN|.|we|Here (l_prep) of_5\IN|a|associated (l_pobj) hepatitis_7\NN|NONE
7248170
D010634_D005355 NONE Phenobarbitone_0\NNP| (r_npadvmod) induced_2\VBN|.|relationship|:|of (r_amod) enlargement_3\NN|NONE (l_appos) relationship_12\NN|induced|.|:|of (l_prep) to_13\TO|its (l_pobj) cirrhosis_18\NN|NONE
D010634_D008103 CID phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|intragastrically|ascites|tetrachloride|increased|. (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D010634_D008103 CID phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D002251_D013163 NONE tetrachloride_55\NN|intragastrically|in|ascites|increased|. (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less
D002251_D013163 NONE tetrachloride_82\NN|initial|"|dose|the|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less
D010634_D001201 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|intragastrically|ascites|tetrachloride|increased|. (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|.
D010634_D001201 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|.
D002251_D008103 CID tetrachloride_55\NN|intragastrically|in|ascites|increased|. (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D002251_D008103 CID tetrachloride_82\NN|initial|"|dose|the|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D010634_D006529 CID Phenobarbitone_0\NNP| (r_npadvmod) induced_2\VBN|.|relationship|:|of (r_amod) enlargement_3\NN|NONE (l_prep) of_4\IN|induced|.|relationship|: (l_pobj) liver_6\NN|NONE
D010634_D006529 CID phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|intragastrically|ascites|tetrachloride|increased|. (r_prep) given_56\VBN|NONE (l_conj) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (l_prep) by_72\IN|from|was (l_pcomp) giving_73\VBG|NONE (l_prep) at_83\IN|calibrating (l_pobj) peak_85\NN|NONE (l_prep) of_86\IN|the (l_pobj) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D010634_D006529 CID phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D002251_D006529 NONE tetrachloride_15\NN| (r_advmod) induced_17\VBN|carbon (r_amod) cirrhosis_18\NN|NONE (r_pobj) to_13\TO|its (r_prep) relationship_12\NN|induced|.|:|of (r_appos) enlargement_3\NN|NONE (l_prep) of_4\IN|induced|.|relationship|: (l_pobj) liver_6\NN|NONE
D002251_D006529 NONE tetrachloride_55\NN|intragastrically|in|ascites|increased|. (r_advmod) given_56\VBN|NONE (l_conj) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (l_prep) by_72\IN|from|was (l_pcomp) giving_73\VBG|NONE (l_prep) at_83\IN|calibrating (l_pobj) peak_85\NN|NONE (l_prep) of_86\IN|the (l_pobj) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D002251_D006529 NONE tetrachloride_82\NN|initial|"|dose|the|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (l_prep) at_83\IN|calibrating (l_pobj) peak_85\NN|NONE (l_prep) of_86\IN|the (l_pobj) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D010634_D001284 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|intragastrically|ascites|tetrachloride|increased|. (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less (l_conj) atrophy_44\NN|,|after||and
D010634_D001284 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less (l_conj) atrophy_44\NN|,|after||and
D002251_D001201 NONE tetrachloride_55\NN|intragastrically|in|ascites|increased|. (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|.
D002251_D001201 NONE tetrachloride_82\NN|initial|"|dose|the|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|.
D010634_D013163 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|intragastrically|ascites|tetrachloride|increased|. (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less
D010634_D013163 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less
D002251_D005355 NONE tetrachloride_15\NN| (r_advmod) induced_17\VBN|carbon (r_amod) cirrhosis_18\NN|NONE
D002251_D001284 NONE tetrachloride_55\NN|intragastrically|in|ascites|increased|. (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less (l_conj) atrophy_44\NN|,|after||and
D002251_D001284 NONE tetrachloride_82\NN|initial|"|dose|the|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|intragastrically|in|ascites|tetrachloride|. (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|intragastrically|in|tetrachloride|increased|. (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|plasma|,|less (l_conj) atrophy_44\NN|,|after||and
17242861
D010862_D012640 NONE pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|model|,|, (r_amod) seizures_7\NNS|NONE
D010862_D012640 NONE pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|model|,|, (r_amod) seizures_7\NNS|NONE (r_pobj) to_3\IN|NONE (r_prep) susceptibility_2\NN|NONE (r_pobj) for_1\IN|NONE (r_prep) QTLs_0\NNS|used|,|and|have|not|been (r_nsubjpass) reported_19\VBN|NONE (l_conj) used_27\VBN|,|and|have|QTLs|not|been (l_xcomp) localize_29\VB|previously|been|CSS|have|not|. (l_dobj) genes_32\NNS|to (l_compound) susceptibility_31\NN|NONE (l_compound) seizure_30\NN|NONE
D010862_D012640 NONE pilocarpine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) seizures_12\NNS|NONE
D010862_D012640 NONE pilocarpine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) seizures_26\NNS|NONE
D010862_D004833 CID pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|model|,|, (r_amod) seizures_7\NNS|NONE (l_appos) model_10\NN|,|induced|, (l_prep) of_11\IN|a (l_pobj) epilepsy_14\NN|NONE
15278670
D004737_D012640 NONE enflurane_12\NN|and (r_conj) sevoflurane_10\NN|NONE (r_pobj) between_9\IN|the|convulsive (r_prep) threshold_8\NN|NONE (l_amod) convulsive_7\JJ|the|between
D004737_D012640 NONE enflurane_14\NN|or (r_conj) sevoflurane_12\NN|NONE (r_pobj) of_11\IN|higher (r_prep) concentrations_10\NNS|were|when|decreased|and (r_nsubjpass) administered_16\VBN|.|rise|marked (l_conj) decreased_23\VBD|were|when|concentrations|and (l_nsubj) pressure_20\NN|in|,|in|and|significantly (l_prep) at_21\IN|blood|the (l_pobj) convulsions_22\NNS|NONE
D004737_D012640 NONE enflurane_37\NN|and|. (r_conj) %_33\NN|NONE (r_pobj) in_31\IN|pressure|,|in|and|significantly (r_conj) decreased_23\VBD|were|when|concentrations|and (l_nsubj) pressure_20\NN|in|,|in|and|significantly (l_prep) at_21\IN|blood|the (l_pobj) convulsions_22\NNS|NONE
D008012_D003866 NONE lidocaine_10\JJ|NONE (r_compound) toxicity_11\NN|NONE (r_pobj) of_9\IN|convulsive|the (r_prep) effect_8\NN|carries|sevoflurane|that|but (r_dobj) reduces_5\VBZ|.|is|It (l_conj) carries_13\VBZ|sevoflurane|effect|that|but (l_prep) due_16\IN|risk (l_pcomp) to_17\IN|NONE (l_pobj) depression_19\NN|NONE
C009250_D064420 NONE sevoflurane_4\NN|carries|effect|that|but (r_nsubj) reduces_5\VBZ|.|is|It (l_dobj) effect_8\NN|carries|sevoflurane|that|but (l_prep) of_9\IN|convulsive|the (l_pobj) toxicity_11\NN|NONE
C009250_D003866 NONE sevoflurane_4\NN|carries|effect|that|but (r_nsubj) reduces_5\VBZ|.|is|It (l_conj) carries_13\VBZ|sevoflurane|effect|that|but (l_prep) due_16\IN|risk (l_pcomp) to_17\IN|NONE (l_pobj) depression_19\NN|NONE
D008012_D012640 CID lidocaine_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) convulsions_8\NNS|NONE
D008012_D012640 CID lidocaine_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) convulsions_8\NNS|NONE
D008012_D012640 CID lidocaine_16\NN|(|mg.kg().min(|) (r_compound) infusion_17\NN|NONE (r_pobj) with_15\IN|,|increasing|+/|threshold|)|.|) (r_prep) was_8\VBD|NONE (l_nsubj) threshold_2\NN|,|increasing|with|+/|)|.|) (l_amod) convulsive_1\JJ|(|)|The|mean
D008012_D012640 CID lidocaine_10\JJ|NONE (r_compound) toxicity_11\NN|NONE (r_pobj) of_9\IN|convulsive|the (r_prep) effect_8\NN|carries|sevoflurane|that|but (l_amod) convulsive_7\JJ|the|of
C009250_D012640 NONE sevoflurane_3\NN|NONE (r_pobj) of_2\IN|on|.|The (r_prep) effects_1\NNS|NONE (l_prep) on_4\IN|.|of|The (l_pobj) convulsions_8\NNS|NONE
C009250_D012640 NONE sevoflurane_3\NN|NONE (l_prep) on_4\IN|NONE (l_pobj) convulsions_8\NNS|NONE
C009250_D012640 NONE sevoflurane_40\NN|NONE (r_pobj) of_39\IN|the|tidal (r_prep) concentration_38\NN|%|when (r_nsubj) was_41\VBD|mg.|) (r_relcl) l(-1_31\NN|NONE (r_pobj) to_26\IN|significantly (r_prep) increasing_24\VBG|,|with|+/|threshold|)|.|) (r_advcl) was_8\VBD|NONE (l_nsubj) threshold_2\NN|,|increasing|with|+/|)|.|) (l_amod) convulsive_1\JJ|(|)|The|mean
C009250_D012640 NONE sevoflurane_10\NN|NONE (r_pobj) between_9\IN|the|convulsive (r_prep) threshold_8\NN|NONE (l_amod) convulsive_7\JJ|the|between
C009250_D012640 NONE sevoflurane_12\NN|NONE (r_pobj) of_11\IN|higher (r_prep) concentrations_10\NNS|were|when|decreased|and (r_nsubjpass) administered_16\VBN|.|rise|marked (l_conj) decreased_23\VBD|were|when|concentrations|and (l_nsubj) pressure_20\NN|in|,|in|and|significantly (l_prep) at_21\IN|blood|the (l_pobj) convulsions_22\NNS|NONE
C009250_D012640 NONE sevoflurane_28\NN|NONE (r_pobj) in_25\IN|in|pressure|,|and|significantly (r_prep) decreased_23\VBD|were|when|concentrations|and (l_nsubj) pressure_20\NN|in|,|in|and|significantly (l_prep) at_21\IN|blood|the (l_pobj) convulsions_22\NNS|NONE
C009250_D012640 NONE sevoflurane_4\NN|carries|effect|that|but (r_nsubj) reduces_5\VBZ|.|is|It (l_dobj) effect_8\NN|carries|sevoflurane|that|but (l_amod) convulsive_7\JJ|the|of
D001030_D012640 NONE Apamin_0\NNP|was|tendency|but|) (r_nsubj) had_5\VBD|NONE (l_dobj) tendency_7\NN|Apamin|was|but|) (l_acl) decrease_9\VB|a (l_dobj) threshold_12\NN|to (l_amod) convulsive_11\JJ|(|+/|)|the
D008012_D064420 NONE lidocaine_10\JJ|NONE (r_compound) toxicity_11\NN|NONE
3856631
D001663_D052016 NONE bilirubin_10\NN|NONE (r_amod) elevations_11\NNS|transient|neutropenia|,|and|serum (r_conj) transaminase_8\NN|.|toxicities (l_appos) neutropenia_13\NN|transient|elevations|,|and|serum (l_conj) mucositis_16\NN|and|,
D008727_D054198 NONE methotrexate_18\NNP|dose|designed|intravenous|a (r_compound) regimen_19\NN|NONE (r_pobj) with_12\IN|were|.|children (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_prep) with_2\IN|developed|Twenty (l_pobj) leukemia_5\NN|NONE
D008727_D054198 NONE methotrexate_28\NNP|of|CSF (r_compound) concentrations_29\NNS|without (r_dobj) maintain_26\VB|and|to (r_conj) achieve_24\VB|was|that (r_xcomp) designed_22\VBN|dose|intravenous|methotrexate|a (r_relcl) regimen_19\NN|NONE (r_pobj) with_12\IN|were|.|children (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_prep) with_2\IN|developed|Twenty (l_pobj) leukemia_5\NN|NONE
D008727_D054198 NONE methotrexate_4\NN|.|treatment (r_nsubj) is_5\VBZ|NONE (l_attr) treatment_8\NN|methotrexate|. (l_prep) for_9\IN|an|effective (l_pobj) induction_11\NN|NONE (l_prep) after_14\IN|the|of (l_pobj) relapse_16\NN|NONE (l_prep) in_17\IN|meningeal (l_pobj) leukemia_20\NN|NONE
D001663_D064420 NONE bilirubin_10\NN|NONE (r_amod) elevations_11\NNS|transient|neutropenia|,|and|serum (r_conj) transaminase_8\NN|.|toxicities (r_attr) were_5\VBD|NONE (l_nsubj) toxicities_3\NNS|.|transaminase
D008727_D002493 NONE methotrexate_18\NNP|dose|designed|intravenous|a (r_compound) regimen_19\NN|NONE (r_pobj) with_12\IN|were|.|children (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_relcl) developed_7\VBD|Twenty|with (l_dobj) disease_9\NN|who
D008727_D002493 NONE methotrexate_28\NNP|of|CSF (r_compound) concentrations_29\NNS|without (r_dobj) maintain_26\VB|and|to (r_conj) achieve_24\VB|was|that (r_xcomp) designed_22\VBN|dose|intravenous|methotrexate|a (r_relcl) regimen_19\NN|NONE (r_pobj) with_12\IN|were|.|children (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_relcl) developed_7\VBD|Twenty|with (l_dobj) disease_9\NN|who
D001663_D009503 NONE bilirubin_10\NN|NONE (r_amod) elevations_11\NNS|transient|neutropenia|,|and|serum (r_conj) transaminase_8\NN|.|toxicities (l_appos) neutropenia_13\NN|transient|elevations|,|and|serum
D008727_D008577 NONE methotrexate_10\NNP|NONE (r_pobj) with_5\IN|meningeal (r_prep) leukemia_4\NN|NONE
15957009
D014236_D008569 NONE metrifonate_15\NN|intraperitoneally||and|mg/kg|p.o.|(|, (r_conj) Ro4368554_2\NNP|,|.|deficits|Both|) (r_nsubj) reversed_24\VBD|NONE (l_dobj) deficits_26\NNS|,|Ro|.|Both|)
D012701_D008569 NONE 5-HT(6_45\CD|receptor|,|,|other|possibly (r_compound) antagonists_48\NNS|may|be|mechanisms|in|that|and (r_conj) involved_31\VBN|NONE (r_ccomp) suggesting_25\VBG|In|improve|,|it|cholinergic|.|,|, (r_advcl) reversed_16\VBD|NONE (l_dobj) cholinergic_18\JJ|In|suggesting|improve|,|it|.|,|, (l_conj) deficit_23\NN|a|and
D012601_D008569 CID scopolamine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) induced_27\VBN|memory (r_acl) deficits_26\NNS|,|Ro|.|Both|)
C507242_D008569 NONE Ro4368554_5\NN|antagonist|performance|in|. (r_nsubj) restores_6\VBZ|NONE (l_prep) in_9\IN|Ro|antagonist|performance|. (l_pobj) models_13\NNS|NONE (l_prep) of_14\IN|cholinergic|in (l_pobj) deficiency_16\NN|NONE
C507242_D008569 NONE Ro4368554_2\NNP|,|.|deficits|Both|) (r_nsubj) reversed_24\VBD|NONE (l_dobj) deficits_26\NNS|,|Ro|.|Both|)
C507242_D008569 NONE Ro4368554_4\NN|did|not|although|deficit (r_nsubj) improve_7\VB|In|suggesting|,|it|cholinergic|.|,|, (r_advcl) reversed_16\VBD|NONE (l_dobj) cholinergic_18\JJ|In|suggesting|improve|,|it|.|,|, (l_conj) deficit_23\NN|a|and
C507242_D008569 NONE Ro4368554_39\NN|NONE (r_pobj) by_38\IN|of|the (r_prep) facilitation_34\NN|NONE (r_pobj) in_32\IN|may|be|mechanisms|that|and|antagonists (r_prep) involved_31\VBN|NONE (r_ccomp) suggesting_25\VBG|In|improve|,|it|cholinergic|.|,|, (r_advcl) reversed_16\VBD|NONE (l_dobj) cholinergic_18\JJ|In|suggesting|improve|,|it|.|,|, (l_conj) deficit_23\NN|a|and
D014364_D008569 NONE TRP_31\NNP|NONE (r_compound) depletion_32\NN|(|,|,|mg/kg|mg/kg|and|and|i.p. (r_conj) scopolamine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) induced_27\VBN|memory (r_acl) deficits_26\NNS|,|Ro|.|Both|)
15188772
D004837_D009202 NONE epinephrine_15\NN|NONE (r_pobj) of_14\IN| (r_prep) mg_13\NN|.|woman|markers (r_nsubj) developed_16\VBN|NONE (l_dobj) markers_44\NNS|.|woman|mg (l_prep) of_45\IN|biochemical|elevated|stunning (l_pobj) necrosis_47\NN|NONE
D004837_D017682 CID epinephrine_15\NN|NONE (r_pobj) of_14\IN| (r_prep) mg_13\NN|.|woman|markers (r_nsubj) developed_16\VBN|NONE (l_dobj) markers_44\NNS|.|woman|mg (l_amod) stunning_18\JJ|biochemical|elevated|of
D004837_D062787 NONE epinephrine_12\NN|iatrogenic|accidental (r_amod) overdose_13\NN|to
D004837_D018487 NONE epinephrine_12\NN|iatrogenic|accidental (r_amod) overdose_13\NN|to (r_pobj) due_8\IN|.|ventricular|systolic|left|Severe (r_prep) dysfunction_7\NN|NONE
D004837_D018487 NONE epinephrine_15\NN|NONE (r_pobj) of_14\IN| (r_prep) mg_13\NN|.|woman|markers (r_nsubj) developed_16\VBN|NONE (l_dobj) markers_44\NNS|.|woman|mg (l_amod) stunning_18\JJ|biochemical|elevated|of (l_relcl) characterized_21\VBN|myocardial (l_conj) left_32\VBD|by|was|that|and|, (l_dobj) dysfunction_37\NN|NONE
D002395_D009202 NONE Catecholamine_0\NN| (r_npadvmod) induced_2\VBN|due (r_amod) cardiomyopathy_3\NN|for|.|has|been
D002395_D009202 NONE catecholamines_10\NNS|NONE (r_pobj) of_8\IN|chronic (r_prep) excess_7\NN|to (r_pobj) due_4\IN|induced (r_prep) cardiomyopathy_3\NN|for|.|has|been
17615423
C413408_D012206 CID atazanavir_16\NNS|,|and (r_conj) amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|.|and|Severe (r_conj) rhabdomyolysis_1\NN|NONE
C413408_D012206 CID atazanavir_14\NNS|and|, (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE
D019821_D015658 NONE Simvastatin_0\NNP|human|patient|virus (r_nmod) medications_11\NNS|all|temporarily|given|were|and (l_compound) virus_10\NN|Simvastatin|human|patient
C413408_D058186 CID atazanavir_16\NNS|,|and (r_conj) amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|.|and|Severe
C413408_D058186 CID atazanavir_14\NNS|and|, (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE (l_conj) failure_21\NN|and
D000638_D012206 CID amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|.|and|Severe (r_conj) rhabdomyolysis_1\NN|NONE
D000638_D012206 CID amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|and|, (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE
D000638_D058186 CID amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|.|and|Severe
D000638_D058186 CID amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|and|, (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE (l_conj) failure_21\NN|and
D000638_D015658 NONE amiodarone_2\NN|, (r_conj) Simvastatin_0\NNP|human|patient|virus (r_nmod) medications_11\NNS|all|temporarily|given|were|and (l_compound) virus_10\NN|Simvastatin|human|patient
D019821_D058186 CID simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|.|and|Severe
D019821_D058186 CID simvastatin_9\NN|NONE (l_conj) amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|and|, (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE (l_conj) failure_21\NN|and
D019821_D012206 CID simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|.|and|Severe (r_conj) rhabdomyolysis_1\NN|NONE
D019821_D012206 CID simvastatin_9\NN|NONE (l_conj) amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|and|, (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE
D019821_D012206 CID simvastatin_14\NN|NONE (r_amod) metabolism_15\NN|that (r_dobj) inhibit_13\VBP|concomitant (r_relcl) drugs_11\NNS|NONE (r_pobj) of_9\IN|the (r_prep) presence_8\NN|NONE (r_pobj) in_6\IN|risk|is|. (r_prep) increased_5\VBN|NONE (l_nsubjpass) risk_1\NN|in|is|. (l_prep) of_2\IN|The (l_pobj) rhabdomyolysis_3\NN|NONE
12584269
D016559_D007674 CID FK506_14\NNP|better|was|whereas (r_nsubjpass) tolerated_19\VBN|effect|study|.|, (r_advcl) demonstrated_3\VBD|NONE (l_dobj) effect_7\NN|tolerated|study|.|, (l_amod) nephrotoxic_6\JJ|synergistic|a|of
D020123_D005355 NONE SRL_3\NNP|FK (r_compound) combination_4\NN|degree|compared|. (r_nsubj) showed_5\VBD|NONE (l_dobj) degree_10\NN|combination|compared|. (l_prep) of_11\IN|only|a|higher (l_pobj) fibrosis_12\NN|NONE
D016572_D007674 CID CsA_9\NNP|NONE (r_pobj) of_8\IN|synergistic|a|nephrotoxic (r_prep) effect_7\NN|tolerated|study|.|, (l_amod) nephrotoxic_6\JJ|synergistic|a|of
D020123_D007674 CID SRL_5\NN|,|.|is|act (r_nsubj) seems_6\VBZ|,|but|nephrotoxic|These (r_conj) are_1\VBP|NONE (l_acomp) nephrotoxic_2\JJ|,|but|seems|These
D020123_D007674 CID SRL_5\NN|,|.|is|act (r_nsubj) seems_6\VBZ|,|but|nephrotoxic|These (l_xcomp) act_8\VB|,|.|is|SRL (l_advcl) displaying_10\VBG|to|differently (l_dobj) effects_14\NNS|NONE (l_amod) nephrotoxic_13\JJ|only|minor
D020123_D007674 CID SRL_7\NN|where|was|with (r_nsubjpass) combined_9\VBN|treatment (l_prep) with_10\IN|where|was|SRL (l_pobj) indications_14\NNS|NONE (l_prep) of_15\IN|a|calcineurin|inhibitor (l_pobj) effect_19\NN|NONE (l_amod) nephrotoxic_18\JJ|a|synergistic
D020123_D007674 CID SRL_11\NNP|plus (r_conj) CsA_9\NNP|NONE (r_pobj) of_8\IN|synergistic|a|nephrotoxic (r_prep) effect_7\NN|tolerated|study|.|, (l_amod) nephrotoxic_6\JJ|synergistic|a|of
D020123_D007674 CID SRL_16\NNP|plus (r_conj) FK506_14\NNP|better|was|whereas (r_nsubjpass) tolerated_19\VBN|effect|study|.|, (r_advcl) demonstrated_3\VBD|NONE (l_dobj) effect_7\NN|tolerated|study|.|, (l_amod) nephrotoxic_6\JJ|synergistic|a|of
D016559_D005355 NONE FK506_1\NNP|SRL (r_nmod) combination_4\NN|degree|compared|. (r_nsubj) showed_5\VBD|NONE (l_dobj) degree_10\NN|combination|compared|. (l_prep) of_11\IN|only|a|higher (l_pobj) fibrosis_12\NN|NONE
14976857
D011405_D054092 NONE propafenone_26\NN|a (r_compound) overdose_27\NN|NONE (r_pobj) by_24\IN|probably|was (r_agent) precipitated_23\VBN|shunt|.|,|and|in (r_conj) occurred_9\VBD|NONE (l_nsubj) shunt_1\NN|precipitated|.|,|and|in (l_prep) via_4\IN|of|This (l_pobj) ovale_8\NN|NONE
D011405_D004437 NONE propafenone_9\NN|in (r_compound) overdose_10\NN|NONE (l_prep) in_11\IN|propafenone (l_pobj) woman_14\NN|NONE (l_prep) with_15\IN|a|young (l_pobj) anomaly_18\NN|NONE
D011405_-1 NONE propafenone_9\NN|in (r_compound) overdose_10\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|Transient|.|like (r_acl) syndrome_6\NN|NONE
D011405_D062787 NONE propafenone_9\NN|in (r_compound) overdose_10\NN|NONE
D011405_D062787 NONE propafenone_26\NN|a (r_compound) overdose_27\NN|NONE
11166519
D003042_D012640 CID cocaine_1\NN| (r_npadvmod) induced_3\VBN|.|:|sensitivity|Acute (r_amod) seizures_4\NNS|NONE
D003042_D012640 CID cocaine_22\NN|NONE (r_pobj) of_21\IN|a|single (r_prep) injection_20\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|behavioral (r_acl) seizures_15\NNS|NONE
D003042_D012640 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) seizures_17\NNS|NONE
6209318
D008801_D014202 CID mexiletine_16\NN|the (r_amod) group_17\NN|NONE (r_pobj) in_14\IN|more|than (r_prep) frequent_13\JJ|effects|. (r_acomp) were_11\VBD|NONE (l_nsubj) effects_3\NNS|.|frequent (l_appos) tremor_6\JJ|,|side|,|recognized
D008801_D012817 CID mexiletine_16\NN|the (r_amod) group_17\NN|NONE (r_pobj) in_14\IN|more|than (r_prep) frequent_13\JJ|effects|. (r_acomp) were_11\VBD|NONE (l_nsubj) effects_3\NNS|.|frequent (l_appos) tremor_6\JJ|,|side|,|recognized (l_conj) problems_9\NNS|and|particularly
D008801_D009203 NONE mexiletine_9\NN|Perlongets (r_pobj) of_8\IN|sustained|the|release (r_prep) form_7\NN|NONE (r_pobj) of_3\IN|antiarrhythmic|The (r_prep) effects_2\NNS|were|.|in (r_nsubjpass) evaluated_16\VBN|NONE (l_prep) in_17\IN|were|effects|. (l_pobj) trial_23\NN|NONE (l_prep) in_24\IN|a|blind|placebo (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) infarction_31\NN|NONE
D008801_D009203 NONE Perlongets_13\NNP|mexiletine (r_pobj) of_8\IN|sustained|the|release (r_prep) form_7\NN|NONE (r_pobj) of_3\IN|antiarrhythmic|The (r_prep) effects_2\NNS|were|.|in (r_nsubjpass) evaluated_16\VBN|NONE (l_prep) in_17\IN|were|effects|. (l_pobj) trial_23\NN|NONE (l_prep) in_24\IN|a|blind|placebo (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) infarction_31\NN|NONE
D008801_D001145 NONE mexiletine_1\NN|antiarrhythmic|International|coronary|Report|.|: (r_nmod) trial_6\NN|NONE (l_appos) Report_9\NNP|antiarrhythmic|International|coronary|.|mexiletine|: (l_prep) on_10\IN|I. (l_pobj) arrhythmia_11\NN|NONE
D008801_D003643 NONE mexiletine_6\NN|the|%|(|) (r_amod) group_7\NN|NONE (r_pobj) in_4\IN|than|more (r_prep) deaths_3\NNS|There
20196116
D000995_D017114 CID Antituberculosis_0\NNP|therapy||failure|profile|. (r_nsubj) induced_3\VBN|NONE (l_dobj) failure_6\NN|therapy||profile|Antituberculosis|.
D000995_D017114 CID Antituberculosis_0\NN|failure|( (r_compound) therapy_1\NN|.|ALF (l_appos) failure_6\NN|(|Antituberculosis
D000995_D017114 CID Antituberculosis_0\NN|failure|( (r_compound) therapy_1\NN|.|ALF (l_appos) failure_6\NN|(|Antituberculosis (l_appos) ALF_10\NNP|)|acute|ATT)associated|liver|(
D000995_D017114 CID Antituberculosis_0\NN|failure|( (r_compound) therapy_1\NN|.|ALF (r_nsubj) is_12\VBZ|NONE (l_attr) ALF_18\NNP|therapy|.
D001663_D001927 NONE bilirubin_11\NN|: (l_appos) time_21\NN|,|serum|dL|(|) (l_conj) encephalopathy_37\NN|prothrombin|and|prolongation|,
20477932
D003042_D064420 NONE cocaine_6\NN|including (r_compound) toxicity_7\NN|NONE
D003042_D064420 NONE cocaine_24\NN|the|and (r_conj) brain_22\NN||induced (r_nmod) behaviour_27\NN|NONE (r_pobj) in_20\IN|oxidative (r_prep) status_19\NN|NONE (r_pobj) between_17\IN|the (r_prep) association_16\NN|an|in|but (r_conj) increase_10\NN|NONE (r_pobj) including_8\VBG|cocaine (r_prep) toxicity_7\NN|NONE
C052342_D008569 NONE topiramate_22\NN|NONE (r_pobj) by_21\IN|NONE (r_prep) prevention_20\NN|of|,|and (r_conj) involvement_9\NN|and|:|learning (r_appos) memory_2\NN|Cocaine|. (l_conj) learning_4\VBG|involvement|and|: (l_dobj) impairments_5\NNS|NONE
D003042_D008569 CID Cocaine_0\NN|.|memory (r_nsubj) causes_1\VBZ|NONE (l_dobj) memory_2\NN|Cocaine|. (l_conj) learning_4\VBG|involvement|and|: (l_dobj) impairments_5\NNS|NONE
D003042_D007859 CID Cocaine_0\NN|.|memory (r_nsubj) causes_1\VBZ|NONE (l_dobj) memory_2\NN|Cocaine|. (l_conj) learning_4\VBG|involvement|and|: (l_dobj) impairments_5\NNS|NONE
C052342_D007859 NONE topiramate_22\NN|NONE (r_pobj) by_21\IN|NONE (r_prep) prevention_20\NN|of|,|and (r_conj) involvement_9\NN|and|:|learning (r_appos) memory_2\NN|Cocaine|. (l_conj) learning_4\VBG|involvement|and|: (l_dobj) impairments_5\NNS|NONE
D003042_D019970 NONE cocaine_43\NN|NONE (r_compound) administration_44\NN|NONE (r_pobj) of_42\IN|an|experimental|in (r_prep) model_41\NN|NONE (r_pobj) in_38\IN|.|Therefore|were|activity (r_prep) evaluated_37\VBN|NONE (l_nsubjpass) activity_2\NN|in|.|Therefore|were (l_appos) stress_5\NN|,|NFkappaB|, (l_conj) synthase_10\NN|oxidative|, (l_conj) therapy_31\NN|nitric|,|neuronal|(|oxide|activity (l_prep) for_32\IN|proposed|a (l_pobj) addiction_34\NN|NONE
D009569_D019970 NONE oxide_9\NN|nitric|,|neuronal|therapy|(|activity (r_compound) synthase_10\NN|oxidative|, (l_conj) therapy_31\NN|nitric|,|neuronal|(|oxide|activity (l_prep) for_32\IN|proposed|a (l_pobj) addiction_34\NN|NONE
C052342_D019970 NONE topiramate_26\NN|NONE (r_pobj) of_25\IN|the (r_prep) effect_24\NN|spatial|and|memory|as (r_conj) learning_17\NN|,|)|nNOS (r_conj) activity_14\NN|nitric|,|neuronal|therapy|(|oxide (r_conj) synthase_10\NN|oxidative|, (l_conj) therapy_31\NN|nitric|,|neuronal|(|oxide|activity (l_prep) for_32\IN|proposed|a (l_pobj) addiction_34\NN|NONE
7265370
C020743_D053040 NONE dyazide_3\RB|NONE (r_compound) therapy_4\NN|nephrolithiasis|. (r_dobj) complicating_2\VBG|NONE (l_nsubj) nephrolithiasis_1\JJ|therapy|.
C020743_D053040 NONE triamterene_16\JJ|NONE (r_compound) therapy_17\NN|NONE (r_pobj) of_13\IN||for (r_prep) years_12\NNS|NONE (r_pobj) after_10\IN|case|.|is|in (r_prep) reported_6\VBN|NONE (l_nsubjpass) case_1\NN|.|is|after|in (l_prep) of_2\IN|A (l_pobj) nephrolithiasis_4\NN|NONE
D014223_D053040 CID Triamterene_0\JJ|NONE (r_compound) nephrolithiasis_1\JJ|therapy|.
D014223_D053040 CID triamterene_3\JJ|NONE (r_compound) nephrolithiasis_4\NN|NONE
D014223_D053040 CID triamterene_2\JJ|NONE (r_compound) nephrolithiasis_3\NN|NONE
D014223_D006973 NONE triamterene_3\JJ|NONE (r_compound) nephrolithiasis_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) case_1\NN|.|is|after|in (r_nsubjpass) reported_6\VBN|NONE (l_prep) after_10\IN|case|.|is|in (l_pobj) years_12\NNS|NONE (l_prep) for_18\IN|of| (l_pobj) hypertension_19\NN|NONE
C020743_D006973 NONE triamterene_16\JJ|NONE (r_compound) therapy_17\NN|NONE (r_pobj) of_13\IN||for (r_prep) years_12\NNS|NONE (l_prep) for_18\IN|of| (l_pobj) hypertension_19\NN|NONE
424937
D008750_D056486 CID methyldopa_6\NN|NONE (r_pobj) by_5\IN|.|Patterns (r_agent) induced_4\VBN|NONE (l_nsubj) Patterns_0\NNS|by|. (l_prep) of_1\IN|NONE (l_pobj) injury_3\NN|NONE
D008750_D056486 CID methyldopa_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) hepatitis_25\NN|NONE
D008750_D056486 CID methyldopa_14\NN|NONE (r_pobj) between_13\IN|the|causal (r_prep) relationship_12\NN|,|.|was|In|with|in (r_nsubjpass) proved_19\VBN|NONE (l_prep) with_20\IN|,|.|was|In|in|relationship (l_pobj) recurrence_22\NN|NONE (l_prep) of_23\IN|to|the|within (l_pobj) hepatitis_24\NN|NONE
D008750_D017114 NONE methyldopa_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) hepatitis_25\NN|NONE (r_pobj) of_21\IN|a|prior (r_prep) episode_20\NN|NONE (r_pobj) after_17\IN|when|drug|year|was|accidentally (r_prep) recommenced_14\VBN|hepatitis|patient|. (r_advcl) developed_6\VBD|NONE (l_dobj) hepatitis_8\NN|patient|recommenced|.
D008750_D017093 NONE methyldopa_17\NN|been|for|had|who (r_dobj) taking_16\VBG|,|, (r_relcl) another_11\DT|resolution|over (r_nsubj) showed_22\VBD|,|in|having|and (r_conj) presented_5\VBN|.|patient|, (l_prep) in_6\IN|,|having|and|showed (l_pobj) failure_8\NN|NONE
D008750_D008107 NONE methyldopa_7\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|liver (r_acl) disease_4\NN|NONE
D008750_D008107 NONE methyldopa_14\NN|NONE (l_conj) dysfunction_17\NN|and
20470218
D008727_D056784 NONE methotrexate_32\NN|syndrome|)|dose|,|n||( (r_compound) toxicity_33\NN|,|posterior|leukoencephalopathy|)|n|,|(|stroke|reversible (r_conj) syndrome_6\NN|.|complications (l_compound) leukoencephalopathy_5\JJ|,|posterior|toxicity|)|n|,|(|stroke|reversible
D008727_D020521 NONE methotrexate_32\NN|syndrome|)|dose|,|n||( (r_compound) toxicity_33\NN|,|posterior|leukoencephalopathy|)|n|,|(|stroke|reversible (r_conj) syndrome_6\NN|.|complications (l_conj) stroke_13\NN|,|posterior|toxicity|leukoencephalopathy|)|n|,|(|reversible
D008727_D064420 NONE methotrexate_32\NN|syndrome|)|dose|,|n||( (r_compound) toxicity_33\NN|,|posterior|leukoencephalopathy|)|n|,|(|stroke|reversible
D008727_D004833 NONE methotrexate_32\NN|syndrome|)|dose|,|n||( (r_compound) toxicity_33\NN|,|posterior|leukoencephalopathy|)|n|,|(|stroke|reversible (r_conj) syndrome_6\NN|.|complications (l_conj) stroke_13\NN|,|posterior|toxicity|leukoencephalopathy|)|n|,|(|reversible (l_conj) epilepsy_22\NN|,|)|n||(
D008727_D007177 NONE methotrexate_32\NN|syndrome|)|dose|,|n||( (r_compound) toxicity_33\NN|,|posterior|leukoencephalopathy|)|n|,|(|stroke|reversible (l_conj) syndrome_40\NN|)|methotrexate|dose|,|n||( (l_prep) of_41\IN|events|and|, (l_pobj) secretion_45\NN|NONE
15572383
D004317_D011507 CID adriamycin_10\NNS|NONE (r_pobj) by_9\IN|.|,|was|proteinuria|After (r_agent) induced_8\VBN|NONE (l_nsubjpass) proteinuria_6\NN|.|,|by|was|After
D004317_D011507 CID adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|,|.|anticipated
D004317_D011507 CID adriamycin_12\NNS|positively|with|ACE (r_advcl) correlated_4\VBD|NONE (l_prep) with_5\IN|positively|adriamycin|ACE (l_pobj) rise_8\NN|NONE (l_prep) in_9\IN|the|relative (l_pobj) proteinuria_10\NN|NONE
D004317_D009404 NONE adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|,|.|anticipated (l_amod) nephrotic_5\JJ|elicited|,|range|damage
D004317_D005923 NONE adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|,|.|anticipated (l_conj) damage_11\NN|elicited|,|range|nephrotic (l_conj) glomerulosclerosis_15\NN|renal|interstitial|and
D004317_D007674 NONE adriamycin_12\NNS| (r_advmod) induced_14\VBN|renal (r_amod) damage_16\NN|NONE
D004317_D007674 NONE adriamycin_23\NNS|NONE (r_pobj) of_22\IN|in|a|single (r_prep) injection_21\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|of|the (r_acl) severity_13\NN|NONE (l_prep) of_14\IN|induced|the (l_pobj) damage_16\NN|NONE
D004317_D007674 NONE adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|,|.|anticipated (l_conj) damage_11\NN|elicited|,|range|nephrotic
D004317_D007674 NONE adriamycin_10\NNS| (r_advmod) induced_12\VBN|in|renal (r_amod) damage_14\NN|NONE
7582165
D000305_D004342 NONE corticosteroids_5\NNS|NONE (r_pobj) to_4\IN|diagnosis|:|.|allergic (r_prep) reactions_3\NNS|NONE
D010248_D004342 NONE paramethasone_3\NN|NONE (r_pobj) from_2\IN|NONE (r_prep) different_1\JJ|NONE (r_amod) Corticosteroids_0\NNS|reactions|also (r_nsubj) produced_5\VBD|,|however|;|were|few|. (l_dobj) reactions_7\NNS|Corticosteroids|also (l_compound) hypersensitivity_6\NN|in
D010248_D004342 NONE paramethasone_16\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) caused_14\VBN||pseudo|a (r_acl) allergy_13\NN|NONE
18208574
D006493_D013927 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) thrombocytopenia_15\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) patients_10\NNS|NONE (r_pobj) in_9\IN|NONE (r_prep) thrombosis_8\NN|density|.
D006493_D013927 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|a|assay|step (r_amod) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|a|induced|step (l_prep) with_21\IN|HIT|(|antigen|) (l_pobj) thrombosis_22\NN|NONE
D006493_D013927 CID heparin_33\JJ|high|a (r_compound) concentration_34\NN|NONE (r_pobj) of_30\IN|inhibition (r_prep) characteristics_29\NNS|;|.|assay|correlate (r_dobj) utilizes_26\VBZ|NONE (l_advcl) correlate_1\VB|;|.|characteristics|assay (l_dobj) density_3\NN|To (l_prep) of_7\IN|inhibition|optical|and (l_pobj) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|a|induced|step (l_prep) with_21\IN|HIT|(|antigen|) (l_pobj) thrombosis_22\NN|NONE
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) thrombocytopenia_15\NN|NONE
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|a|assay|step (r_amod) thrombocytopenia_15\NN|NONE
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|a|assay|step (r_amod) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|a|induced|step (l_nmod) HIT_17\NN|(|antigen|with|)
D006493_D013921 CID heparin_33\JJ|high|a (r_compound) concentration_34\NN|NONE (r_pobj) of_30\IN|inhibition (r_prep) characteristics_29\NNS|;|.|assay|correlate (r_dobj) utilizes_26\VBZ|NONE (l_advcl) correlate_1\VB|;|.|characteristics|assay (l_dobj) density_3\NN|To (l_prep) of_7\IN|inhibition|optical|and (l_pobj) thrombocytopenia_15\NN|NONE
D006493_D013921 CID heparin_33\JJ|high|a (r_compound) concentration_34\NN|NONE (r_pobj) of_30\IN|inhibition (r_prep) characteristics_29\NNS|;|.|assay|correlate (r_dobj) utilizes_26\VBZ|NONE (l_advcl) correlate_1\VB|;|.|characteristics|assay (l_dobj) density_3\NN|To (l_prep) of_7\IN|inhibition|optical|and (l_pobj) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|a|induced|step (l_nmod) HIT_17\NN|(|antigen|with|)
D006493_D013921 CID heparin_21\NN|NONE (r_pobj) to_20\IN|NONE (r_prep) exposure_19\NN|NONE (r_pobj) after_18\IN|with (r_prep) Patients_0\NNS|.|in|were (l_prep) with_1\IN|after (l_pobj) decrease_6\NN|NONE (l_conj) thrombocytopenia_11\NNP|%|in|or|)
D006493_D013921 CID heparin_48\NN|NONE (r_pobj) of_47\IN|high (r_prep) concentration_46\NN|NONE (r_pobj) with_44\IN| (r_prep) inhibition_43\NN|who|assay (r_dobj) had_24\VBD|,|] (r_relcl) heparin_21\NN|NONE (r_pobj) to_20\IN|NONE (r_prep) exposure_19\NN|NONE (r_pobj) after_18\IN|with (r_prep) Patients_0\NNS|.|in|were (l_prep) with_1\IN|after (l_pobj) decrease_6\NN|NONE (l_conj) thrombocytopenia_11\NNP|%|in|or|)
19884587
D009582_D008850 CID Nitrofurantoins_0\NNS|were|AOR|.|with (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|Nitrofurantoins|were|AOR|. (l_pobj) anophthalmia_4\NN|NONE (l_conj) microphthalmos_6\NNS|or
D009582_D002971 CID Nitrofurantoins_0\NNS|were|AOR|.|with (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|Nitrofurantoins|were|.|with (l_appos) AOR_26\NNP|,|CI|AOR|=|.|;|(|syndrome (l_conj) lip_58\NN|,|AOR|=|CI|(|)|;|,|;|defects|)|CI|.|(|and
D009582_D002972 CID Nitrofurantoins_0\NNS|were|AOR|.|with (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|Nitrofurantoins|were|.|with (l_appos) AOR_26\NNP|,|CI|AOR|=|.|;|(|syndrome (l_conj) lip_58\NN|,|AOR|=|CI|(|)|;|,|;|defects|)|CI|.|(|and (l_prep) with_59\IN|cleft (l_pobj) palate_61\NN|NONE
D004917_D000014 NONE erythromycins_4\NNS|,|,|used|, (r_conj) penicillins_2\NNS|Reassuringly|were|not|,|with|. (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|Reassuringly|penicillins|were|not|,|. (l_pobj) defects_22\NNS|NONE
D009582_D000014 CID nitrofurantoins_2\NNS|and (r_conj) Sulfonamides_0\NNS|.|,|indicating|were|with (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|Sulfonamides|.|,|indicating|were (l_pobj) defects_8\NNS|NONE
D013449_D000014 CID Sulfonamides_0\NNS|.|,|indicating|were|with (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|Sulfonamides|.|,|indicating|were (l_pobj) defects_8\NNS|NONE
D009582_D018636 CID Nitrofurantoins_0\NNS|were|AOR|.|with (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|Nitrofurantoins|were|.|with (l_appos) syndrome_24\NN|,|CI|AOR|=|.|;|AOR|(
D010406_D000014 NONE penicillins_2\NNS|Reassuringly|were|not|,|with|. (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|Reassuringly|penicillins|were|not|,|. (l_pobj) defects_22\NNS|NONE
D009582_D006344 CID Nitrofurantoins_0\NNS|were|AOR|.|with (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|Nitrofurantoins|were|.|with (l_appos) AOR_26\NNP|,|CI|AOR|=|.|;|(|syndrome (l_appos) defects_41\NNS|,|AOR|=|CI|(|)|;|,|;|)|lip|CI|.|(|and
D009582_D000853 CID Nitrofurantoins_0\NNS|were|AOR|.|with (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|Nitrofurantoins|were|AOR|. (l_pobj) anophthalmia_4\NN|NONE
D013449_D018636 CID Sulfonamides_0\NNS|with|were (r_nsubjpass) associated_2\VBN|confidence|,|,|)|CI|syndrome|;|.|% (r_ccomp) interval_17\NN|NONE (l_appos) syndrome_30\NN|confidence|,|,|)|associated|CI|;|.|%
D013449_D000757 CID Sulfonamides_0\NNS|with|were (r_nsubjpass) associated_2\VBN|confidence|,|,|)|CI|syndrome|;|.|% (l_prep) with_3\IN|were|Sulfonamides (l_pobj) AOR_9\NNP|NONE (l_amod) anencephaly_4\NNS|OR|(|]|[|adjusted|.
D002511_D000014 NONE cephalosporins_7\NNS|,|and (r_conj) erythromycins_4\NNS|,|,|used|, (r_conj) penicillins_2\NNS|Reassuringly|were|not|,|with|. (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|Reassuringly|penicillins|were|not|,|. (l_pobj) defects_22\NNS|NONE
17343925
D012906_D034381 CID smoking_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) influence_1\NN|associated|been|not|,|.|has (r_nsubjpass) estimated_13\VBN|NONE (l_advcl) associated_20\VBN|been|influence|not|,|.|has (l_prep) with_21\IN|has|although|been|positively|smoking (l_pcomp) hearing_22\VBG|NONE (l_dobj) loss_23\NN|NONE
D012906_D034381 CID smoking_16\NN|has|although|been|positively|with (r_nsubjpass) associated_20\VBN|been|influence|not|,|.|has (l_prep) with_21\IN|has|although|been|positively|smoking (l_pcomp) hearing_22\VBG|NONE (l_dobj) loss_23\NN|NONE
8387218
D016049_D018149 CID didanosine_24\NN|NONE (r_dobj) ceasing_23\VBG|NONE (r_pcomp) on_22\IN|to (r_prep) returned_19\VBN|and|not|.|,|did|treatment (r_conj) require_16\VB|patients|were|curves|but (r_conj) developed_2\VBD|NONE (l_dobj) curves_5\VBZ|patients|were|require|but
D015215_D015658 NONE zidovudine_17\NNP|NONE (r_pobj) to_16\IN|NONE (r_prep) intolerant_15\JJ|AZT|positive|HIV (r_amod) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
D015215_D015658 NONE AZT_19\NNP|intolerant|positive|HIV (r_appos) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
D015215_D064420 NONE zidovudine_17\NNP|NONE (r_pobj) to_16\IN|NONE (r_prep) intolerant_15\JJ|AZT|positive|HIV (r_amod) individuals_14\NNS|NONE (r_pobj) in_9\IN|ddI (r_prep) didanosine_5\NN|NONE (r_pobj) of_4\IN|and|toxicity|The|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|and|of|The|)
D015215_D064420 NONE AZT_19\NNP|intolerant|positive|HIV (r_appos) individuals_14\NNS|NONE (r_pobj) in_9\IN|ddI (r_prep) didanosine_5\NN|NONE (r_pobj) of_4\IN|and|toxicity|The|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|and|of|The|)
D016049_D003920 NONE didanosine_24\NN|NONE (r_dobj) ceasing_23\VBG|NONE (r_pcomp) on_22\IN|to (r_prep) returned_19\VBN|and|not|.|,|did|treatment (r_conj) require_16\VB|patients|were|curves|but (r_conj) developed_2\VBD|NONE (l_dobj) curves_5\VBZ|patients|were|require|but (l_amod) characteristic_6\JJ|tolerance (l_prep) of_7\IN|NONE (l_pobj) diabetes_8\NNS|NONE
D016049_D064420 NONE didanosine_5\NN|NONE (r_pobj) of_4\IN|and|toxicity|The|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|and|of|The|)
D016049_D064420 NONE ddI_7\NN|in (r_appos) didanosine_5\NN|NONE (r_pobj) of_4\IN|and|toxicity|The|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|and|of|The|)
D016049_D015658 NONE didanosine_5\NN|NONE (l_prep) in_9\IN|ddI (l_pobj) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
D016049_D015658 NONE ddI_7\NN|in (r_appos) didanosine_5\NN|NONE (l_prep) in_9\IN|ddI (l_pobj) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
1639466
D004656_D006973 NONE enalapril_33\NN| (r_npadvmod) treated_35\VBN|(|or|treated|n|=|, (r_amod) 8)_39\CD|)|(|untreated|hypertensive (r_appos) controls_27\NNS|:|three (r_appos) groups_23\NNS|NONE (r_pobj) to_21\IN|after|.|randomly|were (r_prep) assigned_20\VBN|NONE (l_prep) after_2\IN|.|randomly|were|to (l_pobj) clipping_3\VBG|weeks (l_prep) of_4\IN|NONE (l_pobj) artery_7\NN|NONE (l_appos) rats_10\NNS|(|one|,|)|Hg|renal (l_amod) hypertensive_9\JJ|NONE
D004656_D006973 NONE enalapril_33\NN| (r_npadvmod) treated_35\VBN|(|or|treated|n|=|, (r_amod) 8)_39\CD|)|(|untreated|hypertensive (r_appos) controls_27\NNS|:|three (l_amod) hypertensive_26\JJ|)|(|)|untreated
D004656_D006973 NONE enalapril_25\NN| (r_npadvmod) treated_27\VBN|the (r_amod) group_28\NN|NONE (r_pobj) in_23\IN|(|compared|+/ (r_prep) lower_22\JJR|In|higher|.|,|size|in|but (l_prep) compared_37\VBN|(|in|+/ (l_prep) with_38\IN|NONE (l_pobj) controls_41\NNS|NONE (l_amod) hypertensive_40\JJ|)|(|the|+/
D002118_D000419 NONE calcium_8\NN|the|nitrendipine (r_compound) channel_9\NN|NONE (l_appos) nitrendipine_11\NN|the|calcium (l_conj) angiotensin_14\NN|blocker|or (l_acl) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|,|blood
D004656_D005921 NONE enalapril_14\JJ|NONE (r_compound) treatment_15\NN|NONE (r_pobj) after_13\IN|excretion|.|did|not (r_prep) change_12\VB|but|flow|, (l_nsubj) excretion_7\NN|.|did|not|after (l_conj) glomerulosclerosis_9\NN|albumin|and
D009568_D005921 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|,|index|Furthermore|was|.|compared|significantly (r_prep) increased_6\VBN|NONE (l_nsubjpass) index_3\NN|,|in|Furthermore|was|.|compared|significantly (l_compound) glomerulosclerosis_2\NN|NONE
D009568_D000419 CID nitrendipine_11\NN|the|calcium (l_conj) angiotensin_14\NN|blocker|or (l_acl) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|,|blood
D009568_D000419 CID nitrendipine_5\NN| (r_npadvmod) treated_7\VBN|the|group (r_amod) albuminuria_9\NN|NONE
D009568_D006978 NONE nitrendipine_7\NN|of|Adverse|. (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) rats_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) hypertension_14\NN|NONE
D009568_D006978 NONE nitrendipine_11\NN|the|calcium (r_appos) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|was|in (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|was|effect (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN||two|,
D000809_D000419 NONE angiotensin_14\NN|blocker|or (l_acl) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|,|blood
D009568_D009400 CID nitrendipine_7\NN|of|Adverse|. (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE
D002118_D009400 NONE calcium_4\NN|the (r_compound) channel_5\NN|NONE (r_pobj) of_2\IN|Adverse|nitrendipine|. (r_prep) effect_1\NN|NONE (l_appos) nitrendipine_7\NN|of|Adverse|. (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE
D002118_D006978 NONE calcium_4\NN|the (r_compound) channel_5\NN|NONE (r_pobj) of_2\IN|Adverse|nitrendipine|. (r_prep) effect_1\NN|NONE (l_appos) nitrendipine_7\NN|of|Adverse|. (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) rats_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) hypertension_14\NN|NONE
D002118_D006978 NONE calcium_8\NN|the|nitrendipine (r_compound) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|was|in (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|was|effect (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN||two|,
D004656_D000419 NONE enalapril_18\NN|on (r_dobj) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|,|blood
D004656_D006978 NONE enalapril_18\NN|on (r_dobj) converting_15\VBG|the (r_acl) angiotensin_14\NN|blocker|or (r_conj) nitrendipine_11\NN|the|calcium (r_appos) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|was|in (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|was|effect (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN||two|,
D009568_D006973 NONE nitrendipine_42\NN||n (r_advmod) treated_44\VBN|(|or|treated|n|=|, (r_conj) 8)_39\CD|)|(|untreated|hypertensive (r_appos) controls_27\NNS|:|three (r_appos) groups_23\NNS|NONE (r_pobj) to_21\IN|after|.|randomly|were (r_prep) assigned_20\VBN|NONE (l_prep) after_2\IN|.|randomly|were|to (l_pobj) clipping_3\VBG|weeks (l_prep) of_4\IN|NONE (l_pobj) artery_7\NN|NONE (l_appos) rats_10\NNS|(|one|,|)|Hg|renal (l_amod) hypertensive_9\JJ|NONE
D009568_D006973 NONE nitrendipine_42\NN||n (r_advmod) treated_44\VBN|(|or|treated|n|=|, (r_conj) 8)_39\CD|)|(|untreated|hypertensive (r_appos) controls_27\NNS|:|three (l_amod) hypertensive_26\JJ|)|(|)|untreated
D009568_D006973 NONE nitrendipine_5\NN| (r_npadvmod) treated_7\VBN|the|group (r_amod) albuminuria_9\NN|NONE (r_pobj) in_3\IN|,|compared|In|.|from|progressively|to (r_prep) increased_10\VBD|NONE (l_prep) compared_20\VBN|,|in|In|.|from|progressively|to (l_prep) with_21\IN|NONE (l_pobj) hr_26\NN|NONE (l_prep) in_27\IN|mg/ (l_pobj) controls_30\NNS|NONE (l_amod) hypertensive_29\JJ|the
D009568_D006973 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|,|index|Furthermore|was|.|compared|significantly (r_prep) increased_6\VBN|NONE (l_prep) compared_13\VBN|,|index|in|Furthermore|was|.|significantly (l_prep) with_14\IN|NONE (l_pobj) controls_17\NNS|NONE (l_amod) hypertensive_16\JJ|the|)|.|(
D009568_D006973 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|+/|(|the|) (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|In|higher|.|lower|,|size|but (r_prep) was_5\VBD|NONE (l_conj) lower_22\JJR|In|higher|.|,|size|in|but (l_prep) compared_37\VBN|(|in|+/ (l_prep) with_38\IN|NONE (l_pobj) controls_41\NNS|NONE (l_amod) hypertensive_40\JJ|)|(|the|+/
D000809_D006978 NONE angiotensin_14\NN|blocker|or (r_conj) nitrendipine_11\NN|the|calcium (r_appos) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|was|in (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|was|effect (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN||two|,
16858720
D014859_D006470 NONE warfarin_1\JJ| (r_compound) drug_3\NN|A (r_compound) interaction_4\NN|to|.|in|have|considered|could (r_nsubj) contributed_7\VBN|NONE (l_prep) to_8\IN|.|in|have|considered|interaction|could (l_pobj) haemorrhage_10\NN|NONE
D014859_D006470 NONE warfarin_1\JJ| (r_compound) drug_3\NN|A (r_compound) interaction_4\NN|to|.|in|have|considered|could (r_nsubj) contributed_7\VBN|NONE (l_conj) considered_34\VBN|to|.|in|have|interaction|could (l_nsubjpass) complication_32\NN|was|being (l_amod) bleeding_31\VBG|the
D014859_D006470 NONE warfarin_19\JJ|the (r_compound) patients_20\NNS|NONE (r_pobj) of_17\IN|(|)|| (r_prep) %_15\NN|in|and (r_pobj) in_11\IN|to|.|have|considered|interaction|could (r_prep) contributed_7\VBN|NONE (l_prep) to_8\IN|.|in|have|considered|interaction|could (l_pobj) haemorrhage_10\NN|NONE
D014859_D006470 NONE warfarin_19\JJ|the (r_compound) patients_20\NNS|NONE (r_pobj) of_17\IN|(|)|| (r_prep) %_15\NN|in|and (r_pobj) in_11\IN|to|.|have|considered|interaction|could (r_prep) contributed_7\VBN|NONE (l_conj) considered_34\VBN|to|.|in|have|interaction|could (l_nsubjpass) complication_32\NN|was|being (l_amod) bleeding_31\VBG|the
D014859_D002543 CID warfarin_4\NN|NONE (r_pobj) by_3\IN|influence (r_agent) induced_2\VBN|.|Cerebral (r_acl) haemorrhage_1\NN|NONE
D014859_D002543 CID warfarin_9\RB| (r_npadvmod) induced_11\VBN|cerebral (r_amod) haemorrhages_13\NNS|NONE
D014859_D002543 CID warfarin_16\JJ|to (r_pobj) due_14\IN|frequency|To|. (r_prep) evaluate_1\VB|NONE (l_dobj) frequency_3\NN|To|due|. (l_prep) of_8\IN|the|severity|, (l_pobj) haemorrhages_13\NNS|NONE
D014859_D002543 CID warfarin_18\JJ| (r_compound) drug_20\NN|in (r_compound) interactions_21\NNS|and (r_conj) warfarin_16\JJ|to (r_pobj) due_14\IN|frequency|To|. (r_prep) evaluate_1\VB|NONE (l_dobj) frequency_3\NN|To|due|. (l_prep) of_8\IN|the|severity|, (l_pobj) haemorrhages_13\NNS|NONE
D014859_D002543 CID warfarin_8\JJ|NONE (r_nmod) interactions_13\NNS|haemorrhage|have|could|whether (r_nsubj) caused_16\VBN|to (l_dobj) haemorrhage_19\NN|interactions|have|could|whether
D014859_D002543 CID warfarin_10\JJ| (r_compound) drug_12\NN|and (r_conj) warfarin_8\JJ|NONE (r_nmod) interactions_13\NNS|haemorrhage|have|could|whether (r_nsubj) caused_16\VBN|to (l_dobj) haemorrhage_19\NN|interactions|have|could|whether
D014859_D002543 CID warfarin_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) to_16\IN|NONE (r_prep) related_15\VBN|NONE (r_amod) as_14\IN|Among|were|. (r_prep) assessed_13\VBN|NONE (l_prep) Among_0\IN|as|were|. (l_pobj) patients_2\NNS|NONE (l_prep) with_3\IN| (l_pobj) haemorrhage_5\NN|NONE
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|cerebral (r_amod) haemorrhages_4\NNS|problem|.
D014859_D002543 CID warfarin_4\RB| (r_npadvmod) related_6\VBN|cerebral (r_amod) haemorrhages_8\NNS|NONE
D014859_D002543 CID warfarin_26\NN|NONE (r_pobj) with_25\IN|to (r_prep) interact_24\VB|NONE (r_xcomp) known_22\VBN|NONE (r_acl) drugs_21\NNS|when (r_dobj) prescribing_20\VBG|caution|been|if|had (r_advcl) taken_18\VBN|proportion|.|been|have|might (r_advcl) prevented_12\VBN|NONE (l_nsubjpass) proportion_2\NN|.|been|have|taken|might (l_prep) of_3\IN|A|significant (l_pobj) haemorrhages_8\NNS|NONE
3173179
D002216_D006973 NONE captopril_13\NN|NONE (r_pobj) of_12\IN|withdrawal|the|and (r_prep) introduction_11\NN|NONE (l_conj) withdrawal_16\NN|the|and|of (l_prep) in_19\IN|the|of (l_pobj) woman_23\NN|NONE (l_prep) with_24\IN|asymptomatic|a (l_pobj) hypertension_26\NN|NONE
D002216_D009203 NONE captopril_13\NN|NONE (r_pobj) of_12\IN|withdrawal|the|and (r_prep) introduction_11\NN|NONE (r_pobj) with_9\IN|infarction|in (r_prep) coincided_8\VBD|a (l_nsubj) infarction_7\NN|in|with
D014700_D009203 CID Verapamil_0\NNP|as|. (r_compound) withdrawal_1\NN|NONE (l_prep) as_2\IN|Verapamil|. (l_pobj) cause_5\NN|NONE (l_prep) of_6\IN|a|possible (l_pobj) infarction_8\NN|NONE
D014700_D009203 CID verapamil_18\NN|NONE (r_pobj) of_17\IN|the|in (r_prep) withdrawal_16\NN|the|and|of (r_conj) introduction_11\NN|NONE (r_pobj) with_9\IN|infarction|in (r_prep) coincided_8\VBD|a (l_nsubj) infarction_7\NN|in|with
D014700_D006973 NONE Verapamil_0\NNP|as|. (r_compound) withdrawal_1\NN|NONE (l_prep) as_2\IN|Verapamil|. (l_pobj) cause_5\NN|NONE (l_prep) of_6\IN|a|possible (l_pobj) infarction_8\NN|NONE (l_prep) in_9\IN|with|myocardial (l_pobj) woman_12\NN|NONE (l_amod) hypertensive_11\JJ|a
D014700_D006973 NONE verapamil_18\NN|NONE (r_pobj) of_17\IN|the|in (r_prep) withdrawal_16\NN|the|and|of (l_prep) in_19\IN|the|of (l_pobj) woman_23\NN|NONE (l_prep) with_24\IN|asymptomatic|a (l_pobj) hypertension_26\NN|NONE
12202650
D002211_D063806 NONE Capsaicin_0\NN| (r_npadvmod) induced_2\VBN|muscle (r_amod) pain_4\NN|.|excitability
D002211_D010146 CID Capsaicin_0\NNS|was|.|induce|into (r_nsubjpass) injected_7\VBN|NONE (l_advcl) induce_13\VB|was|.|Capsaicin|into (l_dobj) pain_14\NN|in|to
1833784
D015647_D006948 NONE 38393_17\CD|NONE (r_nummod) SKF_16\NNP|the|D (r_appos) agonist_15\NN|effect|whereas (r_nsubj) had_18\VBD|.|with|, (r_advcl) Pretreatment_0\NN|NONE (l_prep) with_1\IN|had|.|, (l_pobj) agonist_4\NN|NONE (l_appos) hyperactivity_10\NN|the|D
-1_D006948 NONE PHNO_5\NNP|NONE (r_npadvmod) enhanced_6\VBN|induced (r_amod) hyperactivity_10\NN|the|D
C534628_D006948 NONE 23390_12\CD|NONE (r_nummod) SCH_11\NNP|D|the|selective (r_appos) antagonist_10\NN|NONE (r_pobj) by_6\IN|hyperactivity|was (r_agent) blocked_5\VBN|fluphenazine|antagonist|and|.|, (l_nsubjpass) hyperactivity_3\NN|was|by
D004298_D006948 NONE dopamine_8\NN|and (r_conj) D1_5\NN|NONE (r_nmod) receptors_9\NNS|NONE (r_pobj) of_4\IN|in|an (r_prep) involvement_3\NN|NONE (l_prep) in_10\IN|an|of (l_pcomp) mediating_11\VBG|NONE (l_dobj) hyperactivity_15\NN|NONE
D009538_D006948 CID nicotine_12\NN| (r_npadvmod) induced_14\VBN|in (r_amod) hyperactivity_15\NN|NONE
D009538_D006948 CID Nicotine_0\NNP|,|.|increase|had|but (r_nsubj) caused_5\VBD|NONE (l_dobj) increase_8\NN|,|.|Nicotine|had|but (l_prep) in_9\IN|a|significant|habituated (l_pobj) activity_11\NN|NONE
D009538_D006948 CID Nicotine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) hyperactivity_3\NN|was|by
D009538_D006948 CID nicotine_7\NN| (r_npadvmod) induced_9\VBN|enhanced (r_amod) hyperactivity_10\NN|the|D
D009538_D006948 CID nicotine_5\NN|acute (r_compound) injection_6\NN|that|hyperactivity (r_nsubj) induces_7\VBZ|results|. (l_dobj) hyperactivity_10\NN|that|injection
D020891_D006948 NONE raclopride_18\NN|NONE (l_ccomp) blocked_5\VBN|fluphenazine|antagonist|and|.|, (l_nsubjpass) hyperactivity_3\NN|was|by
D005476_D006948 NONE fluphenazine_23\NN|blocked|antagonist|and|.|, (r_conj) raclopride_18\NN|NONE (l_ccomp) blocked_5\VBN|fluphenazine|antagonist|and|.|, (l_nsubjpass) hyperactivity_3\NN|was|by
3371379
D014700_D020258 CID Verapamil_0\NNP|.||neurotoxicity (r_npadvmod) induced_2\VBN|NONE (l_dobj) neurotoxicity_4\NN|.|Verapamil|
D014700_D020258 CID verapamil_11\NN|NONE (r_pobj) with_10\IN|combined (r_prep) treatment_9\NN|NONE (r_pobj) after_7\IN|of (r_prep) signs_3\NNS|NONE (l_prep) of_4\IN|after (l_pobj) neurotoxicity_6\NN|NONE
D002118_D020258 NONE calcium_19\NN|NONE (r_compound) entry_20\NN|the (r_compound) blocker_21\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) discontinuation_16\NN|NONE (r_pobj) after_15\IN|complete (r_prep) recovery_14\NN|.|patients (r_dobj) showed_12\VBD|NONE (l_nsubj) patients_1\NNS|.|recovery (l_prep) with_2\IN|Two (l_pobj) signs_3\NNS|NONE (l_prep) of_4\IN|after (l_pobj) neurotoxicity_6\NN|NONE
D002220_D020258 CID carbamazepine_3\NN|NONE (r_compound) neurotoxicity_4\NN|.|Verapamil|
D002220_D020258 CID carbamazepine_5\JJ|NONE (r_compound) neurotoxicity_6\NN|NONE
20080419
D010862_D004827 CID pilocarpine_24\NN|NONE (r_pobj) by_23\IN|in (r_agent) induced_22\VBN|of|a (r_acl) model_19\NN|NONE (l_prep) of_20\IN|induced|a (l_pobj) epilepsy_21\NN|NONE
10457883
16938416
C032109_D050197 NONE esters_38\NNS|administered|reported|dose|and|atherosclerosis|testosterone|) (r_appos) therapy_33\NN|NONE (l_conj) atherosclerosis_42\NN|administered|reported|dose|and|testosterone|)|esters
D004967_D050197 NONE estrogen_30\NN| (r_compound) testosterone_32\NN|administered|reported|dose|and|atherosclerosis|)|esters (r_compound) therapy_33\NN|NONE (l_conj) atherosclerosis_42\NN|administered|reported|dose|and|testosterone|)|esters
D013739_D050197 CID testosterone_3\NN|is|with|. (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|is|.|testosterone (l_pobj) atherosclerosis_7\NN|NONE
D013739_D050197 CID testosterone_32\NN|administered|reported|dose|and|atherosclerosis|)|esters (r_compound) therapy_33\NN|NONE (l_conj) atherosclerosis_42\NN|administered|reported|dose|and|testosterone|)|esters
D013739_D050197 CID testosterone_7\NN|dose (r_compound) therapy_8\NN|adversely|atherosclerosis|and|indicate|may|that (r_nsubj) affect_11\VB|.|results (l_dobj) atherosclerosis_12\NN|therapy|adversely|and|indicate|may|that
D002784_D003920 NONE cholesterol_9\NN|,|pressure (r_compound) level_10\NN|, (r_conj) diabetes_7\NNS|NONE
D000431_D003920 NONE alcohol_17\NN|NONE (r_compound) use_18\NN|blood|systolic|or|, (r_conj) pressure_14\NN|,|cholesterol (r_conj) level_10\NN|, (r_conj) diabetes_7\NNS|NONE
17612891
D003024_D012559 NONE clozapine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) commencement_14\NN|NONE (r_pobj) after_13\IN|onset|male|. (r_prep) developed_7\VBD|NONE (l_nsubj) male_4\NN|onset|after|. (l_prep) with_5\IN|old|A (l_pobj) schizophrenia_6\NN|NONE
D003024_D009205 CID clozapine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Acute (r_acl) myocarditis_1\NN|NONE
D003024_D009205 CID clozapine_10\NN|NONE (r_pobj) of_9\IN|the (r_prep) commencement_8\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|of|A (r_acl) case_1\NN|.|highlighting|,|is (l_prep) of_2\IN|associated|A (l_pobj) myocarditis_4\NN|NONE
D003024_D009205 CID clozapine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) commencement_14\NN|NONE (r_pobj) after_13\IN|onset|male|. (r_prep) developed_7\VBD|NONE (l_dobj) onset_10\NN|after|male|. (l_prep) of_11\IN|a|sudden (l_pobj) myocarditis_12\NN|NONE
D003024_D009205 CID clozapine_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|recognized|an (r_acl) complication_5\NN|.|Myocarditis (r_attr) is_1\VBZ|NONE (l_nsubj) Myocarditis_0\NNP|complication|.
D003024_D011618 NONE clozapine_2\NN|NONE (r_pobj) Considering_0\VBG|standard (r_csubj) remains_3\VBZ|there|.|need|, (l_attr) standard_6\NN|Considering (l_prep) in_7\IN|the|gold (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) psychosis_11\NN|NONE
12716030
D006493_D006470 NONE heparin_7\VBN|In|.|,|volume (r_nsubj) enhanced_8\VBD|NONE (l_dobj) volume_11\NN|In|.|,|heparin (l_prep) over_13\IN|hematoma|.fold|the (l_pobj) that_14\DT|NONE (l_acl) seen_15\VBN|NONE (l_prep) in_16\IN|NONE (l_pobj) control_17\NN|NONE (l_dobj) animals_19\NNS|NONE (l_conj) bleeding_22\NN|ICH|and
D006493_D002543 NONE heparin_7\VBN|In|.|,|volume (r_nsubj) enhanced_8\VBD|NONE (l_prep) In_0\IN|.|,|volume|heparin (l_pobj) induction_2\NN|NONE (l_compound) ICH_1\NNP|using
D006493_D002543 NONE heparin_7\VBN|In|.|,|volume (r_nsubj) enhanced_8\VBD|NONE (l_dobj) volume_11\NN|In|.|,|heparin (l_prep) over_13\IN|hematoma|.fold|the (l_pobj) that_14\DT|NONE (l_acl) seen_15\VBN|NONE (l_prep) in_16\IN|NONE (l_pobj) control_17\NN|NONE (l_dobj) animals_19\NNS|NONE (l_compound) ICH_18\NNP|and|bleeding
D006493_D006406 CID heparin_7\VBN|In|.|,|volume (r_nsubj) enhanced_8\VBD|NONE (l_dobj) volume_11\NN|In|.|,|heparin (l_compound) hematoma_10\NN|over|.fold|the
16274958
D017255_D055154 CID acitretin_3\NN|Recurrent|and|. (r_conj) dysphonia_1\NN|NONE
D017255_D055154 CID acitretin_15\NN|NONE (r_pobj) by_14\IN|was|she|while (r_agent) treated_13\VBN|.|We|case (r_advcl) report_1\VBP|NONE (l_dobj) case_3\NN|.|We|treated (l_prep) of_4\IN|the (l_pobj) woman_6\NN|NONE (l_acl) complaining_7\VBG|a (l_prep) of_8\IN|NONE (l_pobj) dysphonia_9\NN|NONE
D017255_D055154 CID acitretin_10\NN| (r_advmod) induced_12\VBN|NONE (r_amod) dysphonia_13\NN|NONE
19631624
D002188_D007859 NONE cannabis_12\NN|NONE (r_compound) users_13\NNS|NONE (r_pobj) in_11\IN|frontocortical (r_prep) hypoactivity_10\NN|and|parahippocampal (r_conj) hyperactivity_7\NN|:|in|. (r_appos) Deficits_0\NNS|NONE (l_prep) in_1\IN|:|hyperactivity|. (l_pobj) learning_2\NN|NONE (l_conj) memory_4\NN|and
D018817_D008569 CID ecstasy_5\NN|NONE (r_compound) users_6\NNS|NONE (r_pobj) in_4\IN|correlates|Learning|and (r_prep) deficits_3\NNS|NONE
D018817_D008569 CID ecstasy_6\NN|NONE (r_compound) users_7\NNS|impairments|that (r_nsubj) display_8\VBP|consistently|It|has|been|. (l_dobj) impairments_9\NNS|users|that (l_prep) in_10\IN|NONE (l_pobj) performance_14\NN|NONE (l_nmod) learning_11\NN|NONE (l_conj) memory_13\NN|and
D002188_D006948 NONE cannabis_12\NN|NONE (r_compound) users_13\NNS|NONE (r_pobj) in_11\IN|frontocortical (r_prep) hypoactivity_10\NN|and|parahippocampal (r_conj) hyperactivity_7\NN|:|in|.
D018817_D020258 NONE ecstasy_1\NN| (r_npadvmod) specific_3\JJ|These (r_amod) effects_4\NNS|to|may|be|. (r_nsubjpass) related_7\VBN|NONE (l_prep) to_8\IN|may|be|effects|. (l_pobj) vulnerability_10\NN|NONE (l_prep) to_16\IN|of|the (l_pobj) effects_19\NNS|NONE (l_amod) neurotoxic_18\JJ|of|the
D018817_D020258 NONE ecstasy_21\NN|NONE (r_pobj) of_20\IN|the|neurotoxic (r_prep) effects_19\NNS|NONE (l_amod) neurotoxic_18\JJ|of|the
D018817_D006948 NONE ecstasy_13\NN| (r_npadvmod) specific_15\JJ|in (r_amod) hyperactivity_16\NN|,|.|analysis|left
D002188_D008569 NONE cannabis_12\NN|NONE (r_compound) users_13\NNS|NONE (r_pobj) in_11\IN|frontocortical (r_prep) hypoactivity_10\NN|and|parahippocampal (r_conj) hyperactivity_7\NN|:|in|. (r_appos) Deficits_0\NNS|NONE (l_prep) in_1\IN|:|hyperactivity|. (l_pobj) learning_2\NN|NONE (l_conj) memory_4\NN|and
D018817_D007859 CID ecstasy_5\NN|NONE (r_compound) users_6\NNS|NONE (r_pobj) in_4\IN|correlates|Learning|and (r_prep) deficits_3\NNS|NONE
D018817_D007859 CID ecstasy_6\NN|NONE (r_compound) users_7\NNS|impairments|that (r_nsubj) display_8\VBP|consistently|It|has|been|. (l_dobj) impairments_9\NNS|users|that (l_prep) in_10\IN|NONE (l_pobj) performance_14\NN|NONE (l_nmod) learning_11\NN|NONE (l_conj) memory_13\NN|and
1732369
D004317_D009202 CID Doxorubicin_0\NNP|agent|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_6\NN|Doxorubicin|. (l_acl) known_7\VBN|effective|anticancer|chemotherapeutic|an (l_xcomp) cause_9\VB|NONE (l_dobj) cardiomyopathy_13\NN|to
D004280_D006331 NONE dobutamine_21\NN|NONE (r_compound) infusion_22\NN|differentiate (r_dobj) using_20\VBG|,|.|was|develop|study (r_xcomp) performed_19\VBN|NONE (l_advcl) develop_1\VB|,|.|was|using|study (l_dobj) test_7\NN|To (l_prep) for_8\IN|echocardiographic|sensitive|screening|a (l_pobj) damage_10\NN|NONE
D004317_D009369 NONE doxorubicin_13\NN| (r_npadvmod) treated_15\VBN|term|of|asymptomatic (r_amod) survivors_19\NNS|NONE (l_prep) of_20\IN|term|treated|asymptomatic (l_pobj) cancer_22\NN|NONE
D004317_D009369 NONE doxorubicin_13\NN|to (r_pobj) due_11\IN|cardiac (r_amod) damage_10\NN|NONE (r_pobj) for_8\IN|echocardiographic|sensitive|screening|a (r_prep) test_7\NN|To (r_dobj) develop_1\VB|,|.|was|using|study (r_advcl) performed_19\VBN|NONE (l_xcomp) using_20\VBG|,|.|was|develop|study (l_xcomp) differentiate_24\VB|infusion (l_dobj) survivors_29\NNS|to (l_prep) of_30\IN|term|treated|asymptomatic (l_pobj) cancer_32\NN|NONE
D004317_D009369 NONE doxorubicin_35\NN|NONE (r_pobj) with_34\IN|from (r_prep) treated_33\VBN|of|term|asymptomatic (r_acl) survivors_29\NNS|to (l_prep) of_30\IN|term|treated|asymptomatic (l_pobj) cancer_32\NN|NONE
D004317_D006331 NONE doxorubicin_13\NN|to (r_pobj) due_11\IN|cardiac (r_amod) damage_10\NN|NONE
D004317_D006331 NONE doxorubicin_35\NN|NONE (r_pobj) with_34\IN|from (r_prep) treated_33\VBN|of|term|asymptomatic (r_acl) survivors_29\NNS|to (r_dobj) differentiate_24\VB|infusion (r_xcomp) using_20\VBG|,|.|was|develop|study (r_xcomp) performed_19\VBN|NONE (l_advcl) develop_1\VB|,|.|was|using|study (l_dobj) test_7\NN|To (l_prep) for_8\IN|echocardiographic|sensitive|screening|a (l_pobj) damage_10\NN|NONE
D004280_D009369 NONE Dobutamine_0\NNP|indicator|:|.|echocardiography (r_nsubj) stress_1\VBP|NONE (l_appos) indicator_6\NN|:|Dobutamine|.|echocardiography (l_prep) of_7\IN|a|sensitive (l_pobj) function_10\NN|NONE (l_prep) in_11\IN|myocardial|diminished (l_pobj) survivors_19\NNS|NONE (l_prep) of_20\IN|term|treated|asymptomatic (l_pobj) cancer_22\NN|NONE
D004280_D009369 NONE dobutamine_21\NN|NONE (r_compound) infusion_22\NN|differentiate (r_dobj) using_20\VBG|,|.|was|develop|study (l_xcomp) differentiate_24\VB|infusion (l_dobj) survivors_29\NNS|to (l_prep) of_30\IN|term|treated|asymptomatic (l_pobj) cancer_32\NN|NONE
3629586
D002511_D006402 NONE cephalosporin_15\JJ|in (r_amod) hematotoxicity_16\NN|NONE
D002511_D006402 NONE Cephalosporin_0\JJ|NONE (r_amod) antibiotics_1\NNS|.|variety|characterized (r_nsubj) cause_2\VBP|NONE (l_dobj) variety_4\NN|antibiotics|.|characterized (l_prep) of_5\IN|,|a (l_pobj) disturbances_7\NNS|NONE
D002511_D006402 NONE cephalosporin_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rechallenge_1\VB|NONE (r_pobj) Upon_0\IN|in|syndrome|,|was (r_prep) reproduced_10\VBN|compared|period|.|;|dogs (l_nsubjpass) syndrome_8\NN|in|,|Upon|was
D002511_D006402 NONE cephalosporin_20\NN| (r_advmod) induced_22\VBN|blood|described|the (r_amod) dyscrasias_24\NNS|NONE (r_pobj) to_18\IN|NONE (r_prep) similar_17\JJ|NONE (r_amod) hematotoxicity_16\NN|can|provides|and|administration|that
D002511_D006402 NONE cephalosporin_20\NN| (r_advmod) induced_22\VBN|blood|described|the (r_amod) dyscrasias_24\NNS|NONE
D015790_D009503 CID cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|In|,|.|administration|thrombocytopenia (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE (l_conj) neutropenia_25\NN|,
C021341_D064420 NONE cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_prep) In_0\IN|,|.|administration|thrombocytopenia|incidence (l_pobj) studies_4\NNS|NONE (l_compound) toxicity_3\NN|four|subacute
D015790_D013921 CID cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_ccomp) thrombocytopenia_28\NN|In|,|.|administration|incidence
C021341_D006402 NONE cefazedone_6\NN|and (r_conj) cefonicid_4\NN|NONE (r_pobj) of_3\IN|model|.|hematologic|The|: (r_prep) effects_2\NNS|NONE (l_appos) model_13\NN|of|.|hematologic|The|: (l_prep) of_14\IN|potential|a (l_pobj) hematotoxicity_16\NN|NONE
C021341_D006402 NONE cefazedone_29\NN|mg/kg|or| (r_conj) cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|.|and|compromising (r_conj) was_3\VBD|NONE (l_attr) compromising_6\NN|occurred|anemia|.|and (l_prep) of_7\IN|the|most (l_pobj) cytopenias_9\NNS|NONE
C021341_D006402 NONE cefazedone)-treated_20\VBN|cefonicid|( (r_amod) dogs_21\NNS|compared|period|.|reproduced|; (r_nsubj) showed_22\VBD|NONE (l_ccomp) reproduced_10\VBN|compared|period|.|;|dogs (l_nsubjpass) syndrome_8\NN|in|,|Upon|was
C021341_D006402 NONE cefazedone_11\NN|or (r_conj) cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|can|provides|and|hematotoxicity|that (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|can|provides|and|administration|that
C021341_D006402 NONE cefazedone_11\NN|or (r_conj) cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|can|provides|and|hematotoxicity|that (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|can|provides|and|administration|that (l_amod) similar_17\JJ|NONE (l_prep) to_18\IN|NONE (l_pobj) dyscrasias_24\NNS|NONE
D015790_D064420 NONE cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_prep) In_0\IN|,|.|administration|thrombocytopenia|incidence (l_pobj) studies_4\NNS|NONE (l_compound) toxicity_3\NN|four|subacute
C021341_D009503 CID cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|In|,|.|administration|thrombocytopenia (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE (l_conj) neutropenia_25\NN|,
C021341_D013921 CID cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_ccomp) thrombocytopenia_28\NN|In|,|.|administration|incidence
D015790_D006402 NONE cefonicid_4\NN|NONE (r_pobj) of_3\IN|model|.|hematologic|The|: (r_prep) effects_2\NNS|NONE (l_appos) model_13\NN|of|.|hematologic|The|: (l_prep) of_14\IN|potential|a (l_pobj) hematotoxicity_16\NN|NONE
D015790_D006402 NONE cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|.|and|compromising (r_conj) was_3\VBD|NONE (l_attr) compromising_6\NN|occurred|anemia|.|and (l_prep) of_7\IN|the|most (l_pobj) cytopenias_9\NNS|NONE
D015790_D006402 NONE cefonicid_16\NN|(|cefazedone)treated (r_amod) dogs_21\NNS|compared|period|.|reproduced|; (r_nsubj) showed_22\VBD|NONE (l_ccomp) reproduced_10\VBN|compared|period|.|;|dogs (l_nsubjpass) syndrome_8\NN|in|,|Upon|was
D015790_D006402 NONE cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|can|provides|and|hematotoxicity|that (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|can|provides|and|administration|that
D015790_D006402 NONE cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|can|provides|and|hematotoxicity|that (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|can|provides|and|administration|that (l_amod) similar_17\JJ|NONE (l_prep) to_18\IN|NONE (l_pobj) dyscrasias_24\NNS|NONE
D015790_D000740 CID cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|In|,|.|administration|thrombocytopenia (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE
D015790_D000740 CID cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|.|and|compromising (r_conj) was_3\VBD|NONE (l_nsubj) anemia_2\NN|occurred|.|and|compromising
C021341_D000740 CID cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|the|to|intravenous (r_prep) administration_8\NN|In|,|.|thrombocytopenia|incidence (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|In|,|.|administration|thrombocytopenia (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE
C021341_D000740 CID cefazedone_29\NN|mg/kg|or| (r_conj) cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|.|and|compromising (r_conj) was_3\VBD|NONE (l_nsubj) anemia_2\NN|occurred|.|and|compromising
14698717
D010672_D004827 NONE phenytoin_10\JJ|in (r_compound) treatment_11\NN|NONE (l_prep) in_12\IN|phenytoin (l_pobj) patients_15\NNS|NONE (l_amod) epileptic_14\JJ|some
D010672_D011605 NONE phenytoin_6\NN|NONE (r_pobj) with_5\IN|in (r_prep) treatment_4\NN|to (r_pobj) due_2\IN|.|Acute (r_amod) psychosis_1\NN|NONE
D010672_D011605 NONE phenytoin_10\JJ|for (r_compound) treatment_11\NN|NONE (r_dobj) following_9\VBG|NONE (r_acl) psychosis_8\NN|who
D010672_D011605 NONE phenytoin_10\JJ|in (r_compound) treatment_11\NN|NONE (r_pobj) following_9\VBG|that (r_prep) occur_8\VBP|the|psychotic (r_relcl) symptoms_6\NNS|may|result|that
D010672_D012640 NONE phenytoin_10\JJ|in (r_compound) treatment_11\NN|NONE (r_pobj) following_9\VBG|that (r_prep) occur_8\VBP|the|psychotic (r_relcl) symptoms_6\NNS|may|result|that (r_nsubj) be_17\VB|.|case (l_attr) result_20\NN|may|symptoms|that (l_amod) unrelated_24\JJ|,|of|the|direct (l_prep) to_25\IN|NONE (l_pobj) seizures_26\NNS|NONE
D010672_D014277 NONE phenytoin_10\JJ|for (r_compound) treatment_11\NN|NONE (l_prep) for_12\IN|phenytoin (l_pobj) neuralgia_14\NN|NONE
17931375
D006493_D003288 CID heparin_10\JJ|on|subcutaneous (r_compound) injection_11\NN|NONE (l_prep) on_12\IN|heparin|subcutaneous (l_pobj) bruising_13\VBG|NONE
D006493_D003288 CID heparin_24\NN|NONE (r_pobj) of_23\IN|subcutaneous|the (r_prep) injection_22\NN|NONE (r_pobj) of_19\IN|the (r_prep) administration_18\NN|NONE (r_pobj) following_16\VBG|the|of (r_prep) effect_8\NN|to (l_prep) of_9\IN|the|following (l_pobj) duration_11\NN|NONE (l_prep) on_12\IN|injection (l_pobj) bruising_13\VBG|NONE
D006493_D003288 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (l_dobj) bruising_5\NN|to|following
D006493_D003288 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (r_acl) methods_2\NNS|described|widely|been|Although|have|and (r_nsubjpass) studied_17\VBN|little|is|,|.|effect (r_advcl) documented_35\JJ|NONE (l_nsubjpass) effect_22\NN|little|studied|is|,|. (l_prep) of_23\IN|the (l_pobj) duration_25\NN|NONE (l_prep) on_26\IN|injection (l_pobj) occurrence_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) bruising_30\VBG|NONE
D006493_D003288 CID heparin_6\NN|areas (r_pobj) on_4\IN|the (r_prep) bruising_3\NN|NONE
D006493_D003288 CID heparin_18\NN|NONE (r_pobj) of_17\IN|subcutaneous|the (r_prep) administration_16\NN|NONE (r_pobj) following_13\VBG|effect|that|duration (r_prep) had_6\VBD|.|It|was (l_dobj) effect_8\NN|that|duration|following (l_prep) on_9\IN|an (l_pobj) bruising_10\VBG|NONE
D006493_D010146 CID heparin_10\JJ|on|subcutaneous (r_compound) injection_11\NN|NONE (l_prep) on_12\IN|heparin|subcutaneous (l_pobj) bruising_13\VBG|NONE (l_conj) pain_15\NN|and
D006493_D010146 CID heparin_24\NN|NONE (r_pobj) of_23\IN|subcutaneous|the (r_prep) injection_22\NN|NONE (r_pobj) of_19\IN|the (r_prep) administration_18\NN|NONE (r_pobj) following_16\VBG|the|of (r_prep) effect_8\NN|to (l_prep) of_9\IN|the|following (l_pobj) duration_11\NN|NONE (l_prep) on_12\IN|injection (l_pobj) bruising_13\VBG|NONE (l_conj) pain_15\NN|and
D006493_D010146 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (l_dobj) bruising_5\NN|to|following (l_conj) pain_7\NN|and
D006493_D010146 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (r_acl) methods_2\NNS|described|widely|been|Although|have|and (r_nsubjpass) studied_17\VBN|little|is|,|.|effect (r_advcl) documented_35\JJ|NONE (l_nsubjpass) effect_22\NN|little|studied|is|,|. (l_prep) of_23\IN|the (l_pobj) duration_25\NN|NONE (l_prep) on_26\IN|injection (l_pobj) occurrence_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) bruising_30\VBG|NONE (l_conj) pain_32\NN|and
D006493_D010146 CID heparin_18\NN|NONE (r_pobj) of_17\IN|subcutaneous|the (r_prep) administration_16\NN|NONE (r_pobj) following_13\VBG|effect|that|duration (r_prep) had_6\VBD|.|It|was (l_dobj) effect_8\NN|that|duration|following (l_prep) on_9\IN|an (l_pobj) bruising_10\VBG|NONE (l_conj) pain_12\NN|and
2696505
D009599_D006973 NONE nitroprusside_31\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) discontinuation_29\NN|NONE (r_pobj) after_28\IN|associated|;|.|hypertension|in|was (r_prep) observed_24\VBN|NONE (l_nsubjpass) hypertension_22\NN|associated|;|.|in|was|after
D009599_D007022 CID nitroprusside_6\RB|and (l_prep) for_7\IN|NONE (l_pobj) hypotension_9\NN|NONE
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|NONE (r_amod) hypotension_13\NN|induced|and (r_conj) hypotension_8\NN|,|In|in|.|were
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|NONE (r_amod) hypotension_13\NN|induced|and
D009599_D016534 CID nitroprusside_31\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) discontinuation_29\NN|NONE (r_pobj) after_28\IN|associated|;|.|hypertension|in|was (r_prep) observed_24\VBN|NONE (l_ccomp) associated_3\VBN|;|.|hypertension|in|was|after (l_advcl) increase_13\NN|with|infusion|was (l_prep) in_14\IN|NONE (l_pobj) rate_16\NN|NONE (l_conj) output_19\NN|and|heart
D007741_D007022 CID labetalol_4\NN|NONE (l_conj) nitroprusside_6\RB|and (l_prep) for_7\IN|NONE (l_pobj) hypotension_9\NN|NONE
D007741_D007022 CID labetalol_5\RB| (r_npadvmod) induced_7\VBN|hypotension|and (r_amod) hypotension_8\NN|,|In|in|.|were
D007741_D007022 CID labetalol_5\RB| (r_npadvmod) induced_7\VBN|hypotension|and (r_amod) hypotension_8\NN|,|In|in|.|were (l_conj) hypotension_13\NN|induced|and
10579464
D003024_D002375 CID clozapine_2\NN|and (r_conj) NRA0160_0\NNP|,|significantly|.|exceed|in|catalepsy (r_nsubj) induced_4\VBN|NONE (l_dobj) catalepsy_5\NN|NRA|,|significantly|.|exceed|in
D008694_D006948 CID methamphetamine_8\NN|NONE (r_pobj) by_7\IN|in (r_agent) induced_6\VBN|locomotor (r_acl) hyperactivity_5\NN|NRA|.
D008694_D006948 CID MAP_10\NNP|)|( (r_appos) methamphetamine_8\NN|NONE (r_pobj) by_7\IN|in (r_agent) induced_6\VBN|locomotor (r_acl) hyperactivity_5\NN|NRA|.
C121249_D006948 NONE NRA0160_0\NNP|hyperactivity|. (r_nsubj) antagonized_3\VBN|NONE (l_dobj) hyperactivity_5\NN|NRA|.
D003024_D006948 NONE clozapine_2\NN|and (r_conj) NRA0160_0\NNP|hyperactivity|. (r_nsubj) antagonized_3\VBN|NONE (l_dobj) hyperactivity_5\NN|NRA|.
C121249_D002375 CID NRA0160_0\NNP|,|significantly|.|exceed|in|catalepsy (r_nsubj) induced_4\VBN|NONE (l_dobj) catalepsy_5\NN|NRA|,|significantly|.|exceed|in
19356307
C032208_D003704 NONE alcohol_13\NN|NONE (r_pobj) of_5\IN|The|dementia (r_prep) effects_4\NNS|.|using|were (l_compound) dementia_3\NN|The|of
D012601_D008569 CID scopolamine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) impaired_10\VBN|NONE
D012601_D008569 CID scopolamine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) impaired_10\VBN|NONE (r_amod) memory_9\NN|to (r_dobj) improve_8\VB|strong (r_acl) ability_6\NN|oils (r_dobj) showed_4\VBD|alcohol|.|deficit|improve|only|however|,|and|,|; (r_ccomp) relieved_20\VBD|NONE (l_dobj) deficit_22\NN|alcohol|.|improve|showed|only|however|,|and|,|; (l_prep) of_23\IN|the|in (l_pobj) memory_25\NN|NONE
C032208_D008569 NONE alcohol_19\NN|.|deficit|improve|showed|only|however|,|and|,|; (r_nsubj) relieved_20\VBD|NONE (l_ccomp) showed_4\VBD|alcohol|.|deficit|improve|only|however|,|and|,|; (l_dobj) ability_6\NN|oils (l_acl) improve_8\VB|strong (l_dobj) memory_9\NN|to (l_amod) impaired_10\VBN|NONE
C032208_D008569 NONE alcohol_19\NN|.|deficit|improve|showed|only|however|,|and|,|; (r_nsubj) relieved_20\VBD|NONE (l_dobj) deficit_22\NN|alcohol|.|improve|showed|only|however|,|and|,|; (l_prep) of_23\IN|the|in (l_pobj) memory_25\NN|NONE
D012601_D003704 NONE scopolamine_9\NN|NONE (r_pobj) by_8\IN|Components|. (r_agent) induced_7\VBN|NONE (l_nsubj) Components_0\NNS|by|. (l_prep) of_1\IN|NONE (l_pobj) dementia_6\NN|NONE
C008281_D003704 NONE limonene_8\NN|NONE (r_nmod) alcohol_13\NN|NONE (r_pobj) of_5\IN|The|dementia (r_prep) effects_4\NNS|.|using|were (l_compound) dementia_3\NN|The|of
2273650
D012601_D000647 CID scopolamine_3\NN|NONE (r_pobj) by_2\IN|NONE (r_agent) produced_1\VBN|NONE (r_acl) Amnesia_0\NNP|were|given|by|,|facilitated|and
D012601_D000647 CID scopolamine_5\NN|partially|Similarly|but|amnesia|,|failed (r_nsubj) reversed_7\VBD|NONE (l_dobj) amnesia_12\NN|partially|Similarly|but|scopolamine|,|failed
D012601_D000647 CID scopolamine_5\NN|partially|Similarly|but|amnesia|,|failed (r_nsubj) reversed_7\VBD|NONE (l_conj) failed_23\VBD|partially|Similarly|but|amnesia|scopolamine|, (l_xcomp) reverse_25\VB|significantly|.|cycloheximide (l_dobj) amnesia_30\NN|to
D012601_D000647 CID scopolamine_9\NN| (r_npadvmod) induced_11\VBN|the (r_amod) amnesia_12\NN|partially|Similarly|but|scopolamine|,|failed
D012601_D000647 CID scopolamine_9\NN| (r_npadvmod) induced_11\VBN|the (r_amod) amnesia_12\NN|partially|Similarly|but|scopolamine|,|failed (r_dobj) reversed_7\VBD|NONE (l_conj) failed_23\VBD|partially|Similarly|but|amnesia|scopolamine|, (l_xcomp) reverse_25\VB|significantly|.|cycloheximide (l_dobj) amnesia_30\NN|to
D009270_D000647 NONE naloxone_37\NN|during (r_dobj) administered_36\VBN|in|memory|the (r_acl) retrieval_32\NN|morphine|also|. (r_dobj) facilitated_29\VBD|were|given|by|Amnesia|,|and (r_conj) reversed_7\VBN|NONE (l_nsubjpass) Amnesia_0\NNP|were|given|by|,|facilitated|and
D009020_D000647 NONE morphine_9\NN|NONE (r_pobj) by_8\IN|were|given|Amnesia|,|facilitated|and (r_agent) reversed_7\VBN|NONE (l_nsubjpass) Amnesia_0\NNP|were|given|by|,|facilitated|and
D009020_D000647 NONE morphine_27\NN|also|retrieval|. (r_nsubj) facilitated_29\VBD|were|given|by|Amnesia|,|and (r_conj) reversed_7\VBN|NONE (l_nsubjpass) Amnesia_0\NNP|were|given|by|,|facilitated|and
D003513_D000647 CID cycloheximide_5\NN|and (r_conj) scopolamine_3\NN|NONE (r_pobj) by_2\IN|NONE (r_agent) produced_1\VBN|NONE (r_acl) Amnesia_0\NNP|were|given|by|,|facilitated|and
D003513_D000647 CID cycloheximide_22\NN|significantly|.|reverse (r_nsubj) failed_23\VBD|partially|Similarly|but|amnesia|scopolamine|, (r_conj) reversed_7\VBD|NONE (l_dobj) amnesia_12\NN|partially|Similarly|but|scopolamine|,|failed
D003513_D000647 CID cycloheximide_22\NN|significantly|.|reverse (r_nsubj) failed_23\VBD|partially|Similarly|but|amnesia|scopolamine|, (l_xcomp) reverse_25\VB|significantly|.|cycloheximide (l_dobj) amnesia_30\NN|to
D003513_D000647 CID cycloheximide_27\RB| (r_advmod) induced_29\VBN|the (r_amod) amnesia_30\NN|to (r_dobj) reverse_25\VB|significantly|.|cycloheximide (r_xcomp) failed_23\VBD|partially|Similarly|but|amnesia|scopolamine|, (r_conj) reversed_7\VBD|NONE (l_dobj) amnesia_12\NN|partially|Similarly|but|scopolamine|,|failed
D003513_D000647 CID cycloheximide_27\RB| (r_advmod) induced_29\VBN|the (r_amod) amnesia_30\NN|to
18217897
D013792_D009369 NONE Thalidomide_0\NNP|in|activity|has (r_nsubj) limited_2\VBN|NONE (l_prep) in_7\IN|activity|has|Thalidomide (l_pobj) lymphomas_15\NNS|NONE (l_appos) trial_20\NN|indolent|Hodgkin|relapsed|: (l_prep) of_21\IN|a|phase|II (l_pobj) Cancer_23\NNP|NONE
D013792_D008228 NONE Thalidomide_0\NNP|in|activity|has (r_nsubj) limited_2\VBN|NONE (l_prep) in_7\IN|activity|has|Thalidomide (l_pobj) lymphomas_15\NNS|NONE
D013792_D009101 NONE Thalidomide_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Thalidomide (l_prep) with_5\IN|immunomodulatory|an (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|demonstrated (l_pobj) myeloma_10\NN|NONE
C467567_D008223 NONE lenalidomide_31\NN|generation|the|,|immunomodulatory (r_appos) agent_29\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) reported_23\VBN|the|activity|higher (r_acl) level_22\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) contrast_17\NN|rate|and|to (r_conj) demonstrate_4\VB|results|. (l_dobj) rate_8\NN|contrast|and|to (l_prep) in_13\IN|an|response|to|important (l_pobj) lymphomas_15\NNS|NONE
D013792_D008223 NONE Thalidomide_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Thalidomide (l_prep) with_5\IN|immunomodulatory|an (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|demonstrated (l_pobj) myeloma_10\NN|NONE (l_conj) lymphoma_14\NN|multiple|, (l_conj) lymphoma_17\NN|cell|and|mantle
D013792_D008223 NONE thalidomide_16\NN|.|daily|,|Between|tolerated|patients|with (r_dobj) received_15\VBD|NONE (l_nsubj) patients_8\NNS|.|daily|thalidomide|,|Between|tolerated|with (l_prep) with_9\IN| (l_pobj) lymphomas_14\NNS|NONE
D013792_D008223 NONE thalidomide_12\NN|NONE (r_pobj) to_9\IN|an|response|important|in (r_prep) rate_8\NN|contrast|and|to (l_prep) in_13\IN|an|response|to|important (l_pobj) lymphomas_15\NNS|NONE
D013792_D007938 NONE Thalidomide_0\NNP|in|activity|has (r_nsubj) limited_2\VBN|NONE (l_prep) in_7\IN|activity|has|Thalidomide (l_pobj) lymphomas_15\NNS|NONE (l_appos) trial_20\NN|indolent|Hodgkin|relapsed|: (l_prep) of_21\IN|a|phase|II (l_pobj) Cancer_23\NNP|NONE (l_conj) B._27\NNP|the|and (l_compound) Leukemia_25\NNP|Group
D013792_D020522 NONE Thalidomide_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Thalidomide (l_prep) with_5\IN|immunomodulatory|an (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|demonstrated (l_pobj) myeloma_10\NN|NONE (l_conj) lymphoma_14\NN|multiple|,
3070035
D002216_D051437 NONE captopril_2\NN| (r_npadvmod) induced_4\VBN|renal (r_amod) insufficiency_6\NN|NONE
D002216_D051437 NONE captopril_4\NN| (r_npadvmod) induced_6\VBN|renal (r_amod) failure_8\NN|NONE
D002216_D058186 CID captopril_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatment_25\NN|NONE (r_pobj) following_24\VBG|of|sudden (r_prep) deterioration_20\NN|who (l_prep) of_21\IN|sudden|following (l_pobj) function_23\NN|NONE
D002216_D006978 NONE captopril_2\NN| (r_npadvmod) induced_4\VBN|renal (r_amod) insufficiency_6\NN|NONE (r_pobj) of_1\IN|after|. (r_prep) Reversibility_0\NN|NONE (l_prep) after_7\IN|of|. (l_pobj) use_9\NN|NONE (l_prep) in_10\IN|prolonged (l_pobj) case_13\NN|NONE (l_prep) of_14\IN|unusual|an (l_pobj) hypertension_16\NN|NONE
D002216_D006973 NONE captopril_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatment_25\NN|NONE (r_pobj) following_24\VBG|of|sudden (r_prep) deterioration_20\NN|who (r_dobj) developed_18\VBD|,|a|solitary (r_relcl) kidney_15\NN|NONE (r_pobj) to_12\IN|renal|occluded|an (r_prep) artery_11\NN|NONE (r_pobj) with_7\IN|severe (r_prep) hypertension_6\NN|NONE
1987816
D008094_D011141 CID Lithium_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) polyuria_3\NN|.|related
4008111
D000638_D012848 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|sinoatrial|. (r_amod) block_4\NN|NONE
D000638_D012848 CID amiodarone_7\NN|in|chronic (r_compound) administration_8\NN|to (r_pobj) due_4\JJ|syndrome|,|block|We|. (r_prep) observed_1\VBD|NONE (l_dobj) block_3\NN|syndrome|,|We|.|due
D000638_D012848 CID amiodarone_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) dosage_3\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Reduction_0\NN|.|in (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|Reduction|. (l_pobj) disappearance_9\NN|NONE (l_prep) of_10\IN|the|persistence|and (l_pobj) block_13\NN|NONE
D000638_D013617 NONE amiodarone_7\NN|in|chronic (r_compound) administration_8\NN|to (r_pobj) due_4\JJ|syndrome|,|block|We|. (r_prep) observed_1\VBD|NONE (l_dobj) syndrome_24\NN|,|block|We|.|due (l_conj) tachycardia_27\NN|White|and
D000638_D009202 NONE amiodarone_7\NN|in|chronic (r_compound) administration_8\NN|to (l_prep) in_9\IN|amiodarone|chronic (l_pobj) boy_14\NN|NONE (l_prep) with_15\IN|a|old (l_pobj) cardiomyopathy_17\NN|NONE
D000638_D012804 NONE amiodarone_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) dosage_3\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Reduction_0\NN|.|in (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|Reduction|. (l_pobj) disappearance_9\NN|NONE (l_conj) persistence_16\NN|the|and|of (l_prep) of_17\IN|the (l_pobj) bradycardia_20\NNP|NONE
D000638_D014927 NONE amiodarone_7\NN|in|chronic (r_compound) administration_8\NN|to (r_pobj) due_4\JJ|syndrome|,|block|We|. (r_prep) observed_1\VBD|NONE (l_dobj) syndrome_24\NN|,|block|We|.|due
3425586
D003622_D000743 CID Dapsone_0\NN| (r_npadvmod) associated_2\VBN|Heinz|body|.|in|hemolytic (r_amod) anemia_6\NN|NONE
D003622_D000743 CID dapsone_23\NN|NONE (r_pobj) of_22\IN|associated|a (r_prep) dose_21\NN|while (r_dobj) taking_19\VBG|anemia|.|woman (r_advcl) developed_12\VBD|NONE (l_dobj) anemia_17\NN|.|woman|taking
D003622_D000743 CID dapsone_21\NN|does|not|anemia|at|since (r_nsubj) cause_24\VB|sensitivity|in|,|to (l_dobj) anemia_26\NN|does|not|dapsone|at|since
D003622_D007918 NONE dapsone_23\NN|NONE (r_pobj) of_22\IN|associated|a (r_prep) dose_21\NN|while (r_dobj) taking_19\VBG|anemia|.|woman (r_advcl) developed_12\VBD|NONE (l_nsubj) woman_2\NN|anemia|.|taking (l_conj) leprosy_11\NN|with|Cambodian|A
D003622_D006461 NONE dapsone_23\NN|NONE (r_pobj) of_22\IN|associated|a (r_prep) dose_21\NN|while (l_acl) associated_32\VBN|of|a (l_prep) with_33\IN|not|usually (l_pobj) hemolysis_35\NN|NONE
15338796
D000420_D008173 NONE salbutamol_19\NN|NONE (r_pobj) of_18\IN|cumulative (r_prep) doses_17\NNS|NONE (r_pobj) of_15\IN|NONE (r_prep) administration_14\NN|NONE (r_pobj) after_13\IN|obstructive|lung (r_prep) disease_12\NN|NONE
D000420_D014202 CID salbutamol_4\NN|NONE (r_pobj) of_3\IN|side|.|quantified|,|Tremor (r_prep) effects_2\NNS|NONE (l_compound) Tremor_0\NNP|side|.|quantified|of|,
D000420_D014202 CID salbutamol_6\NN|NONE (r_pobj) of_5\IN|tremor|side (r_prep) effects_4\NNS|To (l_compound) tremor_2\JJ|side|of
D000420_D014202 CID salbutamol_19\NN|NONE (r_pobj) of_18\IN|cumulative (r_prep) doses_17\NNS|NONE (r_pobj) of_15\IN|NONE (r_prep) administration_14\NN|NONE (r_pobj) after_13\IN|obstructive|lung (r_prep) disease_12\NN|NONE (r_pobj) with_9\IN| (r_prep) patients_8\NNS|NONE (r_pobj) in_6\IN|we|tremor|determine|. (r_prep) assessed_4\VBD|NONE (l_dobj) tremor_5\NN|in|we|determine|.
D000420_D014202 CID Salbutamol_0\NNP|significantly|severity|.|in (r_nsubj) increased_2\VBD|NONE (l_dobj) severity_4\NN|significantly|.|Salbutamol|in (l_compound) tremor_3\NN|NONE
3358181
D012312_D014693 CID ritodrine_6\JJ|NONE (r_compound) therapy_7\NN|NONE (r_pobj) after_5\IN|cesarean (r_prep) section_4\NN|NONE (r_pobj) during_2\IN|:|interaction|.|Ventricular (r_prep) tachyarrhythmias_1\NNS|NONE
D010656_D007022 NONE phenylephrine_22\NN|such (l_relcl) treat_24\VB|NONE (l_dobj) patients_26\NNS|to|with (l_amod) hypotensive_25\JJ|NONE
D012312_D002318 NONE ritodrine_15\NN|NONE (r_pobj) of_14\IN|an (r_prep) infusion_13\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) cessation_10\NN|even (r_pobj) after_9\IN|cardiovascular|serious (r_prep) complications_7\NNS|NONE
D010656_D013610 NONE phenylephrine_22\NN|such (l_relcl) treat_24\VB|NONE (l_prep) with_27\IN|patients|to (l_pobj) tachycardia_28\NNS|NONE
D012312_D007752 NONE ritodrine_6\RB|NONE (l_prep) for_7\IN|NONE (l_pobj) labor_9\NN|NONE
D012312_D007752 NONE ritodrine_19\NN|NONE (r_pobj) of_18\IN|effects|residual|betamimetic|and|the (r_prep) effects_17\NNS|NONE (r_pobj) between_13\IN|NONE (r_prep) interactions_12\NNS|may|patients|that (r_dobj) risk_11\VB|case|. (l_nsubj) patients_4\NNS|may|that|interactions (l_acl) receiving_5\VBG|NONE (l_dobj) ritodrine_6\RB|NONE (l_prep) for_7\IN|NONE (l_pobj) labor_9\NN|NONE
19581773
D012254_D004172 NONE ribavirin_21\RB|and (r_conj) alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|for|old|A|.|experienced|sudden (r_prep) diplopia_7\NN|NONE
D012254_D019698 NONE ribavirin_8\JJ|and (r_conj) interferon_6\NN|pegylated|for (r_nmod) treatment_9\NN|NONE (l_prep) for_10\IN|interferon|pegylated (l_pobj) C._13\NNP|NONE
D012254_D019698 NONE ribavirin_21\RB|and (r_conj) alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|for|old|A|.|experienced|sudden (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|old|after|A|.|experienced|sudden (l_pobj) C_25\NNP|NONE
D012254_D019698 NONE ribavirin_21\RB|and (r_conj) alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|for|old|A|.|experienced|sudden (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|old|after|A|.|experienced|sudden (l_pobj) C_25\NNP|NONE (l_appos) CHC_27\NNP|hepatitis|chronic|(|)
D012254_D019698 NONE ribavirin_12\RB|pegylated|IFN|and|for (r_conj) alpha-2b_10\CD|NONE (l_prep) for_13\IN|pegylated|IFN|and|ribavirin (l_pobj) CHC_14\NNP|NONE
C417083_D004172 NONE alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|for|old|A|.|experienced|sudden (r_prep) diplopia_7\NN|NONE
C417083_D009157 CID interferon_6\NN|pegylated|for (r_nmod) treatment_9\NN|NONE (r_pobj) during_4\IN|of (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|during (l_pobj) myasthenia_3\NN|NONE
C417083_D009157 CID alpha-2b_10\CD|NONE (r_pobj) of_7\IN|combination (r_prep) therapy_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|The|ocular (r_acl) myasthenia_2\NN|is|rarely
C417083_D009157 CID IFN_35\NNP|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|various|the|eye (r_prep) complications_33\NNS|NONE (r_pobj) of_29\IN|a (r_prep) review_28\NN|NONE (r_pobj) with_26\IN|.|therefore|reported|case|,|;|we (r_prep) present_23\VBP|NONE (l_ccomp) reported_18\VBN|.|therefore|case|,|;|we|with (l_nsubjpass) myasthenia_2\NN|is|rarely
C417083_D019698 NONE interferon_6\NN|pegylated|for (r_nmod) treatment_9\NN|NONE (l_prep) for_10\IN|interferon|pegylated (l_pobj) C._13\NNP|NONE
C417083_D019698 NONE alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|for|old|A|.|experienced|sudden (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|old|after|A|.|experienced|sudden (l_pobj) C_25\NNP|NONE
C417083_D019698 NONE alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|for|old|A|.|experienced|sudden (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|old|after|A|.|experienced|sudden (l_pobj) C_25\NNP|NONE (l_appos) CHC_27\NNP|hepatitis|chronic|(|)
C417083_D019698 NONE alpha-2b_10\CD|NONE (l_prep) for_13\IN|pegylated|IFN|and|ribavirin (l_pobj) CHC_14\NNP|NONE
C417083_D019698 NONE IFN_35\NNP|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|various|the|eye (r_prep) complications_33\NNS|NONE (r_pobj) of_29\IN|a (r_prep) review_28\NN|NONE (r_pobj) with_26\IN|.|therefore|reported|case|,|;|we (r_prep) present_23\VBP|NONE (l_ccomp) reported_18\VBN|.|therefore|case|,|;|we|with (l_nsubjpass) myasthenia_2\NN|is|rarely (l_acl) associated_3\VBN|The|ocular (l_prep) with_4\IN|NONE (l_pobj) therapy_6\NN|NONE (l_prep) of_7\IN|combination (l_pobj) alpha-2b_10\CD|NONE (l_prep) for_13\IN|pegylated|IFN|and|ribavirin (l_pobj) CHC_14\NNP|NONE
D012254_D009157 CID ribavirin_8\JJ|and (r_conj) interferon_6\NN|pegylated|for (r_nmod) treatment_9\NN|NONE (r_pobj) during_4\IN|of (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|during (l_pobj) myasthenia_3\NN|NONE
D012254_D009157 CID ribavirin_12\RB|pegylated|IFN|and|for (r_conj) alpha-2b_10\CD|NONE (r_pobj) of_7\IN|combination (r_prep) therapy_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|The|ocular (r_acl) myasthenia_2\NN|is|rarely
9088814
D000527_D007022 CID E1-induced_5\JJ|prolonged|haemodilution|prostaglandin|and|on (r_amod) hypotension_6\NN|NONE
D000527_D007022 CID E1_5\NN|NONE (l_appos) hypotension_8\NN|prolonged|prostaglandin
D000527_D007022 CID PGE1)-induced_7\JJ|haemodilution|and|( (r_amod) hypotension_8\NN|prolonged|prostaglandin
D000527_D007022 CID PGE1_10\NNP|NONE (r_pobj) with_9\IN|maintain|was|.|hypotension (r_prep) induced_8\VBN|NONE (l_nsubjpass) hypotension_1\NN|maintain|was|.|with
D000527_D007022 CID PGE1-induced_13\JJ|haemodilution|and (r_amod) hypotension_14\NN|NONE
D003911_D020141 NONE dextran_23\NN|NONE (r_amod) solution_24\NN|NONE (r_pobj) of_22\IN|the|same (r_prep) amount_21\NN|NONE (r_pobj) with_18\IN|it (r_prep) replacing_16\VBG|mL|and (r_conj) withdrawing_9\VBG|NONE (r_pcomp) by_8\IN|were|Haemodilution|was|and|, (r_prep) produced_7\VBN|NONE (l_nsubjpass) Haemodilution_0\NN|were|by|was|and|,
D001663_D007022 NONE bilirubin_68\NN|and (r_conj) LDH_65\NNP|, (r_conj) SGPT_63\NNP|, (r_appos) SGOT_61\NNP|.|increases (r_nsubj) showed_69\VBD|,|at|decrease|showed|and|and|AKBR|after|, (r_conj) showed_23\VBD|NONE (l_prep) after_42\IN|,|at|decrease|showed|and|showed|and|AKBR|, (l_pobj) start_44\NN|and|after|at (l_prep) of_45\IN|the (l_pobj) hypotension_46\NN|NONE
D000527_D008107 CID PGE1-induced_13\JJ|haemodilution|and (r_amod) hypotension_14\NN|NONE (r_pobj) of_12\IN| (r_prep) min_11\NN|NONE (r_pobj) of_7\IN|prolonged|a (r_prep) combination_6\NN|would|impairment|that (r_nsubj) cause_19\VB|.|results (l_dobj) impairment_20\NN|would|that|combination (l_prep) of_21\IN|NONE (l_pobj) function_23\NN|NONE
D000527_D020141 NONE E1-induced_5\JJ|prolonged|haemodilution|prostaglandin|and|on (r_amod) hypotension_6\NN|NONE (l_conj) haemodilution_8\NN|prolonged|Einduced|prostaglandin|and|on
D000527_D020141 NONE E1_5\NN|NONE (l_appos) hypotension_8\NN|prolonged|prostaglandin (l_conj) haemodilution_10\NN|and|(|PGE)induced
D000527_D020141 NONE PGE1)-induced_7\JJ|haemodilution|and|( (r_amod) hypotension_8\NN|prolonged|prostaglandin (l_conj) haemodilution_10\NN|and|(|PGE)induced
D000527_D020141 NONE PGE1-induced_13\JJ|haemodilution|and (r_amod) hypotension_14\NN|NONE (l_conj) haemodilution_17\NN|PGEinduced|and
18726058
D010208_D003389 NONE papaverine_13\NN|NONE (r_pobj) with_11\IN|a|few (r_prep) cases_10\NNS|NONE (r_pobj) in_7\IN|been|has|.|dysfunction (r_prep) described_6\VBN|NONE (l_nsubjpass) dysfunction_3\NN|been|in|has|.
D010208_D003389 NONE papaverine_8\NN|NONE (r_pobj) from_7\IN|nerve|potential (r_prep) deficits_6\NNS|to
D010208_D020301 NONE hydrochloride_1\NN|.|vasodilator (r_nsubj) is_2\VBZ|NONE (l_attr) vasodilator_7\NN|hydrochloride|. (l_acl) used_8\VBD|a|acting (l_xcomp) manage_10\VB|NONE (l_dobj) vasospasm_11\NN|to|during
D010208_D020301 NONE papaverine_18\NN|for|who (r_dobj) received_16\VBD|those (l_prep) for_19\IN|papaverine|who (l_pobj) vasospasm_20\NN|NONE
D010208_D020301 NONE papaverine_1\NN|was|as|. (r_nsubjpass) used_3\VBN|NONE (l_prep) as_4\IN|papaverine|was|. (l_pobj) action_8\NN|NONE (l_acl) manage_10\VB|therapeutic|a|direct (l_dobj) vasospasm_11\NN|in|to
D010208_D020301 NONE papaverine_1\NN|.|with|was (l_prep) for_2\IN|Topical (l_pobj) treatment_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) vasospasm_6\NN|NONE
17639754
D064704_D006470 CID levofloxacin_20\JJ|and (r_conj) warfarin_18\NN|NONE (r_pobj) between_17\IN|the (r_prep) interaction_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) result_13\NN|to (r_attr) be_11\VB|that (r_xcomp) appear_9\VBP|bleeding|serious (r_relcl) complications_7\NNS|NONE (l_compound) bleeding_6\NN|serious|appear
D014859_D006470 CID warfarin_18\NN|NONE (r_pobj) between_17\IN|the (r_prep) interaction_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) result_13\NN|to (r_attr) be_11\VB|that (r_xcomp) appear_9\VBP|bleeding|serious (r_relcl) complications_7\NNS|NONE (l_compound) bleeding_6\NN|serious|appear
19473225
D000596_D010523 NONE acid_24\NN|related|its (r_compound) glutamine_25\NN|and (r_conj) glutamate_18\NN|although|were|ameliorate (r_nsubjpass) claimed_27\VBN|neuropathy|still|factor|.|, (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|still|factor|.|,
D000596_D020258 NONE acid_24\NN|related|its (r_compound) glutamine_25\NN|and (r_conj) glutamate_18\NN|although|were|ameliorate (r_nsubjpass) claimed_27\VBN|neuropathy|still|factor|.|, (l_xcomp) ameliorate_29\VB|although|were|glutamate (l_dobj) neurotoxicity_31\NN|to
D018698_D010523 NONE glutamate_3\NN|term (r_compound) supplementation_4\NN|.|protect (r_nsubj) failed_5\VBD|NONE (l_xcomp) protect_7\VB|.|supplementation (l_prep) against_8\IN|to (l_pobj) neurotoxicity_10\NN|NONE
D018698_D010523 NONE glutamate_18\NN|although|were|ameliorate (r_nsubjpass) claimed_27\VBN|neuropathy|still|factor|.|, (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|still|factor|.|,
D018698_D010523 NONE glutamine_25\NN|and (r_conj) glutamate_18\NN|although|were|ameliorate (r_nsubjpass) claimed_27\VBN|neuropathy|still|factor|.|, (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|still|factor|.|,
D018698_D010523 NONE glutamate_9\NN|for (r_compound) supplementation_10\NN|NONE (l_prep) for_11\IN|glutamate (l_pcomp) preventing_12\VBG|NONE (l_dobj) neuropathy_17\NN|in
D018698_D010523 NONE glutamate_8\NN|at (r_compound) supplementation_9\NN|protect|that (r_nsubj) fails_14\VBZ|the (l_xcomp) protect_16\VB|supplementation|that (l_prep) against_17\IN|to (l_pobj) neurotoxicity_19\NN|NONE
D018698_D020258 NONE glutamate_18\NN|although|were|ameliorate (r_nsubjpass) claimed_27\VBN|neuropathy|still|factor|.|, (l_xcomp) ameliorate_29\VB|although|were|glutamate (l_dobj) neurotoxicity_31\NN|to
D018698_D020258 NONE glutamine_25\NN|and (r_conj) glutamate_18\NN|although|were|ameliorate (r_nsubjpass) claimed_27\VBN|neuropathy|still|factor|.|, (l_xcomp) ameliorate_29\VB|although|were|glutamate (l_dobj) neurotoxicity_31\NN|to
D018698_D010051 NONE glutamate_26\NN|NONE (r_pobj) by_25\IN|had|.|,|:|were|and||been|,|received|at (r_agent) supplemented_24\VBN|NONE (l_ccomp) were_6\VBD|had|.|by|,|:|and||been|,|received|at (l_nsubj) patients_5\NNS|available (l_compound) cancer_4\NN|ovarian|three
D017239_D010051 NONE PAC_16\NNP| (r_npadvmod) containing_18\VBG|the|same (r_amod) regimen_19\NN|NONE (r_pobj) of_13\IN|six (r_prep) cycles_12\NNS|NONE (r_pobj) following_10\VBG|NONE (r_prep) analysis_9\NN|NONE (r_pobj) for_8\IN|NONE (r_prep) available_7\JJ|patients (r_acomp) were_6\VBD|had|.|by|,|:|and||been|,|received|at (l_nsubj) patients_5\NNS|available (l_compound) cancer_4\NN|ovarian|three
D017239_D020258 NONE paclitaxel_12\NN|NONE (r_pobj) with_11\IN|PAC (r_prep) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|limiting|a (r_prep) factor_8\NN|neuropathy|claimed|still|.|, (r_attr) is_3\VBZ|NONE (l_advcl) claimed_27\VBN|neuropathy|still|factor|.|, (l_xcomp) ameliorate_29\VB|although|were|glutamate (l_dobj) neurotoxicity_31\NN|to
D017239_D020258 NONE PAC_14\NNP|with (r_appos) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|limiting|a (r_prep) factor_8\NN|neuropathy|claimed|still|.|, (r_attr) is_3\VBZ|NONE (l_advcl) claimed_27\VBN|neuropathy|still|factor|.|, (l_xcomp) ameliorate_29\VB|although|were|glutamate (l_dobj) neurotoxicity_31\NN|to
D017239_D020258 NONE PAC_30\NNP|NONE (r_compound) neurotoxicity_31\NN|to
D017239_D010523 CID paclitaxel_12\NN|NONE (r_pobj) of_11\IN|peripheral (r_prep) neurotoxicity_10\NN|NONE
D017239_D010523 CID paclitaxel_12\NN|NONE (r_pobj) with_11\IN|PAC (r_prep) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|limiting|a (r_prep) factor_8\NN|neuropathy|claimed|still|.|, (r_attr) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|still|factor|.|,
D017239_D010523 CID PAC_14\NNP|with (r_appos) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|limiting|a (r_prep) factor_8\NN|neuropathy|claimed|still|.|, (r_attr) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|still|factor|.|,
D017239_D010523 CID PAC_30\NNP|NONE (r_compound) neurotoxicity_31\NN|to (r_dobj) ameliorate_29\VB|although|were|glutamate (r_xcomp) claimed_27\VBN|neuropathy|still|factor|.|, (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|still|factor|.|,
D017239_D010523 CID PAC_13\NNP| (r_npadvmod) induced_15\VBN|peripheral (r_amod) neuropathy_17\NN|in
D017239_D010523 CID PAC_21\NNP|NONE (r_pobj) of_20\IN|peripheral (r_prep) neurotoxicity_19\NN|NONE
435349
D013390_D005207 CID Suxamethonium_0\JJ|.|and|observed|infusion (r_compound) rate_2\NN|NONE (l_conj) observed_4\JJ|.|and|Suxamethonium|infusion (l_dobj) fasciculations_5\NNS|NONE
D013390_D013746 NONE Sch_20\NNP|when|mg|was (r_nsubjpass) exceeded_24\VBN|there|either|response|when (r_advcl) was_7\VBD|was|infusion|. (l_attr) response_10\NN|there|exceeded|either|when (l_prep) to_11\IN|no|muscular (l_pobj) stimulation_13\NN|NONE (l_compound) tetanic_12\JJ|of|or
3827439
D000666_D058186 CID amphotericin_6\JJ|NONE (r_pobj) from_5\IN|Recurrent|renal|reversible|acute|. (r_prep) failure_4\NN|NONE
D000666_D058186 CID B_18\NNP|NONE (r_pobj) of_16\IN|the (r_prep) administration_15\NN|on|immediately (r_dobj) following_13\VBG|renal|acute (r_acl) failure_11\NN|patient|.
D000666_D058186 CID amphotericin_3\JJ|that|.|We|activate (r_advmod) propose_1\VBP|NONE (l_conj) activate_15\VB|that|.|amphotericin|We (l_advcl) contributing_20\VBG|in|,|feedback|,|may|, (l_prep) to_21\IN|thereby (l_pobj) failure_24\NN|NONE
D000666_D005355 NONE B_18\NNP|NONE (r_pobj) of_16\IN|the (r_prep) administration_15\NN|on|immediately (r_dobj) following_13\VBG|renal|acute (r_acl) failure_11\NN|patient|. (r_dobj) developed_8\VBD|NONE (l_nsubj) patient_1\NN|.|failure (l_prep) with_2\IN|and|A|disseminated (l_pobj) cirrhosis_4\NN|NONE
D000666_D013174 NONE B_18\NNP|NONE (r_pobj) of_16\IN|the (r_prep) administration_15\NN|on|immediately (r_dobj) following_13\VBG|renal|acute (r_acl) failure_11\NN|patient|. (r_dobj) developed_8\VBD|NONE (l_nsubj) patient_1\NN|.|failure (l_conj) disseminated_6\VBN|and|A|with (l_dobj) sporotrichosis_7\NN|NONE
20667451
D003474_D003072 NONE Curcumin_0\NN|.|dysfunction (r_nsubj) ameliorates_1\VBZ|NONE (l_dobj) dysfunction_3\NN|.|Curcumin
D003474_D003072 NONE curcumin_14\NN|chronic (r_compound) administration_15\NN|NONE (r_pobj) of_12\IN|the|on (r_prep) effect_11\NN|to (l_prep) on_16\IN|the|of (l_pobj) impairment_23\NN|NONE
D003474_D003072 NONE curcumin_1\NN|Concomitant (r_compound) administration_2\NN|and|.|impairment|decreased (r_nsubj) prevented_3\VBD|NONE (l_dobj) impairment_6\NN|and|.|administration|decreased
D003474_D003072 NONE curcumin_4\NN|effect|that (r_nsubj) has_5\VBZ|.|results (l_dobj) effect_7\NN|curcumin|that (l_prep) in_8\IN|beneficial (l_pcomp) mitigating_9\VBG|NONE (l_dobj) deterioration_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) functions_14\NNS|NONE
D003474_D003072 NONE curcumin_4\NN|that|as|be|can|phenobarbitone (r_nsubjpass) considered_7\VBN|.|findings (l_advcl) phenobarbitone_16\NN|that|as|be|can|curcumin (l_prep) in_20\IN|to|and|therapy (l_pcomp) preventing_21\VBG|NONE (l_dobj) impairment_23\NN|NONE
D002220_D003072 CID carbamazepine_10\NN|and (r_conj) phenobarbitone_8\NN|NONE (r_pobj) in_7\IN|oxidative (r_prep) damage_6\NN|administered|cognitive|and (r_conj) dysfunction_3\NN|.|Curcumin
D002220_D003072 CID carbamazepine_6\NN|and (r_conj) phenobarbitone_4\NN|,|antiepileptic|The (r_conj) drugs_2\NNS|.|known (r_nsubj) are_7\VBP|NONE (l_acomp) known_9\JJ|.|drugs (l_xcomp) cause_11\VB|well (l_dobj) impairment_13\NN|to
D002220_D003072 CID carbamazepine_19\NN| (r_npadvmod) induced_21\VBN|and (r_conj) phenobarbitone-_17\JJ|stress|and|cognitive (r_nmod) impairment_23\NN|NONE
D002220_D003072 CID carbamazepine_5\NN|and (r_conj) phenobarbitone_3\NN|NONE (r_pobj) of_2\IN|The|for (r_prep) administration_1\NN|.|impairment (r_nsubj) caused_8\VBD|NONE (l_dobj) impairment_11\NN|administration|. (l_prep) of_12\IN|a|significant (l_pobj) learning_13\NN|stress (l_conj) memory_15\NN|as|and
D002220_D003072 CID carbamazepine_24\NN|and (r_conj) phenobarbitone_22\NN|NONE (r_pobj) with_21\IN|without (r_prep) treated_20\VBN|NONE (r_acl) rats_19\NNS|NONE (r_pobj) in_18\IN|oxidative (r_prep) damage_17\NN|and|cognitive (r_conj) functions_14\NNS|NONE
D002220_D003072 CID carbamazepine_18\NN|NONE (r_compound) therapy_19\NN|to|in|and (r_conj) phenobarbitone_16\NN|that|as|be|can|curcumin (l_prep) in_20\IN|to|and|therapy (l_pcomp) preventing_21\VBG|NONE (l_dobj) impairment_23\NN|NONE
D010634_D003072 CID phenobarbitone_8\NN|NONE (r_pobj) in_7\IN|oxidative (r_prep) damage_6\NN|administered|cognitive|and (r_conj) dysfunction_3\NN|.|Curcumin
D010634_D003072 CID phenobarbitone_4\NN|,|antiepileptic|The (r_conj) drugs_2\NNS|.|known (r_nsubj) are_7\VBP|NONE (l_acomp) known_9\JJ|.|drugs (l_xcomp) cause_11\VB|well (l_dobj) impairment_13\NN|to
D010634_D003072 CID phenobarbitone-_17\JJ|stress|and|cognitive (r_nmod) impairment_23\NN|NONE
D010634_D003072 CID phenobarbitone_3\NN|NONE (r_pobj) of_2\IN|The|for (r_prep) administration_1\NN|.|impairment (r_nsubj) caused_8\VBD|NONE (l_dobj) impairment_11\NN|administration|. (l_prep) of_12\IN|a|significant (l_pobj) learning_13\NN|stress (l_conj) memory_15\NN|as|and
D010634_D003072 CID phenobarbitone_22\NN|NONE (r_pobj) with_21\IN|without (r_prep) treated_20\VBN|NONE (r_acl) rats_19\NNS|NONE (r_pobj) in_18\IN|oxidative (r_prep) damage_17\NN|and|cognitive (r_conj) functions_14\NNS|NONE
D010634_D003072 CID phenobarbitone_16\NN|that|as|be|can|curcumin (l_prep) in_20\IN|to|and|therapy (l_pcomp) preventing_21\VBG|NONE (l_dobj) impairment_23\NN|NONE
12907309
C121465_D005334 NONE MPEP_3\NNP|NONE (r_pobj) of_2\IN|antagonist|,|Neuroprotective|,|in (r_prep) action_1\NN|is|.|with (r_nsubjpass) associated_17\VBN|NONE (l_prep) with_18\IN|is|action|. (l_pobj) decrease_20\NN|NONE (l_prep) in_21\IN|a (l_pobj) outflow_23\NN|NONE (l_conj) inhibition_25\NN|in|and|dopamine (l_prep) of_26\IN|NONE (l_pobj) hyperthermia_27\NN|NONE
C121465_D005334 NONE MPEP_3\NNP|NONE (r_pobj) by_2\IN|NONE (r_agent) rendered_1\VBN|NONE (r_acl) Neuroprotection_0\NNP|,|.|with|and|with|may|be (r_nsubjpass) associated_6\VBN|NONE (l_conj) with_29\IN|,|.|Neuroprotection|and|with|may|be (l_pobj) decrease_31\NN|NONE (l_prep) in_32\IN|a (l_pobj) hyperthermia_33\NN|NONE
C121465_D020258 NONE MPEP_3\NNP|NONE (r_pobj) of_2\IN|antagonist|,|Neuroprotective|,|in (r_prep) action_1\NN|is|.|with (l_prep) in_10\IN|antagonist|,|Neuroprotective|,|of (l_pobj) neurotoxicity_15\NN|NONE
D008694_D020258 NONE methamphetamine_11\NN| (r_npadvmod) induced_13\VBN|dopaminergic (r_amod) neurotoxicity_15\NN|NONE
D008694_D064420 NONE methamphetamine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) toxicity_21\NN|NONE
C121465_D064420 NONE MPEP_12\NNP|NONE (r_pobj) by_11\IN|the|of (r_prep) blockade_8\NN|may|neurones|that (r_nsubj) protect_14\VB|.|results (l_dobj) neurones_16\NNS|may|blockade|that (l_prep) against_17\IN|dopaminergic (l_pobj) toxicity_21\NN|NONE
D004298_D005334 NONE dopamine_22\NN|in|and|inhibition (r_compound) outflow_23\NN|NONE (l_conj) inhibition_25\NN|in|and|dopamine (l_prep) of_26\IN|NONE (l_pobj) hyperthermia_27\NN|NONE
D004298_D005334 NONE dopamine_15\NN|the|induced|in (r_compound) efflux_16\NN|NONE (r_pobj) of_10\IN|due|the (r_prep) reduction_9\NN|NONE (r_pobj) with_7\IN|,|.|Neuroprotection|with|and|may|be (r_prep) associated_6\VBN|NONE (l_conj) with_29\IN|,|.|Neuroprotection|and|with|may|be (l_pobj) decrease_31\NN|NONE (l_prep) in_32\IN|a (l_pobj) hyperthermia_33\NN|NONE
D004298_D020258 NONE dopamine_22\NN|in|and|inhibition (r_compound) outflow_23\NN|NONE (r_pobj) in_21\IN|a (r_prep) decrease_20\NN|NONE (r_pobj) with_18\IN|is|action|. (r_prep) associated_17\VBN|NONE (l_nsubjpass) action_1\NN|is|.|with (l_prep) in_10\IN|antagonist|,|Neuroprotective|,|of (l_pobj) neurotoxicity_15\NN|NONE
D008694_D005334 CID methamphetamine_11\NN| (r_npadvmod) induced_13\VBN|dopaminergic (r_amod) neurotoxicity_15\NN|NONE (r_pobj) in_10\IN|antagonist|,|Neuroprotective|,|of (r_prep) action_1\NN|is|.|with (r_nsubjpass) associated_17\VBN|NONE (l_prep) with_18\IN|is|action|. (l_pobj) decrease_20\NN|NONE (l_prep) in_21\IN|a (l_pobj) outflow_23\NN|NONE (l_conj) inhibition_25\NN|in|and|dopamine (l_prep) of_26\IN|NONE (l_pobj) hyperthermia_27\NN|NONE
D008694_D005334 CID methamphetamine_12\NN| (r_npadvmod) induced_14\VBN|dopamine|the|in (r_amod) efflux_16\NN|NONE (r_pobj) of_10\IN|due|the (r_prep) reduction_9\NN|NONE (r_pobj) with_7\IN|,|.|Neuroprotection|with|and|may|be (r_prep) associated_6\VBN|NONE (l_conj) with_29\IN|,|.|Neuroprotection|and|with|may|be (l_pobj) decrease_31\NN|NONE (l_prep) in_32\IN|a (l_pobj) hyperthermia_33\NN|NONE
11391224
D003042_D006974 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|acute|renal (r_amod) failure_28\NN|and|,|crescentic (r_conj) glomerulonephritis_20\NN|,|Schonlein (r_conj) nephritis_17\NN|, (r_conj) nephritis_12\NN|microangiopathy (r_dobj) lupus_11\NN|cases|.|,| (r_conj) included_2\VBD|NONE (l_dobj) cases_3\NNS|.|lupus|,| (l_prep) of_4\IN|NONE (l_pobj) hypertension_6\NN|NONE
D003042_D058186 CID cocaine_23\NN| (r_npadvmod) related_25\VBN|acute|renal (r_amod) failure_28\NN|and|,|crescentic
D003042_D011695 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|acute|renal (r_amod) failure_28\NN|and|,|crescentic (r_conj) glomerulonephritis_20\NN|,|Schonlein (r_conj) nephritis_17\NN|,
D003042_D008181 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|acute|renal (r_amod) failure_28\NN|and|,|crescentic (r_conj) glomerulonephritis_20\NN|,|Schonlein (r_conj) nephritis_17\NN|, (r_conj) nephritis_12\NN|microangiopathy
D003042_D005921 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|acute|renal (r_amod) failure_28\NN|and|,|crescentic (r_conj) glomerulonephritis_20\NN|,|Schonlein
D003042_D057049 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|acute|renal (r_amod) failure_28\NN|and|,|crescentic (r_conj) glomerulonephritis_20\NN|,|Schonlein (r_conj) nephritis_17\NN|, (r_conj) nephritis_12\NN|microangiopathy (r_dobj) lupus_11\NN|cases|.|,| (l_nsubj) microangiopathy_9\NN|nephritis
14596845
D013395_D006948 CID sucrose_6\NN|had|that (r_dobj) experienced_4\VBN|The (r_relcl) animals_1\NNS|in|hyperactive|.|compared (r_nsubj) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|in|animals|.|compared
D013395_D006948 CID sucrose_25\NN|chow|four|)|(|,|control|,|chow (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|in|hyperactive|animals|. (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|in|animals|.|compared
D013395_D006948 CID sucrose_50\NN|,|or (r_conj) amphetamine_44\NN|NONE (r_pobj) with_43\IN|ad|libitum (r_prep) chow_42\NN|chow|four|)|(|,|control|,|sucrose (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|in|hyperactive|animals|. (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|in|animals|.|compared
D000661_D006948 CID amphetamine_15\NN|NONE (r_pobj) of_14\IN|a|low (r_prep) dose_13\NN|NONE (r_pobj) to_10\IN|cross|behavioral| (r_prep) sensitization_9\NN|.|diet
D000661_D006948 CID amphetamine_24\NN|NONE (r_pobj) of_23\IN|low|a (r_prep) dose_22\NN|NONE (r_pobj) to_19\IN|sensitization|would|rats|whether (r_prep) show_14\VB|study|. (l_dobj) sensitization_18\NN|would|to|rats|whether
D000661_D006948 CID amphetamine_14\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) response_12\NN|NONE (r_pobj) in_11\IN|hyperactive|animals|.|compared (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|in|animals|.|compared
D000661_D006948 CID amphetamine_30\NN|NONE (r_compound) injection_31\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) followed_28\VBN|and|chow|%|libitum (r_acl) sucrose_25\NN|chow|four|)|(|,|control|,|chow (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|in|hyperactive|animals|. (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|in|animals|.|compared
D000661_D006948 CID amphetamine_37\NN|NONE (r_compound) injection_38\NN|NONE (r_pobj) by_36\IN|NONE (r_agent) followed_35\VBN|cyclic (r_acl) chow_34\NN|four|)|(|,|control|,|chow|sucrose (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|in|hyperactive|animals|. (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|in|animals|.|compared
D000661_D006948 CID amphetamine_44\NN|NONE (r_pobj) with_43\IN|ad|libitum (r_prep) chow_42\NN|chow|four|)|(|,|control|,|sucrose (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|in|hyperactive|animals|. (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|in|animals|.|compared
D000661_D019966 NONE amphetamine_15\NN|NONE (r_pobj) of_14\IN|a|low (r_prep) dose_13\NN|NONE (r_pobj) to_10\IN|cross|behavioral| (r_prep) sensitization_9\NN|.|diet (r_dobj) causes_5\VBZ|NONE (l_nsubj) diet_1\NN|.|sensitization (l_acl) promoting_2\VBG|A (l_dobj) dependency_4\NN|NONE
19445921
C066201_D009203 NONE A_5\NN|salvianolic (l_prep) on_6\IN|acid (l_pobj) infarction_11\NN|NONE
C066201_D009203 NONE A_13\NN|salvianolic (r_pobj) of_10\IN|on|cardioprotective|the (r_prep) potential_9\NN|to (l_prep) on_14\IN|of|cardioprotective|the (l_pobj) infarction_19\NN|NONE
C066201_D009203 NONE A_9\DT|that (r_appos) salvianolic_7\JJ|effect (r_nsubj) has_13\VBZ|.|results (l_dobj) effect_17\NN|salvianolic (l_prep) against_18\IN|a|significant|protective (l_pobj) infarction_23\NN|NONE
D000244_D012131 NONE ADP_13\NNP|/ (r_nmod) O_15\NNP|control|decreased|and (r_conj) ratio_11\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) characterized_6\VBN|respiratory|mitochondrial (r_acl) dysfunction_5\NN|In|.|in|,|was
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|in|myocardial (r_amod) infarction_11\NN|NONE
D007545_D009203 CID isoproterenol_15\NN| (r_npadvmod) induced_17\VBN|in|myocardial (r_amod) infarction_19\NN|NONE
D007545_D009203 CID isoproterenol_19\NN| (r_npadvmod) induced_21\VBN|myocardial (r_amod) infarction_23\NN|NONE
D007545_D012131 NONE isoproterenol_19\NN| (r_npadvmod) treated_21\VBN|NONE (r_amod) rats_22\NNS|NONE (r_pobj) in_18\IN|dysfunction|In|.|,|was (r_prep) observed_17\VBN|NONE (l_nsubjpass) dysfunction_5\NN|In|.|in|,|was
C066201_D006331 NONE A_4\NN|and|dysfunction|for|of|improved (r_appos) Administration_0\NN|NONE (l_conj) dysfunction_17\NN|and|for|of|improved|A
D007545_D006331 NONE isoproterenol_13\NN| (r_npadvmod) induced_15\VBN|and|injury|attenuated|cardiac (r_amod) dysfunction_17\NN|and|for|of|improved|A
D007545_D009202 NONE isoproterenol_13\NN| (r_npadvmod) induced_15\VBN|and|injury|attenuated|cardiac (r_amod) dysfunction_17\NN|and|for|of|improved|A (l_conj) injury_20\NN|induced|and|attenuated|cardiac
D007545_D009202 NONE isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|myocardial (r_amod) damage_12\NN|NONE
C066201_D009202 NONE A_4\NN|and|dysfunction|for|of|improved (r_appos) Administration_0\NN|NONE (l_conj) dysfunction_17\NN|and|for|of|improved|A (l_conj) injury_20\NN|induced|and|attenuated|cardiac
C066201_D009202 NONE A_6\NN|salvianolic (r_pobj) of_3\IN|against|The|protective (r_prep) role_2\NN|was|.|further|by (l_prep) against_7\IN|of|The|protective (l_pobj) damage_12\NN|NONE
7930386
D002997_D012893 CID Clomipramine_0\NNP| (r_npadvmod) induced_2\VBN|sleep (r_amod) disturbance_4\NN|not|.|action|does
D002997_D012893 CID clomipramine_15\NN|NONE (r_compound) administration_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|role|,|,|to|on (r_conj) examine_6\VB|was|.|study (l_dobj) role_8\NN|,|,|to|on|induced (l_prep) of_9\IN|the (l_pobj) disturbance_11\NN|NONE
9587734
D013390_D006947 CID suxamethonium_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) use_19\NN|NONE (r_pobj) following_17\VBG|a|of (r_prep) case_5\NN|report|. (l_prep) of_6\IN|following|a (l_pobj) arrest_8\NN|NONE (l_conj) death_11\NN|cardiac|and (l_prep) as_12\IN|subsequent (l_pobj) result_14\NN|NONE (l_prep) of_15\IN|a (l_pobj) hyperkalaemia_16\NN|NONE
D013390_D006947 CID suxamethonium_35\NN|NONE (r_pobj) of_34\IN|the (r_prep) administration_33\NN|NONE (r_pobj) following_31\VBG|no|of (r_prep) signs_15\NNS|,|.|there|Apart (l_prep) of_16\IN|no|following (l_conj) of_21\IN|or|damage (l_pobj) any_22\DT|NONE (l_prep) of_23\IN|NONE (l_pobj) conditions_28\NNS|NONE (l_prep) for_29\IN|known|other|the|predisposing (l_pobj) hyperkalaemia_30\NN|NONE
D013390_D001919 CID suxamethonium_5\NN|NONE (l_appos) arrest_10\NN|, (l_amod) bradycardia_7\NN|cardiac
D013390_D004342 CID suxamethonium_11\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) hypersensitivity_9\NN|NONE
D013390_D003643 NONE Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|following|.|and|cardiac|death (r_amod) arrest_4\NN|NONE (l_conj) death_6\NN|following|.|and|cardiac|induced
D013390_D003643 NONE suxamethonium_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) use_19\NN|NONE (r_pobj) following_17\VBG|a|of (r_prep) case_5\NN|report|. (l_prep) of_6\IN|following|a (l_pobj) arrest_8\NN|NONE (l_conj) death_11\NN|cardiac|and
D013390_D003643 NONE suxamethonium_11\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) hypersensitivity_9\NN|NONE (r_pobj) by_8\IN|death|was|that|associated|, (r_agent) caused_7\VBN|.|It|is (l_nsubjpass) death_5\NN|by|was|that|associated|,
D013390_D006323 CID Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|following|.|and|cardiac|death (r_amod) arrest_4\NN|NONE
D013390_D006323 CID suxamethonium_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) use_19\NN|NONE (r_pobj) following_17\VBG|a|of (r_prep) case_5\NN|report|. (l_prep) of_6\IN|following|a (l_pobj) arrest_8\NN|NONE
D013390_D006323 CID suxamethonium_5\NN|NONE (l_appos) arrest_10\NN|,
11752354
D004967_D009203 NONE estrogen_38\NN|NONE (r_pobj) of_37\IN|the|presence|,|and (r_prep) dose_36\NN|we|:|In|.|and|,|,|enrolled (r_dep) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D004967_D009203 NONE estrogen_38\NN|NONE (r_pobj) of_37\IN|the|presence|,|and (r_prep) dose_36\NN|we|:|In|.|and|,|,|enrolled (r_dep) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS||and|and (l_relcl) had_93\VBN||control (l_dobj) infarction_96\NN|matched|and|who|not|had
D017135_D009203 NONE desogestrel_19\NN||third (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D017135_D009203 NONE desogestrel_19\NN||third (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS||and|and (l_relcl) had_93\VBN||control (l_dobj) infarction_96\NN|matched|and|who|not|had
D003276_D009203 CID contraceptives_1\NNS|NONE (l_conj) risk_4\NN|and|.|Oral (l_prep) of_5\IN|the (l_pobj) infarction_7\NN|NONE
D003276_D009203 CID contraceptives_7\NNS|NONE (r_pobj) of_5\IN|and|the|risk (r_prep) use_4\NN|NONE (l_conj) risk_10\NN|and|the|of (l_prep) of_11\IN|the (l_pobj) infarction_13\NN|NONE
D003276_D009203 CID contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D003276_D009203 CID contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS||and|and (l_relcl) had_93\VBN||control (l_dobj) infarction_96\NN|matched|and|who|not|had
D003276_D009203 CID contraceptive_39\NN|NONE (r_pobj) of_36\IN|any (r_prep) type_35\NN|compared|,|who (r_dobj) used_33\VBD|NONE (r_relcl) women_31\NNS|NONE (r_pobj) among_30\IN|myocardial (r_prep) infarction_29\NN|NONE
D003276_D009203 CID contraceptives_5\NNS|who (r_dobj) used_3\VBD|NONE (r_relcl) women_1\NNS|NONE (r_pobj) Among_0\IN|:|for|ratio|interval|, (r_prep) was_10\VBD|.|risk|was|among (r_ccomp) increased_53\VBN|NONE (l_nsubjpass) risk_48\NN|was|.|was|among (l_prep) of_49\IN|The (l_pobj) infarction_51\NN|NONE
D003276_D009203 CID contraceptives_62\NNS|who (r_dobj) used_57\VBD|NONE (r_relcl) women_55\NNS|NONE (r_pobj) among_54\IN|was|.|risk|was (r_prep) increased_53\VBN|NONE (l_nsubjpass) risk_48\NN|was|.|was|among (l_prep) of_49\IN|The (l_pobj) infarction_51\NN|NONE
D003276_D009203 CID contraceptives_12\NNS|had|who (r_dobj) used_10\VBD|NONE (r_relcl) women_8\NNS|NONE (r_pobj) among_7\IN|NONE (r_prep) similar_6\JJ|.|risk (r_acomp) was_5\VBD|NONE (l_nsubj) risk_1\NN|.|similar (l_prep) of_2\IN|The (l_pobj) infarction_4\NN|NONE
C033273_D009203 NONE gestodene_21\NN|i.e.|or|and|levonorgestrel|(|,|) (r_conj) desogestrel_19\NN||third (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
C033273_D009203 NONE gestodene_21\NN|i.e.|or|and|levonorgestrel|(|,|) (r_conj) desogestrel_19\NN||third (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS||and|and (l_relcl) had_93\VBN||control (l_dobj) infarction_96\NN|matched|and|who|not|had
D011372_D009203 NONE progestagen_10\NN|NONE (r_pobj) of_9\IN|included|the (r_prep) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D011372_D009203 NONE progestagen_10\NN|NONE (r_pobj) of_9\IN|included|the (r_prep) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS||and|and (l_relcl) had_93\VBN||control (l_dobj) infarction_96\NN|matched|and|who|not|had
D016912_D009203 NONE levonorgestrel_30\JJ|i.e.|or|gestodene|and|(|,|) (r_conj) desogestrel_19\NN||third (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D016912_D009203 NONE levonorgestrel_30\JJ|i.e.|or|gestodene|and|(|,|) (r_conj) desogestrel_19\NN||third (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|identified|association|We|, (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|association|according|We|, (l_conj) enrolled_66\VBD|dose|we|:|In|.|and|,|, (l_dobj) women_68\NNS||through|,|year (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS||and|and (l_relcl) had_93\VBN||control (l_dobj) infarction_96\NN|matched|and|who|not|had
7444978
D013307_D004409 CID streptomycin_48\NNS|NONE (r_pobj) to_47\IN|more (r_prep) sensitive_46\JJ|cochlea|that (r_acomp) is_44\VBZ|NONE (r_ccomp) indicating_40\VBG|,|.|;|occurred|sensitivities|within|from (r_advcl) occurred_23\VBD|NONE (l_ccomp) occurred_4\VBD|,|.|;|sensitivities|within|from|indicating (l_nsubj) movements_1\NNS|in
D013307_D004409 CID streptomycin_48\NNS|NONE (l_prep) than_49\IN|NONE (l_pobj) site_51\NN|NONE (l_amod) responsible_57\JJ|vestibular|the|(|) (l_prep) for_58\IN|NONE (l_pobj) dyskinesias_60\NNS|NONE
D013307_D003638 CID streptomycin_48\NNS|NONE (r_pobj) to_47\IN|more (r_prep) sensitive_46\JJ|cochlea|that (r_acomp) is_44\VBZ|NONE (r_ccomp) indicating_40\VBG|,|.|;|occurred|sensitivities|within|from (r_advcl) occurred_23\VBD|NONE (l_ccomp) occurred_4\VBD|,|.|;|sensitivities|within|from|indicating (l_nsubj) movements_1\NNS|in (l_conj) deafness_3\NN|and|Abnormal
D013307_D020258 NONE streptomycin_11\NNS|NONE (r_pobj) of_10\IN|neurotoxic (r_prep) effects_9\NNS|NONE (l_amod) neurotoxic_8\JJ|of
18544179
D005283_D009325 NONE fentanyl_1\NN|NONE (r_dobj) Omitting_0\VBG|without|nausea|,|after|,|. (r_csubj) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|without|Omitting|,|after|,|.
D005283_D009325 NONE fentanyl_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Omission_0\NN|did|.|incidence|but|not|,|reduce (r_nsubj) reduce_5\VB|NONE (l_conj) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_conj) moderate_23\JJ|incidence|to|did|prior|and/or|, (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D005283_D009325 NONE fentanyl_37\NN||fentanyl (r_nmod) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_conj) moderate_23\JJ|incidence|to|did|prior|and/or|, (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D005283_D009325 NONE fentanyl_39\NN|fentanyl| (r_compound) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_conj) moderate_23\JJ|incidence|to|did|prior|and/or|, (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D005283_D009325 NONE fentanyl_3\NN|the (r_compound) groups_4\NNS|NONE (r_dobj) Combining_0\VBG|(|benefits|,|decreased|.|reducing|P (r_csubj) revealed_5\VBD|NONE (l_advcl) reducing_15\VBG|(|benefits|,|Combining|decreased|.|P (l_dobj) nausea_17\NN|prior (l_conj) vomiting_19\NN|and|postoperative (l_conj) nausea_21\NN|and
D005283_D009325 NONE fentanyl_3\NN|the (r_compound) groups_4\NNS|NONE (r_dobj) Combining_0\VBG|(|benefits|,|decreased|.|reducing|P (r_csubj) revealed_5\VBD|NONE (l_advcl) decreased_57\VBN|(|benefits|,|Combining|.|reducing|P (l_nsubjpass) nausea_50\NN|while|P|was|(|)|from
C009250_D007022 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|no (r_amod) effect_12\NN|depression|and (r_dobj) had_7\VBD|Fentanyl|but|.|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|,|respiratory|increased
C009250_D010146 NONE sevoflurane_12\NN|NONE (r_pobj) after_11\IN|without|nausea|Omitting|,|,|. (r_prep) reduces_2\VBZ|NONE (l_prep) without_7\IN|nausea|Omitting|,|after|,|. (l_pcomp) increasing_8\VBG|NONE (l_dobj) pain_9\NN|NONE
C009250_D010146 NONE sevoflurane_23\NN|in (r_compound) anaesthesia_24\NN|NONE (r_pobj) after_22\IN|the||first (r_prep) h_21\NN|NONE (r_pobj) in_17\IN|incidence|.|study (r_prep) examined_5\VBD|NONE (l_dobj) incidence_7\NN|.|study|in (l_prep) of_10\IN|and|the|severity (l_pobj) nausea_12\NN|NONE (l_conj) vomiting_14\NN|postoperative|and (l_conj) pain_16\NN|and
D003907_D014839 NONE dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_dobj) incidence_19\NN|to|did|prior|and/or|moderate|, (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
C009250_D001919 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|no (r_amod) effect_12\NN|depression|and (r_dobj) had_7\VBD|Fentanyl|but|.|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|,|respiratory|increased (l_conj) bradycardia_20\NN|and
C009250_D020250 NONE sevoflurane_9\NN|NONE (r_pobj) with_8\IN|of (r_prep) advantages_1\NNS|NONE (r_pobj) Despite_0\IN|.|nausea|frequently (r_prep) occurs_15\VBZ|NONE (l_nsubj) nausea_12\NN|.|Despite|frequently (l_conj) vomiting_14\NN|postoperative|and
C009250_D020250 NONE sevoflurane_23\NN|in (r_compound) anaesthesia_24\NN|NONE (r_pobj) after_22\IN|the||first (r_prep) h_21\NN|NONE (r_pobj) in_17\IN|incidence|.|study (r_prep) examined_5\VBD|NONE (l_dobj) incidence_7\NN|.|study|in (l_prep) of_10\IN|and|the|severity (l_pobj) nausea_12\NN|NONE (l_conj) vomiting_14\NN|postoperative|and
C009250_D020250 NONE sevoflurane_31\NN|an|unnecessary (r_relcl) supplement_29\NN|to (r_attr) be_23\VB|it|,|.|exacerbated (r_xcomp) appears_21\VBZ|NONE (l_advcl) exacerbated_2\VBD|be|it|,|. (l_dobj) nausea_4\NN|As|had|fentanyl|and (l_conj) vomiting_6\VBG|postoperative|and
C009250_D010149 NONE sevoflurane_31\NN|an|unnecessary (r_relcl) supplement_29\NN|to (r_attr) be_23\VB|it|,|.|exacerbated (r_xcomp) appears_21\VBZ|NONE (l_advcl) exacerbated_2\VBD|be|it|,|. (l_dobj) nausea_4\NN|As|had|fentanyl|and (l_conj) vomiting_6\VBG|postoperative|and (l_prep) without_7\IN|NONE (l_pobj) improvement_9\NN|NONE (l_prep) in_10\IN|an (l_pobj) pain_12\NN|NONE
C009250_D014839 NONE sevoflurane_12\NN|NONE (r_pobj) after_11\IN|without|nausea|Omitting|,|,|. (r_prep) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|without|Omitting|,|after|,|. (l_conj) vomiting_5\NN|and
C009250_D009325 NONE sevoflurane_12\NN|NONE (r_pobj) after_11\IN|without|nausea|Omitting|,|,|. (r_prep) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|without|Omitting|,|after|,|.
D003907_D009325 NONE dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_conj) moderate_23\JJ|incidence|to|did|prior|and/or|, (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D003907_D020250 NONE dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (r_conj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|did|.|but|not|Omission|,|reduce (l_prep) of_9\IN|the|overall (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D003907_D020250 NONE Dexamethasone_0\NNP|effect|. (r_nsubj) had_1\VBD|NONE (l_dobj) effect_4\NN|Dexamethasone|. (l_prep) on_5\IN|no|significant (l_pobj) incidence_7\NN|NONE (l_prep) of_10\IN|severity|or|the (l_pobj) nausea_12\NN|NONE (l_conj) vomiting_14\NN|and|postoperative
D005283_D014839 NONE fentanyl_1\NN|NONE (r_dobj) Omitting_0\VBG|without|nausea|,|after|,|. (r_csubj) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|without|Omitting|,|after|,|. (l_conj) vomiting_5\NN|and
D005283_D014839 NONE fentanyl_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Omission_0\NN|did|.|incidence|but|not|,|reduce (r_nsubj) reduce_5\VB|NONE (l_conj) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_dobj) incidence_19\NN|to|did|prior|and/or|moderate|, (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
D005283_D014839 NONE fentanyl_37\NN||fentanyl (r_nmod) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_dobj) incidence_19\NN|to|did|prior|and/or|moderate|, (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
D005283_D014839 NONE fentanyl_39\NN|fentanyl| (r_compound) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (l_dobj) incidence_19\NN|to|did|prior|and/or|moderate|, (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
D005283_D012131 CID Fentanyl_0\NNP|but|.|movement|had|did (r_nsubj) reduce_2\VB|NONE (l_conj) had_7\VBD|Fentanyl|but|.|movement|did (l_conj) depression_16\NN|effect|and
D005283_D020250 CID fentanyl_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Omission_0\NN|did|.|incidence|but|not|,|reduce (r_nsubj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|did|.|but|not|Omission|,|reduce (l_prep) of_9\IN|the|overall (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D005283_D020250 CID fentanyl_37\NN||fentanyl (r_nmod) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (r_conj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|did|.|but|not|Omission|,|reduce (l_prep) of_9\IN|the|overall (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D005283_D020250 CID fentanyl_39\NN|fentanyl| (r_compound) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN||and (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|respectively|, (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|incidence|to|did|and/or|moderate|, (r_advmod) reduce_17\VB|did|.|incidence|but|not|Omission|, (r_conj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|did|.|but|not|Omission|,|reduce (l_prep) of_9\IN|the|overall (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D005283_D020250 CID fentanyl_3\NN|the (r_compound) groups_4\NNS|NONE (r_dobj) Combining_0\VBG|(|benefits|,|decreased|.|reducing|P (r_csubj) revealed_5\VBD|NONE (l_advcl) reducing_15\VBG|(|benefits|,|Combining|decreased|.|P (l_dobj) nausea_17\NN|prior (l_conj) vomiting_19\NN|and|postoperative
D005283_D020250 CID fentanyl_1\NN|As|nausea|had|and (r_nsubj) exacerbated_2\VBD|be|it|,|. (l_dobj) nausea_4\NN|As|had|fentanyl|and (l_conj) vomiting_6\VBG|postoperative|and
D005283_D001919 CID Fentanyl_0\NNP|but|.|movement|had|did (r_nsubj) reduce_2\VB|NONE (l_conj) had_7\VBD|Fentanyl|but|.|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|,|respiratory|increased (l_conj) bradycardia_20\NN|and
D005283_D010146 NONE fentanyl_1\NN|NONE (r_dobj) Omitting_0\VBG|without|nausea|,|after|,|. (r_csubj) reduces_2\VBZ|NONE (l_prep) without_7\IN|nausea|Omitting|,|after|,|. (l_pcomp) increasing_8\VBG|NONE (l_dobj) pain_9\NN|NONE
D005283_D010146 NONE fentanyl_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) omission_9\NN|NONE (r_pobj) by_7\IN|NONE (r_prep) unaffected_6\JJ|severity|. (r_acomp) were_5\VBD|NONE (l_nsubj) severity_1\NN|unaffected|. (l_compound) Pain_0\NN|requirements|and
D005283_D010149 NONE fentanyl_1\NN|As|nausea|had|and (r_nsubj) exacerbated_2\VBD|be|it|,|. (l_dobj) nausea_4\NN|As|had|fentanyl|and (l_conj) vomiting_6\VBG|postoperative|and (l_prep) without_7\IN|NONE (l_pobj) improvement_9\NN|NONE (l_prep) in_10\IN|an (l_pobj) pain_12\NN|NONE
D005283_D007022 CID Fentanyl_0\NNP|but|.|movement|had|did (r_nsubj) reduce_2\VB|NONE (l_conj) had_7\VBD|Fentanyl|but|.|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|,|respiratory|increased
C009250_D012131 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|no (r_amod) effect_12\NN|depression|and (r_dobj) had_7\VBD|Fentanyl|but|.|movement|did (l_conj) depression_16\NN|effect|and
17241784
D019821_D009135 CID statin_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBD|Progressive|.|with (r_acl) myopathy_1\NNS|NONE
D019821_D009135 CID Statins_0\NNS|myopathy|necrotizing|can|. (r_nsubj) cause_2\VB|NONE (l_ccomp) myopathy_5\NN|necrotizing|can|Statins|.
D019821_D009135 CID statins_9\NNS|whereby|myopathy|may (r_nsubj) induce_11\VB|a|persists|, (l_dobj) myopathy_13\NN|whereby|statins|may
D019821_D009135 CID statins_4\NNS|may|myopathy|that (r_nsubj) initiate_6\VB|.|observations (l_dobj) myopathy_11\NN|may|statins|that
D019821_D009135 CID statins_13\NNS|NONE (r_pobj) by_12\IN|the (r_prep) induction_11\NN|may (r_dobj) involve_9\VB|uncertain|.|mechanism|but (r_conj) is_5\VBZ|NONE (l_nsubj) mechanism_1\NN|involve|uncertain|.|but (l_prep) of_2\IN|The (l_pobj) myopathy_4\NN|NONE
D019821_-1 NONE Statins_0\NNS|myopathy|necrotizing|can|. (r_nsubj) cause_2\VB|NONE (l_ccomp) myopathy_5\NN|necrotizing|can|Statins|. (l_conj) hyperCKaemia_7\NN|and
19308880
D014635_D003221 CID acid_10\NN|NONE (r_pobj) with_8\IN|adverse|serious|drug|a (r_prep) reaction_7\NN|.|,|review|: (r_appos) Confusion_0\NN|NONE
D014635_D003221 CID acid_10\NN|NONE (r_pobj) with_8\IN|frequently (r_prep) observed_7\VBD|drug|an|adverse (r_acl) reaction_5\NN|Confusion|. (r_attr) is_1\VBZ|NONE (l_nsubj) Confusion_0\NN|reaction|.
D014635_D003221 CID acid_17\NN|NONE (r_pobj) with_15\IN|since (r_prep) reported_12\VBN|NONE (r_acl) confusion_11\NN|NONE
D014635_D003221 CID acid_9\NN|NONE (r_pobj) with_7\IN|cases|.|:|were (r_prep) reported_6\VBN|NONE (l_nsubjpass) cases_2\NNS|.|:|with|were (l_prep) of_3\IN| (l_pobj) confusion_4\NN|NONE
D014635_D003221 CID acid_10\NN|)|%|( (r_compound) exposure_11\NN|NONE (r_pobj) following_8\VBG|two|the|first (r_prep) weeks_7\NNS|NONE (r_pobj) during_3\IN|mostly|Confusion|. (r_prep) occurred_2\VBD|NONE (l_nsubj) Confusion_0\NN|mostly|during|.
D014635_D003221 CID acid_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) confusion_4\NN|reaction|that
18182964
D003000_D006970 NONE clonidine_4\NN|NONE (r_pobj) on_3\IN|,|.|resolved|common|Drowsiness|but (r_prep) was_1\VBD|NONE (l_nsubj) Drowsiness_0\NN|,|.|resolved|common|on|but
D003000_D006970 NONE clonidine_2\NN|NONE (r_dobj) prescribing_1\VBG|NONE (r_acl) Physicians_0\NNS|and|should|advise|for|. (r_nsubj) monitor_4\VB|NONE (l_conj) advise_8\VB|Physicians|and|should|for|. (l_dobj) patients_9\NNS|NONE (l_prep) about_10\IN|NONE (l_pobj) likelihood_13\NN|NONE (l_prep) of_14\IN|the|high (l_pobj) drowsiness_16\NN|NONE
D003000_D001919 CID clonidine_10\NN|NONE (r_pobj) with_9\IN|compared (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|of|more (r_prep) incidents_3\NNS|There|. (l_prep) of_4\IN|in|more (l_pobj) bradycardia_5\NN|NONE
D003000_D001919 CID clonidine_17\NN|NONE (r_pobj) with_16\IN|not (r_prep) treated_15\VBN|but|differences|% (r_acl) those_13\DT|NONE (r_pobj) with_12\IN|NONE (r_prep) compared_11\VBN|with (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|of|more (r_prep) incidents_3\NNS|There|. (l_prep) of_4\IN|in|more (l_pobj) bradycardia_5\NN|NONE
D003000_D001919 CID clonidine_2\NN|NONE (r_dobj) prescribing_1\VBG|NONE (r_acl) Physicians_0\NNS|and|should|advise|for|. (r_nsubj) monitor_4\VB|NONE (l_prep) for_5\IN|Physicians|and|should|advise|. (l_pobj) bradycardia_6\NN|NONE
D008774_D001289 NONE methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE
D008774_D001289 NONE methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE (l_appos) ADHD_23\NNP|)|hyperactivity|(
D008774_D001289 NONE methylphenidate_25\NN|,|to|n (r_conj) clonidine_18\NN|In|children|randomly|.|were|, (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|In|randomly|.|were|clonidine|, (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D008774_D001289 NONE methylphenidate_34\NN|and (r_conj) clonidine_32\NN|(|placebo|or|n|,|n|)||,|(| (r_conj) methylphenidate_25\NN|,|to|n (r_conj) clonidine_18\NN|In|children|randomly|.|were|, (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|In|randomly|.|were|clonidine|, (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D008774_D001289 NONE methylphenidate_6\NN|NONE (r_pobj) with_5\IN|or|alone (r_conj) used_2\VBN|,|, (r_acl) Clonidine_0\NNP|.|and|safe|tolerated (r_nsubj) appears_8\VBZ|NONE (l_conj) tolerated_12\VBN|.|Clonidine|and|safe (l_prep) in_13\IN|well (l_pobj) ADHD_15\NNP|NONE
D003000_D001289 NONE Clonidine_0\NNP|NONE (l_prep) for_1\IN|II (l_pobj) disorder_7\NN|NONE
D003000_D001289 NONE clonidine_7\NN|NONE (r_pobj) of_6\IN|tolerability|and|the (r_prep) safety_3\NN|To (r_dobj) examine_1\VB|or|with|alone (r_csubj) used_8\VBN|NONE (l_conj) with_11\IN|or|alone|examine (l_pobj) methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE
D003000_D001289 NONE clonidine_7\NN|NONE (r_pobj) of_6\IN|tolerability|and|the (r_prep) safety_3\NN|To (r_dobj) examine_1\VB|or|with|alone (r_csubj) used_8\VBN|NONE (l_conj) with_11\IN|or|alone|examine (l_pobj) methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE (l_appos) ADHD_23\NNP|)|hyperactivity|(
D003000_D001289 NONE clonidine_18\NN|In|children|randomly|.|were|, (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|In|randomly|.|were|clonidine|, (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D003000_D001289 NONE clonidine_32\NN|(|placebo|or|n|,|n|)||,|(| (r_conj) methylphenidate_25\NN|,|to|n (r_conj) clonidine_18\NN|In|children|randomly|.|were|, (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|In|randomly|.|were|clonidine|, (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D003000_D001289 NONE Clonidine_0\NNP|.|and|safe|tolerated (r_nsubj) appears_8\VBZ|NONE (l_conj) tolerated_12\VBN|.|Clonidine|and|safe (l_prep) in_13\IN|well (l_pobj) ADHD_15\NNP|NONE
20528871
C104457_D006402 CID AraG_8\NNP|NONE (r_pobj) than_7\IN|the (r_prep) combination_6\NN|NONE (r_pobj) for_4\IN|NONE (r_prep) greater_3\JJR|was|toxicity|.|, (r_acomp) was_2\VBD|NONE (l_nsubj) toxicity_1\NN|was|.|greater|,
D005047_D015458 NONE etoposide_5\RB|in|, (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|refractory|lymphoblastic|relapsed|and|/
D005047_D015458 NONE etoposide_14\NN|NONE (r_pobj) of_13\IN|VP| (r_prep) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D005047_D015458 NONE VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D005047_D016399 NONE etoposide_5\RB|in|, (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|refractory|lymphoblastic|relapsed|and|/
D005047_D016399 NONE etoposide_14\NN|NONE (r_pobj) of_13\IN|VP| (r_prep) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D005047_D016399 NONE VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
C104457_D015458 NONE nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|refractory|lymphoblastic|relapsed|and|/
C104457_D015458 NONE nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
C104457_D015458 NONE AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D003520_D015458 NONE cyclophosphamide_8\NN|and|, (r_conj) etoposide_5\RB|in|, (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|refractory|lymphoblastic|relapsed|and|/
D003520_D015458 NONE cyclophosphamide_19\NN|and|CPM|(|chemotherapy|)|and (r_conj) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D003520_D015458 NONE CPM_21\NNP|cyclophosphamide|and|(|chemotherapy|)|and (r_appos) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
C104457_D016399 NONE nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|refractory|lymphoblastic|relapsed|and|/
C104457_D016399 NONE nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
C104457_D016399 NONE AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D003520_D016399 NONE cyclophosphamide_8\NN|and|, (r_conj) etoposide_5\RB|in|, (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|refractory|lymphoblastic|relapsed|and|/
D003520_D016399 NONE cyclophosphamide_19\NN|and|CPM|(|chemotherapy|)|and (r_conj) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D003520_D016399 NONE CPM_21\NNP|cyclophosphamide|and|(|chemotherapy|)|and (r_appos) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|was|as|in|. (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|was|combination|as|. (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|cell|or|refractory
D005047_D009422 NONE etoposide_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) synchrony_12\NN|NONE (r_pobj) in_11\IN|salvage (r_prep) therapy_10\NN|NONE (r_pobj) as_8\IN|AraG (r_prep) giving_6\VBG|NONE (r_pcomp) of_5\IN|the (r_prep) safety_4\NN|.|,|experience|monitored (r_dobj) supports_2\VBZ|NONE (l_advcl) monitored_24\VBN|.|,|experience|safety (l_nsubjpass) toxicity_20\NN|closely|be|although|must
D003520_D009422 NONE cyclophosphamide_16\NN|and (r_conj) etoposide_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) synchrony_12\NN|NONE (r_pobj) in_11\IN|salvage (r_prep) therapy_10\NN|NONE (r_pobj) as_8\IN|AraG (r_prep) giving_6\VBG|NONE (r_pcomp) of_5\IN|the (r_prep) safety_4\NN|.|,|experience|monitored (r_dobj) supports_2\VBZ|NONE (l_advcl) monitored_24\VBN|.|,|experience|safety (l_nsubjpass) toxicity_20\NN|closely|be|although|must
C104457_D009422 CID AraG_8\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) attributable_5\JJ|common|side|The (r_amod) effects_4\NNS|.|neuropathy (r_nsubj) included_9\VBD|NONE (l_dobj) neuropathy_17\NN|.|effects
C104457_D009422 CID AraG_7\NN|as (r_dobj) giving_6\VBG|NONE (r_pcomp) of_5\IN|the (r_prep) safety_4\NN|.|,|experience|monitored (r_dobj) supports_2\VBZ|NONE (l_advcl) monitored_24\VBN|.|,|experience|safety (l_nsubjpass) toxicity_20\NN|closely|be|although|must
C104457_D059352 CID AraG_8\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) attributable_5\JJ|common|side|The (r_amod) effects_4\NNS|.|neuropathy (r_nsubj) included_9\VBD|NONE (l_dobj) neuropathy_17\NN|.|effects (l_conj) pain_20\NN|Grade|and|sensory
10704919
D017665_D006461 NONE hydroxyl_32\NN|(|) (r_dobj) inactivated_30\VBN|by|indicating|effect|.|is (r_parataxis) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|by|inactivated|indicating|.|is (l_amod) hemolytic_1\JJ|of|The
D017665_D006461 NONE hydroxyl_32\NN|(|) (r_dobj) inactivated_30\VBN|by|indicating|effect|.|is (r_parataxis) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|by|inactivated|effect|.|is (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|is|that|not|to
D013629_D006461 CID tamoxifen_6\NN|NONE (r_pobj) by_5\IN|Hemolysis|related|. (r_agent) induced_4\VBN|NONE (l_nsubj) Hemolysis_0\NNP|by|related|.
D013629_D006461 CID TAM_0\NNP|.|hemolysis (r_nsubj) induces_1\VBZ|NONE (l_dobj) hemolysis_2\NN|.|TAM
D013629_D006461 CID TAM_13\NNP|hemolysis|. (r_nsubj) induces_14\VBZ|,|but|extension|variable (r_conj) is_4\VBZ|NONE (l_nsubj) extension_1\NN|,|but|variable|induces (l_prep) of_2\IN|The (l_pobj) hemolysis_3\NN|NONE
D013629_D006461 CID TAM_13\NNP|hemolysis|. (r_nsubj) induces_14\VBZ|,|but|extension|variable (l_dobj) hemolysis_16\NN|TAM|.
D013629_D006461 CID TAM_4\NNP|NONE (r_pobj) of_3\IN|The|hemolytic (r_prep) effect_2\NN|by|inactivated|indicating|.|is (l_amod) hemolytic_1\JJ|of|The
D013629_D006461 CID TAM_4\NNP|NONE (r_pobj) of_3\IN|The|hemolytic (r_prep) effect_2\NN|by|inactivated|indicating|.|is (r_nsubjpass) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|by|inactivated|effect|.|is (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|is|that|not|to
D013629_D006461 CID TAM_36\NNP| (r_npadvmod) induced_38\VBN|NONE (r_amod) hemolysis_39\NN|is|that|not|to (r_nsubjpass) related_42\VBN|NONE (r_ccomp) indicating_34\VBG|by|inactivated|effect|.|is (r_advcl) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|by|inactivated|indicating|.|is (l_amod) hemolytic_1\JJ|of|The
D013629_D006461 CID TAM_36\NNP| (r_npadvmod) induced_38\VBN|NONE (r_amod) hemolysis_39\NN|is|that|not|to
D013629_D006461 CID TAM_17\NNP| (r_npadvmod) induced_19\VBN|NONE (r_amod) hemolysis_20\NN|NONE
D013629_D006461 CID TAM_3\NNP|NONE (r_pobj) by_2\IN|NONE (r_agent) caused_1\VBN|NONE (r_acl) Hemolysis_0\NNP|not|was|excluding|according|by|.|,|,
D013629_D006461 CID TAM_3\NNP|NONE (r_pobj) by_2\IN|NONE (r_agent) caused_1\VBN|NONE (r_acl) Hemolysis_0\NNP|not|was|excluding|according|by|.|,|, (r_nsubjpass) preceded_6\VBN|NONE (l_prep) excluding_18\VBG|not|was|according|by|.|Hemolysis|,|, (l_pobj) mechanism_24\NN|also (l_prep) of_25\IN|type|a|osmotic (l_pobj) hemolysis_26\NN|NONE
D013629_D006461 CID TAM_15\NNP|a|and|decreased|in (r_compound) incorporation_16\NN|NONE (r_pobj) to_12\IN|protection|is|that (r_prep) related_11\VBN|effects|avoided (l_nsubjpass) protection_5\NN|is|to|that (l_prep) from_6\IN|the|by (l_pobj) hemolysis_7\NN|NONE
D013629_D006461 CID TAM_2\NNP| (r_npadvmod) induced_4\VBN|.|from|hemolysis|,|Therefore|,|leading (r_amod) results_6\NNS|NONE (l_compound) hemolysis_5\NN|.|from|,|Therefore|induced|,|leading
D013629_D001943 NONE Tamoxifen_0\NNP|drug|.|,|changes (r_nsubj) induces_18\VBZ|NONE (l_nsubj) drug_7\NN|.|Tamoxifen|,|changes (l_acl) prescribed_10\VBN|antiestrogenic|the (l_prep) in_11\IN|widely (l_pobj) chemotherapy_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) cancer_16\NN|NONE
D013629_D001943 NONE TAM_2\NNP|, (r_appos) Tamoxifen_0\NNP|drug|.|,|changes (r_nsubj) induces_18\VBZ|NONE (l_nsubj) drug_7\NN|.|Tamoxifen|,|changes (l_acl) prescribed_10\VBN|antiestrogenic|the (l_prep) in_11\IN|widely (l_pobj) chemotherapy_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) cancer_16\NN|NONE
D011188_D006461 NONE K(+_11\NNP|NONE (r_pobj) of_10\IN|from|)|the (r_prep) leakage_9\NN|NONE (r_pobj) by_7\IN|not|was|excluding|according|.|Hemolysis|,|, (r_agent) preceded_6\VBN|NONE (l_nsubjpass) Hemolysis_0\NNP|not|was|excluding|according|by|.|,|,
D011188_D006461 NONE K(+_11\NNP|NONE (r_pobj) of_10\IN|from|)|the (r_prep) leakage_9\NN|NONE (r_pobj) by_7\IN|not|was|excluding|according|.|Hemolysis|,|, (r_agent) preceded_6\VBN|NONE (l_prep) excluding_18\VBG|not|was|according|by|.|Hemolysis|,|, (l_pobj) mechanism_24\NN|also (l_prep) of_25\IN|type|a|osmotic (l_pobj) hemolysis_26\NN|NONE
D013629_D000743 CID Tamoxifen_0\NNP|drug|.|,|changes (r_nsubj) induces_18\VBZ|NONE (l_dobj) changes_19\NNS|drug|.|Tamoxifen|, (l_prep) in_20\IN|NONE (l_pobj) shape_23\NN|NONE (l_prep) of_24\IN|normal|discoid (l_pobj) erythrocytes_25\NNS|NONE (l_conj) anemia_28\NN|and
D013629_D000743 CID TAM_2\NNP|, (r_appos) Tamoxifen_0\NNP|drug|.|,|changes (r_nsubj) induces_18\VBZ|NONE (l_dobj) changes_19\NNS|drug|.|Tamoxifen|, (l_prep) in_20\IN|NONE (l_pobj) shape_23\NN|NONE (l_prep) of_24\IN|normal|discoid (l_pobj) erythrocytes_25\NNS|NONE (l_conj) anemia_28\NN|and
D013629_D000743 CID TAM_6\NNP|NONE (r_pobj) of_5\IN|the|on (r_prep) effects_4\NNS|.|,|attempting|work (r_dobj) evaluates_2\VBZ|NONE (l_advcl) attempting_12\VBG|.|,|work|effects (l_xcomp) identify_14\VB|NONE (l_dobj) mechanisms_17\NNS|to (l_prep) on_18\IN|involvement|underlying|the|and (l_pobj) anemia_23\NN|NONE
D013629_D000743 CID TAM_19\NNP| (r_npadvmod) induced_21\VBN|hemolytic (r_amod) anemia_23\NN|NONE
D013629_D000743 CID TAM_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_agent) promoted_11\VBN|mechanical (r_acl) stability_10\NN|,|resulting (r_dobj) decreased_8\VBD|and|shape|defects|. (l_conj) resulting_15\VBG|,|stability (l_prep) in_16\IN|NONE (l_pobj) anemia_18\NN|NONE
D010100_D006461 NONE oxygen_7\NN|oxidation|and (r_compound) consumption_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) absence_5\NN|NONE (r_pobj) by_4\IN|determined|.|further|was|This (r_agent) evidenced_3\VBN|NONE (l_conj) determined_13\VBN|by|.|further|was|This (l_prep) in_14\IN|NONE (l_pobj) parallel_15\NN|NONE (l_prep) with_16\IN|NONE (l_pobj) hemolysis_20\NN|NONE
D024502_D006461 NONE tocopherol_13\NN|NONE (r_pobj) of_10\IN|low|acetate|and (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|by|inactivated|indicating|.|is (l_amod) hemolytic_1\JJ|of|The
D024502_D006461 NONE tocopherol_13\NN|NONE (r_pobj) of_10\IN|low|acetate|and (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|by|inactivated|effect|.|is (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|is|that|not|to
D024502_D006461 NONE T_17\NNP|)||alpha|( (r_appos) tocopherol_13\NN|NONE (r_pobj) of_10\IN|low|acetate|and (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|by|inactivated|indicating|.|is (l_amod) hemolytic_1\JJ|of|The
D024502_D006461 NONE T_17\NNP|)||alpha|( (r_appos) tocopherol_13\NN|NONE (r_pobj) of_10\IN|low|acetate|and (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|by|inactivated|effect|.|is (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|is|that|not|to
D024502_D006461 NONE acetate_23\NN|low|of|and (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|by|inactivated|indicating|.|is (l_amod) hemolytic_1\JJ|of|The
D024502_D006461 NONE acetate_23\NN|low|of|and (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|by|inactivated|effect|.|is (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|is|that|not|to
D024502_D006461 NONE TAc_27\NNS|)|tocopherol|( (r_appos) acetate_23\NN|low|of|and (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|by|inactivated|indicating|.|is (l_amod) hemolytic_1\JJ|of|The
D024502_D006461 NONE TAc_27\NNS|)|tocopherol|( (r_appos) acetate_23\NN|low|of|and (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|inactivated|indicating|effect|.|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|by|inactivated|effect|.|is (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|is|that|not|to
D024505_D006461 NONE tocopherols_9\NNS|NONE (r_pobj) by_8\IN|from|the (r_prep) protection_5\NN|is|to|that (l_prep) from_6\IN|the|by (l_pobj) hemolysis_7\NN|NONE
10683478
D001058_D006948 CID apomorphine_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) hyperactivity_8\NN|NONE
D004298_D007035 NONE dopamine_28\NN|distinct (r_relcl) changes_26\NNS|to (r_dobj) produce_24\VB|hypothermia|and|to|, (r_conj) induce_19\VB|its (l_dobj) hypothermia_20\NN|and|to|produce|,
D001058_D007035 CID Apomorphine_0\NNP|,|ability|.|due|was (r_nsubjpass) selected_8\VBN|NONE (l_dobj) ability_17\NN|,|.|Apomorphine|due|was (l_acl) induce_19\VB|its (l_dobj) hypothermia_20\NN|and|to|produce|,
D001058_D007035 CID apomorphine_11\NN|upon|can|Moreover|conditions|,|. (l_prep) as_13\IN|to (l_pobj) hypothermia_17\NN|such
D018491_D007035 NONE agonist_5\NN|,|, (r_appos) Apomorphine_0\NNP|,|ability|.|due|was (r_nsubjpass) selected_8\VBN|NONE (l_dobj) ability_17\NN|,|.|Apomorphine|due|was (l_acl) induce_19\VB|its (l_dobj) hypothermia_20\NN|and|to|produce|,
12041669
D000961_D000741 NONE globulin_1\NN|NONE (l_prep) in_2\IN|.|Antithymocyte (l_pobj) treatment_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) anemia_12\NN|NONE
D000961_D000741 NONE globulin_5\NN|NONE (r_compound) therapy_6\NN|due|who|antithymocyte|for (r_dobj) received_3\VBD|A (l_prep) for_7\IN|due|who|therapy|antithymocyte (l_pobj) anemia_9\NN|NONE
D000961_D000741 NONE globulin_3\NN|of (r_dobj) Use_0\NN|may|.|treatment (r_nsubj) be_5\VB|NONE (l_attr) treatment_8\NN|may|Use|. (l_prep) of_9\IN|optimal|the (l_pobj) anemia_16\NN|NONE
D010396_D000741 CID penicillamine_8\NN| (r_npadvmod) induced_10\VBN|aplastic (r_amod) anemia_12\NN|NONE
D010396_D000741 CID penicillamine_14\NN|NONE (r_compound) therapy_15\NN|is|.|patient (r_nsubjpass) described_17\VBN|NONE (l_nsubjpass) patient_1\NN|is|.|therapy (l_relcl) received_3\VBD|A (l_prep) for_7\IN|due|who|therapy|antithymocyte (l_pobj) anemia_9\NN|NONE
D010396_D000741 CID penicillamine_12\NN| (r_npadvmod) induced_14\VBN|aplastic (r_amod) anemia_16\NN|NONE
12536034
D020888_D004832 CID vigabatrin_15\NN|and (r_conj) carbamazepine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) administration_11\NN|NONE (r_pobj) after_10\IN|.|authors|patients (r_prep) present_2\VBP|NONE (l_dobj) patients_4\NNS|.|authors|after (l_prep) with_5\IN|three (l_pobj) epilepsy_9\NN|NONE
D005680_D004832 NONE acid_4\NN| (r_npadvmod) transmitted_6\VBN|thalamocortical (r_amod) circuitry_8\NN|The|.|aminobutyric|for (r_compound) accounts_9\VBZ|NONE (l_prep) for_10\IN|The|.|circuitry|aminobutyric (l_pobj) part_13\NN|NONE (l_prep) of_14\IN|major|a (l_pobj) neurophysiology_17\NN|NONE (l_prep) of_18\IN|the|underlying (l_pobj) epilepsy_21\NN|NONE
D002220_D004832 CID carbamazepine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) administration_11\NN|NONE (r_pobj) after_10\IN|.|authors|patients (r_prep) present_2\VBP|NONE (l_dobj) patients_4\NNS|.|authors|after (l_prep) with_5\IN|three (l_pobj) epilepsy_9\NN|NONE
10365197
D003042_D019970 NONE cocaine_1\NN| (r_npadvmod) dependent_3\JJ|with|disorders|,| (r_amod) outpatients_4\NNS|.|were|on (l_prep) with_5\IN|disorders|,||dependent (l_pobj) disorder_10\NN|NONE (l_appos) CIMD_12\NNP|(|mood|)|induced
D003042_D019970 NONE cocaine_6\NN| (r_npadvmod) induced_8\VBN|(|CIMD|mood|) (r_amod) disorder_10\NN|NONE (l_appos) CIMD_12\NNP|(|mood|)|induced
D003042_D001523 NONE Cocaine_0\NN| (r_npadvmod) induced_2\VBN|:|rates|.|mood (r_amod) disorder_4\NN|NONE (l_appos) rates_7\NNS|:|.|mood|induced (l_conj) symptoms_10\NNS|and|prevalence|in (l_amod) psychiatric_9\JJ|NONE
D003042_D001523 NONE cocaine_14\NN| (r_npadvmod) dependent_16\JJ|outpatient|an (r_amod) sample_17\NN|NONE (r_pobj) in_11\IN|symptoms|and|prevalence (r_prep) rates_7\NNS|:|.|mood|induced (l_conj) symptoms_10\NNS|and|prevalence|in (l_amod) psychiatric_9\JJ|NONE
D003042_D001523 NONE cocaine_1\NN| (r_npadvmod) dependent_3\JJ|with|disorders|,| (r_amod) outpatients_4\NNS|.|were|on (r_nsubjpass) compared_24\VBN|NONE (l_prep) on_25\IN|.|were|outpatients (l_pobj) measures_26\NNS|NONE (l_prep) of_27\IN|NONE (l_pobj) symptoms_29\NNS|NONE (l_amod) psychiatric_28\JJ|NONE
D003042_D001523 NONE cocaine_6\NN| (r_npadvmod) induced_8\VBN|(|CIMD|mood|) (r_amod) disorder_10\NN|NONE (r_pobj) with_5\IN|disorders|,||dependent (r_prep) outpatients_4\NNS|.|were|on (r_nsubjpass) compared_24\VBN|NONE (l_prep) on_25\IN|.|were|outpatients (l_pobj) measures_26\NNS|NONE (l_prep) of_27\IN|NONE (l_pobj) symptoms_29\NNS|NONE (l_amod) psychiatric_28\JJ|NONE
D003042_D019964 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|:|rates|.|mood (r_amod) disorder_4\NN|NONE
D003042_D019964 CID cocaine_14\NN| (r_npadvmod) dependent_16\JJ|outpatient|an (r_amod) sample_17\NN|NONE (r_pobj) in_11\IN|symptoms|and|prevalence (r_prep) rates_7\NNS|:|.|mood|induced (r_appos) disorder_4\NN|NONE
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|with|disorders|,| (r_amod) outpatients_4\NNS|.|were|on (l_prep) with_5\IN|disorders|,||dependent (l_pobj) disorder_10\NN|NONE
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|with|disorders|,| (r_amod) outpatients_4\NNS|.|were|on (l_conj) disorders_17\NNS|with|,||dependent
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|with|disorders|,| (r_amod) outpatients_4\NNS|.|were|on (l_conj) disorders_17\NNS|with|,||dependent (l_conj) disorder_22\NN|or|,|mood|other
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|(|CIMD|mood|) (r_amod) disorder_10\NN|NONE
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|(|CIMD|mood|) (r_amod) disorder_10\NN|NONE (r_pobj) with_5\IN|disorders|,||dependent (r_prep) outpatients_4\NNS|.|were|on (l_conj) disorders_17\NNS|with|,||dependent
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|(|CIMD|mood|) (r_amod) disorder_10\NN|NONE (r_pobj) with_5\IN|disorders|,||dependent (r_prep) outpatients_4\NNS|.|were|on (l_conj) disorders_17\NNS|with|,||dependent (l_conj) disorder_22\NN|or|,|mood|other
16160878
D014579_D001919 NONE II_8\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) injection_4\NN|and|hypertension|Intracerebroventricular|stimulates|. (r_nsubj) causes_9\NNS|NONE (l_dobj) hypertension_10\NN|and|injection|Intracerebroventricular|stimulates|. (l_conj) bradycardia_12\NN|and
D003345_D010409 NONE corticosterone_35\NN|induced (r_compound) level_36\NN|,|and|administration|erection|effect|,|was|. (r_conj) had_12\VBD|NONE (l_dobj) erection_25\NN|,|and|administration|effect|level|,|was|.
D014579_D006973 NONE II_8\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) injection_4\NN|and|hypertension|Intracerebroventricular|stimulates|. (r_nsubj) causes_9\NNS|NONE (l_dobj) hypertension_10\NN|and|injection|Intracerebroventricular|stimulates|.
D001058_D010409 CID apomorphine_21\NN| (r_npadvmod) induced_23\VBN|and|behavior|penile (r_amod) erection_25\NN|,|and|administration|effect|level|,|was|.
D014579_D001523 NONE II_6\NNP|in|that|be|may (r_nsubjpass) involved_9\VBN|data|. (l_prep) in_10\IN|that|be|may|II (l_pobj) aspects_12\NNS|NONE (l_prep) of_13\IN|some (l_pobj) disorders_15\NNS|NONE
D014579_D010409 NONE II_11\NNP|NONE (r_pobj) of_8\IN|central|the (r_prep) administration_7\NN|,|and|erection|effect|level|,|was|. (r_nsubj) had_12\VBD|NONE (l_dobj) erection_25\NN|,|and|administration|effect|level|,|was|.
2385256
D008274_D009157 CID magnesium_6\NN|NONE (r_compound) administration_7\NN|NONE (r_pobj) after_5\IN|NONE (r_prep) weakness_4\NN|NONE (r_pobj) as_3\IN|NONE (r_prep) presenting_2\VBG|.|Myasthenia (r_acl) gravis_1\NN|NONE
D008274_D009157 CID magnesium_3\NN|NONE (r_compound) administration_4\NN|NONE (r_pobj) after_2\IN|NONE (r_prep) paralysis_1\NN|in|been|has|Although (r_nsubjpass) described_7\VBN|it|has|not|previously|be|.|been|, (l_prep) in_8\IN|paralysis|been|has|Although (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) gravis_13\NN|NONE
D008274_D009468 NONE magnesium_17\NN|for|parenteral (r_compound) administration_18\NN|NONE (r_pobj) after_15\IN|quadriplegic|who (r_prep) became_12\VBD|neuromuscular (r_relcl) disease_10\NN|NONE
D008274_D011782 NONE magnesium_17\NN|for|parenteral (r_compound) administration_18\NN|NONE (r_pobj) after_15\IN|quadriplegic|who (r_prep) became_12\VBD|neuromuscular (l_acomp) quadriplegic_14\JJ|who|after
D008274_D010243 NONE magnesium_3\NN|NONE (r_compound) administration_4\NN|NONE (r_pobj) after_2\IN|NONE (r_prep) paralysis_1\NN|in|been|has|Although
D008274_D020511 NONE magnesium_10\NN|NONE (r_pobj) of_9\IN|the|neuromuscular (r_prep) effects_8\NNS|NONE (r_pobj) to_5\IN|unusually (r_prep) sensitive_4\JJ|who (r_acomp) are_2\VBP|NONE (r_relcl) Patients_0\NNS|of|should|.|be (r_nsubjpass) suspected_13\VBN|NONE (l_prep) of_14\IN|Patients|should|.|be (l_pcomp) having_15\VBG|NONE (l_dobj) disorder_18\NN|NONE (l_prep) of_19\IN|an|underlying (l_pobj) transmission_21\NN|NONE
D008274_D011225 NONE magnesium_17\NN|for|parenteral (r_compound) administration_18\NN|NONE (l_prep) for_19\IN|parenteral|magnesium (l_pobj) preeclampsia_20\NN|NONE
3076126
D009525_D009135 CID niacin_35\NN|or (r_conj) gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
D015248_D009135 CID gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
D009525_D009212 NONE niacin_35\NN|or (r_conj) gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
D016572_D009212 NONE cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
D008148_D009135 NONE lovastatin_23\NN|NONE (r_pobj) with_22\IN|,|in|has|,|in|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
D009525_D051437 NONE niacin_35\NN|or (r_conj) gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|,|with|has|,|in|rarely|.|been (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D008148_D051437 CID lovastatin_23\NN|NONE (r_pobj) with_22\IN|,|in|has|,|in|rarely|.|been (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|,|with|has|,|in|rarely|.|been (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D008148_D009212 CID lovastatin_23\NN|NONE (r_pobj) with_22\IN|,|in|has|,|in|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
D015248_D051437 NONE gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|,|with|has|,|in|rarely|.|been (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D016572_D009135 CID cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
D016572_D051437 NONE cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|,|with|has|,|in|rarely|.|been (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D015248_D009212 NONE gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|,|with|in|has|,|rarely|.|been (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
1592014
D003042_D020521 NONE cocaine_8\NN|NONE (r_pobj) of_7\IN|(|) (r_prep) t1/2_5\NN|half| (r_appos) life_3\NN|occur|The|but|short|, (r_nsubj) is_9\VBZ|NONE (l_conj) occur_29\VB|life|The|but|short|, (l_nsubj) some_14\DT|.|hours|can (l_prep) of_15\IN|NONE (l_pobj) consequences_17\NNS|NONE (l_prep) of_18\IN|the (l_pobj) use_20\NN|NONE (l_prep) as_23\IN|its|,|, (l_pobj) seizures_24\NNS|such (l_conj) strokes_26\NNS|and
C005618_D012640 CID benzoylecgonine_6\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
C005618_D012640 CID benzoylecgonine_11\NN|the|major|BE|of (r_appos) metabolite_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) potential_3\NN|We|cause|,|. (r_dobj) evaluated_1\VBD|NONE (l_advcl) cause_17\VB|potential|We|,|. (l_dobj) seizures_18\NNS|to
C005618_D012640 CID BE_13\VB|the|major|benzoylecgonine|of (r_appos) metabolite_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) potential_3\NN|We|cause|,|. (r_dobj) evaluated_1\VBD|NONE (l_advcl) cause_17\VB|potential|We|,|. (l_dobj) seizures_18\NNS|to
C005618_D012640 CID BE_0\VB| (r_advmod) Induced_2\VBN|NONE (r_amod) seizures_3\NNS|frequently|and|.|had
C005618_D012640 CID BE_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|NONE (r_acl) those_20\DT|,|multiple|characterized|,|and|resulted|. (r_nsubj) were_24\VBD|NONE (l_advcl) characterized_7\VBN|,|multiple|,|and|resulted|those|. (l_nsubjpass) seizures_4\NNS|were|and|best|resulted|as|Whereas
C005618_D012640 CID BE_0\VB| (r_advmod) Injected_2\VBN|have (r_amod) rats_3\NNS|activity|.|without (l_relcl) have_7\VB|Injected (l_dobj) seizures_8\NNS|not|that|did
C005618_D012640 CID BE_0\VB| (r_advmod) Injected_2\VBN|have (r_amod) rats_3\NNS|activity|.|without (r_nsubj) had_9\VBD|NONE (l_prep) without_19\IN|rats|activity|. (l_pobj) seizures_20\NNS|NONE
C005618_D012640 CID BE_5\VB| (r_advmod) induced_7\VBN|and (r_conj) cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in
C005618_D012640 CID BE_5\VB| (r_advmod) induced_7\VBN|and (r_conj) cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in (r_nsubj) differ_9\VBP|The (r_relcl) finding_1\NN|mechanism|and|emphasizes|. (r_nsubj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|and|emphasizes|finding|. (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
C005618_D012640 CID BE_32\VB|,|importance (r_conj) emphasizes_24\VBZ|mechanism|and|finding|. (r_conj) suggests_13\VBZ|NONE (l_nsubj) finding_1\NN|mechanism|and|emphasizes|. (l_relcl) differ_9\VBP|The (l_nsubj) seizures_8\NNS|in
C005618_D012640 CID BE_32\VB|,|importance (r_conj) emphasizes_24\VBZ|mechanism|and|finding|. (r_conj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|and|emphasizes|finding|. (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
D003042_D003643 NONE cocaine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) seizures_4\NNS|were|and|best|resulted|as|Whereas (r_nsubjpass) characterized_7\VBN|,|multiple|,|and|resulted|those|. (l_conj) resulted_16\VBD|were|and|seizures|best|as|Whereas (l_prep) in_17\IN|NONE (l_pobj) death_18\NN|NONE
D003042_D003643 NONE cocaine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) seizures_4\NNS|were|and|best|resulted|as|Whereas (r_nsubjpass) characterized_7\VBN|,|multiple|,|and|resulted|those|. (r_advcl) were_24\VBD|NONE (l_conj) resulted_36\VBD|,|multiple|characterized|,|and|those|. (l_prep) in_37\IN|rarely (l_pobj) death_38\NN|NONE
C005618_D003643 NONE BE_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|NONE (r_acl) those_20\DT|,|multiple|characterized|,|and|resulted|. (r_nsubj) were_24\VBD|NONE (l_advcl) characterized_7\VBN|,|multiple|,|and|resulted|those|. (l_conj) resulted_16\VBD|were|and|seizures|best|as|Whereas (l_prep) in_17\IN|NONE (l_pobj) death_18\NN|NONE
C005618_D003643 NONE BE_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|NONE (r_acl) those_20\DT|,|multiple|characterized|,|and|resulted|. (r_nsubj) were_24\VBD|NONE (l_conj) resulted_36\VBD|,|multiple|characterized|,|and|those|. (l_prep) in_37\IN|rarely (l_pobj) death_38\NN|NONE
D003042_D012640 CID cocaine_4\NN|NONE (r_compound) metabolite_5\NN|the|in (r_amod) benzoylecgonine_6\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
D003042_D012640 CID cocaine_8\NN|NONE (r_pobj) of_7\IN|(|) (r_prep) t1/2_5\NN|half| (r_appos) life_3\NN|occur|The|but|short|, (r_nsubj) is_9\VBZ|NONE (l_conj) occur_29\VB|life|The|but|short|, (l_nsubj) some_14\DT|.|hours|can (l_prep) of_15\IN|NONE (l_pobj) consequences_17\NNS|NONE (l_prep) of_18\IN|the (l_pobj) use_20\NN|NONE (l_prep) as_23\IN|its|,|, (l_pobj) seizures_24\NNS|such
D003042_D012640 CID cocaine_9\NN|NONE (r_pobj) of_8\IN|the|major|BE|benzoylecgonine (r_prep) metabolite_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) potential_3\NN|We|cause|,|. (r_dobj) evaluated_1\VBD|NONE (l_advcl) cause_17\VB|potential|We|,|. (l_dobj) seizures_18\NNS|to
D003042_D012640 CID cocaine_19\NN|NONE (r_pobj) of_18\IN|equimolar (r_prep) amounts_17\NNS|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|NONE (r_acl) those_13\DT|NONE (r_pobj) than_12\IN|longer (r_prep) latencies_11\NNS|NONE (r_dobj) had_8\VBD|seizures|frequently|and|. (r_conj) occurred_4\VBD|NONE (l_nsubj) seizures_3\NNS|frequently|and|.|had
D003042_D012640 CID cocaine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) seizures_4\NNS|were|and|best|resulted|as|Whereas
D003042_D012640 CID cocaine_15\NN| (r_npadvmod) injected_17\VBN|NONE (r_amod) animals_18\NNS|NONE (r_pobj) than_14\IN|more|locomotor (r_prep) activity_13\NN|rats|.|without (r_dobj) had_9\VBD|NONE (l_nsubj) rats_3\NNS|activity|.|without (l_relcl) have_7\VB|Injected (l_dobj) seizures_8\NNS|not|that|did
D003042_D012640 CID cocaine_15\NN| (r_npadvmod) injected_17\VBN|NONE (r_amod) animals_18\NNS|NONE (r_pobj) than_14\IN|more|locomotor (r_prep) activity_13\NN|rats|.|without (r_dobj) had_9\VBD|NONE (l_prep) without_19\IN|rats|activity|. (l_pobj) seizures_20\NNS|NONE
D003042_D012640 CID cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in
D003042_D012640 CID cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in (r_nsubj) differ_9\VBP|The (r_relcl) finding_1\NN|mechanism|and|emphasizes|. (r_nsubj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|and|emphasizes|finding|. (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) seizures_22\NNS|NONE (r_pobj) for_18\IN|one (r_prep) mechanism_17\NN|and|emphasizes|finding|. (r_dobj) suggests_13\VBZ|NONE (l_nsubj) finding_1\NN|mechanism|and|emphasizes|. (l_relcl) differ_9\VBP|The (l_nsubj) seizures_8\NNS|in
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) seizures_22\NNS|NONE
D003042_D012640 CID cocaine_29\NN|a (r_compound) metabolite_30\NN|NONE (r_pobj) of_27\IN|the (r_prep) importance_26\NN|,|BE (r_dobj) emphasizes_24\VBZ|mechanism|and|finding|. (r_conj) suggests_13\VBZ|NONE (l_nsubj) finding_1\NN|mechanism|and|emphasizes|. (l_relcl) differ_9\VBP|The (l_nsubj) seizures_8\NNS|in
D003042_D012640 CID cocaine_29\NN|a (r_compound) metabolite_30\NN|NONE (r_pobj) of_27\IN|the (r_prep) importance_26\NN|,|BE (r_dobj) emphasizes_24\VBZ|mechanism|and|finding|. (r_conj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|and|emphasizes|finding|. (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
1867351
D015767_D008288 NONE mefloquine_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treatment_8\NN|and|malaria (r_conj) prophylaxis_6\NN|NONE (l_compound) malaria_5\NN|and|treatment
21029050
D013390_D001049 CID succinylcholine_9\NN|NONE (r_pobj) after_8\IN|gene|in|. (r_prep) mutations_2\NNS|NONE (l_prep) in_3\IN|gene|.|after (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN|NONE (l_pobj) apnea_7\NN|NONE
D013390_D001049 CID succinylcholine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) action_9\NN|NONE (r_pobj) of_8\IN|prolonged|a (r_prep) duration_7\NN|NONE (r_pobj) with_4\IN| (r_prep) patients_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) eleven_0\CD|,|indicating|.|mutations (r_nsubj) had_12\VBD|NONE (l_advcl) indicating_17\VBG|,|.|eleven|mutations (l_ccomp) is_20\VBZ|NONE (l_attr) reason_23\NN|this|that (l_prep) for_24\IN|the|possible (l_pobj) period_27\NN|NONE (l_prep) of_28\IN|a|prolonged (l_pobj) apnea_29\NN|NONE
322550
D009599_D007022 CID nitroprusside_8\RB| (r_advmod) induced_10\VBN|NONE (r_amod) hypotension_11\NN|NONE
D009599_D007022 CID nitroprusside_1\JJ|NONE (r_amod) infusion_2\NN|increased|decrease|before|and|. (r_nsubj) produced_3\VBD|NONE (l_dobj) decrease_6\NN|increased|infusion|before|and|. (l_prep) in_7\IN|further|a (l_pobj) pressure_10\NN|NONE
D009599_D007022 CID Nitroprusside_0\NNP|but|change|.|,|decreases (r_nsubj) caused_1\VBD|NONE (l_dobj) decreases_3\NNS|but|change|.|,|Nitroprusside (l_prep) in_4\IN|significant (l_pobj) pressure_7\NN|NONE
D009599_D007022 NONE nitroprusside_1\JJ|infusion|of|low (r_amod) levels_4\NNS|NONE (r_pobj) During_0\IN|dynamics|levels|but|do|,|.|produce|not|markedly (r_prep) alter_10\VB|NONE (l_conj) produce_31\VBP|dynamics|levels|During|but|do|,|.|not|markedly (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|and|blood|arterial
D014867_D002303 NONE H2O_22\NNP|of|high|) (r_punct) levels_16\NNS|dynamics|During|but|do|,|.|produce|not|markedly (r_conj) alter_10\VB|NONE (l_conj) produce_31\VBP|dynamics|levels|During|but|do|,|.|not|markedly (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|and|blood|arterial
D014867_D007022 NONE H2O_22\NNP|of|high|) (r_punct) levels_16\NNS|dynamics|During|but|do|,|.|produce|not|markedly (r_conj) alter_10\VB|NONE (l_conj) produce_31\VBP|dynamics|levels|During|but|do|,|.|not|markedly (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|and|blood|arterial
D009599_D002303 NONE nitroprusside_1\JJ|NONE (r_amod) infusion_2\NN|increased|decrease|before|and|. (r_nsubj) produced_3\VBD|NONE (l_conj) increased_13\VBN|infusion|decrease|before|and|. (l_conj) decreased_17\VBD|and|significantly|rate (l_dobj) output_19\NN|NONE
D009599_D002303 NONE nitroprusside_1\JJ|infusion|of|low (r_amod) levels_4\NNS|NONE (r_pobj) During_0\IN|dynamics|levels|but|do|,|.|produce|not|markedly (r_prep) alter_10\VB|NONE (l_conj) produce_31\VBP|dynamics|levels|During|but|do|,|.|not|markedly (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|and|blood|arterial
3031535
D006220_D002375 CID haloperidol_28\NN|NONE (r_pobj) by_27\IN|NONE (r_agent) induced_26\VBN|whereas|in|neurons|important (r_advcl) are_22\VBP|that|neurons|role|, (r_advcl) have_6\VBP|results|. (l_dobj) role_9\NN|are|that|neurons|, (l_prep) in_10\IN|important|an (l_pobj) manifestation_12\NN|NONE (l_prep) of_13\IN|induced|the (l_pobj) catalepsy_14\NN|NONE
D006220_D002375 CID haloperidol_28\NN|NONE (r_pobj) by_27\IN|NONE (r_agent) induced_26\VBN|whereas|in|neurons|important (r_advcl) are_22\VBP|that|neurons|role|, (l_prep) in_24\IN|induced|whereas|neurons|important (l_pobj) catalepsy_25\NN|NONE
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN|NONE (r_pobj) by_5\IN|.|involvement (r_agent) induced_4\VBN|NONE (l_nsubj) involvement_1\NN|.|by (l_prep) in_2\IN|Noradrenergic (l_pobj) catalepsy_3\NN|NONE
D013759_D002375 CID THC_17\NNP|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|the|of (r_acl) manifestation_12\NN|NONE (l_prep) of_13\IN|induced|the (l_pobj) catalepsy_14\NN|NONE
D013759_D002375 CID THC_17\NNP|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|the|of (r_acl) manifestation_12\NN|NONE (r_pobj) in_10\IN|important|an (r_prep) role_9\NN|are|that|neurons|, (r_dobj) have_6\VBP|results|. (l_advcl) are_22\VBP|that|neurons|role|, (l_prep) in_24\IN|induced|whereas|neurons|important (l_pobj) catalepsy_25\NN|NONE
9284778
D017402_D008107 NONE chlorofluorocarbons_14\NNS|NONE (r_pobj) of_13\IN|sparing (r_prep) substitutes_12\NNS|NONE (r_pobj) as_8\IN|NONE (r_prep) used_7\VBN|NONE (r_acl) hydrochlorofluorocarbons_6\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|.|of (r_acl) Epidemic_0\NN|NONE (l_prep) of_1\IN|.|caused (l_pobj) disease_3\NN|NONE
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD|NONE (r_pobj) as_8\IN|same|the (r_prep) way_7\NN|NONE (r_pobj) in_4\IN|.|form|compounds|are (r_prep) metabolised_3\VBN|NONE (l_advcl) form_14\VB|.|in|compounds|are (l_dobj) intermediates_18\NNS|to (l_relcl) implicated_23\VBN|reactive|halide|, (l_prep) in_24\IN|which|have|been (l_pobj) hepatotoxicity_26\NN|NONE
D006221_D056486 NONE halothane_11\NN|NONE (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD|NONE (r_pobj) as_8\IN|same|the (r_prep) way_7\NN|NONE (r_pobj) in_4\IN|.|form|compounds|are (r_prep) metabolised_3\VBN|NONE (l_advcl) form_14\VB|.|in|compounds|are (l_dobj) intermediates_18\NNS|to (l_relcl) implicated_23\VBN|reactive|halide|, (l_prep) in_24\IN|which|have|been (l_pobj) hepatotoxicity_26\NN|NONE
D006221_D056486 NONE halothane_28\NN|NONE (r_pobj) of_27\IN|the (r_prep) hepatotoxicity_26\NN|NONE
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN|(||)|)|HCFC|and (r_conj) HCFC_23\NNP|( (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|.|We (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C072959_D008107 CID 124_30\CD|NONE (r_nummod) HCFC_29\NNP|(||)|)|and|chloro,,,tetrafluoroethane (r_appos) HCFC_23\NNP|( (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|.|We (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C072959_D008107 CID 124_8\CD|and| (r_conj) HCFCs_5\NNS|in|can|whether (r_nsubj) result_10\VB|to (l_prep) in_11\IN|can|HCFCs|whether (l_pobj) disease_14\NN|NONE
D014269_D056486 NONE trifluoroacetyl_16\NNS|NONE (r_compound) halide_17\NN|reactive|implicated|, (r_compound) intermediates_18\NNS|to (l_relcl) implicated_23\VBN|reactive|halide|, (l_prep) in_24\IN|which|have|been (l_pobj) hepatotoxicity_26\NN|NONE
D014269_D056486 NONE trifluoroacetyl_17\NN| (r_npadvmod) altered_19\VBN|liver (r_amod) proteins_21\NNS|that|are (r_nsubjpass) involved_23\VBN|,|results|known|. (r_ccomp) suggest_15\VBP|NONE (l_advcl) known_11\VBN|,|results|involved|. (l_nsubjpass) mechanism_3\NN|is|not|Although (l_prep) of_4\IN|exact|the (l_pobj) hepatotoxicity_5\NN|NONE
C067411_D056486 NONE 124_9\CD|and| (r_conj) HCFCs_6\NNS|NONE (r_pobj) to_5\IN|Repeated|of (r_prep) exposure_1\NN|in|.|can (r_nsubj) result_11\VB|NONE (l_prep) in_12\IN|exposure|.|can (l_pobj) injury_15\NN|NONE
C072959_D056486 NONE 124_9\CD|and| (r_conj) HCFCs_6\NNS|NONE (r_pobj) to_5\IN|Repeated|of (r_prep) exposure_1\NN|in|.|can (r_nsubj) result_11\VB|NONE (l_prep) in_12\IN|exposure|.|can (l_pobj) injury_15\NN|NONE
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|.|of (r_acl) Epidemic_0\NN|NONE (l_prep) of_1\IN|.|caused (l_pobj) disease_3\NN|NONE
D010126_D008107 NONE ozone_9\NN| (r_npadvmod) sparing_11\VBG|of (r_amod) substitutes_12\NNS|NONE (r_pobj) as_8\IN|NONE (r_prep) used_7\VBN|NONE (r_acl) hydrochlorofluorocarbons_6\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|.|of (r_acl) Epidemic_0\NN|NONE (l_prep) of_1\IN|.|caused (l_pobj) disease_3\NN|NONE
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|.|We (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C067411_D008107 CID 123_24\CD|(|)|)|HCFC|and|chloro,,,tetrafluoroethane (r_nummod) HCFC_23\NNP|( (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|.|We (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C067411_D008107 CID 124_8\CD|and| (r_conj) HCFCs_5\NNS|in|can|whether (r_nsubj) result_10\VB|to (l_prep) in_11\IN|can|HCFCs|whether (l_pobj) disease_14\NN|NONE
8752018
D008094_D001714 NONE Lithium_0\NN|treatment|. (r_nsubj) remains_1\VBZ|NONE (l_attr) treatment_6\NN|Lithium|. (l_prep) for_7\IN|a|line (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|acute|the (l_pobj) disorder_15\NN|NONE
D008094_D001714 NONE lithium_10\NN|NONE (r_pobj) from_9\IN|divalproex|patients (r_prep) switching_6\VBG|NONE (l_dobj) patients_8\NNS|divalproex|from (l_amod) bipolar_7\JJ|NONE
D008094_D001714 NONE lithium_8\NN|NONE (r_pobj) of_7\IN|,|with|,|fully (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_acl) attributed_31\VBN|,|motivational|the (l_prep) to_32\IN|NONE (l_pobj) lithium_33\NN|NONE (l_prep) in_34\IN|NONE (l_pobj) patients_37\NNS|NONE (l_amod) bipolar_36\JJ|our
D008094_D001714 NONE lithium_33\NN|NONE (l_prep) in_34\IN|NONE (l_pobj) patients_37\NNS|NONE (l_amod) bipolar_36\JJ|our
D008094_D001714 NONE lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_amod) bipolar_14\JJ|experiencing
D008094_D011141 NONE lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|as|common (r_prep) effects_13\NNS|NONE (l_prep) as_18\IN|,|adverse|the|of|common (l_pobj) polyuria_19\NN|such
D008094_D011141 NONE lithium_25\NN|side|subtle|as (r_compound) effects_27\NNS|understudied|.|written|, (r_nsubj) remain_40\VBP|NONE (l_advcl) written_4\VBN|understudied|.|effects|, (l_prep) about_5\IN|much|has|been|Although (l_pobj) management_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) effects_13\NNS|NONE (l_prep) as_18\IN|,|adverse|the|of|common (l_pobj) polyuria_19\NN|such
D014635_D003072 NONE sodium_13\NN|to (r_dobj) divalproex_12\NN|by (r_advcl) reduced_7\VBN|cognitive|associated|. (r_acl) deficits_6\NNS|NONE
D014635_D003072 NONE sodium_13\NN|alleviate|to (r_dobj) divalproex_12\NN|from|patients (l_xcomp) alleviate_15\VB|sodium|to (l_dobj) impairments_20\NNS|to
D014635_D003072 NONE sodium_17\NN|NONE (r_pobj) with_15\IN|,|,|fully|of (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_conj) motivational_26\JJ|,|attributed|the (l_conj) deficits_30\NNS|,|or
D014635_D003072 NONE sodium_6\NN|In|.|alternative|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|sodium|.|, (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE
D014635_D003072 NONE sodium_6\NN|In|.|alternative|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|sodium|.|, (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE
D014635_D003072 NONE sodium_6\NN|In|.|alternative|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|sodium|.|, (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE (l_conj) impairments_26\NNS|,|and
D014635_D001714 NONE sodium_13\NN|alleviate|to (r_dobj) divalproex_12\NN|from|patients (r_advcl) switching_6\VBG|NONE (l_dobj) patients_8\NNS|divalproex|from (l_amod) bipolar_7\JJ|NONE
D014635_D001714 NONE sodium_17\NN|NONE (r_pobj) with_15\IN|,|,|fully|of (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_acl) attributed_31\VBN|,|motivational|the (l_prep) to_32\IN|NONE (l_pobj) lithium_33\NN|NONE (l_prep) in_34\IN|NONE (l_pobj) patients_37\NNS|NONE (l_amod) bipolar_36\JJ|our
D014635_D001714 NONE sodium_6\NN|In|.|alternative|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|sodium|.|, (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_amod) bipolar_14\JJ|experiencing
D008094_D003072 CID Lithium_0\NN| (r_npadvmod) associated_2\VBN|cognitive|reduced|. (r_amod) deficits_6\NNS|NONE
D008094_D003072 CID lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|as|common (r_prep) effects_13\NNS|NONE (r_pobj) of_8\IN|the (r_prep) management_7\NN|NONE (r_pobj) about_5\IN|much|has|been|Although (r_prep) written_4\VBN|understudied|.|effects|, (r_advcl) remain_40\VBP|NONE (l_nsubj) effects_27\NNS|understudied|.|written|, (l_prep) as_29\IN|side|lithium|subtle (l_pobj) deficits_31\NNS|such
D008094_D003072 CID lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|as|common (r_prep) effects_13\NNS|NONE (r_pobj) of_8\IN|the (r_prep) management_7\NN|NONE (r_pobj) about_5\IN|much|has|been|Although (r_prep) written_4\VBN|understudied|.|effects|, (r_advcl) remain_40\VBP|NONE (l_nsubj) effects_27\NNS|understudied|.|written|, (l_prep) as_29\IN|side|lithium|subtle (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|,|cognitive (l_prep) of_34\IN|impairments|and|, (l_pobj) creativity_35\NN|NONE
D008094_D003072 CID lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|as|common (r_prep) effects_13\NNS|NONE (r_pobj) of_8\IN|the (r_prep) management_7\NN|NONE (r_pobj) about_5\IN|much|has|been|Although (r_prep) written_4\VBN|understudied|.|effects|, (r_advcl) remain_40\VBP|NONE (l_nsubj) effects_27\NNS|understudied|.|written|, (l_prep) as_29\IN|side|lithium|subtle (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|,|cognitive (l_conj) impairments_39\NNS|of|and|,
D008094_D003072 CID lithium_25\NN|side|subtle|as (r_compound) effects_27\NNS|understudied|.|written|, (l_prep) as_29\IN|side|lithium|subtle (l_pobj) deficits_31\NNS|such
D008094_D003072 CID lithium_25\NN|side|subtle|as (r_compound) effects_27\NNS|understudied|.|written|, (l_prep) as_29\IN|side|lithium|subtle (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|,|cognitive (l_prep) of_34\IN|impairments|and|, (l_pobj) creativity_35\NN|NONE
D008094_D003072 CID lithium_25\NN|side|subtle|as (r_compound) effects_27\NNS|understudied|.|written|, (l_prep) as_29\IN|side|lithium|subtle (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|,|cognitive (l_conj) impairments_39\NNS|of|and|,
D008094_D003072 CID lithium_10\NN|NONE (r_pobj) from_9\IN|divalproex|patients (r_prep) switching_6\VBG|NONE (l_advcl) divalproex_12\NN|from|patients (l_xcomp) alleviate_15\VB|sodium|to (l_dobj) impairments_20\NNS|to
D008094_D003072 CID lithium_8\NN|NONE (r_pobj) of_7\IN|,|with|,|fully (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_conj) motivational_26\JJ|,|attributed|the (l_conj) deficits_30\NNS|,|or
D008094_D003072 CID lithium_33\NN|NONE (r_pobj) to_32\IN|NONE (r_prep) attributed_31\VBN|,|motivational|the (r_acl) cognitive_24\JJ|NONE (l_conj) motivational_26\JJ|,|attributed|the (l_conj) deficits_30\NNS|,|or
D008094_D003072 CID lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE
D008094_D003072 CID lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE
D008094_D003072 CID lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE (l_conj) impairments_26\NNS|,|and
D008094_D014202 NONE lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|as|common (r_prep) effects_13\NNS|NONE (l_prep) as_18\IN|,|adverse|the|of|common (l_pobj) polyuria_19\NN|such (l_conj) tremor_21\NN|and
D008094_D014202 NONE lithium_25\NN|side|subtle|as (r_compound) effects_27\NNS|understudied|.|written|, (r_nsubj) remain_40\VBP|NONE (l_advcl) written_4\VBN|understudied|.|effects|, (l_prep) about_5\IN|much|has|been|Although (l_pobj) management_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) effects_13\NNS|NONE (l_prep) as_18\IN|,|adverse|the|of|common (l_pobj) polyuria_19\NN|such (l_conj) tremor_21\NN|and
7516729
D014700_D001919 CID verapamil_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|dependent (r_acl) bradycardia_3\NNS|was|.|by
6727060
D008787_D005767 NONE metoclopramide_23\RB|for|in|he|after (r_dobj) took_22\VBD|in|.|movements (l_prep) for_24\IN|metoclopramide|in|he|after (l_pobj) disorder_26\NN|NONE
D008787_D004409 CID metoclopramide_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|tardive (r_acl) dyskinesia_4\JJ|NONE
D008787_D004409 CID metoclopramide_23\RB|for|in|he|after (r_dobj) took_22\VBD|in|.|movements (r_advcl) appeared_3\VBD|NONE (l_nsubj) movements_2\NNS|took|in|.
D008787_D004409 CID metoclopramide_2\JJ|the (r_compound) administration_3\NN|When|was (r_nsubjpass) discontinued_5\VBN|,|movements|to|.|gradually (r_advcl) improved_11\VBD|NONE (l_nsubj) movements_9\NNS|,|to|.|discontinued|gradually
983936
D006854_D009202 NONE hydrocortisone_8\NN|,|and (l_prep) on_9\IN|NONE (l_pobj) injury_14\NN|NONE
D001241_D009202 NONE acid_3\NN|NONE (l_conj) dipyridamole_5\NN|acetylsalicylic|, (l_conj) hydrocortisone_8\NN|,|and (l_prep) on_9\IN|NONE (l_pobj) injury_14\NN|NONE
D004837_D009203 NONE epinephrine_9\NN|( (r_amod) infusion_10\NN|myocardial|diffuse (r_appos) injury_7\NN|NONE (r_dobj) producing_4\VBG|NONE (r_pcomp) for_3\IN|)|reproducible|A (r_prep) model_2\NN|been|study|has|. (r_nsubjpass) developed_14\VBN|NONE (l_advcl) study_16\VB|model|been|has|. (l_dobj) effects_19\NNS|to (l_prep) of_20\IN|the|cardioprotective (l_pobj) agents_21\NNS|NONE (l_relcl) alter_26\VB|or|maneuvers (l_dobj) evolution_28\NN|might|which (l_prep) of_29\IN|the (l_pobj) infarction_32\NN|NONE
D004837_D009202 CID epinephrine_10\NN| (r_npadvmod) induced_12\VBN|in|myocardial (r_amod) injury_14\NN|NONE
D004837_D009202 CID epinephrine_9\NN|( (r_amod) infusion_10\NN|myocardial|diffuse (r_appos) injury_7\NN|NONE
D004176_D009202 NONE dipyridamole_5\NN|acetylsalicylic|, (l_conj) hydrocortisone_8\NN|,|and (l_prep) on_9\IN|NONE (l_pobj) injury_14\NN|NONE
11431197
D011899_D009395 CID Ranitidine_0\NNP| (r_npadvmod) induced_2\VBN|.|in|interstitial|acute (r_amod) nephritis_5\NN|NONE
D011899_D009395 CID ranitidine_5\NN| (r_npadvmod) induced_7\VBN|acute|interstitial (r_amod) nephritis_10\NN|NONE
12757899
D012834_D013226 NONE silver_3\NN| (r_npadvmod) stained_5\VBN|and|neurons (r_amod) CA3_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) extent_1\NN|.|was|after (r_nsubjpass) evaluated_12\VBN|NONE (l_prep) after_15\IN|.|was|extent (l_pobj) SE_16\NNP|days
D008094_D013226 CID lithium_17\NN| (r_compound) pilocarpine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) SE_22\NNP|NONE
D004958_D001930 NONE Estradiol_0\NN|in|injury|but|. (r_nsubj) reduces_1\VBZ|NONE (l_dobj) injury_6\NN|Estradiol|in|but|.
D004958_D013226 NONE estradiol_7\NN|NONE (r_pobj) of_4\IN|rats|the|in|and (r_prep) effects_3\NNS|.|We (l_conj) rats_14\NNS|of|the|in|and (l_acl) subjected_15\VBN|female|ovariectomized (l_prep) to_16\IN|NONE (l_pobj) SE_22\NNP|NONE
D007608_D013226 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|SE|kainic (r_amod) status_13\NN|NONE (l_appos) SE_16\NNP|induced|kainic (l_amod) epilepticus_14\NN|(
D007608_D013226 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|SE|kainic (r_amod) status_13\NN|NONE (l_appos) SE_16\NNP|induced|kainic
D004958_D012640 NONE Estradiol_0\NN|in|injury|but|. (r_nsubj) reduces_1\VBZ|NONE (l_dobj) injury_6\NN|Estradiol|in|but|. (l_amod) induced_4\VBN|hippocampal|in (l_npadvmod) seizure_2\NN|
D004958_D012640 NONE estradiol_7\NN|NONE (r_pobj) of_6\IN|the|on (r_prep) effects_5\NNS|by|that|be|may (l_prep) on_8\IN|of|the (l_pobj) threshold_10\NN|NONE (l_compound) seizure_9\NN|and|damage
D007608_D001930 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|SE|kainic (r_amod) status_13\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|)|rats|Estrogens|. (r_advcl) protect_1\VBP|NONE (l_dobj) rats_3\NNS|induced|)|Estrogens|. (l_prep) from_4\IN|ovariectomized (l_pobj) injury_6\NN|NONE
D010862_D013226 CID pilocarpine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) SE_22\NNP|NONE
8073369
D009538_D002543 CID nicotine_30\NN|treated|all (r_nmod) chicks_34\NNS|NONE (r_pobj) in_28\IN|seen|hemorrhage|,|however|.|; (r_prep) occurred_27\VBD|NONE (l_nsubj) hemorrhage_26\NN|seen|,|in|however|.|;
C007112_D001176 CID coniine_2\NN|has|and|produce|However|,|is|. (r_nsubj) failed_4\VBN|NONE (l_xcomp) produce_6\VB|has|and|However|,|is|coniine|. (l_dobj) arthrogryposis_7\NN|to
C007112_D001176 CID coniine_15\RB| (r_npadvmod) induced_17\VBN|NONE (r_amod) arthrogryposis_18\NN|NONE
D009538_D009140 NONE nicotine_7\NN|NONE (r_compound) sulfate_8\NN|and|both (r_conj) coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|flexion|.
D009538_D009140 NONE nicotine_7\NN|NONE (r_compound) sulfate_8\NN|and|both (r_conj) coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|flexion|. (r_nsubj) were_9\VBD|NONE (l_attr) flexion_11\NN|deformations|. (l_prep) of_14\IN|excessive|extension|or (l_pobj) toes_18\NNS|NONE
C007112_D009140 NONE coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|flexion|.
C007112_D009140 NONE coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|flexion|. (r_nsubj) were_9\VBD|NONE (l_attr) flexion_11\NN|deformations|. (l_prep) of_14\IN|excessive|extension|or (l_pobj) toes_18\NNS|NONE
15863244
D010894_D006345 NONE piroxicam_23\NN|selective|based|COX (r_nmod) inhibitor_31\NN|NONE (r_pobj) to_22\IN|NONE (r_prep) exposed_21\VBN|rat (r_acl) fetuses_20\NNS|NONE (r_pobj) for_18\IN|analysis|was|. (r_prep) performed_17\VBN|NONE (l_nsubjpass) analysis_3\NN|for|was|. (l_prep) for_4\IN|statistical|The|pooled (l_pobj) defects_15\NNS|NONE
D010894_D009139 CID piroxicam_24\NN|NONE (r_pobj) of_23\IN|the|highest (r_prep) dose_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|NONE (r_acl) rats_17\NNS|NONE (r_pobj) in_16\IN|were|toxicity|. (r_prep) found_15\VBN|NONE (l_nsubjpass) toxicity_1\NN|in|were|. (l_appos) retardation_5\NN|Maternal|, (l_conj) increase_8\NN|intrauterine|,|growth|and (l_prep) of_9\IN|NONE (l_pobj) variations_13\NNS|NONE
D010894_D064420 NONE piroxicam_19\NN|NONE (r_compound) study_20\NN|and (r_conj) DFU_17\NNP|cyclooxygenase|selective|in| (r_appos) inhibitors_11\NNS|NONE (r_pobj) of_4\IN|developmental (r_prep) toxicity_3\NN|NONE
D010894_D064420 NONE piroxicam_17\NN|NONE (r_pobj) of_11\IN|developmental|the|DFU (r_prep) toxicity_10\NN|to
D010894_D064420 NONE piroxicam_24\NN|NONE (r_pobj) of_23\IN|the|highest (r_prep) dose_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|NONE (r_acl) rats_17\NNS|NONE (r_pobj) in_16\IN|were|toxicity|. (r_prep) found_15\VBN|NONE (l_nsubjpass) toxicity_1\NN|in|were|.
C106876_D064420 NONE DFU_17\NNP|cyclooxygenase|selective|in| (r_appos) inhibitors_11\NNS|NONE (r_pobj) of_4\IN|developmental (r_prep) toxicity_3\NN|NONE
C106876_D064420 NONE DFU_22\NNP|developmental|the|of (r_conj) toxicity_10\NN|to
C106876_D064420 NONE phenyl-2(5H)-furanon_26\XX|NONE (l_ccomp) was_5\VBD|)|,dimethyl(fluorophenyl)(methylsulphonyl|)|; (l_xcomp) evaluate_7\VB|aim (l_dobj) toxicity_10\NN|to
C106876_D064420 NONE DFU_10\NNP|observed|the|developmental (r_nmod) toxicity_12\NN|NONE
D010894_D009436 NONE piroxicam_23\NN|selective|based|COX (r_nmod) inhibitor_31\NN|NONE (r_pobj) to_22\IN|NONE (r_prep) exposed_21\VBN|rat (r_acl) fetuses_20\NNS|NONE (r_pobj) for_18\IN|analysis|was|. (r_prep) performed_17\VBN|NONE (l_nsubjpass) analysis_3\NN|for|was|. (l_prep) for_4\IN|statistical|The|pooled (l_pobj) defects_15\NNS|NONE
D010894_D005317 CID piroxicam_24\NN|NONE (r_pobj) of_23\IN|the|highest (r_prep) dose_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|NONE (r_acl) rats_17\NNS|NONE (r_pobj) in_16\IN|were|toxicity|. (r_prep) found_15\VBN|NONE (l_nsubjpass) toxicity_1\NN|in|were|. (l_appos) retardation_5\NN|Maternal|,
9495837
D012601_D000647 CID scopolamine_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|NONE (r_acl) amnesia_15\NN|to
D004025_D000647 CID dicyclomine_26\NN|and|)|i.p.|mg (r_conj) kg-1_22\NNP|in|( (r_appos) scopolamine_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|NONE (r_acl) amnesia_15\NN|to
D000109_D000647 NONE acetylcholine_73\NN|extracellular (r_amod) levels_75\NNS|NONE (r_pobj) in_72\IN|an (r_prep) increase_71\NN|NONE (r_pobj) through_69\IN|NONE (r_prep) /-)-PG-9_68\NFP|have|+|,|profiles|ratio|. (r_punct) shown_44\VBN|NONE (l_dobj) ratio_48\NN|have|+|/)PG|,|profiles|. (l_relcl) be_53\VB|M/M|of|an|selectivity (l_acomp) responsible_54\JJ|might|that (l_prep) for_55\IN|NONE (l_pobj) antinociception_57\NN|NONE (l_conj) effect_63\NN|and|the|induced (l_amod) amnesic_62\JJ|the
C087567_D000647 NONE /-)-PG-9_2\.|able|+|.|( (r_nsubj) was_11\VBD|NONE (l_acomp) able_12\JJ|+|.|/)PG|( (l_xcomp) prevent_14\VB|NONE (l_dobj) amnesia_15\NN|to
C087567_D000647 NONE /-)-PG-9_5\NFP|(|+ (r_conj) of_2\IN|Affinity|deferens|determined (r_prep) profiles_1\NNS|have|+|/)PG|,|ratio|. (r_nsubj) shown_44\VBN|NONE (l_dobj) ratio_48\NN|have|+|/)PG|,|profiles|. (l_relcl) be_53\VB|M/M|of|an|selectivity (l_acomp) responsible_54\JJ|might|that (l_prep) for_55\IN|NONE (l_pobj) antinociception_57\NN|NONE (l_conj) effect_63\NN|and|the|induced (l_amod) amnesic_62\JJ|the
C087567_D000647 NONE /-)-PG-9_68\NFP|have|+|,|profiles|ratio|. (r_punct) shown_44\VBN|NONE (l_dobj) ratio_48\NN|have|+|/)PG|,|profiles|. (l_relcl) be_53\VB|M/M|of|an|selectivity (l_acomp) responsible_54\JJ|might|that (l_prep) for_55\IN|NONE (l_pobj) antinociception_57\NN|NONE (l_conj) effect_63\NN|and|the|induced (l_amod) amnesic_62\JJ|the
11875660
D001374_D009436 NONE 5-azacytidine_6\NN|NONE (r_pobj) by_5\IN|at (r_agent) induced_4\VBN|the (r_acl) exencephaly_3\NNS|let|.|We|,
17532790
D001971_D010300 NONE bromocriptine_36\NN||L|or (r_conj) DOPA_34\NNP|occurring|,|the|using (r_appos) changes_8\NNS|In|,|we|. (l_acl) occurring_9\VBG|DOPA|,|the|using (l_prep) at_10\IN|NONE (l_pobj) level_13\NN|NONE (l_acl) obtained_17\VBN|protein|the|in (l_prep) from_18\IN|NONE (l_pobj) model_25\NN|NONE (l_prep) of_26\IN|the|treated|unilaterally|rat (l_pobj) PD_27\NNP|NONE
D007980_D004409 CID DOPA_12\NNP||L| (r_npadvmod) induced_14\VBN|NONE (r_amod) dyskinesia_15\NN|NONE
D007980_D004409 CID DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among
D007980_D004409 CID DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among (l_appos) LID_7\NNP|induced
D007980_D004409 CID DOPA_31\NNP|NONE (r_pobj) with_28\IN|a|prolonged (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|motor|the (r_relcl) complications_13\NNS|NONE (r_pobj) among_10\IN|.|dyskinesia (r_prep) is_9\VBZ|NONE (l_nsubj) dyskinesia_5\NN|.|among
D007980_D004409 CID DOPA_31\NNP|NONE (r_pobj) with_28\IN|a|prolonged (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|motor|the (r_relcl) complications_13\NNS|NONE (r_pobj) among_10\IN|.|dyskinesia (r_prep) is_9\VBZ|NONE (l_nsubj) dyskinesia_5\NN|.|among (l_appos) LID_7\NNP|induced
D007980_D004409 CID DOPA_5\NNP|NONE (r_pobj) with_2\IN|allocated|Rats|. (r_prep) treated_1\VBD|NONE (l_conj) allocated_7\VBN|Rats|with|. (l_prep) to_8\IN|were (l_pobj) groups_10\NNS|NONE (l_acl) based_11\VBN|two (l_prep) on_12\IN|NONE (l_pobj) presence_14\NN|NONE (l_conj) absence_16\NN|or|the (l_prep) of_17\IN|NONE (l_pobj) LID_18\NNP|NONE
D016627_D010300 NONE 6-hydroxydopamine_21\CD| (r_compound) lesion_23\NN|NONE (r_compound) rat_24\NN|the|treated|unilaterally|of (r_compound) model_25\NN|NONE (l_prep) of_26\IN|the|treated|unilaterally|rat (l_pobj) PD_27\NNP|NONE
D007980_D010300 NONE DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among (r_nsubj) is_9\VBZ|NONE (l_prep) among_10\IN|.|dyskinesia (l_pobj) complications_13\NNS|NONE (l_relcl) arise_15\VBP|motor|the (l_prep) in_16\IN|after|that (l_pobj) patients_23\NNS|NONE (l_nmod) disease_19\NN|)|PD|(
D007980_D010300 NONE DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among (r_nsubj) is_9\VBZ|NONE (l_prep) among_10\IN|.|dyskinesia (l_pobj) complications_13\NNS|NONE (l_relcl) arise_15\VBP|motor|the (l_prep) in_16\IN|after|that (l_pobj) patients_23\NNS|NONE (l_nmod) PD_21\NNP|)|disease|(
D007980_D010300 NONE DOPA_31\NNP|NONE (r_pobj) with_28\IN|a|prolonged (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|motor|the (l_prep) in_16\IN|after|that (l_pobj) patients_23\NNS|NONE (l_nmod) disease_19\NN|)|PD|(
D007980_D010300 NONE DOPA_31\NNP|NONE (r_pobj) with_28\IN|a|prolonged (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|motor|the (l_prep) in_16\IN|after|that (l_pobj) patients_23\NNS|NONE (l_nmod) PD_21\NNP|)|disease|(
D007980_D010300 NONE DOPA_34\NNP|occurring|,|the|using (r_appos) changes_8\NNS|In|,|we|. (l_acl) occurring_9\VBG|DOPA|,|the|using (l_prep) at_10\IN|NONE (l_pobj) level_13\NN|NONE (l_acl) obtained_17\VBN|protein|the|in (l_prep) from_18\IN|NONE (l_pobj) model_25\NN|NONE (l_prep) of_26\IN|the|treated|unilaterally|rat (l_pobj) PD_27\NNP|NONE
11198499
C023754_D007022 CID tizanidine_5\NN|NONE (r_pobj) of_4\IN|the|in (r_prep) initiation_3\NN|NONE (r_dobj) following_1\VBG|. (r_acl) Hypotension_0\NN|NONE
C023754_D007022 CID tizanidine_29\NN|NONE (r_pobj) of_28\IN|for|the (r_prep) addition_27\NN|NONE (r_pobj) following_25\VBG|hypotension|who (r_prep) developed_23\VBD|NONE (l_dobj) hypotension_24\NN|who|following
D017706_D006973 NONE lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|old|,|a (r_acl) boy_7\NN|authors|.|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|authors|.|boy (l_dobj) hypertension_21\NN|to
D000809_D009128 NONE angiotensin_14\NN|, (r_appos) lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|old|,|a (r_acl) boy_7\NN|authors|.|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|authors|.|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_prep) following_25\VBG|hypotension|who (l_pobj) addition_27\NN|NONE (l_prep) for_35\IN|of|the (l_pobj) treatment_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) spasticity_39\NN|NONE
C023754_D006973 NONE tizanidine_5\NN|NONE (r_pobj) of_4\IN|the|in (r_prep) initiation_3\NN|NONE (l_prep) in_6\IN|of|the (l_pobj) patient_8\NN|NONE (l_acl) treated_9\VBN|a (l_prep) with_10\IN|NONE (l_pobj) angiotensin_12\NN|NONE (l_acl) converting_13\VBG|an (l_prep) for_16\IN|inhibitor (l_pobj) hypertension_18\NN|NONE
C023754_D006973 NONE tizanidine_29\NN|NONE (r_pobj) of_28\IN|for|the (r_prep) addition_27\NN|NONE (r_pobj) following_25\VBG|hypotension|who (r_prep) developed_23\VBD|NONE (r_relcl) hypertension_21\NN|to
C023754_D006973 NONE tizanidine_4\NN|NONE (r_pobj) of_3\IN|possible|The (r_prep) interaction_2\NN|.|be|should|in|prescribing (r_nsubjpass) kept_11\VBN|NONE (l_advcl) prescribing_15\VBG|interaction|.|be|should|in (l_xcomp) treat_18\VB|therapy|when (l_dobj) hypertension_20\NN|to
D000809_D006973 NONE angiotensin_12\NN|NONE (l_acl) converting_13\VBG|an (l_prep) for_16\IN|inhibitor (l_pobj) hypertension_18\NN|NONE
D000809_D006973 NONE angiotensin_14\NN|, (r_appos) lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|old|,|a (r_acl) boy_7\NN|authors|.|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|authors|.|boy (l_dobj) hypertension_21\NN|to
C023754_D009128 NONE tizanidine_29\NN|NONE (r_pobj) of_28\IN|for|the (r_prep) addition_27\NN|NONE (l_prep) for_35\IN|of|the (l_pobj) treatment_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) spasticity_39\NN|NONE
C023754_D009128 NONE tizanidine_4\NN|NONE (r_pobj) of_3\IN|possible|The (r_prep) interaction_2\NN|.|be|should|in|prescribing (r_nsubjpass) kept_11\VBN|NONE (l_advcl) prescribing_15\VBG|interaction|.|be|should|in (l_xcomp) treat_18\VB|therapy|when (l_dobj) hypertension_20\NN|to (l_conj) spasticity_22\NN|or|in|either
D017706_D009128 NONE lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|old|,|a (r_acl) boy_7\NN|authors|.|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|authors|.|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_prep) following_25\VBG|hypotension|who (l_pobj) addition_27\NN|NONE (l_prep) for_35\IN|of|the (l_pobj) treatment_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) spasticity_39\NN|NONE
D000809_D007022 NONE angiotensin_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN|a (r_acl) patient_8\NN|NONE (r_pobj) in_6\IN|of|the (r_prep) initiation_3\NN|NONE (r_dobj) following_1\VBG|. (r_acl) Hypotension_0\NN|NONE
D000809_D007022 NONE angiotensin_4\NN|NONE (r_pobj) with_3\IN|Adults|chronically (r_prep) treated_2\VBN|.|ability|may (r_csubj) have_9\VB|NONE (l_dobj) ability_12\NN|.|treated|may (l_acl) respond_14\VB|a|limited (l_prep) to_15\IN|to|blocked (l_pobj) hypotension_16\NN|NONE
D000809_D007022 NONE angiotensin_14\NN|, (r_appos) lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|old|,|a (r_acl) boy_7\NN|authors|.|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|authors|.|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_dobj) hypotension_24\NN|who|following
D017706_D007022 CID lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|old|,|a (r_acl) boy_7\NN|authors|.|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|authors|.|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_dobj) hypotension_24\NN|who|following
8423889
D000928_D009069 NONE antidepressant_20\JJ|the (r_amod) fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|in|increased|of|the (r_prep) amount_4\NN|We|. (l_prep) of_5\IN|after|in|increased|the (l_pobj) disability_7\NN|NONE
D004298_D010300 NONE dopamine_6\NN| (r_npadvmod) antagonistic_8\JJ|in|relevant|a|of (r_amod) capacity_9\NN|NONE (l_prep) in_12\IN|relevant|a|antagonistic|of (l_pobj) patients_16\NNS|NONE (l_compound) disease_15\NN|Parkinson
D005473_D009069 CID fluoxetine_5\NN|NONE (r_amod) medication_6\NN|NONE (r_pobj) after_4\IN|.|of (r_prep) Increase_0\NNP|NONE (l_prep) of_1\IN|after|. (l_pobj) disability_3\NN|NONE
D005473_D009069 CID fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|in|increased|of|the (r_prep) amount_4\NN|We|. (l_prep) of_5\IN|after|in|increased|the (l_pobj) disability_7\NN|NONE
D005473_D010300 NONE fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|in|increased|of|the (r_prep) amount_4\NN|We|. (l_prep) in_8\IN|after|increased|of|the (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|four (l_pobj) disease_15\NN|NONE
D005473_D010300 NONE fluoxetine_11\NN|NONE (r_pobj) of_10\IN|in|relevant|a|antagonistic (r_prep) capacity_9\NN|NONE (l_prep) in_12\IN|relevant|a|antagonistic|of (l_pobj) patients_16\NNS|NONE (l_compound) disease_15\NN|Parkinson
D000928_D010300 NONE antidepressant_20\JJ|the (r_amod) fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|in|increased|of|the (r_prep) amount_4\NN|We|. (l_prep) in_8\IN|after|increased|of|the (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|four (l_pobj) disease_15\NN|NONE
1420741
D016572_D003424 NONE cyclosporin_16\NN|NONE (r_pobj) to_15\IN|NONE (r_prep) similar_14\JJ|immunosuppressive (r_amod) properties_13\NNS|NONE (r_pobj) with_11\IN|an (r_prep) antibiotic_10\NN|.|of|: (r_appos) Treatment_0\NN|NONE (l_prep) of_1\IN|.|antibiotic|: (l_pobj) disease_4\NN|NONE
D005672_D015212 NONE acid_13\NN|NONE (r_pobj) of_11\IN|at|the (r_prep) use_10\NN|NONE (l_prep) at_14\IN|of|the (l_pobj) level_17\NN|NONE (l_prep) in_18\IN|the|cytokine (l_pobj) disease_21\NN|NONE
D005672_D003424 NONE acid_7\NN|NONE (r_pobj) with_5\IN|Crohn (r_prep) disease_4\NN|NONE
D005672_D003424 NONE acid_28\NN|fusidic|in (r_compound) treatment_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) tolerability_25\NN|and|the (r_conj) pharmacodynamics_23\NNS|to (r_dobj) estimate_21\VB|Because|study|,|was|. (r_advcl) undertaken_19\VBN|NONE (l_prep) Because_0\IN|estimate|study|,|was|. (l_pobj) need_3\NN|of (l_prep) for_4\IN|the (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) treatments_9\NNS|NONE (l_prep) for_10\IN|new (l_pobj) disease_13\NN|NONE
D005672_D003424 NONE acid_9\NN|fusidic|may|of|that|in (r_nsubj) be_11\VB|results|. (l_prep) in_14\IN|fusidic|may|acid|of|that (l_pobj) patients_21\NNS|NONE (l_compound) disease_20\NN|chronic|selected|active|Crohn|is
18703024
D006220_D002375 CID haloperidol_3\NN| (r_npadvmod) induced_5\VBN|or|locomotion (r_amod) catalepsy_6\NN|NONE
D016291_D002375 NONE MK-801-induced_8\JJ|NONE (r_compound) locomotion_9\NN|induced|or (r_conj) catalepsy_6\NN|NONE
11679859
D011346_D017109 CID prochlorperazine_3\NN|NONE (r_pobj) of_2\IN|Intravenous (r_prep) administration_1\NN|.|incidence|not|does (r_nsubj) affect_12\VB|NONE (l_dobj) incidence_14\NN|.|administration|not|does (l_prep) of_15\IN|the (l_pobj) akathisia_16\NN|NONE
D011346_D017109 CID prochlorperazine_12\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) administration_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) akathisia_7\NN|NONE
D011346_D017109 CID prochlorperazine_10\NN|by|when|was (r_nsubjpass) administered_12\VBN|%|in|A (r_advcl) reduction_3\NN|was|not|. (l_prep) in_4\IN|%|administered|A (l_pobj) incidence_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) akathisia_8\NN|NONE
D011346_D014839 NONE prochlorperazine_8\NN|NONE (l_prep) for_9\IN|NONE (l_pobj) headache_10\NN|NONE (l_conj) nausea_12\NN|, (l_conj) vomiting_15\NN|,|or
D011346_D009325 NONE prochlorperazine_8\NN|NONE (l_prep) for_9\IN|NONE (l_pobj) headache_10\NN|NONE (l_conj) nausea_12\NN|,
D011346_D009325 NONE prochlorperazine_3\NN|NONE (r_pobj) of_2\IN|in|The (r_prep) efficacy_1\NN|likewise|not|did|made|,|affected|. (l_prep) in_4\IN|The|of (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) headache_8\NN|NONE (l_conj) nausea_10\NN|and
D011346_D006261 NONE prochlorperazine_8\NN|NONE (l_prep) for_9\IN|NONE (l_pobj) headache_10\NN|NONE
D011346_D006261 NONE prochlorperazine_3\NN|NONE (r_pobj) of_2\IN|in|The (r_prep) efficacy_1\NN|likewise|not|did|made|,|affected|. (l_prep) in_4\IN|The|of (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) headache_8\NN|NONE
3828020
D010665_D002544 CID phenylpropanolamine_8\NN|NONE (r_pobj) of_7\IN|oral|a|single (r_prep) dose_6\NN|NONE (r_pobj) with_2\IN|Cerebral|. (r_prep) infarction_1\NN|NONE
D010665_D002544 CID PPA_20\NNP|NONE (r_pobj) of_19\IN|oral|single|a (r_prep) dose_18\NN|NONE (r_dobj) taking_14\VBG|NONE (r_pcomp) after_13\IN|infarction|who (r_prep) suffered_9\VBD|a|young (l_dobj) infarction_12\NN|after|who
2396046
D010634_D006528 NONE phenobarbital_35\NN|NONE (r_dobj) containing_34\VBG|same|the (r_acl) diet_33\NN|NONE (r_dobj) fed_30\VBD|developed|nodules|.|diet|, (r_conj) fed_10\VBD|NONE (l_nsubj) nodules_3\NNS|developed|.|diet|,|fed (l_conj) carcinomas_6\NNS|hepatic|or|preneoplastic|No|developed
D010634_D006528 NONE phenobarbital_35\NN|NONE (r_dobj) containing_34\VBG|same|the (r_acl) diet_33\NN|NONE (r_dobj) fed_30\VBD|developed|nodules|.|diet|, (r_conj) fed_10\VBD|NONE (l_advcl) developed_26\VBN|nodules|.|diet|,|fed (l_nsubj) nodule_21\NN|in|while (l_conj) carcinoma_25\NN|one|preneoplastic|and
D010634_D006528 NONE phenobarbital_39\RB| (r_npadvmod) containing_41\VBG|devoid|the (r_amod) diet_45\NN|NONE (r_dobj) fed_37\VBD|,|,|%|respectively|.|incidence|fed (r_conj) was_9\VBD|NONE (l_nsubj) incidence_1\NN|,|,|%|respectively|.|fed|fed (l_prep) of_2\IN|The (l_conj) of_6\IN|nodules|and (l_pobj) carcinomas_8\NNS|NONE
D002794_D006528 CID choline_13\NN| (r_npadvmod) supplemented_15\VBN|the|plain (r_amod) diet_16\NN|developed|nodules|.|,|fed (r_dobj) fed_10\VBD|NONE (l_nsubj) nodules_3\NNS|developed|.|diet|,|fed (l_conj) carcinomas_6\NNS|hepatic|or|preneoplastic|No|developed
D002794_D006528 CID choline_13\NN| (r_npadvmod) supplemented_15\VBN|the|plain (r_amod) diet_16\NN|developed|nodules|.|,|fed (r_dobj) fed_10\VBD|NONE (l_advcl) developed_26\VBN|nodules|.|diet|,|fed (l_nsubj) nodule_21\NN|in|while (l_conj) carcinoma_25\NN|one|preneoplastic|and
D002794_D006528 CID choline_23\NN| (r_npadvmod) devoid_25\JJ|the|plain (r_amod) diet_26\NN|rats|in|in|%|,|and|, (r_dobj) fed_20\VBD|,|,|%|respectively|.|incidence|fed (r_conj) was_9\VBD|NONE (l_nsubj) incidence_1\NN|,|,|%|respectively|.|fed|fed (l_prep) of_2\IN|The (l_conj) of_6\IN|nodules|and (l_pobj) carcinomas_8\NNS|NONE
D002794_D006528 CID choline_42\NN| (r_npadvmod) devoid_44\JJ|containing|the (r_amod) diet_45\NN|NONE (r_dobj) fed_37\VBD|,|,|%|respectively|.|incidence|fed (r_conj) was_9\VBD|NONE (l_nsubj) incidence_1\NN|,|,|%|respectively|.|fed|fed (l_prep) of_2\IN|The (l_conj) of_6\IN|nodules|and (l_pobj) carcinomas_8\NNS|NONE
9698967
D008619_D019954 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|,
D004837_D004387 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (l_prep) for_51\IN|,|II|ASA|min|classification|,|male (l_pobj) correction_52\NN|NONE (l_prep) of_53\IN|NONE (l_pobj) contracture_56\NN|NONE
D008619_D004387 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (l_prep) for_51\IN|,|II|ASA|min|classification|,|male (l_pobj) correction_52\NN|NONE (l_prep) of_53\IN|NONE (l_pobj) contracture_56\NN|NONE
D008619_D011595 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial
D008619_D006973 CID mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_prep) in_2\IN|,|accompanied|An|, (l_pobj) pressure_4\NN|NONE
D004837_D014474 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|, (l_prep) of_17\IN|loss|incomprehensible|and (l_pobj) consciousness_18\NN|NONE
D004837_D019954 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|,
D008619_D001281 CID mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE
D008619_D014474 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|, (l_prep) of_17\IN|loss|incomprehensible|and (l_pobj) consciousness_18\NN|NONE
D004837_D006973 CID adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_prep) in_2\IN|,|accompanied|An|, (l_pobj) pressure_4\NN|NONE
D004837_D011595 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial
D004837_D001281 CID adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|II|ASA|classification|,|male|for (r_appos) group_28\NN|.|was|increase|,|in (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|.|was|group|,|in (l_acl) accompanied_6\VBN|,|in|An|, (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE
1616457
D010424_D000647 CID pentobarbital_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|NONE (r_acl) amnesia_4\NN|NONE
D010424_D000647 CID pentobarbital_15\NN|(|,|mg/kg (r_nmod) ip_20\NNP|NONE (r_pobj) by_14\IN|NONE (r_agent) produced_13\VBN|NONE (r_acl) amnesia_12\NN|NONE
12589964
D004317_D009202 CID doxorubicin_14\NN| (r_npadvmod) induced_16\VBN|cardiomyopathy (r_amod) rats_18\NNS|NONE (r_pobj) in_13\IN|myocardial (r_prep) damage_12\NN|NONE
D004317_D009202 CID doxorubicin_14\NN| (r_npadvmod) induced_16\VBN|cardiomyopathy (r_amod) rats_18\NNS|NONE (l_amod) cardiomyopathy_17\NN|induced
D004317_D009202 CID doxorubicin_20\NN|NONE (r_pobj) of_19\IN|rat|a|cardiomyopathy (r_prep) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE
D004317_D009202 CID doxorubicin_20\NN|NONE (r_pobj) of_19\IN|rat|a|cardiomyopathy (r_prep) model_18\NN|NONE (l_appos) cardiomyopathy_23\NN|rat|a|of
D004317_D009202 CID DOX)-induced_22\VBN|( (r_amod) cardiomyopathy_23\NN|rat|a|of (r_appos) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE
D004317_D009202 CID DOX)-induced_22\VBN|( (r_amod) cardiomyopathy_23\NN|rat|a|of
D004317_D009202 CID DOX_6\NNP|NONE (r_pobj) after_5\IN|of (r_prep) markers_1\NNS|NONE (r_pobj) Among_0\IN|cTnT|.|ability|, (r_prep) showed_11\VBD|NONE (l_dobj) ability_14\NN|cTnT|.|Among|, (l_acl) detect_16\VB|greatest|the (l_dobj) damage_18\NN|to
D004317_D066126 NONE DOX_13\NNP|NONE (r_pobj) after_12\IN|of|,|the (r_prep) amount_7\NN|NONE (r_pobj) between_5\IN|a (r_prep) discrepancy_4\NN|there|due|Although (r_attr) was_2\VBD|it|.|,|likely (r_advcl) is_33\VBZ|NONE (l_acomp) likely_34\JJ|was|it|.|, (l_ccomp) indicates_41\VBZ|NONE (l_conj) be_55\VB|and|that|induced|damage|after|cTnT|DOX (l_attr) marker_58\NN|cTnT|should|that (l_prep) for_59\IN|a|useful (l_pobj) prediction_61\NN|NONE (l_prep) of_62\IN|the (l_pobj) cardiotoxicity_65\NN|NONE
D004317_D066126 NONE DOX_40\NNP|and|that|be|induced|damage|after|cTnT (r_nsubj) indicates_41\VBZ|NONE (l_conj) be_55\VB|and|that|induced|damage|after|cTnT|DOX (l_attr) marker_58\NN|cTnT|should|that (l_prep) for_59\IN|a|useful (l_pobj) prediction_61\NN|NONE (l_prep) of_62\IN|the (l_pobj) cardiotoxicity_65\NN|NONE
D004317_D005355 NONE DOX_8\NNP|NONE (r_pobj) given_7\VBN|all (r_prep) rats_6\NNS|NONE (r_pobj) from_4\IN|NONE (r_prep) hearts_3\NNS|NONE (r_pobj) of_2\IN|Histological (r_prep) evaluation_1\NN|degrees|. (r_nsubj) revealed_9\VBD|NONE (l_dobj) degrees_12\NNS|evaluation|. (l_prep) of_13\IN|slight|significant (l_pobj) fibrosis_17\NN|NONE
D004317_D064420 NONE DOX_3\NNP|the (r_compound) rats_4\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Eighteen_0\CD|.|during|prematurely|of (r_nsubj) died_5\VBD|NONE (l_prep) of_7\IN|.|during|prematurely|Eighteen (l_pobj) toxicity_9\NN|NONE
D004317_D006331 NONE doxorubicin_20\NN|NONE (r_pobj) of_19\IN|rat|a|cardiomyopathy (r_prep) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE (r_pobj) of_12\IN|the (r_prep) diagnosis_11\NN|NONE (r_pobj) for_9\IN|We|,|examined|and|value (r_prep) investigated_1\VBD|NONE (l_conj) examined_27\VBD|We|,|for|and|value (l_dobj) relationship_29\NN|we|. (l_prep) with_35\IN|between|the (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) disorders_40\NNS|NONE
D004317_D006331 NONE DOX)-induced_22\VBN|( (r_amod) cardiomyopathy_23\NN|rat|a|of (r_appos) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE (r_pobj) of_12\IN|the (r_prep) diagnosis_11\NN|NONE (r_pobj) for_9\IN|We|,|examined|and|value (r_prep) investigated_1\VBD|NONE (l_conj) examined_27\VBD|We|,|for|and|value (l_dobj) relationship_29\NN|we|. (l_prep) with_35\IN|between|the (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) disorders_40\NNS|NONE
D004317_D017202 NONE DOX_6\NNP|NONE (r_pobj) after_5\IN|of (r_prep) markers_1\NNS|NONE (l_prep) of_2\IN|after (l_pobj) injury_4\NN|NONE
11379838
D000928_D001714 CID Antidepressant_0\NNP| (r_npadvmod) induced_2\VBN|.|:|identification|in (r_amod) mania_3\NN|NONE
D000928_D001714 CID Antidepressant_0\NNP| (r_npadvmod) induced_2\VBN|.|:|identification|in (r_amod) mania_3\NN|NONE (l_prep) in_4\IN|induced|.|:|identification (l_pobj) patients_6\NNS|NONE (l_amod) bipolar_5\JJ|NONE
D000928_D001714 CID antidepressants_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|NONE (r_acl) mania_7\NN|NONE
D000928_D001714 CID antidepressants_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|NONE (r_acl) mania_7\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) switching_5\VBG|NONE (r_pcomp) of_4\IN|possible (r_prep) risks_3\NNS|NONE (r_pobj) about_1\IN|NONE (r_prep) Concerns_0\NNS|.|interfere (r_nsubj) continue_11\VBP|NONE (l_xcomp) interfere_13\VB|.|Concerns (l_prep) with_14\IN|to (l_pobj) establishment_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) paradigm_21\NN|NONE (l_prep) for_22\IN|an|optimal|treatment (l_pobj) depression_24\NN|NONE
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|previous|,|manic|assessed|used|inhibitors (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|previous|,|manic|assessed|used|inhibitors (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|previous|,|manic|assessed|used|inhibitors (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|(
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|previous|,|manic|assessed|used|inhibitors (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|previous|,|manic|assessed|used|inhibitors (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|previous|,|assessed|used|type|inhibitors
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|electroconvulsive|and (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|previous|,|manic|assessed|type|inhibitors (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|electroconvulsive|and (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|previous|,|manic|assessed|type|inhibitors (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|electroconvulsive|and (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|previous|,|manic|assessed|type|inhibitors (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|(
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|electroconvulsive|and (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|previous|,|manic|assessed|type|inhibitors (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|electroconvulsive|and (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|previous|,|manic|assessed|type|inhibitors (r_acl) episodes_39\NNS|NONE (l_amod) manic_38\JJ|previous|,|assessed|used|type|inhibitors
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|and|,|and (r_conj) use_66\NN|SSRIs|particularly|,|reuptake|serotonin|,|selective|, (r_conj) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|and|,|and (r_conj) use_66\NN|SSRIs|particularly|,|reuptake|serotonin|,|selective|, (r_conj) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|and|,|and (r_conj) use_66\NN|SSRIs|particularly|,|reuptake|serotonin|,|selective|, (r_conj) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|(
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|and|,|and (r_conj) use_66\NN|SSRIs|particularly|,|reuptake|serotonin|,|selective|, (r_conj) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|and|,|and (r_conj) use_66\NN|SSRIs|particularly|,|reuptake|serotonin|,|selective|, (r_conj) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|previous|,|assessed|used|type|inhibitors
D017367_D001714 CID inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D017367_D001714 CID inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D017367_D001714 CID inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|(
D017367_D001714 CID inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D017367_D001714 CID inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|previous|,|assessed|used|type|inhibitors
D017367_D001714 CID SSRIs_62\NNPS|use|particularly|,|reuptake|serotonin|,|selective|, (r_appos) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D017367_D001714 CID SSRIs_62\NNPS|use|particularly|,|reuptake|serotonin|,|selective|, (r_appos) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|.|Patients|were (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|with|were (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D017367_D001714 CID SSRIs_62\NNPS|use|particularly|,|reuptake|serotonin|,|selective|, (r_appos) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|(
D017367_D001714 CID SSRIs_62\NNPS|use|particularly|,|reuptake|serotonin|,|selective|, (r_appos) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|did|, (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|,|number (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP||DSM|)|bipolar|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D017367_D001714 CID SSRIs_62\NNPS|use|particularly|,|reuptake|serotonin|,|selective|, (r_appos) inhibitors_60\NNS|previous|,|manic|assessed|used|type (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|previous|,|assessed|used|type|inhibitors
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|(|and|,|;|(|%|episodes (r_prep) experienced_42\JJ|all (r_parataxis) patients_11\NNS|NONE (r_pobj) of_9\IN||and|% (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|Switches|episodes|. (r_prep) occurred_5\VBD|NONE (l_nsubj) Switches_0\NNS|episodes|.|in (l_prep) to_1\IN|NONE (l_pobj) hypomania_2\NN|NONE
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|(|and|,|;|(|%|episodes (r_prep) experienced_42\JJ|all (r_parataxis) patients_11\NNS|NONE (r_pobj) of_9\IN||and|% (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|Switches|episodes|. (r_prep) occurred_5\VBD|NONE (l_nsubj) Switches_0\NNS|episodes|.|in (l_prep) to_1\IN|NONE (l_pobj) hypomania_2\NN|NONE (l_conj) mania_4\NN|or
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|(|and|,|;|(|%|episodes (r_prep) experienced_42\JJ|all (l_dobj) episodes_44\NNS|(|and|in|,|;|(|% (l_amod) manic_43\JJ|NONE
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|(|and|,|;|(|%|episodes (r_prep) experienced_42\JJ|all (r_parataxis) patients_11\NNS|NONE (r_pobj) of_9\IN||and|% (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|Switches|episodes|. (r_prep) occurred_5\VBD|NONE (l_npadvmod) episodes_56\NNS|Switches|.|in (l_amod) hypomanic_55\JJ|experienced
7977601
11206082
D005680_D012640 NONE GABA(A_24\NNP|)|other|receptor (r_nmod) ligands_27\NNS|NONE (r_pobj) of_22\IN|pharmacological|various (r_prep) effects_21\NNS|NONE (r_pobj) to_18\IN|differentially (r_prep) sensitive_17\JJ|lines|also|. (r_acomp) are_14\VBP|NONE (l_nsubj) lines_2\NNS|also|.|sensitive (l_acl) selected_3\VBN|Two|mouse (l_prep) for_4\IN|NONE (l_pobj) sensitivities_6\NNS|NONE (l_prep) to_7\IN|differential (l_pobj) seizures_13\NNS|NONE
D005680_D012640 NONE GABA(A_44\NNP|receptor|the|benzodiazepine (r_nmod) site_48\NN|NONE (r_pobj) of_42\IN|inverse|an (r_prep) agonist_41\NN|beta|CCM|methyl||)|, (r_appos) carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
D001569_D012640 NONE benzodiazepine_47\NN|receptor|the|GABA(A (r_amod) site_48\NN|NONE (r_pobj) of_42\IN|inverse|an (r_prep) agonist_41\NN|beta|CCM|methyl||)|, (r_appos) carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
C036150_D012640 CID carboline_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) seizures_13\NNS|NONE
C036150_D012640 CID carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
C036150_D012640 CID CCM_36\NNP|agonist|beta|methyl||)|, (r_appos) carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
D010852_D012640 CID picrotoxin-_25\NN|after (r_amod) seizures_30\NNS|,|the|vigilance|and
D010433_D012640 CID pentylenetetrazol_27\NN| (r_npadvmod) induced_29\VBN|and (r_conj) picrotoxin-_25\NN|after (r_amod) seizures_30\NNS|,|the|vigilance|and
D003975_D012640 NONE diazepam_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) anxiolysis_5\NN|,|with|We|sedation|. (r_dobj) measured_1\VBD|NONE (l_dobj) sedation_17\NN|anxiolysis|,|with|We|. (l_prep) by_18\IN|induced (l_pcomp) recording_19\VBG|NONE (l_dobj) states_22\NNS|NONE (l_conj) seizures_30\NNS|,|the|vigilance|and
D003975_D012640 NONE diazepam_14\NN| (r_npadvmod) induced_16\VBN|by (r_amod) sedation_17\NN|anxiolysis|,|with|We|. (l_prep) by_18\IN|induced (l_pcomp) recording_19\VBG|NONE (l_dobj) states_22\NNS|NONE (l_conj) seizures_30\NNS|,|the|vigilance|and
18951540
D007980_D004409 CID levodopa_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) dyskinesias_8\NNS|NONE
D007980_D010300 NONE levodopa_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) dyskinesias_8\NNS|NONE (l_prep) in_9\IN|induced (l_pobj) disease_12\NN|NONE
17879945
D019438_D050197 CID ritonavir_5\VBZ|NONE (r_compound) treatment_6\NN|that|to|formation (r_nsubj) increases_7\VBZ|.|previously|We|have (l_dobj) formation_10\NN|treatment|that|to (l_compound) lesion_9\NN|in|atherosclerotic
4027862
D003891_D003693 CID Desipramine_0\NN| (r_npadvmod) induced_2\VBN|at|. (r_amod) delirium_3\NN|NONE
D003891_D003693 CID Desipramine_7\NNP|patient|.|was|delirium (r_nsubj) developed_8\VBD|NONE (l_dobj) delirium_10\NN|patient|.|was|Desipramine
7862923
D002220_D019965 NONE Carbamazepine_0\NNP|to|among|.|was (r_nsubjpass) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|schizophrenic|using|six
D002220_D012559 NONE Carbamazepine_0\NNP|to|among|.|was (r_nsubjpass) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|psychotic|difficult|using|six
D003024_D019965 NONE clozapine_26\NN|or (r_conj) chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|psychotic|difficult|schizophrenic|six (r_acl) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|schizophrenic|using|six
D002746_D012559 NONE chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|psychotic|difficult|schizophrenic|six (r_acl) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|psychotic|difficult|using|six
C036006_D012559 NONE oxcarbazepine_7\NN|NONE (r_pobj) to_3\IN|Carbamazepine|among|.|was (r_prep) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|psychotic|difficult|using|six
D006220_D019965 NONE haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|psychotic|difficult|schizophrenic|six (r_acl) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|schizophrenic|using|six
D002746_D019965 NONE chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|psychotic|difficult|schizophrenic|six (r_acl) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|schizophrenic|using|six
C036006_D019965 NONE oxcarbazepine_7\NN|NONE (r_pobj) to_3\IN|Carbamazepine|among|.|was (r_prep) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|schizophrenic|using|six
D003024_D012559 NONE clozapine_26\NN|or (r_conj) chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|psychotic|difficult|schizophrenic|six (r_acl) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|psychotic|difficult|using|six
D006220_D012559 NONE haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|psychotic|difficult|schizophrenic|six (r_acl) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|psychotic|difficult|using|six
18221780
D016202_D010146 NONE NMDA_3\NNP|of|antagonist (r_compound) enhancement_5\NN|NONE (r_pobj) in_2\IN|:|comparisons|Sex|in|. (r_prep) differences_1\NNS|NONE (l_prep) in_9\IN|:|comparisons|Sex|.|in (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a|capsaicin (l_pobj) pain_15\NN|NONE
D016202_D010146 NONE NMDA_9\NNP|morphine|and (r_compound) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|a|dimorphic (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|between|a|dimorphic (l_pobj) model_17\NN|NONE (l_compound) pain_16\NN|distinguished|a|persistent
D002211_D059787 NONE capsaicin_11\NN|a|of (r_compound) model_12\NN|NONE (r_pobj) in_9\IN|:|comparisons|Sex|.|in (r_prep) differences_1\NNS|NONE (l_appos) comparisons_17\NNS|:|Sex|in|.|in (l_prep) to_18\IN|NONE (l_pobj) models_20\NNS|NONE (l_prep) of_21\IN|two (l_pobj) pain_23\NN|NONE
D009020_D059787 NONE morphine_7\NN|NONE (r_compound) antihyperalgesia_8\NN|NONE (r_pobj) of_6\IN|NMDA|antagonist (r_prep) enhancement_5\NN|NONE (r_pobj) in_2\IN|:|comparisons|Sex|in|. (r_prep) differences_1\NNS|NONE (l_appos) comparisons_17\NNS|:|Sex|in|.|in (l_prep) to_18\IN|NONE (l_pobj) models_20\NNS|NONE (l_prep) of_21\IN|two (l_pobj) pain_23\NN|NONE
D009020_D059787 NONE morphine_21\NN|NONE (r_pobj) of_20\IN|antinociceptive|the (r_prep) effects_19\NNS|In|to|.|antagonists (r_dobj) enhance_16\VBP|NONE (l_prep) In_0\IN|effects|to|.|antagonists (l_pobj) models_3\NNS|, (l_compound) pain_2\NN|acute
D009020_D059787 NONE morphine_2\NN|NONE (r_compound) antinociception_3\NN|NONE (r_pobj) of_1\IN|by (r_prep) Enhancement_0\NN|.|was|in|with|, (r_nsubjpass) seen_7\VBN|NONE (l_prep) in_8\IN|.|was|with|Enhancement|, (l_pobj) males_10\NNS|NONE (l_prep) in_13\IN|and|both|females (l_pobj) models_17\NNS|NONE (l_compound) pain_16\NN|acute|the
D009020_D059787 NONE morphine_12\NN|NMDA|and (r_conj) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|a|dimorphic (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|between|a|dimorphic (l_pobj) model_17\NN|NONE (l_relcl) distinguished_21\VBN|a|persistent|pain (l_prep) from_22\IN|that|can|be (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) models_28\NNS|NONE (l_compound) pain_27\NN|acute
D003915_D059787 NONE dextromethorphan_5\NNP|NONE (r_pobj) by_4\IN|of (r_prep) Enhancement_0\NN|.|was|in|with|, (r_nsubjpass) seen_7\VBN|NONE (l_prep) in_8\IN|.|was|with|Enhancement|, (l_pobj) males_10\NNS|NONE (l_prep) in_13\IN|and|both|females (l_pobj) models_17\NNS|NONE (l_compound) pain_16\NN|acute|the
D002211_D010146 NONE capsaicin_11\NN|a|of (r_compound) model_12\NN|NONE (l_prep) of_13\IN|a|capsaicin (l_pobj) pain_15\NN|NONE
D002211_D006930 CID capsaicin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) administration_9\NN|NONE (r_pobj) by_8\IN|,|To|was|.|,|immersed|hyperalgesia (r_agent) induced_7\VBN|NONE (l_nsubjpass) hyperalgesia_5\NN|,|by|To|was|.|,|immersed
D016202_D059787 NONE NMDA_3\NNP|of|antagonist (r_compound) enhancement_5\NN|NONE (r_pobj) in_2\IN|:|comparisons|Sex|in|. (r_prep) differences_1\NNS|NONE (l_appos) comparisons_17\NNS|:|Sex|in|.|in (l_prep) to_18\IN|NONE (l_pobj) models_20\NNS|NONE (l_prep) of_21\IN|two (l_pobj) pain_23\NN|NONE
D016202_D059787 NONE aspartate_11\NNP|(|)|NMDA|methyl (r_nmod) antagonists_15\NNS|effects|In|to|. (r_nsubj) enhance_16\VBP|NONE (l_prep) In_0\IN|effects|to|.|antagonists (l_pobj) models_3\NNS|, (l_compound) pain_2\NN|acute
D016202_D059787 NONE NMDA_13\NNP|(|aspartate|)|methyl (r_nmod) antagonists_15\NNS|effects|In|to|. (r_nsubj) enhance_16\VBP|NONE (l_prep) In_0\IN|effects|to|.|antagonists (l_pobj) models_3\NNS|, (l_compound) pain_2\NN|acute
D016202_D059787 NONE NMDA_9\NNP|morphine|and (r_compound) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|a|dimorphic (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|between|a|dimorphic (l_pobj) model_17\NN|NONE (l_relcl) distinguished_21\VBN|a|persistent|pain (l_prep) from_22\IN|that|can|be (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) models_28\NNS|NONE (l_compound) pain_27\NN|acute
D009020_D010146 NONE morphine_7\NN|NONE (r_compound) antihyperalgesia_8\NN|NONE (r_pobj) of_6\IN|NMDA|antagonist (r_prep) enhancement_5\NN|NONE (r_pobj) in_2\IN|:|comparisons|Sex|in|. (r_prep) differences_1\NNS|NONE (l_prep) in_9\IN|:|comparisons|Sex|.|in (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a|capsaicin (l_pobj) pain_15\NN|NONE
D009020_D010146 NONE morphine_12\NN|NMDA|and (r_conj) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|a|dimorphic (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|between|a|dimorphic (l_pobj) model_17\NN|NONE (l_compound) pain_16\NN|distinguished|a|persistent
17261653
D003000_D001919 CID Clonidine_0\NNP|in|bradycardia| (r_npadvmod) induced_2\VBN|%|. (l_dobj) bradycardia_3\NN|in|Clonidine|
7858459
C007744_D020258 NONE fluorocitrate_16\NN|and (r_conj) fluoroacetate_14\NN|NONE (r_pobj) by_13\IN|a|,|deficiency|cycle|Krebs (r_prep) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|pathogenesis|. (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|.|due (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
D002955_D020258 NONE acid_2\NN|Because|unlikely (r_nsubj) was_3\VBD|fluorouracil|.|highly|neurotoxicity|was|, (r_advcl) suspected_21\VBN|NONE (l_nsubjpass) neurotoxicity_12\NN|fluorouracil|.|was|highly|was|,
D005472_D009369 NONE 5-fluorouracil_3\CD|/ (r_punct) folinic_5\JJ|dose|infusion (r_amod) therapy_8\NN|regimen|has|recently|. (r_nsubj) become_11\VBN|NONE (l_attr) regimen_14\NN|has|therapy|recently|. (l_prep) for_15\IN|a|popular (l_pobj) cancers_17\NNS|NONE
D005472_D003128 CID 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|the|and|day|first (r_prep) dose_29\NN|folinic|acid (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (l_prep) into_16\IN|,|then|lasting (l_pobj) coma_19\NN|NONE
D005472_D003221 CID 5-fluorouracil_10\CD|NONE (r_punct) of_9\IN|and|dose|acid|a (r_prep) infusion_8\NN|NONE (r_pobj) by_3\IN|.|confusion (r_agent) induced_2\VBN|NONE (l_nsubj) confusion_1\NN|.|by
D005472_D003221 CID 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|the|and|day|first (r_prep) dose_29\NN|folinic|acid (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|He|,|and|.|lapsed (l_prep) of_5\IN|neurologic|acute (l_pobj) confusion_7\NN|NONE
D005472_D003221 CID 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|the|and|day|first (r_prep) dose_29\NN|folinic|acid (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|He|,|and|.|lapsed (l_prep) of_5\IN|neurologic|acute (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|,
D002955_D009369 NONE acid_6\NN|NONE (r_compound) infusion_7\NN|folinic|dose (r_compound) therapy_8\NN|regimen|has|recently|. (r_nsubj) become_11\VBN|NONE (l_attr) regimen_14\NN|has|therapy|recently|. (l_prep) for_15\IN|a|popular (l_pobj) cancers_17\NNS|NONE
D002955_D003128 CID acid_38\NN|folinic|dose (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (l_prep) into_16\IN|,|then|lasting (l_pobj) coma_19\NN|NONE
D005463_D020258 NONE fluoroacetate_14\NN|NONE (r_pobj) by_13\IN|a|,|deficiency|cycle|Krebs (r_prep) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|pathogenesis|. (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|.|due (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
D013831_D020258 NONE thiamine_18\NN|or|,|deficiency (r_compound) deficiency_19\NN|a|,|cycle|Krebs|by (r_conj) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|pathogenesis|. (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|.|due (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
D005472_D020258 NONE 5-fluorouracil_18\CD|.|was|highly|neurotoxicity|was|, (r_punct) suspected_21\VBN|NONE (l_nsubjpass) neurotoxicity_12\NN|fluorouracil|.|was|highly|was|,
D005472_D020258 NONE 5-fluorouracil_3\CD|NONE (r_punct) neurotoxicity_4\NN|NONE
D002945_D013274 NONE cisplatinum_11\NN|chemotherapy (l_appos) hours_24\NNS|,|etoposide (l_conj) acid_28\NN|and|m/|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
D002955_D001523 NONE acid_38\NN|folinic|dose (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|He|,|and|.|lapsed (l_prep) of_5\IN|neurologic|acute (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|, (l_conj) irritability_11\NN|and
D002955_D003221 CID acid_13\NN|and|dose|of|a (r_conj) infusion_8\NN|NONE (r_pobj) by_3\IN|.|confusion (r_agent) induced_2\VBN|NONE (l_nsubj) confusion_1\NN|.|by
D002955_D003221 CID acid_38\NN|folinic|dose (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|He|,|and|.|lapsed (l_prep) of_5\IN|neurologic|acute (l_pobj) confusion_7\NN|NONE
D002955_D003221 CID acid_38\NN|folinic|dose (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|He|,|and|.|lapsed (l_prep) of_5\IN|neurologic|acute (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|,
D005047_D013274 NONE etoposide_13\NN|,|hours (r_conj) cisplatinum_11\NN|chemotherapy (l_appos) hours_24\NNS|,|etoposide (l_conj) acid_28\NN|and|m/|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
D002955_D013274 NONE acid_28\NN|and|m/|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
C007419_D020258 NONE dihydrouracil_22\VBN|NONE (r_compound) dehydrogenase_23\NN|NONE (r_compound) deficiency_24\NN|or|,|thiamine (r_conj) deficiency_19\NN|a|,|cycle|Krebs|by (r_conj) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|pathogenesis|. (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|.|due (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
D005472_D013274 NONE 5-fluorouracil_18\CD|mg|(|/|,|dose (r_punct) m2/24_23\NN|acid|and|) (r_compound) hours_24\NNS|,|etoposide (l_conj) acid_28\NN|and|m/|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
D005472_D001523 NONE 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|the|and|day|first (r_prep) dose_29\NN|folinic|acid (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|then|into (r_advcl) lapsed_15\VBD|He|,|and|.|symptoms (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|He|,|and|.|lapsed (l_prep) of_5\IN|neurologic|acute (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|, (l_conj) irritability_11\NN|and
2234245
D003676_D064420 NONE desferrioxamine_10\NN|NONE (r_pobj) of_9\IN|higher|the (r_prep) doses_8\NNS|NONE (r_dobj) receiving_5\VBG|NONE (r_acl) patients_4\NNS|NONE (r_pobj) in_3\IN|.|or|toxicity|coincided (r_prep) appeared_2\VBD|NONE (l_nsubj) toxicity_1\NN|.|in|or|coincided
D003676_D014786 NONE desferrioxamine_8\NN|NONE (r_dobj) receiving_7\VBG|hemodialyzed (r_acl) patients_6\NNS|NONE (r_pobj) in_4\IN|Ocular|. (r_prep) toxicity_3\NN|NONE
D003676_D014786 NONE desferrioxamine_10\NN|NONE (r_dobj) receiving_9\VBG|weekly||hemodialyzed (r_acl) patients_8\NNS|period (r_pobj) During_0\IN|for|were|.|for (r_prep) monitored_25\VBN|NONE (l_prep) for_26\IN|were|.|During|for (l_pobj) detection_27\NN|NONE (l_prep) of_28\IN|NONE (l_pobj) toxicity_30\NN|NONE
D003676_D014786 NONE desferrioxamine_15\NN|NONE (r_dobj) receiving_14\VBG|hemodialyzed (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|an|infrequent (r_prep) complication_10\NN|that|not|toxicity (r_attr) is_6\VBZ|data|. (l_nsubj) toxicity_5\NN|that|not|complication
D003676_D034381 NONE Desferrioxamine_0\NNP|NONE (r_compound) withdrawal_1\NN|in|reversal|.|and|, (r_nsubj) resulted_2\VBD|NONE (l_conj) reversal_22\NN|in|.|withdrawal|and|, (l_prep) of_23\IN|a|complete (l_pcomp) hearing_24\NN|NONE (l_dobj) loss_25\NN|in|in
D003676_D006311 NONE desferrioxamine_8\NN|NONE (r_dobj) receiving_7\VBG|hemodialyzed (r_acl) patients_6\NNS|NONE (r_pobj) in_4\IN|Ocular|. (r_prep) toxicity_3\NN|NONE
D003676_D006311 NONE desferrioxamine_10\NN|NONE (r_dobj) receiving_9\VBG|weekly||hemodialyzed (r_acl) patients_8\NNS|period (r_pobj) During_0\IN|for|were|.|for (r_prep) monitored_25\VBN|NONE (l_prep) for_26\IN|were|.|During|for (l_pobj) detection_27\NN|NONE (l_prep) of_28\IN|NONE (l_pobj) toxicity_30\NN|NONE
D003676_D006311 NONE desferrioxamine_15\NN|NONE (r_dobj) receiving_14\VBG|hemodialyzed (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|an|infrequent (r_prep) complication_10\NN|that|not|toxicity (r_attr) is_6\VBZ|data|. (l_nsubj) toxicity_5\NN|that|not|complication
-1_D064420 NONE aluminium_19\NN|or (r_conj) ferritin_17\NN|serum (r_nmod) levels_21\NNS|NONE (r_pobj) of_16\IN|the (r_prep) normalization_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) coincided_12\VBD|.|in|or|toxicity (r_conj) appeared_2\VBD|NONE (l_nsubj) toxicity_1\NN|.|in|or|coincided
17437408
D010862_D012640 CID pilocarpine_11\NN| (r_npadvmod) induced_13\VBN|in (r_amod) seizures_14\NNS|NONE
18020536
D001569_D004244 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|.|with|was|However|,|inability|, (r_nsubjpass) associated_8\VBN|NONE (l_prep) with_9\IN|.|was|However|,|inability|use|, (l_pobj) dizziness_10\NN|NONE
D001569_D005221 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|.|with|was|However|,|inability|, (r_nsubjpass) associated_8\VBN|NONE (l_npadvmod) inability_12\NN|.|with|was|However|,|use|, (l_acl) sleep_14\VB|NONE (l_prep) after_15\IN|to (l_pcomp) awaking_16\VBG|and|with (l_prep) at_17\IN|in|during (l_pobj) night_18\NN|NONE (l_conj) tiredness_20\NN|and
D001569_D003866 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|.|with|was|However|,|inability|, (r_nsubjpass) associated_8\VBN|NONE (l_npadvmod) inability_12\NN|.|with|was|However|,|use|, (l_acl) sleep_14\VB|NONE (l_prep) after_15\IN|to (l_conj) with_31\IN|and|awaking (l_pobj) symptoms_34\NNS|NONE
D001569_D007319 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|.|with|was|However|,|inability|, (r_nsubjpass) associated_8\VBN|NONE (l_npadvmod) inability_12\NN|.|with|was|However|,|use|, (l_acl) sleep_14\VB|NONE
9625142
D001663_D000744 NONE bilirubin_21\NN|NONE (r_pobj) in_19\IN|decrease|a|and|gradual (r_prep) increase_18\NN|returned|,|.|there (l_conj) decrease_24\NN|in|a|and|gradual (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE
D047090_D000744 NONE lactam_11\NN|the (r_compound) antibiotic_12\NN|NONE (r_dobj) withholding_8\VBG|NONE (r_pcomp) after_7\IN|gradually|transaminases|to|Although (r_prep) returned_4\VBD|,|increase|.|there (r_advcl) was_15\VBD|NONE (l_attr) increase_18\NN|returned|,|.|there (l_conj) decrease_24\NN|in|a|and|gradual (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE
D002443_D000744 CID ceftriaxone_11\NN|NONE (r_pobj) by_10\IN|hepatitis|. (r_prep) induced_9\VBN|NONE (l_nsubj) hepatitis_1\NNP|by|. (l_appos) anemia_5\NN|Acute|,
D002443_-1 NONE ceftriaxone_11\NN|NONE (r_pobj) by_10\IN|hepatitis|. (r_prep) induced_9\VBN|NONE (l_nsubj) hepatitis_1\NNP|by|. (l_appos) anemia_5\NN|Acute|, (l_conj) erythroblastocytopenia_8\NN|,|and|autoimmune|hemolytic
D002443_D056486 CID ceftriaxone_11\NN|NONE (r_pobj) by_10\IN|hepatitis|. (r_prep) induced_9\VBN|NONE (l_nsubj) hepatitis_1\NNP|by|.
D002443_D056486 CID ceftriaxone_12\NN|NONE (r_dobj) ingesting_10\VBG|shortly (r_pcomp) after_9\IN|.|man|hepatitis (r_prep) developed_5\VBD|NONE (l_dobj) hepatitis_7\NN|.|man|after
D001663_-1 NONE bilirubin_21\NN|NONE (r_pobj) in_19\IN|decrease|a|and|gradual (r_prep) increase_18\NN|returned|,|.|there (l_conj) decrease_24\NN|in|a|and|gradual (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE (l_conj) erythroblastocytopenia_35\NN|an|and|autoimmune|hemolytic
D047090_-1 NONE lactam_11\NN|the (r_compound) antibiotic_12\NN|NONE (r_dobj) withholding_8\VBG|NONE (r_pcomp) after_7\IN|gradually|transaminases|to|Although (r_prep) returned_4\VBD|,|increase|.|there (r_advcl) was_15\VBD|NONE (l_attr) increase_18\NN|returned|,|.|there (l_conj) decrease_24\NN|in|a|and|gradual (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE (l_conj) erythroblastocytopenia_35\NN|an|and|autoimmune|hemolytic
16403073
D007654_D016171 CID Ketoconazole_0\NNP|without|pointes|. (r_nsubj) induced_1\VBD|NONE (l_dobj) pointes_4\FW|Ketoconazole|without|.
D007654_D016171 CID ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|and|who (l_dobj) pointes_18\FW|after
D007654_D016171 CID ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|and|who (l_dobj) pointes_18\FW|after (l_appos) TdP_20\NN|(|de|)
D007654_D016171 CID ketoconazole_13\RB|and|by|induce|may|that|interval|, (r_nsubj) prolong_16\VB|We (l_conj) induce_20\VB|and|by|may|that|ketoconazole|interval|, (l_dobj) TdP._21\NN|NONE
D007654_D008133 CID ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|and|who (r_conj) developed_9\VBD|with|a (l_dobj) interval_14\NN|and|who|torsades
D007654_D008133 CID ketoconazole_5\JJ|when|is|to (r_nsubjpass) administered_7\VBN|.|This|for (l_prep) to_8\IN|when|is|ketoconazole (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) factors_12\NNS|NONE (l_prep) for_13\IN|risk (l_pobj) syndrome_17\NN|NONE
D007654_D009181 NONE ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (l_prep) for_25\IN|ketoconazole (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) infection_29\NN|NONE
D007654_D003324 NONE ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|and|who (r_conj) developed_9\VBD|with|a (r_relcl) woman_3\NN|.|We (l_prep) with_4\IN|a|developed (l_pobj) disease_7\NN|NONE
3341566
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|in|sodium (r_amod) hypotension_13\NN|NONE
D009599_D007022 CID SNP_21\NNP|the (r_compound) group_22\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) that_18\DT|NONE (r_pobj) with_17\IN|NONE (r_prep) compared_16\VBN|NONE (r_prep) higher_15\RBR|lower|output|.|During (r_acomp) was_8\VBD|NONE (l_prep) During_0\IN|higher|lower|output|. (l_pobj) hypotension_4\NN|NONE
D009599_D007022 CID SNP_7\NNP|HEM (r_compound) groups_8\NNS|NONE (r_pobj) in_3\IN|.|P|,|,|mm|during|respectively (r_prep) Hg_2\NNP|NONE (l_prep) during_12\IN|.|P|in|,|,|mm|respectively (l_pobj) hypotension_13\NN|NONE
D009599_D006470 NONE nitroprusside_10\RB| (r_advmod) induced_12\VBN|in|sodium (r_amod) hypotension_13\NN|NONE (r_pobj) during_8\IN|NONE (r_prep) than_7\IN|greater|variation|.|during (r_prep) is_3\VBZ|NONE (l_prep) during_5\IN|greater|variation|than|. (l_pobj) hemorrhage_6\NN|NONE
D009599_D006470 NONE nitroprusside_28\NN|to|pressure|for|was|. (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|to|pressure|nitroprusside|was|. (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|by|either|or
D009599_D006470 NONE nitroprusside_28\NN|to|pressure|for|was|. (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|to|pressure|nitroprusside|was|. (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|by|either|or (l_appos) HEM_16\NNP|NONE
D009599_D006470 NONE SNP_30\NNP|(|)|,| (r_dep) n_32\CC|NONE (r_npadvmod) nitroprusside_28\NN|to|pressure|for|was|. (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|to|pressure|nitroprusside|was|. (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|by|either|or
D009599_D006470 NONE SNP_30\NNP|(|)|,| (r_dep) n_32\CC|NONE (r_npadvmod) nitroprusside_28\NN|to|pressure|for|was|. (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|to|pressure|nitroprusside|was|. (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|by|either|or (l_appos) HEM_16\NNP|NONE
D009599_D006470 NONE SNP_21\NNP|the (r_compound) group_22\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) that_18\DT|NONE (r_pobj) with_17\IN|NONE (r_prep) compared_16\VBN|NONE (r_prep) higher_15\RBR|lower|output|.|During (r_acomp) was_8\VBD|NONE (l_prep) During_0\IN|higher|lower|output|. (l_pobj) hypotension_4\NN|NONE (l_amod) induced_3\VBN|NONE (l_npadvmod) HEM_1\NNP|
D009599_D006470 NONE SNP_17\NNP|the (r_compound) group_18\NN|NONE (r_pobj) in_15\IN|NONE (r_prep) Hg_14\NNP|+/|P|. (r_appos) mm_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) compared_8\VBN|,|in|mm|. (r_prep) Hg_2\NNP|NONE (l_prep) in_3\IN|,|compared|mm|. (l_pobj) group_6\NN|NONE (l_compound) HEM_5\NNP|the
D009599_D006470 NONE SNP_7\NNP|HEM (r_compound) groups_8\NNS|NONE (l_nmod) HEM_5\NNP|SNP
15009014
D001285_D006940 NONE atropine_16\NN|NONE (r_pobj) by_10\IN|.|were|increases|also (r_agent) abolished_9\VBN|NONE (l_nsubjpass) increases_2\NNS|.|were|by|also (l_prep) in_3\IN|The|evoked (l_pobj) flow_6\NN|NONE
D002211_D006940 CID Capsaicin_0\NNS|.|to|induced (r_nsubj) applied_7\VBN|NONE (l_conj) induced_13\VBN|.|Capsaicin|to (l_dobj) increases_14\NNS|provoked (l_prep) in_15\IN|and (l_pobj) flow_20\NN|NONE
19058010
D007545_D009203 CID isoproterenol_9\JJ|NONE (r_pobj) in_8\IN|tea (r_prep) combination_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|.|infarction (r_nsubj) induced_10\VBN|NONE (l_dobj) infarction_12\NN|Effect|.
D007545_D009203 CID isoproterenol_37\NN|NONE (r_pobj) in_36\IN|ATPases (r_prep) bound_34\VBN|on|the|of|weight|combined|, (r_acl) effects_9\NNS|to (r_dobj) investigate_6\VB|was|ISO)induced|.|study (r_xcomp) aimed_4\VBN|NONE (l_parataxis) ISO)-induced_39\VBN|was|investigate|.|study (l_dobj) infarction_41\NN|(
D007545_D009203 CID ISO)-induced_39\VBN|was|investigate|.|study (l_dobj) infarction_41\NN|(
D007545_D009203 CID ISO_14\NN|NONE (r_pobj) during_13\IN|the|synergistic|protective|of (r_prep) effect_6\NN|induced|.|findings (r_dobj) indicate_2\VBP|NONE (l_ccomp) induced_15\VBN|effect|.|findings (l_dobj) infarction_17\NN|NONE
D010936_D009203 NONE tea_3\NN|in (r_nmod) combination_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|.|infarction (r_nsubj) induced_10\VBN|NONE (l_dobj) infarction_12\NN|Effect|.
D010936_D009203 NONE tea_12\NN|NONE (r_pobj) of_10\IN|bound|on|the|weight|combined|, (r_prep) effects_9\NNS|to (r_dobj) investigate_6\VB|was|ISO)induced|.|study (r_xcomp) aimed_4\VBN|NONE (l_parataxis) ISO)-induced_39\VBN|was|investigate|.|study (l_dobj) infarction_41\NN|(
D010936_D009203 NONE tea_9\NN|NONE (r_pobj) of_7\IN|the|during|synergistic|protective (r_prep) effect_6\NN|induced|.|findings (r_dobj) indicate_2\VBP|NONE (l_ccomp) induced_15\VBN|effect|.|findings (l_dobj) infarction_17\NN|NONE
D014810_D009203 NONE E_6\NN|and|green (r_conj) tea_3\NN|in (r_nmod) combination_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|.|infarction (r_nsubj) induced_10\VBN|NONE (l_dobj) infarction_12\NN|Effect|.
D014810_D009203 NONE E_15\NN|green|and (r_conj) tea_12\NN|NONE (r_pobj) of_10\IN|bound|on|the|weight|combined|, (r_prep) effects_9\NNS|to (r_dobj) investigate_6\VB|was|ISO)induced|.|study (r_xcomp) aimed_4\VBN|NONE (l_parataxis) ISO)-induced_39\VBN|was|investigate|.|study (l_dobj) infarction_41\NN|(
D014810_D009203 NONE E_12\NN|and|green (r_conj) tea_9\NN|NONE (r_pobj) of_7\IN|the|during|synergistic|protective (r_prep) effect_6\NN|induced|.|findings (r_dobj) indicate_2\VBP|NONE (l_ccomp) induced_15\VBN|effect|.|findings (l_dobj) infarction_17\NN|NONE
2096243
C017367_D019965 CID Carmofur_0\NN| (r_npadvmod) induced_2\VBN|.|mental|organic (r_amod) disorders_5\NNS|NONE
C017367_D019965 CID carmofur_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) leukoencephalopathy_22\NN|NONE (r_pobj) of_18\IN|the (r_prep) onset_17\NN|NONE (r_pobj) after_15\IN|prognostic|the (r_prep) period_14\NN|NONE (r_pobj) in_11\IN|old|a (r_prep) female_10\NN|NONE (r_pobj) in_5\IN|was|disorder|. (r_prep) observed_4\VBN|NONE (l_nsubjpass) disorder_2\NN|was|in|.
C017367_D056784 CID carmofur_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) leukoencephalopathy_22\NN|NONE
C017367_D056784 CID carmofur_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) leukoencephalopathy_5\JJ|uncommonly|Consequently|,|may|.|in
C017367_D010554 NONE carmofur_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) leukoencephalopathy_5\JJ|uncommonly|Consequently|,|may|.|in (r_nsubj) result_8\VB|NONE (l_prep) in_9\IN|uncommonly|Consequently|,|may|leukoencephalopathy|. (l_pobj) syndrome_12\NN|NONE
3676049
D007530_D007022 CID isoflurane_6\RB| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE
D007530_D007022 CID isoflurane_12\RB| (r_npadvmod) induced_14\VBN|in (r_amod) hypotension_15\NN|NONE
D007530_D007022 CID isoflurane_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) dose_17\NN|NONE (r_dobj) increasing_15\VBG|NONE (r_pcomp) by_14\IN|maintained|,|and|.|hypotension|was (r_prep) induced_13\VBN|NONE (l_nsubjpass) hypotension_1\NN|by|maintained|,|and|.|was
D008628_D007022 NONE Hg_11\NNP|NONE (r_pobj) of_6\IN|average|an (r_prep) MAP_5\NNP|NONE (r_pobj) to_2\IN|Controlled (r_prep) hypotension_1\NN|by|maintained|,|and|.|was
D014978_D013345 NONE xenon-133_24\.|by|after|were|Flow (r_punct) measured_4\VBN|NONE (l_prep) after_9\IN|by|were|Flow|xenon (l_pobj) haemorrhage_12\NN|days
D010100_D007022 NONE oxygen_8\NN|NONE (r_pobj) for_7\IN|metabolic|cerebral (r_prep) rate_6\NN|and|Cerebral|blood (r_conj) flow_2\NN|.|were|during (r_nsubjpass) measured_10\VBN|NONE (l_prep) during_11\IN|flow|.|were (l_pobj) hypotension_15\NN|NONE
D007530_D002532 NONE isoflurane_6\RB| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE (l_prep) in_10\IN|induced (l_pobj) patients_11\NNS|NONE (l_acl) subjected_12\VBN|NONE (l_prep) for_15\IN|to (l_pobj) aneurysms_17\NNS|NONE
D007530_D002532 NONE isoflurane_12\RB| (r_npadvmod) induced_14\VBN|in (r_amod) hypotension_15\NN|NONE (l_prep) in_16\IN|induced (l_pobj) patients_18\NNS|NONE (l_acl) subjected_19\VBN| (l_prep) to_20\IN|NONE (l_pobj) craniotomy_21\NN|NONE (l_prep) for_22\IN|NONE (l_pobj) clipping_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) aneurysm_27\NN|NONE
D007530_D000783 NONE isoflurane_7\JJ|the (r_amod) concentration_8\NN|to|After|was|. (r_nsubjpass) reduced_10\VBN|NONE (l_prep) After_0\IN|concentration|to|was|. (l_pobj) clipping_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) aneurysm_5\NN|NONE
D010100_D002532 NONE oxygen_8\NN|NONE (r_pobj) for_7\IN|metabolic|cerebral (r_prep) rate_6\NN|and|Cerebral|blood (r_conj) flow_2\NN|.|were|during (r_nsubjpass) measured_10\VBN|NONE (l_prep) during_11\IN|flow|.|were (l_pobj) hypotension_15\NN|NONE (l_prep) in_16\IN|induced (l_pobj) patients_18\NNS|NONE (l_acl) subjected_19\VBN| (l_prep) to_20\IN|NONE (l_pobj) craniotomy_21\NN|NONE (l_prep) for_22\IN|NONE (l_pobj) clipping_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) aneurysm_27\NN|NONE
10706004
D011188_D003866 NONE K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|deteriorated|Na+binding (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|reversible|a (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D009569_D003866 NONE NO_2\JJ| (r_compound) synthase_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Inhibition_0\NN|.|hypertension (r_nsubj) induced_5\VBD|NONE (l_dobj) hypertension_8\NN|Inhibition|. (l_acl) accompanied_9\VBN|reversible|a (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D019331_D006973 NONE ester_49\NN|/|day||/|mg (r_appos) kg_40\NNS|NONE (r_pobj) with_36\IN|synthase (r_prep) inhibition_35\NN|NONE (r_pobj) by_31\IN|NONE (r_prep) rats_30\NNS|NONE (r_pobj) in_29\IN|for (r_prep) induced_28\VBN|assess|.|response|we|, (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|assess|.|induced|we|, (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|,|Na|cardiac|( (l_pobj) hypertension_27\NN|NONE
D019331_D006973 NONE NAME_53\NNP|)|arginine|methyl (r_appos) ester_49\NN|/|day||/|mg (r_appos) kg_40\NNS|NONE (r_pobj) with_36\IN|synthase (r_prep) inhibition_35\NN|NONE (r_pobj) by_31\IN|NONE (r_prep) rats_30\NNS|NONE (r_pobj) in_29\IN|for (r_prep) induced_28\VBN|assess|.|response|we|, (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|assess|.|induced|we|, (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|,|Na|cardiac|( (l_pobj) hypertension_27\NN|NONE
D012964_D003866 NONE Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D012964_D003866 NONE Na+-binding_21\NN|deteriorated|of (r_compound) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|reversible|a (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D012964_D003866 NONE Na_26\UH|(|the|, (r_nmod) K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|deteriorated|Na+binding (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|reversible|a (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D009569_D006973 CID oxide_17\NN|NONE (r_npadvmod) deficient_18\JJ|nitric (r_amod) hypertension_19\NN|NONE
D009569_D006973 CID NO_2\DT|NONE (r_det) synthesis_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Inhibition_0\NN|.|hypertension (r_nsubj) induces_4\VBZ|NONE (l_dobj) hypertension_6\NN|.|Inhibition
D009569_D006973 CID NO_24\JJ| (r_npadvmod) deficient_26\JJ|NONE (r_amod) hypertension_27\NN|NONE
D009569_D006973 CID NO_32\JJ| (r_compound) synthase_34\NN|with (r_compound) inhibition_35\NN|NONE (r_pobj) by_31\IN|NONE (r_prep) rats_30\NNS|NONE (r_pobj) in_29\IN|for (r_prep) induced_28\VBN|assess|.|response|we|, (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|assess|.|induced|we|, (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|,|Na|cardiac|( (l_pobj) hypertension_27\NN|NONE
D009569_D006973 CID NO_2\JJ| (r_compound) synthase_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Inhibition_0\NN|.|hypertension (r_nsubj) induced_5\VBD|NONE (l_dobj) hypertension_8\NN|Inhibition|.
D000255_D006973 NONE ATP_4\NNP|and (r_conj) sodium_2\NN|of (r_nmod) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|.|of (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D000255_D006973 NONE ATP_20\NNP| (r_npadvmod) binding_22\VBG|the (r_amod) site_23\NN|NONE (r_pobj) of_18\IN|higher (r_prep) affinity_17\NN|to (r_pobj) due_14\IN|Na|,|,|K)ATPase|(|, (r_prep) increased_12\VBD|of|.|the|,|revealed|After (r_parataxis) activity_6\NN|NONE (l_prep) After_0\IN|of|.|increased|the|,|revealed (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D000255_D006973 NONE ATP_33\NNP|NONE (r_pobj) for_32\IN|the|lowered|Km (r_prep) value_31\NN|NONE (r_pobj) from_27\IN|as (r_prep) revealed_26\VBN|of|.|increased|the|,|After (r_advcl) activity_6\NN|NONE (l_prep) After_0\IN|of|.|increased|the|,|revealed (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D012964_D006973 NONE sodium_2\NN|of (r_nmod) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|.|of (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D012964_D006973 NONE Na_10\UH|,|(|cardiac|the (r_nmod) K)-ATPase_12\NNP|NONE (r_pobj) of_6\IN|sodium (r_prep) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|.|of (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D012964_D006973 NONE sodium_9\NN|intracellular (r_compound) level_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) elevation_6\NN|was|In|in|,|. (r_nsubjpass) documented_12\VBN|NONE (l_prep) In_0\IN|was|in|,|elevation|. (l_pobj) models_2\NNS|NONE (l_prep) of_3\IN|several (l_pobj) hypertension_4\NN|NONE
D012964_D006973 NONE Na+_11\NNP|NONE (r_pobj) of_10\IN|transmembraneous (r_prep) transport_9\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) disturbances_6\NNS|NONE (r_pobj) of_5\IN|molecular|the (r_prep) basis_4\NN|To (r_dobj) assess_1\VB|.|induced|response|we|, (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|assess|.|induced|we|, (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|,|Na|cardiac|( (l_pobj) hypertension_27\NN|NONE
D012964_D006973 NONE Na_20\UH|,|to|cardiac|( (r_nmod) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|,|Na|cardiac|( (l_pobj) hypertension_27\NN|NONE
D012964_D006973 NONE Na_9\NNP|,|,|K)ATPase|(|,|due (r_npadvmod) increased_12\VBD|of|.|the|,|revealed|After (r_parataxis) activity_6\NN|NONE (l_prep) After_0\IN|of|.|increased|the|,|revealed (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D012964_D006973 NONE Na+-extrusion_12\NN|NONE (r_pobj) by_10\IN|from|as (r_agent) accompanied_9\VBN|reversible|a (r_acl) hypertension_8\NN|Inhibition|.
D012964_D006973 NONE Na+-binding_21\NN|deteriorated|of (r_compound) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|reversible|a (r_acl) hypertension_8\NN|Inhibition|.
D012964_D006973 NONE Na_26\UH|(|the|, (r_nmod) K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|deteriorated|Na+binding (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|reversible|a (r_acl) hypertension_8\NN|Inhibition|.
D011188_D006973 NONE K)-ATPase_12\NNP|NONE (r_pobj) of_6\IN|sodium (r_prep) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|.|of (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D011188_D006973 NONE K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|,|Na|cardiac|( (l_pobj) hypertension_27\NN|NONE
D011188_D006973 NONE K)-ATPase_11\NNP|Na|,|,|(|,|due (r_nsubj) increased_12\VBD|of|.|the|,|revealed|After (r_parataxis) activity_6\NN|NONE (l_prep) After_0\IN|of|.|increased|the|,|revealed (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D011188_D006973 NONE K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|deteriorated|Na+binding (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|reversible|a (r_acl) hypertension_8\NN|Inhibition|.
10737864
D003000_D001919 CID clonidine_14\NN|NONE (r_pobj) given_12\VBN|withdrawal (r_prep) induces_15\VBZ|,|and|pattern|Given (l_dobj) withdrawal_17\NN|given (l_conj) bradycardia_19\NNP|and|sympathetic
D003000_D001919 CID clonidine_24\NN|on|developmental (r_poss) effects_27\NNS|that|would|other (r_nsubj) mirror_35\VB|,|we|exhibits|. (r_ccomp) hypothesized_22\VBD|NONE (l_ccomp) exhibits_5\VBZ|,|mirror|we|. (l_conj) induces_15\VBZ|,|and|pattern|Given (l_dobj) withdrawal_17\NN|given (l_conj) bradycardia_19\NNP|and|sympathetic
D003000_D001919 CID clonidine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) bradycardia_22\NN|baseline|cardiac|and
12617329
D014508_D007674 NONE urea_10\NN|and (r_conj) creatinine_8\NN|NONE (r_pobj) of_7\IN|in|the (r_prep) concentrations_6\NNS|glutathione|and (r_dobj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|Nephrotoxicity|.|was (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|by|.|was
D006170_D007674 NONE Arabic_6\JJ|NONE (r_pobj) with_4\IN|on (r_prep) treatment_3\NN|NONE (l_prep) on_7\IN|with (l_pobj) nephrotoxicity_9\NN|NONE
D006170_D007674 NONE Arabic_14\JJ|NONE (r_pobj) with_12\IN|NONE (r_prep) rats_11\NNS|NONE (r_pobj) of_10\IN|on (r_prep) treatment_9\NN|NONE (l_prep) on_15\IN|of (l_pobj) failure_18\NN|NONE (l_acl) induced_19\VBN|acute|renal (l_agent) by_20\IN|NONE (l_pobj) nephrotoxicity_25\NN|NONE
D006170_D007674 NONE Arabic_6\JJ|gum (r_amod) treatment_7\NN|that|has|amelioration (r_nsubj) induced_9\VBN|could|.|be|It (l_dobj) amelioration_12\NN|that|has|treatment (l_prep) of_13\IN|a|modest (l_pobj) some_14\DT|NONE (l_prep) of_15\IN|NONE (l_pobj) indices_20\NNS|NONE (l_prep) of_21\IN|the|histological (l_pobj) nephrotoxicity_23\NN|NONE
D005839_D007683 NONE GM_1\NNP| (r_npadvmod) induced_3\VBN|tubular|The|proximal (r_amod) necrosis_6\NN|.|be
D005839_D007683 NONE GM_16\NNP|than|with (r_dobj) given_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|less (r_prep) severe_12\JJ|to (r_acomp) be_9\VB|.|necrosis (r_xcomp) appeared_7\VBD|NONE (l_nsubj) necrosis_6\NN|.|be
D005839_D007683 NONE GM_25\NNP|NONE (r_pobj) given_24\VBN|NONE (r_acl) those_23\DT|NONE (r_pobj) in_22\IN|NONE (r_prep) than_21\IN|GM|with (r_prep) given_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|less (r_prep) severe_12\JJ|to (r_acomp) be_9\VB|.|necrosis (r_xcomp) appeared_7\VBD|NONE (l_nsubj) necrosis_6\NN|.|be
D005839_D007674 NONE gentamicin_8\NN|in (r_amod) nephrotoxicity_9\NN|NONE
D005839_D007674 NONE gentamicin_21\NN|(|GM|) (r_nmod) nephrotoxicity_25\NN|NONE
D005839_D007674 NONE GM_23\NNP|(|)|gentamicin (r_nmod) nephrotoxicity_25\NN|NONE
D005839_D007674 NONE GM_22\NNP|NONE (r_compound) nephrotoxicity_23\NN|NONE
D006170_D058186 CID Arabic_14\JJ|NONE (r_pobj) with_12\IN|NONE (r_prep) rats_11\NNS|NONE (r_pobj) of_10\IN|on (r_prep) treatment_9\NN|NONE (l_prep) on_15\IN|of (l_pobj) failure_18\NN|NONE
D005839_D058186 CID gentamicin_21\NN|(|GM|) (r_nmod) nephrotoxicity_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|acute|renal (r_acl) failure_18\NN|NONE
D005839_D058186 CID GM_23\NNP|(|)|gentamicin (r_nmod) nephrotoxicity_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|acute|renal (r_acl) failure_18\NN|NONE
D006170_D007683 NONE Arabic_20\JJ|together (r_pobj) with_18\IN|GM|than (r_prep) given_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|less (r_prep) severe_12\JJ|to (r_acomp) be_9\VB|.|necrosis (r_xcomp) appeared_7\VBD|NONE (l_nsubj) necrosis_6\NN|.|be
D003404_D007674 NONE creatinine_8\NN|NONE (r_pobj) of_7\IN|in|the (r_prep) concentrations_6\NNS|glutathione|and (r_dobj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|Nephrotoxicity|.|was (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|by|.|was
D005978_D007674 NONE glutathione_16\NN|concentrations|and (r_conj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|Nephrotoxicity|.|was (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|by|.|was
D005978_D007674 NONE GSH_18\NNP|,|in|reduced (r_appos) glutathione_16\NN|concentrations|and (r_conj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|Nephrotoxicity|.|was (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|by|.|was
6466532
D006024_D001919 NONE glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|and|i.v. (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE
D006024_D001919 NONE glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|prevent|,|before (r_prep) effectiveness_1\NN|was|,|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|following|to (l_conj) bradycardia_30\NNP|and
D001285_D001919 NONE atropine_5\NN|and|in|i.v. (r_conj) glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|and|i.v. (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE
D001285_D001919 NONE atropine_12\NN|micrograms|and (r_conj) kg-1_10\NNS|NONE (r_dobj) glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|prevent|,|before (r_prep) effectiveness_1\NN|was|,|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|following|to (l_conj) bradycardia_30\NNP|and
D013390_D001145 NONE suxamethonium_17\NN|NONE (r_pobj) of_16\IN|repeated (r_prep) doses_15\NNS|NONE (r_pobj) following_13\VBG|arrhythmias|and (r_prep) bradycardia_10\NN|NONE (l_conj) arrhythmias_12\NNS|and|following
D013390_D001145 NONE suxamethonium_35\NN|NONE (r_pobj) of_34\IN|repeated (r_prep) doses_33\NNS|NONE (r_pobj) following_31\VBG|arrhythmia|to (r_prep) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|following|to
D013390_D001919 CID suxamethonium_17\NN|NONE (r_pobj) of_16\IN|repeated (r_prep) doses_15\NNS|NONE (r_pobj) following_13\VBG|arrhythmias|and (r_prep) bradycardia_10\NN|NONE
D013390_D001919 CID suxamethonium_35\NN|NONE (r_pobj) of_34\IN|repeated (r_prep) doses_33\NNS|NONE (r_pobj) following_31\VBG|arrhythmia|to (r_prep) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|following|to (l_conj) bradycardia_30\NNP|and
D001285_D001145 NONE atropine_5\NN|and|in|i.v. (r_conj) glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|and|i.v. (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE (l_conj) arrhythmias_12\NNS|and|following
D001285_D001145 NONE atropine_12\NN|micrograms|and (r_conj) kg-1_10\NNS|NONE (r_dobj) glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|prevent|,|before (r_prep) effectiveness_1\NN|was|,|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|following|to
D006024_D001145 NONE glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|and|i.v. (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE (l_conj) arrhythmias_12\NNS|and|following
D006024_D001145 NONE glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|prevent|,|before (r_prep) effectiveness_1\NN|was|,|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|following|to
9199746
D014640_D013290 NONE vancomycin_14\NNP|and (l_prep) for_15\IN|NONE (l_pobj) endophthalmitis_20\NN|NONE
D000583_D064420 NONE amikacin_4\RB|NONE (l_nsubj) toxicity_1\NN|.
D000617_D009877 NONE aminoglycosides_2\NNS|substantially|have|prognosis|Although (r_nsubj) improved_5\VBN|infarction|recovery|.|may|, (l_dobj) prognosis_7\NN|aminoglycosides|substantially|have|Although (l_prep) in_8\IN|visual (l_pobj) endophthalmitis_9\NN|NONE
D019793_D013684 NONE fluorescein_1\NN|NONE (r_amod) angiography_2\NN|closure|.|Fundus (r_nsubj) confirmed_3\VBD|NONE (l_dobj) closure_6\NN|.|Fundus|angiography (l_conj) telangiectasis_8\NN|macular|capillary|and
D000583_D013290 NONE amikacin_6\JJ|following (r_prep) presumed_5\VBN|NONE (l_prep) following_9\VBG|amikacin (l_pobj) treatment_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) amikacin_12\JJ|NONE (l_conj) vancomycin_14\NNP|and (l_prep) for_15\IN|NONE (l_pobj) endophthalmitis_20\NN|NONE
D000583_D013290 NONE amikacin_12\JJ|NONE (l_conj) vancomycin_14\NNP|and (l_prep) for_15\IN|NONE (l_pobj) endophthalmitis_20\NN|NONE
D000617_D007238 NONE aminoglycosides_2\NNS|substantially|have|prognosis|Although (r_nsubj) improved_5\VBN|infarction|recovery|.|may|, (r_advcl) impair_14\VB|NONE (l_nsubj) infarction_12\NN|recovery|improved|.|may|,
D000583_D012164 CID amikacin_6\JJ|following (l_pobj) toxicity_8\NN|NONE
D000583_D012164 CID amikacin_12\JJ|NONE (r_pobj) with_11\IN|NONE (r_prep) treatment_10\NN|NONE (r_pobj) following_9\VBG|amikacin (r_prep) presumed_5\VBN|NONE (l_prep) amikacin_6\JJ|following (l_pobj) toxicity_8\NN|NONE
D014640_D012164 NONE vancomycin_14\NNP|and (r_conj) amikacin_12\JJ|NONE (r_pobj) with_11\IN|NONE (r_prep) treatment_10\NN|NONE (r_pobj) following_9\VBG|amikacin (r_prep) presumed_5\VBN|NONE (l_prep) amikacin_6\JJ|following (l_pobj) toxicity_8\NN|NONE
17175308
D020123_D007674 NONE SRL_13\NNP|NONE (r_pobj) with_12\IN|due|,|as|was|)|cohort (r_prep) treated_11\VBN|NONE (l_prep) due_18\IN|,|as|was|with|)|cohort (l_pobj) nephropathy_22\NN|to (l_advmod) CAN_24\VB|n|(|(|chronic|allograft
D020123_D011507 CID sirolimus_4\VB|NONE (r_pobj) to_3\TO|in (r_prep) conversion_2\NN|NONE (r_pobj) after_1\IN|. (r_prep) Proteinuria_0\NNP|NONE
D020123_D011507 CID sirolimus_11\NN|NONE (r_compound) therapy_12\NN|NONE (r_pobj) of_10\IN|a (r_prep) consequence_9\NN|NONE (r_pobj) as_7\IN|,|has|recently|been|remained|.|proteinuria|, (r_prep) reported_6\VBN|NONE (l_nsubjpass) proteinuria_3\NN|,|has|recently|been|remained|.|as|,
D020123_D011507 CID SRL_18\NN|NONE (r_compound) conversion_19\NN|NONE (r_pobj) after_17\IN|proteinuria (r_prep) displayed_14\VBD|or|who (l_dobj) proteinuria_16\NN|after
D020123_D011507 CID SRL_8\NN|NONE (r_pobj) of_7\IN|the|as (r_prep) use_6\NN|NONE (r_pobj) after_4\IN|proteinuria|common|. (r_prep) was_2\VBD|NONE (l_nsubj) proteinuria_1\NN|after|common|.
D020123_D051436 NONE SRL_13\NNP|NONE (r_pobj) with_12\IN|due|,|as|was|)|cohort (r_prep) treated_11\VBN|NONE (l_prep) due_18\IN|,|as|was|with|)|cohort (l_pobj) nephropathy_22\NN|to
3750012
D010396_D001172 NONE penicillamine_4\NN|NONE (l_conj) therapy_7\NN|and (l_prep) for_8\IN|chloroquine (l_pobj) arthritis_10\NN|NONE
D010396_D001172 NONE penicillamine_16\NN|NONE (l_conj) therapy_19\NN|and (l_prep) for_20\IN|chloroquine (l_pobj) arthritis_22\NN|NONE
D002738_D001172 NONE chloroquine_6\NN|for (r_amod) therapy_7\NN|and (l_prep) for_8\IN|chloroquine (l_pobj) arthritis_10\NN|NONE
D002738_D001172 NONE chloroquine_18\NN|for (r_compound) therapy_19\NN|and (l_prep) for_20\IN|chloroquine (l_pobj) arthritis_22\NN|NONE
D002738_D009157 CID chloroquine_6\NN|for (r_amod) therapy_7\NN|and (r_conj) penicillamine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|.|Myasthenia (r_acl) gravis_1\NN|NONE
D002738_D009157 CID chloroquine_18\NN|for (r_compound) therapy_19\NN|and (r_conj) penicillamine_16\NN|NONE (r_pobj) after_15\IN|gravis|who (r_prep) had_7\VBD|unique|a (l_dobj) gravis_14\NN|after|who
D010396_D009157 CID penicillamine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|.|Myasthenia (r_acl) gravis_1\NN|NONE
D010396_D009157 CID penicillamine_16\NN|NONE (r_pobj) after_15\IN|gravis|who (r_prep) had_7\VBD|unique|a (l_dobj) gravis_14\NN|after|who
18186898
D019259_D009135 CID lamivudine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) augmented_22\VBN|and|which|by|is (r_conj) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|have|that|may (r_prep) resulted_12\VBN|.|We (l_nsubj) dysfunction_7\NN|have|that|from|may (l_conj) myopathy_9\NNS|and|tubular|patient
D016559_D000138 NONE tacrolimus_1\NN|and|was|replaced|be|Although (r_nsubjpass) suspected_3\VBN|NONE (l_xcomp) be_5\VB|and|tacrolimus|was|replaced|Although (l_attr) cause_7\NN|to (l_prep) of_8\IN|the (l_pobj) acidosis_14\NN|NONE
D016559_D000138 NONE tacrolimus_1\NN|and|was|replaced|be|Although (r_nsubjpass) suspected_3\VBN|NONE (l_conj) replaced_17\VBN|and|tacrolimus|was|be|Although (l_agent) by_18\IN|was (l_pobj) sirolimus_19\NN|NONE (l_conj) acidosis_21\NN|,
D020123_D000138 NONE sirolimus_19\NN|NONE (r_pobj) by_18\IN|was (r_agent) replaced_17\VBN|and|tacrolimus|was|be|Although (r_conj) suspected_3\VBN|NONE (l_xcomp) be_5\VB|and|tacrolimus|was|replaced|Although (l_attr) cause_7\NN|to (l_prep) of_8\IN|the (l_pobj) acidosis_14\NN|NONE
D020123_D000138 NONE sirolimus_19\NN|NONE (l_conj) acidosis_21\NN|,
D019259_D005198 CID lamivudine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) augmented_22\VBN|and|which|by|is (r_conj) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|have|that|may (r_prep) resulted_12\VBN|.|We (l_nsubj) dysfunction_7\NN|have|that|from|may
D016559_D009135 CID tacrolimus_20\NN|NONE (r_pobj) by_19\IN|and|which|is|augmented (r_agent) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|have|that|may (r_prep) resulted_12\VBN|.|We (l_nsubj) dysfunction_7\NN|have|that|from|may (l_conj) myopathy_9\NNS|and|tubular|patient
D019259_D028361 NONE lamivudine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) augmented_22\VBN|and|which|by|is (r_conj) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE
D016559_D028361 NONE tacrolimus_20\NN|NONE (r_pobj) by_19\IN|and|which|is|augmented (r_agent) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE
D016559_D005198 CID tacrolimus_20\NN|NONE (r_pobj) by_19\IN|and|which|is|augmented (r_agent) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|have|that|may (r_prep) resulted_12\VBN|.|We (l_nsubj) dysfunction_7\NN|have|that|from|may
D019259_D006509 NONE Lamivudine_0\NNP|.|because|was (r_nsubjpass) added_2\VBN|NONE (l_prep) because_3\IN|.|Lamivudine|was (l_pobj) infection_9\NN|of
16330293
12084448
D007069_D009207 CID ifosfamide_27\NN|NONE (r_pobj) of_26\IN|for|the (r_prep) infusion_25\NN|NONE (r_pobj) after_23\IN|myoclonus (r_prep) disabling_14\VBG|a|of (l_dobj) myoclonus_16\NN|after
D007069_D009207 CID ifosfamide_12\JJ|NONE (r_pobj) of_11\IN|NONE (r_prep) infusion_10\NN|NONE (r_pobj) during_9\IN|of|,|the|following|findings (r_prep) presence_6\NN|.|associated|,|In (r_nsubj) suggest_31\VBP|NONE (l_ccomp) associated_36\VBN|.|,|In|presence (l_nsubjpass) myoclonus_34\NN|with|that|is
D007069_D009207 CID IFX_41\NNP|NONE (r_pobj) of_40\IN|the (r_prep) use_39\NN|NONE (r_pobj) with_37\IN|myoclonus|that|is (r_prep) associated_36\VBN|.|,|In|presence (l_nsubjpass) myoclonus_34\NN|with|that|is
D007069_D001927 CID Ifosfamide_0\NNP|presenting|. (r_compound) encephalopathy_1\NN|NONE
D007069_D010954 NONE ifosfamide_27\NN|NONE (r_pobj) of_26\IN|for|the (r_prep) infusion_25\NN|NONE (l_prep) for_28\IN|of|the (l_pobj) plasmacytoma_29\NN|NONE
D007069_D020820 NONE Ifosfamide_0\NNP|presenting|. (r_compound) encephalopathy_1\NN|NONE (l_acl) presenting_2\VBG|Ifosfamide|. (l_prep) with_3\IN|NONE (l_pobj) asterixis_4\NNS|NONE
D007069_D020820 NONE ifosfamide_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) administration_1\NN|and|was|resolved (r_nsubjpass) discontinued_5\VBN|NONE (l_conj) resolved_12\VBD|administration|and|was (l_nsubj) asterixis_11\NNS|within|completely|.
D007069_D020820 NONE ifosfamide_12\JJ|NONE (r_pobj) of_11\IN|NONE (r_prep) infusion_10\NN|NONE (r_pobj) during_9\IN|of|,|the|following|findings (r_prep) presence_6\NN|.|associated|,|In (l_prep) of_7\IN|,|the|following|during|findings (l_pobj) asterixis_8\NNS|NONE
D007069_D020820 NONE IFX_41\NNP|NONE (r_pobj) of_40\IN|the (r_prep) use_39\NN|NONE (r_pobj) with_37\IN|myoclonus|that|is (r_prep) associated_36\VBN|.|,|In|presence (r_ccomp) suggest_31\VBP|NONE (l_nsubj) presence_6\NN|.|associated|,|In (l_prep) of_7\IN|,|the|following|during|findings (l_pobj) asterixis_8\NNS|NONE
15458908
D020849_D005705 NONE Raloxifene_0\NNP|not|risk|.|did|disease|, (r_nsubj) increase_3\VB|NONE (l_dep) disease_20\NN|not|risk|.|Raloxifene|did|,
D020849_D005705 NONE Raloxifene_0\NNP|was|was|with|,|but (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|was|with|,|Raloxifene|but (l_attr) risk_16\NN|.|there (l_prep) for_17\IN|no|increased (l_pobj) cataracts_18\NNS|NONE (l_conj) disease_21\NN|,
D020849_D054556 CID raloxifene_11\NN|During|:|with|was|.|, (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|During|:|was|.|raloxifene|, (l_pobj) risk_17\NN|NONE (l_prep) for_18\IN|increased|an (l_pobj) thromboembolism_20\NN|NONE
D020849_D054556 CID Raloxifene_0\NNP|was|was|with|,|but (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|was|was|,|Raloxifene|but (l_pobj) risk_6\NN|NONE (l_prep) for_7\IN|an|increased (l_pobj) thromboembolism_9\NN|NONE
D020849_D004714 NONE Raloxifene_0\NNP|not|risk|.|did|disease|, (r_nsubj) increase_3\VB|NONE (l_dep) disease_20\NN|not|risk|.|Raloxifene|did|, (l_appos) CI_27\NNP|gallbladder|RR|(|; (l_appos) hyperplasia_34\NN|)|.|,|%
D020849_D004714 NONE Raloxifene_0\NNP|was|was|with|,|but (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|was|with|,|Raloxifene|but (l_attr) risk_16\NN|.|there (l_prep) for_17\IN|no|increased (l_pobj) cataracts_18\NNS|NONE (l_conj) disease_21\NN|, (l_conj) hyperplasia_24\NN|,|gallbladder
D020849_D002386 NONE Raloxifene_0\NNP|not|risk|.|did|disease|, (r_nsubj) increase_3\VB|NONE (l_dobj) risk_4\NN|not|.|Raloxifene|did|disease|, (l_prep) for_5\IN|NONE (l_pobj) cataracts_6\NNS|NONE
D020849_D002386 NONE Raloxifene_0\NNP|was|was|with|,|but (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|was|with|,|Raloxifene|but (l_attr) risk_16\NN|.|there (l_prep) for_17\IN|no|increased (l_pobj) cataracts_18\NNS|NONE
D020849_D010024 NONE Raloxifene_4\NNP|,|trial|, (r_compound) Evaluation_5\NNP|NONE (r_pobj) of_3\IN|The|Multiple (r_prep) Outcomes_2\NNPS|women|.|with (r_nsubj) enrolled_17\VBD|NONE (l_prep) with_21\IN|women|.|Outcomes (l_pobj) osteoporosis_22\NN|NONE
D020849_D016889 NONE Raloxifene_0\NNP|not|risk|.|did|disease|, (r_nsubj) increase_3\VB|NONE (l_dep) disease_20\NN|not|risk|.|Raloxifene|did|, (l_appos) CI_27\NNP|gallbladder|RR|(|; (l_appos) hyperplasia_34\NN|)|.|,|% (l_appos) %_40\NN|endometrial|( (l_conj) cancer_49\NN|,|;|;|%|RR|.||or
D020849_D016889 NONE Raloxifene_0\NNP|was|was|with|,|but (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|was|with|,|Raloxifene|but (l_attr) risk_16\NN|.|there (l_prep) for_17\IN|no|increased (l_pobj) cataracts_18\NNS|NONE (l_conj) disease_21\NN|, (l_conj) hyperplasia_24\NN|,|gallbladder (l_conj) cancer_28\NN|or|endometrial|,
17491223
D017256_D017202 NONE Sestamibi_46\NNP|photon (r_nmod) emission_50\NN|NONE (r_dobj) using_43\VBG|,|ischemia (r_conj) detecting_36\VBG|NONE (l_dobj) ischemia_41\NN|,|using
D004280_D017202 CID dobutamine_14\NN| (r_npadvmod) induced_16\VBN|myocardial (r_amod) ischemia_18\NN|NONE
D004280_D017202 CID dobutamine_8\NN| (r_npadvmod) induced_10\VBN|myocardial (r_amod) ischemia_12\NN|NONE
D004280_D017202 CID dobutamine_37\NN| (r_npadvmod) induced_39\VBN|myocardial (r_amod) ischemia_41\NN|,|using
D017256_D007511 NONE Sestamibi_46\NNP|photon (r_nmod) emission_50\NN|NONE (r_dobj) using_43\VBG|,|ischemia (r_conj) detecting_36\VBG|NONE (r_pcomp) for_35\IN|To|compared|value|,|,|computed (r_prep) assess_3\VB|.|: (l_conj) computed_51\VBD|To|compared|value|for|,|, (l_advcl) assess_60\VB|tomography (l_dobj) presence_62\NN|to (l_prep) of_65\IN|the|absence|or (l_pobj) ischemia_66\NN|NONE
D004280_D007511 NONE dobutamine_37\NN| (r_npadvmod) induced_39\VBN|myocardial (r_amod) ischemia_41\NN|,|using (r_dobj) detecting_36\VBG|NONE (r_pcomp) for_35\IN|To|compared|value|,|,|computed (r_prep) assess_3\VB|.|: (l_conj) computed_51\VBD|To|compared|value|for|,|, (l_advcl) assess_60\VB|tomography (l_dobj) presence_62\NN|to (l_prep) of_65\IN|the|absence|or (l_pobj) ischemia_66\NN|NONE
10091617
D012642_D010300 NONE Selegiline_0\NNP|.|study|hypotension||: (r_advmod) induced_2\VBN|NONE (l_dobj) hypotension_4\NN|.|study|Selegiline||: (l_prep) in_5\IN|postural (l_pobj) disease_8\NN|NONE
D012642_D010300 NONE selegiline_30\NN|to (r_dobj) receive_27\VB|NONE (r_xcomp) randomized_25\VBN|in|an|increased (r_acl) mortality_15\NN|trial|and|compared (r_dobj) found_12\VBD|NONE (l_nsubj) trial_11\NN|mortality|and|compared (l_nmod) Group_7\NNP|(|UKPDRG|) (l_compound) Disease_5\NNP|Parkinson|Research
D012642_D010300 NONE selegiline_30\NN|to (r_dobj) receive_27\VB|NONE (r_xcomp) randomized_25\VBN|in|an|increased (r_acl) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|an|increased (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D012642_D010300 NONE selegiline_30\NN|to (r_dobj) receive_27\VB|NONE (r_xcomp) randomized_25\VBN|in|an|increased (r_acl) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|an|increased (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE (l_appos) PD_23\NNP|)|(|Parkinson
D012642_D010300 NONE selegiline_17\RB|NONE (r_dobj) receiving_16\VBG|PD (r_acl) patients_15\NNS|NONE (l_compound) PD_14\NNP|receiving
D012642_D010300 NONE selegiline_18\NN|NONE (r_pobj) on_17\IN|was|in|which (r_prep) marked_10\VBN|systolic|,|lost|orthostatic (l_prep) in_11\IN|was|on|which (l_pobj) patients_16\NNS|NONE (l_compound) PD_15\NNP|
D007980_D007024 NONE dopa_11\NNP|and|with (r_conj) therapy_5\NN|was|that|with (r_nsubjpass) associated_13\VBN|Recently|,|.|we (l_prep) with_14\IN|was|that|therapy (l_pobj) hypotension_18\NN|NONE
D007980_D007024 NONE dopa_13\NNP|NONE (r_pobj) with_10\IN|NONE (r_prep) combination_9\NN|NONE (r_pobj) in_8\IN|that (r_prep) selegiline_7\NN|is|with (r_nsubjpass) associated_15\VBN|previous|our (l_prep) with_16\IN|is|selegiline (l_pobj) hypotension_19\NN|NONE
D012642_D007024 CID Selegiline_0\NNP|.|study|hypotension||: (r_advmod) induced_2\VBN|NONE (l_dobj) hypotension_4\NN|.|study|Selegiline||:
D012642_D007024 CID selegiline_7\NN|NONE (r_pobj) with_6\IN|dopa|and (r_prep) therapy_5\NN|was|that|with (r_nsubjpass) associated_13\VBN|Recently|,|.|we (l_prep) with_14\IN|was|that|therapy (l_pobj) hypotension_18\NN|NONE
D012642_D007024 CID selegiline_25\NN|NONE (r_pobj) of_24\IN|NONE (r_prep) withdrawal_23\NN|NONE (r_pobj) by_22\IN|which|was (r_agent) abolished_21\VBN|orthostatic|selective|systolic (r_relcl) hypotension_18\NN|NONE
D012642_D007024 CID selegiline_29\NN|in (r_dobj) stopping_28\VBG|NONE (l_prep) in_30\IN|selegiline (l_pobj) expectation_32\NN|NONE (l_acl) shed_36\VB|the (l_prep) on_38\IN|this|that|light|might (l_pobj) mechanisms_40\NNS|NONE (l_relcl) causes_45\VBZ|the (l_dobj) hypotension_47\NN|drug|by
D012642_D007024 CID selegiline_18\NN|NONE (r_pobj) on_17\IN|was|in|which (r_prep) marked_10\VBN|systolic|,|lost|orthostatic (r_relcl) hypotension_7\NN|.|tilt
D012642_D007024 CID selegiline_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) withdrawal_7\NN|days (r_pobj) after_6\IN|hypotension|was|and|.|abolished (r_prep) ameliorated_3\VBN|NONE (l_nsubjpass) hypotension_1\NN|was|and|.|after|abolished
D012642_D007024 CID selegiline_1\NN|NONE (r_dobj) Stopping_0\VBG|pressures|also|.|significantly (r_csubj) reduced_4\VBD|NONE (l_dobj) pressures_11\NNS|Stopping|also|.|significantly
D012642_D007024 CID selegiline_7\NN|is|with (r_nsubjpass) associated_15\VBN|previous|our (l_prep) with_16\IN|is|selegiline (l_pobj) hypotension_19\NN|NONE
D007980_D010300 NONE dopa_36\NN|with|. (r_nsubj) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_nsubj) trial_11\NN|mortality|and|compared (l_nmod) Group_7\NNP|(|UKPDRG|) (l_compound) Disease_5\NNP|Parkinson|Research
D007980_D010300 NONE dopa_36\NN|with|. (r_nsubj) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|an|increased (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D007980_D010300 NONE dopa_36\NN|with|. (r_nsubj) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|an|increased (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE (l_appos) PD_23\NNP|)|(|Parkinson
D007980_D010300 NONE dopa_43\NN|alone (r_dobj) taking_40\VBG|NONE (r_acl) those_39\DT|NONE (r_pobj) with_38\IN|.|dopa (r_prep) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_nsubj) trial_11\NN|mortality|and|compared (l_nmod) Group_7\NNP|(|UKPDRG|) (l_compound) Disease_5\NNP|Parkinson|Research
D007980_D010300 NONE dopa_43\NN|alone (r_dobj) taking_40\VBG|NONE (r_acl) those_39\DT|NONE (r_pobj) with_38\IN|.|dopa (r_prep) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|an|increased (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D007980_D010300 NONE dopa_43\NN|alone (r_dobj) taking_40\VBG|NONE (r_acl) those_39\DT|NONE (r_pobj) with_38\IN|.|dopa (r_prep) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|an|increased (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE (l_appos) PD_23\NNP|)|(|Parkinson
2951327
D005996_D007022 CID nitroglycerin_103\NN|or (r_conj) hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE
D009638_D007022 NONE norepinephrine_76\NN|the|(|release (r_amod) rate_78\NN|NONE (r_pobj) of_74\IN|no (r_prep) augmentation_73\NN|and|)|min|no (r_conj) tachycardia_70\NN|%|||or|p|,|but (r_conj) +/-_45\NN|.|+/|observed|,|pressure (r_appos) was_29\VBD|NONE (l_conj) observed_90\VBN|.|+/|+/|,|pressure (l_advcl) is_93\VBZ|were|, (l_prep) in_94\IN|which (l_pobj) contrast_95\NN|NONE (l_prep) to_96\IN|NONE (l_pobj) hypotension_98\NN|NONE
D005996_D013610 NONE nitroglycerin_103\NN|or (r_conj) hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE (r_pobj) to_96\IN|NONE (r_prep) contrast_95\NN|NONE (r_pobj) in_94\IN|which (r_prep) is_93\VBZ|were|, (r_advcl) observed_90\VBN|.|+/|+/|,|pressure (r_conj) was_29\VBD|NONE (l_appos) +/-_45\NN|.|+/|observed|,|pressure (l_conj) tachycardia_70\NN|%|||or|p|,|but
D006830_D013610 NONE hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE (r_pobj) to_96\IN|NONE (r_prep) contrast_95\NN|NONE (r_pobj) in_94\IN|which (r_prep) is_93\VBZ|were|, (r_advcl) observed_90\VBN|.|+/|+/|,|pressure (r_conj) was_29\VBD|NONE (l_appos) +/-_45\NN|.|+/|observed|,|pressure (l_conj) tachycardia_70\NN|%|||or|p|,|but
D009638_D013610 NONE norepinephrine_76\NN|the|(|release (r_amod) rate_78\NN|NONE (r_pobj) of_74\IN|no (r_prep) augmentation_73\NN|and|)|min|no (r_conj) tachycardia_70\NN|%|||or|p|,|but
D006830_D007022 CID hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE
19657887
D000431_D004417 CID alcohol_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) ingestion_7\NN|NONE (r_pobj) after_5\IN| (r_prep) hour_4\NN|NONE (r_pobj) In_0\IN|,|malaise|.|he (r_prep) developed_12\VBD|NONE (l_dobj) malaise_13\NN|In|,|.|he (l_prep) with_14\IN|NONE (l_pobj) flushing_15\NN|NONE (l_prep) of_16\IN|NONE (l_pobj) face_18\NN|NONE (l_conj) tachycardia_20\NN|,|the (l_conj) dyspnea_23\NN|,|and
D000431_D013610 CID alcohol_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) ingestion_7\NN|NONE (r_pobj) after_5\IN| (r_prep) hour_4\NN|NONE (r_pobj) In_0\IN|,|malaise|.|he (r_prep) developed_12\VBD|NONE (l_dobj) malaise_13\NN|In|,|.|he (l_prep) with_14\IN|NONE (l_pobj) flushing_15\NN|NONE (l_prep) of_16\IN|NONE (l_pobj) face_18\NN|NONE (l_conj) tachycardia_20\NN|,|the
D000431_D005483 CID alcohol_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) ingestion_7\NN|NONE (r_pobj) after_5\IN| (r_prep) hour_4\NN|NONE (r_pobj) In_0\IN|,|malaise|.|he (r_prep) developed_12\VBD|NONE (l_dobj) malaise_13\NN|In|,|.|he (l_prep) with_14\IN|NONE (l_pobj) flushing_15\NN|NONE (l_prep) of_16\IN|NONE (l_pobj) face_18\NN|NONE
D004221_D013610 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|with (r_amod) syndrome_10\NN|.|he|after|, (l_prep) with_11\IN|like (l_pcomp) flushing_12\NN|NONE (l_conj) tachycardia_14\NN|,|after
D004221_D005483 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|with (r_amod) syndrome_10\NN|.|he|after|, (l_prep) with_11\IN|like (l_pcomp) flushing_12\NN|NONE
D004221_D007022 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|with (r_amod) syndrome_10\NN|.|he|after|, (l_prep) with_11\IN|like (l_pcomp) flushing_12\NN|NONE (l_conj) tachycardia_14\NN|,|after (l_conj) hypotension_18\NN|,|and
2071257
D012601_D000647 NONE scopolamine_13\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) caused_11\VBN|NONE (r_acl) amnesia_10\NN|NONE
D005997_D008569 NONE glycerylphosphorylcholine_15\NN|NONE (r_pobj) of_10\IN|on|the (r_prep) effects_9\NNS|to (l_prep) on_23\IN|the|of (l_pobj) impairment_25\NN|NONE
D005997_D008569 NONE GFC_21\NNP|L|alpha|| (r_appos) glycerylphosphorylcholine_15\NN|NONE (r_pobj) of_10\IN|on|the (r_prep) effects_9\NNS|to (l_prep) on_23\IN|the|of (l_pobj) impairment_25\NN|NONE
D012601_D008569 CID scopolamine_28\NN|NONE (r_pobj) by_27\IN|NONE (r_agent) induced_26\VBN|memory (r_acl) impairment_25\NN|NONE
D012601_D008569 CID scopolamine_20\NN|NONE (r_pobj) by_19\IN|NONE (r_agent) induced_18\VBN|of (r_acl) impairment_13\NN|to (l_prep) of_14\IN|induced (l_pobj) attention_15\NN|NONE (l_conj) memory_17\NN|and
D005997_D000647 NONE phosphorylcholine_8\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effect_0\NN|NONE (l_prep) on_9\IN|.|of (l_pobj) amnesia_10\NN|NONE
2375138
D008874_D006323 CID midazolam_2\RB| (r_npadvmod) associated_4\VBN|.|cardiorespiratory|death|Possible|and|intramuscular (r_amod) arrest_6\NN|NONE
D008874_D006323 CID midazolam_17\NN|NONE (r_pobj) of_16\IN|intramuscular (r_prep) administration_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) associated_12\VBN|the|of|published|first (r_acl) case_6\NN|report|. (l_prep) of_7\IN|the|associated|published|first (l_pobj) arrest_9\NN|NONE
D008874_D003643 NONE midazolam_2\RB| (r_npadvmod) associated_4\VBN|.|cardiorespiratory|death|Possible|and|intramuscular (r_amod) arrest_6\NN|NONE (l_conj) death_8\NN|.|cardiorespiratory|Possible|associated|and|intramuscular
D008874_D003643 NONE midazolam_17\NN|NONE (r_pobj) of_16\IN|intramuscular (r_prep) administration_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) associated_12\VBN|the|of|published|first (r_acl) case_6\NN|report|. (l_prep) of_7\IN|the|associated|published|first (l_pobj) arrest_9\NN|NONE (l_conj) death_11\NN|and|cardiorespiratory
1436384
C070935_D020258 NONE LY274614_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_prep) rodents_11\NNS|NONE (r_pobj) in_10\IN|striatal|dopamine (r_prep) neurons_9\NNS|NONE (r_pobj) toward_6\IN|induced (r_prep) neurotoxicity_5\NN|NONE
C070935_D020258 NONE LY274614_23\NNP|that|antagonist (r_nsubj) is_24\VBZ|and|that|effect|receptors (r_conj) involves_18\VBZ|the (l_nsubj) effect_8\NN|and|is|that|receptors (l_amod) neurotoxic_7\JJ|the|of
D000661_D020258 CID amphetamine_2\NN| (r_npadvmod) induced_4\VBN|toward (r_amod) neurotoxicity_5\NN|NONE
D000661_D020258 CID amphetamine_10\NN|related|toward (r_nmod) compounds_13\NNS|NONE (r_pobj) of_9\IN|neurotoxic|the (r_prep) effect_8\NN|and|is|that|receptors (l_amod) neurotoxic_7\JJ|the|of
D000596_D020258 NONE acid_18\NN|an|excitatory (r_compound) antagonist_19\NN|, (r_appos) LY274614_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_prep) rodents_11\NNS|NONE (r_pobj) in_10\IN|striatal|dopamine (r_prep) neurons_9\NNS|NONE (r_pobj) toward_6\IN|induced (r_prep) neurotoxicity_5\NN|NONE
D004298_D020258 NONE dopamine_8\NN|striatal|in (r_compound) neurons_9\NNS|NONE (r_pobj) toward_6\IN|induced (r_prep) neurotoxicity_5\NN|NONE
D004298_D020258 NONE dopamine_16\NN|nigrostriatal (r_compound) neurons_17\NNS|NONE (r_pobj) toward_14\IN|related|amphetamine (r_prep) compounds_13\NNS|NONE (r_pobj) of_9\IN|neurotoxic|the (r_prep) effect_8\NN|and|is|that|receptors (l_amod) neurotoxic_7\JJ|the|of
D016202_D020258 NONE NMDA_19\NNP|NONE (r_compound) receptors_20\NNS|and|is|that|effect (r_dobj) involves_18\VBZ|the (l_nsubj) effect_8\NN|and|is|that|receptors (l_amod) neurotoxic_7\JJ|the|of
D016202_D020258 NONE NMDA_26\NNP|an|receptor|with (r_compound) antagonist_28\NN|LY|that (r_attr) is_24\VBZ|and|that|effect|receptors (r_conj) involves_18\VBZ|the (l_nsubj) effect_8\NN|and|is|that|receptors (l_amod) neurotoxic_7\JJ|the|of
12443032
D003042_D002637 CID Cocaine_0\NN|pain (r_nsubj) related_1\VBN|we|tip|:|are|? (l_dobj) pain_3\NN|Cocaine
D003042_D002637 CID cocaine_6\NN|NONE (r_pobj) of_5\IN|the|produce (r_prep) tendency_4\NN|.|,|be|In (l_acl) produce_8\VB|of|the (l_dobj) pain_10\NN|to
D003042_D002637 CID cocaine_6\NN|NONE (r_pobj) of_5\IN|the|produce (r_prep) tendency_4\NN|.|,|be|In (r_nsubj) ought_11\MD|NONE (l_xcomp) be_13\VB|.|,|tendency|In (l_advcl) faced_22\VBN|to|in (l_prep) with_23\IN|when (l_pobj) victim_26\NN|NONE (l_prep) of_27\IN|is|young|a (l_pobj) pain_29\NN|NONE
D003042_D002637 CID cocaine_7\NN|NONE (r_compound) use_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|of|The (r_acl) mechanism_1\NN|and|is|discussed (l_prep) of_2\IN|related|The (l_pobj) pain_4\NN|NONE
11135224
D017239_D002289 NONE Paclitaxel_0\NNP|NONE (l_conj) cisplatin_2\NN|.|, (l_conj) chemotherapy_7\NN|,|and (l_prep) within_8\IN|combination (l_pobj) approach_12\NN|NONE (l_prep) in_13\IN|therapeutic|multidisciplinary|a (l_pobj) carcinoma_18\NN|NONE
D017239_D002289 NONE paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|response|,|and (r_conj) rate_12\NN|,|the (r_conj) feasibility_9\NN|to|treat (r_dobj) determine_7\VB|.|objective (l_xcomp) treat_26\VB|to|feasibility (l_dobj) NSCLC_28\NN|to
D017239_D002289 NONE paclitaxel_30\NN|NONE (r_pobj) of_29\IN|m(|a|(|) (r_prep) combination_28\NN|NONE (r_pobj) with_26\IN|,|were|)|given|.|cisplatin|given|gemcitabine|on|given|patients|)|,|on|)|and (r_prep) treated_25\VBN|NONE (l_nsubjpass) patients_7\NNS|,|were|)|given|.|cisplatin|given|gemcitabine|on|with|given|)|,|on|)|and (l_prep) with_8\IN|naive|consecutive|five (l_pobj) NSCLC_11\NNP|NONE
D017239_D002289 NONE paclitaxel_3\NN|NONE (r_pobj) of_2\IN|and|The|,|gemcitabine (r_prep) combination_1\NN|is|and|.|shows|well (r_nsubjpass) tolerated_11\VBN|NONE (l_conj) shows_13\VBZ|combination|is|and|.|well (l_prep) in_16\IN|activity (l_pobj) NSCLC_18\NNP|NONE
C056507_D064420 NONE gemcitabine_23\NN|NONE (r_compound) combination_24\NN|a|,|cisplatin (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|response|,|and
D002945_D002289 NONE cisplatin_2\NN|.|, (l_conj) chemotherapy_7\NN|,|and (l_prep) within_8\IN|combination (l_pobj) approach_12\NN|NONE (l_prep) in_13\IN|therapeutic|multidisciplinary|a (l_pobj) carcinoma_18\NN|NONE
D002945_D002289 NONE Cisplatin_0\NN| (r_npadvmod) based_2\VBN|chemotherapy (r_amod) combinations_4\NNS|.|quality (r_nsubj) improve_5\VBP|NONE (l_dobj) quality_6\NN|.|combinations (l_prep) in_11\IN|of (l_pobj) carcinoma_16\NN|NONE
D002945_D002289 NONE Cisplatin_0\NN| (r_npadvmod) based_2\VBN|chemotherapy (r_amod) combinations_4\NNS|.|quality (r_nsubj) improve_5\VBP|NONE (l_dobj) quality_6\NN|.|combinations (l_prep) in_11\IN|of (l_pobj) carcinoma_16\NN|NONE (l_appos) NSCLC_18\NNP|)|advanced|(|lung|nonsmall
D002945_D002289 NONE cisplatin_20\NN|a|combination|, (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|response|,|and (r_conj) rate_12\NN|,|the (r_conj) feasibility_9\NN|to|treat (r_dobj) determine_7\VB|.|objective (l_xcomp) treat_26\VB|to|feasibility (l_dobj) NSCLC_28\NN|to
D002945_D002289 NONE cisplatin_47\NN|,|were|)|given|.|given|gemcitabine|on|with|given|patients|)|,|on|)|and (r_conj) treated_25\VBN|NONE (l_nsubjpass) patients_7\NNS|,|were|)|given|.|cisplatin|given|gemcitabine|on|with|given|)|,|on|)|and (l_prep) with_8\IN|naive|consecutive|five (l_pobj) NSCLC_11\NNP|NONE
D002945_D002289 NONE cisplatin_5\NN|, (r_conj) paclitaxel_3\NN|NONE (r_pobj) of_2\IN|and|The|,|gemcitabine (r_prep) combination_1\NN|is|and|.|shows|well (r_nsubjpass) tolerated_11\VBN|NONE (l_conj) shows_13\VBZ|combination|is|and|.|well (l_prep) in_16\IN|activity (l_pobj) NSCLC_18\NNP|NONE
D017239_D064420 NONE paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|response|,|and
D002945_D064420 NONE cisplatin_20\NN|a|combination|, (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|response|,|and
C056507_D002289 NONE gemcitabine_5\NN|NONE (r_compound) combination_6\NN|within (r_compound) chemotherapy_7\NN|,|and (l_prep) within_8\IN|combination (l_pobj) approach_12\NN|NONE (l_prep) in_13\IN|therapeutic|multidisciplinary|a (l_pobj) carcinoma_18\NN|NONE
C056507_D002289 NONE gemcitabine_23\NN|NONE (r_compound) combination_24\NN|a|,|cisplatin (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|response|,|and (r_conj) rate_12\NN|,|the (r_conj) feasibility_9\NN|to|treat (r_dobj) determine_7\VB|.|objective (l_xcomp) treat_26\VB|to|feasibility (l_dobj) NSCLC_28\NN|to
C056507_D002289 NONE gemcitabine_65\NN|,|were|)|given|.|cisplatin|given|on|with|given|patients|)|,|on|)|and (r_conj) treated_25\VBN|NONE (l_nsubjpass) patients_7\NNS|,|were|)|given|.|cisplatin|given|gemcitabine|on|with|given|)|,|on|)|and (l_prep) with_8\IN|naive|consecutive|five (l_pobj) NSCLC_11\NNP|NONE
C056507_D002289 NONE gemcitabine_8\NN|of|and|The|, (r_conj) combination_1\NN|is|and|.|shows|well (r_nsubjpass) tolerated_11\VBN|NONE (l_conj) shows_13\VBZ|combination|is|and|.|well (l_prep) in_16\IN|activity (l_pobj) NSCLC_18\NNP|NONE
3403780
D000082_D017093 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|,|acidosis (r_amod) coma_3\NN|NONE (l_appos) acidosis_6\NN|.|associated|, (l_conj) failure_11\NN|,|metabolic
D000082_D003128 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|,|acidosis (r_amod) coma_3\NN|NONE
D000082_D058186 CID paracetamol_13\JJ|NONE (r_compound) ingestion_14\NN|NONE (r_pobj) following_12\VBG|failure|and|acute|renal (r_prep) failure_8\NN|.|,|is|case (l_conj) failure_11\NN|and|following|acute|renal
D000082_D058186 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|,|acidosis (r_amod) coma_3\NN|NONE (l_appos) acidosis_6\NN|.|associated|, (l_conj) failure_11\NN|,|metabolic
D000082_D000138 CID Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|,|acidosis (r_amod) coma_3\NN|NONE (l_appos) acidosis_6\NN|.|associated|,
D000082_D000138 CID paracetamol_13\JJ|NONE (r_compound) ingestion_14\NN|NONE (r_pobj) following_12\VBG|failure|and|acute|renal (r_prep) failure_8\NN|.|,|is|case (r_nsubjpass) presented_16\VBN|NONE (l_nsubjpass) case_1\NN|.|,|is|failure (l_prep) of_2\IN|A (l_pobj) acidosis_4\NN|NONE
D000082_D017114 CID paracetamol_13\JJ|NONE (r_compound) ingestion_14\NN|NONE (r_pobj) following_12\VBG|failure|and|acute|renal (r_prep) failure_8\NN|.|,|is|case (l_conj) failure_11\NN|and|following|acute|renal
2632720
D006854_D006973 NONE cortisol_8\NN|urinary|plasma (r_compound) levels_9\NNS|In|been|had|.|demonstrated|following (r_nsubjpass) achieved_12\VBN|NONE (l_conj) demonstrated_22\VBD|In|been|had|levels|.|following (l_dobj) hypertension_23\NN|NONE
D007654_D003480 NONE ketoconazole_16\JJ|NONE (r_pobj) with_15\IN|a|term (r_prep) basis_14\NN|NONE (r_pobj) on_9\IN|patients|developed|. (r_prep) treated_8\VBN|NONE (l_nsubj) patients_3\NNS|on|developed|. (l_prep) with_4\IN| (l_pobj) syndrome_7\NN|NONE
D007654_D006973 CID ketoconazole_7\JJ|prolonged (r_compound) treatment_8\NN|NONE (r_pobj) of_5\IN|a (r_prep) complication_4\NN|NONE (r_pobj) as_2\IN|.|Arterial (r_prep) hypertension_1\NN|NONE
D007654_D006973 CID ketoconazole_16\JJ|NONE (r_pobj) with_15\IN|a|term (r_prep) basis_14\NN|NONE (r_pobj) on_9\IN|patients|developed|. (r_prep) treated_8\VBN|NONE (l_advcl) developed_17\VBN|patients|on|. (l_dobj) hypertension_19\NN|NONE
D007654_D006973 CID ketoconazole_14\JJ|yet|monitoring|, (r_compound) therapy_15\NN|NONE (r_dobj) following_13\VBG|In|been|had|levels|.|demonstrated (r_prep) achieved_12\VBN|NONE (l_conj) demonstrated_22\VBD|In|been|had|levels|.|following (l_dobj) hypertension_23\NN|NONE
D007654_D006973 CID ketoconazole_12\NN|NONE (r_pobj) of_11\IN|high (r_prep) doses_10\NNS|NONE (r_pobj) with_8\IN|term (r_prep) treatment_7\NN|that|blockade|may (r_nsubj) induce_14\VB|.|findings (l_dobj) blockade_16\NN|that|may|treatment (l_acl) leading_17\VBG|enzyme (l_prep) to_18\IN|NONE (l_pobj) hypertension_22\NN|NONE
17042910
C065179_D006973 NONE atorvastatin_5\NN|NONE (r_pobj) of_4\IN|oxidant|.|in (r_prep) effects_3\NNS|NONE (l_prep) in_6\IN|oxidant|of|. (l_pobj) hypertension_10\NN|NONE
C065179_D006973 NONE Atorvastatin_0\NNP|properties|. (r_nsubj) possesses_4\VBZ|NONE (l_dobj) properties_6\NNS|Atorvastatin|. (l_relcl) reported_10\VBN|pleiotropic (l_xcomp) improve_12\VB|have|been|that (l_prep) through_15\IN|function|to (l_pobj) availability_17\NN|NONE (l_prep) of_18\IN|increased (l_pobj) production_23\NN|NONE (l_prep) in_24\IN|O|reduced|NO (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
C065179_D006973 NONE Ato_2\NNP|) (r_appos) Atorvastatin_0\NNP|properties|. (r_nsubj) possesses_4\VBZ|NONE (l_dobj) properties_6\NNS|Atorvastatin|. (l_relcl) reported_10\VBN|pleiotropic (l_xcomp) improve_12\VB|have|been|that (l_prep) through_15\IN|function|to (l_pobj) availability_17\NN|NONE (l_prep) of_18\IN|increased (l_pobj) production_23\NN|NONE (l_prep) in_24\IN|O|reduced|NO (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
D013481_D006973 NONE superoxide_19\NN|NONE (r_advmod) increased_18\VBN|(|is|by|hypertension|and (r_conj) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|(|is|by|increased|and
D013481_D006973 NONE O2-_21\NNPS|)|(|. (r_nmod) production_23\NN|characterized (r_appos) Dexamethasone_0\NNP|NONE (l_parataxis) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|(|is|by|increased|and
D013481_D006973 NONE O2-_22\JJ|reduced|NO|in (r_compound) production_23\NN|NONE (l_prep) in_24\IN|O|reduced|NO (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
D003907_D006973 CID dexamethasone_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) hypertension_10\NN|NONE
D003907_D006973 CID Dexamethasone_0\NNP|NONE (l_parataxis) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|(|is|by|increased|and
D003907_D006973 CID Dex)-induced_2\JJ|NONE (r_amod) hypertension_3\NN|(|is|by|increased|and
D009569_D006973 NONE oxide_12\NN|)|NO|( (r_nmod) deficiency_16\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|endothelial (r_acl) dysfunction_8\NN|NONE (r_pobj) by_6\IN|(|is|hypertension|increased|and (r_agent) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|(|is|by|increased|and
D009569_D006973 NONE NO_14\NNP|)|oxide|( (r_intj) deficiency_16\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|endothelial (r_acl) dysfunction_8\NN|NONE (r_pobj) by_6\IN|(|is|hypertension|increased|and (r_agent) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|(|is|by|increased|and
D009569_D006973 NONE NO_19\DT|O|reduced|in (r_amod) production_23\NN|NONE (l_prep) in_24\IN|O|reduced|NO (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
3780846
D006220_D009127 CID haloperidol_7\NN|.|In|in|was|, (r_nsubjpass) used_14\VBN|NONE (l_prep) in_15\IN|.|In|was|,|haloperidol (l_pobj) order_16\NN|NONE (l_acl) block_18\VB|NONE (l_conj) estimate_24\VB|to|and|activation (l_dobj) degree_27\NN|to (l_prep) of_28\IN|the|real (l_pobj) tolerance_30\NN|NONE (l_prep) to_31\IN|the (l_pobj) rigidity_33\NN|NONE
D006220_D009127 CID Haloperidol_0\NNP|rigidity|. (r_nsubj) enhanced_1\VBD|NONE (l_dobj) rigidity_3\NN|Haloperidol|.
D009020_D009127 CID morphine_14\NN|NONE (r_pobj) by_13\IN|in (r_agent) produced_12\VBN|the|muscular (r_acl) rigidity_11\NN|NONE
D009020_D009127 CID morphine_10\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) produced_8\VBN|the|muscular (r_acl) rigidity_7\NN|NONE
D009020_D009127 CID morphine_9\NN|NONE (r_pobj) of_8\IN|(|)|a|test|mg/kg (r_prep) dose_7\NN|controls (r_dobj) given_4\VBN|.|rigidity (r_csubj) showed_15\VBD|NONE (l_dobj) rigidity_18\NN|.|given
D009020_D009127 CID morphine_6\NN|NONE (r_pobj) with_5\IN|for|Rats|h|withdrawn|showed|.|showed|and (r_prep) treated_1\VBD|NONE (l_conj) showed_27\VBD|for|Rats|h|withdrawn|showed|.|with|and (l_dobj) rigidity_29\NN|half|after
D009020_D009127 CID morphine_35\NN|NONE (r_pobj) of_34\IN|was|test|group|the (r_prep) dose_33\NN|NONE (r_pobj) after_30\IN|half|rigidity (r_prep) showed_27\VBD|for|Rats|h|withdrawn|showed|.|with|and (l_dobj) rigidity_29\NN|half|after
D009020_D009127 CID morphine_16\NN|NONE (r_pobj) of_15\IN|an|in (r_prep) action_14\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) due_11\JJ|to (r_acomp) be_10\VB|is|which (r_xcomp) assumed_8\VBN|,|, (r_relcl) rigidity_4\NN|that|can|by|be
D009020_D018476 CID morphine_6\NN|NONE (r_pobj) with_5\IN|for|Rats|h|withdrawn|showed|.|showed|and (r_prep) treated_1\VBD|NONE (l_conj) showed_27\VBD|for|Rats|h|withdrawn|showed|.|with|and (l_prep) after_30\IN|half|rigidity (l_pobj) dose_33\NN|NONE (l_relcl) was_37\VBD|test|group|the|of (l_conj) were_46\VBD|and|less|that|not (l_acomp) akinetic_47\JJ|NONE
D009020_D018476 CID morphine_35\NN|NONE (r_pobj) of_34\IN|was|test|group|the (r_prep) dose_33\NN|NONE (l_relcl) was_37\VBD|test|group|the|of (l_conj) were_46\VBD|and|less|that|not (l_acomp) akinetic_47\JJ|NONE
3693336
D014229_D003866 NONE Triazolam_0\NNP|episodes|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) episodes_4\NNS|.|Triazolam| (l_prep) in_8\IN|of|brief (l_pobj) patient_11\NN|NONE (l_amod) depressed_10\JJ|a
D014229_D003866 NONE triazolam_3\NN|NONE (r_pobj) of_2\IN|Large (r_prep) doses_1\NNS|episodes|repeatedly|. (r_nsubj) induced_5\VBD|NONE (l_dobj) episodes_7\NNS|repeatedly|.|doses (l_prep) in_10\IN|brief|of (l_pobj) woman_14\NN|NONE (l_amod) depressed_12\JJ|elderly|a
D014229_D001714 CID Triazolam_0\NNP|episodes|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) episodes_4\NNS|.|Triazolam| (l_prep) of_5\IN|in|brief (l_pobj) mania_7\NN|NONE
D014229_D001714 CID triazolam_3\NN|NONE (r_pobj) of_2\IN|Large (r_prep) doses_1\NNS|episodes|repeatedly|. (r_nsubj) induced_5\VBD|NONE (l_dobj) episodes_7\NNS|repeatedly|.|doses (l_prep) of_8\IN|brief|in (l_pobj) mania_9\NN|NONE
D014229_D001714 CID triazolam_10\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) action_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) duration_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) coincident_3\JJ|excitement|. (r_acomp) was_2\VBD|NONE (l_nsubj) excitement_1\NN|coincident|. (l_amod) Manic_0\JJ|NONE
12523465
C022189_D006212 CID zonisamide_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Visual|. (r_acl) hallucinations_1\NNS|NONE
C022189_D006212 CID zonisamide_29\NN|NONE (r_amod) treatment_30\NN|NONE (r_pobj) after_28\IN|status (r_prep) altered_25\VBD|and|hallucinations|who (r_conj) experienced_20\VBD|three (r_relcl) patients_18\NNS|we|reported|.|begun|, (r_dobj) describe_16\VBP|NONE (l_advcl) reported_6\VBN|we|.|patients|begun|, (l_nsubjpass) hallucinations_2\NNS|not|as|Although|have|been
C022189_D006212 CID zonisamide_29\NN|NONE (r_amod) treatment_30\NN|NONE (r_pobj) after_28\IN|status (r_prep) altered_25\VBD|and|hallucinations|who (r_conj) experienced_20\VBD|three (l_dobj) hallucinations_23\NNS|and|altered|who
C022189_D012640 NONE Zonisamide_0\NNP|drug|. (r_nsubj) is_1\VBZ|NONE (l_attr) drug_7\NN|.|Zonisamide (l_acl) used_8\VBN|antiepileptic|a|spectrum (l_xcomp) treat_10\VB|NONE (l_dobj) types_12\NNS|to (l_prep) of_13\IN|various (l_pobj) seizures_14\NNS|NONE
15649445
D012110_D004409 CID reserpine_1\NN|.|uptake|haloperidol|treatments|elicit|and (r_nsubj) change_6\VBP|NONE (l_conj) elicit_12\VBP|.|reserpine|uptake|haloperidol|treatments|and (l_dobj) dyskinesia_14\NN|NONE
D012110_D004409 CID Reserpine-_0\NNP|models|. (l_conj) dyskinesia_6\NN|and
D012110_D004409 CID Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|related|putative (l_pobj) dyskinesia_13\JJ|NONE
D012110_D004409 CID Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|related|putative (l_pobj) dyskinesia_13\JJ|NONE (l_appos) TD_15\NN|tardive
D012110_D004409 CID reserpine_12\NN|NONE (r_pobj) by_10\IN|In|dyskinesia|,|.|authors (r_prep) induced_7\VBD|NONE (l_dobj) dyskinesia_9\NN|In|by|,|.|authors
D018698_D004409 NONE glutamate_9\NN|synaptosomal (r_compound) uptake_10\NN|.|reserpine|haloperidol|treatments|elicit|and (r_dobj) change_6\VBP|NONE (l_conj) elicit_12\VBP|.|reserpine|uptake|haloperidol|treatments|and (l_dobj) dyskinesia_14\NN|NONE
D018698_D004409 NONE glutamate_5\NN|NONE (r_compound) uptake_6\NN|NONE (r_pobj) in_4\IN|a (r_prep) decrease_3\NN|,|Importantly|with|negatively|. (r_nsubj) correlates_7\VBZ|NONE (l_prep) with_9\IN|,|decrease|Importantly|negatively|. (l_pobj) increase_11\NN|NONE (l_prep) in_12\IN|an (l_pobj) incidence_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) diskinesia_17\NN|NONE
D006220_D004409 CID haloperidol_4\NN|.|reserpine|uptake|treatments|elicit|and (r_compound) change_6\VBP|NONE (l_conj) elicit_12\VBP|.|reserpine|uptake|haloperidol|treatments|and (l_dobj) dyskinesia_14\NN|NONE
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|orofacial (r_amod) dyskinesia_6\NN|and
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|orofacial (r_amod) dyskinesia_6\NN|and (r_conj) Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|related|putative (l_pobj) dyskinesia_13\JJ|NONE
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|orofacial (r_amod) dyskinesia_6\NN|and (r_conj) Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|related|putative (l_pobj) dyskinesia_13\JJ|NONE (l_appos) TD_15\NN|tardive
D006220_D004409 CID haloperidol_15\NN|subchronic (r_compound) administration_16\NN|to|and|acute (r_conj) reserpine_12\NN|NONE (r_pobj) by_10\IN|In|dyskinesia|,|.|authors (r_prep) induced_7\VBD|NONE (l_dobj) dyskinesia_9\NN|In|by|,|.|authors
18631865
D020123_D051436 NONE rapamycin_16\NNS|sirolimus|,|mToR|, (r_nmod) inhibitors_20\NNS|NONE (r_pobj) of_15\IN|mammalian (r_prep) target_14\NN|NONE (r_pobj) to_12\IN|in|from (r_prep) conversion_8\NN|NONE (l_prep) in_25\IN|from|to (l_pobj) recipients_28\NNS|NONE (l_prep) with_29\IN|renal|transplant (l_pobj) nephropathy_32\NN|NONE
D020123_D051436 NONE sirolimus_23\NN|rapamycin|,|mToR|, (r_appos) inhibitors_20\NNS|NONE (r_pobj) of_15\IN|mammalian (r_prep) target_14\NN|NONE (r_pobj) to_12\IN|in|from (r_prep) conversion_8\NN|NONE (l_prep) in_25\IN|from|to (l_pobj) recipients_28\NNS|NONE (l_prep) with_29\IN|renal|transplant (l_pobj) nephropathy_32\NN|NONE
D020123_D011507 CID sirolimus_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) due_3\JJ|proteinuria|Whether (r_acomp) was_2\VBD|unsolved|.|observed (l_nsubj) proteinuria_1\NN|due|Whether
D020123_D011507 CID sirolimus_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) due_3\JJ|proteinuria|Whether (r_acomp) was_2\VBD|unsolved|.|observed (r_csubj) remained_14\VBD|NONE (l_advcl) observed_22\VBN|unsolved|.|was (l_nsubjpass) proteinuria_19\NN|has|during|in|until|been
D020123_D011507 CID sirolimus_24\NN|NONE (r_compound) therapy_25\NN|NONE (r_pobj) during_23\IN|has|in|until|been|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (r_advcl) remained_14\VBD|NONE (l_csubj) was_2\VBD|unsolved|.|observed (l_nsubj) proteinuria_1\NN|due|Whether
D020123_D011507 CID sirolimus_24\NN|NONE (r_compound) therapy_25\NN|NONE (r_pobj) during_23\IN|has|in|until|been|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (l_nsubjpass) proteinuria_19\NN|has|during|in|until|been
D020123_D011507 CID sirolimus_34\NN|de (r_nmod) novo_36\NNP|who (r_dobj) received_33\VBD|NONE (r_relcl) patients_31\NNS|NONE (r_pobj) in_30\IN|and|transplantation (r_conj) in_26\IN|has|during|until|been|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (r_advcl) remained_14\VBD|NONE (l_csubj) was_2\VBD|unsolved|.|observed (l_nsubj) proteinuria_1\NN|due|Whether
D020123_D011507 CID sirolimus_34\NN|de (r_nmod) novo_36\NNP|who (r_dobj) received_33\VBD|NONE (r_relcl) patients_31\NNS|NONE (r_pobj) in_30\IN|and|transplantation (r_conj) in_26\IN|has|during|until|been|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (l_nsubjpass) proteinuria_19\NN|has|during|in|until|been
1085609
D007538_D012640 CID isoniazid_6\NN|NONE (r_amod) therapy_7\NN|to (r_pobj) due_4\IN|pyridoxine|responsive|.|Neonatal (r_amod) convulsions_3\NNS|NONE
D007538_D012640 CID isoniazid_6\NN|therapy (r_pobj) on_5\IN|because|A|old|daily (r_prep) infant_4\NN|.|was|after (r_nsubjpass) admitted_18\VBN|NONE (l_prep) after_19\IN|.|was|infant (l_pobj) days_21\NNS|NONE (l_prep) of_22\IN| (l_pobj) fits_24\NNS|NONE
D007538_D012640 CID isoniazid_19\NN|an|of (r_relcl) aetiology_13\NN|NONE (r_dobj) suggesting_11\VBG|,|.|within|fits (r_advcl) ceased_2\VBD|NONE (l_nsubj) fits_1\NNS|,|.|within|suggesting
D011736_D012640 NONE pyridoxine_1\NN|due|responsive|.|Neonatal (r_nmod) convulsions_3\NNS|NONE
D011736_D012640 NONE pyridoxine_9\NN|NONE (r_dobj) administering_7\VBG|NONE (r_pcomp) of_6\IN| (r_prep) hours_5\NNS|NONE (r_pobj) within_3\IN|,|.|suggesting|fits (r_prep) ceased_2\VBD|NONE (l_nsubj) fits_1\NNS|,|.|within|suggesting
D011736_D012640 NONE pyridoxine_15\JJ|secondary (r_compound) deficiency_16\NN|NONE (r_pobj) of_14\IN|isoniazid|an (r_prep) aetiology_13\NN|NONE (r_dobj) suggesting_11\VBG|,|.|within|fits (r_advcl) ceased_2\VBD|NONE (l_nsubj) fits_1\NNS|,|.|within|suggesting
D007538_D014376 NONE isoniazid_6\NN|therapy (r_pobj) on_5\IN|because|A|old|daily (r_prep) infant_4\NN|.|was|after (l_prep) because_13\IN|on|A|old|daily (l_pobj) tuberculosis_16\NN|of
891050
D004176_D001002 NONE dipyridamole_6\NN|, (r_conj) heparin_4\JJ|NONE (r_pobj) with_3\IN|and|She|rose|was|; (r_prep) treated_2\VBN|NONE (l_conj) rose_20\VBD|and|with|She|was|; (l_conj) stopped_37\VBN|and|after|,|above|;|.|output (l_prep) after_28\IN|,|was|treatment (l_pobj) onset_30\NN|months (l_prep) of_31\IN|the (l_pobj) anuria_32\NN|NONE
D003276_D006463 CID contraceptives_17\NNS|NONE (r_dobj) taking_15\VBG|a (r_acl) woman_14\NN|NONE (r_pobj) in_12\IN|)|the|HUS|hemolytic|uremic|( (r_prep) syndrome_8\NN|NONE
D003276_D006463 CID contraceptives_17\NNS|NONE (r_dobj) taking_15\VBG|a (r_acl) woman_14\NN|NONE (r_pobj) in_12\IN|)|the|HUS|hemolytic|uremic|( (r_prep) syndrome_8\NN|NONE (l_appos) HUS_10\NNP|)|the|hemolytic|uremic|in|(
D006493_D001002 NONE heparin_4\JJ|NONE (r_pobj) with_3\IN|and|She|rose|was|; (r_prep) treated_2\VBN|NONE (l_conj) rose_20\VBD|and|with|She|was|; (l_conj) stopped_37\VBN|and|after|,|above|;|.|output (l_prep) after_28\IN|,|was|treatment (l_pobj) onset_30\NN|months (l_prep) of_31\IN|the (l_pobj) anuria_32\NN|NONE
7199841
C004616_D010243 CID CE_11\NN|seven| (r_nmod) %_15\NN|NONE (r_pobj) of_8\IN|subarachnoid (r_prep) injection_7\NN|that (r_dobj) received_5\VBD|the|)| (r_relcl) animals_3\NNS|NONE (r_pobj) Of_0\IN|.|limb|developed (r_prep) paralysis_21\NN|NONE
D002045_D010243 NONE bupivacaine_6\NN|that (r_dobj) received_5\VBD|the (r_relcl) animals_3\NNS|NONE (r_pobj) of_1\IN|,|saline (r_prep) None_0\NN|.|to (r_nsubj) titrated_14\VBN|NONE (l_prep) to_15\IN|None|. (l_pobj) paralysis_23\NN|NONE
C004616_D013118 CID CE_12\NNP|that (r_dobj) received_9\VBD|the (r_relcl) animals_7\NNS|NONE (r_pobj) of_5\IN||the|spinal (r_prep) cords_4\NNS|NONE (r_pobj) Of_0\IN|NONE (r_prep) 13_14\CD|necrosis|, (r_nsubj) showed_15\VBD|normal|roots|.|; (l_dobj) necrosis_17\NN||,
11256525
D000588_D001002 NONE amine_26\NN|and (r_conj) furosemide_24\NN|dose (r_nmod) infusion_27\NN|NONE (r_pobj) despite_20\IN|hours|which (r_prep) lasted_17\VBD|,|sudden|a (r_relcl) anuria_14\NN|NONE
D019808_D006331 NONE losartan_5\NN|Due|.|was (l_compound) dysfunction_4\NN|NONE
D000809_D012078 NONE angiotensin_24\NN|the|)|RAS|( (r_compound) system_25\NN|NONE (r_pobj) of_20\IN|strong|a (r_prep) activation_19\NN|NONE (r_pobj) in_16\IN|In|.|certainly|stenosis|, (r_prep) resulted_15\VBD|NONE (l_nsubj) stenosis_6\NN|In|.|certainly|in|,
D019808_D001002 CID losartan_4\NN|NONE (r_amod) administration_5\NN|in (r_dobj) following_3\VBG|Repeated|transient|. (r_prep) anuria_2\NN|NONE
D019808_D001002 CID losartan_27\NN|NONE (r_amod) administration_28\NN|NONE (r_pobj) after_26\IN|who|episodes (r_prep) developed_20\VBD|and|insufficiency|solitary|a (l_dobj) episodes_22\NNS|who|after (l_prep) of_23\IN|two (l_pobj) anuria_25\NN|NONE
D019808_D001002 CID losartan_9\NN|NONE (r_pobj) of_8\IN| (r_prep) mg_7\NN|NONE (r_pobj) of_5\IN|first|the (r_prep) dose_4\NN|.|Surprisingly|in|, (r_nsubj) resulted_10\VBD|NONE (l_prep) in_11\IN|.|Surprisingly|dose|, (l_pobj) anuria_14\NN|NONE
D019808_D001002 CID losartan_7\NN|again|and|by|later|was|developed|,|, (r_nsubjpass) prescribed_9\VBN|NONE (l_conj) developed_22\VBD|again|and|by|later|was|losartan|,|, (l_dobj) episode_25\NN|patient|,|after|. (l_prep) of_26\IN|a|lasting|second (l_pobj) anuria_28\NN|NONE
D019808_D014652 NONE losartan_12\NN|that|and|used|complications|can (r_nsubj) cause_14\VB|the (l_dobj) complications_17\NNS|that|losartan|and|used|can (l_prep) in_18\IN|serious|unexpected (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_22\NN|NONE
D005665_D001002 NONE furosemide_24\NN|dose (r_nmod) infusion_27\NN|NONE (r_pobj) despite_20\IN|hours|which (r_prep) lasted_17\VBD|,|sudden|a (r_relcl) anuria_14\NN|NONE
D019808_D051436 NONE losartan_27\NN|NONE (r_amod) administration_28\NN|NONE (r_pobj) after_26\IN|who|episodes (r_prep) developed_20\VBD|and|insufficiency|solitary|a (r_relcl) kidney_14\NN|NONE (l_conj) insufficiency_18\NN|and|solitary|developed|a
D000809_D006333 NONE angiotensin_24\NN|the|)|RAS|( (r_compound) system_25\NN|NONE (r_pobj) of_20\IN|strong|a (r_prep) activation_19\NN|NONE (r_pobj) in_16\IN|In|.|certainly|stenosis|, (r_prep) resulted_15\VBD|NONE (l_nsubj) stenosis_6\NN|In|.|certainly|in|, (l_acl) combined_7\VBN|renal|artery (l_prep) with_8\IN|NONE (l_pobj) failure_10\NN|NONE
D000804_D014652 NONE II_9\NNP|receptor (r_compound) antagonist_11\NN|the|angiotensin (r_compound) losartan_12\NN|that|and|used|complications|can (r_nsubj) cause_14\VB|the (l_dobj) complications_17\NNS|that|losartan|and|used|can (l_prep) in_18\IN|serious|unexpected (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_22\NN|NONE
D019808_D006973 NONE losartan_27\NN|NONE (r_amod) administration_28\NN|NONE (r_pobj) after_26\IN|who|episodes (r_prep) developed_20\VBD|and|insufficiency|solitary|a (r_relcl) kidney_14\NN|NONE (r_pobj) with_11\IN|hypertensive|a|old (r_prep) man_10\NN|NONE (l_amod) hypertensive_9\JJ|a|old|with
3412544
D010615_D014516 NONE phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|renal|, (l_conj) bladder_16\NN|or
D010615_D014516 NONE phenacetin_13\NN|NONE (r_pobj) of_12\IN|,|increased (r_prep) consumption_11\NN|NONE (l_relcl) increased_17\VBD|of|, (l_conj) for_30\IN|but|risk|which|also (l_pobj) cancer_32\NN|not
D010615_D007680 CID phenacetin_13\NN|NONE (r_pobj) of_12\IN|,|increased (r_prep) consumption_11\NN|NONE (l_relcl) increased_17\VBD|of|, (l_dobj) risk_19\NN|but|which|also|for (l_prep) for_20\IN|the (l_pobj) cancer_21\NN|NONE (l_prep) of_22\IN|NONE (l_pobj) pelvis_25\NN|NONE (l_conj) bladder_27\NN|the|renal|and
D010615_D007680 NONE phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|renal|, (l_conj) bladder_16\NN|or
D000082_D007681 NONE paracetamol_1\JJ|Does|?|cancer (r_nsubj) cause_2\VB|NONE (l_dobj) cancer_4\NN|Does|paracetamol|? (l_conj) necrosis_8\NN|urothelial|or
D000082_D007681 NONE paracetamol_24\NNP|or|either (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (r_pobj) of_9\IN|or|renal|papillary|cancer (r_prep) necrosis_6\NN|NONE
D000082_D007681 NONE paracetamol_12\JJ|NONE (r_compound) consumption_13\NN|NONE (r_pobj) from_11\IN|increased|or|for|any|an (r_prep) risk_10\NN|to (l_prep) for_14\IN|increased|or|from|any|an (l_pobj) necrosis_17\NN|NONE
D000082_D001749 NONE paracetamol_24\NNP|or|either (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|renal|, (l_conj) bladder_16\NN|or
D000082_D014516 NONE paracetamol_24\NNP|or|either (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|renal|, (l_conj) bladder_16\NN|or
D000082_D014516 NONE paracetamol_12\JJ|NONE (r_compound) consumption_13\NN|NONE (r_pobj) from_11\IN|increased|or|for|any|an (r_prep) risk_10\NN|to (r_dobj) substantiate_7\VB|NONE (r_xcomp) unable_5\JJ|,|was|By|we|. (r_acomp) were_4\VBD|NONE (l_advcl) was_25\VBD|,|By|we|.|unable (l_attr) suggestion_27\NN|there|although (l_prep) of_28\IN|a (l_pobj) association_30\NN|NONE (l_prep) with_31\IN|an (l_pobj) cancer_32\NN|NONE (l_prep) of_33\IN|NONE (l_pobj) ureter_35\NN|NONE
D000082_D014523 NONE paracetamol_1\JJ|Does|?|cancer (r_nsubj) cause_2\VB|NONE (l_dobj) cancer_4\NN|Does|paracetamol|?
D000082_D007680 NONE paracetamol_24\NNP|or|either (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|renal|, (l_conj) bladder_16\NN|or
D000082_D009369 NONE paracetamol_12\JJ|NONE (r_compound) consumption_13\NN|NONE (r_pobj) from_11\IN|increased|or|for|any|an (r_prep) risk_10\NN|to (l_conj) any_19\DT|increased|or|from|for|an (l_prep) of_20\IN|NONE (l_pobj) cancers_22\NNS|NONE
D010615_D007681 CID phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (r_pobj) of_9\IN|or|renal|papillary|cancer (r_prep) necrosis_6\NN|NONE
D010615_D007681 CID phenacetin_13\NN|NONE (r_pobj) of_12\IN|,|increased (r_prep) consumption_11\NN|NONE (r_pobj) by_10\IN|risk|fold|was|. (r_agent) increased_7\VBN|NONE (l_nsubjpass) risk_1\NN|fold|was|.|by (l_prep) of_2\IN|The (l_pobj) necrosis_5\NN|NONE
D010615_D001749 CID phenacetin_13\NN|NONE (r_pobj) of_12\IN|,|increased (r_prep) consumption_11\NN|NONE (l_relcl) increased_17\VBD|of|, (l_dobj) risk_19\NN|but|which|also|for (l_prep) for_20\IN|the (l_pobj) cancer_21\NN|NONE (l_prep) of_22\IN|NONE (l_pobj) pelvis_25\NN|NONE (l_conj) bladder_27\NN|the|renal|and
D010615_D001749 NONE phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|renal|ureter|, (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|renal|, (l_conj) bladder_16\NN|or
9862868
D004997_D002780 CID estradiol_9\NNP|and|extrahepatic|)|EE|( (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|determine|.|We|models (r_dobj) used_1\VBD|NONE (l_dobj) models_3\NNS|determine|.|We|cholestasis (l_prep) of_4\IN|rat (l_pobj) cholestasis_6\NN|NONE
D004997_D002780 CID EE_11\NNP|and|extrahepatic|)|(|estradiol (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|determine|.|We|models (r_dobj) used_1\VBD|NONE (l_dobj) models_3\NNS|determine|.|We|cholestasis (l_prep) of_4\IN|rat (l_pobj) cholestasis_6\NN|NONE
D004997_D001651 NONE estradiol_9\NNP|and|extrahepatic|)|EE|( (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|determine|.|We|models
D004997_D001651 NONE EE_11\NNP|and|extrahepatic|)|(|estradiol (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|determine|.|We|models
2008831
D008755_D000787 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|intracoronary (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|without|in|.|were (r_nsubjpass) studied_8\VBN|NONE (l_prep) without_25\IN|effects|in|.|were (l_pobj) angina_26\NN|NONE (l_appos) pectoris_27\NN|NONE
D008755_D013035 NONE methylergonovine_19\NN|NONE (r_pobj) of_18\IN|a|low (r_prep) dose_17\NN|NONE (r_pobj) of_13\IN|intracoronary|an (r_prep) injection_12\NN|which (r_dobj) use_9\VBP|spasm|,|provocation|, (r_relcl) tests_6\NNS|and|be|that|sensitivity (l_compound) spasm_4\NN|use|,|provocation|,
D008755_D000788 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|direct|intracoronary|in (r_prep) administration_4\NN|NONE (l_prep) in_7\IN|direct|intracoronary|of (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_conj) without_11\IN|and (l_pobj) angina_13\NN|NONE
D008755_D000788 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|intracoronary (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|without|in|.|were (r_nsubjpass) studied_8\VBN|NONE (l_prep) in_9\IN|without|effects|.|were (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN| (l_pobj) angina_14\NN|NONE
D008755_D000788 NONE methylergonovine_19\NN|NONE (r_pobj) of_18\IN|a|low (r_prep) dose_17\NN|NONE (r_pobj) of_13\IN|intracoronary|an (r_prep) injection_12\NN|which (r_dobj) use_9\VBP|spasm|,|provocation|, (r_relcl) tests_6\NNS|and|be|that|sensitivity (r_nsubj) have_21\VBP|.|results (l_dobj) sensitivity_24\NN|and|be|that|tests (l_prep) in_25\IN|high|a (l_pobj) angina_27\NN|NONE
D008755_D002637 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|intracoronary (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|without|in|.|were (r_nsubjpass) studied_8\VBN|NONE (l_prep) in_9\IN|without|effects|.|were (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN| (l_pobj) angina_14\NN|NONE (l_conj) patients_17\NNS|variant|and (l_prep) with_18\IN| (l_pobj) pain_21\NN|and|in
17020434
D001241_D020521 NONE aspirin_24\NN|by|risk|that (r_nsubj) reduces_26\VBZ|and|risk|,|warfarin|that|by (r_conj) reduces_13\VBZ|have|data|. (l_dobj) risk_15\NN|and|,|warfarin|that|reduces|by (l_prep) of_16\IN|the (l_pobj) stroke_17\NN|NONE
D001241_D020521 NONE aspirin_12\NN|NONE (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_dobj) strokes_15\NNS|NONE
D014812_D004617 NONE K_16\NNP|antagonist (r_compound) drugs_18\NNS|NONE (r_pobj) as_14\IN|as|in (r_prep) efficient_13\JJ|to (l_prep) in_19\IN|as|as (l_pobj) prevention_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) events_24\NNS|NONE
C081309_D004617 NONE Irbesartan_10\NNP|NONE (r_pobj) with_9\IN|Atrial|(|The|W|study|)|Clopidogrel (r_prep) Trial_8\NN|has|is|. (r_nsubj) demonstrated_19\VBN|NONE (l_ccomp) is_22\VBZ|has|Trial|. (l_acomp) superior_23\JJ|warfarin|that (l_xcomp) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|therapy|clopidogrel (l_pobj) events_37\NNS|prevention
C479958_D001281 NONE Idraparinux_0\NNP|.|is|in|being (r_nsubjpass) evaluated_9\VBN|NONE (l_prep) in_10\IN|.|is|Idraparinux|being (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) fibrillation_14\NN|NONE
D000809_D001281 NONE Angiotensin_0\NN| (r_npadvmod) converting_2\VBG|and|enzyme|drugs (r_amod) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|inhibitors|. (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE
D000804_D020257 NONE II_7\CD|angiotensin|blocking (r_nummod) drugs_11\NNS|and|enzyme|converting (r_conj) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|inhibitors|. (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE (l_prep) through_17\IN|atrial (l_pobj) remodelling_19\NN|NONE
D014859_D004617 NONE warfarin_21\NN|superior|that (r_nsubj) is_22\VBZ|has|Trial|. (l_acomp) superior_23\JJ|warfarin|that (l_xcomp) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|therapy|clopidogrel (l_pobj) events_37\NNS|prevention
C426686_D004617 NONE Ximelagatran_0\NN|.|be|withdrawn|,|was|but (r_nsubjpass) found_9\VBN|NONE (l_xcomp) be_11\VB|.|withdrawn|,|was|Ximelagatran|but (l_acomp) efficient_13\JJ|to (l_prep) in_19\IN|as|as (l_pobj) prevention_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) events_24\NNS|NONE
D000804_D001281 NONE II_7\CD|angiotensin|blocking (r_nummod) drugs_11\NNS|and|enzyme|converting (r_conj) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|inhibitors|. (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE
D014859_D001281 NONE warfarin_21\NN|superior|that (r_nsubj) is_22\VBZ|has|Trial|. (r_ccomp) demonstrated_19\VBN|NONE (l_nsubj) Trial_8\NN|has|is|. (l_compound) Clopidogrel_7\NNP|Atrial|with|(|The|W|study|) (l_compound) Fibrillation_6\NNP|NONE
C055162_D004617 NONE Clopidogrel_7\NNP|Atrial|with|(|The|W|study|) (r_compound) Trial_8\NN|has|is|. (r_nsubj) demonstrated_19\VBN|NONE (l_ccomp) is_22\VBZ|has|Trial|. (l_acomp) superior_23\JJ|warfarin|that (l_xcomp) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|therapy|clopidogrel (l_pobj) events_37\NNS|prevention
C055162_D004617 NONE clopidogrel_28\JJ|in|)|to|therapy (r_dobj) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|therapy|clopidogrel (l_pobj) events_37\NNS|prevention
D001241_D001281 NONE aspirin_30\NN|plus (r_conj) clopidogrel_28\JJ|in|)|to|therapy (r_dobj) platelet_25\NN|NONE (r_xcomp) superior_23\JJ|warfarin|that (r_acomp) is_22\VBZ|has|Trial|. (r_ccomp) demonstrated_19\VBN|NONE (l_nsubj) Trial_8\NN|has|is|. (l_compound) Clopidogrel_7\NNP|Atrial|with|(|The|W|study|) (l_compound) Fibrillation_6\NNP|NONE
D014812_D056486 NONE K_16\NNP|antagonist (r_compound) drugs_18\NNS|NONE (r_pobj) as_14\IN|as|in (r_prep) efficient_13\JJ|to (r_acomp) be_11\VB|.|withdrawn|,|was|Ximelagatran|but (r_xcomp) found_9\VBN|NONE (l_conj) withdrawn_30\VBN|.|be|,|was|Ximelagatran|but (l_prep) because_31\IN|been|has|recently (l_pobj) tests_36\NNS|of (l_compound) function_35\NN|abnormal
C426686_D056486 CID Ximelagatran_0\NN|.|be|withdrawn|,|was|but (r_nsubjpass) found_9\VBN|NONE (l_conj) withdrawn_30\VBN|.|be|,|was|Ximelagatran|but (l_prep) because_31\IN|been|has|recently (l_pobj) tests_36\NNS|of (l_compound) function_35\NN|abnormal
C055162_D001281 NONE Clopidogrel_7\NNP|Atrial|with|(|The|W|study|) (l_compound) Fibrillation_6\NNP|NONE
C055162_D001281 NONE clopidogrel_28\JJ|in|)|to|therapy (r_dobj) platelet_25\NN|NONE (r_xcomp) superior_23\JJ|warfarin|that (r_acomp) is_22\VBZ|has|Trial|. (r_ccomp) demonstrated_19\VBN|NONE (l_nsubj) Trial_8\NN|has|is|. (l_compound) Clopidogrel_7\NNP|Atrial|with|(|The|W|study|) (l_compound) Fibrillation_6\NNP|NONE
C081309_D001281 NONE Irbesartan_10\NNP|NONE (r_pobj) with_9\IN|Atrial|(|The|W|study|)|Clopidogrel (r_prep) Trial_8\NN|has|is|. (l_compound) Clopidogrel_7\NNP|Atrial|with|(|The|W|study|) (l_compound) Fibrillation_6\NNP|NONE
D000809_D020257 NONE Angiotensin_0\NN| (r_npadvmod) converting_2\VBG|and|enzyme|drugs (r_amod) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|inhibitors|. (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE (l_prep) through_17\IN|atrial (l_pobj) remodelling_19\NN|NONE
D001241_D004617 NONE aspirin_30\NN|plus (r_conj) clopidogrel_28\JJ|in|)|to|therapy (r_dobj) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|therapy|clopidogrel (l_pobj) events_37\NNS|prevention
D014859_D020521 NONE warfarin_12\NN|and|risk|,|that|reduces|by (r_nsubj) reduces_13\VBZ|have|data|. (l_dobj) risk_15\NN|and|,|warfarin|that|reduces|by (l_prep) of_16\IN|the (l_pobj) stroke_17\NN|NONE
D014859_D020521 NONE warfarin_8\VB|,|in|Overall|with|,|superior|.|, (r_nsubj) is_9\VBZ|NONE (l_acomp) superior_10\JJ|,|in|Overall|with|,|warfarin|.|, (l_prep) to_11\IN|NONE (l_pobj) aspirin_12\NN|NONE (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_dobj) strokes_15\NNS|NONE
11745184
D004999_D001943 NONE WR-2721_7\NNP|(|)|cisplatin (r_nmod) amifostine_9\NN|NONE (r_pobj) of_4\IN|II|.|:|A|for|E (r_prep) trial_3\NN|NONE (l_prep) for_11\IN|II|.|:|A|of|E (l_pobj) carcinoma_14\NN|NONE
D004999_D001943 NONE amifostine_9\NN|NONE (r_pobj) of_4\IN|II|.|:|A|for|E (r_prep) trial_3\NN|NONE (l_prep) for_11\IN|II|.|:|A|of|E (l_pobj) carcinoma_14\NN|NONE
D004999_D001943 NONE amifostine_10\NN|plus (r_conj) cisplatin_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) combination_6\NN|NONE (r_pobj) of_4\IN|II|A (r_prep) study_3\NN|was|in|regimen|but|, (r_nsubjpass) conducted_12\VBN|NONE (l_prep) in_13\IN|was|regimen|but|study|, (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) carcinoma_19\NN|NONE
D002945_D020258 NONE cisplatin_10\NN|NONE (r_pobj) with_9\IN|been|has|Although|effect (r_prep) observed_8\VBN|toxicities|,|have|.|use (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|,|observed|have|.|use (l_acl) associated_17\VBN|limiting|the (l_prep) with_18\IN|NONE (l_pcomp) cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|(|,|e.g.|,|) (l_conj) neurotoxicity_28\NN|,|and
D002945_D020258 NONE cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|(|,|e.g.|,|) (l_conj) neurotoxicity_28\NN|,|and
D002945_D001943 NONE cisplatin_5\NN|WR|(|) (r_nmod) amifostine_9\NN|NONE (r_pobj) of_4\IN|II|.|:|A|for|E (r_prep) trial_3\NN|NONE (l_prep) for_11\IN|II|.|:|A|of|E (l_pobj) carcinoma_14\NN|NONE
D002945_D001943 NONE Cisplatin_0\NNP|used|activity|. (r_nsubj) has_1\VBZ|NONE (l_advcl) used_6\VBN|Cisplatin|activity|. (l_prep) as_7\IN|when (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|second|line (l_pobj) carcinoma_17\NN|NONE
D002945_D001943 NONE cisplatin_10\NN|NONE (r_pobj) with_9\IN|been|has|Although|effect (r_prep) observed_8\VBN|toxicities|,|have|.|use (r_advcl) limited_31\VBN|NONE (l_dobj) use_33\NN|toxicities|,|observed|have|. (l_prep) as_34\IN|its (l_pobj) treatment_36\NN|NONE (l_prep) for_37\IN|a (l_pobj) carcinoma_39\NN|NONE
D002945_D001943 NONE cisplatin_19\NN|NONE (r_pcomp) with_18\IN|NONE (r_prep) associated_17\VBN|limiting|the (r_acl) toxicities_16\NNS|,|observed|have|.|use (r_nsubj) limited_31\VBN|NONE (l_dobj) use_33\NN|toxicities|,|observed|have|. (l_prep) as_34\IN|its (l_pobj) treatment_36\NN|NONE (l_prep) for_37\IN|a (l_pobj) carcinoma_39\NN|NONE
D002945_D001943 NONE cisplatin_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) combination_6\NN|NONE (r_pobj) of_4\IN|II|A (r_prep) study_3\NN|was|in|regimen|but|, (r_nsubjpass) conducted_12\VBN|NONE (l_prep) in_13\IN|was|regimen|but|study|, (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) carcinoma_19\NN|NONE
D002945_D006311 CID cisplatin_10\NN|NONE (r_pobj) with_9\IN|been|has|Although|effect (r_prep) observed_8\VBN|toxicities|,|have|.|use (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|,|observed|have|.|use (l_acl) associated_17\VBN|limiting|the (l_prep) with_18\IN|NONE (l_pcomp) cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|(|,|e.g.|,|)
D002945_D006311 CID cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|(|,|e.g.|,|)
D002945_D006311 CID cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|.|also|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|.|also|trials (l_nsubjpass) incidence_10\NN|were|that (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|induced|,
D002945_D006311 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|ototoxicity|, (r_amod) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|induced|,
D004999_D006311 NONE amifostine_5\NN|and (r_conj) cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|.|also|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|.|also|trials (l_nsubjpass) incidence_10\NN|were|that (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|induced|,
D004999_D009369 NONE amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|.|effect (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|was|with|. (l_amod) protective_4\JJ|Neither|a|reduced|nor (l_npadvmod) tumor_2\NN|
D004999_D064420 NONE amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|.|effect (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|was|with|. (l_conj) reduced_7\VBN|protective|Neither|a|nor (l_dobj) toxicity_8\NN|to
D002945_D064420 NONE cisplatin_10\NN|NONE (r_pobj) with_9\IN|been|has|Although|effect (r_prep) observed_8\VBN|toxicities|,|have|.|use (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|,|observed|have|.|use
D002945_D064420 NONE cisplatin_19\NN|NONE (r_pcomp) with_18\IN|NONE (r_prep) associated_17\VBN|limiting|the (r_acl) toxicities_16\NNS|,|observed|have|.|use
D002945_D064420 NONE cisplatin_20\VB|NONE (r_acl) amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|.|effect (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|was|with|. (l_conj) reduced_7\VBN|protective|Neither|a|nor (l_dobj) toxicity_8\NN|to
D002945_D009422 CID cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|.|also|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|.|also|trials (l_nsubjpass) incidence_10\NN|were|that (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|induced|, (l_conj) neuropathy_22\NN|,|and
D002945_D009422 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|ototoxicity|, (r_amod) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|induced|, (l_conj) neuropathy_22\NN|,|and
D004999_D007674 NONE amifostine_5\NN|and (r_conj) cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|.|also|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|.|also|trials (l_nsubjpass) incidence_10\NN|were|that (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE
D004999_D009422 NONE amifostine_5\NN|and (r_conj) cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|.|also|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|.|also|trials (l_nsubjpass) incidence_10\NN|were|that (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|induced|, (l_conj) neuropathy_22\NN|,|and
D002945_D007674 CID cisplatin_10\NN|NONE (r_pobj) with_9\IN|been|has|Although|effect (r_prep) observed_8\VBN|toxicities|,|have|.|use (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|,|observed|have|.|use (l_acl) associated_17\VBN|limiting|the (l_prep) with_18\IN|NONE (l_pcomp) cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE
D002945_D007674 CID cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE
D002945_D007674 CID cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|.|also|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|.|also|trials (l_nsubjpass) incidence_10\NN|were|that (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE
D002945_D007674 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|ototoxicity|, (r_amod) nephrotoxicity_17\NN|NONE
D002945_D009369 NONE cisplatin_20\VB|NONE (r_acl) amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|.|effect (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|was|with|. (l_amod) protective_4\JJ|Neither|a|reduced|nor (l_npadvmod) tumor_2\NN|
8410052
D010862_D002544 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|prolonged (r_amod) status_13\NN|NONE (r_pobj) by_8\IN|Infarcts|were|epilepticus|. (r_agent) evoked_7\VBN|NONE (l_nsubjpass) Infarcts_0\NNS|were|by|epilepticus|. (l_prep) in_1\IN|NONE (l_pobj) reticulata_5\NNS|NONE
D010862_D013226 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|prolonged (r_amod) status_13\NN|NONE (r_pobj) by_8\IN|Infarcts|were|epilepticus|. (r_agent) evoked_7\VBN|NONE (l_advmod) epilepticus_14\NN|Infarcts|were|by|.
D019344_D001480 NONE lactate_10\NN|NONE (r_pobj) of_9\IN|at (r_prep) infusion_8\NN|or|by (r_pobj) by_7\IN|.|injury|was (r_agent) produced_6\VBN|NONE (l_nsubjpass) injury_1\NN|.|by|was (l_prep) in_2\IN|Focal (l_pobj) cortex_4\NN|NONE
14657095
D000666_D006333 CID B_20\NNP|NONE (r_pobj) with_18\IN|who|for|failure|after (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|who|for|with|after
D000666_D006333 CID AmB_22\NNP|amphotericin (r_appos) B_20\NNP|NONE (r_pobj) with_18\IN|who|for|failure|after (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|who|for|with|after
D000666_D006333 CID AmB._12\NN|NONE (r_pobj) for_11\IN|after|posaconazole|was (r_prep) substituted_10\VBN|NONE (r_advcl) resolved_6\VBD|and|His|echocardiographic|failure (r_acl) abnormalities_2\NNS|NONE (l_conj) failure_5\NN|resolved|and|His|echocardiographic
D000666_D064420 NONE AmB._12\NN|NONE (r_pobj) of_11\IN|the|rare (r_prep) toxicity_10\NN|to
C101425_D006333 NONE posaconazole_8\NN|for|after|was (r_nsubjpass) substituted_10\VBN|NONE (r_advcl) resolved_6\VBD|and|His|echocardiographic|failure (r_acl) abnormalities_2\NNS|NONE (l_conj) failure_5\NN|resolved|and|His|echocardiographic
D000666_D003047 NONE B_20\NNP|NONE (r_pobj) with_18\IN|who|for|failure|after (r_prep) developed_5\VBD|a (l_prep) for_24\IN|who|failure|with|after (l_pobj) coccidioidomycosis_26\NN|NONE
D000666_D003047 NONE AmB_22\NNP|amphotericin (r_appos) B_20\NNP|NONE (r_pobj) with_18\IN|who|for|failure|after (r_prep) developed_5\VBD|a (l_prep) for_24\IN|who|failure|with|after (l_pobj) coccidioidomycosis_26\NN|NONE
D000666_D002311 CID B_6\NNP|amphotericin (r_compound) therapy_7\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) related_3\VBN|dilated|Reversible|. (r_acl) cardiomyopathy_2\NN|NONE
D000666_D002311 CID B_20\NNP|NONE (r_pobj) with_18\IN|who|for|failure|after (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|who|for|with|after (l_amod) cardiomyopathy_7\NN|dilated|heart
D000666_D002311 CID AmB_22\NNP|amphotericin (r_appos) B_20\NNP|NONE (r_pobj) with_18\IN|who|for|failure|after (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|who|for|with|after (l_amod) cardiomyopathy_7\NN|dilated|heart
2334618
D009020_D013610 NONE morphine_26\NN|NONE (r_compound) infusion_27\NN|the (r_compound) group_28\NN|NONE (r_pobj) in_24\IN|(|ventricular|P|ectopic|) (r_prep) beats_17\NNS|)|and|P|( (r_conj) tachyarrhythmias_7\NNS|NONE
D009020_D018879 CID morphine_26\NN|NONE (r_compound) infusion_27\NN|the (r_compound) group_28\NN|NONE (r_pobj) in_24\IN|(|ventricular|P|ectopic|) (r_prep) beats_17\NNS|)|and|P|(
D002045_D001049 NONE bupivacaine_34\NN|NONE (r_pobj) of_31\IN|continuous|a|extradural (r_prep) infusion_30\NN|NONE (r_dobj) receiving_26\VBG|mean|in|five (r_acl) patients_25\NNS|and|five|receiving|mean (r_conj) patients_10\NNS|NONE (r_pobj) between_8\IN|.|was|incidence (r_prep) compared_7\VBN|NONE (l_nsubjpass) incidence_1\NN|between|.|was (l_prep) of_2\IN|The (l_pobj) apnoea_5\NN|NONE
D009020_D001049 NONE morphine_17\NN|NONE (r_pobj) of_16\IN|i.v.|continuous|a (r_prep) infusion_15\NN|NONE (r_dobj) receiving_11\VBG|and|five|patients|mean (r_acl) patients_10\NNS|NONE (r_pobj) between_8\IN|.|was|incidence (r_prep) compared_7\VBN|NONE (l_nsubjpass) incidence_1\NN|between|.|was (l_prep) of_2\IN|The (l_pobj) apnoea_5\NN|NONE
D009020_D020181 CID morphine_25\NN|a (r_compound) infusion_26\NN|who (r_dobj) had_23\VBD|NONE (r_relcl) patients_21\NNS|NONE (r_pobj) in_20\IN|obstructive|frequently|. (r_prep) occurred_17\VBD|NONE (l_nsubj) obstructive_1\JJ|frequently|in|. (l_appos) P_3\NN|(|Both (l_conj) apnoea_10\NN|and|)|.
D009020_D020182 CID morphine_25\NN|a (r_compound) infusion_26\NN|who (r_dobj) had_23\VBD|NONE (r_relcl) patients_21\NNS|NONE (r_pobj) in_20\IN|obstructive|frequently|. (r_prep) occurred_17\VBD|NONE (l_nsubj) obstructive_1\JJ|frequently|in|. (l_appos) P_3\NN|(|Both (l_conj) apnoea_10\NN|and|)|.
8437969
D002927_D007938 NONE cimetidine_27\NN|hour|while (r_dobj) receiving_23\VBG|,|developed|episodes (r_advcl) recurrent_14\JJ|with|old|.|A|and|history (r_appos) man_4\NN|NONE (l_prep) with_5\IN|recurrent|old|.|A|and|history (l_pobj) leukemia_6\NN|NONE
D002927_D001145 NONE cimetidine_6\NN|NONE (r_compound) administration_7\NN|NONE (r_pobj) to_5\IN|were|temporally|arrhythmias (r_prep) related_4\VBN|and|,|.|,|after|recur (l_nsubjpass) arrhythmias_1\NNS|to|were|temporally
D011899_D001145 NONE ranitidine_18\NN|NONE (r_compound) treatment_19\NN|NONE (r_pobj) during_17\IN|did|not (r_prep) recur_16\VB|and|,|.|,|related|after (r_conj) disappeared_9\VBD|NONE (l_ccomp) related_4\VBN|and|,|.|,|after|recur (l_nsubjpass) arrhythmias_1\NNS|to|were|temporally
D002927_D054138 CID cimetidine_7\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Sinus (r_acl) arrest_1\NN|NONE
D002927_D054138 CID cimetidine_27\NN|hour|while (r_dobj) receiving_23\VBG|,|developed|episodes (r_advcl) recurrent_14\JJ|with|old|.|A|and|history (l_appos) episodes_17\NNS|,|developed|receiving (l_prep) of_18\IN|brief (l_pobj) arrest_21\NN|NONE
D002927_D054138 CID cimetidine_14\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|reported|first|of|the (r_acl) case_5\NN|This|. (l_prep) of_6\IN|associated|reported|first|the (l_pobj) arrest_8\NN|NONE
D002927_D001919 CID cimetidine_7\NN|NONE (r_pobj) of_6\IN|intermittent|intravenous (r_prep) infusions_5\NNS|NONE (r_pobj) of_2\IN|The (r_prep) administration_1\NN|infrequently|with|is|. (r_nsubjpass) associated_10\VBN|NONE (l_prep) with_11\IN|administration|infrequently|is|. (l_pobj) development_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) bradyarrhythmias_15\NNS|NONE
D002927_D006331 NONE cimetidine_27\NN|hour|while (r_dobj) receiving_23\VBG|,|developed|episodes (r_advcl) recurrent_14\JJ|with|old|.|A|and|history (r_appos) man_4\NN|NONE (l_conj) history_9\NN|recurrent|with|old|.|A|and (l_prep) of_10\IN|no (l_pobj) disease_12\NN|NONE
2870085
C047847_D002637 NONE flestolol_6\NN|NONE (r_compound) infusion_7\NN|In|was|.|be|, (r_nsubjpass) found_9\VBN|NONE (l_xcomp) be_11\VB|In|was|.|infusion|, (l_acomp) safe_12\JJ|to (l_conj) effective_14\JJ|and (l_prep) in_15\IN|NONE (l_pcomp) controlling_16\VBG|NONE (l_dobj) pain_18\NN|NONE
C047847_D013610 NONE Flestolol_0\NNP|.|attenuation (r_nsubj) produced_1\VBD|NONE (l_dobj) attenuation_6\NN|.|Flestolol (l_prep) of_7\IN|dependent|a (l_pobj) tachycardia_11\NN|NONE
D007545_D013610 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) tachycardia_11\NN|NONE
C047847_D013617 NONE Flestolol_0\NNP|.|effectively|rate|in (r_nsubj) reduced_2\VBD|NONE (l_prep) in_5\IN|.|Flestolol|effectively|rate (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) tachyarrhythmia_9\NN|NONE
C047847_D000789 NONE flestolol_6\NN|NONE (r_compound) infusion_7\NN|In|was|.|be|, (r_nsubjpass) found_9\VBN|NONE (l_prep) In_0\IN|was|.|infusion|be|, (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) angina_4\NN|NONE
7053303
D002927_D003704 CID cimetidine_10\NN|possibly|to (r_pobj) due_8\IN|of|one (r_amod) case_4\NN|.|There (l_prep) of_5\IN|due|one (l_pobj) dementia_6\NN|NONE
D002927_D003704 CID cimetidine_40\JJ|NONE (r_compound) levels_41\NNS|who|above (r_dobj) had_39\VBD|liver (r_relcl) disease_37\NN|NONE (r_pobj) without_33\IN| (r_prep) patients_32\NNS|NONE (r_pobj) of_30\IN|a (r_prep) group_29\NN|NONE (r_pobj) in_27\IN|(|with|hr|) (r_prep) cimetidine_10\NN|possibly|to (r_pobj) due_8\IN|of|one (r_amod) case_4\NN|.|There (l_prep) of_5\IN|due|one (l_pobj) dementia_6\NN|NONE
D002927_D003704 CID cimetidine_3\NN|alone|high (r_compound) levels_4\NNS|not|.|,|dementia|Thus|do|always (r_nsubj) induce_9\VB|NONE (l_dobj) dementia_10\NN|not|.|,|Thus|do|always|levels
D002927_D008107 NONE cimetidine_10\NN|possibly|to (l_prep) in_27\IN|(|with|hr|) (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) without_33\IN| (l_pobj) disease_37\NN|NONE
D002927_D008107 NONE cimetidine_40\JJ|NONE (r_compound) levels_41\NNS|who|above (r_dobj) had_39\VBD|liver (r_relcl) disease_37\NN|NONE
D002927_D007674 NONE cimetidine_10\NN|possibly|to (l_prep) in_27\IN|(|with|hr|) (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) without_33\IN| (l_pobj) disease_37\NN|NONE
D002927_D007674 NONE cimetidine_40\JJ|NONE (r_compound) levels_41\NNS|who|above (r_dobj) had_39\VBD|liver (r_relcl) disease_37\NN|NONE
12921865
D005680_D012640 NONE acid_21\NN|that|positively (l_appos) receptor_26\NN|the|)|)|(|aminobutyric|GABA(A (l_prep) against_27\IN|NONE (l_pobj) increase_29\NN|NONE (l_prep) in_30\IN|the (l_pobj) sensitivity_31\NN|NONE (l_prep) to_32\IN|NONE (l_pobj) effects_35\NNS|NONE (l_prep) of_36\IN|convulsant|the (l_pobj) cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|(|cocaine|) (l_compound) seizure_44\NN|NONE
D005680_D012640 NONE GABA(A_23\NNP|the|)|)|(|aminobutyric|receptor (r_appos) acid_21\NN|that|positively (l_appos) receptor_26\NN|the|)|)|(|aminobutyric|GABA(A (l_prep) against_27\IN|NONE (l_pobj) increase_29\NN|NONE (l_prep) in_30\IN|the (l_pobj) sensitivity_31\NN|NONE (l_prep) to_32\IN|NONE (l_pobj) effects_35\NNS|NONE (l_prep) of_36\IN|convulsant|the (l_pobj) cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|(|cocaine|) (l_compound) seizure_44\NN|NONE
D005680_D012640 NONE GABA(A_4\NN|)|these|positive (r_nmod) modulators_6\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) All_0\DT|,|expression|inhibited|. (r_nsubj) suppressed_7\VBD|NONE (l_dobj) expression_9\NN|All|,|inhibited|. (l_prep) of_10\IN|the (l_pobj) seizures_12\NNS|NONE
D013256_D001523 NONE steroids_1\NNS|actions|. (r_nsubj) demonstrate_2\VBP|NONE (l_dobj) actions_4\NNS|.|steroids (l_relcl) have_6\VBP|pharmacological (l_dobj) relevance_7\NN|that (l_prep) for_8\IN|NONE (l_pobj) host_10\NN|NONE (l_prep) of_11\IN|a (l_pobj) disorders_15\NNS|NONE
D011280_D012640 NONE Allopregnanolone_0\NN|.|were|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|.|were|Allopregnanolone (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|anticonvulsant|and|) (l_prep) of_52\IN|)|(|effect (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE pregnan-20-one_6\NNP|NONE (r_advmod) 3alpha_2\CD|(|,|)|pregnanolone (r_appos) Allopregnanolone_0\NN|.|were|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|.|were|Allopregnanolone (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|anticonvulsant|and|) (l_prep) of_52\IN|)|(|effect (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE pregnanolone_9\NN|alpha|(|,|) (r_appos) Allopregnanolone_0\NN|.|were|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|.|were|Allopregnanolone (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|anticonvulsant|and|) (l_prep) of_52\IN|)|(|effect (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE pregnan-20-one_15\NNP|ganaxolone|and (r_parataxis) pregnanolone_9\NN|alpha|(|,|) (r_appos) Allopregnanolone_0\NN|.|were|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|.|were|Allopregnanolone (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|anticonvulsant|and|) (l_prep) of_52\IN|)|(|effect (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE allopregnanolone_24\NN|NONE (r_pobj) of_23\IN|a|synthetic (r_prep) derivative_22\NN|)|( (r_appos) ganaxolone_18\NN|and|pregnanone (r_conj) pregnanolone_9\NN|alpha|(|,|) (r_appos) Allopregnanolone_0\NN|.|were|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|.|were|Allopregnanolone (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|anticonvulsant|and|) (l_prep) of_52\IN|)|(|effect (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE allopregnanolone_16\NN|whereas|development (r_nsubj) inhibited_19\VBD|All|,|expression|. (r_advcl) suppressed_7\VBD|NONE (l_dobj) expression_9\NN|All|,|inhibited|. (l_prep) of_10\IN|the (l_pobj) seizures_12\NNS|NONE
C105051_D012640 NONE ganaxolone_18\NN|and|pregnanone (r_conj) pregnanolone_9\NN|alpha|(|,|) (r_appos) Allopregnanolone_0\NN|.|were|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|.|were|Allopregnanolone (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|anticonvulsant|and|) (l_prep) of_52\IN|)|(|effect (l_pobj) seizures_56\NNS|NONE
C105051_D012640 NONE pregnan-20-one_31\NNP|NONE (r_appos) 3alpha_25\CD|NONE (r_appos) allopregnanolone_24\NN|NONE (r_pobj) of_23\IN|a|synthetic (r_prep) derivative_22\NN|)|( (r_appos) ganaxolone_18\NN|and|pregnanone (r_conj) pregnanolone_9\NN|alpha|(|,|) (r_appos) Allopregnanolone_0\NN|.|were|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|.|were|Allopregnanolone (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|anticonvulsant|and|) (l_prep) of_52\IN|)|(|effect (l_pobj) seizures_56\NNS|NONE
C105051_D012640 NONE ganaxolone_18\NN|and|only (r_conj) allopregnanolone_16\NN|whereas|development (r_nsubj) inhibited_19\VBD|All|,|expression|. (r_advcl) suppressed_7\VBD|NONE (l_dobj) expression_9\NN|All|,|inhibited|. (l_prep) of_10\IN|the (l_pobj) seizures_12\NNS|NONE
D013256_D009422 NONE steroids_1\NNS|actions|. (r_nsubj) demonstrate_2\VBP|NONE (l_dobj) actions_4\NNS|.|steroids (l_relcl) have_6\VBP|pharmacological (l_dobj) relevance_7\NN|that (l_prep) for_8\IN|NONE (l_pobj) host_10\NN|NONE (l_prep) of_11\IN|a (l_pobj) disorders_15\NNS|NONE
D013256_D012640 NONE steroids_4\NNS|NONE (l_prep) against_5\IN|neuroactive (l_pobj) seizures_9\NNS|NONE
D013256_D012640 NONE steroid_13\NN|to (l_relcl) modulate_16\VBP|synthetic|two|one|endogenous|neuroactive (l_dobj) acid_21\NN|that|positively (l_appos) receptor_26\NN|the|)|)|(|aminobutyric|GABA(A (l_prep) against_27\IN|NONE (l_pobj) increase_29\NN|NONE (l_prep) in_30\IN|the (l_pobj) sensitivity_31\NN|NONE (l_prep) to_32\IN|NONE (l_pobj) effects_35\NNS|NONE (l_prep) of_36\IN|convulsant|the (l_pobj) cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|(|cocaine|) (l_compound) seizure_44\NN|NONE
D003042_D012640 CID cocaine_6\NN|kindled| (r_compound) seizures_9\NNS|NONE
D003042_D012640 CID cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|(|cocaine|) (l_compound) seizure_44\NN|NONE
D003042_D012640 CID cocaine_41\NN|repeated|(|)|kindling (r_compound) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|(|cocaine|) (l_compound) seizure_44\NN|NONE
D003042_D012640 CID cocaine_53\NN| (r_npadvmod) kindled_55\VBN|in (r_amod) seizures_56\NNS|NONE
D003042_D012640 CID cocaine_10\NN|NONE (r_pobj) of_7\IN|daily (r_prep) administration_6\NN|NONE (r_pobj) by_4\IN|were|Kindled|.|for (r_agent) induced_3\VBN|NONE (l_csubjpass) Kindled_0\VBN|were|by|.|for (l_dobj) seizures_1\NNS|NONE
16904497
D014221_D011128 NONE triamcinolone_16\NN|NONE (r_pobj) of_15\IN|epidural (r_prep) injection_14\NN|NONE (r_pobj) by_12\IN|possibly (r_agent) caused_11\VBN|of|a (r_acl) report_5\NN|case|. (l_prep) of_6\IN|a|caused (l_pobj) syndrome_9\NN|NONE
D002045_D011128 CID bupivacaine_18\NN|and (r_conj) triamcinolone_16\NN|NONE (r_pobj) of_15\IN|epidural (r_prep) injection_14\NN|NONE (r_pobj) by_12\IN|possibly (r_agent) caused_11\VBN|of|a (r_acl) report_5\NN|case|. (l_prep) of_6\IN|a|caused (l_pobj) syndrome_9\NN|NONE
D013256_D010146 NONE steroid_16\NN|epidural (r_compound) injection_17\NN|NONE (r_pobj) for_14\IN|was|woman|. (r_prep) scheduled_13\VBN|NONE (l_nsubjpass) woman_4\NN|for|was|. (l_prep) with_5\IN|old|A (l_pobj) pain_11\NN|NONE
D013256_D011128 NONE steroid_5\NN|epidural (r_compound) injection_6\NN|NONE (r_pobj) after_3\IN|equina|.|report|: (r_prep) syndrome_2\NN|NONE
D013256_D009422 NONE steroid_10\NN|epidural (r_compound) injections_11\NNS|NONE (r_pobj) after_8\IN|continued|for (r_prep) vigilance_4\NN|Clinical|and (l_prep) for_5\IN|continued|after (l_pobj) deterioration_7\NN|NONE
D013256_D011843 NONE steroid_11\NN|medications|,|epidural (r_compound) injections_12\NNS|physical|, (r_conj) therapy_8\NN|.|methods (r_attr) are_6\VBP|NONE (l_nsubj) methods_2\NNS|therapy|. (l_prep) of_3\IN|Conventional|treatment (l_pobj) radiculopathy_5\NN|NONE
D013256_D017116 NONE steroid_16\NN|epidural (r_compound) injection_17\NN|NONE (r_pobj) for_14\IN|was|woman|. (r_prep) scheduled_13\VBN|NONE (l_nsubjpass) woman_4\NN|for|was|. (l_prep) with_5\IN|old|A (l_pobj) pain_11\NN|NONE
12596116
D015282_D000860 NONE Octreotide_0\NNP|.||hypoxemia (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypoxemia_3\NN|.||Octreotide
D015282_D006976 CID Octreotide_0\NNP|.||hypoxemia (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypoxemia_3\NN|.||Octreotide (l_conj) hypertension_6\NN|and|in
D015282_D006976 CID octreotide_10\NN|hypertension|,|after|.|enhance (r_advmod) developed_2\VBD|NONE (l_nsubj) hypertension_1\NN|,|after|.|octreotide|enhance
D015282_D005402 NONE octreotide_10\NN|hypertension|,|after|.|enhance (r_advmod) developed_2\VBD|NONE (l_advcl) enhance_13\VB|hypertension|,|after|.|octreotide (l_dobj) resolution_14\NN|to (l_prep) of_15\IN|NONE (l_pobj) fistula_17\NN|NONE
16337777
D010862_D004833 CID pilocarpine_49\NN|the|of (r_amod) model_50\NN|NONE (l_prep) of_51\IN|the|pilocarpine (l_pobj) epilepsy_54\NN|NONE
D010862_D013226 NONE pilocarpine_49\NN|the|of (r_amod) model_50\NN|NONE (r_pobj) of_47\IN|the|chronic (r_prep) phase_46\NN|NONE (r_pobj) in_43\IN|abnormalities|to (r_prep) provoke_18\VB|NONE (r_xcomp) sufficient_16\JJ|generation|whether|would (r_acomp) be_15\VB|In|.|,|we (l_nsubj) generation_8\NN|whether|sufficient|would (l_prep) during_11\IN|of|increased (l_pobj) epilepticus_13\NN|NONE
D010862_D004827 NONE pilocarpine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|experimental|the|of (r_acl) model_7\NN|NONE (l_prep) of_8\IN|induced|experimental|the (l_pobj) epilepsy_9\NN|NONE
18503483
D016559_D020968 CID tacrolimus_2\NN| (r_npadvmod) associated_4\VBN|brachial (r_amod) neuritis_6\NN|NONE
C107135_D020968 NONE everolimus_10\NN|NONE (r_pobj) to_9\TO|in (r_prep) conversion_8\NN|NONE (r_pobj) after_7\IN||of|.|report (r_prep) Recovery_0\NN|NONE (l_prep) of_1\IN||.|after|report (l_pobj) neuritis_6\NN|NONE
11334364
D000082_D066126 NONE acetaminophen_13\RB| (r_advmod) induced_15\VBN|toxicity|, (r_amod) nephrotoxicity_16\NN|NONE (l_conj) toxicity_22\NN|induced|, (l_conj) cardiotoxicity_27\NN|lung|and|induced
D000082_D066126 NONE acetaminophen_16\RB|to|toxicity (r_advmod) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (l_dobj) cardiotoxicity_31\NN|NONE
D000082_D066126 NONE AAP)-induced_18\VBN|,|amiodarone|( (r_compound) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung (r_nmod) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (l_dobj) cardiotoxicity_31\NN|NONE
D000638_D066126 NONE amiodarone_18\NN| (r_npadvmod) induced_20\VBN|lung|and|cardiotoxicity (r_amod) toxicity_22\NN|induced|, (l_conj) cardiotoxicity_27\NN|lung|and|induced
D000638_D066126 NONE amiodarone_21\NN|,|AAP)induced|( (r_appos) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung (r_nmod) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (l_dobj) cardiotoxicity_31\NN|NONE
D000638_D066126 NONE AMI)-induced_23\JJ|and|doxorubicin|,|nephrotoxicity|(|lung (r_amod) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (l_dobj) cardiotoxicity_31\NN|NONE
D000638_D007674 NONE amiodarone_18\NN| (r_npadvmod) induced_20\VBN|lung|and|cardiotoxicity (r_amod) toxicity_22\NN|induced|, (r_conj) nephrotoxicity_16\NN|NONE
D000638_D007674 NONE amiodarone_21\NN|,|AAP)induced|( (r_appos) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
D000638_D007674 NONE AMI)-induced_23\JJ|and|doxorubicin|,|nephrotoxicity|(|lung (r_amod) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
C511402_D009336 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|lung|and|induced (r_conj) toxicity_22\NN|induced|, (r_conj) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
C511402_D009336 NONE GSPE_31\NNP|NONE (r_pobj) by_30\IN|effectively|was|which (r_agent) blocked_29\VBN|in (r_relcl) necrosis_20\NN|NONE
C511402_D008171 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|lung|and|induced (r_conj) toxicity_22\NN|induced|,
C511402_D008171 NONE extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|study|. (l_acl) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen
C511402_D008171 NONE GSPE_12\NNP|)|proanthocyanidin|(|IH (r_appos) extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|study|. (l_acl) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen
D000082_D007674 CID acetaminophen_13\RB| (r_advmod) induced_15\VBN|toxicity|, (r_amod) nephrotoxicity_16\NN|NONE
D000082_D007674 CID acetaminophen_16\RB|to|toxicity (r_advmod) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
D000082_D007674 CID AAP)-induced_18\VBN|,|amiodarone|( (r_compound) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
D000638_D009336 CID amiodarone_18\NN| (r_npadvmod) induced_20\VBN|lung|and|cardiotoxicity (r_amod) toxicity_22\NN|induced|, (r_conj) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
D000638_D009336 CID AMI_11\NNP|, (r_conj) AAP_9\NNP|the|all|as|, (r_appos) drugs_4\NNS|death|.|,|in|Interestingly (r_nsubj) induced_14\VBD|NONE (l_prep) in_17\IN|death|.|,|drugs|Interestingly (l_pobj) addition_18\NN|NONE (l_prep) to_19\IN|NONE (l_pobj) necrosis_20\NN|NONE
C511402_D017695 NONE GSPE_30\NNP|than (r_compound) preexposure_31\NN|NONE (r_pobj) of_29\IN|the (r_prep) absence_28\NN|NONE (r_pobj) in_26\IN|a|by|of (r_prep) variety_17\NN|NONE (r_pobj) with_15\IN|massive|tissue (r_prep) damage_14\NN|NONE
D000638_D008171 CID amiodarone_18\NN| (r_npadvmod) induced_20\VBN|lung|and|cardiotoxicity (r_amod) toxicity_22\NN|induced|,
D000638_D008171 CID amiodarone_21\NN|,|AAP)induced|( (r_appos) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung (r_nmod) toxicity_25\NN|to|acetaminophen
D000638_D008171 CID AMI)-induced_23\JJ|and|doxorubicin|,|nephrotoxicity|(|lung (r_amod) toxicity_25\NN|to|acetaminophen
D004317_D007674 NONE doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|lung|and|induced (r_conj) toxicity_22\NN|induced|, (r_conj) nephrotoxicity_16\NN|NONE
D004317_D007674 NONE doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (r_conj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
D004317_D007674 NONE DOX)-induced_30\JJ|(|in (r_amod) cardiotoxicity_31\NN|NONE (r_dobj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (r_conj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
D000082_D009336 CID acetaminophen_13\RB| (r_advmod) induced_15\VBN|toxicity|, (r_amod) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
D000082_D009336 CID AAP_9\NNP|the|all|as|, (r_appos) drugs_4\NNS|death|.|,|in|Interestingly (r_nsubj) induced_14\VBD|NONE (l_prep) in_17\IN|death|.|,|drugs|Interestingly (l_pobj) addition_18\NN|NONE (l_prep) to_19\IN|NONE (l_pobj) necrosis_20\NN|NONE
C511402_D007674 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|lung|and|induced (r_conj) toxicity_22\NN|induced|, (r_conj) nephrotoxicity_16\NN|NONE
C511402_D007674 NONE extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|study|. (l_acl) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
C511402_D007674 NONE GSPE_12\NNP|)|proanthocyanidin|(|IH (r_appos) extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|study|. (l_acl) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung
D004317_D008171 NONE doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|lung|and|induced (r_conj) toxicity_22\NN|induced|,
D004317_D008171 NONE doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (r_conj) toxicity_25\NN|to|acetaminophen
D004317_D008171 NONE DOX)-induced_30\JJ|(|in (r_amod) cardiotoxicity_31\NN|NONE (r_dobj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (r_conj) toxicity_25\NN|to|acetaminophen
D000082_D008171 NONE acetaminophen_13\RB| (r_advmod) induced_15\VBN|toxicity|, (r_amod) nephrotoxicity_16\NN|NONE (l_conj) toxicity_22\NN|induced|,
D000082_D008171 NONE acetaminophen_16\RB|to|toxicity (r_advmod) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen
D000082_D008171 NONE AAP)-induced_18\VBN|,|amiodarone|( (r_compound) nephrotoxicity_19\NN|and|doxorubicin|AMI)induced|,|(|lung (r_nmod) toxicity_25\NN|to|acetaminophen
D004317_D009336 CID doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|lung|and|induced (r_conj) toxicity_22\NN|induced|, (r_conj) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
D004317_D009336 CID DOX_13\NNP|and (r_conj) AMI_11\NNP|, (r_conj) AAP_9\NNP|the|all|as|, (r_appos) drugs_4\NNS|death|.|,|in|Interestingly (r_nsubj) induced_14\VBD|NONE (l_prep) in_17\IN|death|.|,|drugs|Interestingly (l_pobj) addition_18\NN|NONE (l_prep) to_19\IN|NONE (l_pobj) necrosis_20\NN|NONE
C511402_D066126 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|lung|and|induced
C511402_D066126 NONE extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|study|. (l_acl) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (l_dobj) cardiotoxicity_31\NN|NONE
C511402_D066126 NONE GSPE_12\NNP|)|proanthocyanidin|(|IH (r_appos) extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|study|. (l_acl) prevent_15\VB|the|of (l_dobj) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (l_dobj) cardiotoxicity_31\NN|NONE
D004317_D066126 CID doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|lung|and|induced
D004317_D066126 CID doxorubicin_28\NN|and|AMI)induced|,|nephrotoxicity|(|lung (l_dobj) cardiotoxicity_31\NN|NONE
D004317_D066126 CID DOX)-induced_30\JJ|(|in (r_amod) cardiotoxicity_31\NN|NONE
19346865
D008795_D007239 NONE metronidazole_4\NN|)|They|dosage|had|.|treat|been|( (r_dobj) taking_3\VBG|NONE (l_advcl) treat_23\VB|)|They|dosage|metronidazole|had|.|been|( (l_dobj) infection_25\NN|to
D008795_D001927 CID metronidazole_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) encephalopathy_8\NN|NONE (r_pobj) in_4\IN|:|.|colliculus|inferior|findings|Reversible (r_prep) lesion_3\NN|NONE
D008795_D001927 CID metronidazole_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) encephalopathy_8\NN|NONE
D008795_D001927 CID metronidazole_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) encephalopathy_12\NN|NONE (r_pobj) in_8\IN|inferior|reversible|colliculus (r_prep) lesions_7\NNS|to|,|focus
D008795_D001927 CID metronidazole_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) encephalopathy_12\NN|NONE
D008795_D001927 CID metronidazole_20\NN| (r_npadvmod) induced_22\VBN|;|years|(|range (r_amod) encephalopathy_23\NN|NONE
D008795_D001927 CID metronidazole_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) encephalopathy_14\NN|NONE (r_pobj) for_10\IN|the (r_prep) characteristic_9\NN|NONE (r_pobj) as_7\IN|could|next|be|,|lesions|. (r_prep) considered_6\VBN|NONE (l_nsubjpass) lesions_3\NNS|could|next|as|be|,|.
D008795_D001927 CID metronidazole_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) encephalopathy_14\NN|NONE
3970039
D003520_D002277 CID Cyclophosphamide_0\NNP|NONE (r_compound) therapy_1\NN|.|risk (r_nsubj) increases_2\VBZ|NONE (l_dobj) risk_4\NN|therapy|. (l_prep) of_5\IN|the (l_pobj) carcinoma_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) bladder_9\NN|NONE
D000477_D015470 CID agents_4\NNS|NONE (r_pobj) with_2\IN|Patients (r_prep) treated_1\VBN|risk|and|,|associated (r_csubj) have_5\VBP|NONE (l_dobj) risk_8\NN|and|,|associated|treated (l_prep) of_9\IN|increased|an (l_pobj) development_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
D000477_D015470 CID agents_19\NNS|.|with|are (r_nsubjpass) associated_23\VBN|risk|and|,|treated (r_conj) have_5\VBP|NONE (l_dobj) risk_8\NN|and|,|associated|treated (l_prep) of_9\IN|increased|an (l_pobj) development_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
D000477_D009369 NONE agents_31\NNS|,|,|immunosuppressive (r_appos) drugs_27\NNS|NONE (r_pobj) of_25\IN|the|in (r_prep) use_24\NN|.|for|is|,|be|should (r_nsubjpass) reserved_41\VBN|Data|being|,|still|and|are (r_conj) collected_14\VBN|NONE (l_nsubjpass) Data_0\NNS|being|,|still|reserved|and|are (l_prep) on_1\IN|NONE (l_pobj) risk_5\NN|NONE (l_prep) of_6\IN|possible|the|increased (l_pobj) malignancy_7\NN|NONE
D003520_D001172 NONE cyclophosphamide_17\NN|and (r_conj) azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|and|several|of (r_acl) studies_7\NNS|have|increased|There|. (l_prep) of_8\IN|term|and|treated|several (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) arthritis_12\NN|NONE
D000477_D001172 NONE agents_31\NNS|,|,|immunosuppressive (r_appos) drugs_27\NNS|NONE (r_pobj) of_25\IN|the|in (r_prep) use_24\NN|.|for|is|,|be|should (r_nsubjpass) reserved_41\VBN|Data|being|,|still|and|are (r_conj) collected_14\VBN|NONE (l_nsubjpass) Data_0\NNS|being|,|still|reserved|and|are (l_prep) on_1\IN|NONE (l_pobj) risk_5\NN|NONE (l_prep) of_6\IN|possible|the|increased (l_pobj) malignancy_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) arthritis_10\NN|NONE
D000477_D001172 NONE agents_31\NNS|,|,|immunosuppressive (r_appos) drugs_27\NNS|NONE (r_pobj) of_25\IN|the|in (r_prep) use_24\NN|.|for|is|,|be|should (l_prep) in_33\IN|of|the (l_pobj) treatment_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) arthritis_38\NN|NONE
D003520_D009369 NONE cyclophosphamide_17\NN|and (r_conj) azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|and|several|of (r_acl) studies_7\NNS|have|increased|There|. (r_attr) been_2\VBN|NONE (l_conj) increased_29\VBN|have|There|.|studies (l_nsubjpass) incidence_20\NN|not|is (l_prep) of_21\IN|the (l_pobj) most_22\JJS|NONE (l_prep) of_23\IN|NONE (l_pobj) cancers_26\NNS|NONE
D003520_D001749 CID Cyclophosphamide_0\NNP|NONE (r_compound) therapy_1\NN|.|risk (r_nsubj) increases_2\VBZ|NONE (l_dobj) risk_4\NN|therapy|. (l_prep) of_5\IN|the (l_pobj) carcinoma_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) bladder_9\NN|NONE
D000477_D008228 CID agents_4\NNS|NONE (r_pobj) with_2\IN|Patients (r_prep) treated_1\VBN|risk|and|,|associated (r_csubj) have_5\VBP|NONE (l_conj) associated_23\VBN|risk|and|,|treated (l_prep) with_24\IN|.|agents|are (l_pobj) development_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) lymphoma_32\NN|NONE
D000477_D008228 CID agents_19\NNS|.|with|are (r_nsubjpass) associated_23\VBN|risk|and|,|treated (l_prep) with_24\IN|.|agents|are (l_pobj) development_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) lymphoma_32\NN|NONE
D001379_D009369 NONE azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|and|several|of (r_acl) studies_7\NNS|have|increased|There|. (r_attr) been_2\VBN|NONE (l_conj) increased_29\VBN|have|There|.|studies (l_nsubjpass) incidence_20\NN|not|is (l_prep) of_21\IN|the (l_pobj) most_22\JJS|NONE (l_prep) of_23\IN|NONE (l_pobj) cancers_26\NNS|NONE
D001379_D001172 NONE azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|and|several|of (r_acl) studies_7\NNS|have|increased|There|. (l_prep) of_8\IN|term|and|treated|several (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) arthritis_12\NN|NONE
D001379_D008228 CID azathioprine_21\NN|both|alkylating|and (r_conj) agents_19\NNS|.|with|are (r_nsubjpass) associated_23\VBN|risk|and|,|treated (l_prep) with_24\IN|.|agents|are (l_pobj) development_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) lymphoma_32\NN|NONE
D001379_D015470 NONE azathioprine_21\NN|both|alkylating|and (r_conj) agents_19\NNS|.|with|are (r_nsubjpass) associated_23\VBN|risk|and|,|treated (r_conj) have_5\VBP|NONE (l_dobj) risk_8\NN|and|,|associated|treated (l_prep) of_9\IN|increased|an (l_pobj) development_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
2266990
D008454_D001068 CID mazindol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) attributable_2\JJ|Side (r_amod) effects_1\NNS|appetite (r_nsubj) included_5\VBN|in|was|;|.|dosage (l_dobj) appetite_7\NN|effects
D008454_D001068 CID mazindol_35\NN|NONE (r_amod) dosage_36\NN|in|included|was|;|. (r_nsubjpass) reduced_38\VBN|NONE (l_ccomp) included_5\VBN|in|was|;|.|dosage (l_dobj) appetite_7\NN|effects
D008454_D020388 NONE mazindol_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) dystrophy_10\NN|NONE
D008454_D020388 NONE mazindol_7\NN|NONE (r_pobj) of_6\IN|controlled|a|month|inhibitor|,|, (r_prep) trial_5\NN|.|in|We (r_dobj) conducted_1\VBD|NONE (l_prep) in_16\IN|trial|.|We (l_pobj) boys_18\NNS|NONE (l_prep) with_19\IN| (l_pobj) dystrophy_21\NN|NONE
D008454_D020388 NONE Mazindol_0\JJ|NONE (r_compound) doses_1\NNS|.|not|progression (r_nsubj) slow_3\VBP|NONE (l_dobj) progression_5\NN|doses|.|not (l_prep) of_6\IN|the (l_pobj) weakness_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) dystrophy_10\NN|NONE
D008454_D014987 CID mazindol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) attributable_2\JJ|Side (r_amod) effects_1\NNS|appetite (r_nsubj) included_5\VBN|in|was|;|.|dosage (l_dobj) appetite_7\NN|effects (l_appos) mouth_14\NN|,|)|%|decreased|(|change|,
D008454_D014987 CID mazindol_35\NN|NONE (r_amod) dosage_36\NN|in|included|was|;|. (r_nsubjpass) reduced_38\VBN|NONE (l_ccomp) included_5\VBN|in|was|;|.|dosage (l_dobj) appetite_7\NN|effects (l_appos) mouth_14\NN|,|)|%|decreased|(|change|,
D008454_D018908 NONE Mazindol_0\JJ|NONE (r_compound) doses_1\NNS|.|not|progression (r_nsubj) slow_3\VBP|NONE (l_dobj) progression_5\NN|doses|.|not (l_prep) of_6\IN|the (l_pobj) weakness_7\NN|NONE
D008454_D012817 CID mazindol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) attributable_2\JJ|Side (r_amod) effects_1\NNS|appetite (r_nsubj) included_5\VBN|in|was|;|.|dosage (l_dobj) appetite_7\NN|effects (l_appos) change_21\NN|,|)|mouth|%|decreased|(|, (l_conj) symptoms_29\NNS|%|and|,|)|(|behavioral
D008454_D012817 CID mazindol_35\NN|NONE (r_amod) dosage_36\NN|in|included|was|;|. (r_nsubjpass) reduced_38\VBN|NONE (l_ccomp) included_5\VBN|in|was|;|.|dosage (l_dobj) appetite_7\NN|effects (l_appos) change_21\NN|,|)|mouth|%|decreased|(|, (l_conj) symptoms_29\NNS|%|and|,|)|(|behavioral
6861444
D009638_D006973 CID noradrenaline_3\NN|NONE (r_pobj) of_2\IN|Intrarenal (r_prep) infusion_1\NN|at|hypertension|. (r_nsubj) caused_4\VBD|NONE (l_dobj) hypertension_5\NN|infusion|at|.
D009638_D006973 CID noradrenaline_8\NN|intrarenal|chronic (r_amod) infusion_9\NN|NONE (r_pobj) after_5\IN|NONE (r_prep) hypertension_4\NN|by|that|is
D009638_D006973 CID noradrenaline_18\NN|NONE (r_dobj) circulating_17\VBG|NONE (r_pcomp) of_16\IN|higher (r_prep) levels_15\NNS|and|by (r_pobj) by_12\IN|hypertension|that|is (r_agent) produced_11\VBN|results|. (l_nsubjpass) hypertension_4\NN|by|that|is
137340
D010830_D006948 NONE physostigmine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) attenuated_10\VBN|by|was|and|hyperactivity|. (r_conj) potentiated_6\VBN|NONE (l_nsubjpass) hyperactivity_4\NN|by|was|and|attenuated|.
D012701_D006948 NONE serotonin_22\NN|a (r_compound) depletor_23\NN|change|,|pretreatment|On|,|.|, (r_nsubj) caused_25\VBD|NONE (l_dobj) change_28\NN|,|pretreatment|On|,|.|depletor|, (l_prep) in_29\IN|significant|no (l_pobj) hyperactivity_31\NN|NONE
D009388_D006948 NONE neostigmine_6\NN|both|and|penetrate|, (r_conj) methscopolamine_4\NN|.|,|,|effect|In (r_nsubj) had_18\VBD|NONE (l_dobj) effect_20\NN|.|,|,|methscopolamine|In (l_prep) on_21\IN|no (l_pobj) hyperactivity_23\NN|NONE
D012601_D006948 CID scopolamine_8\NN|NONE (r_pobj) by_7\IN|was|and|attenuated|hyperactivity|. (r_agent) potentiated_6\VBN|NONE (l_nsubjpass) hyperactivity_4\NN|by|was|and|attenuated|.
D010134_D006948 NONE chlorophenylalamine_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) pretreatment_5\NN|change|,|On|,|.|depletor|, (r_nsubj) caused_25\VBD|NONE (l_dobj) change_28\NN|,|pretreatment|On|,|.|depletor|, (l_prep) in_29\IN|significant|no (l_pobj) hyperactivity_31\NN|NONE
D019832_D006948 NONE methscopolamine_4\NN|.|,|,|effect|In (r_nsubj) had_18\VBD|NONE (l_dobj) effect_20\NN|.|,|,|methscopolamine|In (l_prep) on_21\IN|no (l_pobj) hyperactivity_23\NN|NONE
D009020_D006948 CID morphine_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) increase_8\NN|NONE (l_prep) in_9\IN|induced (l_pobj) activity_11\NN|NONE
D009020_D006948 CID morphine_7\NN| (r_npadvmod) induced_9\VBN|the|in (r_amod) increase_10\NN|NONE (l_prep) in_11\IN|induced|the (l_pobj) activity_13\NN|NONE
D009020_D006948 CID morphine_7\NN| (r_compound) HC1_9\NNP|NONE (r_pobj) of_6\IN| (r_prep) mg/kg_5\NN|NONE (r_pobj) of_3\IN|subcutaneous|The (r_prep) administration_2\NN|.|increase (r_nsubj) produced_10\VBD|NONE (l_dobj) increase_13\NN|administration|. (l_prep) in_14\IN|marked|a (l_pobj) activity_16\NN|NONE
D009020_D006948 CID morphine_1\NN| (r_npadvmod) induced_3\VBN|The (r_amod) hyperactivity_4\NN|by|was|and|attenuated|.
D009020_D006948 CID morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) produced_24\VBN|the (r_acl) hyperactivity_23\NN|NONE
227508
D008750_D007022 CID methyldopa_8\NN|NONE (r_pobj) of_3\IN|hypotensive|The (r_prep) effect_2\NN|partially|.|by|was|also (l_amod) hypotensive_1\JJ|The|of
D003000_D006973 NONE clonidine_17\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) produced_14\VBN|blood|and|rate (r_acl) pressure_10\NN|NONE (r_pobj) in_8\IN|the (r_prep) decrease_7\NN|.|In|,|hypertensive|,|inhibited (r_dobj) rats_5\NNS|NONE (l_amod) hypertensive_4\JJ|.|In|,|,|decrease|inhibited
D003000_D006973 NONE clonidine_7\NN|membranes (r_preconj) In_0\IN|,|,|binding|and|not|influence|did (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
D003000_D006973 NONE clonidine_42\NN| (r_npadvmod) suppressible_44\NN|of (r_amod) binding_45\NN|.|not|)|naloxone|did (r_dobj) influence_41\VB|,|,|binding|and|not|In|did (r_conj) influence_18\VB|NONE (l_prep) In_0\IN|,|,|binding|and|not|influence|did (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
-1_D006973 NONE nalozone_31\NN|NONE (r_pobj) by_30\IN|NONE (r_agent) reversed_29\VBN|,|micrograms|was|mg/kg|,|or (r_conj) inhibited_27\VBN|.|In|,|hypertensive|,|decrease (r_conj) rats_5\NNS|NONE (l_amod) hypertensive_4\JJ|.|In|,|,|decrease|inhibited
-1_D006973 NONE 3H]-naloxone_23\CD|NONE (r_pobj) of_21\IN|stereoselective (r_prep) binding_20\NN|,|,|and|not|In|influence|did (r_dobj) influence_18\VB|NONE (l_prep) In_0\IN|,|,|binding|and|not|influence|did (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
-1_D006973 NONE 3H]-dihydroergocryptine_48\CD||( (r_nummod) nM_51\NNP|NONE (r_pobj) of_46\IN|suppressible (r_prep) binding_45\NN|.|not|)|naloxone|did (r_dobj) influence_41\VB|,|,|binding|and|not|In|did (r_conj) influence_18\VB|NONE (l_prep) In_0\IN|,|,|binding|and|not|influence|did (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
D009270_D006973 NONE naloxone_30\NN|.|not|binding|)|did (r_nsubj) influence_41\VB|,|,|binding|and|not|In|did (r_conj) influence_18\VB|NONE (l_prep) In_0\IN|,|,|binding|and|not|influence|did (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
D009270_D007022 NONE naloxone_14\NN|NONE (r_pobj) by_13\IN|partially|.|was|effect|also (r_agent) reversed_12\VBN|NONE (l_nsubjpass) effect_2\NN|partially|.|by|was|also (l_amod) hypotensive_1\JJ|The|of
16680561
C476217_D006261 CID cinacalcet_15\NN|NONE (r_pobj) with_14\IN|%|desipramine|when (r_prep) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|following|adverse (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|frequent|been|.|have|nausea|for|, (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|, (l_conj) headache_31\NN|and|(|)
C476217_D006261 CID cinacalcet_43\NN|or|either (r_conj) desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|reported|frequent|been|.|have|nausea|, (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|, (l_conj) headache_31\NN|and|(|)
C476217_D009325 CID cinacalcet_15\NN|NONE (r_pobj) with_14\IN|%|desipramine|when (r_prep) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|following|adverse (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|frequent|been|.|have|nausea|for|, (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|,
C476217_D009325 CID cinacalcet_43\NN|or|either (r_conj) desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|reported|frequent|been|.|have|nausea|, (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|,
D003891_D006261 CID desipramine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) treatment_6\NN|NONE (r_dobj) following_5\VBG|alone|adverse (r_acl) events_4\NNS|subjects (r_dobj) reported_2\VBD|frequent|been|.|have|nausea|for|, (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|, (l_conj) headache_31\NN|and|(|)
D003891_D006261 CID desipramine_13\NN|%|with|when (r_dobj) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|following|adverse (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|frequent|been|.|have|nausea|for|, (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|, (l_conj) headache_31\NN|and|(|)
D003891_D006261 CID desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|reported|frequent|been|.|have|nausea|, (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|, (l_conj) headache_31\NN|and|(|)
D003891_D009325 CID desipramine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) treatment_6\NN|NONE (r_dobj) following_5\VBG|alone|adverse (r_acl) events_4\NNS|subjects (r_dobj) reported_2\VBD|frequent|been|.|have|nausea|for|, (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|,
D003891_D009325 CID desipramine_13\NN|%|with|when (r_dobj) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|following|adverse (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|frequent|been|.|have|nausea|for|, (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|,
D003891_D009325 CID desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|reported|frequent|been|.|have|nausea|, (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|reported|frequent|been|.|have|for|,
7881871
D011692_D011507 CID aminonucleoside_12\NN|puromycin|PAN)induced|( (r_nmod) nephropathy_15\NN|NONE (r_pobj) of_9\IN|the (r_prep) pathogenesis_8\NN|NONE (r_pobj) in_6\IN|with|have|.|,|species|been (r_prep) implicated_5\VBN|NONE (l_prep) with_17\IN|have|in|.|,|species|been (l_pcomp) reducing_20\VBG|NONE (l_dobj) proteinuria_22\NN|significantly|antioxidants
D011692_D011507 CID PAN)-induced_14\JJ|puromycin|aminonucleoside|( (r_amod) nephropathy_15\NN|NONE (r_pobj) of_9\IN|the (r_prep) pathogenesis_8\NN|NONE (r_pobj) in_6\IN|with|have|.|,|species|been (r_prep) implicated_5\VBN|NONE (l_prep) with_17\IN|have|in|.|,|species|been (l_pcomp) reducing_20\VBG|NONE (l_dobj) proteinuria_22\NN|significantly|antioxidants
D011692_D011507 CID PAN_14\NNP|NONE (r_compound) nephropathy_15\NN|NONE (r_pobj) in_13\IN|proteinuric|the (r_prep) injury_12\NN|NONE
D010100_D011507 NONE oxygen_1\NN|Reactive (r_compound) species_2\NNS|with|have|in|.|,|been (r_nsubjpass) implicated_5\VBN|NONE (l_prep) with_17\IN|have|in|.|,|species|been (l_pcomp) reducing_20\VBG|NONE (l_dobj) proteinuria_22\NN|significantly|antioxidants
D010100_D007674 NONE oxygen_1\NN|Reactive (r_compound) species_2\NNS|with|have|in|.|,|been (r_nsubjpass) implicated_5\VBN|NONE (l_prep) in_6\IN|with|have|.|,|species|been (l_pobj) pathogenesis_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) nephropathy_15\NN|NONE
D011692_D007674 CID aminonucleoside_7\NN| (r_advmod) induced_9\VBN|puromycin (r_amod) nephropathy_10\NN|NONE
D011692_D007674 CID aminonucleoside_12\NN|puromycin|PAN)induced|( (r_nmod) nephropathy_15\NN|NONE
D011692_D007674 CID PAN)-induced_14\JJ|puromycin|aminonucleoside|( (r_amod) nephropathy_15\NN|NONE
D011692_D007674 CID PAN_14\NNP|NONE (r_compound) nephropathy_15\NN|NONE
16740173
6666578
D010396_D001018 CID penicillamine_2\NN||angiopathy|.|in (r_compound) induced_4\VBN|NONE (l_advmod) angiopathy_5\NN||.|in|penicillamine
9249847
D014700_D013611 CID verapamil_7\NN|in|cardiomyopathy|and|catheter (r_nmod) ablation_10\NN|NONE (r_pobj) after_6\IN|Iatrogenically|tachycardia|. (r_prep) induced_1\VBD|NONE (l_dobj) tachycardia_5\NN|Iatrogenically|.|after
D014700_D013611 CID verapamil_10\NN|antegrade|unidirectional|of (r_nmod) block_14\NN|NONE (r_pobj) after_9\IN|escape|after|junctional (r_prep) beats_8\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|without|,|, (r_acl) QRS_0\UH|attack|. (r_nsubj) established_22\VBD|NONE (l_dobj) attack_25\NN|.|QRS (l_compound) AVRT_24\NN|frequent
D014700_D002311 NONE verapamil_7\NN|in|cardiomyopathy|and|catheter (r_nmod) ablation_10\NN|NONE (l_conj) cardiomyopathy_24\NN|in|verapamil|and|catheter
D014700_D014927 NONE verapamil_7\NN|in|cardiomyopathy|and|catheter (r_nmod) ablation_10\NN|NONE (l_prep) in_11\IN|verapamil|cardiomyopathy|and|catheter (l_pobj) patient_13\NN|NONE (l_prep) with_14\IN|a (l_pobj) syndrome_20\NN|NONE
3107448
D005905_D003924 NONE glyburide_18\NN|NONE (r_amod) therapy_19\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) initiation_16\NN|soon (r_pobj) after_15\IN|.|syndrome|patients (r_prep) developed_7\VBD|NONE (l_nsubj) patients_1\NNS|after|.|syndrome (l_prep) with_2\IN|Two (l_pobj) mellitus_6\NN|NONE
D005905_D056486 CID Glyburide_0\NN| (r_npadvmod) induced_2\VBN|. (r_amod) hepatitis_3\NN|NONE
D005905_D056486 CID glyburide_1\NN|NONE (r_pobj) For_0\IN|,|reports|sulfonylurea|,|. (r_prep) exist_15\VBP|NONE (l_nsubj) reports_12\NNS|,|sulfonylurea|,|For|. (l_prep) of_13\IN|two|brief (l_pobj) hepatotoxicity_14\NN|NONE
D005905_D056486 CID glyburide_18\NN|NONE (r_amod) therapy_19\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) initiation_16\NN|soon (r_pobj) after_15\IN|.|syndrome|patients (r_prep) developed_7\VBD|NONE (l_dobj) syndrome_13\NN|after|.|patients
D005905_D056486 CID Glyburide_0\NNP|illness|.|can (r_nsubj) produce_2\VB|NONE (l_dobj) illness_8\NN|.|can|Glyburide
D013453_D056486 NONE sulfonylureas_14\NNS|NONE (r_pobj) with_13\IN|has|.|,|been|infrequently|,|hepatotoxicity|common (r_prep) reported_10\VBN|NONE (l_nsubjpass) hepatotoxicity_3\NN|has|.|with|,|been|infrequently|,|common
D013453_D056486 NONE sulfonylurea_7\NN|,|reports|,|For|. (r_nsubj) exist_15\VBP|NONE (l_nsubj) reports_12\NNS|,|sulfonylurea|,|For|. (l_prep) of_13\IN|two|brief (l_pobj) hepatotoxicity_14\NN|NONE
6387529
D003975_D000379 NONE diazepam_3\NN|NONE (r_pobj) of_2\IN|and|propranolol|.|Behavioral (r_prep) effects_1\NNS|NONE (l_conj) propranolol_5\NN|of|and|.|Behavioral (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE (l_conj) agoraphobia_12\NNP|and|panic
D003975_D000379 NONE diazepam_6\NN|NONE (r_pobj) of_5\IN|dose|and|oral|( (r_prep) doses_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|dose (r_nsubj) propranolol_27\NN|dose|were|in|. (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|were|in|.|propranolol (l_prep) on_47\IN|)|for|median|of|a (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE (l_conj) agoraphobia_56\NNP|and|panic
D011433_D000379 NONE propranolol_5\NN|of|and|.|Behavioral (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE (l_conj) agoraphobia_12\NNP|and|panic
D011433_D000379 NONE propranolol_27\NN|dose|were|in|. (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|were|in|.|propranolol (l_prep) on_47\IN|)|for|median|of|a (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE (l_conj) agoraphobia_56\NNP|and|panic
D003975_D008569 CID diazepam_12\NN|NONE (r_pobj) for_11\IN|NONE (r_prep) greater_10\JJR|.|decrease (r_acomp) was_9\VBD|drugs|but|recall (r_conj) impaired_2\VBD|NONE (l_dobj) recall_5\NN|drugs|but|was
D003975_D016584 NONE diazepam_3\NN|NONE (r_pobj) of_2\IN|and|propranolol|.|Behavioral (r_prep) effects_1\NNS|NONE (l_conj) propranolol_5\NN|of|and|.|Behavioral (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE
D003975_D016584 NONE diazepam_6\NN|NONE (r_pobj) of_5\IN|dose|and|oral|( (r_prep) doses_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|dose (r_nsubj) propranolol_27\NN|dose|were|in|. (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|were|in|.|propranolol (l_prep) on_47\IN|)|for|median|of|a (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE
D011433_D008569 CID propranolol_14\NN|NONE (r_advcl) diazepam_12\NN|NONE (r_pobj) for_11\IN|NONE (r_prep) greater_10\JJR|.|decrease (r_acomp) was_9\VBD|drugs|but|recall (r_conj) impaired_2\VBD|NONE (l_dobj) recall_5\NN|drugs|but|was
D011433_D016584 NONE propranolol_5\NN|of|and|.|Behavioral (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE
D011433_D016584 NONE propranolol_27\NN|dose|were|in|. (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|were|in|.|propranolol (l_prep) on_47\IN|)|for|median|of|a (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE
18083142
D004298_D001008 NONE dopamine_9\NN|mice|hydroxylase (r_compound) knockout_13\NN|NONE (r_pobj) of_8\IN|the (r_prep) performance_7\NN|in|In|examine|,|we|. (r_dobj) evaluated_5\VBD|NONE (l_advcl) examine_36\VB|in|In|,|we|.|performance (l_dobj) contribution_38\NN|to (l_prep) of_39\IN|the (l_pobj) signaling_41\NN|NONE (l_prep) to_42\IN|noradrenergic (l_pobj) anxiety_46\NN|NONE
D004298_D001008 NONE dopamine_17\NN|beta||a (r_nmod) hydroxylase_20\NN|DBH|)|( (r_nmod) inhibitor_24\NN|,|of (r_appos) administration_12\NN|NONE (r_pobj) following_11\VBG|was|.|in|also|anxiety (r_prep) attenuated_6\VBN|NONE (l_nsubjpass) anxiety_3\NN|was|.|in|following|also
D015016_D001008 NONE yohimbine_48\NN|)|alpha(|the (r_appos) antagonist_47\NN|the|antagonist|and (r_conj) prazosin_42\NN|while|effect (r_nsubj) had_49\VBD|with|,|that (r_advcl) pretreatment_10\NN|In|.|,|we (l_prep) with_11\IN|had|,|that (l_pobj) antagonist_17\NN|NONE (l_acl) propranolol_18\NN|receptor|adrenergic|the (l_dobj) behavior_26\NN|in (l_amod) like_25\JJ|induced|blocked (l_npadvmod) anxiety_23\NN|
D011433_D001008 NONE propranolol_18\NN|receptor|adrenergic|the (l_dobj) behavior_26\NN|in (l_amod) like_25\JJ|induced|blocked (l_npadvmod) anxiety_23\NN|
D003042_D001008 CID cocaine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) anxiety_15\NN|NONE
D003042_D001008 CID cocaine_4\NN|rewarding|underlying (r_poss) effects_7\NNS|mechanisms|While|extensively|have|been (r_nsubjpass) studied_10\VBN|,|.|to|has|been|attention (r_advcl) paid_17\VBN|NONE (l_dative) to_18\IN|,|.|has|been|studied|attention (l_pobj) states_22\NNS|NONE (l_acl) induced_23\VBN|unpleasant|behavioral|the (l_agent) by_24\IN|NONE (l_pobj) cocaine_25\NN|NONE (l_prep) as_28\IN|, (l_pobj) anxiety_29\NN|such
D003042_D001008 CID cocaine_25\NN|NONE (l_prep) as_28\IN|, (l_pobj) anxiety_29\NN|such
D003042_D001008 CID cocaine_43\NN| (r_npadvmod) induced_45\VBN|NONE (r_amod) anxiety_46\NN|NONE
D003042_D001008 CID cocaine_4\NN|,|behavior|measured|that|dependently (r_nsubj) increased_8\VBN|:|We|. (l_dobj) behavior_12\NN|,|measured|that|dependently|cocaine (l_amod) like_11\JJ|in (l_npadvmod) anxiety_9\NN|NONE
D003042_D001008 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) anxiety_3\NN|was|.|in|following|also
D003042_D001008 CID cocaine_20\NN| (r_npadvmod) induced_22\VBN|blocked|like (r_amod) behavior_26\NN|in (l_amod) like_25\JJ|induced|blocked (l_npadvmod) anxiety_23\NN|
D003042_D001008 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) anxiety_17\NN|NONE
D011224_D001008 NONE prazosin_42\NN|while|effect (r_nsubj) had_49\VBD|with|,|that (r_advcl) pretreatment_10\NN|In|.|,|we (l_prep) with_11\IN|had|,|that (l_pobj) antagonist_17\NN|NONE (l_acl) propranolol_18\NN|receptor|adrenergic|the (l_dobj) behavior_26\NN|in (l_amod) like_25\JJ|induced|blocked (l_npadvmod) anxiety_23\NN|
D009638_D001008 NONE Norepinephrine_0\NN|through (r_compound) signaling_1\VBG|critical|. (r_nsubj) is_7\VBZ|NONE (l_acomp) critical_8\JJ|signaling|. (l_prep) for_9\IN|NONE (l_pobj) expression_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) anxiety_15\NN|NONE
D009638_D001008 NONE norepinephrine_22\NN|which (r_dobj) lack_21\VBP|(|/|Dbh|,|,|) (r_relcl) mice_18\NNS|dopamine|hydroxylase (r_appos) knockout_13\NN|NONE (r_pobj) of_8\IN|the (r_prep) performance_7\NN|in|In|examine|,|we|. (r_dobj) evaluated_5\VBD|NONE (l_advcl) examine_36\VB|in|In|,|we|.|performance (l_dobj) contribution_38\NN|to (l_prep) of_39\IN|the (l_pobj) signaling_41\NN|NONE (l_prep) to_42\IN|noradrenergic (l_pobj) anxiety_46\NN|NONE
D009638_D001008 NONE NE_24\NNP|NONE (r_appos) norepinephrine_22\NN|which (r_dobj) lack_21\VBP|(|/|Dbh|,|,|) (r_relcl) mice_18\NNS|dopamine|hydroxylase (r_appos) knockout_13\NN|NONE (r_pobj) of_8\IN|the (r_prep) performance_7\NN|in|In|examine|,|we|. (r_dobj) evaluated_5\VBD|NONE (l_advcl) examine_36\VB|in|In|,|we|.|performance (l_dobj) contribution_38\NN|to (l_prep) of_39\IN|the (l_pobj) signaling_41\NN|NONE (l_prep) to_42\IN|noradrenergic (l_pobj) anxiety_46\NN|NONE
D004221_D001008 NONE disulfiram_14\NN|NONE (r_pobj) of_13\IN|,|inhibitor (r_prep) administration_12\NN|NONE (r_pobj) following_11\VBG|was|.|in|also|anxiety (r_prep) attenuated_6\VBN|NONE (l_nsubjpass) anxiety_3\NN|was|.|in|following|also
3173180
D008795_D006463 CID metronidazole_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) after_4\IN|uraemic|. (r_prep) syndrome_3\NN|NONE
D008795_D006463 CID metronidazole_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treatment_17\NN|NONE (r_pobj) after_16\IN|who|syndrome (r_prep) developed_10\VBD|six (l_dobj) syndrome_15\NN|after|who
D008795_D006463 CID metronidazole_4\NN|NONE (r_pobj) of_3\IN|the|in (r_prep) involvement_2\NN|is|firmly|not|While (l_prep) in_5\IN|the|of (l_pobj) aetiology_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) syndrome_13\NN|NONE
D008795_D006463 CID metronidazole_4\NN|NONE (r_pobj) of_3\IN|the|in (r_prep) involvement_2\NN|is|firmly|not|While (r_nsubjpass) established_16\VBN|.|action|link|, (r_advcl) suggest_43\VBP|NONE (l_nsubj) action_20\NN|.|established|link|, (l_conj) evidence_33\NN|of|in|the (l_prep) of_34\IN|reported|the (l_pobj) changes_36\NNS|NONE (l_prep) in_37\IN|oxidation (l_pobj) syndrome_42\NN|NONE
D008795_D006463 CID metronidazole_4\NN|NONE (r_pobj) of_3\IN|the|in (r_prep) involvement_2\NN|is|firmly|not|While (r_nsubjpass) established_16\VBN|.|action|link|, (r_advcl) suggest_43\VBP|NONE (l_dobj) link_46\NN|.|established|action|, (l_prep) between_47\IN|a|possible (l_pobj) treatment_49\NN|NONE (l_conj) cases_52\NNS|metronidazole|and (l_prep) of_53\IN|some (l_pobj) syndrome_58\NN|NONE
D008795_D006463 CID metronidazole_48\NN|and|cases (r_amod) treatment_49\NN|NONE (r_pobj) between_47\IN|a|possible (r_prep) link_46\NN|.|established|action|, (r_dobj) suggest_43\VBP|NONE (l_advcl) established_16\VBN|.|action|link|, (l_nsubjpass) involvement_2\NN|is|firmly|not|While (l_prep) in_5\IN|the|of (l_pobj) aetiology_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) syndrome_13\NN|NONE
D008795_D006463 CID metronidazole_48\NN|and|cases (r_amod) treatment_49\NN|NONE (r_pobj) between_47\IN|a|possible (r_prep) link_46\NN|.|established|action|, (r_dobj) suggest_43\VBP|NONE (l_nsubj) action_20\NN|.|established|link|, (l_conj) evidence_33\NN|of|in|the (l_prep) of_34\IN|reported|the (l_pobj) changes_36\NNS|NONE (l_prep) in_37\IN|oxidation (l_pobj) syndrome_42\NN|NONE
D008795_D006463 CID metronidazole_48\NN|and|cases (r_amod) treatment_49\NN|NONE (l_conj) cases_52\NNS|metronidazole|and (l_prep) of_53\IN|some (l_pobj) syndrome_58\NN|NONE
2578334
D001564_D011230 CID benzo[a]-pyrene_53\NN|,|,|three|the|nitrosourea (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|of|the (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|was|AzC|.|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|during|was|.|to (l_advcl) test_1\VB|,|,|azacytidine|(|inhibitor|mg/kg|)|, (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|that|role|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D008770_D011230 CID nitrosourea_65\NN|,|,|three|benzo[a]pyrene|the (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|of|the (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|was|AzC|.|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|during|was|.|to (l_advcl) test_1\VB|,|,|azacytidine|(|inhibitor|mg/kg|)|, (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|that|role|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D019813_D011230 CID 1,2-dimethylhydrazine_71\CD|and|mg/kg|(|) (r_conj) 60_67\CD|||mg/kg|,DMH|methyl|N (r_appos) nitrosourea_65\NN|,|,|three|benzo[a]pyrene|the (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|of|the (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|was|AzC|.|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|during|was|.|to (l_advcl) test_1\VB|,|,|azacytidine|(|inhibitor|mg/kg|)|, (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|that|role|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D019813_D011230 CID 1,2-DMH_73\NNP|||mg/kg||methyl|N (r_appos) nitrosourea_65\NN|,|,|three|benzo[a]pyrene|the (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|of|the (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|was|AzC|.|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|during|was|.|to (l_advcl) test_1\VB|,|,|azacytidine|(|inhibitor|mg/kg|)|, (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|that|role|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D001374_D011230 CID 5-azacytidine_0\RB|.|initiation (r_nsubj) potentiates_1\VBZ|NONE (l_dobj) initiation_2\NN|azacytidine|. (l_acl) induced_3\VBN|NONE (l_agent) by_4\IN|NONE (l_pobj) carcinogens_5\NNS|NONE
D001374_D011230 CID 5-azacytidine_22\JJ|,|,|(|inhibitor|mg/kg|)|,|test (r_punct) 5-AzC_24\CD|during|was|.|to (l_advcl) test_1\VB|,|,|azacytidine|(|inhibitor|mg/kg|)|, (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|that|role|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D001374_D011230 CID 5-AzC_24\CD|during|was|.|to (l_advcl) test_1\VB|,|,|azacytidine|(|inhibitor|mg/kg|)|, (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|that|role|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
8669433
D010615_D007676 CID phenacetin_16\NN|NONE (r_pobj) with_15\IN|a (r_prep) comparison_14\NN|.|Habitual|of|:|as (r_appos) use_1\NN|NONE (l_prep) as_4\IN|.|Habitual|comparison|of|: (l_pobj) factor_7\NN|NONE (l_prep) for_8\IN|a|risk (l_pobj) failure_11\NN|NONE
D010615_D007676 CID phenacetin_14\NN|NONE (r_pobj) of_13\IN|habitual (r_prep) use_12\NN|is|with|,|that|with (r_nsubjpass) associated_16\VBN|studies|. (l_prep) with_17\IN|is|with|use|,|that (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) failure_23\NN|NONE
D010615_D007676 CID phenacetin_14\NN|NONE (r_pobj) of_13\IN|habitual (r_prep) use_12\NN|is|with|,|that|with (r_nsubjpass) associated_16\VBN|studies|. (l_prep) with_17\IN|is|with|use|,|that (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) failure_23\NN|NONE (l_conj) disease_29\NN|and|renal|chronic
D010615_D007676 CID phenacetin_14\NN|NONE (r_pobj) of_13\IN|habitual (r_prep) use_12\NN|is|with|,|that|with (r_nsubjpass) associated_16\VBN|studies|. (l_prep) with_17\IN|is|with|use|,|that (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) failure_23\NN|NONE (l_conj) disease_29\NN|and|renal|chronic (l_appos) ESRD_31\NNP|stage|)|(|renal
D010615_D007676 CID phenacetin_5\NN|may|,|that|to|with (r_nsubj) contribute_9\VB|studies|. (l_prep) to_10\IN|may|,|that|phenacetin|with (l_pobj) burden_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) ESRD_14\NNP|NONE
D000082_D007676 NONE acetaminophen_3\NN|NONE (r_pobj) of_2\IN|.|Habitual|comparison|:|as (r_prep) use_1\NN|NONE (l_prep) as_4\IN|.|Habitual|comparison|of|: (l_pobj) factor_7\NN|NONE (l_prep) for_8\IN|a|risk (l_pobj) failure_11\NN|NONE
D000082_D007676 NONE acetaminophen_27\NN|NONE (r_pobj) of_26\IN|habitual (r_prep) use_25\NN|also|is|,|with|with|that (r_nsubjpass) associated_30\VBN|.|studies|However|, (l_prep) with_31\IN|also|is|use|,|with|that (l_pobj) failure_34\NN|NONE
D000082_D007676 NONE acetaminophen_27\NN|NONE (r_pobj) of_26\IN|habitual (r_prep) use_25\NN|also|is|,|with|with|that (r_nsubjpass) associated_30\VBN|.|studies|However|, (l_prep) with_31\IN|also|is|use|,|with|that (l_pobj) failure_34\NN|NONE (l_conj) ESRD_36\NNP|renal|and|chronic
D000082_D007676 NONE acetaminophen_7\RB|both|and (r_conj) phenacetin_5\NN|may|,|that|to|with (r_nsubj) contribute_9\VB|studies|. (l_prep) to_10\IN|may|,|that|phenacetin|with (l_pobj) burden_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) ESRD_14\NNP|NONE
D000082_D007676 NONE acetaminophen_6\NN|NONE (r_pobj) of_5\IN|alone|habitual (r_prep) use_4\NN|that|risk (r_nsubj) increases_8\VBZ|The (l_dobj) risk_10\NN|use|that (l_prep) of_11\IN|the (l_pobj) ESRD_12\NNP|NONE
8741744
D009538_D009069 NONE nicotine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) caused_27\VBN|,|(|the|early|(|field|kg(|i.m.|min|locomotor|)|)|) (r_acl) hypoactivity_26\NN|lesions|.|,|,|enhanced|Compared
D009538_D009069 NONE nicotine_48\NN| (r_npadvmod) induced_50\VBN|min|later|the|( (r_amod) hyperactivity_51\NN|,|and|raised (r_dobj) enhanced_39\VBD|lesions|.|,|,|Compared|hypoactivity (r_advcl) blunted_14\VBD|NONE (l_dobj) hypoactivity_26\NN|lesions|.|,|,|enhanced|Compared
D009538_D006948 CID nicotine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) caused_27\VBN|,|(|the|early|(|field|kg(|i.m.|min|locomotor|)|)|) (r_acl) hypoactivity_26\NN|lesions|.|,|,|enhanced|Compared (r_dobj) blunted_14\VBD|NONE (l_advcl) enhanced_39\VBD|lesions|.|,|,|Compared|hypoactivity (l_dobj) hyperactivity_51\NN|,|and|raised
D009538_D006948 CID nicotine_48\NN| (r_npadvmod) induced_50\VBN|min|later|the|( (r_amod) hyperactivity_51\NN|,|and|raised
2894766
D012460_D002305 CID sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|for|was (r_dobj) receiving_25\VBG|a|,|old (r_relcl) man_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) developed_15\VBN|positive (r_acl) autoantibodies_14\NNS|of|,|echocardiographic|and (r_conj) evidence_7\NN|,|,|Pneumonitis|pleural|bilateral|. (l_prep) of_8\IN|,|echocardiographic|autoantibodies|and (l_pobj) tamponade_10\NN|NONE
D012460_D008180 CID Sulfasalazine_0\NNP| (r_npadvmod) induced_2\VBN|lupus|. (r_amod) erythematosus_4\NN|NONE
D012460_D008180 CID sulfasalazine_7\RB| (r_npadvmod) induced_9\VBN|,|manifested (r_amod) lupus_10\NN|that|patient
D012460_D008180 CID sulfasalazine_3\NN|who|treat (r_dobj) use_2\VBP|NONE (r_relcl) Physicians_0\NNS|aware|.|should (r_nsubj) be_12\VB|NONE (l_acomp) aware_13\JJ|.|Physicians|should (l_prep) of_14\IN|NONE (l_pobj) signs_16\NNS|NONE (l_prep) of_17\IN|the (l_pobj) syndrome_22\NN|NONE
D012460_D008180 CID sulfasalazine_18\NN| (r_npadvmod) induced_20\VBN|lupus (r_amod) syndrome_22\NN|NONE
D012460_D012700 NONE sulfasalazine_7\RB| (r_npadvmod) induced_9\VBN|,|manifested (r_amod) lupus_10\NN|that|patient (l_relcl) manifested_13\VBD|,|induced (l_prep) with_14\IN|in|which (l_pobj) serositis_15\NN|NONE
D012460_D003093 NONE sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|for|was (r_dobj) receiving_25\VBG|a|,|old (l_prep) for_31\IN|therapy|who|was (l_pobj) colitis_34\NN|NONE
D012460_D011014 CID sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|for|was (r_dobj) receiving_25\VBG|a|,|old (r_relcl) man_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) developed_15\VBN|positive (r_acl) autoantibodies_14\NNS|of|,|echocardiographic|and (r_conj) evidence_7\NN|,|,|Pneumonitis|pleural|bilateral|. (r_appos) effusions_4\NNS|NONE (l_dep) Pneumonitis_0\NNP|,|,|pleural|bilateral|evidence|.
D012460_D010996 CID sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|for|was (r_dobj) receiving_25\VBG|a|,|old (r_relcl) man_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) developed_15\VBN|positive (r_acl) autoantibodies_14\NNS|of|,|echocardiographic|and (r_conj) evidence_7\NN|,|,|Pneumonitis|pleural|bilateral|. (r_appos) effusions_4\NNS|NONE
D012460_D015212 NONE sulfasalazine_3\NN|who|treat (r_dobj) use_2\VBP|NONE (l_xcomp) treat_5\VB|who|sulfasalazine (l_dobj) patients_6\NNS|to (l_prep) with_7\IN|NONE (l_pobj) disease_10\NN|NONE
D012460_D015212 NONE sulfasalazine_18\NN| (r_npadvmod) induced_20\VBN|lupus (r_amod) syndrome_22\NN|NONE (r_pobj) of_17\IN|the (r_prep) signs_16\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) aware_13\JJ|.|Physicians|should (r_acomp) be_12\VB|NONE (l_nsubj) Physicians_0\NNS|aware|.|should (l_relcl) use_2\VBP|NONE (l_xcomp) treat_5\VB|who|sulfasalazine (l_dobj) patients_6\NNS|to (l_prep) with_7\IN|NONE (l_pobj) disease_10\NN|NONE
19729346
D010098_D010146 NONE oxycodone_18\NN|NONE (r_pobj) of_14\IN|single|mg|a|in (r_prep) dose_13\NN|NONE (r_pobj) of_9\IN|the|neurocognitive|objective (r_prep) effects_8\NNS|years|)|and|.|study|adults|, (r_dobj) measured_2\VBD|NONE (l_dobj) adults_39\NNS|years|effects|)|and|.|study|, (l_relcl) suffering_43\VBG|NONE (l_prep) from_44\IN|were|who|not (l_pobj) pain_49\NN|NONE
D010098_D059350 NONE oxycodone_30\NN|NONE (r_pobj) of_26\IN|mg|a (r_prep) dose_25\NN|NONE (r_pobj) to_22\IN|NONE (r_prep) response_21\NN|NONE (r_pobj) in_20\IN|NONE (r_prep) changes_19\NNS|from|are|not|who (r_dobj) suffering_11\VBG|older|healthy (l_prep) from_12\IN|are|changes|not|who (l_pobj) pain_14\NN|NONE
14513889
D007654_D009422 NONE Ketoconazole_0\NNP|sequelae||. (r_npadvmod) induced_2\VBN|NONE (l_dobj) sequelae_4\NNS|Ketoconazole||.
20633755
D013390_D001049 CID Suxamethonium_0\NNS|apnea|. (r_nsubj) induced_1\VBD|NONE (l_dobj) apnea_3\NN|Suxamethonium|.
D013390_D001049 CID Suxamethonium_0\JJ|.|apnea (r_nsubj) causes_1\VBZ|NONE (l_dobj) apnea_3\NN|Suxamethonium|.
D009943_D001049 CID poisons_17\NNS|NONE (r_pobj) by_12\IN|gets|enzyme|in (r_agent) deactivated_11\VBN|NONE (r_relcl) patients_5\NNS|NONE (r_pobj) in_4\IN|prolonged (r_prep) apnea_3\NN|Suxamethonium|.
D009943_D001049 CID compound_14\NN|NONE (r_pobj) by_12\IN|suicidal (r_prep) attempt_11\NN|NONE (r_pobj) about_9\IN|the (r_prep) information_8\NN|from|was|because (r_nsubjpass) concealed_16\VBN|.|apnea (r_advcl) ensued_5\VBD|NONE (l_nsubj) apnea_1\NN|.|concealed
8319760
D000804_D009404 NONE II_43\NNP|at|a|angiotensin|receptor|, (r_compound) antagonist_45\NN|.|,|)|induced|by|was|markedly (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D000804_D011507 NONE II_43\NNP|at|a|angiotensin|receptor|, (r_compound) antagonist_45\NN|.|,|)|induced|by|was|markedly (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D001806_D009404 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|, (r_conj) hypoalbuminemia_9\NN|, (r_conj) proteinuria_7\NN|such (r_pobj) as_6\IN|nephrotic (r_prep) syndromes_4\NNS|NONE
D019808_D009401 NONE 753_1\CD|NONE (r_nummod) Dup_0\NN|.|development (r_nsubj) prevents_2\VBZ|NONE (l_dobj) development_4\NN|Dup|. (l_prep) of_5\IN|the (l_pobj) nephrosis_10\NN|puromycin
D000804_D006937 NONE II_43\NNP|at|a|angiotensin|receptor|, (r_compound) antagonist_45\NN|.|,|)|induced|by|was|markedly (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
D011692_D009401 NONE aminonucleoside_7\NN| (r_advmod) induced_9\VBN|NONE (r_amod) nephrosis_10\NN|puromycin
D011692_D009401 NONE aminonucleoside_17\NN| (r_advmod) induced_19\VBN|NONE (r_amod) nephrosis_20\NN|puromycin
D011692_D009404 CID aminonucleoside_26\NN|by|,|in|appearance (r_advmod) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D019808_D006937 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
D019808_D006937 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
D019808_D011507 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D019808_D011507 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D011692_D006937 CID aminonucleoside_26\NN|by|,|in|appearance (r_advmod) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
D019808_D034141 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D019808_D034141 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D001806_D011507 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|, (r_conj) hypoalbuminemia_9\NN|, (r_conj) proteinuria_7\NN|such
D000809_D009401 NONE angiotensin_10\NN|the|in (r_compound) system_11\NN|NONE (l_prep) in_12\IN|the|angiotensin (l_pobj) development_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) nephrosis_20\NN|puromycin
D001806_D034141 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|, (r_conj) hypoalbuminemia_9\NN|,
D000804_D034141 NONE II_43\NNP|at|a|angiotensin|receptor|, (r_compound) antagonist_45\NN|.|,|)|induced|by|was|markedly (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D011692_D011507 CID aminonucleoside_26\NN|by|,|in|appearance (r_advmod) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D011692_D034141 CID aminonucleoside_26\NN|by|,|in|appearance (r_advmod) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D019808_D009404 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D019808_D009404 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|.|,|)|induced|antagonist|was|markedly (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|.|,|)|antagonist|by|was|markedly (l_nsubj) appearance_1\NN|by|,|aminonucleoside|in (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D001806_D006937 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|,
11147747
D018490_D014549 CID antidepressants_1\NNS|NONE (l_conj) incontinence_4\NN|.|and|Serotonergic
D018490_D014549 CID antidepressants_8\NNS|NONE (r_pobj) to_6\IN|NONE (r_prep) secondary_5\JJ|NONE (r_amod) incontinence_4\NN|be|could|that|by
D020280_D014549 CID sertraline_22\NN|inhibitors|and|,|as|the|third|selective|serotonin (r_conj) paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
C047426_D014549 CID venlafaxine_10\NN|while (r_dobj) taking_9\VBG|incontinence|who (r_advcl) experienced_6\VBD||male (l_dobj) incontinence_7\NN|who|taking
C047426_D014549 CID venlafaxine_35\NNP|NONE (r_pobj) on_34\IN|effect|who (r_prep) developed_30\VBD|a (r_relcl) third_28\NN|inhibitors|and|,|as|the|selective|serotonin|sertraline (r_conj) paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
D017374_D014549 CID paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
D016651_D014549 CID carbonate_12\NN|were|patients|also (r_dobj) taking_10\VBG||the (r_relcl) cases_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) 2_1\CD|NONE (r_pobj) In_0\IN|both|,|have|.|to|could (r_prep) contributed_23\VBN|NONE (l_prep) to_24\IN|both|,|In|have|.|could (l_pobj) incontinence_26\NN|NONE
D012701_D014549 NONE serotonin_17\NN|inhibitors|and|,|as|the|third|selective|sertraline (r_compound) paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
20882060
D009496_D002375 NONE neurotensin_3\NN|NONE (l_prep) on_4\IN|pallidal (l_pobj) catalepsy_9\NN|NONE
D009496_D002375 NONE neurotensin_3\NN|NONE (r_pobj) of_2\IN|Bilateral (r_prep) infusions_1\NNS|catalepsy|in|. (r_nsubj) reversed_8\VBD|NONE (l_dobj) catalepsy_13\NN|infusions|in|.
D006220_D002375 CID haloperidol_5\NN| (r_npadvmod) induced_7\VBN|:|studies|parkinsonian (r_amod) catalepsy_9\NN|NONE
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|parkinsonian (r_amod) catalepsy_13\NN|infusions|in|.
D006220_D010302 NONE haloperidol_12\NN| (r_npadvmod) induced_14\VBN|parkinsonian (r_amod) symptoms_16\NNS|NONE
D009496_D010302 NONE neurotensin_10\NN|NONE (l_prep) on_11\IN|pallidal (l_pobj) symptoms_16\NNS|NONE
3496378
D014217_D056486 CID troleandomycin_3\NN| (r_npadvmod) induced_5\VBN|acute (r_amod) hepatitis_7\NN|NONE
D014217_D056486 CID troleandomycin_9\NN||in (r_npadvmod) induced_11\VBN|a (r_relcl) patient_6\NN|NONE (r_pobj) of_4\IN|the (r_prep) case_3\NN|followed|.|We (r_dobj) report_1\VBP|NONE (l_ccomp) followed_14\VBN|.|We|case (l_nsubjpass) hepatitis_12\NN|was|by
D014217_D056486 CID troleandomycin_8\NN| (r_npadvmod) induced_10\VBN|acute (r_amod) hepatitis_12\NN|that|can|cholestasis
D014217_D002779 CID troleandomycin_3\NN| (r_npadvmod) induced_5\VBN|acute (r_amod) hepatitis_7\NN|NONE (r_pobj) after_2\IN|.|Prolonged (r_prep) cholestasis_1\NN|NONE
D014217_D002779 CID troleandomycin_9\NN||in (r_npadvmod) induced_11\VBN|a (r_relcl) patient_6\NN|NONE (r_pobj) of_4\IN|the (r_prep) case_3\NN|followed|.|We (r_dobj) report_1\VBP|NONE (l_ccomp) followed_14\VBN|.|We|case (l_agent) by_15\IN|was|hepatitis (l_pobj) cholestasis_18\NN|NONE
D014217_D002779 CID troleandomycin_8\NN| (r_npadvmod) induced_10\VBN|acute (r_amod) hepatitis_12\NN|that|can|cholestasis (r_dobj) follow_7\VB|observation|. (l_nsubj) cholestasis_5\NN|hepatitis|that|can
D014217_D007565 CID troleandomycin_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) after_2\IN|and|Jaundice|for|.|associated (r_prep) occurred_1\VBD|NONE (l_nsubj) Jaundice_0\NN|after|and|for|.|associated
D014217_D004802 CID troleandomycin_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) after_2\IN|and|Jaundice|for|.|associated (r_prep) occurred_1\VBD|NONE (l_conj) associated_11\VBN|after|and|Jaundice|for|. (l_prep) with_12\IN|was (l_pobj) hypereosinophilia_13\NNS|NONE
16005948
D003042_D064420 NONE cocaine_3\NN|NONE (r_compound) toxicity_4\NN|NONE
-1_D064420 NONE GNC92H2_12\NNP|NONE (r_pobj) of_11\IN|,|higher|,|mg/kg|reduced|)|the|seizures (r_prep) dose_10\NN|NONE (r_pobj) with_7\IN|.|was|blockade (r_prep) observed_6\VBN|NONE (l_nsubjpass) blockade_1\NN|.|was|with (l_prep) of_2\IN|Significant (l_pobj) toxicity_4\NN|NONE
-1_D003643 NONE GNC92H2_12\NNP|NONE (r_pobj) of_11\IN|,|higher|,|mg/kg|reduced|)|the|seizures (r_prep) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|higher|,|mg/kg|reduced|)|the|of (l_prt) up_29\IN|by (l_prep) to_30\TO|NONE (l_pobj) %_32\NN|NONE (l_conj) death_34\NN|and|
-1_D003643 NONE GNC92H2_2\NNP|,|death|Importantly|injection|. (r_nsubj) prevented_3\VBD|NONE (l_dobj) death_4\NN|,|Importantly|GNCH|injection|.
D003042_D062787 NONE cocaine_4\NN|NONE (r_pobj) of_3\IN|illicit|The (r_prep) use_2\NN|in (r_nsubj) continues_5\VBZ|elusive|. (l_prep) in_6\IN|use (l_pobj) proportions_8\NNS|NONE (l_conj) treatment_10\NN|epidemic|and (l_prep) for_11\IN|NONE (l_pobj) overdose_13\NN|NONE
D003042_D003643 NONE cocaine_3\NN|NONE (r_compound) toxicity_4\NN|NONE (r_pobj) of_2\IN|Significant (r_prep) blockade_1\NN|.|was|with (r_nsubjpass) observed_6\VBN|NONE (l_prep) with_7\IN|.|was|blockade (l_pobj) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|higher|,|mg/kg|reduced|)|the|of (l_prt) up_29\IN|by (l_prep) to_30\TO|NONE (l_pobj) %_32\NN|NONE (l_conj) death_34\NN|and|
D003042_D003643 NONE cocaine_8\NN|even (r_compound) injection_9\NN|,|death|Importantly|GNCH|. (r_dobj) prevented_3\VBD|NONE (l_dobj) death_4\NN|,|Importantly|GNCH|injection|.
-1_D062787 NONE GNC92H2_6\NNP|NONE (r_pobj) of_1\IN|as|. (r_prep) Evaluation_0\NN|NONE (l_prep) as_7\IN|of|. (l_pobj) immunotherapy_9\NN|NONE (l_prep) for_10\IN|an (l_pobj) overdose_12\NN|NONE
-1_D062787 NONE GNC92H2_7\NNP|NONE (r_pobj) of_3\IN|therapeutic|The (r_prep) potential_2\NN|using|was|. (r_nsubjpass) examined_9\VBN|NONE (l_advcl) using_10\VBG|potential|was|. (l_dobj) model_12\NN|NONE (l_prep) of_13\IN|a (l_pobj) overdose_15\NN|NONE
-1_D062787 NONE GNC92H2_7\NNP|NONE (r_pobj) of_6\IN|as|important|the (r_prep) potential_5\NN|results|. (l_prep) as_8\IN|important|of|the (l_pobj) tool_11\NN|NONE (l_prep) against_12\IN|a|therapeutic (l_pobj) overdose_14\NN|NONE
-1_D012640 NONE GNC92H2_12\NNP|NONE (r_pobj) of_11\IN|,|higher|,|mg/kg|reduced|)|the|seizures (r_prep) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|higher|,|mg/kg|reduced|)|the|of
D003042_D012640 CID cocaine_3\NN|NONE (r_compound) toxicity_4\NN|NONE (r_pobj) of_2\IN|Significant (r_prep) blockade_1\NN|.|was|with (r_nsubjpass) observed_6\VBN|NONE (l_prep) with_7\IN|.|was|blockade (l_pobj) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|higher|,|mg/kg|reduced|)|the|of
11897407
D007545_D009203 CID isoproterenol_6\NN| (r_npadvmod) induced_8\VBN|in|myocardial (r_amod) infarction_10\NN|NONE
D007545_D009203 CID isoproterenol_22\NN| (r_npadvmod) induced_24\VBN|myocardial|acute (r_amod) infarction_27\NN|NONE
C067171_D009203 NONE glucarate_2\NN|NONE (l_prep) for_3\IN||.|mTc (l_pobj) detection_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) infarction_10\NN|NONE
C067171_D009203 NONE glucarate_2\NN|easy|used|,|stable|and|. (r_nsubj) was_3\VBD|NONE (l_conj) used_14\VBN|easy|,|glucarate|stable|and|. (l_xcomp) study_16\VB|was (l_dobj) biodistribution_18\NN|to (l_prep) in_19\IN|its (l_pobj) rats_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) infarction_27\NN|NONE
D005937_D007238 NONE acid_9\NN|NONE (r_pobj) on_7\IN|NONE (r_prep) based_6\VBN|new|avid|A (r_acl) radiopharmaceutical_5\NN|was|in|. (l_amod) avid_4\JJ|new|based|A (l_npadvmod) infarct_2\NN|
D007545_D007238 NONE isoproterenol_18\NN|NONE (r_pobj) with_17\IN|be|easily|can (r_prep) obtained_16\VBN|.|ligation|model (r_conj) implies_7\VBZ|NONE (l_nsubj) model_2\NN|.|ligation|obtained (l_acl) used_3\VBN|The|animal (l_xcomp) produce_5\VB|NONE (l_dobj) infarction_6\NN|to
D007545_D007238 NONE isoproterenol_12\JJ|NONE (r_compound) administration_13\NN|NONE (r_pobj) after_11\IN| (r_prep) h_10\NN|infarct|rats|that (r_npadvmod) developed_6\VBD|studies|. (l_dobj) infarct_8\NN|rats|h|that
567256
D004054_D000230 NONE diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE
D004054_D008113 CID diethylstilbestrol_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|the (r_acl) liver_3\NN|NONE
D004054_D008113 CID diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE (r_pobj) of_21\IN|a|differentiated (r_prep) adenocarcinoma_20\NN|NONE (r_pobj) for_15\IN|for|who|had|been (r_prep) treated_14\VBN|old|a (r_relcl) man_10\NN|NONE (r_pobj) in_5\IN|.|Angiosarcoma (r_prep) occurred_4\VBD|NONE (l_nsubj) Angiosarcoma_0\NNP|in|. (l_prep) of_1\IN|NONE (l_pobj) liver_3\NN|NONE
D004054_D008113 NONE diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE
D004054_D006394 CID diethylstilbestrol_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|the (r_acl) liver_3\NN|NONE
D004054_D006394 CID diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE (r_pobj) of_21\IN|a|differentiated (r_prep) adenocarcinoma_20\NN|NONE (r_pobj) for_15\IN|for|who|had|been (r_prep) treated_14\VBN|old|a (r_relcl) man_10\NN|NONE (r_pobj) in_5\IN|.|Angiosarcoma (r_prep) occurred_4\VBD|NONE (l_nsubj) Angiosarcoma_0\NNP|in|. (l_prep) of_1\IN|NONE (l_pobj) liver_3\NN|NONE
15515654
D003676_D034381 NONE DFO_5\NNP|in|contributing (r_poss) role_8\NN|NONE (l_prep) in_9\IN|DFO|contributing (l_pobj) development_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) impairment_14\NN|NONE
D003676_D006311 NONE DFO_6\NNP|NONE (r_pobj) than_5\IN|NONE (r_prep) other_4\JJ|,|,|No|ototoxic (r_amod) factor_2\NN|present|. (l_compound) ototoxic_1\JJ|other|,|,|No
D003676_D006319 CID DFO_6\NNP|withdrawal|or (r_compound) reduction_7\NN|NONE (r_pobj) to_5\IN|.|were|Subjects (r_prep) submitted_4\VBN|NONE (l_nsubjpass) Subjects_0\NNS|.|to|were (l_prep) with_1\IN|NONE (l_pobj) SNHL_2\NNP|NONE
18162529
D004967_D006966 NONE estrogen_20\NN| (r_npadvmod) induced_22\VBN|the|LH (r_amod) surge_24\NN|pulsatile|and|LH (r_conj) secretion_17\NN|two|neuroendocrine|necessary|: (r_appos) parameters_9\NNS|hyperprolactinemia|whether (r_dobj) inhibited_6\VBD|first|We|. (l_nsubj) hyperprolactinemia_5\NN|whether|parameters
D013469_D006966 CID sulpiride_7\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Chronic (r_acl) hyperprolactinemia_1\NN|,|in|.|but|frequency
D012313_D006966 NONE acid_5\NN|prolactin|Hypothalamic|messenger|signaling|, (r_compound) levels_6\NNS|.|dependent (l_conj) signaling_9\NN|prolactin|Hypothalamic|messenger|acid|, (l_conj) inhibition_13\NN|prolactin|and|, (l_amod) hyperprolactinemic_12\JJ|of
D004298_D006966 NONE dopamine_5\NN|NONE (r_compound) antagonist_6\NN|the (r_compound) sulpiride_7\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Chronic (r_acl) hyperprolactinemia_1\NN|,|in|.|but|frequency
D013256_D006966 NONE steroid_14\NN| (r_npadvmod) dependent_16\JJ|a (r_amod) manner_17\NN|NONE (r_pobj) in_12\IN|frequency|is|that|by (r_prep) inhibited_8\VBN|data|. (l_agent) by_9\IN|frequency|is|in|that (l_pobj) hyperprolactinemia_11\NN|NONE
D004958_D006966 NONE estradiol_22\NN|NONE (r_pobj) on_21\IN|NONE (r_prep) dependent_20\JJ|.|levels (r_acomp) are_19\VBP|NONE (l_nsubj) levels_6\NNS|.|dependent (l_conj) signaling_9\NN|prolactin|Hypothalamic|messenger|acid|, (l_conj) inhibition_13\NN|prolactin|and|, (l_amod) hyperprolactinemic_12\JJ|of
D004958_D006966 NONE estradiol_30\NN|NONE (r_pobj) of_29\IN|low|chronic (r_prep) levels_28\NNS|NONE (r_pobj) of_25\IN|the (r_prep) presence_24\NN|only (r_pobj) in_22\IN|,|hyperprolactinemia|.|but|frequency (r_conj) caused_8\VBD|NONE (l_nsubj) hyperprolactinemia_1\NN|,|in|.|but|frequency
11587867
D014750_-1 NONE vincristine_28\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposed_26\VBN|NONE (r_acl) areas_25\NNS|NONE (r_pobj) in_24\IN|accompanied|,|pseudocystic (r_prep) transformation_23\NN|of|as
D014750_D054198 NONE vincristine_9\NN|in|intrathecal|accidental (r_compound) instillation_10\NN|NONE (l_prep) in_11\IN|vincristine|intrathecal|accidental (l_pobj) girl_15\NN|NONE (l_prep) with_16\IN|old|a|year (l_pobj) leucemia_20\NN|NONE
D014750_D054198 NONE vincristine_9\NN|in|intrathecal|accidental (r_compound) instillation_10\NN|NONE (l_prep) in_11\IN|vincristine|intrathecal|accidental (l_pobj) girl_15\NN|NONE (l_prep) with_16\IN|old|a|year (l_pobj) leucemia_20\NN|NONE (l_conj) man_25\NN|lymphoblastic|recurrent|and|acute (l_prep) with_26\IN|old|year|a (l_pobj) lymphoma_28\NN|NONE
D014750_D009410 CID vincristine_28\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposed_26\VBN|NONE (r_acl) areas_25\NNS|NONE (r_pobj) in_24\IN|accompanied|,|pseudocystic (r_prep) transformation_23\NN|of|as (r_conj) degeneration_14\NN|.|investigations (l_prep) of_15\IN|as|transformation (l_pobj) myelin_16\NN|NONE (l_conj) axons_18\NNS|and
D014750_D003711 CID vincristine_28\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposed_26\VBN|NONE (r_acl) areas_25\NNS|NONE (r_pobj) in_24\IN|accompanied|,|pseudocystic (r_prep) transformation_23\NN|of|as (r_conj) degeneration_14\NN|.|investigations (l_prep) of_15\IN|as|transformation (l_pobj) myelin_16\NN|NONE (l_conj) axons_18\NNS|and
D014750_D001927 NONE vincristin_6\NN|intrathecal|accidental|report|: (r_compound) administration_7\NN|to (r_pobj) due_2\IN|Fatal|. (r_prep) myeloencephalopathy_1\NN|NONE
2312209
D007548_D009336 NONE dinitrate_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) administration_19\NN|NONE (r_pobj) following_17\VBG|.|sublingually|necrosis|infarction (r_prep) suffered_8\VBD|NONE (l_nsubj) necrosis_7\NN|.|sublingually|following|infarction
D007548_D009203 CID dinitrate_7\NN|NONE (r_pobj) of_5\IN|sublingual (r_prep) administration_4\NN|NONE (r_dobj) following_2\VBG|.|Myocardial (r_prep) infarction_1\NN|NONE
D007548_D009203 CID dinitrate_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) administration_19\NN|NONE (r_pobj) following_17\VBG|.|sublingually|necrosis|infarction (r_prep) suffered_8\VBD|NONE (l_dobj) infarction_12\NN|.|sublingually|necrosis|following
6229975
D013999_D007238 NONE timolol_17\NN|the (r_compound) group_18\NN|NONE (r_pobj) in_15\IN|unchanged (r_prep) remained_13\VBD|,|and|in|.|size|After (r_conj) increased_7\VBD|NONE (l_punct) ,_4\,|and|remained|in|.|size|After (l_punct) infarction_3\NN|NONE
D013999_D009203 NONE timolol_8\NN|after|term (r_compound) treatment_9\NN|NONE (l_prep) after_10\IN|timolol|term (l_pobj) infarction_12\NN|NONE
D013999_D009203 NONE timolol_6\NN|term|on (r_compound) treatment_7\NN|NONE (r_pobj) of_2\IN|after|The (r_prep) effect_1\NN|was|timolol|.|by|in (l_prep) after_11\IN|of|The (l_pobj) infarction_13\NN|NONE
D013999_D009203 NONE timolol_33\NN|was|.|by|in|effect (r_conj) evaluated_15\VBN|NONE (l_nsubjpass) effect_1\NN|was|timolol|.|by|in (l_prep) after_11\IN|of|The (l_pobj) infarction_13\NN|NONE
D013999_D001919 NONE timolol_6\NN| (r_npadvmod) induced_8\VBN|and|increase (r_amod) bradycardia_9\NN|NONE
10901305
D007649_D004204 NONE ketamine_7\NN|NONE (l_prep) to_8\IN|NONE (l_pobj) manipulation_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) fracture_12\NN|NONE (l_conj) dislocation_14\NN|the|or
D007649_D050723 NONE Ketamine_0\NN|NONE (l_dobj) sedation_1\NN|. (l_prep) for_2\IN|NONE (l_pobj) reduction_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) fractures_8\NNS|NONE
D007649_D050723 NONE ketamine_14\NN|NONE (l_prep) for_15\IN|NONE (l_pobj) sedation_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) fractures_23\NNS|NONE
D007649_D050723 NONE ketamine_7\NN|NONE (l_prep) to_8\IN|NONE (l_pobj) manipulation_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) fracture_12\NN|NONE
D007649_D050723 NONE Ketamine_0\NNP|reliably|quickly|.|sedation (r_nsubj) provided_7\VBD|NONE (l_dobj) sedation_9\NN|reliably|quickly|Ketamine|. (l_acl) facilitate_12\VB|adequate (l_dobj) reduction_14\NN|to|effectively (l_prep) of_15\IN|the (l_pobj) fractures_18\NNS|NONE
7988234
D017706_D000799 CID lisinopril_6\NN|NONE (r_compound) therapy_7\NN|NONE (r_pobj) to_5\IN|A|of (r_prep) history_1\NN|.|was (l_prep) of_2\IN|A|to (l_pobj) angioedema_3\NN|NONE
D008790_D000799 CID metoprolol_6\NN|NONE (r_pobj) of_5\IN|the|intravenous (r_prep) administration_4\NN|NONE (r_dobj) following_1\VBG|. (r_prep) Angioedema_0\NNP|NONE
D008790_D000799 CID metoprolol_12\NN|resulting|During|,|,|was|. (r_nsubjpass) given_14\VBN|NONE (l_advcl) resulting_16\VBG|During|metoprolol|,|,|was|. (l_prep) in_17\IN|NONE (l_pobj) angioedema_19\NN|NONE
D013256_D000799 NONE steroids_7\NNS|NONE (r_pobj) with_5\IN|angioedema|.|after (r_prep) resolved_2\VBD|NONE (l_nsubj) angioedema_1\NN|with|.|after
D004155_D000799 NONE diphenhydramine_9\NN|and|intravenous (r_conj) steroids_7\NNS|NONE (r_pobj) with_5\IN|angioedema|.|after (r_prep) resolved_2\VBD|NONE (l_nsubj) angioedema_1\NN|with|.|after
2054792
D004317_D009369 NONE adriamycin_2\NNS|NONE (r_pobj) of_1\IN|.|combined (r_prep) Effect_0\NN|NONE (l_acl) combined_3\VBN|.|of (l_prep) on_8\IN|with (l_pobj) tumor_9\NN|NONE
D004317_D005334 NONE adriamycin_2\NNS|NONE (r_pobj) of_1\IN|.|combined (r_prep) Effect_0\NN|NONE (l_acl) combined_3\VBN|.|of (l_prep) with_4\IN|on (l_pobj) hyperthermia_7\NN|NONE
D004317_D005334 NONE Adriamycin_3\NNP| (r_npadvmod) mediated_5\VBN|toxicities|and|antitumor (r_amod) activity_7\NN|NONE (l_conj) toxicities_11\NNS|and|antitumor|mediated (l_prep) by_12\IN|normal|tissue (l_pobj) hyperthermia_15\NN|NONE
D004317_D005334 NONE Adriamycin_13\NNP| (r_npadvmod) mediated_15\VBN|antitumor|and|effects|both (r_amod) activity_17\NN|.|hyperthermia (r_dobj) enhanced_11\VBD|NONE (l_nsubj) hyperthermia_2\NN|.|activity
D004317_D005334 NONE Adriamycin_7\NNP| (r_npadvmod) mediated_9\VBN|antitumor (r_amod) effect_11\NN|hyperthermia|while (r_dobj) enhances_6\VBZ|,|,|is|toxicity|also|eroded|and|,|Thus (l_nsubj) hyperthermia_5\NN|effect|while
D004317_D064420 NONE Adriamycin_3\NNP| (r_npadvmod) mediated_5\VBN|toxicities|and|antitumor (r_amod) activity_7\NN|NONE (l_conj) toxicities_11\NNS|and|antitumor|mediated
D004317_D064420 NONE Adriamycin_7\NNP| (r_npadvmod) mediated_9\VBN|antitumor (r_amod) effect_11\NN|hyperthermia|while (r_dobj) enhances_6\VBZ|,|,|is|toxicity|also|eroded|and|,|Thus (r_advcl) increased_18\VBN|NONE (l_nsubjpass) toxicity_15\NN|,|,|is|also|eroded|and|,|Thus|enhances
20621845
D002122_D014652 NONE chloride_18\NN|NONE (l_appos) injury_22\NN|calcium
D002122_D014652 NONE CaCl(2))-induced_20\VBN|(|arterial (r_amod) injury_22\NN|calcium
D002122_D017545 CID CaCl2-induced_14\VBN|aortic|thoracic|in (r_amod) aneurysm_17\NN|degeneration
D002122_D017545 CID chloride_18\NN|NONE (r_pobj) by_16\IN|and|to|model|explore (r_prep) establish_5\VB|.|was|metalloproteinases|study|, (l_dobj) model_8\NN|by|and|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE
D002122_D017545 CID chloride_18\NN|NONE (r_pobj) by_16\IN|and|to|model|explore (r_prep) establish_5\VB|.|was|metalloproteinases|study|, (l_dobj) model_8\NN|by|and|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE (l_appos) TAA_14\NNP|aortic|thoracic|)|(
D002122_D017545 CID chloride_18\NN|NONE (r_pobj) by_16\IN|and|to|model|explore (r_prep) establish_5\VB|.|was|metalloproteinases|study|, (r_xcomp) designed_3\VBN|NONE (l_conj) metalloproteinases_39\NNS|.|establish|was|study|, (l_conj) inhibitors_46\NNS|MMPs|and|)|(|matrix (l_prep) in_50\IN|(|)|their|endogenous|TIMPs (l_pobj) formation_52\NN|NONE (l_compound) TAA_51\NNP|NONE
D002122_D017545 CID CaCl(2))-induced_20\VBN|(|arterial (r_amod) injury_22\NN|calcium (r_appos) chloride_18\NN|NONE (r_pobj) by_16\IN|and|to|model|explore (r_prep) establish_5\VB|.|was|metalloproteinases|study|, (l_dobj) model_8\NN|by|and|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE
D002122_D017545 CID CaCl(2))-induced_20\VBN|(|arterial (r_amod) injury_22\NN|calcium (r_appos) chloride_18\NN|NONE (r_pobj) by_16\IN|and|to|model|explore (r_prep) establish_5\VB|.|was|metalloproteinases|study|, (l_dobj) model_8\NN|by|and|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE (l_appos) TAA_14\NNP|aortic|thoracic|)|(
D002122_D017545 CID CaCl(2))-induced_20\VBN|(|arterial (r_amod) injury_22\NN|calcium (r_appos) chloride_18\NN|NONE (r_pobj) by_16\IN|and|to|model|explore (r_prep) establish_5\VB|.|was|metalloproteinases|study|, (r_xcomp) designed_3\VBN|NONE (l_conj) metalloproteinases_39\NNS|.|establish|was|study|, (l_conj) inhibitors_46\NNS|MMPs|and|)|(|matrix (l_prep) in_50\IN|(|)|their|endogenous|TIMPs (l_pobj) formation_52\NN|NONE (l_compound) TAA_51\NNP|NONE
D002122_D017545 CID )_9\-RRB-|study|model|by (r_punct) establishes_2\VBZ|NONE (l_dobj) model_5\NN|study|)|by (l_compound) TAA_4\NNP|a
1835291
D009241_D029424 NONE bromide_5\NN|NONE (r_pobj) of_3\IN|in|bronchodilating|Acute|. (r_prep) effects_2\NNS|NONE (l_prep) in_8\IN|of|bronchodilating|Acute|. (l_pobj) disease_12\NN|NONE
D009241_D029424 NONE bromide_9\NN|)|tablets|micrograms|ipratropium|(|and (r_compound) aerosol_10\NN|NONE (r_pobj) of_7\IN|titrated|single|a (r_prep) dose_6\NN|NONE (r_pobj) of_3\IN|bronchodilator|The (r_prep) effects_2\NNS|.|in|were (r_nsubjpass) compared_37\VBN|NONE (l_prep) in_38\IN|.|effects|were (l_pobj) study_48\NN|NONE (l_prep) in_49\IN|a|crossover|blind|controlled|, (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_58\NN|NONE
D009241_D029424 NONE ipratropium_4\NN|bronchodilator|that|in (r_nsubj) is_5\VBZ|results|. (l_prep) in_13\IN|bronchodilator|ipratropium|that (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) obstruction_18\NN|NONE
D013806_D029424 NONE theophylline_7\NN|and|ipratropium (r_conj) bromide_5\NN|NONE (r_pobj) of_3\IN|in|bronchodilating|Acute|. (r_prep) effects_2\NNS|NONE (l_prep) in_8\IN|of|bronchodilating|Acute|. (l_pobj) disease_12\NN|NONE
D013806_D029424 NONE theophylline_19\NN|acting (r_amod) tablets_20\NNS|)|bromide|micrograms|ipratropium|(|and (r_conj) aerosol_10\NN|NONE (r_pobj) of_7\IN|titrated|single|a (r_prep) dose_6\NN|NONE (r_pobj) of_3\IN|bronchodilator|The (r_prep) effects_2\NNS|.|in|were (r_nsubjpass) compared_37\VBN|NONE (l_prep) in_38\IN|.|effects|were (l_pobj) study_48\NN|NONE (l_prep) in_49\IN|a|crossover|blind|controlled|, (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_58\NN|NONE
D013806_D029424 NONE theophylline_12\NN|NONE (r_pobj) than_10\IN|a|potent (r_prep) bronchodilator_9\NN|ipratropium|that|in (r_attr) is_5\VBZ|results|. (l_prep) in_13\IN|bronchodilator|ipratropium|that (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) obstruction_18\NN|NONE
D013806_D005767 CID theophylline_9\JJ|NONE (r_amod) use_10\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) experienced_7\VBN|NONE (r_acl) those_6\DT|systems|.|were|did|, (r_nsubj) involve_12\VB|NONE (l_dobj) systems_17\NNS|.|were|those|did|,
D013806_D002318 CID theophylline_9\JJ|NONE (r_amod) use_10\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) experienced_7\VBN|NONE (r_acl) those_6\DT|systems|.|were|did|, (r_nsubj) involve_12\VB|NONE (l_dobj) systems_17\NNS|.|were|those|did|,
347884
D006220_D019967 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|double|the|blind (r_prep) study_4\NN|NONE (r_pobj) In_0\IN|.|be|were|,|substances (r_prep) found_11\VBN|NONE (l_xcomp) be_13\VB|In|.|were|,|substances (l_acomp) effective_15\JJ|to (l_prep) in_16\IN|highly (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) syndromes_21\NNS|NONE (l_acl) belonging_22\VBG|psychotic (l_prep) to_24\IN|predominantly (l_pobj) group_27\NN|NONE
2445283
D012254_D000740 CID ribavirin_7\NN|managed|that|effect|,|and (r_nsubj) has_8\VBZ|,|we|From (l_conj) managed_31\VBN|ribavirin|that|effect|,|and (l_nsubjpass) anemia_20\NN|be|.|easily|can
D012254_D006478 NONE ribavirin_5\NN|NONE (r_pobj) of_4\IN|antiviral (r_prep) effect_3\NN|.|and|in (r_conj) Tolerance_0\NN|NONE (l_prep) in_6\IN|effect|.|and (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) fever_11\NN|NONE
D012254_D006478 NONE ribavirin_5\NN|NONE (r_pobj) of_4\IN|antiviral (r_prep) effect_3\NN|and (r_conj) Tolerance_0\NN|was|in|. (r_nsubjpass) studied_7\VBN|NONE (l_prep) in_8\IN|Tolerance|was|. (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN| (l_pobj) fever_14\NN|NONE
D012254_D006478 NONE ribavirin_5\NN|NONE (r_pobj) of_4\IN|antiviral (r_prep) effect_3\NN|and (r_conj) Tolerance_0\NN|was|in|. (r_nsubjpass) studied_7\VBN|NONE (l_prep) in_8\IN|Tolerance|was|. (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN| (l_pobj) fever_14\NN|NONE (l_appos) AHF_16\NNP|(|)|of|Argentine|hemorrhagic
D012254_D006478 NONE ribavirin_7\NN|managed|that|effect|,|and (r_nsubj) has_8\VBZ|,|we|From (l_dobj) effect_11\NN|ribavirin|managed|that|,|and (l_prep) in_12\IN|an|antiviral (l_pobj) cases_14\NNS|NONE (l_prep) of_15\IN|advanced (l_pobj) AHF_16\NNP|NONE
D012254_D006478 NONE ribavirin_5\RB|NONE (r_pobj) of_4\IN|possible|during|The|beneficial (r_prep) effect_3\NN|.|is (l_prep) during_6\IN|possible|of|The|beneficial (l_pobj) days_9\NNS|NONE (l_prep) of_10\IN|the|initial (l_pobj) AHF_11\NNP|NONE
D012254_D014766 NONE ribavirin_2\RB|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|in|. (r_nsubj) resulted_3\VBD|NONE (l_prep) in_4\IN|Administration|. (l_pobj) neutralization_6\NN|NONE (l_prep) of_7\IN|and|a|drop (l_pobj) viremia_8\NN|NONE
17854040
D012964_D006509 NONE na_9\TO|Mutations|virus|. (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_amod) infected_17\JJ|with
D012964_D006509 NONE na_9\TO|Mutations|virus|. (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|for|: (l_amod) infected_37\VBN|African
D012964_D006509 NONE na_21\NN|with|carriers (r_aux) ve_22\VB|investigate|exploratory|an|strains (r_acl) study_4\NN|.|This (l_acl) investigate_6\VB|exploratory|an|strains|ve (l_dobj) virus_12\NN|to (l_compound) B_11\NN|resistant
D012964_D006509 NONE na_21\TO|patients (r_aux) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D012964_D015658 NONE na_9\TO|Mutations|virus|. (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_punct) :_26\:|for|patients (l_punct) infection_25\NN|NONE
D012964_D015658 NONE na_9\TO|Mutations|virus|. (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|for|: (l_amod) infected_37\VBN|African
D012964_D015658 NONE na_21\NN|with|carriers (r_aux) ve_22\VB|investigate|exploratory|an|strains (r_acl) study_4\NN|.|This (r_attr) was_1\VBD|NONE (l_punct) ._41\.|study|This (l_punct) in_37\IN|NONE (l_punct) infection_36\NN|patients
D012964_D015658 NONE na_21\TO|patients (r_aux) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D019259_D015658 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|na|virus|. (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_punct) :_26\:|for|patients (l_punct) infection_25\NN|NONE
D019259_D015658 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|na|virus|. (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|for|: (l_amod) infected_37\VBN|African
D019259_D015658 NONE lamivudine_7\JJ| (r_npadvmod) resistant_9\JJ|B (r_amod) virus_12\NN|to (r_dobj) investigate_6\VB|exploratory|an|strains|ve (r_acl) study_4\NN|.|This (r_attr) was_1\VBD|NONE (l_punct) ._41\.|study|This (l_punct) in_37\IN|NONE (l_punct) infection_36\NN|patients
D019259_D015658 NONE lamivudine_19\NN|selected| (r_compound) na_21\NN|with|carriers (r_aux) ve_22\VB|investigate|exploratory|an|strains (r_acl) study_4\NN|.|This (r_attr) was_1\VBD|NONE (l_punct) ._41\.|study|This (l_punct) in_37\IN|NONE (l_punct) infection_36\NN|patients
D019259_D015658 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|HBV (r_amod) strains_4\NNS|patients|were|in|and|. (r_nsubjpass) detected_6\VBN|NONE (l_conj) patients_28\NNS|were|strains|in|and|. (l_amod) infected_27\VBN|
D019259_D015658 NONE lamivudine_14\NN| (r_npadvmod) resistant_16\JJ|in|HBV (r_amod) strains_17\NNS|NONE (l_prep) in_18\IN|HBV|resistant (l_pcomp) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D019259_D015658 NONE lamivudine_22\NN||treatment|when (r_npadvmod) containing_24\VBG|of|widespread (r_advcl) emergence_16\NN|NONE (r_pobj) in_14\IN|applied|whether|mutations|could (r_prep) result_13\VB|to|be (l_conj) applied_38\VBN|whether|mutations|could|in (l_advcl) is_45\VBZ|become|regimens|widely|,|in (l_acomp) likely_46\JJ|this|as (l_xcomp) have_48\VB|NONE (l_dobj) implications_50\NNS|to (l_prep) in_51\IN|potential (l_pobj) management_53\NN|NONE (l_prep) of_54\IN|the (l_pobj) patients_61\NNS|NONE (l_amod) infected_60\VBN|NONE
D019259_D006509 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|na|virus|. (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_amod) infected_17\JJ|with
D019259_D006509 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|na|virus|. (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|na|Mutations|. (l_appos) patients_18\NNS|B|)|HBV|( (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|for|: (l_amod) infected_37\VBN|African
D019259_D006509 NONE lamivudine_7\JJ| (r_npadvmod) resistant_9\JJ|B (r_amod) virus_12\NN|to (l_compound) B_11\NN|resistant
D019259_D006509 NONE lamivudine_19\NN|selected| (r_compound) na_21\NN|with|carriers (r_aux) ve_22\VB|investigate|exploratory|an|strains (r_acl) study_4\NN|.|This (l_acl) investigate_6\VB|exploratory|an|strains|ve (l_dobj) virus_12\NN|to (l_compound) B_11\NN|resistant
D019259_D006509 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|HBV (r_amod) strains_4\NNS|patients|were|in|and|. (r_nsubjpass) detected_6\VBN|NONE (l_prep) in_7\IN|patients|were|strains|and|. (l_pobj) patients_17\NNS|NONE (l_compound) B_16\NNP|chronic||infected
D019259_D006509 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|HBV (r_amod) strains_4\NNS|patients|were|in|and|. (r_nsubjpass) detected_6\VBN|NONE (l_conj) patients_28\NNS|were|strains|in|and|. (l_amod) infected_27\VBN|
D019259_D006509 NONE lamivudine_14\NN| (r_npadvmod) resistant_16\JJ|in|HBV (r_amod) strains_17\NNS|NONE (l_prep) in_18\IN|HBV|resistant (l_pcomp) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D019259_D006509 NONE lamivudine_22\NN||treatment|when (r_npadvmod) containing_24\VBG|of|widespread (r_advcl) emergence_16\NN|NONE (r_pobj) in_14\IN|applied|whether|mutations|could (r_prep) result_13\VB|to|be (l_conj) applied_38\VBN|whether|mutations|could|in (l_advcl) is_45\VBZ|become|regimens|widely|,|in (l_acomp) likely_46\JJ|this|as (l_xcomp) have_48\VB|NONE (l_dobj) implications_50\NNS|to (l_prep) in_51\IN|potential (l_pobj) management_53\NN|NONE (l_prep) of_54\IN|the (l_pobj) patients_61\NNS|NONE (l_amod) infected_60\VBN|NONE
7468724
D013726_D007752 NONE terbutaline_4\JJ|for (r_compound) treatment_5\NN|NONE (l_prep) for_6\IN|terbutaline (l_pobj) labor_8\NN|NONE
D013726_D007752 NONE terbutaline_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) labor_14\NN|NONE
D013726_D002318 CID terbutaline_4\JJ|for (r_compound) treatment_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Cardiovascular (r_acl) complications_1\NNS|NONE
D013726_D002318 CID terbutaline_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN| (r_acl) patients_8\NNS|NONE (r_pobj) in_4\IN|complications|. (r_prep) occurred_3\VBD|NONE (l_nsubj) complications_2\NNS|in|.
7269015
D003520_D003556 NONE cyclophosphamide_13\NN| (r_npadvmod) induced_15\VBN|and|both (r_conj) radiation_11\NN|NONE (r_nmod) cystitis_16\NN|busulfan|and (r_conj) cystitis_8\NN|NONE
D003520_D003556 NONE cyclophosphamide_13\NN| (r_npadvmod) induced_15\VBN|and|both (r_conj) radiation_11\NN|NONE (r_nmod) cystitis_16\NN|busulfan|and
D002066_D006470 CID Busulfan_0\NNS| (r_npadvmod) induced_2\VBN|hemorrhagic|. (r_amod) cystitis_4\NN|NONE
D002066_D006470 CID busulfan_4\NNS| (r_npadvmod) induced_6\VBN|hemorrhage|a (r_amod) cystitis_8\NN|NONE
D002066_D002277 NONE busulfan_7\NNS|NONE (r_pobj) of_6\IN|known|the (r_prep) tendency_5\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) view_1\NN|induce (r_pobj) In_0\IN|cytology|,|in|is|. (l_advcl) induce_9\VB|view (l_dobj) atypia_11\NN|to (l_conj) carcinoma_13\NN|in|cellular|and
D002066_D003556 CID Busulfan_0\NNS| (r_npadvmod) induced_2\VBN|hemorrhagic|. (r_amod) cystitis_4\NN|NONE
D002066_D003556 CID busulfan_4\NNS| (r_npadvmod) induced_6\VBN|hemorrhage|a (r_amod) cystitis_8\NN|NONE
D002066_D003556 CID busulfan_7\NNS|and|cystitis (r_amod) cystitis_8\NN|NONE
D002066_D003556 CID busulfan_7\NNS|and|cystitis (r_amod) cystitis_8\NN|NONE (l_conj) cystitis_16\NN|busulfan|and
15899738
D003401_D001281 CID creatine_5\NN|monohydrate (r_compound) supplementation_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|Lone|atrial (r_acl) fibrillation_2\NN|NONE
D003401_D001145 NONE creatine_5\NN|reports|.|have (l_prep) to_6\IN|NONE (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) arrhythmia_10\NN|NONE
12615818
D017373_D011085 NONE acetate_1\NN|is|and|.|for|estradiol|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE
D017373_D011085 NONE acetate_1\NN|is|and|.|for|estradiol|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|ovary|)|(|polycystic
D017373_D011085 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE
D017373_D011085 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|ovary|)|(|polycystic
D017373_D011085 NONE CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|Using|.|years|analysis|we (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|Using|.|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|, (l_conj) PCOS_33\NNP|or
D017373_D011085 NONE CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (l_prep) in_16\IN|of|the (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|, (l_conj) PCOS_23\NNP|or
D003276_D054556 NONE contraceptives_23\NNS|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|have|.|risk|studies (r_prep) demonstrated_3\VBN|NONE (l_dobj) risk_6\NN|have|.|compared|studies (l_prep) of_7\IN|increased|an (l_pobj) thromboembolism_9\NN|NONE
D003276_D054556 NONE contraceptives_23\NNS|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|have|.|risk|studies (r_prep) demonstrated_3\VBN|NONE (l_dobj) risk_6\NN|have|.|compared|studies (l_prep) of_7\IN|increased|an (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|venous|associated|)
D004997_D006628 NONE estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D004997_D006628 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D004997_D006628 NONE EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|Using|.|years|analysis|we (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|Using|.|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|,
D004997_D006628 NONE EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (l_prep) in_16\IN|of|the (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|,
D017373_D000152 NONE acetate_1\NN|is|and|.|for|estradiol|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D017373_D000152 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D017373_D000152 NONE CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|Using|.|years|analysis|we (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|Using|.|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE
D017373_D000152 NONE CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (l_prep) in_16\IN|of|the (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE
D017373_D006628 NONE acetate_1\NN|is|and|.|for|estradiol|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D017373_D006628 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D017373_D006628 NONE CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|Using|.|years|analysis|we (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|Using|.|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|,
D017373_D006628 NONE CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (l_prep) in_16\IN|of|the (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|,
D004997_D054556 CID estradiol_14\NN|of|The|. (r_appos) risk_1\NN|NONE (l_prep) of_2\IN|estradiol|The|. (l_pobj) thromboembolism_4\NN|NONE
D004997_D054556 CID EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|venous|VTE|) (r_acl) thromboembolism_9\NN|NONE
D004997_D054556 CID EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|venous|VTE|) (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|venous|associated|)
D004997_D054556 CID EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE
D004997_D054556 CID EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|confounding (r_prep) associated_8\VBN|of|increased|an (r_acl) risk_5\NN|have|.|We|excluded (l_prep) of_6\IN|increased|an|associated (l_pobj) VTE_7\NNP|NONE
D004997_D011085 NONE estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE
D004997_D011085 NONE estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|ovary|)|(|polycystic
D004997_D011085 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE
D004997_D011085 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|and|.|for|estradiol|in (l_attr) option_30\NN|also (l_prep) for_31\IN|treatment|a (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|ovary|)|(|polycystic
D004997_D011085 NONE EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|Using|.|years|analysis|we (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|Using|.|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|, (l_conj) PCOS_33\NNP|or
D004997_D011085 NONE EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (l_prep) in_16\IN|of|the (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|, (l_conj) PCOS_23\NNP|or
D017373_D054556 CID acetate_9\NN|cyproterone (r_oprd) prescribed_7\VBD|NONE (r_acl) women_6\NNS|NONE (r_pobj) in_5\IN|venous (r_prep) thromboembolism_4\NN|NONE
D017373_D054556 CID CPA_15\NNP|/ (r_nmod) EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|venous|VTE|) (r_acl) thromboembolism_9\NN|NONE
D017373_D054556 CID CPA_15\NNP|/ (r_nmod) EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|venous|VTE|) (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|venous|associated|)
D017373_D054556 CID CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE
D017373_D054556 CID CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|confounding (r_prep) associated_8\VBN|of|increased|an (r_acl) risk_5\NN|have|.|We|excluded (l_prep) of_6\IN|increased|an|associated (l_pobj) VTE_7\NNP|NONE
D004997_D000152 NONE estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D004997_D000152 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|and|.|for|is|in (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|and|.|estradiol|is|in (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D004997_D000152 NONE EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|Using|.|years|analysis|we (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|Using|.|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE
D004997_D000152 NONE EE_15\NNP|NONE (r_pobj) of_12\IN|in|the (r_prep) use_11\NN|NONE (l_prep) in_16\IN|of|the (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE
12483326
D002945_D009916 NONE cisplatin_11\NN|NONE (r_pcomp) than_10\IN|,|milder|side (r_prep) effects_9\NNS|to (r_dobj) have_6\VB|carboplatin|known|,|is|Generally|. (r_xcomp) said_4\VBN|NONE (l_ccomp) known_20\JJ|carboplatin|have|,|is|Generally|. (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D002945_D005128 NONE cisplatin_11\NN|NONE (r_pcomp) than_10\IN|,|milder|side (r_prep) effects_9\NNS|to (r_dobj) have_6\VB|carboplatin|known|,|is|Generally|. (r_xcomp) said_4\VBN|NONE (l_ccomp) known_20\JJ|carboplatin|have|,|is|Generally|. (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D016190_D005909 NONE carboplatin_9\NN|NONE (r_pobj) of_8\IN|intracarotid|for (r_prep) injection_7\NN|NONE (l_prep) for_10\IN|of|intracarotid (l_pobj) glioblastomas_12\NNS|NONE
D016190_D005909 NONE carboplatin_10\NN|NONE (r_pobj) of_9\IN|in|for|intracarotid|an (r_prep) injection_8\NN|man|. (l_prep) for_11\IN|in|of|intracarotid|an (l_pobj) glioblastomas_13\NNS|NONE
D016190_D005128 NONE carboplatin_9\NN|NONE (r_pobj) of_8\IN|intracarotid|for (r_prep) injection_7\NN|NONE (r_pobj) after_5\IN|ocular|.|Severe (r_prep) toxicity_4\NN|NONE
D016190_D005128 NONE carboplatin_2\NN|known|have|,|is|Generally|. (r_nsubjpass) said_4\VBN|NONE (l_ccomp) known_20\JJ|carboplatin|have|,|is|Generally|. (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D016190_D005128 NONE carboplatin_16\NN|NONE (r_pobj) of_15\IN|intracarotid|,|reported (r_prep) injection_14\NN|NONE (r_pobj) after_12\IN|However|,|case|.|we (r_prep) experienced_3\VBD|NONE (l_dobj) case_5\NN|However|,|.|after|we (l_prep) of_6\IN|a (l_pobj) toxicity_11\NN|NONE
D016190_D005128 NONE carboplatin_5\NN|NONE (r_pobj) of_4\IN|intracarotid (r_prep) injection_3\NN|When (r_dobj) performing_1\VBG|we|,|must|.|aware (r_advcl) be_9\VB|NONE (l_acomp) aware_10\JJ|we|,|must|.|performing (l_prep) of_11\IN|NONE (l_pobj) toxicity_16\NN|NONE
D016190_D009916 NONE carboplatin_9\NN|NONE (r_pobj) of_8\IN|intracarotid|for (r_prep) injection_7\NN|NONE (r_pobj) after_5\IN|ocular|.|Severe (r_prep) toxicity_4\NN|NONE
D016190_D009916 NONE carboplatin_2\NN|known|have|,|is|Generally|. (r_nsubjpass) said_4\VBN|NONE (l_ccomp) known_20\JJ|carboplatin|have|,|is|Generally|. (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D016190_D009916 NONE carboplatin_16\NN|NONE (r_pobj) of_15\IN|intracarotid|,|reported (r_prep) injection_14\NN|NONE (r_pobj) after_12\IN|However|,|case|.|we (r_prep) experienced_3\VBD|NONE (l_dobj) case_5\NN|However|,|.|after|we (l_prep) of_6\IN|a (l_pobj) toxicity_11\NN|NONE
D016190_D064420 NONE carboplatin_7\NN|NONE (r_amod) toxicity_8\NN|NONE
7292072
D003891_D017180 CID desipramine_4\JJ|NONE (r_amod) toxicity_5\NN|NONE (r_pobj) in_3\IN|.|ventricular|Variant (r_prep) tachycardia_2\NN|NONE
D003891_D017180 CID desipramine_10\NN|NONE (r_amod) toxicity_11\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|variant|ventricular (r_acl) tachycardia_7\NN|NONE
D003891_D064420 NONE desipramine_4\JJ|NONE (r_amod) toxicity_5\NN|NONE
D003891_D064420 NONE desipramine_10\NN|NONE (r_amod) toxicity_11\NN|NONE
9401499
D013988_D000741 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|aplastic|report|:|. (r_amod) anemia_4\NN|NONE
D013988_D000741 CID ticlopidine_8\NN| (r_npadvmod) induced_10\VBN|aplastic (r_amod) anemia_12\NN|NONE
D013988_D000741 CID ticlopidine_2\NN| (r_npadvmod) induced_4\VBN|aplastic|with (r_amod) anemia_6\NN|NONE
D013988_D000380 CID ticlopidine_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) initiation_7\NN|weeks (r_pobj) after_6\IN|,|Agranulocytosis (r_prep) occurred_1\VBD|is|.|examination (l_nsubj) Agranulocytosis_0\NN|,|after
9195768
D018170_D010292 CID sumatriptan_7\NN|NONE (r_pobj) of_5\IN|the (r_prep) use_4\NN|NONE (r_dobj) following_2\VBG|Atypical (r_prep) sensations_1\NNS|of|but|common|.|,
17147461
D000804_D011507 NONE II_52\CD|receptor|angiotensin (r_compound) blockers_54\NNS|converting|or|enzyme (r_conj) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|close|of|,|occurs (r_conj) monitoring_36\NN|,|in|the|of (l_prep) of_37\IN|close|use|,|occurs (l_pobj) proteinuria_38\NN|NONE
D000804_D011507 NONE II_52\CD|receptor|angiotensin (r_compound) blockers_54\NNS|converting|or|enzyme (r_conj) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|close|of|,|occurs (r_conj) monitoring_36\NN|,|in|the|of (l_advcl) occurs_57\VBZ|close|of|use|, (l_nsubj) proteinuria_56\NN|withdrawal|and|if|needed
D000809_D011507 NONE angiotensin_45\NN| (r_npadvmod) converting_47\VBG|blockers|or|enzyme (r_amod) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|close|of|,|occurs (r_conj) monitoring_36\NN|,|in|the|of (l_prep) of_37\IN|close|use|,|occurs (l_pobj) proteinuria_38\NN|NONE
D000809_D011507 NONE angiotensin_45\NN| (r_npadvmod) converting_47\VBG|blockers|or|enzyme (r_amod) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|close|of|,|occurs (r_conj) monitoring_36\NN|,|in|the|of (l_advcl) occurs_57\VBZ|close|of|use|, (l_nsubj) proteinuria_56\NN|withdrawal|and|if|needed
D020123_D011507 CID Sirolimus_0\NNP| (r_npadvmod) associated_2\VBN|and|.|dysfunction (r_amod) proteinuria_3\NN|NONE
D020123_D011507 CID sirolimus_11\NN|with|,|is|,|that|under (r_nsubjpass) associated_13\VBN|However|,|reports|. (l_prep) with_14\IN|sirolimus|,|is|,|that|under (l_pobj) proteinuria_15\NN|NONE
D020123_D011507 CID sirolimus_3\NN| (r_npadvmod) associated_5\VBN|NONE (r_amod) proteinuria_6\NN|NONE
D020123_D011507 CID sirolimus_21\NN|NONE (r_pobj) of_20\IN|the|molecular|on (r_prep) effects_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) knowledge_15\NN|NONE (r_pobj) by_14\IN|occur|,|.|,|be|use|could|occurrence (r_agent) minimised_13\VBN|NONE (l_dep) use_27\NN|occur|,|.|,|be|by|could|occurrence (l_appos) monitoring_36\NN|,|in|the|of (l_prep) of_37\IN|close|use|,|occurs (l_pobj) proteinuria_38\NN|NONE
D020123_D011507 CID sirolimus_21\NN|NONE (r_pobj) of_20\IN|the|molecular|on (r_prep) effects_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) knowledge_15\NN|NONE (r_pobj) by_14\IN|occur|,|.|,|be|use|could|occurrence (r_agent) minimised_13\VBN|NONE (l_dep) use_27\NN|occur|,|.|,|be|by|could|occurrence (l_appos) monitoring_36\NN|,|in|the|of (l_advcl) occurs_57\VBZ|close|of|use|, (l_nsubj) proteinuria_56\NN|withdrawal|and|if|needed
D020123_D011507 CID sirolimus_29\NN|NONE (r_pobj) of_28\IN|,|in|monitoring|the (r_prep) use_27\NN|occur|,|.|,|be|by|could|occurrence (l_appos) monitoring_36\NN|,|in|the|of (l_prep) of_37\IN|close|use|,|occurs (l_pobj) proteinuria_38\NN|NONE
D020123_D011507 CID sirolimus_29\NN|NONE (r_pobj) of_28\IN|,|in|monitoring|the (r_prep) use_27\NN|occur|,|.|,|be|by|could|occurrence (l_appos) monitoring_36\NN|,|in|the|of (l_advcl) occurs_57\VBZ|close|of|use|, (l_nsubj) proteinuria_56\NN|withdrawal|and|if|needed
D020123_D058186 NONE sirolimus_11\NN|with|,|is|,|that|under (r_nsubjpass) associated_13\VBN|However|,|reports|. (l_prep) with_14\IN|sirolimus|,|is|,|that|under (l_pobj) proteinuria_15\NN|NONE (l_conj) dysfunction_19\NN|and
D020123_D058186 NONE sirolimus_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|renal|The|(|)|as|acute (r_acl) dysfunction_3\NN|due|may|.
D020123_D007674 CID Sirolimus_0\NNP| (r_npadvmod) associated_2\VBN|and|.|dysfunction (r_amod) proteinuria_3\NN|NONE (l_conj) dysfunction_6\NN|and|.|associated
D020123_D007674 CID Sirolimus_0\NNP|.|advance (r_nsubj) represents_1\VBZ|NONE (l_dobj) advance_5\NN|.|Sirolimus (l_prep) in_6\IN|major|therapeutic|a (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) rejection_13\NN|NONE (l_conj) nephropathy_17\NN|allograft|acute|and
D020123_D007674 CID sirolimus_1\NN|Because|vasomotor|effects|not|does (r_nsubj) share_4\VB|drug|,|it|.|has|been (r_advcl) designated_18\VBN|NONE (l_oprd) drug_24\NN|,|it|.|has|been|share (l_amod) nephrotoxic_23\JJ|'|a|'
12464714
D004878_D006970 NONE ergotamine_19\NNP|/ (r_nmod) caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (l_appos) nausea_34\NN|common|>|,|The|(|adverse (l_conj) somnolence_42\NN|and|)|.|(
D004878_D004244 NONE ergotamine_19\NNP|/ (r_nmod) caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (r_nsubj) were_25\VBD|NONE (l_attr) dizziness_26\NN|,|events|respectively|,|.
D002110_D008881 NONE caffeine_13\NN|of|Crossover|. (l_prep) in_14\IN|ergotamine|mg|/ (l_pobj) migraine_15\NN|NONE
D002110_D008881 NONE caffeine_22\NN| (r_appos) ergotamine_18\NN|NONE (r_pobj) to_16\IN|mg (r_prep) tablet_15\NN| (r_amod) rizatriptan_12\JJ|NONE (r_pobj) for_10\IN|the (r_prep) preference_9\NN|tablets|.|study|in (r_dobj) assessed_7\VBD|NONE (l_prep) in_26\IN|tablets|preference|.|study (l_pobj) patients_28\NNS|NONE (l_acl) treating_29\VBG| (l_dobj) attack_33\NN|NONE (l_compound) migraine_32\JJ|a|single|with
C093622_D010146 NONE rizatriptan_12\NN|NONE (r_pobj) after_11\IN| (r_prep) h_10\NN|free|.|,|compared|being|percent|, (r_npadvmod) were_6\VBD|NONE (l_acomp) free_8\JJ|.|,|compared|being|percent|h|, (l_npadvmod) pain_7\NN|NONE
C093622_D010146 NONE rizatriptan_31\JJ|superior|within (r_nsubj) being_32\VBG|free|.|,|compared|percent|h|, (r_advcl) were_6\VBD|NONE (l_acomp) free_8\JJ|.|,|compared|being|percent|h|, (l_npadvmod) pain_7\NN|NONE
C093622_D010146 NONE rizatriptan_6\NN|NONE (r_dobj) taking_5\VBG|NONE (r_acl) patients_4\NNS|NONE (r_pobj) of_3\IN| (r_prep) %_2\NN|and|had|.|compared|at|,|free (r_nsubj) were_7\VBD|NONE (l_acomp) free_9\JJ|and|had|.|compared|at|,|% (l_npadvmod) pain_8\NN|NONE
C093622_D004244 CID rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (r_nsubj) were_25\VBD|NONE (l_attr) dizziness_26\NN|,|events|respectively|,|.
D002110_D012001 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no (l_conj) phonophobia_19\NNS|and|,|for
C093622_D012001 NONE Rizatriptan_0\NNP|.|h|superior|also (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|.|h|Rizatriptan|also (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no (l_conj) phonophobia_19\NNS|and|,|for
D002110_D014839 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no
D002110_D004244 NONE caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (r_nsubj) were_25\VBD|NONE (l_attr) dizziness_26\NN|,|events|respectively|,|.
D012701_D008881 NONE 5-HT(1B/1D_4\CD|) (r_nummod) receptor_6\NN|with|a|selective (r_compound) agonist_7\NN|.|Rizatriptan (l_prep) with_8\IN|receptor|a|selective (l_pobj) absorption_11\NN|NONE (l_conj) onset_14\NN|and|oral|rapid (l_prep) in_17\IN|early|of (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|the|acute (l_pobj) migraine_22\NN|NONE
D004878_D014839 NONE ergotamine_5\NN|in|/ (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no
C093622_D006261 NONE rizatriptan_19\JJ|NONE (r_dobj) preferring_18\VBG|NONE (r_acl) patients_17\NNS|NONE (r_pobj) of_16\IN|. (r_prep) %_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) cited_12\VBN|the|for|important|, (r_acl) reason_8\NN|.|relief (r_attr) was_4\VBD|NONE (l_nsubj) relief_1\NN|.|reason (l_prep) of_2\IN|Faster (l_pobj) headache_3\NN|NONE
D004878_D008881 NONE ergotamine_11\NN|in|mg|/ (r_nmod) caffeine_13\NN|of|Crossover|. (l_prep) in_14\IN|ergotamine|mg|/ (l_pobj) migraine_15\NN|NONE
D004878_D008881 NONE ergotamine_18\NN|NONE (r_pobj) to_16\IN|mg (r_prep) tablet_15\NN| (r_amod) rizatriptan_12\JJ|NONE (r_pobj) for_10\IN|the (r_prep) preference_9\NN|tablets|.|study|in (r_dobj) assessed_7\VBD|NONE (l_prep) in_26\IN|tablets|preference|.|study (l_pobj) patients_28\NNS|NONE (l_acl) treating_29\VBG| (l_dobj) attack_33\NN|NONE (l_compound) migraine_32\JJ|a|single|with
C093622_D009325 CID Rizatriptan_0\NNP|.|h|superior|also (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|.|h|Rizatriptan|also (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE
C093622_D009325 CID rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (l_appos) nausea_34\NN|common|>|,|The|(|adverse
C093622_D020795 NONE Rizatriptan_0\NNP|.|h|superior|also (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|.|h|Rizatriptan|also (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no (l_conj) phonophobia_19\NNS|and|,|for (l_conj) photophobia_21\NNS|or
D002110_D009325 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE
D002110_D009325 NONE caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (l_appos) nausea_34\NN|common|>|,|The|(|adverse
D004878_D012001 NONE ergotamine_5\NN|in|/ (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no (l_conj) phonophobia_19\NNS|and|,|for
D002110_D020795 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no (l_conj) phonophobia_19\NNS|and|,|for (l_conj) photophobia_21\NNS|or
D004878_D020795 NONE ergotamine_5\NN|in|/ (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no (l_conj) phonophobia_19\NNS|and|,|for (l_conj) photophobia_21\NNS|or
C093622_D006970 NONE rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (l_appos) nausea_34\NN|common|>|,|The|(|adverse (l_conj) somnolence_42\NN|and|)|.|(
D004878_D009325 NONE ergotamine_5\NN|in|/ (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE
D004878_D009325 NONE ergotamine_19\NNP|/ (r_nmod) caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (l_appos) nausea_34\NN|common|>|,|The|(|adverse
C093622_D014839 NONE Rizatriptan_0\NNP|.|h|superior|also (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|.|h|Rizatriptan|also (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|ergotamine|/ (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|,|no
D002110_D010146 NONE caffeine_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|. (r_acl) %_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) compared_14\VBN|free|.|,|being|percent|h|, (r_prep) were_6\VBD|NONE (l_acomp) free_8\JJ|.|,|compared|being|percent|h|, (l_npadvmod) pain_7\NN|NONE
D002110_D010146 NONE caffeine_35\NN|NONE (r_pobj) on_32\IN|NONE (r_prep) patients_31\NNS|NONE (r_pobj) of_30\IN| (r_prep) %_29\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) compared_26\VBN|and|had|.|at|,|%|free (r_prep) were_7\VBD|NONE (l_acomp) free_9\JJ|and|had|.|compared|at|,|% (l_npadvmod) pain_8\NN|NONE
D002110_D006261 NONE caffeine_29\NN|who (r_dobj) preferred_26\VBD|NONE (r_relcl) patients_24\NNS|NONE (r_pobj) of_23\IN|. (r_prep) %_22\NN|and (r_conj) rizatriptan_19\JJ|NONE (r_dobj) preferring_18\VBG|NONE (r_acl) patients_17\NNS|NONE (r_pobj) of_16\IN|. (r_prep) %_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) cited_12\VBN|the|for|important|, (r_acl) reason_8\NN|.|relief (r_attr) was_4\VBD|NONE (l_nsubj) relief_1\NN|.|reason (l_prep) of_2\IN|Faster (l_pobj) headache_3\NN|NONE
C093622_D008881 NONE rizatriptan_7\JJ|NONE (r_pobj) for_6\IN|NONE (r_prep) preference_5\NN|and (r_conj) efficacy_3\NN|NONE (r_pobj) of_2\IN|caffeine|Crossover|. (r_prep) comparison_1\NN|NONE (l_conj) caffeine_13\NN|of|Crossover|. (l_prep) in_14\IN|ergotamine|mg|/ (l_pobj) migraine_15\NN|NONE
C093622_D008881 NONE Rizatriptan_0\NNP|.|agonist (r_nsubj) is_1\VBZ|NONE (l_attr) agonist_7\NN|.|Rizatriptan (l_prep) with_8\IN|receptor|a|selective (l_pobj) absorption_11\NN|NONE (l_conj) onset_14\NN|and|oral|rapid (l_prep) in_17\IN|early|of (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|the|acute (l_pobj) migraine_22\NN|NONE
C093622_D008881 NONE rizatriptan_12\JJ|NONE (r_pobj) for_10\IN|the (r_prep) preference_9\NN|tablets|.|study|in (r_dobj) assessed_7\VBD|NONE (l_prep) in_26\IN|tablets|preference|.|study (l_pobj) patients_28\NNS|NONE (l_acl) treating_29\VBG| (l_dobj) attack_33\NN|NONE (l_compound) migraine_32\JJ|a|single|with
D004878_D010146 NONE ergotamine_20\NN|.|/ (r_nmod) caffeine_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|. (r_acl) %_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) compared_14\VBN|free|.|,|being|percent|h|, (r_prep) were_6\VBD|NONE (l_acomp) free_8\JJ|.|,|compared|being|percent|h|, (l_npadvmod) pain_7\NN|NONE
D004878_D010146 NONE ergotamine_33\NNP|/|. (r_nmod) caffeine_35\NN|NONE (r_pobj) on_32\IN|NONE (r_prep) patients_31\NNS|NONE (r_pobj) of_30\IN| (r_prep) %_29\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) compared_26\VBN|and|had|.|at|,|%|free (r_prep) were_7\VBD|NONE (l_acomp) free_9\JJ|and|had|.|compared|at|,|% (l_npadvmod) pain_8\NN|NONE
D004878_D006261 NONE ergotamine_27\NN|/ (r_nmod) caffeine_29\NN|who (r_dobj) preferred_26\VBD|NONE (r_relcl) patients_24\NNS|NONE (r_pobj) of_23\IN|. (r_prep) %_22\NN|and (r_conj) rizatriptan_19\JJ|NONE (r_dobj) preferring_18\VBG|NONE (r_acl) patients_17\NNS|NONE (r_pobj) of_16\IN|. (r_prep) %_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) cited_12\VBN|the|for|important|, (r_acl) reason_8\NN|.|relief (r_attr) was_4\VBD|NONE (l_nsubj) relief_1\NN|.|reason (l_prep) of_2\IN|Faster (l_pobj) headache_3\NN|NONE
D002110_D006970 NONE caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|incidence|or (r_prep) >_7\XX|common|nausea|,|The|(|adverse (r_appos) events_4\NNS|,|respectively|,|.|dizziness (l_appos) nausea_34\NN|common|>|,|The|(|adverse (l_conj) somnolence_42\NN|and|)|.|(
18619688
D004317_D003643 NONE Adriamycin_0\NNP| (r_advmod) induced_2\VBN|cardiomyocyte (r_amod) death_5\NN|in|role|.
D004317_D003643 NONE adriamycin_17\NNS|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|death|in|role|. (r_advcl) plays_3\VBZ|NONE (l_nsubj) death_2\NN|in|role|.|induced
C025946_D006333 NONE 3-methyladenine_2\LS|:|, (r_appos) METHODS_0\NNS|was|.|in|inhibitor (r_nsubjpass) used_13\VBN|NONE (l_prep) in_14\IN|METHODS|was|.|inhibitor (l_pobj) model_18\NN|NONE (l_compound) failure_17\NN|of|induced|heart|a
C025946_D006333 NONE 3MA_4\VBN|NONE (r_appos) 3-methyladenine_2\LS|:|, (r_appos) METHODS_0\NNS|was|.|in|inhibitor (r_nsubjpass) used_13\VBN|NONE (l_prep) in_14\IN|METHODS|was|.|inhibitor (l_pobj) model_18\NN|NONE (l_compound) failure_17\NN|of|induced|heart|a
D004317_D006333 CID Adriamycin_0\NNP| (r_advmod) induced_2\VBN|cardiomyocyte (r_amod) death_5\NN|in|role|. (r_nsubj) plays_6\VBZ|NONE (l_prep) in_10\IN|death|role|. (l_pobj) model_13\NN|NONE (l_prep) of_14\IN|rat|a (l_pobj) failure_16\NN|NONE
D004317_D006333 CID adriamycin_7\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|underlying|heart|mechanisms (r_acl) failure_4\NN|.|complicated
D004317_D006333 CID adriamycin_20\NNS|NONE (r_pobj) by_19\IN|NONE (r_agent) induced_18\VBN|of|the (r_acl) progression_14\NN|NONE (l_prep) of_15\IN|the|induced (l_pobj) failure_17\NN|NONE
D004317_D006333 CID adriamycin_20\NNS|NONE (r_pobj) by_19\IN|NONE (r_agent) induced_18\VBN|of|the (r_acl) progression_14\NN|NONE (r_pobj) in_12\IN|whether|was|autophagy (r_prep) involved_11\VBN|develop|to|, (r_ccomp) investigate_7\VB|aim|. (l_advcl) develop_26\VB|involved|to|, (l_dobj) strategy_30\NN|can|that|so|we (l_prep) for_31\IN|a|treatment|novel (l_pobj) failure_33\NN|NONE
D004317_D006333 CID adriamycin_23\NNS|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|of|heart|a|failure (r_acl) model_18\NN|NONE (l_compound) failure_17\NN|of|induced|heart|a
D004317_D006333 CID adriamycin_17\NNS|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|death|in|role|. (r_advcl) plays_3\VBZ|NONE (l_prep) in_7\IN|death|role|.|induced (l_pobj) pathogenesis_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) failure_12\NN|NONE
D004317_D006333 CID adriamycin_13\NNS|NONE (r_pobj) by_12\IN|via (r_agent) caused_11\VBN|heart (r_acl) failure_10\NN|NONE
11250767
D011441_D005921 CID propylthiouracil_13\NN|NONE (l_relcl) developed_25\VBD|NONE (l_nsubj) syndrome_17\NN|in (l_prep) of_18\IN|a (l_pobj) pericarditis_19\NN|NONE (l_conj) fever_21\NN|, (l_conj) glomerulonephritis_24\NN|,|and
D011441_D010493 CID Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|antineutrophil|staining|in|cytoplasmic|.|positive (r_amod) vasculitis_11\NN|NONE (l_prep) in_12\IN|antineutrophil|staining|induced|cytoplasmic|.|positive (l_pobj) conjunction_13\NN|NONE (l_prep) with_14\IN|NONE (l_pobj) pericarditis_15\NN|NONE
D011441_D010493 CID propylthiouracil_5\NN| (r_npadvmod) induced_7\VBN|manifesting (r_amod) vasculitis_8\NN|NONE (l_acl) manifesting_9\VBG|induced (l_prep) with_10\IN|NONE (l_pobj) pericarditis_11\NN|NONE
D011441_D010493 CID propylthiouracil_13\NN|NONE (l_relcl) developed_25\VBD|NONE (l_nsubj) syndrome_17\NN|in (l_prep) of_18\IN|a (l_pobj) pericarditis_19\NN|NONE
D011441_D010493 CID uracil_20\NN|propylthio (r_compound) therapy_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|MPO|positive (r_acl) vasculitis_16\NN|NONE (r_pobj) in_9\IN|prior|no|of (r_prep) reports_6\NNS|review|. (l_prep) of_7\IN|prior|no|in (l_pobj) pericarditis_8\NN|NONE
D011441_D010493 CID uracil_14\NN|NONE (r_compound) therapy_15\NN|NONE (r_appos) propylthio-_13\VB|NONE (r_pobj) to_12\IN|NONE (r_prep) attributable_11\JJ|initial|the|of (r_amod) manifestation_5\NN|may|Pericarditis|. (r_attr) be_2\VB|NONE (l_nsubj) Pericarditis_0\NNP|manifestation|may|.
D011441_D006980 NONE propylthiouracil_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|of|first|case|the (r_acl) report_5\NN|.|We (l_prep) of_6\IN|first|treated|case|the (l_pobj) woman_8\NN|NONE (l_prep) with_9\IN|a (l_pobj) hyperthyroidism_10\NN|NONE
D011441_D014657 NONE Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|antineutrophil|staining|in|cytoplasmic|.|positive (r_amod) vasculitis_11\NN|NONE
D011441_D014657 NONE propylthiouracil_5\NN| (r_npadvmod) induced_7\VBN|manifesting (r_amod) vasculitis_8\NN|NONE
D011441_D014657 NONE uracil_20\NN|propylthio (r_compound) therapy_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|MPO|positive (r_acl) vasculitis_16\NN|NONE
D011441_D014657 NONE uracil_14\NN|NONE (r_compound) therapy_15\NN|NONE (r_appos) propylthio-_13\VB|NONE (r_pobj) to_12\IN|NONE (r_prep) attributable_11\JJ|initial|the|of (r_amod) manifestation_5\NN|may|Pericarditis|. (l_prep) of_6\IN|initial|attributable|the (l_pobj) vasculitis_10\NN|NONE
D011441_D005334 CID propylthiouracil_13\NN|NONE (l_relcl) developed_25\VBD|NONE (l_nsubj) syndrome_17\NN|in (l_prep) of_18\IN|a (l_pobj) pericarditis_19\NN|NONE (l_conj) fever_21\NN|,
11706060
D019344_D000163 NONE lactate_8\NN|in (r_dobj) elevates_6\VBZ|cardiomyopathy|and|Combined|therapy|. (l_prep) in_9\IN|lactate (l_pobj) mice_12\NNS|NONE (l_compound) AIDS_11\NNP|transgenic
D019344_D000163 NONE lactate_18\NN|NONE (l_prep) in_22\IN|(|LA|elevated|plasma|) (l_pobj) AIDS_23\NNP|NONE
D019344_D000163 NONE LA_20\NNP|(|elevated|plasma|in|) (r_appos) lactate_18\NN|NONE (l_prep) in_22\IN|(|LA|elevated|plasma|) (l_pobj) AIDS_23\NNP|NONE
D019344_D000163 NONE LA_10\NNP|NONE (l_prep) in_11\IN|elevated (l_pobj) mice_14\NNS|NONE (l_compound) transgenic_13\JJ|NONE (l_compound) AIDS_12\NNP|NONE
D019259_D000163 NONE lamivudine_43\NN|NONE (r_pobj) of_40\IN|the|HAART (r_prep) combination_39\NN|NONE (r_pobj) with_36\IN|mice|determine|,|.|were (r_prep) treated_35\VBN|NONE (l_nsubjpass) mice_15\NNS|determine|,|with|.|were (l_compound) AIDS_14\NNP|hemizygous|transgenic|old|pol
D019344_D009202 NONE lactate_8\NN|in (r_dobj) elevates_6\VBZ|cardiomyopathy|and|Combined|therapy|. (r_conj) causes_3\VBZ|NONE (l_advmod) cardiomyopathy_4\NN|and|Combined|therapy|.|elevates
D019344_D009202 NONE lactate_18\NN|NONE (r_pobj) in_15\IN|and|CM (r_conj) in_9\IN|is|therapy|.|through (l_pobj) CM_12\NNP|and|in (l_amod) cardiomyopathy_10\NN|)|(
D019344_D009202 NONE lactate_18\NN|NONE (r_pobj) in_15\IN|and|CM (r_conj) in_9\IN|is|therapy|.|through (l_pobj) CM_12\NNP|and|in
D019344_D009202 NONE LA_20\NNP|(|elevated|plasma|in|) (r_appos) lactate_18\NN|NONE (r_pobj) in_15\IN|and|CM (r_conj) in_9\IN|is|therapy|.|through (l_pobj) CM_12\NNP|and|in (l_amod) cardiomyopathy_10\NN|)|(
D019344_D009202 NONE LA_20\NNP|(|elevated|plasma|in|) (r_appos) lactate_18\NN|NONE (r_pobj) in_15\IN|and|CM (r_conj) in_9\IN|is|therapy|.|through (l_pobj) CM_12\NNP|and|in
D019344_D009202 NONE LA_41\NNP|NONE (r_pobj) of_39\IN|NONE (r_prep) determination_38\NN|echocardiography|mice|,|,|At|and|. (r_conj) underwent_7\VBD|NONE (l_dobj) echocardiography_8\RB|mice|,|determination|,|At|and|. (l_appos) quantitation_10\NN|, (l_prep) of_11\IN|encoding (l_pobj) abundance_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) markers_15\NNS|NONE (l_prep) of_16\IN|molecular (l_pobj) CM_17\NNP|NONE
D019344_D009202 NONE LA_10\NNP|NONE (r_pobj) with_8\IN|mitochondrial (r_prep) CM_7\NNP|that|HAART
D019344_D028361 NONE lactate_18\NN|NONE (r_pobj) in_15\IN|and|CM (r_conj) in_9\IN|is|therapy|.|through (r_prep) implicated_8\VBN|NONE (l_prep) through_24\IN|is|in|therapy|. (l_pobj) mechanisms_25\NNS|NONE (l_prep) of_26\IN|NONE (l_pobj) dysfunction_28\NN|NONE
D019344_D028361 NONE LA_20\NNP|(|elevated|plasma|in|) (r_appos) lactate_18\NN|NONE (r_pobj) in_15\IN|and|CM (r_conj) in_9\IN|is|therapy|.|through (r_prep) implicated_8\VBN|NONE (l_prep) through_24\IN|is|in|therapy|. (l_pobj) mechanisms_25\NNS|NONE (l_prep) of_26\IN|NONE (l_pobj) dysfunction_28\NN|NONE
D019469_D000163 NONE indinavir_46\NNS|,|,|zidovudine|and (r_conj) lamivudine_43\NN|NONE (r_pobj) of_40\IN|the|HAART (r_prep) combination_39\NN|NONE (r_pobj) with_36\IN|mice|determine|,|.|were (r_prep) treated_35\VBN|NONE (l_nsubjpass) mice_15\NNS|determine|,|with|.|were (l_compound) AIDS_14\NNP|hemizygous|transgenic|old|pol
D002118_D009202 NONE calcium_30\NN|SERCA|sarcoplasmic|[|)|] (r_compound) ATPase_31\NNP|and|(|ventricular|mRNA|factor (r_conj) encoding_21\VBG|of (r_parataxis) quantitation_10\NN|, (l_prep) of_11\IN|encoding (l_pobj) abundance_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) markers_15\NNS|NONE (l_prep) of_16\IN|molecular (l_pobj) CM_17\NNP|NONE
D015215_D000163 NONE zidovudine_41\NN|,|,|and|indinavir (r_nmod) lamivudine_43\NN|NONE (r_pobj) of_40\IN|the|HAART (r_prep) combination_39\NN|NONE (r_pobj) with_36\IN|mice|determine|,|.|were (r_prep) treated_35\VBN|NONE (l_nsubjpass) mice_15\NNS|determine|,|with|.|were (l_compound) AIDS_14\NNP|hemizygous|transgenic|old|pol
9100294
D020748_D018376 CID 5967_14\CD|NONE (r_prep) 40_12\CD|NONE (r_nummod) Ro_11\NNP|a|channel|, (r_appos) blocker_9\NN|alterations|,|that (r_nsubj) induced_16\VBD|.|investigation (l_dobj) alterations_18\NNS|,|blocker|that
D009543_D018376 CID nifedipine_29\NN|and (r_conj) verapamil_27\NN|only (r_pobj) for_26\IN|statistically (r_prep) significant_24\JJ|incidence|. (r_acomp) was_22\VBD|incidence|was|after|but|, (r_conj) observed_7\VBN|NONE (l_nsubjpass) incidence_2\NN|was|after|but|was|, (l_prep) of_3\IN|A|low (l_pobj) malformations_5\NNS|NONE
D002118_D018376 NONE calcium_7\NN|NONE (r_compound) channel_8\NN|NONE (r_compound) blockers_9\NNS|NONE (r_pobj) to_6\IN|NONE (r_prep) exposed_5\VBN|.|in|Cardiovascular (r_acl) alterations_1\NNS|NONE
D002118_D018376 NONE calcium_7\NN|new (r_compound) channel_8\NN|Ro|a|, (r_compound) blocker_9\NN|alterations|,|that (r_nsubj) induced_16\VBD|.|investigation (l_dobj) alterations_18\NNS|,|blocker|that
D002118_D018376 NONE calcium_10\NN|NONE (r_compound) channel_11\NN|in (r_compound) blockers_12\NNS|that|malformations (r_nsubj) induce_15\VBP|the (l_dobj) malformations_17\NNS|that|blockers
D002118_D018376 NONE calcium_7\NN|NONE (r_compound) channel_8\NN|these (r_compound) blockers_9\NNS|NONE (r_pobj) of_5\IN|NONE (r_prep) one_4\CD|.|rats|were|during (r_dobj) administered_3\VBN|NONE (l_prep) during_10\IN|.|rats|were|one (l_pobj) period_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) morphogenesis_15\NN|NONE (l_conj) offspring_18\NN|cardiac|and (l_acl) examined_19\VBD|the (l_prep) on_20\IN|NONE (l_pobj) day_21\NN|NONE (l_prep) of_23\IN| (l_pobj) gestation_24\NN|NONE (l_prep) for_25\IN|NONE (l_pobj) malformations_27\NNS|NONE
D002118_D018376 NONE calcium_15\NN|NONE (r_compound) channel_16\NN|the|four (r_compound) blockers_17\NNS|NONE (r_pobj) of_12\IN|NONE (r_prep) each_11\DT|NONE (r_pobj) to_10\IN|NONE (r_prep) exposure_9\NN|NONE (r_pobj) after_8\IN|incidence|was|but|was|, (r_prep) observed_7\VBN|NONE (l_nsubjpass) incidence_2\NN|was|after|but|was|, (l_prep) of_3\IN|A|low (l_pobj) malformations_5\NNS|NONE
D014700_D018376 CID verapamil_27\NN|only (r_pobj) for_26\IN|statistically (r_prep) significant_24\JJ|incidence|. (r_acomp) was_22\VBD|incidence|was|after|but|, (r_conj) observed_7\VBN|NONE (l_nsubjpass) incidence_2\NN|was|after|but|was|, (l_prep) of_3\IN|A|low (l_pobj) malformations_5\NNS|NONE
16867021
C052075_D006948 NONE THP_6\NNP|)|locomotor|mg/kg|reduced|i.p. (r_nmod) time_16\NN|speed|,|On|,|and|.|distance (r_npadvmod) traveled_19\VBD|NONE (l_prep) On_0\IN|speed|,|,|and|.|time|distance (l_pobj) hyperactivity_4\NN|NONE
C052075_D006948 NONE THP_0\NNP|.|climbing|profile (r_nsubj) exhibited_1\VBD|NONE (l_dobj) profile_6\NN|.|climbing|THP (l_prep) by_7\IN|like|an (l_pcomp) potentiating_8\VBG|NONE (l_conj) reducing_14\VBG|,|catalepsy (l_dobj) hyperactivity_18\NN|and|reducing
C052075_D002375 CID thioperamide_13\JJ|i.c.v.|and|(|mg/kg|)|(|)| (r_conj) microg_9\NN|R)alpha|RAMH| (r_parataxis) methylhistamine_3\NN|se|,|.|catalepsy|(|did|not (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|se|,|.|(|did|not|methylhistamine
C052075_D002375 CID THP_15\NNP|)|( (r_appos) thioperamide_13\JJ|i.c.v.|and|(|mg/kg|)|(|)| (r_conj) microg_9\NN|R)alpha|RAMH| (r_parataxis) methylhistamine_3\NN|se|,|.|catalepsy|(|did|not (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|se|,|.|(|did|not|methylhistamine
C052075_D002375 CID THP_0\NNP|.|climbing|profile (r_nsubj) exhibited_1\VBD|NONE (l_dobj) profile_6\NN|.|climbing|THP (l_prep) by_7\IN|like|an (l_pcomp) potentiating_8\VBG|NONE (l_dobj) catalepsy_12\NN|,|reducing
D001058_D006948 NONE apomorphine_21\NN|NONE (r_dobj) reducing_20\VBG|and|hyperactivity (r_conj) reducing_14\VBG|,|catalepsy (l_dobj) hyperactivity_18\NN|and|reducing
D000661_D006948 CID amphetamine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperactivity_4\NN|NONE
D000661_D006948 CID amphetamine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) hyperactivity_18\NN|and|reducing
D006220_D006948 NONE haloperidol_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) catalepsy_12\NN|,|reducing (r_dobj) potentiating_8\VBG|NONE (l_conj) reducing_14\VBG|,|catalepsy (l_dobj) hyperactivity_18\NN|and|reducing
D001058_D002375 NONE apomorphine_19\NN| (r_npadvmod) induced_21\VBN|activities|and|climbing (r_amod) behavior_23\NN|effect|to (r_dobj) study_6\VB|was|study|. (l_dobj) effect_8\NN|to|behavior (l_prep) of_9\IN|the (l_pobj) ligands_12\NNS|NONE (l_prep) on_13\IN|H()receptor|histamine (l_pobj) catalepsy_17\NN|NONE
D001058_D002375 NONE apomorphine_12\NN|for|while|were (r_nsubjpass) used_26\VBN|was|Catalepsy|by|.|, (r_advcl) induced_2\VBN|NONE (l_nsubjpass) Catalepsy_0\NNP|used|was|by|.|,
D001058_D002375 NONE apomorphine_21\NN|NONE (r_dobj) reducing_20\VBG|and|hyperactivity (r_conj) reducing_14\VBG|,|catalepsy (r_conj) potentiating_8\VBG|NONE (l_dobj) catalepsy_12\NN|,|reducing
D006220_D002375 CID haloperidol_4\NN|NONE (r_pobj) by_3\IN|used|was|Catalepsy|.|, (r_agent) induced_2\VBN|NONE (l_nsubjpass) Catalepsy_0\NNP|used|was|by|.|,
D006220_D002375 CID haloperidol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) prior_2\RB||.|in|h (r_advmod) resulted_5\VBD|NONE (l_prep) in_6\IN||.|prior|h (l_pobj) increase_11\NN|NONE (l_prep) in_12\IN|P|dependent|)|a|( (l_pobj) catalepsy_14\NN|NONE
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) catalepsy_12\NN|,|reducing
D000661_D002375 NONE amphetamine_25\NN| (r_npadvmod) induced_27\VBN|locomotor|in (r_amod) activities_29\NNS|and|induced|climbing (r_conj) behavior_23\NN|effect|to (r_dobj) study_6\VB|was|study|. (l_dobj) effect_8\NN|to|behavior (l_prep) of_9\IN|the (l_pobj) ligands_12\NNS|NONE (l_prep) on_13\IN|H()receptor|histamine (l_pobj) catalepsy_17\NN|NONE
D000661_D002375 NONE amphetamine_19\NN|(|and|)|mg/kg (r_conj) apomorphine_12\NN|for|while|were (r_nsubjpass) used_26\VBN|was|Catalepsy|by|.|, (r_advcl) induced_2\VBN|NONE (l_nsubjpass) Catalepsy_0\NNP|used|was|by|.|,
D000661_D002375 NONE amphetamine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) hyperactivity_18\NN|and|reducing (r_dobj) reducing_14\VBG|,|catalepsy (r_conj) potentiating_8\VBG|NONE (l_dobj) catalepsy_12\NN|,|reducing
D006632_D002375 NONE histamine_10\NN|H()receptor|on (r_nmod) ligands_12\NNS|NONE (l_prep) on_13\IN|H()receptor|histamine (l_pobj) catalepsy_17\NN|NONE
C069357_D002375 NONE methylhistamine_3\NN|se|,|.|catalepsy|(|did|not (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|se|,|.|(|did|not|methylhistamine
C069357_D002375 NONE RAMH_5\NNP|R)alpha|microg| (r_appos) methylhistamine_3\NN|se|,|.|catalepsy|(|did|not (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|se|,|.|(|did|not|methylhistamine
19269743
D002211_D010146 CID capsaicin_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) pain_12\NN|NONE
D002211_D010146 CID capsaicin_21\NN|NONE (r_pobj) of_20\IN|microg|three (r_prep) doses_19\NNS|NONE (r_pobj) of_17\IN|intradermal|separated (r_prep) injections_16\NNS|In|given|volunteers|,|,|)|. (r_dobj) received_14\VBD|NONE (l_prep) In_0\IN|given|volunteers|,|,|)|injections|. (l_pobj) order_1\NN|NONE (l_acl) address_3\VB|NONE (l_dobj) memory_8\NN|to (l_compound) pain_7\NN|term
D002211_D010146 CID capsaicin_11\NN|)|(|p<. (r_compound) doses_12\NNS|NONE (r_pobj) across_10\IN|magnitude|regardless|reliably|,|to (r_prep) discriminate_5\VB|NONE (l_dobj) magnitude_7\NN|regardless|reliably|,|across|to (l_compound) pain_6\NN|duration|and
84204
D002927_D008107 NONE cimetidine_19\FW|,|)|as|both|P|(|renal (r_conj) dysfunction_8\NN|.|patients
D002927_D003221 CID cimetidine_7\NN| (r_npadvmod) associated_9\VBN|mental (r_amod) confusion_11\NN|NONE
D002927_D003221 CID cimetidine_3\NN| (r_npadvmod) associated_5\VBN|mental (r_amod) confusion_7\NN|NONE
D002927_D051437 NONE cimetidine_19\FW|,|)|as|both|P|(|renal (r_conj) dysfunction_8\NN|.|patients
11027905
D016202_D009437 NONE aspartate_13\NNP|(|,|as|NMDA|) (r_nmod) antagonists_17\NNS|that|may|,|effective (r_nsubj) be_24\VB|have|studies|. (l_acomp) effective_25\JJ|that|antagonists|may|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_prep) as_36\IN|,|pain|difficult (l_pobj) pain_38\NN|such
D016202_D009437 NONE NMDA_15\NNP|(|,|aspartate|as|) (r_nmod) antagonists_17\NNS|that|may|,|effective (r_nsubj) be_24\VB|have|studies|. (l_acomp) effective_25\JJ|that|antagonists|may|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_prep) as_36\IN|,|pain|difficult (l_pobj) pain_38\NN|such
D016202_D010146 NONE aspartate_13\NNP|(|,|as|NMDA|) (r_nmod) antagonists_17\NNS|that|may|,|effective (r_nsubj) be_24\VB|have|studies|. (l_acomp) effective_25\JJ|that|antagonists|may|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_compound) pain_32\NN|as|,|difficult
D016202_D010146 NONE NMDA_15\NNP|(|,|aspartate|as|) (r_nmod) antagonists_17\NNS|that|may|,|effective (r_nsubj) be_24\VB|have|studies|. (l_acomp) effective_25\JJ|that|antagonists|may|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_compound) pain_32\NN|as|,|difficult
D007649_D009437 NONE ketamine_21\NN|such (r_pobj) as_20\IN|(|,|aspartate|NMDA|) (r_prep) antagonists_17\NNS|that|may|,|effective (r_nsubj) be_24\VB|have|studies|. (l_acomp) effective_25\JJ|that|antagonists|may|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_prep) as_36\IN|,|pain|difficult (l_pobj) pain_38\NN|such
D007649_D009437 NONE Ketamine_0\NNP|can|analgesia|. (r_nsubj) improve_2\VB|NONE (l_dobj) analgesia_4\NN|can|Ketamine|. (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_prep) as_11\IN|difficult|pain|, (l_pobj) pain_13\NN|such
D007649_D010146 NONE ketamine_21\NN|such (r_pobj) as_20\IN|(|,|aspartate|NMDA|) (r_prep) antagonists_17\NNS|that|may|,|effective (r_nsubj) be_24\VB|have|studies|. (l_acomp) effective_25\JJ|that|antagonists|may|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_compound) pain_32\NN|as|,|difficult
D007649_D010146 NONE ketamine_7\NN|NONE (r_pobj) of_6\IN|.|)|(|subhypnotic (r_prep) doses_5\NNS|NONE (r_pobj) of_3\IN|slow|A (r_prep) bolus_2\NN|was|to|. (r_nsubjpass) given_16\VBN|NONE (l_dative) to_17\IN|bolus|was|. (l_pobj) patients_20\NNS|NONE (l_relcl) was_23\VBD|cancer| (l_nsubj) pain_22\NN|unrelieved|in
D007649_D010146 NONE Ketamine_0\NN|intensity|significantly|in|. (r_nsubj) reduced_8\VBD|NONE (l_dobj) intensity_11\NN|significantly|in|Ketamine|. (l_compound) pain_10\NN|the
D007649_D010146 NONE Ketamine_0\NNP|can|analgesia|. (r_nsubj) improve_2\VB|NONE (l_dobj) analgesia_4\NN|can|Ketamine|. (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_compound) pain_7\NN|difficult|,|as
D007649_D009369 NONE ketamine_4\NN|NONE (l_prep) in_5\IN|intravenous (l_pobj) patients_7\NNS|NONE (l_compound) cancer_6\NN|on
D007649_D009369 NONE ketamine_7\NN|NONE (r_pobj) of_6\IN|.|)|(|subhypnotic (r_prep) doses_5\NNS|NONE (r_pobj) of_3\IN|slow|A (r_prep) bolus_2\NN|was|to|. (r_nsubjpass) given_16\VBN|NONE (l_dative) to_17\IN|bolus|was|. (l_pobj) patients_20\NNS|NONE (l_compound) cancer_19\NN|was|
D009020_D009369 NONE morphine_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) on_8\IN|cancer (r_prep) patients_7\NNS|NONE (l_compound) cancer_6\NN|on
D009020_D009369 NONE morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_prep) unrelieved_24\JJ|pain|in (r_acomp) was_23\VBD|cancer| (r_relcl) patients_20\NNS|NONE (l_compound) cancer_19\NN|was|
D009020_D009437 NONE morphine_3\NN|in (r_compound) analgesia_4\NN|can|Ketamine|. (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_prep) as_11\IN|difficult|pain|, (l_pobj) pain_13\NN|such
D009020_D010146 NONE morphine_4\NN|NONE (r_pobj) to_3\IN|not (r_prep) responsive_2\JJ|NONE (r_amod) Pain_0\NN|problematic|often|.
D009020_D010146 NONE morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_prep) unrelieved_24\JJ|pain|in (r_acomp) was_23\VBD|cancer| (l_nsubj) pain_22\NN|unrelieved|in
D009020_D010146 NONE morphine_3\NN|in (r_compound) analgesia_4\NN|can|Ketamine|. (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_compound) pain_7\NN|difficult|,|as
3409645
D008727_D007172 CID methotrexate_23\NNP|NONE (r_pobj) of_22\IN|the (r_prep) taking_21\NN|found|and|common|and|.|Impotence (r_conj) was_1\VBD|NONE (l_nsubj) Impotence_0\NN|found|taking|and|common|and|.
7234705
D011342_D008133 NONE procainamide_5\NN|can|with|syndrome|that (r_nsubj) produce_7\VB|cases|. (l_dobj) syndrome_14\NN|can|with|that|procainamide
D011342_D018879 NONE procainamide_6\NN|orally|In|was|.|for|, (r_nsubjpass) administered_8\VBN|NONE (l_prep) for_10\IN|orally|In|was|procainamide|.|, (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|NONE (l_pobj) contractions_16\NNS|NONE
D011342_D017180 CID Procainamide_0\NNP|.||tachycardia (r_npadvmod) induced_2\VBN|NONE (l_dobj) tachycardia_5\NN|.|Procainamide|
D011342_D017180 CID procainamide_3\RB| (r_advmod) induced_5\VBN|polymorphous|ventricular (r_amod) tachycardia_8\NNS|NONE
D011342_D017180 CID procainamide_17\NN|NONE (r_pobj) of_16\IN| (r_prep) mg_15\IN|NONE (r_pobj) of_11\IN|intravenous|for (r_prep) administration_10\NN|NONE (r_pobj) after_8\IN|In|.|tachycardia|, (r_prep) appeared_7\VBD|NONE (l_nsubj) tachycardia_6\NN|In|.|,|after
D011342_D017180 CID procainamide_17\NN|NONE (r_pobj) of_16\IN| (r_prep) mg_15\IN|NONE (r_pobj) of_11\IN|intravenous|for (r_prep) administration_10\NN|NONE (l_prep) for_18\IN|of|intravenous (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|the (l_pobj) tachycardia_24\NN|NONE
D011342_D017180 CID procainamide_16\NN|NONE (r_amod) therapy_17\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) continuation_14\NN|NONE (r_pobj) despite_13\IN|did|not|,|.|tachycardia (r_prep) reoccur_24\VB|In|pacemaker|,|was|and|, (l_nsubj) tachycardia_21\NN|did|not|,|.|despite
D011342_D017180 CID procainamide_5\NN|can|with|syndrome|that (r_nsubj) produce_7\VB|cases|. (l_prep) with_15\IN|can|syndrome|that|procainamide (l_pobj) tachycardia_18\NN|NONE
D011342_D001282 NONE procainamide_6\NN|orally|In|was|.|for|, (r_nsubjpass) administered_8\VBN|NONE (l_prep) for_10\IN|orally|In|was|procainamide|.|, (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|NONE (l_pobj) contractions_16\NNS|NONE (l_conj) flutter_19\NN|or|chronic|ventricular|premature
1549199
D007980_D011618 NONE levodopa_13\RB| (r_npadvmod) induced_15\VBN|disturbances|, (r_amod) psychosis_16\NN|orthostatic|,
D007980_D064420 NONE levodopa_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) for_8\IN|NONE (r_prep) dose_7\NN|NONE (r_dobj) starting_6\NN|no|single (r_acl) correct_5\JJ|there|While (r_attr) is_2\VBZ|,|,|.|can|on|following|be|individuals (r_advcl) started_16\VBN|NONE (l_prep) following_27\VBG|,|,|.|can|is|on|be|individuals (l_pobj) rule_30\NN|NONE (l_relcl) attempt_33\VB|the|general (l_xcomp) titrate_35\VB|to|not (l_dobj) levodopa_38\NN|to (l_relcl) lead_49\VB|to|"|,|carbidopa| (l_prep) to_50\IN|which|can (l_pobj) toxicity_51\NN|NONE
D007980_D064420 NONE levodopa_38\NN|to (l_relcl) lead_49\VB|to|"|,|carbidopa| (l_prep) to_50\IN|which|can (l_pobj) toxicity_51\NN|NONE
D007980_D020447 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|disturbances|, (r_amod) psychosis_16\NN|orthostatic|, (l_conj) disturbances_19\NNS|induced|, (l_conj) parasomnias_21\NNS|or|sleep
D002230_D064420 NONE carbidopa_36\NN|to|"|lead|,| (r_compound) levodopa_38\NN|to (l_relcl) lead_49\VB|to|"|,|carbidopa| (l_prep) to_50\IN|which|can (l_pobj) toxicity_51\NN|NONE
D007980_D007024 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|disturbances|, (r_amod) psychosis_16\NN|orthostatic|, (r_conj) hypotension_11\NN|,|gastrointestinal
D007980_D012893 NONE levodopa_13\RB| (r_npadvmod) induced_15\VBN|disturbances|, (r_amod) psychosis_16\NN|orthostatic|, (l_conj) disturbances_19\NNS|induced|,
D007980_D005767 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|disturbances|, (r_amod) psychosis_16\NN|orthostatic|, (r_conj) hypotension_11\NN|,|gastrointestinal (r_conj) disorders_8\NNS|such
18308784
C035054_D007859 NONE Rg1_1\NNP|.|impairment (r_nsubj) restores_2\VBZ|NONE (l_dobj) impairment_4\NN|Rg|. (l_prep) of_5\IN|the|induced (l_pobj) learning_6\VBG|NONE
C035054_D007859 NONE Rg1_0\NNP|NONE (l_advcl) ameliorate_11\VB|,|. (l_dobj) impairment_14\NN|as|,|could
C035054_D007859 NONE Rg1_11\NN|NONE (r_pobj) of_10\IN|on|the (r_prep) effect_9\NN|to (l_prep) on_12\IN|of|the (l_pobj) impairment_14\NN|NONE
D009020_D007859 CID morphine_10\NN|chronic|in (r_compound) administration_11\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|the|of (r_acl) impairment_4\NN|Rg|. (l_prep) of_5\IN|the|induced (l_pobj) learning_6\VBG|NONE
D009020_D007859 CID morphine_17\NN|mechanism|and|chronic (r_compound) administration_18\NN|NONE (r_pobj) by_15\IN|learning (r_prep) impairment_14\NN|NONE
D036145_D007859 NONE ginsenoside_4\NN|NONE (r_pobj) as_2\IN|,|could|impairment (r_prep) ameliorate_11\VB|,|. (l_dobj) impairment_14\NN|as|,|could
18768591
D004317_D034141 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|)|.|/ (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|)|treatment|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE (l_prep) with_31\IN|nephrotic|severe (l_pobj) ascites_32\NNS|NONE (l_conj) lipidemia_34\NN|, (l_conj) hypoalbuminemia_37\VB|,|and
D000450_D009404 NONE aldosterone_1\NN|Plasma (r_compound) levels_2\NNS|in|and|.|followed (r_nsubj) increased_3\VBD|NONE (l_prep) in_4\IN|and|.|followed|levels (l_pobj) mice_6\NNS|NONE (l_amod) nephrotic_5\JJ|of
D012964_D007674 NONE sodium_7\NN|retention|epithelial (r_compound) channel_8\NN|NONE (r_pobj) to_5\IN|.|nephropathy (r_prep) leads_4\VBZ|NONE (l_nsubj) nephropathy_3\NN|.|to
D000450_D005355 NONE aldosterone_1\NN| (r_npadvmod) sensitive_3\JJ|The|kinase (r_amod) SGK1_10\NNP|has|been|participate|. (r_nsubjpass) shown_13\VBN|NONE (l_xcomp) participate_15\VB|has|been|.|SGK (l_conj) mediate_23\VB|in|to|and (l_dobj) fibrosis_25\NN|to
D004317_D011507 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|)|.|/ (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|and|)|treatment|.|/ (l_pobj) proteinuria_5\NN|NONE
D014508_D009404 NONE urea_8\NN|serum (r_compound) concentrations_9\NNS|faster|,|During|in|than|) (r_nsubj) increased_10\VBD|NONE (l_prep) During_0\IN|faster|,|in|than|concentrations|) (l_pobj) course_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) syndrome_5\NN|NONE
D004317_D001201 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|)|.|/ (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|)|treatment|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE (l_prep) with_31\IN|nephrotic|severe (l_pobj) ascites_32\NNS|NONE
D004317_D009404 CID doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|nephrotic (r_amod) syndrome_12\NN|NONE
D004317_D009404 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|)|.|/ (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|)|treatment|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE
D012964_D016055 NONE sodium_7\NN|retention|epithelial (r_compound) channel_8\NN|NONE (l_appos) retention_12\NN|sodium|epithelial
D004317_D005355 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) nephropathy_3\NN|.|to (r_nsubj) leads_4\VBZ|NONE (l_prep) to_5\IN|.|nephropathy (l_pobj) channel_8\NN|NONE (l_appos) retention_12\NN|sodium|epithelial (l_conj) fibrosis_15\NN|(|and|volume|ENaC)dependent
D004317_D006949 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|)|.|/ (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|)|treatment|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE (l_prep) with_31\IN|nephrotic|severe (l_pobj) ascites_32\NNS|NONE (l_conj) lipidemia_34\NN|,
D004317_D007674 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) nephropathy_3\NN|.|to
D004317_D016055 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) nephropathy_3\NN|.|to (r_nsubj) leads_4\VBZ|NONE (l_prep) to_5\IN|.|nephropathy (l_pobj) channel_8\NN|NONE (l_appos) retention_12\NN|sodium|epithelial
D012964_D005355 NONE sodium_7\NN|retention|epithelial (r_compound) channel_8\NN|NONE (l_appos) retention_12\NN|sodium|epithelial (l_conj) fibrosis_15\NN|(|and|volume|ENaC)dependent
1967484
D013469_D004409 NONE sulpiride_11\NN|,|dyskinesia|thought| (r_npadvmod) induced_13\VBN|.|occasionally|been|have (l_dobj) dyskinesia_15\JJ|sulpiride|,|thought|
D013469_D010302 NONE sulpiride_11\NN|,|dyskinesia|thought| (r_npadvmod) induced_13\VBN|.|occasionally|been|have (l_dobj) dyskinesia_15\JJ|sulpiride|,|thought| (l_conj) parkinsonism_17\NN|tardive|and
D013469_D004421 CID Sulpiride_0\NNP|.|dystonia| (r_npadvmod) induced_2\VBN|NONE (l_dobj) dystonia_4\NN|.||Sulpiride
D013469_D004421 CID sulpiride_17\NN|NONE (r_compound) therapy_18\NN|NONE (r_dobj) starting_16\VBG|NONE (r_pcomp) after_15\IN|within|dystonia|who (r_prep) developed_8\VBD|a|old (l_dobj) dystonia_11\NN|within|after|who
D013469_D004421 CID sulpiride_8\NN| (r_npadvmod) induced_10\VBN|tardive (r_amod) dystonia_12\NN|NONE
12707296
D006854_D006973 NONE cortisol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) hypertension_10\NN|NONE
D006854_D006973 NONE cortisol_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) hypertension_15\NN|NONE
D006854_D006973 NONE cortisol_3\NN| (r_npadvmod) induced_5\VBN|in (r_amod) increases_6\NNS|with|are|not|that (l_prep) in_7\IN|induced (l_pobj) pressure_9\NN|NONE
D001120_D006973 NONE arginine_2\NN|with|.|in (r_compound) transport_3\NN|NONE (l_prep) with_6\IN|.|arginine|in (l_pobj) hypertension_10\NN|NONE
D001120_D006973 NONE arginine_4\NN||L| (r_compound) nitric_6\NN|deficient|oxide|A (r_compound) system_8\NN|.|is|in (r_nsubjpass) implicated_10\VBN|NONE (l_prep) in_11\IN|.|system|is (l_pobj) hypertension_15\NN|NONE
D001120_D006973 NONE arginine_19\NN|transport|the (r_compound) system_21\NN|NONE (r_pobj) in_15\IN|NONE (r_prep) abnormalities_14\NNS|NONE (r_pobj) with_13\IN|increases|are|not|that (r_prep) associated_12\VBN|.|We (l_nsubjpass) increases_6\NNS|with|are|not|that (l_prep) in_7\IN|induced (l_pobj) pressure_9\NN|NONE
D009569_D006973 NONE oxide_7\NN|nitric|deficient|A (r_compound) system_8\NN|.|is|in (r_nsubjpass) implicated_10\VBN|NONE (l_prep) in_11\IN|.|system|is (l_pobj) hypertension_15\NN|NONE
2440413
D005680_D012640 NONE GABA_24\NNP| (r_compound) A_26\NNP|the|linked|chloride (r_nmod) channel_31\NN|may|site|that|HCH (r_attr) be_22\VB|.|data (l_nsubj) site_7\NN|may|channel|that|HCH (l_amod) responsible_8\JJ|the|h (l_prep) for_9\IN|NONE (l_pobj) decrease_11\NN|NONE (l_prep) in_12\IN|the (l_pobj) activity_14\NN|NONE (l_compound) seizure_13\NN|NONE
C034818_D012640 CID carboline-3-carboxylate_36\NNP|BCC|MPA|)|,|mercaptopropionic|bicuculline|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
C034818_D012640 CID carboline-3-carboxylate_36\NNP|BCC|MPA|)|,|mercaptopropionic|bicuculline|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
C034818_D012640 CID DMCM_38\NNP|(|strychnine|,dimethoxyethyl|methyl|B||)|or||, (r_appos) carboline-3-carboxylate_36\NNP|BCC|MPA|)|,|mercaptopropionic|bicuculline|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
C034818_D012640 CID DMCM_38\NNP|(|strychnine|,dimethoxyethyl|methyl|B||)|or||, (r_appos) carboline-3-carboxylate_36\NNP|BCC|MPA|)|,|mercaptopropionic|bicuculline|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D001640_D012640 CID bicuculline_26\NN|BCC|MPA|)|,|carbolinecarboxylate|mercaptopropionic|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D001640_D012640 CID bicuculline_26\NN|BCC|MPA|)|,|carbolinecarboxylate|mercaptopropionic|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D001640_D012640 CID BCC_28\NNP|MPA|)|,|carbolinecarboxylate|mercaptopropionic|bicuculline|,|(|STR (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D001640_D012640 CID BCC_28\NNP|MPA|)|,|carbolinecarboxylate|mercaptopropionic|bicuculline|,|(|STR (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D013331_D012640 CID strychnine_42\NN|(|,dimethoxyethyl|methyl|B|DMCM||)|or||, (r_conj) carboline-3-carboxylate_36\NNP|BCC|MPA|)|,|mercaptopropionic|bicuculline|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D013331_D012640 CID strychnine_42\NN|(|,dimethoxyethyl|methyl|B|DMCM||)|or||, (r_conj) carboline-3-carboxylate_36\NNP|BCC|MPA|)|,|mercaptopropionic|bicuculline|,|(|STR (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D013331_D012640 CID STR_44\NNP|BCC|MPA|)|,|carbolinecarboxylate|mercaptopropionic|bicuculline|,|( (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D013331_D012640 CID STR_44\NNP|BCC|MPA|)|,|carbolinecarboxylate|mercaptopropionic|bicuculline|,|( (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D015097_D012640 CID acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D015097_D012640 CID acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D015097_D012640 CID MPA_23\NNP|BCC|)|,|carbolinecarboxylate|mercaptopropionic|bicuculline|,|(|STR (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|not|,|.|however|;|activity|different (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D015097_D012640 CID MPA_23\NNP|BCC|)|,|carbolinecarboxylate|mercaptopropionic|bicuculline|,|(|STR (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D010433_D012640 CID PTZ_27\NNP|NONE (r_pobj) to_24\TO|threshold|to (r_prep) decrease_21\VB|has|hexachlorocyclohexane|)|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D010433_D012640 CID PTZ_13\NNP| (r_npadvmod) induced_15\VBN|NONE (r_amod) seizures_16\NNS|NONE
D010433_D012640 CID PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D010433_D012640 CID PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (r_nsubjpass) decreased_12\VBN|not|,|.|however|;|activity|different (r_ccomp) was_46\VBD|NONE (l_nsubj) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D010433_D012640 CID PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (l_compound) seizure_10\NN|induced
D010433_D012640 CID PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (r_pobj) to_9\IN|may|decreased|h|tolerance|,|that (r_prep) occur_8\VB|.|data (l_advcl) decreased_36\VBN|may|to|h|tolerance|,|that (l_nsubjpass) response_26\NN|since|is (l_prep) to_27\IN|the (l_pobj) agents_34\NNS|NONE (l_amod) inducing_33\VBG|these|two|only (l_npadvmod) seizure_31\NN|
D001556_D012640 NONE hexachlorocyclohexane_5\NN|NONE (r_pobj) of_2\IN|on|Differential|. (r_prep) effects_1\NNS|NONE (l_prep) on_9\IN|of|Differential|. (l_pobj) seizures_13\NNS|NONE
D001556_D012640 NONE lindane_7\NN||gamma (r_appos) hexachlorocyclohexane_5\NN|NONE (r_pobj) of_2\IN|on|Differential|. (r_prep) effects_1\NNS|NONE (l_prep) on_9\IN|of|Differential|. (l_pobj) seizures_13\NNS|NONE
D001556_D012640 NONE hexachlorocyclohexane_2\NN|has|)|been|decrease (r_nsubjpass) shown_19\VBN|NONE (l_xcomp) decrease_21\VB|has|hexachlorocyclohexane|)|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D001556_D012640 NONE HCH_6\NNP|(||ingredient|,|,|)|Gamma (r_appos) hexachlorocyclohexane_2\NN|has|)|been|decrease (r_nsubjpass) shown_19\VBN|NONE (l_xcomp) decrease_21\VB|has|hexachlorocyclohexane|)|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D001556_D012640 NONE lindane_15\NN|NONE (r_pobj) of_12\IN|the|active (r_prep) ingredient_11\NN|(||,|,|)|HCH|Gamma (r_appos) hexachlorocyclohexane_2\NN|has|)|been|decrease (r_nsubjpass) shown_19\VBN|NONE (l_xcomp) decrease_21\VB|has|hexachlorocyclohexane|)|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D001556_D012640 NONE HCH_7\NNP|NONE (r_pobj) to_4\IN|NONE (r_prep) exposure_3\NN|NONE (r_pobj) after_2\IN||and|increase (r_prep) h_1\NN||)|.|after (l_conj) increase_10\VB||after|and (l_prep) to_12\IN|conversely|threshold (l_pobj) seizures_16\NNS|NONE
D001556_D012640 NONE HCH_24\NNP|NONE (r_pobj) to_21\IN|NONE (r_prep) exposure_20\NN|NONE (r_pobj) after_19\IN||h|)|. (r_prep) h_18\NN|NONE (l_dep) h_1\NN||)|.|after (l_conj) increase_10\VB||after|and (l_prep) to_12\IN|conversely|threshold (l_pobj) seizures_16\NNS|NONE
D001556_D012640 NONE HCH_30\NNP|NONE (r_pobj) of_25\IN|intraperitoneal (r_prep) administration_24\NN|NONE (r_pobj) after_22\IN|was|In|,|h|in|severity|. (r_prep) tested_15\VBN|NONE (l_nsubjpass) severity_5\NN|was|In|,|h|in|after|. (l_prep) of_6\IN|the (l_pobj) response_7\NN|NONE (l_prep) to_8\IN|NONE (l_pobj) agents_13\NNS|NONE (l_amod) inducing_12\VBG|other (l_npadvmod) seizure_10\NN|
D001556_D012640 NONE HCH_8\NNP|NONE (r_pobj) of_5\IN|the (r_prep) administration_4\NN|NONE (r_pobj) after_2\IN|,|activity|was|hour (r_prep) increased_18\VBN|response|was|.|h|while|,|regardless|, (l_nsubjpass) activity_11\NN|,|was|hour|after (l_prep) of_12\IN|the (l_pobj) agents_16\NNS|NONE (l_amod) inducing_15\VBG|NONE (l_npadvmod) seizure_13\NN|
D001556_D012640 NONE HCH_31\NNP||after (r_appos) h_27\NN|increased|response|was|.|while|,|regardless|, (r_dep) observed_36\VBN|NONE (l_advcl) increased_18\VBN|response|was|.|h|while|,|regardless|, (l_nsubjpass) activity_11\NN|,|was|hour|after (l_prep) of_12\IN|the (l_pobj) agents_16\NNS|NONE (l_amod) inducing_15\VBG|NONE (l_npadvmod) seizure_13\NN|
D001556_D012640 NONE HCH_22\NNP|NONE (r_pobj) after_19\IN| (r_prep) h_18\NN|may|decreased|to|tolerance|,|that (r_npadvmod) occur_8\VB|.|data (l_prep) to_9\IN|may|decreased|h|tolerance|,|that (l_pobj) activity_11\NN|NONE (l_compound) seizure_10\NN|induced
D001556_D012640 NONE HCH_22\NNP|NONE (r_pobj) after_19\IN| (r_prep) h_18\NN|may|decreased|to|tolerance|,|that (r_npadvmod) occur_8\VB|.|data (l_advcl) decreased_36\VBN|may|to|h|tolerance|,|that (l_nsubjpass) response_26\NN|since|is (l_prep) to_27\IN|the (l_pobj) agents_34\NNS|NONE (l_amod) inducing_33\VBG|these|two|only (l_npadvmod) seizure_31\NN|
D001556_D012640 NONE HCH_20\NNP|may|site|channel|that (r_nsubj) be_22\VB|.|data (l_nsubj) site_7\NN|may|channel|that|HCH (l_amod) responsible_8\JJ|the|h (l_prep) for_9\IN|NONE (l_pobj) decrease_11\NN|NONE (l_prep) in_12\IN|the (l_pobj) activity_14\NN|NONE (l_compound) seizure_13\NN|NONE
D010852_D012640 CID picrotoxin_6\NN|PTX|and (r_conj) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D010852_D012640 CID picrotoxin_6\NN|PTX|and (r_conj) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (r_nsubjpass) decreased_12\VBN|not|,|.|however|;|activity|different (r_ccomp) was_46\VBD|NONE (l_nsubj) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D010852_D012640 CID PTX_8\NNP|and|picrotoxin (r_appos) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D010852_D012640 CID PTX_8\NNP|and|picrotoxin (r_appos) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (r_nsubjpass) decreased_12\VBN|not|,|.|however|;|activity|different (r_ccomp) was_46\VBD|NONE (l_nsubj) activity_17\NN|not|,|.|decreased|however|;|different (l_compound) seizure_16\NN|due
D010852_D012640 CID PTX_16\NNP|and (r_conj) PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (l_compound) seizure_10\NN|induced
D010852_D012640 CID PTX_16\NNP|and (r_conj) PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (r_pobj) to_9\IN|may|decreased|h|tolerance|,|that (r_prep) occur_8\VB|.|data (l_advcl) decreased_36\VBN|may|to|h|tolerance|,|that (l_nsubjpass) response_26\NN|since|is (l_prep) to_27\IN|the (l_pobj) agents_34\NNS|NONE (l_amod) inducing_33\VBG|these|two|only (l_npadvmod) seizure_31\NN|
1527456
D008012_D014012 NONE lignocaine_7\NN|NONE (r_pobj) of_6\IN|intratympanic (r_prep) instillation_5\NN|NONE (r_pobj) by_3\IN||through|.|of (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN||through|.|by (l_pobj) tinnitus_2\NN|NONE
D008012_D014012 NONE lidocaine_9\NN|NONE (r_appos) lignocaine_7\NN|NONE (r_pobj) of_6\IN|intratympanic (r_prep) instillation_5\NN|NONE (r_pobj) by_3\IN||through|.|of (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN||through|.|by (l_pobj) tinnitus_2\NN|NONE
D008012_D014012 NONE lignocaine_12\NN|NONE (r_pobj) of_11\IN|intratympanic (r_prep) instillation_10\NN|NONE (r_pobj) by_8\IN|IST (r_prep) treating_6\VBG|NONE (l_dobj) IST_7\NNP|by
D008012_D014012 NONE lidocaine_14\NN|NONE (r_appos) lignocaine_12\NN|NONE (r_pobj) of_11\IN|intratympanic (r_prep) instillation_10\NN|NONE (r_pobj) by_8\IN|IST (r_prep) treating_6\VBG|NONE (l_dobj) IST_7\NNP|by
2515254
D005996_D008881 CID nitroglycerin_11\NN|NONE (r_pobj) of_10\IN|sided|frontotemporal|a|one (r_prep) application_9\NN|.|patients (r_dobj) received_4\VBD|NONE (l_nsubj) patients_3\NNS|.|application (l_compound) migraine_2\NN|common|Twenty
D005996_D008881 CID nitroglycerin_7\NN|NONE (r_pobj) by_6\IN|.|in|attacks|were (r_agent) induced_5\VBN|NONE (l_nsubjpass) attacks_3\NNS|.|by|in|were (l_compound) migraine_2\NN|Early|onset
D005996_D008881 CID nitroglycerin_13\NN|NONE (r_pobj) with_11\IN|early|onset|an (r_prep) attack_10\NN|who (r_dobj) developed_6\VBD||,|migraine|, (r_relcl) patients_3\NNS|Subsequently|.|in|drug (l_compound) migraine_2\NN||,|,|developed
D005996_D008881 CID nitroglycerin_7\NN|NONE (r_pobj) of_6\IN|inducing|the (r_prep) effect_5\NN|depend|,|.|suggesting|Thus (l_amod) inducing_4\VBG|of|the (l_npadvmod) migraine_2\NN|
D005996_D008881 CID nitroglycerin_7\NN|NONE (r_pobj) of_6\IN|inducing|the (r_prep) effect_5\NN|depend|,|.|suggesting|Thus (r_nsubj) seems_8\VBZ|NONE (l_advcl) suggesting_21\VBG|depend|effect|,|.|Thus (l_ccomp) is_26\VBZ|NONE (l_prep) of_27\IN|that|region (l_pobj) importance_29\NN|NONE (l_prep) in_30\IN|crucial (l_pobj) development_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) crisis_36\NN|NONE (l_compound) migraine_35\JJ|a
D005996_D010146 NONE nitroglycerin_7\NN|NONE (r_pobj) of_6\IN|inducing|the (r_prep) effect_5\NN|depend|,|.|suggesting|Thus (r_nsubj) seems_8\VBZ|NONE (l_xcomp) depend_10\VB|effect|,|.|suggesting|Thus (l_prep) on_11\IN|to (l_pobj) stimulation_13\NN|NONE (l_prep) of_14\IN|direct (l_pobj) site_17\NN|NONE (l_prep) of_18\IN|habitual|the (l_pobj) pain_19\NN|NONE
20080983
D003042_D012893 CID cocaine_23\NN|chronic (r_compound) users_24\NNS|NONE (r_pobj) in_21\IN|daytime (r_prep) sleepiness_20\NN|dosed|on
D003042_D012893 CID cocaine_18\NN|abstinent (r_compound) users_19\NNS|NONE (r_pobj) in_16\IN|daytime (r_prep) sleepiness_15\NN|NONE
C048833_D012893 NONE modafinil_15\NN|NONE (l_conj) sleepiness_20\NN|dosed|on
C048833_D012893 NONE Modafinil_0\NNP|with|.|,|was|measured (r_nsubjpass) associated_2\VBN|NONE (l_advcl) measured_10\VBN|with|.|,|was|Modafinil (l_conj) decrease_22\NN|as|,|and|by (l_prep) in_23\IN|a|significant (l_pobj) sleepiness_26\NN|NONE
C048833_D012893 NONE modafinil_3\NN|sleep|,|.|normalizes (r_nsubj) promotes_4\VBZ|NONE (l_conj) normalizes_8\VBZ|sleep|,|modafinil|. (l_conj) decreases_13\VBZ|and|,|architecture (l_dobj) sleepiness_15\NN|NONE
3125768
D015760_D009127 CID alfentanil_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) rigidity_7\NN|NONE
D015760_D009127 CID alfentanil_8\NN| (r_npadvmod) induced_10\VBN|in (r_amod) rigidity_11\NN|NONE
D015760_D009127 CID alfentanil_9\NN|and|,|rigidity|should|be|used|,|that (r_advcl) prevented_7\VBN|.|observations (l_nsubjpass) rigidity_4\NN|and|,|should|alfentanil|be|used|,|that
C032943_D009127 NONE metocurine_10\NN|NONE (r_pobj) with_9\IN|rigidity|when|was (r_prep) abolished_8\VBN|to|.|variables (l_nsubjpass) rigidity_6\NN|with|when|was
20698227
C473478_D006461 CID sunitinib_16\JJ|such (r_pobj) as_15\IN|angiogenesis (r_prep) inhibitors_13\NNS|NONE (r_pobj) of_11\IN|a (r_prep) number_10\NN|have|been|cause|. (r_nsubjpass) found_21\VBN|ribavirin|inhibit|been|has (l_advcl) cause_23\VB|number|have|been|. (l_dobj) hemolysis_25\NN|to
D012254_D006461 NONE ribavirin_1\RB|found|inhibit|been|has (r_nsubjpass) found_4\VBN|NONE (l_conj) found_21\VBN|ribavirin|inhibit|been|has (l_advcl) cause_23\VB|number|have|been|. (l_dobj) hemolysis_25\NN|to
C471405_D006461 CID sorafenib_18\NNS|and (r_conj) sunitinib_16\JJ|such (r_pobj) as_15\IN|angiogenesis (r_prep) inhibitors_13\NNS|NONE (r_pobj) of_11\IN|a (r_prep) number_10\NN|have|been|cause|. (r_nsubjpass) found_21\VBN|ribavirin|inhibit|been|has (l_advcl) cause_23\VB|number|have|been|. (l_dobj) hemolysis_25\NN|to
C100416_D019698 NONE 2a_14\CD|NONE (r_pobj) by_10\IN|infected|were|. (r_agent) treated_9\VBN|NONE (l_csubjpass) infected_3\VBN|by|were|. (l_prep) with_4\IN|chronically|patients (l_pobj) virus_7\NN|NONE
D012254_D019698 NONE ribavirin_16\RB|and|pegylated|interferon|alpha (r_conj) 2a_14\CD|NONE (r_pobj) by_10\IN|infected|were|. (r_agent) treated_9\VBN|NONE (l_csubjpass) infected_3\VBN|by|were|. (l_prep) with_4\IN|chronically|patients (l_pobj) virus_7\NN|NONE
D012254_D019698 NONE ribavirin_16\RB|and|soluble (r_conj) markers_14\NNS|NONE (r_dobj) angiogenesis_12\NN|NONE (r_pobj) between_11\IN|a (r_prep) link_10\NN|NONE (r_dobj) investigating_8\VBG|the|first|in (r_acl) study_4\NN|induced|This (r_attr) is_1\VBZ|NONE (l_advcl) induced_17\VBD|This|study (l_dobj) anemia_18\NN|and|find (l_prep) in_19\IN|NONE (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) C_23\NNP|NONE
D012254_D000740 NONE ribavirin_16\RB|and|soluble (r_conj) markers_14\NNS|NONE (r_dobj) angiogenesis_12\NN|NONE (r_pobj) between_11\IN|a (r_prep) link_10\NN|NONE (r_dobj) investigating_8\VBG|the|first|in (r_acl) study_4\NN|induced|This (r_attr) is_1\VBZ|NONE (l_advcl) induced_17\VBD|This|study (l_dobj) anemia_18\NN|and|find
D012254_D000743 NONE ribavirin_8\RB|NONE (r_pobj) for_7\IN|NONE (r_prep) treatment_6\NN|NONE (r_pobj) of_5\IN|associated|a (r_prep) target_4\NN|Can|angiogenesis|? (l_acl) associated_9\VBN|a|of (l_dobj) anemia_11\NN|NONE
18261172
D000806_D007674 NONE ACEi_5\NNP|and|/|monitored|ARB|patients (r_nmod) therapy_8\NN|NONE (r_pobj) with_4\IN|increased|.|Srl|and|should|be (r_prep) used_3\VBN|NONE (l_conj) increased_15\VBD|.|Srl|and|with|should|be (l_dobj) dysfunction_17\NN|NONE
D020123_D011507 CID sirolimus_6\NN| (r_npadvmod) based_8\VBN|in (r_amod) immunosuppression_9\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) switch_4\NN|NONE (r_pobj) after_3\IN|.|of (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|.|after (l_pobj) proteinuria_2\NN|NONE
D020123_D011507 CID sirolmus_7\NN|(|IS|effects|immunosuppressive (r_nsubj) lacks_11\VBZ|however|.|,|has|following|proteinuria|;|been (r_ccomp) reported_23\VBN|NONE (l_nsubjpass) proteinuria_17\NN|however|.|,|has|following|;|been|lacks
D020123_D011507 CID Srl_9\NNP|)|drug|)|( (r_appos) sirolmus_7\NN|(|IS|effects|immunosuppressive (r_nsubj) lacks_11\VBZ|however|.|,|has|following|proteinuria|;|been (r_ccomp) reported_23\VBN|NONE (l_nsubjpass) proteinuria_17\NN|however|.|,|has|following|;|been|lacks
D020123_D011507 CID Srl_20\NNP|NONE (r_pobj) with_19\IN|NONE (r_prep) associated_18\VBN|NONE (r_acl) proteinuria_17\NN|however|.|,|has|following|;|been|lacks
D020123_D011507 CID Srl_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|of|the (r_acl) incidence_5\NN|In|.|unknown|, (l_prep) of_6\IN|associated|the (l_pobj) proteinuria_7\NN|NONE
D020123_D011507 CID Srl_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_prep) switch_10\NN|NONE (r_pobj) after_9\IN|in|proteinuria|,|.|may|Thus (r_prep) develop_4\VB|NONE (l_nsubj) proteinuria_2\NN|in|,|.|may|after|Thus
D020123_D011507 CID Srl_0\NNP|increased|.|and|with|should|be (r_nsubjpass) used_3\VBN|NONE (l_prep) with_4\IN|increased|.|Srl|and|should|be (l_pobj) therapy_8\NN|NONE (l_acl) monitored_11\VBD|and|/|ACEi|ARB|patients (l_prep) for_12\IN|NONE (l_pobj) proteinuria_13\NN|NONE
D057911_D007674 NONE ARB_7\NNP|and|/|ACEi|monitored|patients (r_compound) therapy_8\NN|NONE (r_pobj) with_4\IN|increased|.|Srl|and|should|be (r_prep) used_3\VBN|NONE (l_conj) increased_15\VBD|.|Srl|and|with|should|be (l_dobj) dysfunction_17\NN|NONE
D057911_D011507 NONE blocker_6\NN|ARB|(|) (r_nmod) therapy_10\NN|and|ACE (r_conj) inhibitor_1\NN|development|. (r_nsubj) reduced_11\VBN|NONE (l_dobj) development_13\NN|inhibitor|. (l_compound) proteinuria_12\NN|NONE
D057911_D011507 NONE ARB_8\NNP|(|blocker|) (r_nmod) therapy_10\NN|and|ACE (r_conj) inhibitor_1\NN|development|. (r_nsubj) reduced_11\VBN|NONE (l_dobj) development_13\NN|inhibitor|. (l_compound) proteinuria_12\NN|NONE
D057911_D011507 NONE ARB_7\NNP|and|/|ACEi|monitored|patients (r_compound) therapy_8\NN|NONE (l_acl) monitored_11\VBD|and|/|ACEi|ARB|patients (l_prep) for_12\IN|NONE (l_pobj) proteinuria_13\NN|NONE
D000806_D011507 NONE inhibitor_1\NN|development|. (r_nsubj) reduced_11\VBN|NONE (l_dobj) development_13\NN|inhibitor|. (l_compound) proteinuria_12\NN|NONE
D000806_D011507 NONE ACEi_5\NNP|and|/|monitored|ARB|patients (r_nmod) therapy_8\NN|NONE (l_acl) monitored_11\VBD|and|/|ACEi|ARB|patients (l_prep) for_12\IN|NONE (l_pobj) proteinuria_13\NN|NONE
D020123_D007674 NONE sirolmus_7\NN|(|IS|effects|immunosuppressive (r_nsubj) lacks_11\VBZ|however|.|,|has|following|proteinuria|;|been (l_dobj) effects_13\NNS|(|IS|immunosuppressive|sirolmus (l_amod) nephrotoxic_12\JJ|NONE
D020123_D007674 NONE Srl_9\NNP|)|drug|)|( (r_appos) sirolmus_7\NN|(|IS|effects|immunosuppressive (r_nsubj) lacks_11\VBZ|however|.|,|has|following|proteinuria|;|been (l_dobj) effects_13\NNS|(|IS|immunosuppressive|sirolmus (l_amod) nephrotoxic_12\JJ|NONE
D020123_D007674 NONE Srl_20\NNP|NONE (r_pobj) with_19\IN|NONE (r_prep) associated_18\VBN|NONE (r_acl) proteinuria_17\NN|however|.|,|has|following|;|been|lacks (r_nsubjpass) reported_23\VBN|NONE (l_ccomp) lacks_11\VBZ|however|.|,|has|following|proteinuria|;|been (l_dobj) effects_13\NNS|(|IS|immunosuppressive|sirolmus (l_amod) nephrotoxic_12\JJ|NONE
D020123_D007674 NONE Srl_0\NNP|increased|.|and|with|should|be (r_nsubjpass) used_3\VBN|NONE (l_conj) increased_15\VBD|.|Srl|and|with|should|be (l_dobj) dysfunction_17\NN|NONE
7834920
D007538_D014397 NONE isoniazid_9\NN|and|and|patient|.|regimen|discovered (l_prep) for_10\IN|NONE (l_pobj) tuberculosis_12\NN|NONE
D012293_D005921 CID rifampin_6\NN|for|intermittent (r_amod) therapy_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|NONE (r_acl) glomerulonephritis_2\NN|Crescentic|.
D012293_D005921 CID rifampin_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|a (r_acl) patient_14\NN|NONE (r_pobj) in_12\IN|an|unusual|had|of (r_prep) finding_6\NN|.|study (l_prep) of_7\IN|an|unusual|in|had (l_pobj) glomerulonephritis_11\NN|NONE
D012293_D005921 CID rifampin_20\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|a (r_acl) patient_17\NN|NONE (r_pobj) in_15\IN|the|unusual|of (r_prep) occurrence_5\NN|report|. (l_prep) of_6\IN|in|the|unusual (l_pobj) glomerulonephritis_9\NN|NONE
D012293_D005921 CID rifampin_20\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|a (r_acl) patient_17\NN|NONE (r_pobj) in_15\IN|the|unusual|of (r_prep) occurrence_5\NN|report|. (l_prep) of_6\IN|in|the|unusual (l_pobj) glomerulonephritis_9\NN|NONE (l_prep) with_10\IN|progressive (l_pobj) crescents_11\NNS|NONE (l_conj) glomerulonephritis_14\NN|and
D012293_D014397 NONE rifampin_6\NN|for|intermittent (r_amod) therapy_7\NN|NONE (l_prep) for_8\IN|rifampin|intermittent (l_pobj) tuberculosis_10\NN|NONE
D012293_D014397 NONE rifampin_7\NN|NONE (r_pobj) of_6\IN|month|a (r_prep) regimen_5\NN|and|and|patient|.|isoniazid|discovered (r_dobj) underwent_2\VBD|NONE (l_conj) isoniazid_9\NN|and|and|patient|.|regimen|discovered (l_prep) for_10\IN|NONE (l_pobj) tuberculosis_12\NN|NONE
D007538_D051437 NONE isoniazid_9\NN|and|and|patient|.|regimen|discovered (r_conj) underwent_2\VBD|NONE (l_conj) discovered_15\VBN|and|and|patient|.|regimen|isoniazid (l_xcomp) developed_18\VBN|was (l_dobj) signs_19\NNS|have|to|after (l_prep) of_20\IN|NONE (l_pobj) failure_23\NN|NONE
D012293_D051437 CID rifampin_7\NN|NONE (r_pobj) of_6\IN|month|a (r_prep) regimen_5\NN|and|and|patient|.|isoniazid|discovered (r_dobj) underwent_2\VBD|NONE (l_conj) discovered_15\VBN|and|and|patient|.|regimen|isoniazid (l_xcomp) developed_18\VBN|was (l_dobj) signs_19\NNS|have|to|after (l_prep) of_20\IN|NONE (l_pobj) failure_23\NN|NONE
11928786
D016642_D062787 NONE Zyban_0\NNP|.|toxicity (r_nsubj) caused_1\VBD|NONE (l_dobj) toxicity_6\NN|.|Zyban (l_prep) in_7\IN|neurological|significant (l_pobj) overdose_8\NN|NONE
D016642_D064420 NONE Bupropion_0\NNP|Zyban|(|)|. (r_nmod) toxicity_4\NN|NONE
D016642_D064420 NONE Zyban_2\NNP|Bupropion|(|)|. (r_nmod) toxicity_4\NN|NONE
D000241_D012640 NONE adenosine_14\NN|NONE (r_pobj) with_13\IN|successfully|was (r_prep) treated_12\VBN|with|seizures|were|. (r_conj) treated_3\VBN|NONE (l_nsubjpass) seizures_1\NNS|with|treated|were|.
D003975_D013610 NONE diazepam_5\NN|NONE (l_conj) tachycardia_9\NN|and
D016642_D002318 NONE Zyban_0\NNP|.|toxicity (r_nsubj) caused_1\VBD|NONE (l_dobj) toxicity_6\NN|.|Zyban
D016642_D020258 NONE Zyban_0\NNP|.|toxicity (r_nsubj) caused_1\VBD|NONE (l_dobj) toxicity_6\NN|.|Zyban
D000241_D013610 NONE adenosine_14\NN|NONE (r_pobj) with_13\IN|successfully|was (r_prep) treated_12\VBN|with|seizures|were|. (r_conj) treated_3\VBN|NONE (l_prep) with_4\IN|seizures|treated|were|. (l_pobj) diazepam_5\NN|NONE (l_conj) tachycardia_9\NN|and
D003975_D012640 NONE diazepam_5\NN|NONE (r_pobj) with_4\IN|seizures|treated|were|. (r_prep) treated_3\VBN|NONE (l_nsubjpass) seizures_1\NNS|with|treated|were|.
3560095
D005480_D001171 NONE Flurbiprofen_0\NNP|NONE (l_prep) in_1\IN|. (l_pobj) treatment_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) arthritis_7\NN|NONE
D005480_D001171 NONE flurbiprofen_13\JJ|NONE (r_pobj) with_12\IN|were|who|day|at (r_prep) treated_11\VBN|juvenile|,|rheumatoid (r_relcl) arthritis_7\NN|NONE
D005480_D001168 NONE flurbiprofen_13\JJ|NONE (r_pobj) with_12\IN|were|who|day|at (r_prep) treated_11\VBN|juvenile|,|rheumatoid (r_relcl) arthritis_7\NN|NONE (r_pobj) with_4\IN|four|, (r_prep) patients_3\NNS|.|decreases (r_nsubj) had_26\VBD|NONE (l_dobj) decreases_29\NNS|.|patients (l_prep) in_32\IN|significant|from|after (l_pobj) indices_35\NNS|NONE (l_compound) arthritis_34\NN|
8701950
D001241_D000743 NONE aspirin_20\NN|, (r_conj) corticosteroids_18\NNS|fresh|plasma|, (r_conj) replacement_16\NN|,|of (r_appos) discontinuation_4\NN|In|,|.|to (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|In|,|.|discontinuation (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
D016572_D000743 NONE A_19\NNP|FK|In|not|.|does|, (l_appos) drug_28\NN|CyA|cyclosporin|,|with|react (l_acl) known_30\VBN|an|suppressive (l_xcomp) induce_32\VB|already (l_dobj) MAHA_33\NNP|to
D016572_D000743 NONE CyA_21\NN|cyclosporin|,|drug|with|react (r_appos) A_19\NNP|FK|In|not|.|does|, (l_appos) drug_28\NN|CyA|cyclosporin|,|with|react (l_acl) known_30\VBN|an|suppressive (l_xcomp) induce_32\VB|already (l_dobj) MAHA_33\NNP|to
D016559_D000743 CID FK506_4\NNP|.|anemia (r_dobj) complicating_3\VBG|NONE (l_nsubj) anemia_2\NN|FK|.
D016559_D000743 CID tacrolimus_6\NNP|NONE (r_nmod) therapy_8\NN|( (r_appos) FK506_4\NNP|.|anemia (r_dobj) complicating_3\VBG|NONE (l_nsubj) anemia_2\NN|FK|.
D016559_D000743 CID FK506_17\NNP|tacrolimus (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|solid||organ (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|.|We (l_prep) of_4\IN|in| (l_pobj) anemia_7\NN|NONE
D016559_D000743 CID FK506_17\NNP|tacrolimus (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|solid||organ (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|.|We (l_prep) of_4\IN|in| (l_pobj) anemia_7\NN|NONE (l_appos) MAHA_9\NNP|microangiopathic|)|(|hemolytic
D016559_D000743 CID tacrolimus_19\NNP|FK (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|solid||organ (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|.|We (l_prep) of_4\IN|in| (l_pobj) anemia_7\NN|NONE
D016559_D000743 CID tacrolimus_19\NNP|FK (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|solid||organ (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|.|We (l_prep) of_4\IN|in| (l_pobj) anemia_7\NN|NONE (l_appos) MAHA_9\NNP|microangiopathic|)|(|hemolytic
D016559_D000743 CID FK506_6\NNP|NONE (r_pobj) of_5\IN|,|replacement (r_prep) discontinuation_4\NN|In|,|.|to (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|In|,|.|discontinuation (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
D016559_D000743 CID FK506_6\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) reintroduction_4\NN|to|In|,|. (r_nsubj) led_7\VBD|NONE (l_prep) to_8\IN|reintroduction|In|,|. (l_pobj) recurrence_10\NN|NONE (l_prep) of_11\IN|rapid (l_pobj) MAHA_12\NNP|NONE
D016559_D000743 CID FK506-associated_0\VBN|NONE (r_amod) MAHA_1\NNP|but|probably|be|rare
D016559_D000743 CID FK506_9\NNP|In|not|A|.|does|, (r_nsubj) seem_12\VB|NONE (l_oprd) A_19\NNP|FK|In|not|.|does|, (l_appos) drug_28\NN|CyA|cyclosporin|,|with|react (l_acl) known_30\VBN|an|suppressive (l_xcomp) induce_32\VB|already (l_dobj) MAHA_33\NNP|to
D000305_D000743 NONE corticosteroids_18\NNS|fresh|plasma|, (r_conj) replacement_16\NN|,|of (r_appos) discontinuation_4\NN|In|,|.|to (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|In|,|.|discontinuation (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
D004176_D000743 NONE dipyridamole_23\NN|,|and (r_conj) aspirin_20\NN|, (r_conj) corticosteroids_18\NNS|fresh|plasma|, (r_conj) replacement_16\NN|,|of (r_appos) discontinuation_4\NN|In|,|.|to (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|In|,|.|discontinuation (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
18809400
D008063_D010523 NONE acid_7\NN|risk|encourage|that|might|and (r_nsubj) reduce_9\VB|findings|. (l_dobj) risk_11\NN|encourage|that|might|and|acid (l_prep) of_12\IN|the (l_pcomp) developing_13\VBG|NONE (l_dobj) toxicity_16\NN|NONE
D017239_D028361 NONE paclitaxel_7\NN|and|both (r_conj) cisplatin_5\NN|that|impairment (r_nsubj) cause_8\VBP|results|. (l_dobj) impairment_11\NN|that|cisplatin
D017239_D028361 NONE paclitaxel_11\NN|both|and|cisplatin (r_pobj) in_10\IN|an|common|early (r_prep) event_8\NN|In|induced|toxicity|. (r_attr) is_4\VBZ|NONE (l_nsubj) toxicity_3\NN|In|induced|.|event
D002945_D020258 NONE cisplatin_13\NN|both|and|paclitaxel (r_conj) in_10\IN|an|common|early (r_prep) event_8\NN|In|induced|toxicity|. (r_attr) is_4\VBZ|NONE (l_advcl) induced_14\VBN|In|toxicity|.|event (l_dobj) neurotoxicity_15\NN|NONE
D017239_D020258 NONE paclitaxel_11\NN|both|and|cisplatin (r_pobj) in_10\IN|an|common|early (r_prep) event_8\NN|In|induced|toxicity|. (r_attr) is_4\VBZ|NONE (l_advcl) induced_14\VBN|In|toxicity|.|event (l_dobj) neurotoxicity_15\NN|NONE
D008063_D001480 NONE acid_10\NN|NONE (r_pobj) of_6\IN|the|in (r_prep) efficacy_5\NN|apoptosis|and (l_prep) in_11\IN|of|the (l_pcomp) preventing_12\VBG|NONE (l_dobj) damage_14\NN|NONE
D008063_D001480 NONE acid_34\NN|toxic|and (r_conj) agents_29\NNS|NONE (r_pobj) to_27\IN|NONE (r_prep) exposure_26\NN|NONE (r_pobj) after_25\IN|of|the|morphology|and (r_prep) function_19\NN|and (r_conj) apoptosis_16\NN|efficacy|and (r_conj) investigating_3\VBG|approach|. (l_dobj) efficacy_5\NN|apoptosis|and (l_prep) in_11\IN|of|the (l_pcomp) preventing_12\VBG|NONE (l_dobj) damage_14\NN|NONE
D017239_D010523 CID paclitaxel_32\NN|NONE (r_pobj) to_31\IN|(|sensory|)|DRG (r_prep) neurons_30\NNS|dorsal|root (r_appos) ganglion_25\NN|NONE (r_pobj) of_22\IN|primary (r_prep) cultures_21\NNS|NONE (r_dobj) exposing_19\VBG|NONE (r_pcomp) by_18\IN|drugs|that|in|closely (r_prep) mimic_13\VBP|an|of|in|vitro (r_relcl) model_5\NN|induced|We|. (r_dobj) used_1\VBD|NONE (l_xcomp) induced_8\VBD|model|We|. (l_dobj) neuropathy_10\NN|NONE
D002945_D010523 CID cisplatin_34\NN|and (r_conj) paclitaxel_32\NN|NONE (r_pobj) to_31\IN|(|sensory|)|DRG (r_prep) neurons_30\NNS|dorsal|root (r_appos) ganglion_25\NN|NONE (r_pobj) of_22\IN|primary (r_prep) cultures_21\NNS|NONE (r_dobj) exposing_19\VBG|NONE (r_pcomp) by_18\IN|drugs|that|in|closely (r_prep) mimic_13\VBP|an|of|in|vitro (r_relcl) model_5\NN|induced|We|. (r_dobj) used_1\VBD|NONE (l_xcomp) induced_8\VBD|model|We|. (l_dobj) neuropathy_10\NN|NONE
D008063_D009410 NONE acid_7\NN|neuroprotective|plays|if|,|induced (r_nsubj) is_8\VBZ|.|study (l_advcl) plays_18\VBZ|neuroprotective|if|,|acid|induced (l_dobj) role_21\NN|depend|and|damage|,|if (l_prep) in_22\IN|critical|a (l_pobj) cascade_25\NN|NONE
D008063_D009410 NONE acid_35\NN|NONE (r_pobj) of_31\IN|neuroprotective (r_prep) effects_30\NNS|on|if (r_nsubj) depend_36\VBP|and|damage|,|if|role (r_conj) plays_18\VBZ|neuroprotective|if|,|acid|induced (l_dobj) role_21\NN|depend|and|damage|,|if (l_prep) in_22\IN|critical|a (l_pobj) cascade_25\NN|NONE
D002945_D028361 NONE cisplatin_5\NN|that|impairment (r_nsubj) cause_8\VBP|results|. (l_dobj) impairment_11\NN|that|cisplatin
D002945_D028361 NONE cisplatin_13\NN|both|and|paclitaxel (r_conj) in_10\IN|an|common|early (r_prep) event_8\NN|In|induced|toxicity|. (r_attr) is_4\VBZ|NONE (l_nsubj) toxicity_3\NN|In|induced|.|event
D008063_D020258 NONE acid_3\NN|damage|. (r_nsubj) prevents_4\VBZ|NONE (l_dobj) damage_6\NN|acid|. (l_conj) neurotoxicity_8\NN|and|mitochondrial|in
D008063_D020258 NONE acid_7\NN|neuroprotective|plays|if|,|induced (r_nsubj) is_8\VBZ|.|study (l_advcl) induced_12\VBN|neuroprotective|plays|if|,|acid (l_dobj) neurotoxicity_13\NN|NONE
D008063_D020258 NONE acid_35\NN|NONE (r_pobj) of_31\IN|neuroprotective (r_prep) effects_30\NNS|on|if (r_nsubj) depend_36\VBP|and|damage|,|if|role (r_conj) plays_18\VBZ|neuroprotective|if|,|acid|induced (r_advcl) is_8\VBZ|.|study (l_advcl) induced_12\VBN|neuroprotective|plays|if|,|acid (l_dobj) neurotoxicity_13\NN|NONE
D008063_D020258 NONE acid_3\NN|effects|induced (r_nsubj) exerts_4\VBZ|.|it|:|induces|toxicity|and (l_conj) induced_9\VBN|effects|acid (l_dobj) neurotoxicity_10\NN|NONE
D008063_D009422 NONE acid_3\NN|damage|. (r_nsubj) prevents_4\VBZ|NONE (l_dobj) damage_6\NN|acid|. (l_prep) in_9\IN|and|mitochondrial|neurotoxicity (l_pobj) neuropathy_12\NN|NONE
D008063_D028361 NONE acid_3\NN|damage|. (r_nsubj) prevents_4\VBZ|NONE (l_dobj) damage_6\NN|acid|.
D008063_D028361 NONE acid_7\NN|neuroprotective|plays|if|,|induced (r_nsubj) is_8\VBZ|.|study (l_advcl) plays_18\VBZ|neuroprotective|if|,|acid|induced (l_nsubj) damage_17\NN|depend|and|,|if|role
D008063_D028361 NONE acid_35\NN|NONE (r_pobj) of_31\IN|neuroprotective (r_prep) effects_30\NNS|on|if (r_nsubj) depend_36\VBP|and|damage|,|if|role (r_conj) plays_18\VBZ|neuroprotective|if|,|acid|induced (l_nsubj) damage_17\NN|depend|and|,|if|role
D008063_D028361 NONE acid_3\NN|effects|induced (r_nsubj) exerts_4\VBZ|.|it|:|induces|toxicity|and (r_ccomp) rescues_16\VBZ|NONE (l_dobj) toxicity_19\NN|.|it|exerts|:|induces|and
11961407
D011692_D011507 CID PAN_21\NNP|NONE (r_compound) injection_22\NN|NONE (r_pobj) after_20\IN|| (r_prep) days_19\NNS|include|were|at|.|Tissues (r_npadvmod) analyzed_2\VBN|NONE (l_advcl) include_26\VB|were|at|.|days|Tissues (l_dobj) phase_30\NN|to|so|as (l_prep) of_31\IN|(|days|associated|the|acute|both (l_pobj) proteinuria_32\NN|NONE
D011692_D011507 CID PAN_21\NNP|NONE (r_compound) injection_22\NN|NONE (r_pobj) after_20\IN|| (r_prep) days_19\NNS|include|were|at|.|Tissues (r_npadvmod) analyzed_2\VBN|NONE (l_advcl) include_26\VB|were|at|.|days|Tissues (l_dobj) phase_30\NN|to|so|as (l_appos) days_39\NNS|(|associated|of|the|acute|both (l_conj) phase_47\NN|)|and| (l_prep) of_48\IN|the|associated|chronic (l_pobj) proteinuria_49\NN|NONE
D014443_D009401 NONE tyrosine_2\NN|receptor|in|.|GLEPP|Ptpro (r_compound) phosphatase_3\NN|NONE (l_prep) in_7\IN|tyrosine|receptor|.|GLEPP|Ptpro (l_pobj) nephrosis_10\NN|NONE
D011692_D005921 NONE PAN_21\NNP|NONE (r_compound) injection_22\NN|NONE (r_pobj) after_20\IN|| (r_prep) days_19\NNS|include|were|at|.|Tissues (r_npadvmod) analyzed_2\VBN|NONE (l_advcl) include_26\VB|were|at|.|days|Tissues (l_dobj) phase_30\NN|to|so|as (l_appos) days_39\NNS|(|associated|of|the|acute|both (l_conj) phase_47\NN|)|and| (l_acl) associated_50\VBN|the|chronic|of (l_prep) with_51\IN|NONE (l_pobj) glomerulosclerosis_52\NN|NONE
D011692_D009401 CID PAN_9\NNP|rat (r_compound) nephrosis_10\NN|NONE
D011692_D009401 CID aminonucleoside_1\JJ|Puromycin (r_amod) nephrosis_2\NN|by|.|aminonucleoside|was
D011692_D009401 CID aminonucleoside_11\NN|by|.|was|nephrosis (r_advmod) induced_4\VBN|NONE (l_nsubjpass) nephrosis_2\NN|by|.|aminonucleoside|was
D011692_D009401 CID PAN_13\NNP|NONE (r_appos) aminonucleoside_11\NN|by|.|was|nephrosis (r_advmod) induced_4\VBN|NONE (l_nsubjpass) nephrosis_2\NN|by|.|aminonucleoside|was
11581460
D005283_D009127 NONE fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|side|reported|Various (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|.
D005283_D001745 CID fentanyl_22\NN|NONE (r_pobj) of_21\IN|continuous (r_prep) infusion_20\NN|NONE (r_pobj) of_18\IN|a (r_prep) result_17\NN|NONE (r_pobj) as_15\IN|hydronephrosis (r_prep) mimicking_13\VBG|renal|pelvocalyceal (r_acl) dilatation_12\NN|NONE (r_pobj) to_9\IN|NONE (r_prep) leading_8\VBG||of (r_acl) cases_3\NNS|,|Here|are|. (l_prep) of_4\IN||leading (l_pobj) retention_7\NN|NONE
D005283_D006869 NONE fentanyl_22\NN|NONE (r_pobj) of_21\IN|continuous (r_prep) infusion_20\NN|NONE (r_pobj) of_18\IN|a (r_prep) result_17\NN|NONE (r_pobj) as_15\IN|hydronephrosis (r_prep) mimicking_13\VBG|renal|pelvocalyceal (l_dobj) hydronephrosis_14\NN|as
D005283_D001919 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|side|reported|Various (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|. (l_conj) hypotension_12\NN|chest|wall|, (l_conj) depression_15\NN|, (l_conj) bradycardia_18\NN|,|respiratory|and
D005283_D016055 CID fentanyl_12\NN|NONE (r_pobj) of_11\IN|intravenous|continuous (r_prep) infusion_10\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|NONE (r_pobj) as_4\IN|of|Bladder (r_prep) retention_1\NN|:|case|. (l_prep) of_2\IN|Bladder|as (l_pobj) urine_3\NN|NONE
D005283_D007022 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|side|reported|Various (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|. (l_conj) hypotension_12\NN|chest|wall|,
D005283_D012131 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|side|reported|Various (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|. (l_conj) hypotension_12\NN|chest|wall|, (l_conj) depression_15\NN|,
2024540
D004656_D006333 NONE enalapril_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) safety_9\NN|:|and|analysis|.|of (l_prep) in_14\IN|of (l_pobj) phase_18\NN|NONE (l_prep) of_19\IN|initial|the|treatment (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) failure_24\NN|NONE
D000806_D007022 CID inhibitors_10\NNS|NONE (r_appos) enzyme_6\NN|into (r_dobj) converting_5\VBG|NONE (l_prep) into_11\IN|enzyme (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|adjunctive|the (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) failure_20\NN|NONE (l_conj) cases_22\NNS|heart|congestive|, (l_prep) of_23\IN|NONE (l_pobj) hypotension_25\NN|NONE
D000806_D007022 CID inhibitor_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) safety_3\NN|To (r_dobj) assess_1\VB|that|trial|.|compared|was (r_advcl) designed_19\VBN|NONE (l_prep) compared_21\VBD|that|trial|.|assess|was (l_pobj) incidence_23\NN|NONE (l_prep) of_26\IN|the|severity|and (l_pobj) hypotension_28\NN|NONE
D000806_D006333 NONE inhibitors_10\NNS|NONE (r_appos) enzyme_6\NN|into (r_dobj) converting_5\VBG|NONE (l_prep) into_11\IN|enzyme (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|adjunctive|the (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) failure_20\NN|NONE
D004656_D007022 NONE enalapril_8\NN|ACE|the (r_appos) inhibitor_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) safety_3\NN|To (r_dobj) assess_1\VB|that|trial|.|compared|was (r_advcl) designed_19\VBN|NONE (l_prep) compared_21\VBD|that|trial|.|assess|was (l_pobj) incidence_23\NN|NONE (l_prep) of_26\IN|the|severity|and (l_pobj) hypotension_28\NN|NONE
D004656_D007022 NONE enalapril_3\RB|who (r_dobj) received_2\VBD|NONE (r_relcl) Patients_0\NNS|hypotension|. (r_nsubj) experienced_4\VBD|NONE (l_dobj) hypotension_11\NN|Patients|.
D011224_D007022 CID prazosin_14\NN| (r_npadvmod) controlled_16\VBN|a|,|randomized|,|multicenter (r_amod) trial_17\NN|that|.|compared|assess|was (r_nsubjpass) designed_19\VBN|NONE (l_prep) compared_21\VBD|that|trial|.|assess|was (l_pobj) incidence_23\NN|NONE (l_prep) of_26\IN|the|severity|and (l_pobj) hypotension_28\NN|NONE
D011224_D007022 CID prazosin_21\NN|who (r_dobj) received_20\VBD|the (r_relcl) patients_18\NNS|NONE (r_pobj) than_16\IN|%|clinically|(|) (r_prep) hypotension_11\NN|Patients|.
D011224_D006333 NONE prazosin_13\NN|and (r_conj) enalapril_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) safety_9\NN|:|and|analysis|.|of (l_prep) in_14\IN|of (l_pobj) phase_18\NN|NONE (l_prep) of_19\IN|initial|the|treatment (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) failure_24\NN|NONE
19300402
D001920_D003929 NONE Bradykinin_0\NN|inhibitors|receptors|in|and|streptozotocin|and (r_compound) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|. (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D013311_D006930 CID streptozotocin_11\NNS|inhibitors|receptors|in|and|and|Bradykinin (r_conj) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|.
D013311_D006930 CID streptozotocin_1\JJ| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperalgesia_4\NN|NONE
D013311_D006930 CID streptozotocin_1\JJ| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperalgesia_4\NN|NONE (r_pobj) In_0\IN|induced|synthase|,|,|in|seemed (r_prep) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|In|synthase|,|,|in|seemed (l_dobj) hyperalgesia_21\NN||whereas|in
D014750_D006930 CID vincristine_9\NN|NONE (r_pobj) in_8\IN|inhibitors|receptors|and|streptozotocin|and|Bradykinin (r_prep) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|.
D014750_D006930 CID vincristine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) produced_24\VBN|NONE (r_acl) hyperalgesia_23\NN|NONE
D014750_D006930 CID vincristine_18\NN|NONE (r_pobj) in_17\IN||hyperalgesia|whereas (r_prep) induced_20\VBN|In|synthase|,|,|in|seemed (r_advcl) participates_9\VBZ|NONE (l_prep) In_0\IN|induced|synthase|,|,|in|seemed (l_pobj) hyperalgesia_4\NN|NONE
D014750_D006930 CID vincristine_18\NN|NONE (r_pobj) in_17\IN||hyperalgesia|whereas (r_prep) induced_20\VBN|In|synthase|,|,|in|seemed (l_dobj) hyperalgesia_21\NN||whereas|in
D001920_D009437 NONE bradykinin_8\NN|NONE (r_pobj) of_7\IN|small (r_prep) doses_6\NNS|NONE (r_pobj) of_4\IN|concomitant (r_prep) administration_3\NN|can|in|,|Therefore|.|,|effective (r_nsubj) be_16\VB|NONE (l_acomp) effective_17\JJ|can|in|administration|,|Therefore|.|, (l_prep) in_18\IN|NONE (l_pobj) alleviation_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) pain_22\NN|NONE
D013311_D003929 CID streptozotocin_11\NNS|inhibitors|receptors|in|and|and|Bradykinin (r_conj) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|. (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D009569_D003929 NONE oxide_5\NN|nitric (r_compound) synthase_6\NN|NONE (r_compound) inhibitors_7\NNS|receptors|in|and|streptozotocin|and|Bradykinin (r_conj) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|. (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D014750_D003929 NONE vincristine_9\NN|NONE (r_pobj) in_8\IN|inhibitors|receptors|and|streptozotocin|and|Bradykinin (r_prep) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|. (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D001920_D006930 NONE Bradykinin_0\NN|inhibitors|receptors|in|and|streptozotocin|and (r_compound) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|.
D001920_D006930 NONE bradykinin_9\NN|NONE (r_compound) receptors_10\NNS|NONE (r_pobj) of_8\IN|and|but|synthase (r_prep) inhibition_7\NN|activity|hyperalgesia|that (r_nsubj) reduces_21\VBZ|.|results (l_dobj) hyperalgesia_23\NN|activity|inhibition|that
D001920_D006930 NONE bradykinin_19\NN|NO|neuronal|as|synthase (r_conj) activation_15\NN|and|NO|inducible (r_conj) synthase_10\NN|NONE (r_pobj) of_7\IN|both (r_prep) products_6\NNS|that|in|are (r_nsubjpass) involved_21\VBN|It|.|also|was (l_prep) in_22\IN|that|are|products (l_pobj) hyperalgesia_23\NN|NONE
D001920_D006930 NONE bradykinin_14\NN|NONE (r_pobj) of_13\IN|pronociceptive (r_prep) activity_12\NN|NONE (r_pobj) in_10\IN|In|induced|synthase|,|,|seemed (r_prep) participates_9\VBZ|NONE (l_prep) In_0\IN|induced|synthase|,|,|in|seemed (l_pobj) hyperalgesia_4\NN|NONE
D001920_D006930 NONE bradykinin_14\NN|NONE (r_pobj) of_13\IN|pronociceptive (r_prep) activity_12\NN|NONE (r_pobj) in_10\IN|In|induced|synthase|,|,|seemed (r_prep) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|In|synthase|,|,|in|seemed (l_dobj) hyperalgesia_21\NN||whereas|in
D001920_D006930 NONE bradykinin_22\NN|activate|. (r_nsubj) seemed_23\VBD|In|induced|synthase|,|,|in (r_conj) participates_9\VBZ|NONE (l_prep) In_0\IN|induced|synthase|,|,|in|seemed (l_pobj) hyperalgesia_4\NN|NONE
D001920_D006930 NONE bradykinin_22\NN|activate|. (r_nsubj) seemed_23\VBD|In|induced|synthase|,|,|in (r_conj) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|In|synthase|,|,|in|seemed (l_dobj) hyperalgesia_21\NN||whereas|in
D009569_D009437 NONE NO_12\DT|synthase (r_det) inhibitors_14\NNS|receptor|and (r_conj) antagonists_10\NNS|NONE (r_dobj) bradykinin_8\NN|NONE (r_pobj) of_7\IN|small (r_prep) doses_6\NNS|NONE (r_pobj) of_4\IN|concomitant (r_prep) administration_3\NN|can|in|,|Therefore|.|,|effective (r_nsubj) be_16\VB|NONE (l_acomp) effective_17\JJ|can|in|administration|,|Therefore|.|, (l_prep) in_18\IN|NONE (l_pobj) alleviation_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) pain_22\NN|NONE
D009569_D006930 NONE oxide_5\NN|nitric (r_compound) synthase_6\NN|NONE (r_compound) inhibitors_7\NNS|receptors|in|and|streptozotocin|and|Bradykinin (r_conj) antagonists_2\NNS|.|hyperalgesia (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|antagonists|.
D009569_D006930 NONE NO_13\DT|inducible (r_det) synthase_14\NN|of|and|but (r_conj) inhibition_7\NN|activity|hyperalgesia|that (r_nsubj) reduces_21\VBZ|.|results (l_dobj) hyperalgesia_23\NN|activity|inhibition|that
D009569_D006930 NONE NO_18\DT|neuronal|synthase|not (r_det) activity_20\NN|hyperalgesia|inhibition|that (r_nsubj) reduces_21\VBZ|.|results (l_dobj) hyperalgesia_23\NN|activity|inhibition|that
D009569_D006930 NONE NO_9\DT|and|inducible|activation (r_compound) synthase_10\NN|NONE (r_pobj) of_7\IN|both (r_prep) products_6\NNS|that|in|are (r_nsubjpass) involved_21\VBN|It|.|also|was (l_prep) in_22\IN|that|are|products (l_pobj) hyperalgesia_23\NN|NONE
D009569_D006930 NONE NO_13\DT|neuronal|as|bradykinin|synthase (r_det) activation_15\NN|and|NO|inducible (r_conj) synthase_10\NN|NONE (r_pobj) of_7\IN|both (r_prep) products_6\NNS|that|in|are (r_nsubjpass) involved_21\VBN|It|.|also|was (l_prep) in_22\IN|that|are|products (l_pobj) hyperalgesia_23\NN|NONE
D009569_D006930 NONE NO_7\DT|inducible (r_compound) synthase_8\NN|In|induced|,|,|in|seemed (r_nsubj) participates_9\VBZ|NONE (l_prep) In_0\IN|induced|synthase|,|,|in|seemed (l_pobj) hyperalgesia_4\NN|NONE
D009569_D006930 NONE NO_7\DT|inducible (r_compound) synthase_8\NN|In|induced|,|,|in|seemed (r_nsubj) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|In|synthase|,|,|in|seemed (l_dobj) hyperalgesia_21\NN||whereas|in
D009569_D006930 NONE NO_27\DT|synthase|neuronal (r_det) pathway_29\NN|to (r_dobj) activate_25\VB|bradykinin|. (r_xcomp) seemed_23\VBD|In|induced|synthase|,|,|in (r_conj) participates_9\VBZ|NONE (l_prep) In_0\IN|induced|synthase|,|,|in|seemed (l_pobj) hyperalgesia_4\NN|NONE
D009569_D006930 NONE NO_27\DT|synthase|neuronal (r_det) pathway_29\NN|to (r_dobj) activate_25\VB|bradykinin|. (r_xcomp) seemed_23\VBD|In|induced|synthase|,|,|in (r_conj) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|In|synthase|,|,|in|seemed (l_dobj) hyperalgesia_21\NN||whereas|in
11642480
D015283_D003865 NONE citalopram_8\NN|NONE (r_pobj) with_7\IN|by (r_prep) treatment_6\NN|NONE (l_prep) by_9\IN|with (l_pobj) boy_14\NN|NONE (l_prep) with_15\IN|a|old (l_pobj) depression_17\NN|NONE
D015283_D003866 NONE citalopram_7\NN|NONE (r_pobj) on_6\IN|a|depressed (r_prep) adolescent_5\NN|NONE (l_amod) depressed_4\JJ|on|a
D015283_D004409 CID citalopram_7\NN|NONE (r_pobj) on_6\IN|a|depressed (r_prep) adolescent_5\NN|NONE (r_pobj) in_2\IN|.|Palpebral (r_prep) twitching_1\VBG|NONE
D015283_D004409 CID citalopram_8\NN|NONE (r_pobj) with_7\IN|by (r_prep) treatment_6\NN|NONE (l_prep) by_9\IN|with (l_pobj) boy_14\NN|NONE (l_prep) with_15\IN|a|old (l_pobj) depression_17\NN|NONE (l_relcl) exhibited_19\VBD|major (l_dobj) twitching_21\NN|who|during
15859940
D016572_D057049 CID cyclosporine_18\NN|mainly (r_pobj) to_17\IN|NONE (r_prep) secondary_15\JJ|,|drug (r_amod) related_13\VBN|that|cause (r_acomp) was_11\VBD|.|We (l_nsubj) cause_7\NN|that|related (l_prep) of_8\IN|the|frequent (l_pobj) microangiopathy_10\NN|NONE
D016572_D064420 NONE cyclosporine_7\NN|status|(|,|related (r_nmod) toxicity_11\NN|causes|.
D016559_D064420 NONE tacrolimus_9\NN|, (r_conj) cyclosporine_7\NN|status|(|,|related (r_nmod) toxicity_11\NN|causes|.
8595686
D013874_D010146 NONE Thiopentone_0\NN|for|. (r_compound) pretreatment_1\NN|NONE (l_prep) for_2\IN|.|Thiopentone (l_pobj) pain_5\NN|NONE
D013874_D010146 NONE thiopentone_17\NN|whereas|severity|only (r_nsubj) reduces_19\VBZ|incidence|lidocaine|that (r_advcl) reduces_4\VBZ|We|. (l_dobj) incidence_6\NN|reduces|lidocaine|that (l_prep) of_9\IN|the|and|severity (l_pobj) pain_12\NN|NONE
D015742_D010146 CID propofol_3\JJ|in|injection (r_amod) pain_5\NN|NONE
D015742_D010146 CID propofol_3\JJ|injection|in (r_amod) pain_5\NN|study|.
D015742_D010146 CID propofol_10\JJ|injection|in (r_amod) pain_12\NN|NONE
D008012_D010146 NONE lidocaine_3\NN|reduces|incidence|that (r_nsubj) reduces_4\VBZ|We|. (l_dobj) incidence_6\NN|reduces|lidocaine|that (l_prep) of_9\IN|the|and|severity (l_pobj) pain_12\NN|NONE
11263551
D016572_-1 NONE cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|Syndrome|diagnosed|and|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|diagnosed|and|effect|. (l_appos) CIPS_8\NNP|inhibitor|(|The|Pain|)
D016559_-1 NONE tacrolimus_20\NN|or (r_conj) cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|Syndrome|diagnosed|and|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|diagnosed|and|effect|. (l_appos) CIPS_8\NNP|inhibitor|(|The|Pain|)
D016559_D010146 CID tacrolimus_5\VB|NONE (r_compound) trough_6\NN|cyclosporine (r_compound) levels_7\NNS|NONE (r_pobj) of_2\IN|administration|and|The (r_prep) reduction_1\NN|.|to (r_nsubj) led_15\VBD|NONE (l_prep) to_16\IN|reduction|. (l_pobj) relief_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) pain_19\NN|NONE
D016559_D010146 CID tacrolimus_20\NN|or (r_conj) cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|Syndrome|diagnosed|and|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|diagnosed|and|effect|. (l_compound) Pain_5\NNP|inhibitor|(|The|)|CIPS
D016572_D010146 CID cyclosporine-_3\NN|trough (r_nmod) levels_7\NNS|NONE (r_pobj) of_2\IN|administration|and|The (r_prep) reduction_1\NN|.|to (r_nsubj) led_15\VBD|NONE (l_prep) to_16\IN|reduction|. (l_pobj) relief_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) pain_19\NN|NONE
D016572_D010146 CID cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|Syndrome|diagnosed|and|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|diagnosed|and|effect|. (l_compound) Pain_5\NNP|inhibitor|(|The|)|CIPS
D002118_D010146 NONE calcium_12\NN|NONE (r_compound) channel_13\NN|NONE (r_compound) blockers_14\NNS|NONE (r_pobj) of_11\IN|the (r_prep) administration_10\NN|of|and|The (r_conj) reduction_1\NN|.|to (r_nsubj) led_15\VBD|NONE (l_prep) to_16\IN|reduction|. (l_pobj) relief_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) pain_19\NN|NONE
2572625
C013295_D056486 NONE thienodiazepine_27\NN|a (r_amod) derivative_28\NN|developed|a|, (r_appos) patient_6\NN|NONE (l_relcl) developed_8\VBD|derivative|a|, (l_dobj) hepatitis_10\NN|with|who|after
C013295_D047508 NONE thienodiazepine_27\NN|a (r_amod) derivative_28\NN|developed|a|, (r_appos) patient_6\NN|NONE (l_relcl) developed_8\VBD|derivative|a|, (l_prep) with_11\IN|hepatitis|who|after (l_pobj) necrosis_14\NN|NONE
C084599_D056486 CID Clotiazepam_0\NNP| (r_npadvmod) induced_2\VBN|acute|. (r_amod) hepatitis_4\NN|NONE
C084599_D056486 CID clotiazepam_24\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) onset_20\NN|months (r_pobj) after_18\IN|with|hepatitis|who (r_prep) developed_8\VBD|derivative|a|, (l_dobj) hepatitis_10\NN|with|who|after
C084599_D056486 CID clotiazepam_9\NN|chemically (r_xcomp) related_7\VBN|,|The|of (r_acl) administration_1\NN|not|induce|,|did|and|.|with (r_nsubj) interfere_13\VB|NONE (l_conj) induce_19\VB|not|,|did|and|administration|.|with (l_dobj) relapse_21\NN|not|did (l_prep) of_22\IN|any (l_pobj) hepatitis_23\NN|NONE
C084599_D056486 CID clotiazepam_4\NN|hepatitis|suggests|that|and|can (r_nsubj) induce_6\VB|observation|. (l_dobj) hepatitis_8\NN|suggests|that|and|can|clotiazepam
C084599_D056486 CID clotiazepam_4\NN|hepatitis|suggests|that|and|can (r_nsubj) induce_6\VB|observation|. (l_conj) suggests_10\VBZ|hepatitis|that|and|can|clotiazepam (l_ccomp) is_13\VBZ|NONE (l_attr) hepatotoxicity_16\NN|there|that
C084599_D056486 CID clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|there|that (r_attr) is_13\VBZ|NONE (r_ccomp) suggests_10\VBZ|hepatitis|that|and|can|clotiazepam (r_conj) induce_6\VB|observation|. (l_dobj) hepatitis_8\NN|suggests|that|and|can|clotiazepam
C084599_D056486 CID clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|there|that
C084599_D047508 NONE clotiazepam_24\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) onset_20\NN|months (r_pobj) after_18\IN|with|hepatitis|who (r_prep) developed_8\VBD|derivative|a|, (l_prep) with_11\IN|hepatitis|who|after (l_pobj) necrosis_14\NN|NONE
D001569_D056486 NONE benzodiazepines_4\NNS|NONE (r_pobj) of_2\IN|,|The|related (r_prep) administration_1\NN|not|induce|,|did|and|.|with (r_nsubj) interfere_13\VB|NONE (l_conj) induce_19\VB|not|,|did|and|administration|.|with (l_dobj) relapse_21\NN|not|did (l_prep) of_22\IN|any (l_pobj) hepatitis_23\NN|NONE
D001569_D056486 NONE benzodiazepines_21\NNS|and (r_conj) clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|there|that (r_attr) is_13\VBZ|NONE (r_ccomp) suggests_10\VBZ|hepatitis|that|and|can|clotiazepam (r_conj) induce_6\VB|observation|. (l_dobj) hepatitis_8\NN|suggests|that|and|can|clotiazepam
D001569_D056486 NONE benzodiazepines_21\NNS|and (r_conj) clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|there|that
10406016
C007789_D007249 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|.|,|evidence (r_nsubj) exhibited_4\VBD|NONE (l_conj) had_13\VBD|.|,|evidence|rats (l_conj) tended_18\VBD|and|hematomas|, (l_xcomp) have_20\VB|NONE (l_dobj) inflammation_22\NN|after|to
C007789_D020141 CID Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|.|,|evidence (r_nsubj) exhibited_4\VBD|NONE (l_dobj) evidence_5\NN|had|.|,|rats (l_prep) of_6\IN|NONE (l_pobj) clotting_9\NN|NONE
C007789_D020141 CID Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|.|,|evidence (r_nsubj) exhibited_4\VBD|NONE (l_dobj) evidence_5\NN|had|.|,|rats (l_prep) of_6\IN|NONE (l_pobj) clotting_9\NN|NONE (l_conj) hemodilution_11\NN|impaired|blood|and
C007789_D001925 NONE fucoidan_5\RB|.|in|We (l_relcl) reported_10\VBN|sulfated|,|,|the|polysaccharide (l_xcomp) reduce_12\VB|which|been|has (l_dobj) damage_15\NN|to
C007789_D002543 NONE fucoidan_2\JJ|on (r_compound) treatment_3\NN|NONE (l_prep) on_4\IN|fucoidan (l_pobj) hemorrhage_9\NN|NONE
C007789_D002543 NONE fucoidan_5\RB|.|in|We (r_dobj) tested_1\VBD|NONE (l_prep) in_17\IN|.|We|fucoidan (l_pobj) model_20\NN|NONE (l_prep) of_21\IN|rat|induced|a (l_pobj) hemorrhage_23\NN|NONE
C007789_D006406 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|.|,|evidence (r_nsubj) exhibited_4\VBD|NONE (l_conj) had_13\VBD|.|,|evidence|rats (l_dobj) hematomas_15\NNS|and|tended|,
C007789_D006406 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|.|,|evidence (r_nsubj) exhibited_4\VBD|NONE (l_conj) had_13\VBD|.|,|evidence|rats (l_conj) tended_18\VBD|and|hematomas|, (l_xcomp) have_20\VB|NONE (l_dobj) inflammation_22\NN|after|to (l_prep) in_23\IN|less (l_pobj) vicinity_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) hematoma_28\NN|NONE
12820454
D016729_D000740 CID acetate_6\NN|patients|evaluated|.|and (r_dobj) received_2\VBD|NONE (l_conj) evaluated_32\VBN|acetate|patients|.|and (l_prep) for_33\IN|were|by (l_pobj) anemia_34\NN|NONE
D016729_D000740 CID A_10\NNP|CAB|days|)|mg|[|intramuscularly|,|leuprolide|,|( (r_appos) acetate_6\NN|patients|evaluated|.|and (r_dobj) received_2\VBD|NONE (l_conj) evaluated_32\VBN|acetate|patients|.|and (l_prep) for_33\IN|were|by (l_pobj) anemia_34\NN|NONE
D005485_D000740 CID flutamide_23\NN|mg|,|per|, (r_nmod) tid_25\NN|plus||every (r_conj) days_19\NNS|CAB|)|mg|[|intramuscularly|,|A|leuprolide|,|( (r_appos) acetate_6\NN|patients|evaluated|.|and (r_dobj) received_2\VBD|NONE (l_conj) evaluated_32\VBN|acetate|patients|.|and (l_prep) for_33\IN|were|by (l_pobj) anemia_34\NN|NONE
2476560
D001556_D012532 NONE lindane_12\NN|;|.|most|initiated (r_dobj) consider_11\VBP|NONE (l_ccomp) initiated_5\VBN|;|.|most|lindane (l_nsubjpass) Treatment_0\NN|by|usually|is (l_prep) for_1\IN|NONE (l_pobj) scabies_2\NNS|NONE
D001556_D012532 NONE hexachloride_16\NN|)|(|treatment (r_appos) lindane_12\NN|;|.|most|initiated (r_dobj) consider_11\VBP|NONE (l_ccomp) initiated_5\VBN|;|.|most|lindane (l_nsubjpass) Treatment_0\NN|by|usually|is (l_prep) for_1\IN|NONE (l_pobj) scabies_2\NNS|NONE
D001556_D000741 CID lindane_4\NN|is|Evidence (r_dobj) accumulating_2\VBG|can|and|associated|.|toxic (r_csubj) be_6\VB|NONE (l_conj) associated_16\VBN|can|and|.|accumulating|toxic (l_prep) with_17\IN|be|may (l_pobj) anaemia_19\NN|NONE
D001556_D002493 CID lindane_4\NN|is|Evidence (r_dobj) accumulating_2\VBG|can|and|associated|.|toxic (r_csubj) be_6\VB|NONE (l_acomp) toxic_7\JJ|can|and|associated|.|accumulating (l_prep) to_8\IN|NONE (l_pobj) system_12\NN|NONE
3560096
D011188_D006947 NONE potassium_8\NN|to (r_dobj) effect_6\NN|NONE (r_xcomp) known_4\VBN|other|no (r_acl) medications_3\NNS|concomitantly|As|been|had (r_nsubjpass) given_11\VBN|.|,|course|suggestive (r_advcl) is_18\VBZ|NONE (l_acomp) suggestive_19\JJ|given|.|,|course (l_prep) of_20\IN|NONE (l_pobj) relationship_27\NN|NONE (l_prep) between_28\IN|a|cause (l_pobj) sulindac_29\NN|NONE (l_conj) hyperkalemia_31\NN|and
D007213_D006947 CID indomethacin_17\NN|such (r_pobj) as_16\IN|)|( (r_prep) NSAID_13\NNP|antiinflammatory|nonsteroidal (r_appos) agents_11\NNS|NONE (r_pobj) of_8\IN|a (r_prep) complication_7\NN|NONE (r_pobj) as_5\IN|been|recently|has|.|Hyperkalemia (r_prep) recognized_4\VBN|NONE (l_nsubjpass) Hyperkalemia_0\NNP|been|recently|has|as|.
D013467_D006947 CID sulindac_3\NN|NONE (r_compound) therapy_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Hyperkalemia_0\NNP|NONE
D013467_D006947 CID sulindac_22\NN|NONE (r_compound) administration_23\NN|NONE (r_pobj) of_21\IN| (r_prep) days_20\NNS|NONE (r_pobj) within_16\IN|hyperkalemia (r_prep) developed_15\VBD|patients|.|We (l_nsubj) hyperkalemia_6\VBD|within
D013467_D006947 CID sulindac_29\NN|NONE (l_conj) hyperkalemia_31\NN|and
1009330
D011206_D003556 CID iodine_10\NN|kanamycin||and (r_conj) colistin_6\NN|NONE (r_nmod) irrigations_11\NNS|NONE (r_pobj) of_3\IN|A|high (r_prep) percentage_2\NN|.|suggested|and|with|were (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|percentage|.|suggested|and|were (l_pobj) cystitis_16\NN|NONE
C004658_D003556 NONE choloroaniline_10\NN|the|degradation (r_appos) product_7\NN|not|that|factor (r_nsubj) is_11\VBZ|.|results|have (l_attr) factor_15\NN|not|product|that (l_prep) in_16\IN|significant|a (l_pobj) cystitis_22\NN|NONE
C010882_D003556 CID digluconate_19\NN|NONE (r_npadvmod) associated_20\VBN|erosive (r_amod) cystitis_22\NN|NONE
D003091_D003556 CID colistin_6\NN|NONE (r_nmod) irrigations_11\NNS|NONE (r_pobj) of_3\IN|A|high (r_prep) percentage_2\NN|.|suggested|and|with|were (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|percentage|.|suggested|and|were (l_pobj) cystitis_16\NN|NONE
C005253_D003556 NONE Picloxydine_0\NNP|NONE (r_compound) irrigations_1\NNS|have|have|but (r_nsubj) appeared_2\VBD|NONE (l_xcomp) have_4\VB|have|irrigations|but (l_dobj) incidence_7\NN|to (l_prep) of_8\IN|lower|a (l_pobj) cystitis_10\NN|NONE
D007612_D003556 CID kanamycin_4\NN||and|iodine (r_compound) colistin_6\NN|NONE (r_nmod) irrigations_11\NNS|NONE (r_pobj) of_3\IN|A|high (r_prep) percentage_2\NN|.|suggested|and|with|were (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|percentage|.|suggested|and|were (l_pobj) cystitis_16\NN|NONE
19387625
D002211_D006930 CID capsaicin_7\NN| (r_npadvmod) induced_9\VBN|secondary (r_amod) hyperalgesia_11\NN|NONE
D002211_D006930 CID capsaicin_16\NN| (r_npadvmod) induced_18\VBN|secondary (r_amod) hyperalgesia_20\NN|NONE
D002211_D006930 CID capsaicin_20\NN| (r_npadvmod) untreated_22\VBN|control|, (r_amod) condition_25\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) that_18\DT|NONE (r_pobj) to_17\IN|very (r_prep) similar_16\JJ|magnitude|that (r_acomp) is_14\VBZ|was|,|Furthermore|it|. (l_nsubj) magnitude_7\NN|that|similar (l_prep) of_8\IN|the (l_pobj) modulation_10\NN|NONE (l_prep) in_11\IN|attentional (l_pobj) hyperalgesia_13\NN|NONE
D002211_D006930 CID capsaicin_7\NN|and|modulation (r_compound) treatment_8\NN|NONE (r_pobj) between_6\IN|no (r_prep) interaction_5\NN|NONE (r_dobj) showing_3\VBG|affect|findings|,|. (r_csubj) suggest_12\VBP|NONE (l_ccomp) affect_22\VB|showing|findings|,|. (l_nsubj) hyperalgesia_18\NN|that|pain|through|might
D002211_D006930 CID capsaicin_14\NN| (r_npadvmod) induced_16\VBN|and|secondary|attention (r_amod) hyperalgesia_18\NN|that|pain|through|might
D002211_D010146 NONE capsaicin_7\NN| (r_npadvmod) induced_9\VBN|secondary (r_amod) hyperalgesia_11\NN|NONE (r_pobj) in_6\IN|perceived|pain (r_prep) intensity_5\NN|NONE (l_compound) pain_4\NN|perceived|in
D002211_D010146 NONE capsaicin_16\NN| (r_npadvmod) induced_18\VBN|secondary (r_amod) hyperalgesia_20\NN|NONE (r_pobj) in_15\IN|NONE (r_prep) attention_14\NN|NONE (r_pobj) by_13\IN|ratings|that|are|how (r_agent) affected_12\VBN|not|is|.|However|,|it (l_nsubjpass) ratings_10\NNS|by|that|are|how (l_compound) intensity_9\NN|NONE (l_compound) pain_8\NN|NONE
D002211_D010146 NONE capsaicin_7\NN|and|modulation (r_compound) treatment_8\NN|NONE (r_pobj) between_6\IN|no (r_prep) interaction_5\NN|NONE (r_dobj) showing_3\VBG|affect|findings|,|. (r_csubj) suggest_12\VBP|NONE (l_ccomp) affect_22\VB|showing|findings|,|. (l_dobj) pain_24\NN|that|through|hyperalgesia|might
D002211_D010146 NONE capsaicin_14\NN| (r_npadvmod) induced_16\VBN|and|secondary|attention (r_amod) hyperalgesia_18\NN|that|pain|through|might (r_nsubj) affect_22\VB|showing|findings|,|. (l_dobj) pain_24\NN|that|through|hyperalgesia|might
18821488
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16\NNP|methylbutyl)amino]|the|( (r_nmod) WR242511_18\NNP|NONE (r_pobj) of_6\IN|NONE (r_prep) administration_5\NN|NONE (r_pobj) following_4\VBG|in|.|) (r_prep) Toxicity_0\NN|NONE
C068820_D064420 NONE WR242511_18\NNP|NONE (r_pobj) of_6\IN|NONE (r_prep) administration_5\NN|NONE (r_pobj) following_4\VBG|in|.|) (r_prep) Toxicity_0\NN|NONE
C068820_D064420 NONE WR242511_4\NNP|dissociated|that|as|should|not|be (r_nsubjpass) pursued_8\VBN|.|is|It (l_advcl) dissociated_27\VBN|that|as|should|not|WR|be (l_prep) from_28\IN|characteristics|successfully|can|be|unless (l_pobj) those_29\DT|NONE (l_acl) producing_30\VBG|NONE (l_dobj) toxicity_32\NN|NONE
C068820_D011041 NONE WR242511_4\NNP|dissociated|that|as|should|not|be (r_nsubjpass) pursued_8\VBN|.|is|It (l_prep) as_9\IN|dissociated|that|should|not|WR|be (l_pobj) pretreatment_11\NN|NONE (l_prep) for_12\IN|a (l_pobj) poisoning_14\NN|NONE
C068820_D006456 CID WR242511_11\NNP|NONE (r_pobj) of_10\IN|minutes (r_prep) postinjection_9\NN|,|occurred|hemoglobinuria|,|Furthermore|was|and (r_dobj) noted_5\VBN|NONE (l_nsubjpass) hemoglobinuria_3\NN|,|occurred|,|Furthermore|was|and|postinjection
C080436_D064420 NONE 8-aminoquinoline_8\JJ|NONE (r_compound) 8-[(4-amino_9\CD| (r_compound) l_11\NN| (r_compound) methylbutyl)amino]-_13\NN|the|(|hexyloxy)methoxymethylquinoline (r_punct) WR242511_18\NNP|NONE (r_pobj) of_6\IN|NONE (r_prep) administration_5\NN|NONE (r_pobj) following_4\VBG|in|.|) (r_prep) Toxicity_0\NN|NONE
C068820_D008708 NONE WR242511_4\NNP|NONE (l_relcl) produced_7\VBD|,|, (l_dobj) methemoglobinemia_9\NN|in|which
3782049
D008972_D058186 CID molindone_18\NN|NONE (r_compound) administration_19\NN|NONE (r_pobj) following_17\VBG|and|massive|failure (r_prep) rhabdomyolysis_11\NN|to (l_conj) failure_16\NN|following|and|massive
D008972_D012206 CID molindone_6\NN|NONE (r_compound) administration_7\NN|NONE (r_pobj) following_5\VBG|massive (r_prep) rhabdomyolysis_4\NN|NONE
D008972_D012206 CID molindone_18\NN|NONE (r_compound) administration_19\NN|NONE (r_pobj) following_17\VBG|and|massive|failure (r_prep) rhabdomyolysis_11\NN|to
D008972_D012559 NONE molindone_18\NN|NONE (r_compound) administration_19\NN|NONE (r_pobj) following_17\VBG|and|massive|failure (r_prep) rhabdomyolysis_11\NN|to (r_dobj) illustrate_9\VB|.|case|is (r_xcomp) reported_7\VBN|NONE (l_nsubjpass) case_1\NN|illustrate|.|is (l_prep) of_2\IN|The (l_pobj) patient_5\NN|NONE (l_amod) schizophrenic_4\JJ|a
8690168
D006497_D003928 NONE sulphate_3\NN| (r_npadvmod) associated_5\VBN|anionic|heparan|in (r_amod) sites_7\NNS|NONE (l_prep) in_8\IN|anionic|heparan|associated (l_pobj) membrane_12\NN|NONE (l_prep) of_13\IN|basement|glomerular|the (l_pobj) rats_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) nephropathy_20\NN|NONE
D013311_D003928 CID streptozotocin_16\NNS| (r_npadvmod) induced_18\VBN|diabetic (r_amod) nephropathy_20\NN|NONE
C015445_D003920 NONE blue_38\JJ|NONE (r_dobj) employing_33\VBG|after|.|in|were|,|sites (r_advcl) studied_12\VBN|NONE (l_prep) after_17\IN|.|in|employing|were|,|sites (l_pobj) induction_18\NN|months (l_prep) of_19\IN|by (l_pobj) diabetes_20\NNS|NONE
D013311_D003920 NONE streptozotocin_22\NNS|and|in (r_pobj) by_21\IN|of (r_prep) induction_18\NN|months (l_prep) of_19\IN|by (l_pobj) diabetes_20\NNS|NONE
D013311_D003920 NONE streptozotocin_4\JJ| (r_amod) diabetic_6\JJ|with
D006497_D003920 NONE sulphate_1\NN| (r_npadvmod) associated_3\VBN|Heparan|in|anionic (r_amod) sites_5\NNS|after|.|in|employing|were|, (r_nsubjpass) studied_12\VBN|NONE (l_prep) after_17\IN|.|in|employing|were|,|sites (l_pobj) induction_18\NN|months (l_prep) of_19\IN|by (l_pobj) diabetes_20\NNS|NONE
D006497_D003920 NONE sulphate_18\NN|NONE (r_compound) charge_19\NN|barrier|/|a|reduced|heparan (r_compound) density_22\NN|is|in|at|that (r_nsubjpass) found_24\VBN|.|We (l_prep) in_3\IN|is|at|density|that (l_pobj) rats_7\NNS|NONE (l_amod) diabetic_6\JJ|with
1468485
D015237_D006470 NONE alpha_14\NN|NONE (r_pobj) of_11\IN|and|instillation|physiological (r_prep) saline_8\NN|NONE (r_pobj) with_6\IN|bladder (r_prep) irrigation_5\NN|NONE (r_pobj) including_3\VBG|Conservative|,|, (r_prep) treatment_1\NN|.|control (r_nsubj) failed_16\VBD|NONE (l_xcomp) control_19\VB|treatment|. (l_dobj) hemorrhage_20\NN|to|totally
D003520_D006470 CID cyclophosphamide_7\NN| (r_npadvmod) induced_9\VBN|intractable|hemorrhagic (r_amod) cystitis_11\NN|NONE
D003520_D006470 CID cyclophosphamide_10\NN|for (r_compound) therapy_11\NN|to (r_pobj) due_8\IN|case|We|. (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|due|We|. (l_prep) of_4\IN|a (l_pobj) cystitis_7\NN|NONE
D003520_D006470 CID cyclophosphamide_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) treatment_14\NN|NONE (r_pobj) in_12\IN|a|safe (r_prep) alternative_11\NN|.|cystitis|can|form|,|In (r_dobj) offer_8\VB|NONE (l_dobj) cystitis_20\NN|.|can|form|,|In|alternative
D010100_D006470 NONE oxygen_1\NN|for|Hyperbaric|. (r_compound) therapy_2\NN|NONE (l_prep) for_3\IN|Hyperbaric|oxygen|. (l_pobj) control_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) cystitis_11\NN|NONE
D010100_D003556 NONE oxygen_1\NN|for|Hyperbaric|. (r_compound) therapy_2\NN|NONE (l_prep) for_3\IN|Hyperbaric|oxygen|. (l_pobj) control_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) cystitis_11\NN|NONE
D003520_D003556 CID cyclophosphamide_7\NN| (r_npadvmod) induced_9\VBN|intractable|hemorrhagic (r_amod) cystitis_11\NN|NONE
D003520_D003556 CID cyclophosphamide_10\NN|for (r_compound) therapy_11\NN|to (r_pobj) due_8\IN|case|We|. (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|due|We|. (l_prep) of_4\IN|a (l_pobj) cystitis_7\NN|NONE
D003520_D003556 CID cyclophosphamide_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) treatment_14\NN|NONE (r_pobj) in_12\IN|a|safe (r_prep) alternative_11\NN|.|cystitis|can|form|,|In (r_dobj) offer_8\VB|NONE (l_dobj) cystitis_20\NN|.|can|form|,|In|alternative
D003520_D014890 NONE cyclophosphamide_10\NN|for (r_compound) therapy_11\NN|to (l_prep) for_12\IN|cyclophosphamide (l_pobj) granulomatosis_15\NN|NONE
88336
D002719_D013375 NONE chlormethiazole_6\NN|NONE (r_pobj) of_5\IN|high (r_prep) doses_4\NNS|patients|,|for|and|took (r_dobj) received_2\VBD|NONE (l_prep) for_7\IN|patients|,|doses|and|took (l_pobj) symptoms_10\NNS|NONE
D002719_D003128 CID chlormethiazole_10\NN|NONE (r_compound) intoxication_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) those_8\DT|NONE (r_pobj) of_7\IN|NONE (r_prep) two_6\CD|and|nitrazepam (r_conj) overdose_4\NN|NONE (r_pobj) with_2\IN|The (r_prep) patient_1\NN|showing|.|,|to (r_nsubj) conformed_12\VBD|NONE (l_prep) to_13\IN|patient|showing|.|, (l_pobj) criteria_15\NNS|NONE (l_prep) of_16\IN|the (l_pobj) coma_19\NN|'|'
D009567_D013375 NONE nitrazepam_19\NN|NONE (r_pobj) of_18\IN|suicidal|a (r_prep) overdose_17\NN|one|. (r_dobj) took_14\VBD|patients|,|for|doses|and (r_conj) received_2\VBD|NONE (l_prep) for_7\IN|patients|,|doses|and|took (l_pobj) symptoms_10\NNS|NONE
D000431_D062787 NONE alcohol_8\NN|NONE (r_compound) withdrawal_9\NN|NONE (r_compound) symptoms_10\NNS|NONE (r_pobj) for_7\IN|patients|,|doses|and|took (r_prep) received_2\VBD|NONE (l_conj) took_14\VBD|patients|,|for|doses|and (l_dobj) overdose_17\NN|one|.
D000431_D013375 NONE alcohol_8\NN|NONE (r_compound) withdrawal_9\NN|NONE (r_compound) symptoms_10\NNS|NONE
D009567_D003128 CID nitrazepam_3\JJ|and|two (r_amod) overdose_4\NN|NONE (r_pobj) with_2\IN|The (r_prep) patient_1\NN|showing|.|,|to (r_nsubj) conformed_12\VBD|NONE (l_prep) to_13\IN|patient|showing|.|, (l_pobj) criteria_15\NNS|NONE (l_prep) of_16\IN|the (l_pobj) coma_19\NN|'|'
D002719_D062787 NONE chlormethiazole_6\NN|NONE (r_pobj) of_5\IN|high (r_prep) doses_4\NNS|patients|,|for|and|took (r_dobj) received_2\VBD|NONE (l_conj) took_14\VBD|patients|,|for|doses|and (l_dobj) overdose_17\NN|one|.
D002719_D062787 NONE chlormethiazole_10\NN|NONE (r_compound) intoxication_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) those_8\DT|NONE (r_pobj) of_7\IN|NONE (r_prep) two_6\CD|and|nitrazepam (r_conj) overdose_4\NN|NONE
D009567_D062787 CID nitrazepam_19\NN|NONE (r_pobj) of_18\IN|suicidal|a (r_prep) overdose_17\NN|one|.
D009567_D062787 CID nitrazepam_3\JJ|and|two (r_amod) overdose_4\NN|NONE
9334596
D013739_D020018 CID testosterone_5\NN|NONE (r_pobj) for_4\IN|patient|screened|was|. (r_prep) screened_3\VBN|NONE (l_conj) screened_9\VBN|patient|for|was|. (l_prep) on_12\IN|were|for (l_pobj) basis_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) desire_18\NN|NONE
D013739_D020018 CID testosterone_22\NN|or (r_conj) gynecomastia_20\NN|,|low|sexual (r_conj) desire_18\NN|NONE
D013739_D020018 CID testosterone_1\NN|in (r_dobj) Determining_0\VBG|would|%|.|have (l_prep) in_3\IN|testosterone (l_pobj) cases_4\NNS|only (l_prep) of_5\IN|NONE (l_pobj) desire_8\NN|NONE
D013739_D020018 CID testosterone_23\NN|NONE (r_pobj) with_21\IN|the (r_prep) cases_20\NNS|NONE (r_pobj) of_18\IN| (r_prep) %_17\NN|would|.|have|Determining (r_dobj) missed_15\VBN|NONE (l_csubj) Determining_0\VBG|would|%|.|have (l_prep) in_3\IN|testosterone (l_pobj) cases_4\NNS|only (l_prep) of_5\IN|NONE (l_pobj) desire_8\NN|NONE
D013739_D020018 CID testosterone_8\NN|be|that|but|measured|before|in (r_nsubjpass) determined_10\VBN|.|now|We (l_prep) in_12\IN|be|that|but|testosterone|measured|before (l_pobj) cases_13\NNS|only (l_prep) of_14\IN|NONE (l_pobj) desire_17\NN|NONE
D013739_D020018 CID testosterone_14\NN|and/or (r_conj) gynecomastia_12\NN|sexual|low|, (r_conj) desire_10\NN|NONE
D013739_D007027 NONE testosterone_5\NN|low|other|the (r_compound) levels_6\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Most_0\JJS|result|. (r_nsubj) seemed_7\VBD|NONE (l_xcomp) result_9\VB|Most|. (l_prep) from_10\IN|to|because (l_pobj) dysfunction_13\NN|NONE
D001971_D006966 NONE bromocriptine_13\NN|and (l_prep) for_14\IN|NONE (l_pobj) hyperprolactinemia_15\NN|NONE
D013739_D006177 NONE testosterone_5\NN|NONE (r_pobj) for_4\IN|patient|screened|was|. (r_prep) screened_3\VBN|NONE (l_conj) screened_9\VBN|patient|for|was|. (l_prep) on_12\IN|were|for (l_pobj) basis_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) desire_18\NN|NONE (l_conj) gynecomastia_20\NN|,|low|sexual
D013739_D006177 NONE testosterone_22\NN|or (r_conj) gynecomastia_20\NN|,|low|sexual
D013739_D006177 NONE testosterone_14\NN|and/or (r_conj) gynecomastia_12\NN|sexual|low|,
D013739_D010911 NONE testosterone_6\NN|NONE (r_compound) determination_7\NN|NONE (r_pobj) after_5\IN|tumors|.|were (r_prep) discovered_4\VBN|NONE (l_nsubjpass) tumors_2\NNS|.|were|after
C004648_D007006 NONE heptylate_5\NN|NONE (l_conj) gonadotropin_9\NN|testosterone|or (l_prep) for_10\IN|chorionic|human (l_pobj) hypogonadism_11\NN|NONE
C004648_D006966 NONE heptylate_5\NN|NONE (l_conj) gonadotropin_9\NN|testosterone|or (l_prep) for_10\IN|chorionic|human (l_pobj) hypogonadism_11\NN|NONE (l_conj) bromocriptine_13\NN|and (l_prep) for_14\IN|NONE (l_pobj) hyperprolactinemia_15\NN|NONE
D001971_D007006 NONE bromocriptine_13\NN|and (r_conj) hypogonadism_11\NN|NONE
D013739_D007172 NONE testosterone_6\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) results_3\NNS|results|,|compared|.|We|and (l_prep) in_10\IN|of|the (l_pobj) patients_12\NNS|NONE (l_acl) referred_13\VBD|, (l_prep) because_14\IN|NONE (l_pobj) dysfunction_17\NN|of
D013739_D007172 NONE testosterone_5\NN|low|other|the (r_compound) levels_6\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Most_0\JJS|result|. (r_nsubj) seemed_7\VBD|NONE (l_xcomp) result_9\VB|Most|. (l_prep) because_14\IN|to|from (l_conj) have_24\VB|hormone|and|of (l_dobj) role_28\NN|to (l_prep) in_29\IN|only|small|a (l_pobj) dysfunction_31\NN|NONE
D013739_D007172 NONE testosterone_6\NN|NONE (r_pobj) of_4\IN|in (r_prep) effects_3\NNS|Low|and (l_prep) in_10\IN|of (l_pobj) dysfunction_12\NN|NONE
1919871
D000082_D007681 CID paracetamol_22\JJ|in|and (r_conj) aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|concentrating|decreased|urinary|a (r_acl) ability_11\NN|papillary|Renal|RPN|)|.|(|and (r_conj) necrosis_2\NN|NONE
D000082_D007681 CID paracetamol_22\JJ|in|and (r_conj) aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|concentrating|decreased|urinary|a (r_acl) ability_11\NN|papillary|Renal|RPN|)|.|(|and (r_conj) necrosis_2\NN|NONE (l_appos) RPN_4\NNP|ability|papillary|Renal|)|.|(|and
D001241_D007681 CID aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|concentrating|decreased|urinary|a (r_acl) ability_11\NN|papillary|Renal|RPN|)|.|(|and (r_conj) necrosis_2\NN|NONE
D001241_D007681 CID aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|concentrating|decreased|urinary|a (r_acl) ability_11\NN|papillary|Renal|RPN|)|.|(|and (r_conj) necrosis_2\NN|NONE (l_appos) RPN_4\NNP|ability|papillary|Renal|)|.|(|and
8955532
D003911_D006973 NONE dextran_15\NN|NONE (r_pobj) of_11\IN|before (r_prep) clearance_10\NN|NONE (l_prep) before_16\IN|of (l_conj) during_18\IN|and (l_pobj) hypertension_23\NN|NONE
D001920_D006973 NONE bradykinin_4\NN|NONE (l_prep) in_7\IN|receptors (l_pobj) disruption_8\NN|NONE (l_prep) during_15\IN|of (l_pobj) hypertension_17\NN|NONE
D001920_D006973 NONE bradykinin_15\NN|NONE (r_pobj) of_14\IN|/|synthesis (r_prep) release_13\NN|NONE (r_pobj) of_10\IN|the (r_prep) role_9\NN|to|activate (r_dobj) determine_7\VB|.|goal (l_xcomp) activate_17\VB|to|role (l_prep) in_20\IN|to|receptors (l_pobj) disruption_21\NN|NONE (l_prep) during_28\IN|of (l_pobj) hypertension_30\NN|NONE
D001920_D006973 NONE bradykinin_23\NN|NONE (r_pobj) of_22\IN|synthesis|the|/ (r_prep) release_21\NN|NONE (r_pobj) to_17\IN|is|not|activate (r_prep) related_16\VBN|findings|. (l_auxpass) is_14\VBZ|not|to|activate (l_nsubj) disruption_4\NN|that (l_prep) during_11\IN|of (l_pobj) hypertension_13\NN|NONE
D010656_D006973 CID phenylephrine_19\NN| (r_npadvmod) induced_21\VBN|in|acute (r_amod) hypertension_23\NN|NONE
C065679_D006973 NONE Hoe-140_30\NNP|and|microM (r_conj) vehicle_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treated_26\VBN|NONE (r_acl) rats_25\NNS|NONE (r_pobj) in_24\IN|induced|acute (r_prep) hypertension_23\NN|NONE
19037603
D019259_D012216 NONE lamivudine_3\NN|NONE (r_pobj) of_2\IN|with|Prophylactic|. (r_prep) use_1\NN|NONE (l_prep) with_4\IN|Prophylactic|of|. (l_pobj) therapy_7\NN|NONE (l_prep) for_8\IN|immunosuppressive|chronic (l_pobj) disorders_10\NNS|NONE
D019259_D012216 NONE lamivudine_18\NN|NONE (r_pobj) of_17\IN|in|the|prophylactic (r_prep) administration_16\NN|NONE (r_pobj) of_13\IN|the (r_prep) effectiveness_12\NN|NONE (r_pobj) concerning_10\VBG|to|experience (r_prep) report_7\VB|patients|.|objective (r_xcomp) was_5\VBD|NONE (l_attr) patients_30\NNS|report|.|objective (l_prep) with_31\IN|)|positive (l_pobj) disease_33\NN|NONE
D019259_D012216 NONE lamivudine_23\JJ|immunosuppressive (r_compound) therapies_24\NNS|NONE (r_pobj) on_18\IN|who (r_prep) were_17\VBD|,|rheumatologic (r_relcl) diseases_14\NNS|NONE
D006514_D012216 NONE antigen_24\NN|NONE (r_pobj) in_19\IN|of|the|prophylactic (r_prep) administration_16\NN|NONE (r_pobj) of_13\IN|the (r_prep) effectiveness_12\NN|NONE (r_pobj) concerning_10\VBG|to|experience (r_prep) report_7\VB|patients|.|objective (r_xcomp) was_5\VBD|NONE (l_attr) patients_30\NNS|report|.|objective (l_prep) with_31\IN|)|positive (l_pobj) disease_33\NN|NONE
D006514_D012216 NONE Ag_27\NNP|surface|virus (r_appos) antigen_24\NN|NONE (r_pobj) in_19\IN|of|the|prophylactic (r_prep) administration_16\NN|NONE (r_pobj) of_13\IN|the (r_prep) effectiveness_12\NN|NONE (r_pobj) concerning_10\VBG|to|experience (r_prep) report_7\VB|patients|.|objective (r_xcomp) was_5\VBD|NONE (l_attr) patients_30\NNS|report|.|objective (l_prep) with_31\IN|)|positive (l_pobj) disease_33\NN|NONE
D006514_D012216 NONE Ag_9\NNP|positive|with (r_nmod) patients_11\NNS|,|retrospectively|were|.|,|From (l_prep) with_12\IN|Ag|positive (l_pobj) diseases_14\NNS|NONE
809711
D005996_D007022 CID Nitroglycerin_0\NNP|reduce|has|been (r_nsubjpass) shown_3\VBN|.|effect|by|in|, (r_ccomp) potentiated_17\VBN|NONE (l_agent) by_21\IN|.|effect|shown|in|, (l_pobj) agents_22\NNS|NONE (l_relcl) reverse_24\VBP|NONE (l_dobj) hypotension_28\NN|that
D005996_D007022 CID nitroglycerin_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) hypotension_28\NN|that
D005996_D009203 NONE nitroglycerin_9\NN|NONE (r_pobj) of_7\IN|the|beneficial|in (r_prep) effects_6\NNS|NONE (l_prep) in_10\IN|the|beneficial|of (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) infarction_15\NN|NONE
D005996_D009203 NONE Nitroglycerin_0\NNP|reduce|has|been (r_nsubjpass) shown_3\VBN|.|effect|by|in|, (l_xcomp) reduce_5\VB|has|been|Nitroglycerin (l_prep) during_10\IN|elevation|to (l_pobj) infarction_13\NN|NONE
D005996_D009203 NONE nitroglycerin_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) hypotension_28\NN|that (r_dobj) reverse_24\VBP|NONE (r_relcl) agents_22\NNS|NONE (r_pobj) by_21\IN|.|effect|shown|in|, (r_agent) potentiated_17\VBN|NONE (l_ccomp) shown_3\VBN|.|effect|by|in|, (l_xcomp) reduce_5\VB|has|been|Nitroglycerin (l_prep) during_10\IN|elevation|to (l_pobj) infarction_13\NN|NONE
D005996_D009203 NONE nitroglycerin_9\NN|+/|patients (r_dobj) received_7\VBD|NONE (l_nsubj) patients_1\NNS|+/|nitroglycerin (l_prep) with_2\IN|Ten (l_pobj) infarctions_6\NNS|NONE
D005996_D009203 NONE nitroglycerin_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) phenylephrine_6\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) addition_4\NN|not|beneficial|that (r_nsubj) is_9\VBZ|results|. (l_acomp) beneficial_11\JJ|not|addition|that (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) infarction_20\NN|NONE
D010656_D009203 NONE phenylephrine_2\NN|NONE (l_prep) of_3\IN|NONE (l_pobj) effects_6\NNS|NONE (l_prep) in_10\IN|the|beneficial|of (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) infarction_15\NN|NONE
D010656_D009203 NONE phenylephrine_6\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) addition_4\NN|not|beneficial|that (r_nsubj) is_9\VBZ|results|. (l_acomp) beneficial_11\JJ|not|addition|that (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) infarction_20\NN|NONE
17600377
C524754_D009410 NONE coumarate_17\NN|maltolyl|candidate|that (r_nsubj) is_18\VBZ|study|.|,|results (l_attr) candidate_22\NN|maltolyl|coumarate|that (l_relcl) characterized_29\VBN|against|a|effective (l_agent) by_30\IN|is|that (l_pobj) death_34\NN|NONE
D012601_D003072 CID scopolamine_17\NN| (r_npadvmod) injected_19\VBN|NONE (r_amod) rats_20\NNS|in|and (r_pobj) in_16\IN|cognitive (r_prep) decline_15\NN|coumarate|whether|could
C544092_D003072 NONE beta_24\NN|NONE (r_pobj) in_22\IN|and|rats (r_conj) in_16\IN|cognitive (r_prep) decline_15\NN|coumarate|whether|could
C544092_D003072 NONE 42)-infused_34\VBN|NONE (r_amod) rats_35\NNS|amyloid (r_dobj) beta_31\NN|was|attenuate|.|coumarate (r_advcl) found_5\VBN|NONE (l_xcomp) attenuate_7\VB|was|beta|.|coumarate (l_dobj) deficits_9\NNS|to
C524754_D003704 NONE coumarate_7\NN|A|,|,|novel (r_appos) compound_2\NN|.|shows|and|deficits (r_nsubj) attenuates_9\VBZ|NONE (l_conj) shows_13\VBZ|compound|.|and|deficits (l_dobj) effects_15\NNS|NONE (l_prep) in_16\IN|neuroprotective (l_amod) vitro_17\FW|NONE (l_conj) in_19\IN|and (l_pobj) models_22\NNS|NONE (l_compound) dementia_21\NN|NONE
C524754_D003072 NONE coumarate_7\NN|A|,|,|novel (r_appos) compound_2\NN|.|shows|and|deficits (r_nsubj) attenuates_9\VBZ|NONE (l_dobj) deficits_11\NNS|compound|.|shows|and
C524754_D003072 NONE coumarate_11\NN|whether|decline|could (r_nsubj) improve_13\VB|In|,|we (l_dobj) decline_15\NN|coumarate|whether|could
C524754_D003072 NONE coumarate_3\NN|was|attenuate|beta|. (r_nsubjpass) found_5\VBN|NONE (l_xcomp) attenuate_7\VB|was|beta|.|coumarate (l_dobj) deficits_9\NNS|to
C524754_D003072 NONE coumarate_17\NN|maltolyl|candidate|that (r_nsubj) is_18\VBZ|study|.|,|results (l_attr) candidate_22\NN|maltolyl|coumarate|that (l_relcl) characterized_29\VBN|against|a|effective (l_agent) by_30\IN|is|that (l_pobj) death_34\NN|NONE (l_conj) decline_37\NN|spread|neuronal|and (l_prep) of_38\IN|progressive (l_pobj) function_40\NN|NONE
C524754_D000544 NONE coumarate_17\NN|maltolyl|candidate|that (r_nsubj) is_18\VBZ|study|.|,|results (l_attr) candidate_22\NN|maltolyl|coumarate|that (l_prep) against_23\IN|characterized|a|effective (l_pobj) disease_26\NN|NONE
10526274
C056507_D064420 NONE GEM_1\NNP|,|may|.|with|rate|(|) (r_nsubj) obtain_4\VB|NONE (l_prep) with_17\IN|,|may|.|rate|(|)|GEM (l_pobj) toxicity_19\NN|NONE
C056507_D064420 NONE GEM_12\NNP|NONE (r_pobj) of_11\IN|in|the (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|and|the|toxicity (r_prep) efficacy_5\NN|In|were|. (l_conj) toxicity_7\NN|of|and|the
C030852_D064420 NONE VNB_14\NNP|and (r_conj) GEM_12\NNP|NONE (r_pobj) of_11\IN|in|the (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|and|the|toxicity (r_prep) efficacy_5\NN|In|were|. (l_conj) toxicity_7\NN|of|and|the
D002945_D064420 NONE cisplatin_28\NN|NONE (r_dobj) receiving_27\VBG|NONE (r_pcomp) to_26\IN|some (r_prep) contraindication_25\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) those_22\DT|or|advanced (r_conj) NSCLC_20\NNP|NONE (r_pobj) with_18\IN|elderly (r_prep) patients_17\NNS|NONE (r_pobj) in_15\IN|of|the (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|and|the|toxicity (r_prep) efficacy_5\NN|In|were|. (l_conj) toxicity_7\NN|of|and|the
D002945_D002289 NONE cisplatin_20\NN|who|can|not (r_dobj) receive_19\VB|or||or|older|patients (r_relcl) years_11\NNS|.|Gemcitabine (r_npadvmod) age_9\NN|NONE (l_nsubj) Gemcitabine_0\NNP|.|years (l_conj) vinorelbine_2\NN|plus (l_prep) in_3\IN|NONE (l_pobj) patients_8\NNS|NONE (l_compound) carcinoma_7\NN|nonsmall
D002945_D002289 NONE cisplatin_28\NN|NONE (r_dobj) receiving_27\VBG|NONE (r_pcomp) to_26\IN|some (r_prep) contraindication_25\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) those_22\DT|or|advanced (r_conj) NSCLC_20\NNP|NONE
D002945_D002289 NONE cisplatin_33\NN|NONE (r_dobj) receiving_32\VBG|NONE (r_pcomp) to_31\IN|some (r_prep) contraindication_30\NN|who (r_dobj) had_28\VBD|but|age| (r_conj) were_21\VBD|years|and (r_conj) /=_16\NFP|.|,|patients|were|were (r_punct) included_8\VBN|NONE (l_nsubjpass) patients_3\NNS|.|,|were|/=|were (l_prep) with_4\IN|nine (l_pobj) NSCLC_6\NNP|NONE
C030852_D002289 NONE vinorelbine_2\NN|plus (l_prep) in_3\IN|NONE (l_pobj) patients_8\NNS|NONE (l_compound) carcinoma_7\NN|nonsmall
C030852_D002289 NONE VNB_14\NNP|and (r_conj) GEM_12\NNP|NONE (r_pobj) of_11\IN|in|the (r_prep) combination_10\NN|NONE (l_prep) in_15\IN|of|the (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|elderly (l_pobj) NSCLC_20\NNP|NONE
C056507_D002289 NONE Gemcitabine_0\NNP|.|years (l_conj) vinorelbine_2\NN|plus (l_prep) in_3\IN|NONE (l_pobj) patients_8\NNS|NONE (l_compound) carcinoma_7\NN|nonsmall
C056507_D002289 NONE GEM_12\NNP|NONE (r_pobj) of_11\IN|in|the (r_prep) combination_10\NN|NONE (l_prep) in_15\IN|of|the (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|elderly (l_pobj) NSCLC_20\NNP|NONE
6692345
D005200_D063646 NONE FANFT_16\NNP|in (r_compound) carcinogenesis_17\NN|NONE
D005200_D063646 NONE FANFT_30\NNP|NONE (r_pobj) on_29\IN|aspirin|in (r_prep) effect_28\NN|due|that|not (r_nsubj) is_34\VBZ|and|mechanisms|in|that|are|, (r_conj) involved_14\VBN|NONE (l_prep) in_15\IN|and|mechanisms|that|are|is|, (l_pobj) carcinogenesis_17\NN|NONE
D001241_D063646 NONE aspirin_26\NN|on|in (r_poss) effect_28\NN|due|that|not (r_nsubj) is_34\VBZ|and|mechanisms|in|that|are|, (r_conj) involved_14\VBN|NONE (l_prep) in_15\IN|and|mechanisms|that|are|is|, (l_pobj) carcinogenesis_17\NN|NONE
D005200_D013274 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN||The|to (r_prep) administration_3\NN|.|in (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|.|administration (l_pobj) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|of|a|but (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
D005200_D013274 CID FANFT_9\NNP|NONE (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN||The|to (r_prep) administration_3\NN|.|in (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|.|administration (l_pobj) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|of|a|but (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
D005200_D013274 CID FANFT_19\NNP| (r_npadvmod) induced_21\VBN|bladder (r_amod) carcinomas_23\NNS|NONE (r_pobj) of_18\IN|reduced|induction|a|but (r_prep) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|of|a|but (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
D001241_D001749 NONE aspirin_5\NN|NONE (r_pobj) of_4\IN||The|to (r_prep) administration_3\NN|.|in (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|.|administration (l_pobj) incidence_17\NN|NONE (l_prep) of_18\IN|reduced|induction|a|but (l_pobj) carcinomas_23\NNS|NONE
D001241_D013274 NONE aspirin_5\NN|NONE (r_pobj) of_4\IN||The|to (r_prep) administration_3\NN|.|in (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|.|administration (l_pobj) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|of|a|but (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
D005200_D001749 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN||The|to (r_prep) administration_3\NN|.|in (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|.|administration (l_pobj) incidence_17\NN|NONE (l_prep) of_18\IN|reduced|induction|a|but (l_pobj) carcinomas_23\NNS|NONE
D005200_D001749 CID FANFT_9\NNP|NONE (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN||The|to (r_prep) administration_3\NN|.|in (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|.|administration (l_pobj) incidence_17\NN|NONE (l_prep) of_18\IN|reduced|induction|a|but (l_pobj) carcinomas_23\NNS|NONE
D005200_D001749 CID FANFT_19\NNP| (r_npadvmod) induced_21\VBN|bladder (r_amod) carcinomas_23\NNS|NONE
2950248
D004176_D017202 NONE Dipyridamole_0\NNP| (r_npadvmod) induced_2\VBN|myocardial|. (r_amod) ischemia_4\NN|NONE
D004176_D017202 NONE dipyridamole_16\NN|preoperative (r_compound) therapy_17\NN|NONE (r_pobj) of_14\IN|a|side (r_prep) effect_13\NN|NONE (r_pobj) as_10\IN|previously|has|not|.|To|been|this|demonstrated|,|, (r_prep) reported_9\VBN|NONE (l_advcl) demonstrated_27\VBN|previously|has|not|.|To|been|this|as|,|, (l_nsubjpass) ischemia_24\NN|has|although|been|occur
D004176_D017202 NONE dipyridamole_20\NN| (r_dep) induced_22\VBN|myocardial (r_amod) ischemia_24\NN|has|although|been|occur
D004176_D003324 NONE dipyridamole_16\NN|preoperative (r_compound) therapy_17\NN|NONE (r_pobj) of_14\IN|a|side (r_prep) effect_13\NN|NONE (r_pobj) as_10\IN|previously|has|not|.|To|been|this|demonstrated|,|, (r_prep) reported_9\VBN|NONE (l_advcl) demonstrated_27\VBN|previously|has|not|.|To|been|this|as|,|, (l_xcomp) occur_29\VB|has|although|been|ischemia (l_prep) with_34\IN|in|to (l_pobj) disease_37\NN|NONE
D004176_D003324 NONE dipyridamole_20\NN| (r_dep) induced_22\VBN|myocardial (r_amod) ischemia_24\NN|has|although|been|occur (r_nsubjpass) demonstrated_27\VBN|previously|has|not|.|To|been|this|as|,|, (l_xcomp) occur_29\VB|has|although|been|ischemia (l_prep) with_34\IN|in|to (l_pobj) disease_37\NN|NONE
D004176_D007511 NONE dipyridamole_23\NN| (r_npadvmod) induced_25\VBN|the (r_amod) ischemia_26\NN|NONE
D004176_D000787 CID dipyridamole_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) administration_7\NN|NONE (r_pobj) after_6\IN|.|Angina|in (r_prep) occurred_5\VBD|NONE (l_nsubj) Angina_0\NNP|.|after|in
18791946
D002939_D015746 CID ciprofloxacin_16\NNS|NONE (r_pobj) of_14\IN|day|for (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|.|with|man (r_prep) reported_5\VBN|NONE (l_prep) with_6\IN|.|man|after (l_pobj) pain_8\NN|NONE
D002939_D000743 CID ciprofloxacin_7\NNS|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|anaemia|and|Severe (r_acl) thrombocytopenia_1\JJ|case|a|with|.|: (l_conj) anaemia_4\NN|and|Severe|associated
D002939_D000743 CID ciprofloxacin_5\NNS|that|thrombocytopenia|,|in|may (r_nsubj) precipitate_7\VB|.|report (l_dobj) thrombocytopenia_11\JJ|that|,|in|may|ciprofloxacin (l_conj) anaemia_14\NN|and|threatening
D002939_D013921 CID ciprofloxacin_7\NNS|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|anaemia|and|Severe (r_acl) thrombocytopenia_1\JJ|case|a|with|.|:
D002939_D013921 CID ciprofloxacin_5\NNS|that|thrombocytopenia|,|in|may (r_nsubj) precipitate_7\VB|.|report (l_dobj) thrombocytopenia_11\JJ|that|,|in|may|ciprofloxacin
D002939_D014552 NONE ciprofloxacin_16\NNS|NONE (r_pobj) of_14\IN|day|for (r_prep) administration_13\NN|NONE (l_prep) for_17\IN|day|of (l_pobj) suspect_19\NN|NONE (l_prep) of_20\IN|a (l_pobj) infection_23\NN|NONE
D002939_D007565 CID ciprofloxacin_16\NNS|NONE (r_pobj) of_14\IN|day|for (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|.|with|man (r_prep) reported_5\VBN|NONE (l_prep) with_6\IN|.|man|after (l_pobj) pain_8\NN|NONE (l_conj) jaundice_10\NN|abdominal|and
17344566
D013974_D007037 NONE thyroxine_7\NN|.|with (l_compound) taking_6\VBG|old|simvastatin|and|A (l_nsubj) male_5\NN|NONE (l_amod) hypothyroid_4\JJ|NONE
D013974_D009135 NONE thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE (l_conj) myonecrosis_17\NN|compartment|and
D019821_D009135 NONE Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|and|compartment|myonecrosis|associated|. (r_amod) syndrome_6\NN|NONE (l_conj) myonecrosis_8\NN|and|induced|compartment|associated|.
D019821_D009135 NONE simvastatin_9\NN|old|and|taking|A (r_conj) thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE (l_conj) myonecrosis_17\NN|compartment|and
D019821_D007037 NONE Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|and|compartment|myonecrosis|associated|. (r_amod) syndrome_6\NN|NONE (l_acl) associated_9\VBN|and|induced|compartment|myonecrosis|. (l_prep) with_10\IN|NONE (l_pobj) hypothyroidism_11\NN|NONE
D019821_D007037 NONE simvastatin_9\NN|old|and|taking|A (r_conj) thyroxine_7\NN|.|with (l_compound) taking_6\VBG|old|simvastatin|and|A (l_nsubj) male_5\NN|NONE (l_amod) hypothyroid_4\JJ|NONE
D019821_D003161 CID Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|and|compartment|myonecrosis|associated|. (r_amod) syndrome_6\NN|NONE
D019821_D003161 CID simvastatin_9\NN|old|and|taking|A (r_conj) thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE
D013974_D003161 NONE thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE
